id,canonicalSmiles,inchiKey,drugType,blackBoxWarning,name,maximumClinicalTrialPhase,hasBeenWithdrawn,isApproved,tradeNames,synonyms,childChemblIds,description,crossReferences.Wikipedia,crossReferences.drugbank,linkedDiseases.rows,linkedDiseases.count,linkedTargets.rows,linkedTargets.count,yearOfFirstApproval,parentId,crossReferences.DailyMed,crossReferences.PubChem,crossReferences.chEBI,crossReferences.EMA,crossReferences.USAN,crossReferences.TG-GATEs,crossReferences.DrugCentral,crossReferences.INN
CHEMBL127071,Cc1ncccc1OC[C@@H]1CCCN1,YRVIKLBSVVNSHF-JTQLQIEISA-N,Small molecule,False,POZANICLINE,2.0,False,False,[],"['A-87089.0', 'A-870890', 'ABT-089', 'Pozanicline']",['CHEMBL2105650'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,"['A-84,543']",['DB05458'],"['EFO_0003768', 'EFO_0003888', 'MONDO_0004975']",3.0,"['ENSG00000160716', 'ENSG00000101204', 'ENSG00000169684', 'ENSG00000147434']",4,,,,,,,,,,
CHEMBL1692,CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl,XZZXIYZZBJDEEP-UHFFFAOYSA-N,Small molecule,True,IMIPRAMINE HYDROCHLORIDE,4.0,False,True,"['Imipramine hydrochloride', 'Janimine', 'Pramine', 'Praminil', 'Presamine', 'Sarimp', 'Tofranil']","['G-22355', 'Imidobenzyle', 'Imipramine HCl', 'Imipramine hcl', 'Imipramine hydrochloride', 'Imipramine hydrochloride rs', 'Imipramini hydrochloridum', 'Imizine', 'NSC-114900', 'Pryleugan']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for enuresis and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000519', 'MONDO_0024290', 'MONDO_0002050']",3.0,"['ENSG00000103546', 'ENSG00000108576']",2,1959.0,CHEMBL11,['imipramine%20hydrochloride'],"['144211734', '26747552', '26747553', '26751601', '50106516', '50106517', '50106518', '56422890', '855555']",['5882'],,,,,
CHEMBL17860,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,KSMAGQUYOIHWFS-UHFFFAOYSA-N,Small molecule,False,LOFEXIDINE,4.0,False,True,[],['Lofexidine'],['CHEMBL1788132'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for substance withdrawal syndrome and drug dependence and has 6 investigational indications.,['Lofexidine'],['DB04948'],"['EFO_0005800', 'EFO_0003890', 'HP_0001399', 'EFO_0004240', 'EFO_0005611', 'EFO_0010702', 'EFO_0002610', 'EFO_0007191', 'EFO_0005611']",9.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,2018.0,,,['170466275'],['51368'],,,,,
CHEMBL189171,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,FSQKKOOTNAMONP-UHFFFAOYSA-N,Small molecule,False,ACEMETACIN,4.0,False,True,['Emflex'],"['Acemetacin', 'NSC-757413', 'Rantudil']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease.,['Acemetacin'],['DB13783'],['EFO_0005755'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,"['11112782', '124882621', '144207022', '170466043', '174007220', '26746953', '855677']",['31162'],,,,,
CHEMBL2103828,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,LGSDFTPAICUONK-UHFFFAOYSA-N,Small molecule,False,ELINOGREL,2.0,False,False,[],"['Elinogrel', 'PRT 060128', 'PRT-060128', 'Prt060128']",['CHEMBL2105641'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB06350'],"['EFO_0000612', 'EFO_0003086']",2.0,['ENSG00000169313'],1,,,,,,,,,,
CHEMBL2105671,O=C(O)C(O)C(O)C(=O)O.OC[C@H]1CNC[C@@H](O)[C@@H]1O,ULBPPCHRAVUQMC-RWOHWRPJSA-N,Small molecule,False,AFEGOSTAT TARTRATE,2.0,False,False,[],"['AT-2101', 'AT2101', 'Afegostat tartrate', 'HGT-3410', 'Isofagomine tartrate', 'Plicera']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0018150'],1.0,['ENSG00000177628'],1,,CHEMBL206468,,,,,,,,
CHEMBL3184679,COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1,VRQMAABPASPXMW-UHFFFAOYSA-N,Small molecule,False,AZD-4547,2.0,False,False,[],"['ABSK-091', 'ABSK091', 'AZD-4547', 'Azd 4547', 'Azd-4547', 'Azd4547', 'KB-74810']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,,"['EFO_0000707', 'EFO_0000228', 'MONDO_0004992', 'MONDO_0001056', 'EFO_0000708', 'MONDO_0007254', 'EFO_0000326', 'EFO_0008528', 'EFO_0003060', 'EFO_0001378', 'MONDO_0001187']",11.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,,,,['174006594'],,,,,,
CHEMBL3951811,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl,BCSHRERPHLTPEE-NRFANRHFSA-N,Small molecule,False,CEP-37440,1.0,False,False,[],"['Alk-fak inhibitor cep-37440', 'Cep-37440']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB13060'],['EFO_0000616'],1.0,"['ENSG00000169398', 'ENSG00000171094']",2,,,,,,,,,,
CHEMBL3989989,,,Gene,True,AXICABTAGENE CILOLEUCEL,4.0,False,True,['Yescarta'],"['Axicabtagene ciloleucel', 'KTE-C19', 'Yescarta']",,Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0001642', 'EFO_1001469', 'MONDO_0018906', 'EFO_0000574', 'EFO_0000403', 'EFO_0000096']",6.0,['ENSG00000177455'],1,2018.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta'],,,,
CHEMBL4594333,,,Gene,False,ELIVALDOGENE AUTOTEMCEL,4.0,False,True,['Skysona'],"['Elivaldogene autotemcel', 'Lenti-D Drug substance']",,Gene drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for x-linked adrenoleukodystrophy.,,,['Orphanet_43'],1.0,['ENSG00000101986'],1,2021.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/skysona'],['https://searchusan.ama-assn.org/finder/usan/search/ELIVALDOGENE%20AUTOTEMCEL/relevant/1/'],,,
CHEMBL4650272,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1.Cl.Cl,BRCYOXKEDFAUSA-UHFFFAOYSA-N,Small molecule,False,TRILACICLIB DIHYDROCHLORIDE,4.0,False,True,['Cosela'],[],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for small cell lung carcinoma.,,,['EFO_0000702'],1.0,"['ENSG00000105810', 'ENSG00000135446']",2,2021.0,CHEMBL3894860,,,,,,,,
CHEMBL711,O=C1c2ccccc2C(=O)C1c1ccccc1,NFBAXHOPROOJAW-UHFFFAOYSA-N,Small molecule,False,PHENINDIONE,4.0,False,True,"['Dindevan', 'Hedulin']","['Danilone', 'NSC-41693', 'Phenindione', 'Phenylindanedione']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for recurrent thrombophlebitis and has 1 investigational indication.,['Phenindione'],['DB00498'],"['HP_0004419', 'EFO_0002950']",2.0,['ENSG00000167397'],1,1982.0,,,"['11112218', '11532881', '144203926', '170465130', '26748198', '26748199', '50107356', '50107357', '56423141']",['8066'],,,,,
CHEMBL1113,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,QWGDMFLQWFTERH-UHFFFAOYSA-N,Small molecule,True,AMOXAPINE,4.0,False,True,"['Amoxapine', 'Asendin', 'Asendis', 'Defanyl']","['Amoxapine', 'CL 67,772', 'CL 67772', 'CL-67,772', 'CL-67772', 'NSC-759559']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for unipolar depression. This drug has a black box warning from the FDA.,['Amoxapine'],['DB00543'],['EFO_0003761'],1.0,"['ENSG00000149295', 'ENSG00000151577', 'ENSG00000169676', 'ENSG00000069696', 'ENSG00000184845', 'ENSG00000108576', 'ENSG00000103546']",7,1980.0,,['amoxapine'],"['104171096', '11110675', '11110676', '124879022', '124879024', '144203615', '144212669', '170465376', '26747067', '26751577', '50100159', '50104205', '50104206', '85230879', '855963', '90341240']",['2675'],,,,,
CHEMBL2103796,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1.Cl,GPMIHHFZKBVWAZ-LMMKTYIZSA-N,Small molecule,False,BERUBICIN HYDROCHLORIDE,2.0,False,False,[],"['Berubicin hcl', 'Berubicin hydrochloride', 'RTA 744', 'RTA-744', 'WP-744', 'WP744']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000519', 'MONDO_0100342', 'EFO_0005543', 'EFO_0000313']",4.0,"['ENSG00000131747', 'ENSG00000077097']",2,,CHEMBL2110580,,,,,,,,
CHEMBL3617964,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1,QNQZWEGMKJBHEM-UHFFFAOYSA-N,Small molecule,False,ALVELESTAT,2.0,False,False,[],"['AZD-9668', 'AZD9668', 'Alvelestat', 'Azd9668', 'MPH-966', 'MPH966', 'Mph966']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB11863'],"['MONDO_0044881', 'HP_0002110', 'EFO_0000341', 'MONDO_0009061', 'MONDO_0100096']",5.0,['ENSG00000197561'],1,,,,,,,,,,
CHEMBL426161,COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,WPOXAFXHRJYEIC-UHFFFAOYSA-N,Small molecule,False,AZM-475271,2.0,False,False,[],"['Azm 475271', 'Azm-475271', 'M-475271']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000197122', 'ENSG00000097007']",2,,,,,,,,,,
CHEMBL4594304,Cn1cc(S(=O)(=O)[C@@](C)(F)C2CCN(C(=O)Nc3ccon3)CC2)c(C(F)F)n1,NREKKBAMVWQRES-MRXNPFEDSA-N,Small molecule,False,DANICAMTIV,2.0,False,False,[],"['Danicamtiv', 'MYK-491', 'MYK491', 'Myk-491', 'SAR-440181', 'SAR440181']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0003144', 'EFO_0000407']",2.0,"['ENSG00000092054', 'ENSG00000197616', 'ENSG00000078814', 'ENSG00000160808', 'ENSG00000111245', 'ENSG00000106631', 'ENSG00000198336']",7,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/DANICAMTIV/relevant/1/'],,,
CHEMBL1094,NC(=O)OCC(COC(N)=O)c1ccccc1,WKGXYQFOCVYPAC-UHFFFAOYSA-N,Small molecule,True,FELBAMATE,4.0,False,True,"['Felbamate', 'Felbatol', 'Taloxa']","['ADD-03055', 'Felbamate', 'NSC-759866', 'W-554']",['CHEMBL2130858'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,['Felbamate'],['DB00949'],"['MONDO_0002280', 'MONDO_0004985', 'EFO_0000474', 'HP_0001250']",4.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,1993.0,,['felbamate'],"['104171154', '11113343', '144203696', '144212685', '170465178', '50104096', '56422162', '855835', '90340922']",['4995'],,,,,
CHEMBL1201748,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,BMQGVNUXMIRLCK-OAGWZNDDSA-N,Small molecule,True,CABAZITAXEL,4.0,False,True,"['Cabazitaxel accord', 'Jevtana', 'Jevtana kit']","['Cabazitaxel', 'Cabazitaxel acetonate', 'Jevtana', 'NSC-761432', 'TXD 258', 'TXD-258', 'TXD258', 'XRP 6258', 'XRP-6258', 'XRP6258']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 7 approved and 18 investigational indications. This drug has a black box warning from the FDA.,['Cabazitaxel'],['DB06772'],"['EFO_0003085', 'MONDO_0007254', 'EFO_0001663', 'EFO_0005088', 'MONDO_0008315', 'EFO_0003060', 'EFO_0000326', 'EFO_1001094', 'EFO_1000796', 'EFO_0006859', 'EFO_0000519', 'EFO_1000601', 'MONDO_0001657', 'MONDO_0008170', 'EFO_0000702', 'EFO_0000181', 'EFO_1001951', 'EFO_0000196', 'MONDO_0004992', 'MONDO_0021259', 'MONDO_0001056', 'MONDO_0004986', 'EFO_0000673', 'EFO_0000616', 'EFO_0008528']",25.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,2010.0,,,,['63584'],['https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord'],,,,
CHEMBL1508,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,WSEQXVZVJXJVFP-FQEVSTJZSA-N,Small molecule,True,ESCITALOPRAM,4.0,False,True,['Cipralex'],"['Escitalopram', 'Esertia', 'Esitol', 'LU-26-054']",['CHEMBL1200322'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 32 investigational indications. This drug has a black box warning from the FDA.,['Escitalopram'],['DB01175'],"['MONDO_0005184', 'EFO_0003761', 'EFO_0003761', 'EFO_0000712', 'MONDO_0004992', 'EFO_0004262', 'EFO_0003047', 'EFO_0001358', 'MONDO_0004985', 'EFO_1001892', 'EFO_0000313', 'EFO_0003890', 'EFO_0009963', 'EFO_0002610', 'HP_0002381', 'EFO_0004242', 'MONDO_0002009', 'EFO_1001908', 'EFO_0005230', 'EFO_0803321', 'MONDO_0004975', 'MONDO_0002050', 'EFO_1001892', 'EFO_0003884', 'MONDO_0005149', 'MONDO_0002491', 'MONDO_0002009', 'MONDO_0002050', 'HP_0012076', 'EFO_0005687', 'EFO_1001917', 'HP_0000726', 'EFO_0010282', 'EFO_1001919', 'MONDO_0005090', 'EFO_0006788', 'EFO_0000685', 'EFO_0000555']",38.0,['ENSG00000108576'],1,2002.0,,,"['11110983', '11114081', '124879737', '50100207']",['36791'],,,,,
CHEMBL1569,Cl.NC12CC3CC(CC(C3)C1)C2,WOLHOYHSEKDWQH-UHFFFAOYSA-N,Small molecule,False,AMANTADINE HYDROCHLORIDE,4.0,False,True,"['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex er', 'Symadine', 'Symmetrel']","['Adamantanamine hydrochloride', 'Amantadine hcl', 'Amantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 8 investigational indications.,,,"['EFO_1001175', 'EFO_0004247', 'HP_0001300', 'EFO_0007328', 'EFO_0003047', 'MONDO_0004976', 'MONDO_0005301', 'MONDO_0005090', 'EFO_0000544', 'EFO_1001402', 'EFO_1000860', 'MONDO_0043510', 'MONDO_0100096', 'MONDO_0005180', 'EFO_0005411']",15.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,1968.0,CHEMBL660,['amantadine%20hydrochloride'],"['26747411', '26747412', '50105719', '50105720']",['2619'],,,,,
CHEMBL159226,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,VRYMTAVOXVTQEF-UHFFFAOYSA-N,Small molecule,False,MOXISYLYTE,4.0,False,True,"['Erecnos', 'Moxivig']","['Acetoxythymoxamine', 'Carlytene', 'Moxisylyte', 'Moxisylyte hcl', 'Moxisylyte hydrochloride', 'NSC-170448', 'Thymoxamine', 'Thymoxamine hcl', 'Thymoxamine hydrochloride']",['CHEMBL1256739'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and erectile dysfunction.,,['DB09205'],"['EFO_0000319', 'EFO_0004234']",2.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,,,,"['11111464', '11111465', '90340735']",,,,['61'],,
CHEMBL1698,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,HEYVINCGKDONRU-UHFFFAOYSA-N,Small molecule,True,BUPROPION HYDROCHLORIDE,4.0,False,True,"['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100', 'Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']","['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HCl', 'Bupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0005203', 'MONDO_0002009', 'MONDO_0008903', 'EFO_0003768', 'MONDO_0002050', 'EFO_0003761', 'EFO_0004319', 'MONDO_0007079', 'EFO_0009963', 'EFO_0004318', 'EFO_0001073', 'MONDO_0010200', 'MONDO_0007254', 'MONDO_0004985', 'EFO_0004247']",15.0,"['ENSG00000103546', 'ENSG00000142319']",2,1985.0,CHEMBL894,['bupropion%20hydrochloride'],"['144204172', '144212161', '170464747', '26747451', '49681824', '50105906', '573995', '855813']",,,,,,
CHEMBL2107387,Br.Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,VNGRUFUIHGGOOM-UHFFFAOYSA-N,Small molecule,True,VORTIOXETINE HYDROBROMIDE,4.0,False,True,"['Brintellix', 'Trintellix']","['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromide', 'Vortioxetine hydrobromide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for unipolar depression and major depressive disorder. This drug has a black box warning from the FDA.,,,"['EFO_0003761', 'MONDO_0002009']",2.0,"['ENSG00000108576', 'ENSG00000166736', 'ENSG00000178394']",3,2013.0,CHEMBL2104993,['vortioxetine%20hydrobromide'],,['76015'],['https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix'],,,,
CHEMBL2107861,,,Antibody,False,ZALUTUMUMAB,3.0,False,False,[],"['2F8', 'HUMAX-EGFR, 2F8', 'HUMAX-EGFR-2F8', 'HuMax-EGFr', 'Zalutumumab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['EFO_0000707', 'EFO_0004284', 'EFO_0003060', 'EFO_0006859', 'EFO_1001951']",5.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL2108354,,,Antibody,False,UBLITUXIMAB,4.0,False,True,['Briumvi'],"['Briumvi', 'TG-1101', 'Ublituximab', 'Ublituximab xiiy', 'Ublituximab-xiiy']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 8 investigational indications.,,,"['MONDO_0005301', 'EFO_0009441', 'EFO_0004256', 'EFO_1001469', 'MONDO_0018906', 'EFO_0000403', 'EFO_0003840', 'EFO_0000095', 'EFO_0003929', 'EFO_0000096', 'EFO_0000540']",11.0,['ENSG00000156738'],1,2022.0,,,,,,,,,
CHEMBL2108592,,,Antibody drug conjugate,False,EPITUMOMAB CITUXETAN,2.0,False,False,[],"['Epitumomab cituxetan', 'Hmfg 1']",,Antibody drug conjugate drug with a maximum clinical trial phase of II.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL29741,CN(C)CCOc1ccccc1-c1nc(-c2ccccc2)no1,QZULPCPLWGCGSL-UHFFFAOYSA-N,Small molecule,False,IRAMPANEL,2.0,False,False,[],"['BIIR 561', 'BIIR-561', 'BIIR-561 CL', 'Irampanel']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",14,,,,,,,,,,
CHEMBL4297648,[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1,LNLJHGXOFYUARS-OAQYLSRUSA-N,Small molecule,False,SELETALISIB,2.0,False,False,[],"['Seletalisib', 'UCB-5857', 'UCB5857', 'Ucb5857']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12706'],"['EFO_0000699', 'EFO_0000676']",2.0,['ENSG00000171608'],1,,,,,,,,,,
CHEMBL4802176,,,Unknown,False,ONO-5334,2.0,False,False,[],"['ONO-5334', 'Ono-5334']",,Unknown drug with a maximum clinical trial phase of II.,,,,,['ENSG00000143387'],1,,,,,,,,,,
CHEMBL481611,CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1,FWIVDMJALNEADT-SFTDATJTSA-N,Small molecule,False,ODANACATIB,3.0,False,False,[],"['MK-0822', 'MK0822', 'Odanacatib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,['Odanacatib'],['DB06670'],"['EFO_0003854', 'MONDO_0005178', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0003882', 'HP_0000083']",6.0,['ENSG00000143387'],1,,,,,,,,,,
CHEMBL956,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1,MDKGKXOCJGEUJW-UHFFFAOYSA-N,Small molecule,False,SUPROFEN,4.0,True,True,['Profenal'],"['NSC-303611', 'P-(2-thenoyl)hydratropic acid', 'P-2-thenoylhydratropic acid', 'R-25,061', 'R-25061', 'Racemic suprofen', 'Srendam', 'Sulproltin', 'Suprofen', 'Sutoprofen', 'TN-762', 'Topalgic']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for rheumatic disease. It was withdrawn in at least one region.,['Suprofen'],['DB00870'],['EFO_0005755'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,1985.0,,,"['144204194', '170465412', '26748525', '56463227']",['9362'],,,,,
CHEMBL1200328,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl,BFFSMCNJSOPUAY-LMOVPXPDSA-N,Small molecule,True,DULOXETINE HYDROCHLORIDE,4.0,False,True,"['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'Duciltia', 'Duloxetine hydrochloride', 'Duloxetine zentiva', 'Yentreve']","['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hcl', 'Duloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCL', 'LY248686 HCL', 'NSC-759112', 'Xeristar']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 9 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0012532', 'MONDO_0002050', 'HP_0000020', 'EFO_0003761', 'MONDO_0002009', 'EFO_0005230', 'EFO_0005762', 'EFO_1001951', 'MONDO_0005301', 'EFO_0003843', 'EFO_0006788', 'MONDO_0005178', 'EFO_0001358', 'EFO_0002970', 'EFO_1000783', 'EFO_0005687']",16.0,"['ENSG00000103546', 'ENSG00000108576']",2,2004.0,CHEMBL1175,['duloxetine%20hydrochloride'],"['144205741', '170465319', '49681598']",['31526'],['https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-zentiva'],,,,
CHEMBL1615369,CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O,XETBXHPXHHOLOE-UHFFFAOYSA-N,Small molecule,True,DABIGATRAN ETEXILATE MESYLATE,4.0,False,True,['Pradaxa'],"['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilate', 'Dabigatran etexilate mesylate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0010726', 'EFO_0000275', 'EFO_0003827', 'EFO_0000712', 'EFO_0004286', 'EFO_0003907', 'EFO_1000652']",7.0,['ENSG00000180210'],1,2008.0,CHEMBL539697,['dabigatran%20etexilate%20mesylate'],,['70743'],['https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa'],,,,
CHEMBL2103797,Cc1cn([C@H]2C[C@H](OP(=O)([O-])OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],JKXXLIACMWFHSH-FIIWBELYSA-A,Oligonucleotide,False,BEVASIRANIB SODIUM,-1.0,False,False,[],"['Bevasiranib sodium', 'CAND5']",,Oligonucleotide drug.,,,,,"['ENSG00000112715', 'ENSG00000164342']",2,,CHEMBL2110581,,,,,,,,
CHEMBL3545132,,,Antibody drug conjugate,False,MIRVETUXIMAB SORAVTANSINE,4.0,False,True,['Elahere'],"['Elahere', 'IMGN-853', 'IMGN853', 'Mirvetuximab soravtansine', 'Mirvetuximab soravtansine gynx', 'Mirvetuximab soravtansine-gynx']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 4 approved and 5 investigational indications.,,,"['EFO_1001100', 'MONDO_0011962', 'MONDO_0018364', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0002158', 'MONDO_0008170', 'EFO_0005537', 'MONDO_0021092']",9.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000110195']",16,2022.0,,,,,,,,,
CHEMBL3545381,,,Small molecule,False,PLX-7486,1.0,False,False,[],['Plx-7486'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0002171'],1.0,"['ENSG00000198400', 'ENSG00000140538', 'ENSG00000182578', 'ENSG00000148053']",4,,,,,,,,,,
CHEMBL4297232,,,Unknown,False,DICLOFENAC ETALHYALURONATE SODIUM,-1.0,False,False,[],"['Diclofenac etalhyaluronate sodium', 'SI-613 SODIUM']",,Unknown drug.,,,,,"['ENSG00000073756', 'ENSG00000095303']",2,,,,,,,,,,
CHEMBL4297728,,,Antibody,False,CIRMTUZUMAB,3.0,False,False,[],"['Cirmtuzumab', 'UC-961', 'Zilovertamab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,,"['MONDO_0001056', 'EFO_0002618', 'EFO_0003060', 'MONDO_0008170', 'EFO_0008528', 'EFO_0000096', 'MONDO_0008315', 'EFO_0005537', 'EFO_0000403', 'EFO_0000095']",10.0,['ENSG00000185483'],1,,,,,,,,,,
CHEMBL4298212,,,Antibody,False,RAVAGALIMAB,2.0,False,False,[],"['ABBV-323', 'PR-1629977', 'Ravagalimab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000729', 'EFO_0000699', 'EFO_0005809', 'MP_0001845']",4.0,['ENSG00000102245'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/RAVAGALIMAB/relevant/1/'],,,
CHEMBL4594311,,,Gene,False,BETIBEGLOGENE AUTOTEMCEL,4.0,False,True,['Zynteglo'],"['BB-305', 'Betibeglogene autotemcel', 'LentiGlobin BB305', 'Zynteglo']",,Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for beta-thalassemia and beta-thalassemia major and has 1 investigational indication.,,,"['MONDO_0011382', 'Orphanet_848', 'MONDO_0016486']",3.0,['ENSG00000244734'],1,2019.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo'],,,,
CHEMBL4650230,CN1CCC2(CC1)NCC(=O)N2Cc1ccccc1,BSQPTZYKCAULBH-UHFFFAOYSA-N,Small molecule,False,SIMUFILAM,3.0,False,False,['Filora'],"['C-0105', 'C0105', 'C0105M', 'PTI-125', 'PTI-910', 'Simufilam']",['CHEMBL4650231'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['MONDO_0004975', 'MONDO_0004975', 'EFO_0000616', 'EFO_0000616']",4.0,['ENSG00000196924'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SIMUFILAM/relevant/1/'],,,
CHEMBL522892,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,PIQCTGMSNWUMAF-UHFFFAOYSA-N,Small molecule,False,DOVITINIB,3.0,False,False,[],"['CHIR-258', 'Dovitinib', 'GFKI-258', 'NVP-TKI258', 'TKI-258', 'Tki-258']",['CHEMBL4297063'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 25 investigational indications.,,['DB05928'],"['EFO_0000182', 'MONDO_0008667', 'EFO_0000222', 'MONDO_0008315', 'EFO_1001465', 'MONDO_0011719', 'MONDO_0005184', 'EFO_0001378', 'MONDO_0007254', 'MONDO_0001187', 'EFO_0003060', 'EFO_0000231', 'EFO_1000796', 'EFO_0003060', 'MONDO_0002108', 'EFO_0000519', 'EFO_0000756', 'MONDO_0001056', 'EFO_0000770', 'EFO_0000349', 'MONDO_0004992', 'MONDO_0011962', 'EFO_0000681', 'EFO_0000616', 'EFO_0003863']",25.0,"['ENSG00000122025', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000068078', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404']",8,,,,"['103904684', '137275871', '50100092']",,,,,,
CHEMBL1046,NCCCCCC(=O)O,SLXKOJJOQWFEFD-UHFFFAOYSA-N,Small molecule,False,AMINOCAPROIC ACID,4.0,False,True,"['Amicar', 'Aminocaproic', 'Aminocaproic acid', 'Epsikapron']","['.epsilon.-aminocaproic acid', '177 J.D', '177 J.D.', '177 JD', '177-JD', '6-aminocaproic acid', 'Aminocaproic acid', 'CL 10304', 'CL-10304', 'CY-116', 'EACA', 'Epsilcapramin', 'Epsilon-aminocaproic acid', 'Hexanoic acid, 6-amino-', 'NSC-26154', 'NSC-400230']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for hemorrhage and has 4 investigational indications.,['Aminocaproic_acid'],['DB00513'],"['EFO_0005775', 'MP_0001914', 'EFO_1000760', 'MONDO_0015469', 'MP_0001845']",5.0,"['ENSG00000104368', 'ENSG00000122194']",2,1964.0,,['aminocaproic%20acid'],"['11110778', '11110779', '144203632', '170465057', '174007004', '26747439', '26747440', '50105811', '50105812', '57260392', '85230919', '90341441']",['16586'],,,,,
CHEMBL1200440,Cc1cccc(C)c1NC(=O)C1CCCCN1C.Cl,RETIMRUQNCDCQB-UHFFFAOYSA-N,Small molecule,False,MEPIVACAINE HYDROCHLORIDE,4.0,False,True,"['Arestocaine hydrochloride', 'Carbocaine', 'Isocaine hydrochloride', 'Mepivacaine hydrochloride', 'Polocaine', 'Polocaine-mpf', 'Scandicaine', 'Scandonest', 'Scandonest plain']","['Mepivacaine hcl', 'Mepivacaine hydrochloride', 'Mepivacaine monohydrochloride', 'NSC-758674', 'Optocain', 'Scandicain']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1960.0,CHEMBL1087,['mepivacaine%20hydrochloride'],"['144204977', '26748921', '56424124']",['6760'],,,,,
CHEMBL1256,FC(F)OC(Cl)C(F)(F)F,PIWKPBJCKXDKJR-UHFFFAOYSA-N,Small molecule,False,ISOFLURANE,4.0,False,True,"['Aerrane', 'Forane', 'Isoflurane']","['COMPOUND 469', 'COMPOUND-469', 'Isoflurane']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 6 investigational indications.,['Isoflurane'],['DB00753'],"['EFO_0005611', 'HP_0000023', 'EFO_0009686', 'MONDO_0100096', 'EFO_0000713', 'EFO_0003777']",6.0,"['ENSG00000100433', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000082482', 'ENSG00000169427', 'ENSG00000171303', 'ENSG00000145888', 'ENSG00000109738', 'ENSG00000186795']",23,1979.0,,['isoflurane'],"['144206238', '144208029', '50125772']",['6015'],,,,,
CHEMBL1274,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,XWXYUMMDTVBTOU-UHFFFAOYSA-N,Small molecule,True,NILUTAMIDE,4.0,False,True,"['Anadron', 'Nilandron', 'Nilutamide']","['NSC-758683', 'Nilutamide', 'RU 23908', 'RU-23908']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA.,['Nilutamide'],['DB00665'],"['MONDO_0008315', 'MONDO_0008315', 'EFO_0000196', 'EFO_0000673', 'EFO_0000616']",5.0,['ENSG00000169083'],1,1996.0,,['nilutamide'],"['104171203', '11111555', '11111556', '11114201', '124880925', '124880926', '144203764', '144211906', '170465021', '174007285', '26747174', '26747175', '26752242', '50104947', '50104948', '50104949', '50104950', '56463082', '85231160', '90341288']",['7573'],,,,,
CHEMBL1683590,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C,UFNVPOGXISZXJD-JBQZKEIOSA-N,Small molecule,False,ERIBULIN,4.0,False,True,['Halaven'],"['ER-086526', 'Eribulin']","['CHEMBL1683544', 'CHEMBL3526882']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 33 investigational indications.,,['DB08871'],"['MONDO_0001187', 'EFO_0000569', 'MONDO_0004992', 'EFO_0008528', 'MONDO_0004669', 'EFO_0006859', 'Orphanet_145', 'EFO_1001968', 'EFO_0000681', 'EFO_0002617', 'MONDO_0004192', 'EFO_0000691', 'EFO_1000251', 'MONDO_0015523', 'MONDO_0002974', 'EFO_0000389', 'EFO_0000305', 'MONDO_0007254', 'EFO_0005537', 'MONDO_0007254', 'EFO_0001075', 'MONDO_0004992', 'EFO_0003968', 'EFO_0003060', 'EFO_0000616', 'EFO_0000574', 'EFO_0000637', 'EFO_1000984', 'EFO_0000616', 'EFO_0000673', 'EFO_0006861', 'MONDO_0021632', 'MONDO_0016238', 'EFO_0000305', 'EFO_1000613', 'EFO_0003869', 'EFO_0003060', 'EFO_0005537', 'MONDO_0008315']",39.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,2010.0,,,,['63587'],,,,,
CHEMBL3545091,,,Small molecule,False,XEN403,1.0,False,False,[],['Xen403'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000169432'],1,,,,,,,,,,
CHEMBL3545232,Cc1ccc(-c2ccc(OC3CN4CCC3CC4)cn2)cc1,NPDLTEZXGWRMLQ-UHFFFAOYSA-N,Small molecule,False,AQW051,2.0,False,False,[],['Aqw051'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0005090', 'HP_0100543', 'MONDO_0004975']",3.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL3833307,,,Antibody,False,SATRALIZUMAB,4.0,False,True,['Enspryng'],"['RG6168', 'SA-237', 'SA237', 'Sapelizumab', 'Satralizumab', 'Satralizumab mwge', 'Satralizumab-mwge']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for immune system disease and neuromyelitis optica and has 3 investigational indications.,,,"['EFO_0000540', 'EFO_0004256', 'EFO_0004991', 'EFO_0007332', 'EFO_0001361']",5.0,"['ENSG00000160712', 'ENSG00000134352']",2,2020.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/enspryng'],,,,
CHEMBL4072833,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,QUIWHXQETADMGN-UHFFFAOYSA-N,Small molecule,False,EVOBRUTINIB,3.0,False,False,[],"['Evobrutinib', 'M-2951', 'M2951', 'Msc-2364447c', 'Msc2364447c']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,['DB15170'],"['EFO_0003929', 'EFO_0000685', 'MONDO_0005301', 'EFO_0003086', 'MONDO_0007915']",5.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/EVOBRUTINIB/relevant/1/'],,,
CHEMBL428690,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,BIIVYFLTOXDAOV-YVEFUNNKSA-N,Small molecule,False,ALVOCIDIB,3.0,False,False,[],"['Alvocidib', 'Alvocidib freebase', 'Flavopiridol', 'HL 275', 'HL-275', 'HMR 1275', 'HMR-1275', 'L 86 8275', 'L-868275', 'L86-8275', 'MDL 107,826A', 'MDL-107826A', 'NSC-649890']",['CHEMBL2105698'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,['Alvocidib'],['DB03496'],"['EFO_0001378', 'MONDO_0007254', 'EFO_1001469', 'EFO_0009441', 'EFO_0000095', 'EFO_0000616', 'EFO_0000222', 'MONDO_0018906', 'EFO_0000222', 'EFO_0000691', 'EFO_0000191', 'EFO_0000565', 'EFO_0006861', 'MONDO_0008315', 'MONDO_0001023', 'EFO_0001642', 'MONDO_0007576', 'MONDO_0002691', 'EFO_0000403', 'EFO_0000389', 'EFO_0001378', 'EFO_0000095', 'EFO_0000574', 'MONDO_0001023', 'MONDO_0002367', 'MONDO_0011962']",26.0,"['ENSG00000105810', 'ENSG00000135446', 'ENSG00000170312', 'ENSG00000134058', 'ENSG00000136807', 'ENSG00000123374']",6,,,,,,,,,,
CHEMBL4297268,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,AHXICHPPXIGCBN-GPWPDEGDSA-N,Small molecule,False,BMS-275183,2.0,False,False,[],"['Bms 275183', 'Bms-275183']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12144'],"['EFO_0000616', 'EFO_0003060']",2.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL1200710,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21.Cl,WIMWMKZEIBHDTH-UHFFFAOYSA-N,Small molecule,True,CLOMIPRAMINE HYDROCHLORIDE,4.0,False,True,"['Anafranil', 'Anafranil sr', 'Chlorimipramine', 'Clomicalm', 'Clomipramine hydrochloride', 'Tranquax']","['Clomipramine hcl', 'Clomipramine hydrochloride', 'G 34586', 'G-34586', 'NSC-759323']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for obsessive-compulsive disorder and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['MONDO_0002050', 'EFO_0004242']",2.0,['ENSG00000108576'],1,1989.0,CHEMBL415,['clomipramine%20hydrochloride'],"['144212136', '26747483', '50106071', '56422907', '855785']",['3755'],['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/clomicalm'],,,,
CHEMBL1277001,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1,ULRDYYKSPCRXAJ-KRWDZBQOSA-N,Small molecule,False,MIBAMPATOR,2.0,False,False,[],"['LY 451395', 'LY-451395', 'LY451395', 'Mibampator']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12717'],['MONDO_0004975'],1.0,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,,,,
CHEMBL3545174,,,Small molecule,False,GSK2881078,2.0,False,False,[],['Gsk2881078'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['HP_0004326'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL1373,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,YFGHCGITMMYXAQ-UHFFFAOYSA-N,Small molecule,False,MODAFINIL,4.0,False,True,"['Modafinil', 'Provigil']","['CEP 1538', 'CEP-1538', 'CRC-40476', 'CRL 40476', 'CRL-40476', 'DEP-1538', 'Modafinil', 'Modafinil civ', 'Modaphonil', 'Modiodal', 'NSC-751178', 'NSC-759110', 'THN-102 COMPONENT MODAFINIL', 'THN102 COMPONENT MODAFINIL']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 32 investigational indications.,['Modafinil'],['DB00745'],"['EFO_0004698', 'EFO_0003925', 'EFO_0003768', 'HP_0100543', 'EFO_0002610', 'EFO_0007454', 'MONDO_0002050', 'MONDO_0005180', 'EFO_0008568', 'EFO_0005411', 'EFO_0005252', 'HP_0000360', 'EFO_0003833', 'EFO_0004701', 'MONDO_0008170', 'HP_0003419', 'EFO_0005611', 'EFO_0002617', 'MONDO_0004975', 'EFO_0003877', 'EFO_0003918', 'MONDO_0002491', 'EFO_0001358', 'EFO_0000712', 'MONDO_0016158', 'EFO_0000756', 'MONDO_0005090', 'HP_0002015', 'EFO_0003890', 'MONDO_0021107', 'HP_0012378', 'MONDO_0007079', 'EFO_0003888', 'MONDO_0005301', 'EFO_0000174', 'MONDO_0002009']",36.0,['ENSG00000142319'],1,1998.0,,['modafinil'],"['144205023', '170465042', '26719679', '26749058', '26753746']",['77585'],,,,,
CHEMBL440,C=CCC1(C(C)CCC)C(=O)NC(=S)NC1=O,XLOMZPUITCYLMJ-UHFFFAOYSA-N,Small molecule,False,THIAMYLAL,4.0,False,True,[],"['NSC-120815', 'Thiamylal']",['CHEMBL1201065'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Thiamylal'],['DB01154'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,,,['9536'],,,,,
CHEMBL4594262,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=C(O)c1ccccc1,RVPCEXXEUXIPEO-UHFFFAOYSA-N,Small molecule,False,AMLODIPINE BENZOATE,4.0,False,True,['Katerzia'],[],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hypertension.,,,['EFO_0000537'],1.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,2019.0,CHEMBL1491,['amlodipine%20benzoate'],,,,,,,
CHEMBL512351,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1,XHOLNRLADUSQLD-UHFFFAOYSA-N,Small molecule,True,BETRIXABAN,4.0,False,True,['Bevyxxa'],"['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for venous thromboembolism and recurrent thrombophlebitis and has 6 investigational indications. This drug has a black box warning from the FDA.,['Betrixaban'],['DB12364'],"['EFO_0000275', 'EFO_0001421', 'EFO_0003911', 'EFO_0003086', 'EFO_0004286', 'HP_0001907', 'MP_0001914', 'HP_0004419']",8.0,['ENSG00000126218'],1,2017.0,,,,,,,,,
CHEMBL1082407,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,WXCXUHSOUPDCQV-UHFFFAOYSA-N,Small molecule,False,ENZALUTAMIDE,4.0,False,True,['Xtandi'],"['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']",['CHEMBL4594421'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 17 investigational indications.,,['DB08899'],"['EFO_1001469', 'EFO_0007532', 'EFO_0001421', 'MONDO_0008315', 'EFO_0001663', 'MONDO_0008315', 'EFO_0000349', 'EFO_0003086', 'MONDO_0004992', 'MONDO_0008170', 'MONDO_0008315', 'EFO_0000673', 'EFO_0000616', 'MONDO_0100096', 'EFO_0000196', 'EFO_0002618', 'EFO_0000182', 'EFO_0000616', 'MONDO_0100096', 'EFO_0005537', 'MONDO_0001187', 'EFO_0000313', 'MONDO_0007254']",23.0,['ENSG00000169083'],1,2012.0,,['enzalutamide'],['137275964'],['68534'],['https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi'],,,,
CHEMBL1200595,CC(C)(N)Cc1ccc(Cl)cc1.Cl,WEJDYJKJPUPMLH-UHFFFAOYSA-N,Small molecule,False,CHLORPHENTERMINE HYDROCHLORIDE,4.0,True,True,['Pre-sate'],"['Chlorphentermine hcl', 'Chlorphentermine hydrochloride', 'NSC-76098', 'S-62', 'W 2426', 'W-2426']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982. It was withdrawn in at least one region.,,,,,['ENSG00000108576'],1,1982.0,CHEMBL1201269,,"['144205357', '170465307']",,,,,,
CHEMBL1280,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC.Cl,DOQPXTMNIUCOSY-UHFFFAOYSA-N,Small molecule,False,VERAPAMIL HYDROCHLORIDE,4.0,False,True,"['Berkatens', 'Calan', 'Calan sr', 'Cordilox', 'Cordilox i.v.', 'Cordilox mr 240', 'Covera-hs', 'Ethimil mr 240', 'Geangin', 'Half securon sr', 'Isoptin', 'Isoptin Sr', 'Manidon sr', 'Ranvera mr', 'Securon', 'Securon iv', 'Securon mid', 'Securon sr', 'Univer', 'Vera-til sr', 'Verapamil hydrochloride', 'Verapress mr 240', 'Verelan', 'Verelan pm', 'Vertab sr 240', 'Zolvera']","['CP-16533-1', 'LU-20175', 'NSC-272366', 'NSC-657799', 'Verapamil hcl', 'Verapamil hydrochloride', 'Verapamili hydrochloridum']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 4 investigational indications.,,,"['EFO_0000319', 'EFO_0004269', 'EFO_0000400', 'EFO_0003144', 'EFO_0000183', 'EFO_0000275', 'EFO_0000537']",7.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1981.0,CHEMBL6966,['verapamil%20hydrochloride'],"['144208378', '17388668', '26747697', '26747698', '49718106', '50107178', '50107179', '50107180', '507863', '856000']",,,,,,
CHEMBL15870,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,RJMIEHBSYVWVIN-UHFFFAOYSA-N,Small molecule,False,INDOPROFEN,4.0,True,True,[],"['Bor-ind', 'Flosin', 'Flosint', 'Indoprofen', 'Isindone', 'K 4277', 'K-4277', 'NSC-757065', 'Praxis', 'Reumofene']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for rheumatic disease. It was withdrawn in at least one region.,['Indoprofen'],['DB08951'],['EFO_0005755'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,1979.0,,,"['11532964', '144204869', '26748086']",['76162'],,,,,
CHEMBL2107890,,,Antibody drug conjugate,False,TAPLITUMOMAB PAPTOX,2.0,False,False,[],['Taplitumomab paptox'],,Antibody drug conjugate drug with a maximum clinical trial phase of II.,,,,,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL23261,COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1,FEJVSJIALLTFRP-LJQANCHMSA-N,Small molecule,False,DARUSENTAN,3.0,False,False,[],"['Darusentan', 'HMR-4005', 'LU-135252', 'Lu-135252']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,['Darusentan'],['DB04883'],['EFO_0000537'],1.0,"['ENSG00000151617', 'ENSG00000136160']",2,,,,['170466416'],,,,,,
CHEMBL3137308,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2,DREIJXJRTLTGJC-ZLBJMMTISA-N,Small molecule,False,PEFICITINIB,4.0,False,True,[],"['ASP-015K', 'ASP015K', 'Asp-015k', 'JNJ-54781532', 'Peficitinib']",['CHEMBL3137329'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 6 investigational indications.,,,"['EFO_0003086', 'EFO_0000676', 'EFO_0000540', 'EFO_0001421', 'EFO_0000729', 'EFO_0000685']",6.0,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",4,2019.0,,,,,,,,,
CHEMBL384304,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,JRNJNYBQQYBCLE-UHFFFAOYSA-N,Small molecule,False,RG-547,2.0,False,False,[],"['R 547', 'R-547', 'RG-547', 'RO4584820', 'Rg-547', 'Ro 4584820', 'Ro-4584820']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB08094'],['EFO_0000616'],1.0,"['ENSG00000135446', 'ENSG00000123374', 'ENSG00000170312']",3,,,,,,,,,,
CHEMBL3989703,O.O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,LNDYQNTTYXLTNH-RTBBDAMFSA-N,Small molecule,False,TEZAMPANEL,2.0,False,False,[],"['LY293558', 'Tezampanel', 'Tezampanel hydrate']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000171189', 'ENSG00000105737', 'ENSG00000149403', 'ENSG00000164418', 'ENSG00000163873', 'ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",9,,CHEMBL14935,,,,,,,,
CHEMBL3989973,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,CJLUYLRKLUYCEK-UHFFFAOYSA-N,Small molecule,True,PEXIDARTINIB HYDROCHLORIDE,4.0,False,True,['Turalio'],"['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for tenosynovial giant cell tumor. This drug has a black box warning from the FDA.,,,['EFO_1000562'],1.0,"['ENSG00000122025', 'ENSG00000182578', 'ENSG00000157404']",3,2019.0,CHEMBL3813873,,,,,,,,
CHEMBL4085457,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,CBRJPFGIXUFMTM-WDEREUQCSA-N,Small molecule,True,RITLECITINIB,4.0,False,True,[],"['PF-06651600', 'Pf-06651600', 'Ritlecitinib']",['CHEMBL5314649'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for alopecia areata and has 12 investigational indications. This drug has a black box warning from the FDA.,,['DB14924'],"['EFO_1001051', 'EFO_0000384', 'EFO_0004192', 'EFO_1000785', 'EFO_0001421', 'EFO_0001060', 'EFO_0003086', 'EFO_0004192', 'EFO_0000729', 'EFO_0004208', 'MONDO_0005147', 'EFO_0000685', 'EFO_1002028']",13.0,"['ENSG00000105639', 'ENSG00000113263', 'ENSG00000102010', 'ENSG00000135605', 'ENSG00000074966', 'ENSG00000010671']",6,2023.0,,,,,,,,,
CHEMBL4297260,CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@@H](C(=O)N(C)[C@H](C(N)=O)[C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O,MUSGYEMSJUFFHT-UWABRSFTSA-N,Protein,False,AMY-101,2.0,False,False,[],"['Amy 101', 'Amy-101', 'Compstatin 40', 'Compstatin analog peptide cp40']",,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0002508'],1.0,['ENSG00000125730'],1,,,,,,,,,,
CHEMBL1096979,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,BNQDCRGUHNALGH-UHFFFAOYSA-N,Small molecule,False,BENSERAZIDE,4.0,False,True,[],"['Benserazide', 'Benserazide (as hydrochloride)', 'Benserazide hcl', 'Benserazide hydrochloride', 'NSC-755907', 'RO 4-4602', 'RO-4-4602', 'Serazide']",['CHEMBL1255778'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,['Benserazide'],['DB12783'],"['EFO_0004270', 'MONDO_0005180']",2.0,['ENSG00000132437'],1,,,,"['174006784', '90341370']",['64187'],,,,,
CHEMBL207538,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,AURFZBICLPNKBZ-SYBPFIFISA-N,Small molecule,True,BREXANOLONE,4.0,False,True,['Zulresso'],"['Allopregnan-3.alpha.-ol-20-one', 'Allopregnanolone', 'Allotetrahydroprogesterone', 'Brexanolone', 'SAGE-547', 'SGE-102']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,['DB11859'],"['MONDO_0004975', 'EFO_0007453', 'MONDO_0002050', 'HP_0000360', 'MONDO_0043510', 'EFO_0003761', 'EFO_0008526', 'EFO_0003108', 'EFO_0001358', 'EFO_0005407', 'MONDO_0007079']",11.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,2019.0,,['brexanolone'],"['144205595', '26756639']",['50169'],,,,,
CHEMBL2106829,Cc1ccccc1-n1c(C)nc2ccccc2c1=O.Cl,KJUHIXIWKSVBKB-UHFFFAOYSA-N,Small molecule,False,METHAQUALONE HYDROCHLORIDE,4.0,True,True,[],"['Methaqualone hcl', 'Methaqualone hydrochloride', 'NSC-75892']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,CHEMBL282052,,,,,,,,
CHEMBL3542265,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,IHIWYQYVBNODSV-KRWDZBQOSA-N,Small molecule,False,LY2452473,2.0,False,False,[],"['LY-2452473', 'LY2452473', 'Ly2452473', 'OPK-88004', 'TT-701']",['CHEMBL3542296'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB12573'],"['MONDO_0008315', 'EFO_0004234', 'EFO_0000284']",3.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL504652,c1cncc(N2CCC3(CCCN3)C2)c1,NXIPMBQVNTWEEX-UHFFFAOYSA-N,Small molecule,False,TC-2216,1.0,False,False,[],"['TC-2216', 'Tc-2216']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['MONDO_0002050', 'EFO_0005230']",2.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL105442,O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,GFMMXOIFOQCCGU-UHFFFAOYSA-N,Small molecule,False,CI-1040,2.0,False,False,[],"['CI-1040', 'Ci 1040', 'Ci-1040', 'PD-18435', 'PD-184352']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB12429'],"['EFO_0002618', 'EFO_0003860', 'EFO_1001951', 'EFO_0004142', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0003060', 'EFO_0003869']",8.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,"['144206914', '170466835', '174006413']",,,,,,
CHEMBL1200748,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O,QTAOMKOIBXZKND-PPHPATTJSA-N,Small molecule,False,CARBIDOPA,4.0,False,True,"['Carbidopa', 'Lodosyn']","['Carbidopa', 'Carbidopa component of carbilev', 'Carbidopa component of parcopa', 'Carbidopa component of sinemet', 'Carbidopa hydrate', 'Carbidopa monohydrate', 'Carbidopum monohydrate', 'Lodosyn', 'MK-486', 'NSC-751137', 'NSC-758190']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 23 investigational indications.,,,"['EFO_0000712', 'EFO_1001919', 'EFO_0003770', 'Orphanet_1764', 'EFO_0002610', 'EFO_1001402', 'EFO_0000546', 'EFO_0003768', 'MONDO_0005301', 'MONDO_0007113', 'MONDO_0018910', 'HP_0002381', 'EFO_0005252', 'EFO_0005687', 'MONDO_0004979', 'HP_0012532', 'MONDO_0005180', 'HP_0003418', 'EFO_0000537', 'MONDO_0019200', 'EFO_0003888', 'MONDO_0005090', 'EFO_1001175', 'MONDO_0001020', 'EFO_0003843', 'MONDO_0004976', 'EFO_0001365']",27.0,['ENSG00000132437'],1,1975.0,CHEMBL1201236,['carbidopa'],,['3395'],,,,,
CHEMBL2109495,,,Antibody,False,E2.3,1.0,False,False,[],['E2.3'],,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,,"['EFO_0000198', 'EFO_0000565', 'EFO_0001378', 'EFO_0002428']",4.0,"['ENSG00000072274', 'ENSG00000106327']",2,,,,,,,,,,
CHEMBL2111100,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC,JMUHBNWAORSSBD-WKYWBUFDSA-N,Small molecule,False,MIFAMURTIDE ACID,4.0,False,True,[],"['CGP-19835', 'Mifamurtide free acid anhydrous']",['CHEMBL2107354'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications.,,,"['MONDO_0002629', 'EFO_0000637', 'EFO_0000616']",3.0,['ENSG00000167207'],1,2009.0,,,,,,,,,
CHEMBL3686884,CNC(=O)n1ccc2cc(Oc3ccnc(NC(=O)c4ccc(C5CCN(CCO)CC5)cc4)c3)c(OCCOC)cc21,IBHOLSBDZMIPPT-UHFFFAOYSA-N,Small molecule,False,E-7090,2.0,False,False,[],"['E 7090', 'E-7090', 'E7090', 'Tasurgratinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0005221', 'EFO_0003869', 'EFO_0001421', 'EFO_0000616']",4.0,"['ENSG00000066468', 'ENSG00000077782', 'ENSG00000068078']",3,,,,,,,,,,
CHEMBL3707359,,,Unknown,False,DAXIBOTULINUMTOXINA,4.0,False,True,['Daxxify'],"['Daxibotulinumtoxina', 'RTI-150', 'RTI150', 'RTT150']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for skin aging and has 1 investigational indication.,,,"['HP_0000473', 'EFO_0005422']",2.0,['ENSG00000132639'],1,2022.0,,,,,,,,,
CHEMBL395091,CN[C@]1(c2ccccc2Cl)CCCCC1=O,YQEZLKZALYSWHR-ZDUSSCGKSA-N,Small molecule,True,ESKETAMINE,4.0,False,True,[],"['(-)-ketamine', 'Esketamine', 'Jnj-54135419', 'Keta-s', 'Ketamine, (s)-', 'Ketamine, s-', 'Ketaved', 'L-ketamine', 'S-(-)-ketamine', 'S-ketamine']",['CHEMBL2364609'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,['DB11823'],"['MONDO_0002050', 'EFO_0003843', 'MONDO_0002050', 'EFO_0003086', 'EFO_0003761', 'MONDO_0002009', 'EFO_0003761', 'MONDO_0002009', 'EFO_0003890', 'EFO_0801084', 'EFO_0005854', 'EFO_0003843', 'HP_0000360', 'EFO_0009267', 'EFO_0001421', 'EFO_0006834']",16.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,2019.0,,,['144206757'],['60799'],,,,,
CHEMBL107,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,IAKHMKGGTNLKSZ-INIZCTEOSA-N,Small molecule,False,COLCHICINE,4.0,False,True,"['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']","['(-)-colchicine', 'Colchcine', 'Colchicine', 'Colchicinum', 'Colchineos', 'Colchisol', 'Lodoco', 'NSC-757']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for gout and familial mediterranean fever and has 40 investigational indications.,['Colchicine'],,"['EFO_0001378', 'EFO_0000401', 'EFO_0007541', 'EFO_0004220', 'EFO_0003884', 'EFO_0003818', 'EFO_0008586', 'EFO_0000537', 'EFO_0000551', 'EFO_0007427', 'EFO_0005672', 'MONDO_0004976', 'EFO_0004616', 'EFO_0003780', 'EFO_0000694', 'EFO_0001422', 'EFO_0003777', 'EFO_0004274', 'EFO_0003144', 'EFO_1001486', 'EFO_0005221', 'EFO_0006803', 'EFO_0007224', 'EFO_0000275', 'MONDO_0004979', 'MONDO_0100096', 'EFO_0000319', 'MONDO_0018088', 'EFO_0008585', 'EFO_0003863', 'EFO_0001645', 'EFO_0003938', 'EFO_0004264', 'EFO_1001404', 'EFO_0009609', 'EFO_0000612', 'EFO_0003914', 'EFO_0000616', 'EFO_1001129', 'EFO_0004269', 'EFO_0002687', 'MONDO_0008315']",42.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1961.0,,['colchicine'],"['104219585', '11114044', '144204498', '144208745', '144210899', '170465011', '17389095', '17389096', '26752175', '26752176', '49718107', '50085974', '50104821', '50104822', '50113684', '50113685', '50113686', '67636', '90340644']",['27882'],,,['113'],,
CHEMBL1201780,NC(=O)N[C@@H](CCC(=O)O)C(=O)O,LCQLHJZYVOQKHU-VKHMYHEASA-N,Small molecule,False,CARGLUMIC ACID,4.0,False,True,"['Carbaglu', 'Ucedane']","['Carglumic acid', 'N-carbamyl-l-glutamic acid', 'NSC-760124', 'OE 312', 'OE 312 (LABORATORY CODE DESIGNATION)', 'OE-312']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 2 investigational indications.,['Carglumic_acid'],['DB06775'],"['MONDO_0011628', 'HP_0001987', 'Orphanet_927', 'MONDO_0019052', 'MONDO_0004736']",5.0,['ENSG00000021826'],1,2010.0,,['carglumic%20acid'],"['144206097', '170466164']",['71028'],['https://www.ema.europa.eu/en/medicines/human/EPAR/ucedane'],,,,
CHEMBL1213252,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,XDDJGVMJFWAHJX-UHFFFAOYSA-N,Small molecule,True,CLORAZEPIC ACID,4.0,False,True,[],"['4306-CB FREE ACID', 'ABBOTT-35616 FREE ACID', 'Chlorazepate', 'Clorazepate', 'Clorazepic acid']","['CHEMBL2096631', 'CHEMBL2106085']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for seizure and anxiety disorder and has 1 investigational indication. This drug has a black box warning from the FDA.,,['DB00628'],"['HP_0001250', 'EFO_0006788', 'EFO_0005230']",3.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1972.0,,,,['3761'],,,,,
CHEMBL1908391,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,WJEOLQLKVOPQFV-UHFFFAOYSA-N,Small molecule,False,MASITINIB,4.0,False,True,"['Kinavet', 'Masivet']","['AB-1010', 'AB1010', 'Ab-1010', 'Masican', 'Masitinib', 'Masiviera']",['CHEMBL5315058'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for neoplasm and has 16 investigational indications.,,['DB11526'],"['EFO_0002618', 'EFO_0002617', 'EFO_0000616', 'MONDO_0004979', 'MONDO_0100096', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004975', 'EFO_0003840', 'EFO_0000685', 'EFO_0009001', 'EFO_0001378', 'MONDO_0011719', 'MONDO_0004976', 'EFO_0000676', 'MONDO_0016586', 'MONDO_0005301']",17.0,"['ENSG00000157404', 'ENSG00000068078', 'ENSG00000113721', 'ENSG00000134853']",4,2008.0,,,"['124950163', '99460877']",['63450'],,,,,
CHEMBL44657,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,VJJPUSNTGOMMGY-MRVIYFEKSA-N,Small molecule,True,ETOPOSIDE,4.0,False,True,"['Etoposide', 'Toposar', 'Vepesid']","['Etoposide', 'Etoposide resolution mixture', 'Etoposidum', 'NSC-141540', 'Sintopozid', 'VP-16-213']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 133 investigational indications. This drug has a black box warning from the FDA.,['Etoposide'],['DB00773'],"['EFO_0005235', 'EFO_0008524', 'EFO_0000191', 'EFO_0000094', 'EFO_0009441', 'EFO_0003811', 'MONDO_0002158', 'MONDO_0015760', 'MONDO_0001475', 'MONDO_0004992', 'EFO_1000437', 'MONDO_0016717', 'EFO_0000502', 'EFO_0000621', 'EFO_0003025', 'EFO_0000221', 'EFO_1000564', 'MONDO_0002601', 'EFO_0005952', 'EFO_0004281', 'MONDO_0013730', 'EFO_0000209', 'MONDO_0006058', 'EFO_0000637', 'EFO_0000223', 'EFO_0003802', 'EFO_0000211', 'MONDO_0021657', 'MONDO_0019472', 'EFO_0006475', 'EFO_0000180', 'EFO_0000616', 'EFO_0004289', 'MONDO_0002367', 'MONDO_0001056', 'MONDO_0021193', 'MONDO_0005575', 'EFO_1001052', 'EFO_0000558', 'EFO_0000174', 'MONDO_0018906', 'MONDO_0008380', 'EFO_0004256', 'EFO_1000574', 'EFO_0000702', 'MONDO_0008170', 'EFO_0000095', 'EFO_0000632', 'EFO_0000313', 'MONDO_0020077', 'EFO_0000248', 'MONDO_0009348', 'EFO_0000630', 'EFO_1001469', 'EFO_0000198', 'EFO_0000220', 'EFO_1001365', 'MONDO_0003478', 'HP_0001871', 'MONDO_0003001', 'EFO_0000519', 'EFO_1001465', 'EFO_0007362', 'EFO_0003032', 'EFO_0003060', 'MONDO_0002087', 'EFO_1001383', 'EFO_1001968', 'EFO_0003027', 'EFO_1000581', 'MONDO_0016691', 'EFO_0004251', 'MONDO_0003751', 'EFO_0003028', 'EFO_0007416', 'MONDO_0015540', 'EFO_0000437', 'MONDO_0024503', 'EFO_0000309', 'MONDO_0044917', 'EFO_0007498', 'EFO_1000292', 'EFO_0000339', 'EFO_0003833', 'MONDO_0002730', 'MONDO_0004095', 'MONDO_0000870', 'MONDO_0019004', 'EFO_0000514', 'EFO_0000691', 'EFO_1000415', 'MONDO_0000873', 'EFO_0002626', 'EFO_0001061', 'EFO_0004991', 'EFO_0002618', 'MONDO_0015564', 'EFO_0000182', 'MONDO_0016700', 'EFO_0003029', 'EFO_0009538', 'EFO_0004599', 'EFO_1001779', 'EFO_0000222', 'MONDO_0002120', 'EFO_1000026', 'MONDO_0001657', 'MONDO_0100096', 'MONDO_0008903', 'MONDO_0044881', 'EFO_0009254', 'MONDO_0007254', 'EFO_1000796', 'EFO_0003929', 'EFO_0000565', 'EFO_0000218', 'EFO_0000183', 'MONDO_0018944', 'EFO_1000028', 'MONDO_0021364', 'EFO_0005088', 'EFO_1001471', 'EFO_0000574', 'EFO_0002939', 'EFO_0001378', 'EFO_0005543', 'EFO_0002499', 'EFO_0002918', 'EFO_0000571', 'EFO_0000403', 'MONDO_0019471', 'EFO_0002501', 'EFO_0002428', 'MONDO_0008315', 'EFO_1000158', 'EFO_0000708', 'EFO_0000765', 'EFO_0000096']",138.0,"['ENSG00000131747', 'ENSG00000077097']",2,1983.0,,['etoposide'],"['164339423', '56463308']",['4911'],,,['131'],,
CHEMBL4594598,,,Unknown,False,EFTRENONACOG ALFA,4.0,False,True,['Alprolix'],"['Alprolix', 'BIIB-029', 'Eftrenonacog alfa', 'Rfixfc']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for hemophilia b and has 1 investigational indication.,,,"['MONDO_0010604', 'MONDO_0018660']",2.0,['ENSG00000101981'],1,2016.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/alprolix'],,,,
CHEMBL544665,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl,SWZTYAVBMYWFGS-UHFFFAOYSA-N,Small molecule,False,FINGOLIMOD HYDROCHLORIDE,4.0,False,True,['Gilenya'],"['FTY-720 HYDROCHLORIDE', 'FTY720', 'FTY720 HYDROCHLORIDE', 'Fingolimod (as hydrochloride)', 'Fingolimod hcl', 'Fingolimod hydrochlorid', 'Fingolimod hydrochloride', 'Gilenia']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for multiple sclerosis and has 3 investigational indications.,,,"['EFO_0003929', 'MONDO_0004976', 'EFO_0000305', 'MONDO_0005301']",4.0,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']",5,2010.0,CHEMBL314854,['fingolimod%20hydrochloride'],,['63112'],['https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya'],,,,
CHEMBL1201733,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl,MQHIQUBXFFAOMK-UHFFFAOYSA-N,Small molecule,True,PAZOPANIB HYDROCHLORIDE,4.0,False,True,['Votrient'],"['GW-786034B', 'GW786034B', 'Pazopanib (as hydrochloride)', 'Pazopanib hcl', 'Pazopanib hydrochloride', 'Pazopanib monohydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0002087', 'EFO_0003016', 'EFO_0000681', 'EFO_0000501', 'MONDO_0001187', 'MONDO_0015277', 'EFO_1001465', 'MONDO_0008903', 'EFO_1000613', 'EFO_0000349', 'MONDO_0004192', 'MONDO_0002158', 'EFO_0003968', 'MONDO_0004986', 'EFO_0000588', 'EFO_0001663', 'EFO_0000691', 'MONDO_0008315', 'EFO_0000641', 'EFO_0000640', 'MONDO_0008667', 'MONDO_0007254', 'EFO_1001968', 'EFO_0000616', 'EFO_0006861', 'EFO_0000335', 'EFO_0000389', 'MONDO_0008170']",28.0,"['ENSG00000113263', 'ENSG00000182578', 'ENSG00000077782', 'ENSG00000182866', 'ENSG00000068078', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853']",11,2009.0,CHEMBL477772,['pazopanib%20hydrochloride'],,['71217'],['https://www.ema.europa.eu/en/medicines/human/EPAR/votrient'],,,,
CHEMBL1743076,,,Antibody,False,TADOCIZUMAB,2.0,False,False,[],"['C4G1', 'Tadocizumab', 'YM-337', 'YM337']",,Antibody drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000259207', 'ENSG00000005961']",2,,,,,,,,,,
CHEMBL1909283,CC(NN)c1ccccc1,HHRZAEJMHSGZNP-UHFFFAOYSA-N,Small molecule,False,MEBANAZINE,4.0,True,True,[],"['Actamol', 'Mebanazine']",['CHEMBL3186515'],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,['Mebanazine'],['DB09248'],,,"['ENSG00000189221', 'ENSG00000069535']",2,,,,,,,,,,
CHEMBL2107801,COc1cccc(-c2nccc3[nH]c(=O)c(-c4noc(C)n4)cc23)c1,JQOFKKWHXGQABB-UHFFFAOYSA-N,Small molecule,False,RESEQUINIL,2.0,False,False,[],"['AVE-3933', 'Ac-3933', 'Radequinil', 'Resequinil', 'SX-3933']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004975'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL2108702,,,Oligonucleotide,False,IMETELSTAT SODIUM,2.0,False,False,[],"['GRN-163L TRIDECASODIUM SALT', 'GRN163L', 'GRN163L TRIDECASODIUM SALT', 'Imetelstat sodium']",,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0001378', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0008903']",4.0,['ENSG00000164362'],1,,,,,,,,,,
CHEMBL2109574,,,Antibody drug conjugate,False,ASG-5ME,1.0,False,False,[],"['ASG-5ME', 'Asg-5me']",,Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0001663'],1.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000204385']",16,,,,,,,,,,
CHEMBL3545365,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1,GNNDEPIMDAZHRQ-UHFFFAOYSA-N,Small molecule,False,ALTIRATINIB,2.0,False,False,[],"['Altiratinib', 'DCC-2701', 'DP-5164']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004992'],1.0,"['ENSG00000128052', 'ENSG00000120156', 'ENSG00000105976', 'ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']",6,,,,,,,,,,
CHEMBL377300,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,WCWUXEGQKLTGDX-LLVKDONJSA-N,Small molecule,False,BRIVANIB,3.0,False,False,[],"['BMS-540215', 'Brivanib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,['DB11958'],"['EFO_0000313', 'EFO_1001951', 'EFO_0000616', 'EFO_0009708', 'EFO_0000365', 'MONDO_0002974', 'EFO_0000182', 'MONDO_0002691', 'MONDO_0004992', 'MONDO_0008170']",10.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",7,,,,,,,,,,
CHEMBL4297188,Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1,HNFMVVHMKGFCMB-UHFFFAOYSA-N,Small molecule,False,MIRANSERTIB,2.0,False,False,[],"['ARQ 092', 'ARQ 092 FREE BASE', 'ARQ-092', 'ARQ092', 'Arq-092', 'Miransertib']","['CHEMBL4298151', 'CHEMBL4523032']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB14982'],"['MONDO_0011962', 'EFO_0000616', 'EFO_0000616', 'MONDO_0008318', 'EFO_0000574', 'MONDO_0008170']",6.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/MIRANSERTIB/relevant/1/'],,,
CHEMBL4297661,Cn1cnc([N+](=O)[O-])c1C[N+](C)(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Cl)c(Br)c3)ncnc2cn1,MUJMYVFVAWFUJL-SNAWJCMRSA-O,Small molecule,False,TARLOXOTINIB,2.0,False,False,[],"['Tarloxotinib', 'Tarloxotinib cation', 'Tarloxotinib ion']",['CHEMBL4297662'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB14944'],"['EFO_0000181', 'EFO_0003060', 'EFO_0003060']",3.0,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568', 'ENSG00000065361']",4,,,,,,,,,,
CHEMBL4297866,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O,QITOONQVTOGMOJ-IUJXYRIYSA-N,Small molecule,False,ABIVERTINIB MALEATE,3.0,False,False,[],"['A-610MA', 'A610MA', 'AC-0010MA', 'AC0010MA', 'ACEA-100610MA', 'ACEA100610MA', 'Abivertinib maleate', 'Abivertinib maleate dihydrate', 'Ac0010 maleate dihydrate', 'Ac0010ma', 'EX-ACEA-0010MA', 'EX-ACEA0010MA', 'Sti-5656']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0000096', 'EFO_0003060', 'MONDO_0100096']",3.0,"['ENSG00000010671', 'ENSG00000146648']",2,,CHEMBL4297865,,,,,,,,
CHEMBL449,CCC(C)C1(CC)C(=O)NC(=O)NC1=O,ZRIHAIZYIMGOAB-UHFFFAOYSA-N,Small molecule,False,BUTABARBITAL,4.0,False,True,[],"['Butabarbital', 'Butabarbital ciii', 'Butatab', 'Medarsed', 'Nilox', 'Sec-butobarbitone', 'Secbutabarbital', 'Secbutobarbitone', 'Unicelles']",['CHEMBL1200982'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939.,['Butabarbital'],['DB00237'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1939.0,,,,['3228'],,,,,
CHEMBL782,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,JLRGJRBPOGGCBT-UHFFFAOYSA-N,Small molecule,False,TOLBUTAMIDE,4.0,False,True,"['Glyconon', 'Orinase', 'Pramidex', 'Rastinon', 'Tolbutamide']","['1-butyl-3-(p-tolylsulfonyl)urea', 'Arkozal', 'Butamide', 'Diabetamid', 'Ipoglicone', 'NSC-23813', 'NSC-87833', 'Tolbutamide', 'Tolbutamidum', 'Willbutamide']",['CHEMBL1200874'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 6 investigational indications.,['Tolbutamide'],['DB01124'],"['EFO_0000616', 'EFO_0600064', 'MONDO_0005148', 'EFO_0000574', 'HP_0012532', 'MONDO_0004992', 'EFO_0000400', 'EFO_0004220']",8.0,"['ENSG00000187486', 'ENSG00000006071']",2,1961.0,,,"['11111858', '144203830', '144208810', '144213112', '170465238', '17389707', '26751511', '26751513', '50104069', '56436662', '855782']",['27999'],,,['114'],,
CHEMBL1200946,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,JKWKMORAXJQQSR-MOPIKTETSA-N,Small molecule,False,NANDROLONE DECANOATE,4.0,False,True,"['Deca-durabolin', 'Nandrolone decanoate']","['Nandrolone decanoate', 'Nandrolone decanoate ciii']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 3 investigational indications.,,['DB08804'],"['EFO_0003964', 'EFO_0008572', 'EFO_0007312']",3.0,['ENSG00000169083'],1,1983.0,,,"['144205191', '170464711', '29215336']",['7467'],,,,,
CHEMBL18901,Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1,BNFRJXLZYUTIII-UHFFFAOYSA-N,Small molecule,False,EFAPROXIRAL,3.0,False,False,[],"['Efaproxiral', 'RSR-13', 'RSR13']",['CHEMBL2107744'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,['Efaproxiral'],['DB08486'],"['MONDO_0008903', 'EFO_0000616', 'EFO_1000158', 'MONDO_0007254']",4.0,"['ENSG00000206172', 'ENSG00000188536', 'ENSG00000244734']",3,,,,,,,,,,
CHEMBL2095222,,,Protein,False,OCRIPLASMIN,4.0,False,True,['Jetrea'],"['Jetrea', 'MICROPLASMIN', 'Microplasmin (synthetic human)', 'Ocriplasmin', 'Plasmin, micro- (synthetic human)', 'Recombinant human microplasmin']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for abnormal retinal morphology and eye disease and has 6 investigational indications.,,,"['HP_0000479', 'EFO_0009606', 'EFO_1001028', 'EFO_0003966', 'EFO_0003907', 'EFO_0000712', 'EFO_1001231', 'EFO_1001157']",8.0,"['ENSG00000164692', 'ENSG00000108821', 'ENSG00000139219', 'ENSG00000168542', 'ENSG00000187498', 'ENSG00000130635', 'ENSG00000142156', 'ENSG00000060718', 'ENSG00000204291', 'ENSG00000182871', 'ENSG00000171502', 'ENSG00000196739', 'ENSG00000215018', 'ENSG00000134871', 'ENSG00000204262', 'ENSG00000142173', 'ENSG00000204248', 'ENSG00000169031', 'ENSG00000080573', 'ENSG00000163359', 'ENSG00000081052', 'ENSG00000188153', 'ENSG00000172752', 'ENSG00000197565', 'ENSG00000206384', 'ENSG00000101680', 'ENSG00000196569', 'ENSG00000053747', 'ENSG00000112769', 'ENSG00000130702', 'ENSG00000091136', 'ENSG00000172037', 'ENSG00000196878', 'ENSG00000091128', 'ENSG00000135862', 'ENSG00000058085', 'ENSG00000050555', 'ENSG00000115414']",38,2010.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea'],,,['5004'],
CHEMBL2108499,,,Enzyme,False,LANOTEPLASE,2.0,False,False,[],"['7-l-glutamine-245-l-methionine', 'BMS-200980', 'Lanoteplase', 'SUN 9216', 'SUN-9216']",,Enzyme drug with a maximum clinical trial phase of II.,,,,,['ENSG00000104368'],1,,,,,,,,,,
CHEMBL3545020,,,Small molecule,False,MBX-2044,2.0,False,False,[],['Mbx-2044'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005148'],1.0,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL3989512,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,DZMVCVHATYROOS-ZBFGKEHZSA-N,Small molecule,False,SOBLIDOTIN,2.0,False,False,[],"['Auristatin pe', 'Soblidotin', 'TZT-1027']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB12677'],"['EFO_0000616', 'EFO_0000691', 'MONDO_0008903']",3.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL564829,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,RXZMYLDMFYNEIM-UHFFFAOYSA-N,Small molecule,False,MILCICLIB,2.0,False,False,[],"['Milciclib', 'PHA 848125', 'PHA-848125', 'Pha-848125']","['CHEMBL4297668', 'CHEMBL561564']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_1000576', 'EFO_1000581', 'EFO_0000616', 'EFO_0000182']",4.0,"['ENSG00000123374', 'ENSG00000135446', 'ENSG00000170312', 'ENSG00000198400']",4,,,,,,,,,,
CHEMBL1200613,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+],QGUALMNFRILWRA-UHFFFAOYSA-M,Small molecule,True,TOLMETIN SODIUM,4.0,False,True,"['Tolectin', 'Tolectin 600', 'Tolectin ds', 'Tolmetin sodium']","['MCN-2559-21-98', 'NSC-757341', 'Sodium tolmetin', 'Tolmetin sodium', 'Tolmetin sodium anhydrous', 'Tolmetin sodium dihydrate', 'Tolmetin sodium salt dihydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for rheumatoid arthritis and osteoarthritis. This drug has a black box warning from the FDA.,,,"['EFO_0000685', 'MONDO_0005178']",2.0,"['ENSG00000073756', 'ENSG00000095303']",2,1976.0,CHEMBL1020,['tolmetin%20sodium'],['26748279'],['9619'],,,,,
CHEMBL1201010,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,SYWHXTATXSMDSB-GSLJADNHSA-N,Small molecule,False,FLUDROCORTISONE ACETATE,4.0,False,True,"['Astonin', 'Florinef', 'Fludrocortisone acetate', 'Fludrocortone', 'Panotile']","['Fludrocortisone 21-acetate', 'Fludrocortisone acetate', 'Fludrocortisoni acetas', 'Fluorhydrocortisone acetate', 'Fluorocortisol acetate', 'NSC-15186', 'Scherofluron']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 3 approved and 9 investigational indications.,,,"['MONDO_0002050', 'EFO_1001176', 'MONDO_0015128', 'MONDO_0015898', 'MONDO_0100096', 'EFO_0000694', 'MONDO_0005180', 'MONDO_0015129', 'EFO_0006834', 'EFO_0000756', 'MONDO_0011972', 'MONDO_0018479']",12.0,['ENSG00000151623'],1,1955.0,,['fludrocortisone%20acetate'],,['5102'],,,,,
CHEMBL1465,CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O,DQDAYGNAKTZFIW-UHFFFAOYSA-N,Small molecule,False,PHENPROCOUMON,4.0,False,True,"['Liquamar', 'Marcoumar']","['BS-7565', 'Fencumar', 'Marcumar', 'Phenprocoumarol', 'Phenprocoumarole', 'Phenprocoumon', 'Phenprocumone', 'RO-1-4849']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for recurrent thrombophlebitis and has 3 investigational indications.,['Phenprocoumon'],['DB00946'],"['EFO_0000756', 'HP_0004419', 'HP_0004936', 'EFO_0003907']",4.0,['ENSG00000167397'],1,1957.0,,,,['50438'],,,,,
CHEMBL2108332,,,Gene,False,BEPERMINOGENE PERPLASMID,2.0,False,False,[],['Beperminogene perplasmid'],,Gene drug with a maximum clinical trial phase of II.,,,,,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL2108481,,,Unknown,False,ANCROD,3.0,False,False,[],"['Acc-c', 'Ancrod', 'Arvin', 'Arwin', 'Ec 3.4.21.74', 'Protein c activator', 'Proteinase, agkistrodon serine', 'Venombin-a', 'Viprinex']",,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['HP_0004419'],1.0,"['ENSG00000171560', 'ENSG00000171564', 'ENSG00000171557']",3,,,,,,,,,,
CHEMBL2109361,,,Antibody,False,PEMTUMOMAB,3.0,False,False,['Theragyn'],"['Pemtumomab', 'RG-1549']",,Antibody drug with a maximum clinical trial phase of III.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL2109389,,,Antibody,False,IMGATUZUMAB,2.0,False,False,[],"['GA-201', 'GA201', 'HUMA-B', 'HUMAB', 'HuMAB<EGFR>', 'Imgatuzumab', 'RG7160', 'RO-5083945', 'RO5083945']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_1001951', 'EFO_0000616', 'EFO_0003060', 'EFO_0006859']",4.0,"['ENSG00000146648', 'ENSG00000203747']",2,,,,,,,,,,
CHEMBL3219124,COC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1,FJEJHJINOKKDCW-INIZCTEOSA-N,Small molecule,False,AZD-1656,2.0,False,False,[],"['AZD1656', 'Azd 1656', 'Azd-1656', 'Azd1656']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB14810'],"['MONDO_0005147', 'MONDO_0005148', 'MONDO_0100096']",3.0,['ENSG00000106633'],1,,,,,,,,,,
CHEMBL3545169,CC(C)(C)OC(=O)NCCN1CC2CN(CCOc3ccc(C#N)cc3F)CC(C1)O2,BLLNYXOLLAVTRF-UHFFFAOYSA-N,Small molecule,False,AZD1305,2.0,False,False,[],"['Azd 1305', 'Azd-1305', 'Azd1305']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0003911', 'EFO_0000275']",2.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001', 'ENSG00000183873', 'ENSG00000055118']",6,,,,,,,,,,
CHEMBL3545300,,,Small molecule,False,CP-459632,1.0,False,False,[],['Cp-459632'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000066056', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",8,,,,,,,,,,
CHEMBL3707225,,,Small molecule,False,GSK2798745,2.0,False,False,[],"['Gsk-2798745', 'Gsk2798745']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['HP_0012735', 'EFO_0000373', 'MONDO_0003005', 'EFO_0003144', 'EFO_1001134']",5.0,['ENSG00000111199'],1,,,,,,,,,,
CHEMBL3989698,N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1.O=S(=O)(O)O,BKPRVQDIOGQWTG-ICOOEGOYSA-N,Small molecule,True,TRANYLCYPROMINE SULFATE,4.0,False,True,"['Parnate', 'Parstelin', 'Tranylcypromine sulfate']","['NSC-757342', 'Tranylcypromine sulfate', 'Tranylcypromine sulphate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for melancholia and major depressive disorder. This drug has a black box warning from the FDA.,,,"['EFO_1002014', 'MONDO_0002009']",2.0,"['ENSG00000189221', 'ENSG00000069535']",2,1961.0,CHEMBL3989843,['tranylcypromine%20sulfate'],,,,,,,
CHEMBL4442620,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,UELYDGOOJPRWGF-MFOHZAOFSA-N,Small molecule,False,RONICICLIB,2.0,False,False,[],"['BAY10-00394', 'BAY1000394', 'Bay 1000394', 'Bay-1000394', 'Roniciclib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0003060', 'EFO_0000616', 'EFO_0000702']",3.0,"['ENSG00000170312', 'ENSG00000135446', 'ENSG00000123374', 'ENSG00000164885', 'ENSG00000105810', 'ENSG00000134058', 'ENSG00000250506', 'ENSG00000102225', 'ENSG00000117266', 'ENSG00000132964', 'ENSG00000059758', 'ENSG00000248333', 'ENSG00000138395', 'ENSG00000155111', 'ENSG00000058091', 'ENSG00000136807', 'ENSG00000185324', 'ENSG00000065883', 'ENSG00000156345', 'ENSG00000167258']",20,,,,,,,,,,
CHEMBL4802165,,,Antibody,False,BEMARITUZUMAB,3.0,False,False,[],"['Bemarituzumab', 'FPA-144', 'FPA144', 'Fpa144']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0001056', 'EFO_0000616', 'EFO_0003060', 'EFO_0000228', 'MONDO_0007576']",5.0,['ENSG00000066468'],1,,,,,,,,,,
CHEMBL139835,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,UWFYSQMTEOIJJG-FDTZYFLXSA-N,Small molecule,False,CYPROTERONE ACETATE,4.0,False,True,"['Androcur', 'Androcur 10', 'Cyprostat', 'Diane']","['Cyproterone', 'Cyproterone 17.alpha.-acetate', 'Cyproterone acetate', 'NSC-81430', 'SH 714', 'SH-714', 'SH714']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications.,,['DB04839'],"['MONDO_0008315', 'EFO_0003894', 'EFO_0001065', 'EFO_0000673', 'EFO_0000536', 'GO_0042697', 'HP_0031217', 'EFO_0000660']",8.0,"['ENSG00000113580', 'ENSG00000169083', 'ENSG00000082175']",3,,,,"['144204615', '144208884', '144213258', '170465682', '17389953', '26752883', '46500455', '49737417', '90340797']",['50743'],,,,,
CHEMBL1689,Cl.c1ccc(CC2=NCCN2)cc1,RHTNTTODYGNRSP-UHFFFAOYSA-N,Small molecule,False,TOLAZOLINE HYDROCHLORIDE,4.0,False,True,"['Benzidazol', 'Priscol', 'Priscoline']","['Benzazoline hydrochloride', 'NSC-757353', 'TCMDC-125842', 'Tolazoline HCl', 'Tolazoline hcl', 'Tolazoline hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985.,,,,,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000196639', 'ENSG00000113749']",8,1985.0,CHEMBL770,,"['144203890', '14742771', '170465219', '26748277']",,,,,,
CHEMBL2105712,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,USNRYVNRPYXCSP-JUGPPOIOSA-N,Small molecule,False,AFATINIB DIMALEATE,4.0,False,True,"['Gilotrif', 'Giotrif']","['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2', 'BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.,,,"['EFO_0003060', 'EFO_0001378']",2.0,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568']",3,2013.0,CHEMBL1173655,['afatinib%20dimaleate'],,['76003'],['https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif'],,,,
CHEMBL2106643,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)[O-])C(=O)OC2.[Na+],DOZYTHNHLLSNIK-JOKMOOFLSA-M,Small molecule,True,MYCOPHENOLATE SODIUM,4.0,False,True,"['Ceptava', 'Myfortic']","['ERL 080', 'ERL-080', 'Mycophenolate sodium', 'Mycophenolic acid sodium salt', 'Mycophenolic sod', 'NSC-116072', 'Sodium mycophenalate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for multiple sclerosis and has 8 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0005140', 'EFO_0005761', 'EFO_0000699', 'HP_0001871', 'MONDO_0005301', 'EFO_1002048', 'EFO_0003884', 'EFO_0004599', 'EFO_0003086']",9.0,"['ENSG00000106348', 'ENSG00000178035']",2,2004.0,CHEMBL866,['mycophenolic%20sodium'],,['67155'],,,,,
CHEMBL3545264,CC(Oc1ccc2[nH]nc(/C=C/c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,GKJCVYLDJWTWQU-DUXPYHPUSA-N,Small molecule,False,LY-2874455,1.0,False,False,[],"['LY2874455', 'Ly-2874455']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,,,,,,,,,,
CHEMBL3833304,,,Antibody,False,TOSITUMOMAB 131I,3.0,False,False,['Bexxar'],"['Tositumomab (131I)', 'Tositumomab 131i', 'Tositumomab/iodine (131i) tositumomab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,,"['EFO_0000403', 'EFO_0001378', 'MONDO_0000873', 'EFO_0000574', 'EFO_0009441', 'EFO_0000096', 'EFO_0005952', 'EFO_0000191', 'MONDO_0018906', 'EFO_1001469', 'EFO_0003032', 'EFO_0000183', 'EFO_0000309', 'EFO_0000095']",14.0,['ENSG00000156738'],1,,,,,,,,,,
CHEMBL4297255,COC(=O)C1(OC(=O)c2cncn2[C@H](C)c2ccccc2)CC1,DRAFVCKNYNQOKR-GFCCVEGCSA-N,Small molecule,False,ABP-700,2.0,False,False,[],['Abp-700'],,Small molecule drug with a maximum clinical trial phase of II.,,['DB15411'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL452461,O=c1c2c(c1=O)N(CCP(=O)(O)O)CCCN2,BDABGOLMYNHHTR-UHFFFAOYSA-N,Small molecule,False,PERZINFOTEL,2.0,False,False,[],"['EAA-090', 'Perzinfotel']",,Small molecule drug with a maximum clinical trial phase of II.,,['DB12365'],,,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL4650483,,,Antibody,False,ERFONRILIMAB,3.0,False,False,[],"['Erfonrilimab', 'KN-046', 'KN046', 'Kn 046', 'Kn046']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,,"['MONDO_0005184', 'EFO_0000574', 'EFO_0000616', 'EFO_0003060', 'EFO_1000576', 'EFO_0005537', 'EFO_0005922', 'EFO_0002618', 'EFO_0000182']",9.0,"['ENSG00000120217', 'ENSG00000163599']",2,,,,,,,,,,
CHEMBL2107383,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC.Cl,JMHYCBFEEFHTMK-IIUXMCBISA-N,Small molecule,False,VERNAKALANT HYDROCHLORIDE,4.0,False,True,['Brinavess'],"['Brinavess', 'Kynapid', 'RSD-1235', 'RSD1235', 'Vernakalant hcl', 'Vernakalant hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for atrial fibrillation and has 1 investigational indication.,,,"['EFO_0000275', 'EFO_0003911']",2.0,"['ENSG00000162989', 'ENSG00000120457', 'ENSG00000055118', 'ENSG00000171385', 'ENSG00000130037', 'ENSG00000183873']",6,2010.0,CHEMBL2111112,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess'],,,,
CHEMBL220492,CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1,KJADKKWYZYXHBB-XBWDGYHZSA-N,Small molecule,False,TOPIRAMATE,4.0,False,True,"['Epitomax', 'Eprontia', 'Qudexy xr', 'Topamax', 'Topamax sprinkle', 'Topiramate', 'Trokendi xr']","['(-)-topiramate', 'Epitoma', 'Eprontia', 'MCN-4853', 'Qudexy', 'RWJ-17021', 'RWJ-17021-000', 'Sincronil', 'Topamac', 'Topimax', 'Topina', 'Topiramate', 'Topomax', 'USL-255', 'USL255']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 42 investigational indications.,['Topiramate'],['DB00273'],"['HP_0011868', 'EFO_0007191', 'MONDO_0002046', 'EFO_0005203', 'MONDO_0005180', 'EFO_0001073', 'EFO_1001176', 'MONDO_0021187', 'EFO_0007262', 'EFO_0004895', 'EFO_0004211', 'EFO_0001063', 'MONDO_0005299', 'HP_0000726', 'MONDO_0008300', 'HP_0002315', 'MONDO_0005148', 'EFO_0005204', 'EFO_0004263', 'MONDO_0005277', 'EFO_0000400', 'EFO_0004701', 'EFO_0004242', 'EFO_0001358', 'EFO_0004329', 'EFO_0005230', 'EFO_0003768', 'HP_0100543', 'EFO_0003843', 'EFO_0005207', 'MONDO_0002050', 'EFO_0004319', 'MONDO_0005090', 'EFO_0001421', 'EFO_0004699', 'EFO_0000474', 'EFO_0003108', 'EFO_0000195', 'MONDO_0016532', 'MONDO_0005301', 'MONDO_0004985', 'EFO_0000537', 'HP_0001250', 'EFO_0005924', 'EFO_0002610', 'MONDO_0007079']",46.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000167434', 'ENSG00000171189', 'ENSG00000105737', 'ENSG00000149403', 'ENSG00000164418', 'ENSG00000163873', 'ENSG00000104267', 'ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",37,1996.0,,['topiramate'],"['144205025', '144212718', '170464746']",['63631'],,,,,
CHEMBL408513,O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,NCNRHFGMJRPRSK-MDZDMXLPSA-N,Small molecule,False,BELINOSTAT,4.0,False,True,['Beleodaq'],"['Belinostat', 'NSC-726630', 'NSC726630', 'PX-105684', 'PXD-101', 'PXD101']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 31 investigational indications.,['Belinostat'],['DB05015'],"['EFO_0000309', 'EFO_0000403', 'EFO_1000131', 'MONDO_0015760', 'EFO_0000616', 'EFO_0000588', 'MONDO_0002158', 'EFO_0003060', 'EFO_0002913', 'MONDO_0000430', 'EFO_0000222', 'EFO_0005952', 'EFO_0003032', 'EFO_1001469', 'EFO_0000183', 'EFO_0000228', 'EFO_0000466', 'EFO_0001642', 'MONDO_0004992', 'EFO_1001968', 'MONDO_0019471', 'EFO_0000313', 'EFO_0000198', 'MONDO_0002087', 'EFO_0000211', 'EFO_1001051', 'EFO_1000581', 'EFO_0008528', 'EFO_0000574', 'EFO_0000182', 'EFO_0000519', 'EFO_0001378', 'EFO_0000702', 'EFO_1000576', 'MONDO_0018906', 'EFO_1000043']",36.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,2014.0,,['belinostat'],,['61076'],,,,,
CHEMBL4298084,,,Antibody,False,ODRONEXTAMAB,2.0,False,False,[],"['Odronextamab', 'REGN-1979', 'REGN1979', 'Regn1979']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0004289', 'EFO_1001938', 'EFO_0000095', 'EFO_0000096']",4.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000156738']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ODRONEXTAMAB/relevant/1/'],,,
CHEMBL433,CCCC(CCC)C(=O)[O-].[Na+],AEQFSUDEHCCHBT-UHFFFAOYSA-M,Small molecule,True,VALPROATE SODIUM,4.0,False,True,"['Delepsine', 'Depacon', 'Depakine', 'Depakote', 'Depakote CP', 'Depakote ER', 'Epilim', 'Epilim 200', 'Epilim 500', 'Epilim chrono 200', 'Epilim chrono 300', 'Epilim chrono 500', 'Epilim chronosphere', 'Epilim iv', 'Episenta', 'Kentilim', 'Orfiril', 'Orlept', 'Valproate sodium']","['A-44090', 'ABBOTT 44090', 'ABBOTT-44090', 'KW-6066N', 'NSC-732626', 'NSC-757376', 'Natrii valproas', 'Selenica', 'Sodium 2-propylpentanoate', 'Sodium valproate', 'Valproate sodium', 'Valproic acid sodium salt (1:1)', 'Valproic acid, sodium', 'Valproic acid, sodium salt']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for epilepsy and has 25 investigational indications. This drug has a black box warning from the FDA.,['Sodium_valproate'],,"['MONDO_0007079', 'EFO_0000474', 'EFO_0009430', 'EFO_0009963', 'EFO_0003758', 'EFO_0000198', 'MONDO_0019188', 'MONDO_0005277', 'HP_0001250', 'MONDO_0003478', 'EFO_0008526', 'MONDO_0043510', 'EFO_0000519', 'MONDO_0010604', 'EFO_0004192', 'MONDO_0004976', 'EFO_0008525', 'MONDO_0009293', 'EFO_0005762', 'EFO_0009267', 'EFO_0000095', 'HP_0000713', 'MONDO_0018105', 'EFO_0000403', 'MONDO_0004975', 'MONDO_0004985']",26.0,['ENSG00000112294'],1,1996.0,CHEMBL109,['valproate%20sodium'],"['11112073', '144212940', '50106736', '50112990', '57264447', '85231324']",['9925'],,,,,
CHEMBL2107856,,,Oligonucleotide,False,IMETELSTAT,3.0,False,False,[],"['GRN-163L', 'GRN163L', 'Imetelstat']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,,"['MONDO_0044903', 'EFO_0000479', 'EFO_0000621', 'EFO_0001378', 'EFO_0003060', 'EFO_0000198', 'MONDO_0007254', 'EFO_0000574', 'EFO_0002429']",9.0,['ENSG00000164362'],1,,,,,,,,,,
CHEMBL442,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,XCGSFFUVFURLIX-VFGNJEKYSA-N,Small molecule,True,ERGOTAMINE,4.0,False,True,[],"['Ergotamine', 'Ergotamine Tartrate', 'NSC-95090']","['CHEMBL2448612', 'CHEMBL1743258', 'CHEMBL2131781']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for migraine disorder and headache and has 1 investigational indication. This drug has a black box warning from the FDA.,['Ergotamine'],['DB00696'],"['MONDO_0005277', 'HP_0002315', 'MONDO_0005277', 'EFO_0005252']",4.0,"['ENSG00000179546', 'ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",7,1948.0,,,,['64318'],,,,,
CHEMBL4650281,C=CC(=O)N[C@H]1C=C(C)c2c(-c3cnc4ccccc4c3)c3c(N)ncnc3n2C1,MKCYPWYURWOKST-INIZCTEOSA-N,Small molecule,False,CLN-081,1.0,False,False,[],"['CLN-081', 'CLN081', 'Cln 081', 'Cln-081', 'TAS-6417', 'TAS6417', 'TPC-064', 'TPC064', 'Zipalertinib']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0003060'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL603469,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,UIARLYUEJFELEN-LROUJFHJSA-N,Small molecule,False,LESTAURTINIB,3.0,False,False,[],"['A-154475', 'A-154475.0', 'CEP-701', 'Cep-701', 'KT-555', 'KT-5555', 'KT5555', 'Lestaurtinib', 'SP-924', 'SP924', 'SPM-924']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,['Lestaurtinib'],,"['EFO_0001378', 'EFO_0002429', 'EFO_0000479', 'EFO_0000222', 'EFO_0000621', 'MONDO_0008315', 'MONDO_0044903', 'EFO_0000676', 'EFO_0000565']",9.0,"['ENSG00000165731', 'ENSG00000096968', 'ENSG00000122025', 'ENSG00000148053', 'ENSG00000140538', 'ENSG00000198400']",6,,,,"['144206186', '50113274']",,,,,,
CHEMBL1073,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,Small molecule,False,GLIPIZIDE,4.0,False,True,"['Glibenese', 'Glipizide', 'Glucotrol', 'Glucotrol xl', 'Minodiab 2.5', 'Minodiab 5']","['CP-28,720', 'CP-28720', 'Glipizide', 'Glipizide slow release', 'K 4024', 'K-4024', 'NSC-759120']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 2 investigational indications.,['Glipizide'],['DB01067'],"['EFO_0003914', 'MONDO_0005148', 'EFO_0003884', 'EFO_0000400']",4.0,"['ENSG00000187486', 'ENSG00000006071']",2,1984.0,,['glipizide'],"['11111214', '11112714', '144203707', '144212151', '170465089', '50104189', '56422485', '855947']",['5384'],,,,,
CHEMBL1194666,CCN(CC)C(C)C(=O)c1ccccc1,XXEPPPIWZFICOJ-UHFFFAOYSA-N,Small molecule,False,DIETHYLPROPION,4.0,False,True,[],"['.alpha.-benzoyltriethylamine', 'Amfepramone', 'Anfepramone', 'Anferpramon', 'C06954', 'D07444', 'Diethylcathinone', 'Diethylpropion', 'J4.327C']",['CHEMBL1693'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for obesity.,['Amfepramone'],['DB00937'],"['EFO_0001073', 'EFO_0001073']",2.0,"['ENSG00000103546', 'ENSG00000142319']",2,1959.0,,,,['4530'],,,,,
CHEMBL1466,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,Small molecule,False,DICUMAROL,4.0,False,True,['Dicumarol'],"['Bishydroxycoumarin', 'Dicoumarol', 'Dicoumarolum', 'Dicumarol', 'NSC-17860', 'NSC-221570', 'NSC-41834']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1944 and is indicated for recurrent thrombophlebitis.,['Dicoumarol'],['DB00266'],['HP_0004419'],1.0,['ENSG00000167397'],1,1944.0,,,"['11112184', '144203908', '170465275']",['4513'],,,,,
CHEMBL181954,CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,OKJHGOPITGTTIM-DEOSSOPVSA-N,Small molecule,False,NAVEGLITAZAR,2.0,False,False,[],"['LY-519818', 'LY-9818', 'LY519818', 'LY9818', 'Ly519818', 'Naveglitazar']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12662'],['MONDO_0005148'],1.0,"['ENSG00000132170', 'ENSG00000186951']",2,,,,,,,,,,
CHEMBL2109540,,,Antibody,False,ALIROCUMAB,4.0,False,True,['Praluent'],"['Alirocumab', 'REGN-727', 'REGN727', 'SAR-236553', 'SAR236553']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 6 investigational indications.,,,"['EFO_0003914', 'EFO_0000319', 'HP_0100806', 'EFO_0004911', 'HP_0003124', 'HP_0003119', 'Orphanet_309005', 'EFO_0004255', 'MONDO_0018328', 'EFO_0000400', 'EFO_0001645']",11.0,['ENSG00000169174'],1,2015.0,,['alirocumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/praluent'],,,['5016'],
CHEMBL3544936,,,Small molecule,False,XL-844,1.0,False,False,[],['Xl-844'],,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,,"['EFO_0000574', 'EFO_0000095', 'MONDO_0004992']",3.0,"['ENSG00000183765', 'ENSG00000149554']",2,,,,,,,,,,
CHEMBL4091374,O=C(O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1,OQDQIFQRNZIEEJ-UHFFFAOYSA-N,Small molecule,False,LANIFIBRANOR,3.0,False,False,[],"['IVA-337', 'IVA337', 'Iva337', 'Lanifibranor']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB14801'],"['EFO_0000404', 'EFO_0003095', 'EFO_1001249']",3.0,"['ENSG00000132170', 'ENSG00000186951', 'ENSG00000112033']",3,,,,,,,,,,
CHEMBL4297859,,,Antibody drug conjugate,False,AZINTUXIZUMAB VEDOTIN,2.0,False,False,[],"['Abbv-838', 'Azintuxizumab vedotin']",,Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0001378'],1.0,"['ENSG00000026751', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL4594348,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1,UNHZLHSLZZWMNP-LLVKDONJSA-N,Small molecule,False,ELSUBRUTINIB,2.0,False,False,[],"['ABBV-105', 'ABBV105', 'Elsubrutinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0007915', 'EFO_0000685']",2.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ELSUBRUTINIB/relevant/1/'],,,
CHEMBL4650421,,,Unknown,False,RECOMBINANT HUMAN INTERLEUKIN-15,2.0,False,False,[],"['Recombinant human il-15', 'Recombinant human interleukin-15', 'Rhil-15']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000681', 'EFO_0000565', 'MONDO_0004992']",3.0,"['ENSG00000147168', 'ENSG00000100385', 'ENSG00000134470']",3,,,,,,,,,,
CHEMBL1093,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,QTGIAADRBBLJGA-UHFFFAOYSA-N,Small molecule,False,ARTICAINE,4.0,False,True,[],"['40 045', '40-045', 'Articaine', 'Carticaine', 'HOE 045', 'HOE-045', 'Septocaine']",['CHEMBL1200819'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 investigational indications.,['Articaine'],['DB09009'],"['EFO_1001139', 'EFO_1002048', 'EFO_0000649', 'EFO_0003843']",4.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2000.0,,,,,,,,,
CHEMBL1200982,CCC(C)C1(CC)C(=O)[N-]C(=O)NC1=O.[Na+],QORQZMBCPRBCAB-UHFFFAOYSA-M,Small molecule,False,BUTABARBITAL SODIUM,4.0,False,True,"['Butabarb', 'Butabarbital', 'Butabarbital sodium', 'Butalan', 'Buticaps', 'Butisol sodium', 'Sarisol', 'Sarisol no. 1', 'Sarisol no. 2', 'Sodium butabarbital']","['Astrudion', 'Butabarbital sodium', 'Butabarbital sodium salt', 'Loubarb', 'Mebutal', 'NSC-11778', 'Secbutabarbital sodium']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1939.0,CHEMBL449,,,,,,,,
CHEMBL1788132,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl,DWWHMKBNNNZGHF-UHFFFAOYSA-N,Small molecule,False,LOFEXIDINE HYDROCHLORIDE,4.0,False,True,"['Britlofex', 'Lucemyra']","['Lofexidine hcl', 'Lofexidine hydrochloride', 'MDL 14,042', 'MDL-14042', 'NSC-759654']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for substance withdrawal syndrome and has 1 investigational indication.,,,"['EFO_0005800', 'EFO_0005611']",2.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,2018.0,CHEMBL17860,,,,,,,,
CHEMBL2107832,O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F,VIUAUNHCRHHYNE-JTQLQIEISA-N,Small molecule,False,PIMASERTIB,2.0,False,False,['Msc1936369a; as703026; emd 1036239'],"['AS 703026', 'AS-703026', 'AS703026', 'As-703026', 'EMD 1036239', 'EMD-1036239', 'G-02443714', 'MSC-1936369A', 'MSC-1936369B', 'MSC1936369A', 'Msc-1936369', 'Pimasertib']",['CHEMBL4297676'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 13 investigational indications.,,['DB14904'],"['EFO_0000389', 'EFO_0000756', 'EFO_0000641', 'MONDO_0008170', 'EFO_1001951', 'EFO_0003060', 'EFO_0000616', 'MONDO_0007254', 'EFO_0000182', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0016691', 'EFO_0000222', 'EFO_0002618']",14.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,,,,,,,
CHEMBL2108718,,,Oligosaccharide,False,SEMULOPARIN SODIUM,3.0,False,False,[],"['AVE-5026', 'Semuloparin sodium']",,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['HP_0004936', 'EFO_0004286']",2.0,['ENSG00000117601'],1,,,,,,,,,,
CHEMBL2109584,,,Antibody,False,F16SIP 131I,2.0,False,False,[],"['F16SIP', 'F16sip 131i']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004992'],1.0,['ENSG00000041982'],1,,,,,,,,,,
CHEMBL3186534,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,WPEWQEMJFLWMLV-UHFFFAOYSA-N,Small molecule,False,RIVOCERANIB,3.0,False,False,[],"['Apatinib', 'Apatinib free base', 'Rivoceranib', 'YN968D1', 'YN968D1 FREE BASE']",['CHEMBL3545414'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 64 investigational indications.,,['DB14765'],"['EFO_1000359', 'EFO_0004252', 'EFO_0000231', 'MONDO_0007254', 'EFO_0000231', 'EFO_0001061', 'EFO_0000756', 'EFO_0000702', 'MONDO_0008170', 'EFO_0000178', 'EFO_0006859', 'EFO_1001968', 'EFO_0005221', 'MONDO_0003060', 'MONDO_0002120', 'EFO_0004142', 'EFO_0000616', 'MONDO_0001056', 'EFO_0003868', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0011719', 'EFO_0000182', 'EFO_0000313', 'EFO_0000571', 'MONDO_0008903', 'EFO_1001961', 'MONDO_0021063', 'EFO_1001956', 'EFO_0002939', 'EFO_0001071', 'EFO_0005537', 'MONDO_0100342', 'EFO_0000199', 'EFO_0000503', 'MONDO_0002108', 'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869', 'HP_0001541', 'MONDO_0002974', 'EFO_0003891', 'EFO_0000637', 'EFO_0002916', 'EFO_0000182', 'EFO_0005543', 'EFO_0003897', 'EFO_0000181', 'EFO_0000616', 'EFO_0005922', 'EFO_0000691', 'EFO_0000621', 'EFO_0003893', 'MONDO_0018944', 'EFO_0000707', 'EFO_0000211', 'MONDO_0007576', 'EFO_0002618', 'EFO_1002017', 'EFO_0009708', 'EFO_0000365', 'EFO_0000574', 'EFO_0000503', 'EFO_0003860', 'EFO_0000681', 'MONDO_0008315']",67.0,['ENSG00000128052'],1,,,,['124955476'],,,,,,
CHEMBL3786098,C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1,ODMXWZROLKITMS-RISCZKNCSA-N,Small molecule,False,PF-06459988,2.0,False,False,[],"['PF-06459988', 'Pf-06459988']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB14768'],['EFO_0003060'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL3833343,,,Antibody,False,VOBARILIZUMAB,2.0,False,False,[],"['ALX-0061', 'ALX0061', 'Vobarilizumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000685', 'MONDO_0007915']",2.0,['ENSG00000160712'],1,,,,,,,,,,
CHEMBL4116008,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,BGLPECHZZQDNCD-UHFFFAOYSA-N,Small molecule,False,CERDULATINIB,2.0,False,False,[],"['Cerdulatinib', 'PRT-062070', 'Prt-2070', 'RVT-502']",['CHEMBL3991929'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB15499'],"['EFO_0004208', 'EFO_0000095', 'MONDO_0019473', 'MONDO_0018906']",4.0,"['ENSG00000162434', 'ENSG00000105397', 'ENSG00000165025', 'ENSG00000105639']",4,,,,,,,,,,
CHEMBL4297329,C[C@]1(O)C[C@@](N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1,AIFGVDXMHWGOGJ-DIVCQZSQSA-N,Small molecule,False,PIFUSERTIB,2.0,False,False,[],"['Pifusertib', 'TAS 117', 'Tas-117']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB15054'],['EFO_0000616'],1.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-127']
CHEMBL1200592,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,VVOIQBFMTVCINR-WWMZEODYSA-N,Small molecule,False,DESOXYCORTICOSTERONE PIVALATE,4.0,False,True,"['Percorten', 'Zycortal']","['Desoxycorticosterone pivalate', 'Desoxycorticosterone trimethylacetate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,['DB01134'],,,['ENSG00000151623'],1,1982.0,,,['144205152'],['50782'],['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/zycortal'],,,,
CHEMBL1200964,CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl,KFYRPLNVJVHZGT-UHFFFAOYSA-N,Small molecule,True,AMITRIPTYLINE HYDROCHLORIDE,4.0,False,True,"['Amitid', 'Amitril', 'Amitriptyline hydrochloride', 'Cytriptyline', 'Domical', 'Elavil', 'Endep', 'Lentizol', 'Limbitrol 5', 'Saroten', 'Saroten retard', 'Triptafen', 'Triptafen-m', 'Tryptizol', 'Tryptizol-75']","['Amitriptyline hcl', 'Amitriptyline hydrochloride', 'Amitriptylini hydrochloridum', 'Etravil', 'NIH 10794', 'NSC-104210', 'Novoprotect', 'Syneudon']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for unipolar depression and has 3 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0000989', 'EFO_0003761', 'MONDO_0016028', 'EFO_0009387']",4.0,"['ENSG00000103546', 'ENSG00000108576']",2,1961.0,CHEMBL629,['amitriptyline%20hydrochloride'],"['144206673', '144208476', '144213917', '170464758', '17389180', '26747443', '26751626', '49816669', '50105841', '855970']",,,,,,
CHEMBL1201108,Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2.Cl,BTYHAFSDANBVMJ-UHFFFAOYSA-N,Small molecule,False,CONIVAPTAN HYDROCHLORIDE,4.0,False,True,['Vaprisol'],"['CI-1025', 'Conivaptan hcl', 'Conivaptan hydrochloride', 'YM-087', 'YM087']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for heart failure and has 2 investigational indications.,,,"['HP_0002902', 'EFO_0003144', 'EFO_0001421']",3.0,"['ENSG00000126895', 'ENSG00000166148']",2,2005.0,CHEMBL1755,,,['31430'],,,,,
CHEMBL1201534,,,Unknown,False,DANAPAROID SODIUM,4.0,False,True,['Orgaran'],"['Danaparoid', 'Danaparoid sodium', 'ORG 10172', 'ORG-10172', 'Sodium danaparoid']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for recurrent thrombophlebitis and has 1 investigational indication.,,,"['HP_0004419', 'HP_0001873']",2.0,['ENSG00000117601'],1,1996.0,,,,,,,,,
CHEMBL1255840,CC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1,VCRGLZYPNNAVRP-JTQLQIEISA-N,Small molecule,False,NEBOGLAMINE,2.0,False,False,[],"['Cr2249', 'Neboglamine', 'Nebostinel', 'XY-2401']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,"['144204806', '50106666', '90341776']",,,,,,
CHEMBL2074972,COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1,QZVNQOLPLYWLHQ-UHFFFAOYSA-N,Small molecule,False,BENIDIPINE,3.0,False,False,[],"['Benidipine', 'Benidipine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0000319'],1.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,,,,,,,
CHEMBL2107821,NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1,WJIGGYYSZBWCGC-MRXNPFEDSA-N,Small molecule,False,EMIXUSTAT,3.0,False,False,['Acu-4429'],"['ACU-4429', 'Emixustat']",['CHEMBL2107829'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB12608'],"['EFO_1001492', 'MONDO_0019353']",2.0,['ENSG00000116745'],1,,,,,,,,,,
CHEMBL3990028,,,Antibody,False,BLESELUMAB,2.0,False,False,[],"['ASKP-1240', 'ASKP1240', 'Bleselumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0004236', 'EFO_0000676']",2.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL4297526,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21,CYHWMBVXXDIZNZ-KRWDZBQOSA-N,Small molecule,True,REMIMAZOLAM,4.0,False,True,['Byfavo'],"['CNS 7056', 'CNS-7056', 'Cns 7056', 'ONO-2745', 'Remimazolam']","['CHEMBL4297324', 'CHEMBL4594301']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sedation and has 4 investigational indications. This drug has a black box warning from the FDA.,,['DB12404'],"['EFO_0003890', 'EFO_0009868', 'MONDO_0000870', 'EFO_0001421', 'EFO_0003843']",5.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,2020.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/REMIMAZOLAM/relevant/1/'],,,
CHEMBL4650278,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O,AXNUWYROYVRYIM-OQIJCFCCSA-N,Small molecule,False,SNDX-5613,1.0,False,False,[],"['Revumenib sesquifumarate', 'SNDX-50613', 'SNDX-5613', 'SNDX50613', 'SNDX5613', 'Sndx 5613', 'Sndx-5613']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,,"['EFO_0000565', 'EFO_0000222', 'EFO_0000220', 'EFO_1001951']",4.0,"['ENSG00000133895', 'ENSG00000118058']",2,,CHEMBL4650827,,,,,,,,
CHEMBL1200326,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1.Cl,AIKVCUNQWYTVTO-UHFFFAOYSA-N,Small molecule,False,NICARDIPINE HYDROCHLORIDE,4.0,False,True,"['Cardene', 'Cardene sr', 'Nicardipine hydrochloride']","['Barizin', 'Cardepine', 'Dacarel', 'Lecibra', 'Lecibral', 'Lescodil', 'Loxen', 'NSC-757855', 'Nerdipina', 'Nicant', 'Nicapress', 'Nicardal', 'Nicardipine hcl', 'Nicardipine hydrochloride', 'Nicarpin', 'Nicodel', 'Nimicor', 'Perdipina', 'Perdipine', 'RS-69216', 'RS-69216-XX-07-0', 'RS-69216XX07-0', 'Ranvil', 'Ridene', 'Rycarden', 'Rydene', 'Vasodin', 'Vasonase', 'YC-93']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for hypertension and has 3 investigational indications.,,,"['EFO_1000994', 'EFO_0000319', 'EFO_0000537', 'EFO_0005669']",4.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1988.0,CHEMBL1484,['nicardipine%20hydrochloride'],"['144212149', '26747578', '26747579', '50106640', '50106641', '50106642']",,,,,,
CHEMBL1706,Cl.c1ccc2c(CC3=NCCN3)cccc2c1,DJDFFEBSKJCGHC-UHFFFAOYSA-N,Small molecule,False,NAPHAZOLINE HYDROCHLORIDE,4.0,False,True,"['Albalon', 'Antistin-privine', 'Gppe nsl soln', 'Nafazair', 'Naphaz hcl', 'Naphazoline hydrochloride', 'Naphcon forte', 'Opcon', 'Vasocon']","['NSC-35711', 'Naphazoline HCl', 'Naphazoline hcl', 'Naphazoline hydrochloride', 'Naphazoline nitrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 4 approved and 3 investigational indications.,,,"['EFO_0000678', 'MP_0001845', 'HP_0001742', 'EFO_0007328', 'EFO_0003956', 'EFO_0007214', 'EFO_0007486']",7.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1971.0,CHEMBL761,['naphazoline%20hydrochloride'],"['56422379', '855777']",['7470'],,,,,
CHEMBL2108147,,,Enzyme,False,STREPTOKINASE,4.0,False,True,['Kabikinase'],"['Streptokinase', 'Streptokinase c']",,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for recurrent thrombophlebitis and has 6 investigational indications.,,,"['EFO_1000652', 'EFO_1001375', 'HP_0004419', 'EFO_0000612', 'HP_0002140', 'EFO_0008583', 'HP_0004936']",7.0,['ENSG00000122194'],1,1997.0,,,,,,,,,
CHEMBL2109321,,,Antibody,False,CAROTUXIMAB,3.0,False,False,[],"['Carotuximab', 'DE-122', 'TRC-105', 'Trc105', 'c-SN6j']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,,"['MONDO_0007254', 'EFO_1001968', 'MONDO_0004992', 'EFO_0000349', 'EFO_0000640', 'EFO_0002499', 'EFO_0003968', 'MONDO_0003268', 'EFO_1001111', 'MONDO_0008903', 'EFO_0003060', 'EFO_1001465', 'MONDO_0008315', 'EFO_0009708', 'EFO_0000681', 'EFO_0000519', 'EFO_0002893', 'EFO_0001365', 'EFO_0000616', 'EFO_0002501', 'EFO_0000182']",21.0,['ENSG00000106991'],1,,,,,,,,,,
CHEMBL2110580,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1,FIGNGSHKNAHTSH-JJMFXPFOSA-N,Small molecule,False,BERUBICIN,2.0,False,False,[],['Berubicin'],['CHEMBL2103796'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0000519', 'MONDO_0100342', 'EFO_0000519', 'EFO_0005543', 'EFO_0000313']",5.0,"['ENSG00000131747', 'ENSG00000077097']",2,,,,,,,,,,
CHEMBL218490,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,IAVUPMFITXYVAF-XPUUQOCRSA-N,Small molecule,False,DORZOLAMIDE,4.0,False,True,"['Dorzant', 'Trusopt']","['Dorzolamide', 'Dorzolamide, trans-(-)-', 'MK-507', 'Trusopt']",['CHEMBL1201162'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 3 investigational indications.,['Dorzolamide'],['DB00869'],"['EFO_1001069', 'MONDO_0005041', 'MONDO_0005041', 'EFO_0004190', 'EFO_0004683', 'EFO_0004190', 'EFO_1001069']",7.0,['ENSG00000104267'],1,1994.0,,,,['4702'],,,,,
CHEMBL259209,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,GJJFMKBJSRMPLA-UHFFFAOYSA-N,Small molecule,True,MILNACIPRAN,4.0,False,True,[],"['Impulsor', 'Midalcipran', 'Milnacipran']","['CHEMBL4297064', 'CHEMBL3527085']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.,,['DB04896'],"['EFO_0005762', 'HP_0003419', 'EFO_0005687', 'MONDO_0002050', 'EFO_0000555', 'HP_0003418', 'EFO_0003100', 'EFO_0005687', 'EFO_0003761']",9.0,"['ENSG00000103546', 'ENSG00000108576']",2,2009.0,,,,,,,,,
CHEMBL3545168,,,Small molecule,False,IMD-1041,2.0,False,False,[],['Imd-1041'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000341'],1.0,['ENSG00000104365'],1,,,,,,,,,,
CHEMBL450,CCC1(CC)C(=O)NC(=O)N(C)C1=O,FWJKNZONDWOGMI-UHFFFAOYSA-N,Small molecule,False,METHARBITAL,4.0,False,True,['Gemonil'],"['Endiemal', 'Metharbital', 'Metharbital ciii', 'Metharbitone', 'NSC-27156']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for epilepsy.,['Metharbital'],['DB00463'],['EFO_0000474'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,,['144206305'],,,,,,
CHEMBL464,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C,HQMNCQVAMBCHCO-DJRRULDNSA-N,Small molecule,False,ETRETINATE,4.0,True,True,"['Tegison', 'Tigason']","['Acitretin related compound b', 'Ethyl etrinoate', 'Etretinate', 'NSC-297936', 'RO 10-9359', 'RO-10-9359', 'RO-109359']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for psoriasis. It was withdrawn in at least one region.,['Etretinate'],,['EFO_0000676'],1.0,"['ENSG00000204231', 'ENSG00000172819', 'ENSG00000143171', 'ENSG00000077092', 'ENSG00000131759', 'ENSG00000186350']",6,1986.0,,,"['144206054', '170465372', '50112753']",['4913'],,,,,
CHEMBL1492500,CN(C)CC/C=C1\c2ccccc2CSc2ccccc21,PHTUQLWOUWZIMZ-GZTJUZNOSA-N,Small molecule,False,DOTHIEPIN,4.0,False,True,[],"['Dosulepin', 'Dothiepin', 'Dothirpin']",['CHEMBL1711280'],Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression.,,['DB09167'],['EFO_0003761'],1.0,"['ENSG00000103546', 'ENSG00000108576']",2,,,,['11112454'],['36803'],,,,,
CHEMBL3301578,,,Antibody,False,EMIBETUZUMAB,2.0,False,False,[],"['C-8H241', 'Emibetuzumab', 'LA480', 'LY-2875358', 'LY2875358', 'La-480']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0003060', 'MONDO_0004992', 'MONDO_0001056']",3.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL3764045,CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC,ORRNXRYWGDUDOG-UHFFFAOYSA-N,Small molecule,False,TAS-115,1.0,False,False,[],"['Pamufetinib', 'Tas-115']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000128052', 'ENSG00000105976']",2,,,,,,,,,,
CHEMBL415,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,GDLIGKIOYRNHDA-UHFFFAOYSA-N,Small molecule,True,CLOMIPRAMINE,4.0,False,True,[],"['3-chloro-iminodibenzyl', 'Anafranil', 'Anapramine', 'Chlorimipramine', 'Clomicalm', 'Clomipramine', 'NSC-169865']",['CHEMBL1200710'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.,['Clomipramine'],['DB01242'],"['MONDO_0002050', 'EFO_0005230', 'HP_0000726', 'EFO_0004242', 'EFO_0004242', 'EFO_0003761', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0803321']",9.0,['ENSG00000108576'],1,1989.0,,,"['104171137', '11110978', '11110979', '11113368', '124879726', '144203668', '170464702', '26751616', '50100206', '50104278', '90340575']",['47780'],,,['121'],,
CHEMBL483254,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,FPOHNWQLNRZRFC-ZHACJKMWSA-N,Small molecule,True,PANOBINOSTAT,4.0,False,True,['Farydak'],"['LBH-589', 'LBH589', 'Panobinostat', 'Panobinostat hydrate']",['CHEMBL3545368'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 49 investigational indications. This drug has a black box warning from the FDA.,,['DB06603'],"['EFO_0002892', 'EFO_0000349', 'EFO_0003060', 'EFO_0000673', 'EFO_0004252', 'MONDO_0007254', 'EFO_0000519', 'MONDO_0001056', 'EFO_0002617', 'EFO_1000026', 'EFO_0006475', 'EFO_0000403', 'EFO_0000681', 'EFO_0000574', 'EFO_0000756', 'EFO_0002618', 'EFO_1001469', 'EFO_0009441', 'EFO_0001378', 'EFO_0000220', 'EFO_0002429', 'EFO_0002430', 'EFO_0000616', 'EFO_0000565', 'EFO_0006738', 'MONDO_0020547', 'MONDO_0044881', 'MONDO_0002898', 'MONDO_0011382', 'EFO_0001378', 'EFO_0000183', 'MONDO_0044903', 'MONDO_0004992', 'EFO_0005952', 'EFO_1001901', 'EFO_0000339', 'EFO_1001951', 'EFO_0000764', 'EFO_0000182', 'MONDO_0100342', 'EFO_0000198', 'EFO_1000657', 'EFO_0005543', 'EFO_0000222', 'MONDO_0008903', 'MONDO_0008315', 'MONDO_0002691', 'MONDO_0009348', 'MONDO_0021063', 'EFO_1001779', 'EFO_0002913', 'MONDO_0013730']",52.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,2015.0,,,,['85990'],,,,,
CHEMBL1200903,C=CCC1(C(C)CCC)C(=O)[N-]C(=O)NC1=O.[Na+],AXXJTNXVUHVOJW-UHFFFAOYSA-M,Small molecule,False,SECOBARBITAL SODIUM,4.0,True,True,"['Secobarbital sodium', 'Seconal sodium', 'Seconesin', 'Tuinal']","['(rs)-secobarbital sodium', 'Barbosec', 'Evronal sodium', 'Immenoctal', 'NSC-10818', 'Pramil', 'Quinalbarbitone sodium', 'Sebar', 'Secobarbital sodium', 'Synate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950. It was withdrawn in at least one region.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1950.0,CHEMBL447,,,,,,,,
CHEMBL1258517,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,WXUUCRLKXQMWRY-UHFFFAOYSA-N,Small molecule,False,PKI-179,1.0,False,False,[],"['PKI-179', 'Pki-179']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000121879', 'ENSG00000198793']",2,,,,,,,,,,
CHEMBL1789844,,,Antibody,False,IPILIMUMAB,4.0,False,True,['Yervoy'],"['BMS-734016', 'BMS734016', 'Ipilimumab', 'MDX-010', 'MDX-010 MDX-CTLA4', 'MDX-101', 'MDX-CTLA-4', 'MDX010']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 12 approved and 90 investigational indications.,,,"['MONDO_0001056', 'EFO_0007466', 'EFO_0000708', 'EFO_1000984', 'EFO_1001950', 'EFO_0001416', 'EFO_0000365', 'EFO_0004251', 'EFO_0001376', 'EFO_0005952', 'EFO_1001972', 'EFO_0001378', 'MONDO_0002120', 'EFO_0004288', 'MONDO_0008315', 'MONDO_0002087', 'MONDO_0007187', 'EFO_0000339', 'EFO_0006859', 'EFO_0009709', 'EFO_0000096', 'EFO_0008528', 'EFO_0000403', 'EFO_0000389', 'MONDO_0009348', 'MONDO_0002367', 'EFO_1001968', 'EFO_1000355', 'EFO_0003085', 'EFO_1001471', 'EFO_0000621', 'EFO_0000181', 'EFO_0004243', 'MONDO_0011719', 'EFO_1000359', 'EFO_0004284', 'EFO_0003891', 'EFO_0002618', 'EFO_0000198', 'EFO_0000220', 'EFO_1001951', 'EFO_0000228', 'EFO_0000702', 'EFO_0000616', 'EFO_0001075', 'MONDO_0004992', 'MONDO_0001187', 'EFO_0000756', 'EFO_0000519', 'EFO_1000657', 'EFO_0005543', 'EFO_0004142', 'EFO_1001512', 'EFO_0000503', 'EFO_0000588', 'EFO_0001061', 'EFO_0004193', 'EFO_0000196', 'MONDO_0011962', 'MONDO_0008903', 'EFO_1000613', 'EFO_0005537', 'MONDO_0024503', 'EFO_0000673', 'EFO_0004252', 'EFO_0000707', 'MONDO_0020634', 'MONDO_0005184', 'EFO_0000222', 'EFO_0000571', 'MONDO_0008170', 'MONDO_0007254', 'EFO_0000182', 'MONDO_0016642', 'MONDO_0004669', 'EFO_0000558', 'MONDO_0002547', 'EFO_0000349', 'EFO_0000095', 'EFO_0003060', 'MONDO_0007576', 'EFO_1000251', 'EFO_0000681', 'MONDO_0002898', 'EFO_0002916', 'MONDO_0100342', 'MONDO_0017582', 'EFO_0001663', 'EFO_0000313', 'MONDO_0021063', 'EFO_0002617', 'EFO_0000574', 'EFO_0003863', 'EFO_0000770', 'MONDO_0002108', 'EFO_0000691', 'EFO_0008524', 'EFO_0000305', 'EFO_0000764', 'EFO_1001465', 'EFO_0000183', 'EFO_0005221']",102.0,['ENSG00000163599'],1,2011.0,,['ipilimumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy'],,,['4958'],
CHEMBL3707374,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F.Cl,GEDVJGOVRLHFQG-UHFFFAOYSA-N,Small molecule,False,AMISELIMOD HYDROCHLORIDE,2.0,False,False,[],"['Amiselimod hydrochloride', 'MT-1303']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000729', 'MONDO_0007915', 'EFO_0000384']",6.0,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']",5,,CHEMBL3707375,,,,,,,,
CHEMBL4112929,C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O,FSWFYCYPTDLKON-CMJOXMDJSA-N,Small molecule,False,MILVEXIAN,3.0,False,False,[],"['BMS 986177', 'BMS-986177', 'Bms-986177', 'JNJ-70033093', 'Jnj-70033093', 'Milvexian']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0000275', 'MONDO_0000831', 'EFO_0005672']",3.0,['ENSG00000088926'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/MILVEXIAN/relevant/1/'],,,
CHEMBL107367,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,ZZCHHVUQYRMYLW-HKBQPEDESA-N,Small molecule,False,FARGLITAZAR,2.0,False,False,[],"['Farglitazar', 'G1-262570', 'GI-262570', 'GI-262570X', 'GI262570X', 'Gi262570']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,['Farglitazar'],,['EFO_0001422'],1.0,['ENSG00000132170'],1,,,,['144210538'],,,,,,
CHEMBL111659,C#Cc1cncc([C@@H]2CCCN2C)c1,NUPUDYKEEJNZRG-LBPRGKRZSA-N,Small molecule,False,ALTINICLINE,2.0,False,False,[],"['(-)-5-ethynylnicotine', 'Altinicline', 'SIB-1508Y', 'SIB-1765F']",['CHEMBL2146093'],Small molecule drug with a maximum clinical trial phase of II.,['Altinicline'],,,,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL112,CC(=O)Nc1ccc(O)cc1,RZVAJINKPMORJF-UHFFFAOYSA-N,Small molecule,True,ACETAMINOPHEN,4.0,False,True,"['Abdine', 'Acephen', 'Acetaminophen', 'Alvedon', 'Angiers', 'Calpol', 'Calpol six plus', 'Calpol six plus fastmelts', 'Child lemsip', 'Cupanol', 'Dafalgan', 'Datril', 'Disprol', 'Disprol infant', 'Disprol jnr', 'Disprol paed', 'Fennings', 'Galpamol', 'Hedex', 'Infadrops', ""Infants' feverall"", 'Injectapap', 'Junior parapaed', 'Mandanol', 'Medinol', 'Medinol for children', 'Medinol over 6', 'Medinol under 6', 'Medised plain', 'Miradol', 'Neopap', 'Ofirmev', 'Paldesic', 'Panadol', 'Panadol actifast', 'Panadol actifast solb', 'Panadol advan', 'Panadol jnr', 'Panadol oa', 'Panaleve', 'Panaleve 6 plus', 'Paracetamol', 'Paramin', 'Parapaed jnr', 'Parapaed six plus', 'Paravict', 'Perfalgan', 'Phenaphen', 'Placidex', 'Rimadol', 'Salzone', 'Tixymol', 'Tramil 500', 'Tylenol']","['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'Efferalgan', 'N-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilid', 'Paracetamol', 'Paracetamolum', 'Vermidon']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 12 approved and 96 investigational indications. This drug has a black box warning from the FDA.,['Paracetamol'],['DB00316'],"['MONDO_0100096', 'HP_0002315', 'HP_0002013', 'MONDO_0007915', 'EFO_0000685', 'EFO_0000220', 'EFO_0002460', 'EFO_0000384', 'EFO_0005592', 'MONDO_0005147', 'HP_0011110', 'HP_0012076', 'EFO_1001139', 'EFO_0009615', 'Orphanet_365', 'EFO_0000540', 'EFO_0000389', 'EFO_1000783', 'EFO_0010282', 'EFO_0003086', 'MONDO_0005148', 'HP_0002018', 'MONDO_0043510', 'HP_0000175', 'EFO_0000574', 'HP_0000989', 'HP_0002027', 'MONDO_0005180', 'HP_0012115', 'EFO_0000544', 'EFO_0000095', 'EFO_0000339', 'EFO_1001412', 'EFO_0000537', 'EFO_0000403', 'EFO_0000222', 'MONDO_0007254', 'HP_0003419', 'HP_0001945', 'EFO_0004599', 'EFO_0001378', 'EFO_0001068', 'EFO_0004209', 'EFO_0004253', 'EFO_1000831', 'MONDO_0005301', 'MONDO_0005041', 'EFO_0000618', 'EFO_0001073', 'EFO_0005230', 'MONDO_0002367', 'EFO_0004616', 'HP_0100806', 'HP_0000545', 'EFO_0003060', 'EFO_0004255', 'EFO_0000198', 'EFO_0000546', 'EFO_0004197', 'EFO_1000249', 'EFO_0003931', 'EFO_1001216', 'EFO_0004888', 'EFO_0009846', 'HP_0001643', 'EFO_0010072', 'EFO_1000749', 'EFO_0000616', 'EFO_0007160', 'HP_0003418', 'EFO_1001250', 'MONDO_0005277', 'EFO_1001476', 'EFO_0000668', 'EFO_0001074', 'EFO_0000096', 'HP_0012228', 'EFO_0005856', 'EFO_0004269', 'MONDO_0004992', 'HP_0012532', 'MONDO_0005178', 'EFO_0003843', 'EFO_0007486', 'HP_0030833', 'EFO_0004273', 'HP_0100607', 'EFO_0000764', 'EFO_0005762', 'HP_0008419', 'EFO_0005761', 'EFO_0007359', 'MP_0001914', 'MONDO_0100342', 'MONDO_0044917', 'EFO_0011023', 'MONDO_0009291', 'EFO_0005952', 'MONDO_0002258', 'MONDO_0017287', 'EFO_0009267', 'EFO_1000786', 'EFO_0801084', 'MONDO_0024355', 'EFO_0007214', 'EFO_0007328', 'EFO_1001898', 'EFO_0007444']",108.0,"['ENSG00000196689', 'ENSG00000073756', 'ENSG00000095303', 'ENSG00000117480']",4,1968.0,,['acetaminophen'],"['104171293', '11112253', '11114188', '124882135', '144209128', '144210420', '170466797', '17390068', '174007306', '26747171', '56422763']",['46195'],,,['1'],,
CHEMBL1162175,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21,NXHAXEBZOXCDKD-XIXRRVGJSA-N,Small molecule,False,REGRELOR,2.0,False,False,[],['Regrelor'],['CHEMBL261244'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB05553'],"['EFO_0001645', 'EFO_0000319']",2.0,['ENSG00000169313'],1,,,,,,,,,,
CHEMBL1201486,,,Small molecule,True,QUINIDINE POLYGALACTURONATE,4.0,False,True,['Cardioquin'],"['Galactoquin', 'Naticardina', 'Quinidine polygalacturonate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982. This drug has a black box warning from the FDA.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,,,,,,,,,
CHEMBL1614710,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,FGTCROZDHDSNIO-UHFFFAOYSA-N,Small molecule,False,OSI-930,1.0,False,False,[],"['OSI-930', 'Osi 930', 'Osi-930']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB05913'],['EFO_0000616'],1.0,"['ENSG00000157404', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",4,,,,['137276003'],,,,,,
CHEMBL2068724,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2],BUVGWDNTAWHSKI-UHFFFAOYSA-L,Small molecule,False,ACAMPROSATE CALCIUM,4.0,False,True,"['Acamprosate calcium', 'Campral', 'Campral ec']","['Acamprosate calcium', 'NSC-759186', 'SN-102']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2004 and is indicated for alcohol dependence.,,,['MONDO_0007079'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",23,2004.0,CHEMBL1201293,['acamprosate%20calcium'],"['144206019', '144212923']",['51042'],,,,,
CHEMBL2108350,,,Protein,False,CONESTAT ALFA,4.0,False,True,['Ruconest'],"['C1 esterase inhibitor', 'Complement c1 esterase inhibitor', 'Conestat alfa', 'Recombinant human c1 inhibitor', 'Recombinant human c1-inhibitor', 'Rhucin', 'Ruconest']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for hereditary angioedema and has 6 investigational indications.,,,"['EFO_0000508', 'MONDO_0100096', 'HP_0001919', 'EFO_0007224', 'MONDO_0019623', 'EFO_0004599', 'EFO_0008586']",7.0,['ENSG00000149131'],1,2010.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/ruconest'],,,['5152'],
CHEMBL3260567,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,FJCDSQATIJKQKA-UHFFFAOYSA-N,Small molecule,False,VACTOSERTIB,2.0,False,False,[],"['Ew-7197', 'TEW-7197', 'Tew 7197', 'Tew-7197', 'Vactosertib']",['CHEMBL3260908'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,['DB15310'],"['EFO_0000637', 'EFO_0003060', 'EFO_0002618', 'EFO_0009907', 'EFO_0004251', 'EFO_0008528', 'EFO_0000198', 'EFO_0000616', 'EFO_0003897', 'EFO_0001378', 'MONDO_0001056']",11.0,['ENSG00000106799'],1,,,,,,,,,,
CHEMBL3894860,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,PDGKHKMBHVFCMG-UHFFFAOYSA-N,Small molecule,False,TRILACICLIB,4.0,False,True,[],"['G1T28', 'G1t28-1', 'Trilaciclib']",['CHEMBL4650272'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for small cell lung carcinoma and has 6 investigational indications.,,['DB15442'],"['EFO_0003060', 'MONDO_0007254', 'EFO_0003869', 'EFO_0000702', 'EFO_0003968', 'EFO_0005537', 'EFO_0000702']",7.0,"['ENSG00000105810', 'ENSG00000135446']",2,2021.0,,,,,,,,,
CHEMBL3989676,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O,CNDQSXOVEQXJOE-UHFFFAOYSA-N,Small molecule,False,OXYPHENBUTAZONE,4.0,True,True,"['Oxyphenbutazone', 'Tandearil', 'Tanderil', 'Tanderil chloramphen']","['NSC-757261', 'Oxiphenbutazone', 'Oxyphenbutazone', 'Oxyphenbutazone hydrate', 'Oxyphenbutazone monohydrate', 'Phlogase', 'Phlogistol', 'Phlogont']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 approved indications. It was withdrawn in at least one region.,,,"['EFO_0005755', 'EFO_0005752', 'HP_0002829', 'HP_0003326']",4.0,"['ENSG00000073756', 'ENSG00000095303']",2,1960.0,CHEMBL1228,,,,,,,,
CHEMBL4297456,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O,MMHDBUJXLOFTLC-WOYTXXSLSA-N,Protein,False,ATN-161,2.0,False,False,[],"['ATN 161', 'ATN-161', 'Ac-phscn-nh2', 'Atn-161']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_1000158', 'EFO_0000681']",2.0,"['ENSG00000150093', 'ENSG00000161638', 'ENSG00000259207', 'ENSG00000138448']",4,,,,,,,,,,
CHEMBL4297530,CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(=O)O,MRWFZSLZNUJVQW-DEOSSOPVSA-N,Small molecule,False,SAROGLITAZAR,3.0,False,False,[],['Saroglitazar'],,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,['DB13115'],"['HP_0001397', 'Orphanet_309005', 'EFO_0003095', 'EFO_1001486', 'EFO_0001422', 'EFO_0001421', 'EFO_1001249', 'EFO_0003086']",8.0,"['ENSG00000186951', 'ENSG00000132170']",2,,,,,,,,,,
CHEMBL507361,O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,SUDAHWBOROXANE-SECBINFHSA-N,Small molecule,False,MIRDAMETINIB,2.0,False,False,[],"['Mirdametinib', 'PD-0325901', 'Pd 0325901', 'Pd 03525901', 'Pd 901', 'Pd-0325901']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB07101'],"['MONDO_0004992', 'EFO_0000616', 'MONDO_0018975', 'EFO_1001951', 'EFO_0003060']",5.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,['144206915'],['88249'],,['https://searchusan.ama-assn.org/finder/usan/search/MIRDAMETINIB/relevant/1/'],,,
CHEMBL919,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+],GQPXYJNXTAFDLT-UHFFFAOYSA-L,Small molecule,True,FOSPHENYTOIN SODIUM,4.0,False,True,"['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']","['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982', 'Fosphenytoin disodium salt', 'Fosphenytoin sodium']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996. This drug has a black box warning from the FDA.,['Fosphenytoin'],,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1996.0,CHEMBL1201336,['fosphenytoin%20sodium'],,,,,,,
CHEMBL1200395,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,MMMNTDFSPSQXJP-UHFFFAOYSA-N,Small molecule,False,ORPHENADRINE CITRATE,4.0,False,True,"['Norflex', 'Orphenadrine citrate']","['NSC-757238', 'Orphenadine citrate', 'Orphenadrine (citrate)', 'Orphenadrine Citrate', 'Orphenadrine citrate', 'Orphenadrine dihydrogen citrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for pain.,,,['EFO_0003843'],1.0,"['ENSG00000196639', 'ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785', 'ENSG00000103546', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",19,1959.0,CHEMBL900,['orphenadrine%20citrate'],"['11532864', '144204876', '144207092', '144211396', '170464910', '26748176']",['7790'],,,,,
CHEMBL1201269,CC(C)(N)Cc1ccc(Cl)cc1,ZCKAMNXUHHNZLN-UHFFFAOYSA-N,Small molecule,False,CHLORPHENTERMINE,4.0,True,True,[],['Chlorphentermine'],['CHEMBL1200595'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Chlorphentermine'],['DB01556'],,,['ENSG00000108576'],1,1982.0,,,['29216103'],['3646'],,,,,
CHEMBL2106155,COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1.Cl,OJIIZIWOLTYOBS-UHFFFAOYSA-N,Small molecule,False,ENCAINIDE HYDROCHLORIDE,4.0,True,True,[],"['Encainide hcl', 'Encainide hydrochloride', 'MJ 9067-1', 'MJ-9067', 'MJ-9067-1']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. It was withdrawn in at least one region.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1986.0,CHEMBL315838,,['144207047'],['59880'],,,,,
CHEMBL2108131,,,Unknown,False,PLASMINOGEN,3.0,False,False,[],"['Human plasminogen', 'Plasma trypsinogen', 'Plasminogen', 'Profibrinolysin']",,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000712', 'HP_0002140']",2.0,"['ENSG00000171560', 'ENSG00000171564', 'ENSG00000171557']",3,,,,,,,,,,
CHEMBL2109288,,,Antibody drug conjugate,False,BIVATUZUMAB MERTANSINE,1.0,False,False,[],"['BIWA-1-DM1', 'Bivatuzumab mertansine', 'Biwa-4 mertansine']",,Antibody drug conjugate drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000026508']",16,,,,,,,,,,
CHEMBL4113131,C[C@@H]1CN(C(=O)c2ccc(NC(=O)c3cc(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c(N)nn3)cc2)C[C@H](C)N1,GLYMPHUVMRFTFV-QLFBSQMISA-N,Small molecule,False,ENSARTINIB,3.0,False,False,[],"['Ensartinib', 'X-396']",['CHEMBL4297219'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB14860'],"['MONDO_0008903', 'EFO_0003060', 'EFO_0003060', 'EFO_0000756']",4.0,['ENSG00000171094'],1,,,,,,,,,,
CHEMBL4297190,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1,TTZSNFLLYPYKIL-UHFFFAOYSA-N,Small molecule,False,SURUFATINIB,3.0,False,False,[],"['HMPL-012', 'Hmpl-012', 'Sulfatinib', 'Surufatinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,,['DB15106'],"['EFO_0003086', 'EFO_0001421', 'EFO_0000503', 'EFO_0003860', 'EFO_0005537', 'EFO_0003060', 'EFO_0000702', 'EFO_0000616', 'EFO_0002618', 'EFO_0000637', 'EFO_0006859', 'MONDO_0007254', 'EFO_0004142', 'MONDO_0005184', 'EFO_1001901', 'EFO_0000691', 'EFO_1001951', 'EFO_0002892', 'MONDO_0005575', 'EFO_1001968', 'MONDO_0003060', 'MONDO_0002120', 'EFO_0000182', 'EFO_0004252', 'MONDO_0008170', 'MONDO_0002108']",26.0,"['ENSG00000077782', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SURUFATINIB/relevant/1/'],,,
CHEMBL1096380,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,UNRCMCRRFYFGFX-TYPNBTCFSA-N,Small molecule,False,PLINABULIN,3.0,False,False,[],"['NPI-2358', 'Plinabulin']",['CHEMBL4063810'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,['DB05992'],"['EFO_0001378', 'MONDO_0001475', 'EFO_0003060', 'EFO_0000702', 'MONDO_0004992']",5.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL1200322,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,KTGRHKOEFSJQNS-BDQAORGHSA-N,Small molecule,True,ESCITALOPRAM OXALATE,4.0,False,True,"['Escitalopram oxalate', 'Lexapro']","['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)', 'Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-O', 'NSC-758934']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 4 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003761', 'MONDO_0002009', 'EFO_1001919', 'EFO_0004262', 'EFO_0006788', 'EFO_0000555', 'EFO_1001892', 'MONDO_0002050']",8.0,['ENSG00000108576'],1,2002.0,CHEMBL1508,['escitalopram%20oxalate'],"['144205088', '170465453', '26749920', '49681820']",,,,,,
CHEMBL1200409,CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl.O,YECIFGHRMFEPJK-UHFFFAOYSA-N,Small molecule,True,LIDOCAINE HYDROCHLORIDE,4.0,False,True,"['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'Bismodyne', 'Bradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'Dequaspray', 'Emla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'Iglu', 'Instillagel', 'Laryng-o-jet kit', 'Laryngojet', 'Laryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochloride', 'Lidocaine hydrochloride preservative free', 'Lidocaine hydrochloride viscous', 'Lidocaine viscous', 'Lidocaton', 'Lidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100', 'Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'Oragard', 'Pediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'Xylocaine', 'Xylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscous', 'Xylotox e80', 'Zingo']","['Anhydrous lidocaine hydrochloride', 'Lidocaine hcl', 'Lidocaine hydrochloride', 'Lidocaine hydrochloride anhydrous', 'Lidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride usp', 'Lidocaini hydrochloridum', 'Lignocaine (as hydrochloride)', 'Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 3 approved and 16 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000537', 'EFO_0003843', 'MONDO_0004992', 'MONDO_0005277', 'MONDO_0002691', 'EFO_0007490', 'EFO_1001250', 'HP_0012532', 'HP_0003418', 'HP_0000989', 'EFO_0002950', 'EFO_0009552', 'EFO_0001663', 'EFO_0000546', 'EFO_0000400', 'EFO_0002618', 'HP_0002315', 'EFO_1001898', 'EFO_1001996']",19.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1948.0,CHEMBL79,['lidocaine%20hydrochloride'],['56422178'],['60791'],,,,,
CHEMBL1200773,Cc1cccc(C)c1NC(=O)C(C)N.Cl,AMZACPWEJDQXGW-UHFFFAOYSA-N,Small molecule,True,TOCAINIDE HYDROCHLORIDE,4.0,False,True,"['Tonocard', 'Xylotocan']","['Tocainide hcl', 'Tocainide hydrochloride', 'Tocainide monohydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1984.0,CHEMBL1762,,"['144204283', '170465114']",,,,,,
CHEMBL1489,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,NMUSYJAQQFHJEW-KVTDHHQDSA-N,Small molecule,False,AZACITIDINE,4.0,False,True,"['Azacitidine', 'Azacitidine accord', 'Onureg', 'Vidaza']","['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496', 'U-18496', 'Vidaza']","['CHEMBL3250420', 'CHEMBL3250421']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 approved and 56 investigational indications.,['Azacitidine'],['DB00928'],"['MONDO_0007576', 'EFO_1001951', 'MONDO_0018906', 'EFO_0000221', 'EFO_0000403', 'EFO_0006861', 'MONDO_0008170', 'EFO_0000389', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000339', 'EFO_0000569', 'MONDO_0044903', 'EFO_0005952', 'MONDO_0018076', 'EFO_0006859', 'MONDO_0003478', 'EFO_1001257', 'EFO_0003869', 'EFO_0003833', 'EFO_1001779', 'EFO_0000681', 'MONDO_0009348', 'Orphanet_848', 'EFO_0000707', 'EFO_0003811', 'EFO_0001642', 'MONDO_0020077', 'EFO_0001378', 'EFO_0000209', 'MONDO_0044881', 'MONDO_0021063', 'EFO_1000028', 'EFO_0000326', 'EFO_0000574', 'EFO_0002617', 'EFO_0002618', 'EFO_0000220', 'MONDO_0007254', 'MONDO_0000430', 'EFO_0000673', 'EFO_0004251', 'EFO_1000657', 'EFO_0000637', 'EFO_0004252', 'EFO_0000181', 'EFO_0000222', 'EFO_0000183', 'MONDO_0019469', 'EFO_0000198', 'MONDO_0013730', 'HP_0001873', 'EFO_0004289', 'EFO_0000255', 'MONDO_0008315', 'MONDO_0002492', 'MONDO_0002280', 'MONDO_0016586', 'EFO_0000565', 'EFO_0000095', 'EFO_0000616', 'MONDO_0016486', 'EFO_0000211', 'MONDO_0005184']",64.0,"['ENSG00000119772', 'ENSG00000130816']",2,2004.0,,['azacitidine'],"['124890084', '144204583', '144213302', '170465076', '17390033', '26752817', '50105470', '50105471', '50122846', '56320704', '56323580', '90341307']",['2038'],['https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord'],,,,
CHEMBL1628502,CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C,TZDUHAJSIBHXDL-UHFFFAOYSA-N,Small molecule,False,GABAPENTIN ENACARBIL,4.0,False,True,['Horizant'],"['ASP-8825', 'ASP8825', 'GSK1838262', 'Gabapentin enacarbil', 'Gabapentin encarbil', 'Gsk-1838262', 'XP 13512', 'XP-13512', 'XP13512']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for neuralgia and restless legs syndrome and has 4 investigational indications.,,['DB08872'],"['EFO_0003086', 'EFO_0009430', 'EFO_1000783', 'MONDO_0007079', 'EFO_0004270', 'MONDO_0005277']",6.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,2011.0,,['gabapentin%20enacarbil'],,['68840'],,,,,
CHEMBL2108038,,,Antibody,False,MATUZUMAB,2.0,False,False,[],"['EMD-72000', 'Matuzumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0003060', 'MONDO_0008170']",2.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL2108426,,,Enzyme,False,MONTEPLASE,3.0,False,False,[],"['Cleactor', 'Monteplase']",,Enzyme drug with a maximum clinical trial phase of III.,,,,,['ENSG00000104368'],1,,,,,,,,,,
CHEMBL30219,C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+],KDXZREBVGAGZHS-UHFFFAOYSA-M,Small molecule,True,METHOHEXITAL SODIUM,4.0,False,True,"['Brevimytal', 'Brevital', 'Brevital sodium', 'Brietal', 'Brietal sod', 'Methohexitone']","['Enallynymal sodium', 'Methohexital sodium', 'Methohexital sodium salt', 'Sodium methohexital']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1960.0,CHEMBL7413,['methohexital%20sodium'],,['6834'],,,,,
CHEMBL3545155,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1,ZXBFYBLSJMEBEP-UHFFFAOYSA-N,Small molecule,False,JI-101,2.0,False,False,[],"['Angiogenesis inhibitor ji-101', 'CGI-1842', 'JI-101', 'Ji-101']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB12744'],"['MONDO_0021063', 'MONDO_0008170', 'EFO_0000616']",3.0,"['ENSG00000196411', 'ENSG00000113721', 'ENSG00000128052']",3,,,,,,,,,,
CHEMBL4297841,,,Antibody drug conjugate,True,TISOTUMAB VEDOTIN,4.0,False,True,['Tivdak'],"['GCT1015-04', 'HuMax-TF-ADC', 'IGG1-1015-011-1006', 'TF-011-MMAE', 'Tisotumab vedotin', 'Tisotumab vedotin tftv']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0002087', 'MONDO_0002158', 'MONDO_0002974', 'MONDO_0008170', 'MONDO_0004992', 'EFO_0000616']",6.0,"['ENSG00000117525', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,2021.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TISOTUMAB%20VEDOTIN/relevant/1/'],,,
CHEMBL4298016,,,Antibody,False,FROVOCIMAB,2.0,False,False,[],"['Frovocimab', 'LY-3015014', 'LY3015014', 'Ly3015014']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['HP_0003124', 'MONDO_0021187']",2.0,['ENSG00000169174'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/FROVOCIMAB/relevant/1/'],,,
CHEMBL4298139,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1.[Cl-],GONQEUJYYMYNMN-HWAJWLCKSA-N,Small molecule,False,SERDEXMETHYLPHENIDATE CHLORIDE,4.0,False,True,[],"['KP415 Cl', 'Serdexmethylphenidate chloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder.,,,['EFO_0003888'],1.0,"['ENSG00000103546', 'ENSG00000142319']",2,2021.0,CHEMBL4301162,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SERDEXMETHYLPHENIDATE%20CHLORIDE/relevant/1/'],,,
CHEMBL1201837,,,Protein,True,ECALLANTIDE,4.0,False,True,[],"['DX-88', 'Ecallantide', 'Escallantide']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for hereditary angioedema and has 1 investigational indication. This drug has a black box warning from the FDA.,['Ecallantide'],,"['EFO_0005532', 'MONDO_0019623']",2.0,['ENSG00000164344'],1,2009.0,,['ecallantide'],,,,,,['4846'],
CHEMBL2103836,CCC[C@@H](C)C[C@H](N)CC(=O)O,JXEHXYFSIOYTAH-SFYZADRCSA-N,Small molecule,False,IMAGABALIN,3.0,False,False,[],"['Imagabalin', 'PD 0332334', 'PD-0332334', 'PD0332334', 'PF-00195889']",['CHEMBL2105673'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB12105'],"['EFO_1001892', 'HP_0000083', 'EFO_0005230']",3.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,,,,,,,,,,
CHEMBL2108806,,,Oligosaccharide,False,BEMIPARIN SODIUM,4.0,False,True,['Zibor'],"['Badyket', 'Bemiparin sodium', 'Hibor', 'Zivor']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,,"['EFO_0003907', 'MONDO_0100096']",2.0,['ENSG00000117601'],1,,,,,,,,,,
CHEMBL214268,O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1,IPKZCLGGYKRDES-ZDUSSCGKSA-N,Small molecule,False,PHA-543613,1.0,False,False,[],"['J3.179.420J', 'PHA-543,613', 'PHA-543613', 'Pha-00543613', 'Pha-543613']",,Small molecule drug with a maximum clinical trial phase of I.,"['PHA-543,613']",,,,['ENSG00000175344'],1,,,,['144210766'],,,,,,
CHEMBL315795,Cc1ncsc1CCCl,PCLITLDOTJTVDJ-UHFFFAOYSA-N,Small molecule,False,CLOMETHIAZOLE,4.0,False,True,['Heminevrin'],"['Chlormethiazole', 'Clomethiazole', 'Distraneurine', 'SCTZ [AS EDISYLATE]']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications.,['Clomethiazole'],['DB06470'],"['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090']",4.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,"['11113756', '144204482', '170466516', '26751938', '90341262']",,,,,,
CHEMBL3545419,,,Antibody,False,TELISOTUZUMAB,2.0,False,False,[],"['ABT-700', 'Abt-700', 'Telisotuzumab']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL4303323,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,DOCINCLJNAXZQF-LBPRGKRZSA-N,Small molecule,False,ACALISIB,2.0,False,False,[],"['Acalisib', 'CAL-120', 'CAL120', 'GS-9820', 'GS9820', 'Gs-9820']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0001642'],1.0,['ENSG00000171608'],1,,,,,,,,,,
CHEMBL4594403,CC1=CN2CCS(=O)(=O)N=C2C(c2ccc(OC3CCCCC3)cc2)=N1,PXJBHEHFVQVDDS-UHFFFAOYSA-N,Small molecule,False,OSAVAMPATOR,2.0,False,False,[],"['Osavampator', 'Tak-653']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0002050'],1.0,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-129']
CHEMBL4650369,,,Antibody,False,ABELACIMAB,3.0,False,False,[],['Abelacimab'],,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000275', 'EFO_0004286']",2.0,['ENSG00000088926'],1,,,,,,,,,,
CHEMBL1077896,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,ZKMNUMMKYBVTFN-HNNXBMFYSA-N,Small molecule,False,ROPIVACAINE,4.0,False,True,[],"['Ropivacaine', 'Ropivicaine', 'TLC-590', 'TLC590', 'Tlc590']",['CHEMBL1889140'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for pain and has 32 investigational indications.,['Ropivacaine'],['DB00296'],"['EFO_0003843', 'HP_0012532', 'EFO_0007355', 'MONDO_0005178', 'EFO_0003869', 'MONDO_0001572', 'EFO_0003931', 'EFO_0009507', 'EFO_0002950', 'EFO_0009620', 'MONDO_0001056', 'HP_0003040', 'HP_0003470', 'MONDO_0004992', 'EFO_0009676', 'EFO_0001358', 'MONDO_0008170', 'EFO_0005251', 'HP_0000138', 'EFO_0006859', 'MONDO_0007254', 'HP_0030834', 'HP_0000023', 'HP_0000023', 'EFO_0007149', 'EFO_0003843', 'HP_0002027', 'HP_0001822', 'HP_0002017', 'MONDO_0005178', 'EFO_1001909', 'EFO_0007486', 'HP_0001822', 'EFO_0004616', 'EFO_1001250']",35.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1996.0,,,['26758019'],['8890'],,,,,
CHEMBL1200420,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.Cl,PLYSCVSCYOQVRP-UHFFFAOYSA-N,Small molecule,True,MIDAZOLAM HYDROCHLORIDE,4.0,False,True,"['Buccolam', 'Dormicum', 'Hypnovel', 'Midazolam hydrochloride', 'Midazolam hydrochloride (autoinjector)', 'Midazolam hydrochloride preservative free', 'Midozalam hydrochloride', 'Rocam', 'Seizalam', 'Versed']","['Midazolam hcl', 'Midazolam hydrochloride', 'Midazolam hydrochloride civ', 'NSC-751451', 'RO 21-3981/003', 'RO-213981001', 'Ro-213981-003', 'SHP-615', 'SHP615']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for amnesia and has 11 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0002009', 'EFO_0000274', 'EFO_0008526', 'EFO_0000618', 'MONDO_0005148', 'EFO_0000662', 'EFO_0000616', 'MONDO_0018076', 'MONDO_0002050', 'MONDO_0004985', 'EFO_1001454', 'EFO_1001884']",12.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1985.0,CHEMBL655,['midazolam%20hydrochloride'],"['144206166', '170465015', '49731994']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/buccolam'],,,,
CHEMBL1738,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,BMKDZUISNHGIBY-ZETCQYMHSA-N,Small molecule,False,DEXRAZOXANE,4.0,False,True,['Cardioxane'],"['ADR-529', 'Dexrazoxane', 'ICRF-187', 'NSC-169780', 'Razoxane, (s)-', 'Razoxane, d-']",['CHEMBL1200778'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 24 investigational indications.,['Dexrazoxane'],['DB00380'],"['EFO_0000502', 'EFO_0000691', 'EFO_1001968', 'MONDO_0000870', 'EFO_1000292', 'MONDO_0005301', 'EFO_0000502', 'EFO_0000565', 'EFO_0000616', 'EFO_0000209', 'EFO_1000158', 'EFO_0000174', 'EFO_0000318', 'HP_0030680', 'EFO_0000220', 'EFO_0000637', 'EFO_1000984', 'EFO_0000621', 'EFO_0000621', 'EFO_0000574', 'EFO_0000198', 'MONDO_0004992', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000222', 'EFO_0002918']",26.0,"['ENSG00000131747', 'ENSG00000077097']",2,1995.0,,,"['144205809', '170464709', '442425']",['50223'],,,,,
CHEMBL188952,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,PIDSZXPFGCURGN-UHFFFAOYSA-N,Small molecule,False,PIRPROFEN,4.0,True,True,[],"['Pirprofen', 'Racemic pirprofen', 'Rangasil 400', 'Rengasil', 'SU 21524', 'SU-21524', 'Seflenyl']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and is indicated for rheumatic disease. It was withdrawn in at least one region.,['Pirprofen'],['DB13722'],['EFO_0005755'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,1987.0,,,,,,,,,
CHEMBL2104954,COc1cc2c(Nc3ccc(Sc4nccn4C)c(Cl)c3)c(C#N)cnc2cc1N1CCC(N2CCCC2)CC1,CVAKNHIXTWLGJO-UHFFFAOYSA-N,Small molecule,False,BALAMAPIMOD,2.0,False,False,[],"['Balamapimod', 'MKI-833']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000126934', 'ENSG00000169032']",2,,,,,,,,,,
CHEMBL2106419,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1.Cl,WMFYOYKPJLRMJI-UHFFFAOYSA-N,Small molecule,False,LERCANIDIPINE HYDROCHLORIDE,4.0,False,True,['Zanidip'],"['Lercanidipine hcl', 'Lercanidipine hydrochloride', 'REC-15/2375']",,Small molecule drug with a maximum clinical trial phase of IV.,,,,,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,CHEMBL250270,,"['144206046', '170465587']",,,,,,
CHEMBL3334567,C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,XYDNMOZJKOGZLS-NSHDSACASA-N,Small molecule,False,SAVOLITINIB,3.0,False,False,[],"['AZD-6094', 'AZD6094', 'Azd-6094', 'HMPL-504', 'Savolitinib', 'Volitinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,['DB12048'],"['EFO_0003863', 'EFO_0000313', 'EFO_1000657', 'EFO_0003060', 'EFO_0000681', 'MONDO_0004992', 'MONDO_0001056', 'EFO_0000503', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0000640', 'EFO_0000616', 'EFO_1001951', 'EFO_1001949']",14.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL3545006,,,Small molecule,False,PWT-33587,1.0,False,False,[],['Pwt-33587'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,,,,,,
CHEMBL3545280,Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N,JCYNMRJCUYVDBC-UHFFFAOYSA-N,Small molecule,False,EFATUTAZONE,2.0,False,False,[],"['Efatutazone', 'Inolitazone']",['CHEMBL3545279'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB11894'],"['MONDO_0004992', 'EFO_1001951', 'EFO_0000616', 'EFO_0000569', 'EFO_0003060', 'MONDO_0002108', 'EFO_0001378', 'EFO_0000365']",8.0,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL3545393,,,Small molecule,False,XL550,3.0,False,False,[],"['CS-3150', 'Esaxerenone', 'XL-550', 'Xl550']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0000537', 'EFO_0000401', 'MONDO_0001422', 'MONDO_0001134']",4.0,['ENSG00000151623'],1,,,,,,,,,,
CHEMBL1083385,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O,FDEODCTUSIWGLK-RSAXXLAASA-N,Small molecule,True,CLOPIDOGREL BISULFATE,4.0,False,True,"['Clopidogrel bisulfate', 'Iscover', 'Plavix']","['Clopidogrel (as bisulfate)', 'Clopidogrel (as hydrogen sulfate)', 'Clopidogrel bisulfate', 'Clopidogrel bisulphate', 'Clopidogrel bms', 'Clopidogrel hydrogen sulfate', 'Clopidogrel hydrogen sulphate', 'Clopidogrel ratiopharm', 'Clopidogrel sulfate', 'Clopidogrel teva', 'Clopidogrel zentiva', 'Clopidogrel-bgr', 'Clopidogrel-bms', 'Isocover', 'Pidogrel', 'SR 25990C', 'SR-25990C']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0005672', 'EFO_0004265', 'EFO_0000612', 'EFO_0001645', 'EFO_0003869', 'HP_0002239', 'EFO_0000712', 'HP_0002140', 'EFO_1000985', 'EFO_0000556']",10.0,['ENSG00000169313'],1,1997.0,CHEMBL1771,['clopidogrel%20bisulfate'],"['144205123', '170465231']",['3759'],['https://www.ema.europa.eu/en/medicines/human/EPAR/iscover'],,,,
CHEMBL1200478,CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1.Cl,KNZADIMHVBBPOA-UHFFFAOYSA-N,Small molecule,False,DYCLONINE HYDROCHLORIDE,4.0,False,True,['Dyclone'],"['Dyclocaine', 'Dyclonine HCl', 'Dyclonine hcl', 'Dyclonine hydrochloride', 'NSC-23018']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,CHEMBL1201217,['dyclonine%20hydrochloride'],"['144204010', '170464776', '26748011', '26748012', '50107329', '50107330', '56422189', '855952']",['4725'],,,,,
CHEMBL2104984,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3F)nc2C)ccc1OC(C)(C)C(=O)O,ZUGQWAYOWCBWGM-UHFFFAOYSA-N,Small molecule,False,SODELGLITAZAR,2.0,False,False,[],"['GW-677954', 'GW677954', 'Sodelglitazar']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0005148', 'EFO_0000195']",2.0,"['ENSG00000132170', 'ENSG00000186951', 'ENSG00000112033']",3,,,,,,,,,,
CHEMBL24072,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,IFFPICMESYHZPQ-UHFFFAOYSA-N,Small molecule,False,PRENYLAMINE,4.0,True,True,[],"['B-436', 'Prenylamine', 'Prenylamine lactate']",['CHEMBL1367944'],Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region.,['Prenylamine'],['DB04825'],['EFO_0000319'],1.0,"['ENSG00000183873', 'ENSG00000198668']",2,,,,,,,,,,
CHEMBL3935857,Nc1nc2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1,BLGWHBSBBJNKJO-UHFFFAOYSA-N,Small molecule,False,SERABELISIB,2.0,False,False,[],"['AGN-PC-0DB6FL', 'INK1117', 'Ink-1117', 'MLN-1117', 'MLN1117', 'Mln-1117', 'Serabelisib', 'TAK-117', 'Tak-117']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB14935'],"['MONDO_0004992', 'EFO_0000681', 'EFO_0003060', 'EFO_0000616', 'EFO_0004230']",5.0,['ENSG00000121879'],1,,,,,,,,,,
CHEMBL3963485,COCc1c(-c2cc3cc(C)cc(OC)c3s2)c2c(N)ncnn2c1CN1CCNC(=O)C1,HNLRRJSKGXOYNO-UHFFFAOYSA-N,Small molecule,False,ROGARATINIB,2.0,False,False,[],"['BAY-1163877', 'Bay-1163877', 'Rogaratinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,['DB15078'],"['MONDO_0007254', 'MONDO_0004992', 'EFO_0008528', 'EFO_0000616', 'MONDO_0001187', 'EFO_0003060']",6.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,,,,,,,,,,
CHEMBL4297809,,,Antibody,True,ELRANATAMAB,4.0,False,True,['Elrexfio'],"['Elranatamab', 'PF-06863135', 'Pf-06863135', 'RN-613', 'RN613']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for multiple myeloma and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0000616', 'EFO_0001378']",2.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000048462']",4,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ELRANATAMAB/relevant/1/'],,,
CHEMBL698,CCCCNc1ccc(C(=O)OCCN(C)C)cc1,GKCBAIGFKIBETG-UHFFFAOYSA-N,Small molecule,False,TETRACAINE,4.0,False,True,"['Ametop', 'Dicaine', 'Pontocaine']","['Amethocaine', 'Tetracaine']",['CHEMBL1255654'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 9 investigational indications.,['Tetracaine'],['DB09085'],"['EFO_0000546', 'EFO_1001054', 'EFO_0004616', 'EFO_1001434', 'MONDO_0005129', 'HP_0000989', 'EFO_1001178', 'EFO_0009552', 'EFO_0003843', 'EFO_0004143', 'MONDO_0041052', 'EFO_0000701']",12.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2005.0,,['tetracaine'],"['11111916', '11111917', '50111267', '90340576']",['9468'],,,,,
CHEMBL741,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,PYZRQGJRPPTADH-UHFFFAOYSA-N,Small molecule,True,LAMOTRIGINE,4.0,False,True,"['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']","['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 10 approved and 21 investigational indications. This drug has a black box warning from the FDA.,['Lamotrigine'],['DB00555'],"['EFO_0000764', 'HP_0001250', 'EFO_0003890', 'MONDO_0005090', 'MONDO_0041052', 'EFO_0000474', 'MONDO_0016532', 'EFO_0009963', 'MONDO_0007079', 'HP_0000726', 'EFO_0002610', 'MONDO_0010826', 'EFO_0003843', 'MONDO_0002050', 'EFO_0000677', 'EFO_0003100', 'HP_0002069', 'EFO_0005230', 'EFO_0001073', 'EFO_0005203', 'HP_0100543', 'EFO_0003761', 'MONDO_0004985', 'EFO_0005611', 'EFO_0004263', 'Orphanet_79292', 'EFO_0008522', 'MONDO_0018975', 'EFO_0007262', 'EFO_0003929', 'EFO_0004247']",31.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1994.0,,['lamotrigine'],"['11113342', '144203730', '170465024', '174006315', '26719658', '50104089', '56423136', '85231112', '855818', '90341162']",['6367'],,,,,
CHEMBL753,CC(COc1ccccc1)N(CCCl)Cc1ccccc1,QZVCTJOXCFMACW-UHFFFAOYSA-N,Small molecule,False,PHENOXYBENZAMINE,4.0,False,True,[],"['Bensylyt', 'Benzylyt', 'Dibenylin', 'Phenoxybenzamine']",['CHEMBL1200787'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for adrenal gland pheochromocytoma and cardiovascular disease and has 1 investigational indication.,['Phenoxybenzamine'],['DB00925'],"['EFO_0005207', 'EFO_0000239', 'EFO_0000319']",3.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1953.0,,,"['104171113', '124879342', '124879343', '144203638', '170465147', '174007411', '26752309', '26752310', '90341231']",['8077'],,,,,
CHEMBL1289494,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,SPMVMDHWKHCIDT-UHFFFAOYSA-N,Small molecule,False,TIVOZANIB,4.0,False,True,['Fotivda'],"['ASP-4130', 'AV-951', 'KIL8951', 'KRN-951', 'Kil-8951', 'Krn-951', 'Tivozanib']","['CHEMBL2105756', 'CHEMBL3426917', 'CHEMBL4784300']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for renal cell carcinoma and has 14 investigational indications.,['Tivozanib'],['DB11800'],"['EFO_0005221', 'MONDO_0002158', 'EFO_0001421', 'EFO_0000681', 'EFO_1001951', 'EFO_0000519', 'MONDO_0008315', 'EFO_0000182', 'EFO_0000616', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001968', 'MONDO_0007254', 'EFO_0000681', 'EFO_0003060']",15.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113721']",5,2017.0,,,['124955473'],,,,,,
CHEMBL1715,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,GHUUBYQTCDQWRA-UHFFFAOYSA-N,Small molecule,True,PIOGLITAZONE HYDROCHLORIDE,4.0,False,True,"['Actos', 'Diabiom', 'Glidipion', 'Glidipion (previously pioglitazone actavis group)', 'Glizofar', 'Pioglitazone hydrochloride']","['Actos', 'NSC-758876', 'Pioglitazone (as hydrochloride)', 'Pioglitazone hcl', 'Pioglitazone hydrochloride', 'Piomed', 'STR-001', 'U-72107A']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for type 2 diabetes mellitus and liver disease and has 7 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0002745', 'MONDO_0004976', 'EFO_0002618', 'MONDO_0005148', 'EFO_0003095', 'EFO_0001421', 'EFO_0003884', 'MONDO_0002009', 'EFO_0003060']",9.0,['ENSG00000132170'],1,1999.0,CHEMBL595,['pioglitazone%20hydrochloride'],"['144204993', '144210901', '170465116', '26748968', '49681546']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion'],,,,
CHEMBL2106227,CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1,IBYCYJFUEJQSMK-UHFFFAOYSA-N,Small molecule,False,ETIFOXINE,3.0,False,False,[],"['36-801', 'Etifoxine', 'HOE 36801', 'HOE-36801']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB08986'],['EFO_0005230'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL2108282,,,Protein,False,CATRIDECACOG,4.0,False,True,['Novothirteen'],"['Catridecacog', 'Novothirteen', 'Tretten']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for rare genetic coagulation disorder and hemorrhage and has 2 investigational indications.,,,"['Orphanet_183654', 'MP_0001914', 'MONDO_0018029', 'MONDO_0002243']",4.0,['ENSG00000124491'],1,2012.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/novothirteen'],,,['5134'],
CHEMBL2109662,,,Protein,False,DALANTERCEPT,3.0,False,False,[],"['ACE-041', 'Dalantercept', 'Delantercept']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['EFO_0000681', 'EFO_0000182', 'EFO_0004142', 'EFO_0000181', 'EFO_0001378']",5.0,"['ENSG00000163217', 'ENSG00000263761']",2,,,,,,,,,,
CHEMBL2336325,CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,JUSFANSTBFGBAF-IRXDYDNUSA-N,Small molecule,False,VISTUSERTIB,2.0,False,False,[],"['AZD-2014', 'AZD2014', 'Azd-2014', 'Vistusertib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 21 investigational indications.,,['DB11925'],"['EFO_0000616', 'EFO_0000707', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0005537', 'EFO_0000702', 'EFO_0003897', 'EFO_1000251', 'MONDO_0016642', 'MONDO_0001187', 'EFO_0000708', 'MONDO_0008315', 'EFO_0000519', 'EFO_0000349', 'EFO_0000503', 'EFO_0000228', 'EFO_1001512', 'EFO_0003060', 'EFO_0000403', 'EFO_0007532', 'Orphanet_145']",21.0,['ENSG00000198793'],1,,,,,,,,,,
CHEMBL3889654,O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1,NYNZQNWKBKUAII-KBXCAEBGSA-N,Small molecule,False,LAROTRECTINIB,4.0,False,True,[],"['ARRY-470', 'BAY-2757556', 'BAY2757556', 'LOXO-101', 'Larotrectinib', 'Loxo-101']",['CHEMBL3989939'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications.,,['DB14723'],"['EFO_0009708', 'MONDO_0002108', 'EFO_1000026', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000616']",6.0,"['ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']",3,2018.0,,,,,,,,,
CHEMBL4559134,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,XIIOFHFUYBLOLW-UHFFFAOYSA-N,Small molecule,False,SELPERCATINIB,4.0,False,True,"['Retevmo', 'Retsevmo']","['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292', 'Selpercatinib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 7 approved and 3 investigational indications.,,,"['EFO_0000501', 'EFO_0003060', 'EFO_0001421', 'MONDO_0015277', 'EFO_0003841', 'EFO_0000616', 'MONDO_0004992', 'HP_0000083', 'MONDO_0002108', 'EFO_0000641']",10.0,"['ENSG00000165731', 'ENSG00000170759', 'ENSG00000108091']",3,2020.0,,['selpercatinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo'],['https://searchusan.ama-assn.org/finder/usan/search/SELPERCATINIB/relevant/1/'],,,
CHEMBL5095030,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(N)=O)C(=O)N1)C(N)=O,JJVZSYKFCOBILL-DPNRMINZSA-N,Protein,False,MOTIXAFORTIDE,3.0,False,False,[],"['4F-BENZOYL-TN-14003', '4F-benzoyl-TN14003', 'BKT-140', 'BKT140', 'BL-8040', 'Bkt140', 'Bl 8040', 'Motixafortide', 'T140', 'TF 14016', 'TF-14016', 'TF14016']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,,"['EFO_0000198', 'EFO_0000616', 'EFO_0000220', 'EFO_0000503', 'MONDO_0011382', 'EFO_0000339', 'EFO_0002916', 'HP_0001915', 'EFO_0000222', 'EFO_0001378', 'EFO_0000183', 'MONDO_0000873']",12.0,['ENSG00000121966'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/MOTIXAFORTIDE/relevant/1/'],,,
CHEMBL679,CNC[C@H](O)c1ccc(O)c(O)c1,UCTWMZQNUQWSLP-VIFPVBQESA-N,Small molecule,False,EPINEPHRINE,4.0,False,True,"['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'Anapen', 'Anaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-q', 'Bronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'Epinephrine', 'Epinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jr', 'Epipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'Primatene', 'Primatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'Simplene', 'Soln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-Free', 'Sus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']","['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'Adrenalinum', 'Epinephrine', 'Epinephrine hcl', 'Epinephrine hydrochloride', 'Epinephrinum', 'Glauposine', 'L-epinephrine hydrochloride', 'Levo-methylaminoethanolcatechol', 'NSC-62786', 'Nephridine', 'Racepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-', 'Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']","['CHEMBL3183376', 'CHEMBL1256958', 'CHEMBL1200818', 'CHEMBL227634']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 19 approved and 34 investigational indications.,['Epinephrine'],['DB00668'],"['MONDO_0001056', 'MONDO_0003061', 'EFO_0000319', 'EFO_0005532', 'HP_0002105', 'EFO_0003060', 'MONDO_0007254', 'EFO_1001250', 'EFO_0007355', 'EFO_0004198', 'EFO_0000544', 'EFO_0003895', 'EFO_0000400', 'HP_0002239', 'EFO_0003956', 'EFO_0006834', 'HP_0011950', 'EFO_0004278', 'EFO_0004209', 'HP_0001742', 'EFO_0003843', 'EFO_0007149', 'EFO_1001087', 'MONDO_0004979', 'EFO_0005251', 'HP_0100543', 'EFO_0009676', 'MONDO_0100053', 'EFO_0004287', 'HP_0011499', 'HP_0006536', 'EFO_0000546', 'EFO_0004610', 'MP_0001914', 'EFO_0005854', 'HP_0012532', 'EFO_0003843', 'EFO_0009492', 'EFO_1001139', 'MONDO_0005041', 'MONDO_0005271', 'EFO_0003144', 'HP_0031273', 'EFO_0009846', 'EFO_0009840', 'EFO_0005306', 'EFO_1001417', 'EFO_0005531', 'EFO_0007486', 'EFO_0004278', 'EFO_1001222', 'MONDO_0002050', 'EFO_0004616']",53.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1976.0,,['epinephrine'],"['11111154', '144205115', '170464973', '26754418', '26754419', '26754420', '29215202', '90341589']",['28918'],,,,,
CHEMBL1200806,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],CDBRNDSHEYLDJV-FVGYRXGTSA-M,Small molecule,True,NAPROXEN SODIUM,4.0,False,True,"['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']","['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodium', 'Naproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 14 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003898', 'EFO_0009454', 'MONDO_0002258', 'EFO_0010072', 'EFO_0004274', 'EFO_0003843', 'EFO_0004616', 'EFO_0002609', 'MONDO_0004975', 'HP_0002315', 'MONDO_0005277', 'MONDO_0002471', 'MONDO_0003937', 'EFO_1001434', 'HP_0003418', 'EFO_0000685', 'MONDO_0005178', 'EFO_1000941', 'HP_0100607']",19.0,"['ENSG00000073756', 'ENSG00000095303']",2,1980.0,CHEMBL154,['naproxen%20sodium'],"['11112047', '11113013', '144204325', '170465301', '50106619', '85231338', '855887']",['7477'],,,,,
CHEMBL128748,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC,ZMGUKFHHNQMKJI-CIOHCNBKSA-N,Small molecule,False,DIMETHYLCURCUMIN,2.0,False,False,[],"['ASCJ-9', 'CHC-004', 'Dimethylcurcumin', 'GO-Y-025', 'Go-Y025']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB06133'],['EFO_0003894'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL1522,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,GBBSUAFBMRNDJC-INIZCTEOSA-N,Small molecule,True,ESZOPICLONE,4.0,False,True,"['Eszopiclone', 'Lunesta']","['(S)-ZOPICLONE', '(S)-Zopiclone', 'Estorra', 'Eszopiclon', 'Eszopiclone', 'Eszopiclone civ', 'GSK-1755165', 'Zopiclone s-form']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for insomnia and has 3 investigational indications. This drug has a black box warning from the FDA.,['Eszopiclone'],['DB00402'],"['EFO_0004698', 'EFO_1001892', 'EFO_0003918', 'EFO_0007191']",4.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,2004.0,,['eszopiclone'],"['144205286', '170465445', '29215492', '49666409']",['53760'],,,,,
CHEMBL2108018,,,Antibody,False,ADECATUMUMAB,2.0,False,False,[],"['Adecatumumab', 'MT-201']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_1001951'],1.0,['ENSG00000119888'],1,,,,,,,,,,
CHEMBL2109582,,,Antibody,False,81C6 131I,2.0,False,False,[],"['81C6', '81c6 131i']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000041982'],1,,,,,,,,,,
CHEMBL3125702,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,DRLCSJFKKILATL-YWCVFVGNSA-N,Small molecule,False,NAVTEMADLIN,2.0,False,False,[],"['AMG 232', 'AMG-232', 'Amg 232', 'KRT-232', 'Krt-232', 'Mdm2 inhibitor amg-232', 'Navtemadlin']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications.,,['DB15299'],"['EFO_0002430', 'EFO_1001471', 'EFO_0000222', 'EFO_0006738', 'EFO_0002429', 'EFO_0000702', 'EFO_0004251', 'EFO_0003060', 'MONDO_0004992', 'EFO_1001465', 'EFO_0001378', 'EFO_0000479', 'MONDO_0011962', 'EFO_0000616', 'MONDO_0044903', 'EFO_1001968', 'EFO_0000756', 'EFO_0000339']",18.0,"['ENSG00000141510', 'ENSG00000135679']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/NAVTEMADLIN/relevant/1/'],,,
CHEMBL3545335,Cc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1,JXSVVZKPEDIRTN-DHZHZOJOSA-N,Small molecule,False,AG-13958,2.0,False,False,[],"['AG 13958', 'Ag-13958']",['CHEMBL3922529'],Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,,,,,,,,,,
CHEMBL3545383,,,Small molecule,False,RG-7167,1.0,False,False,[],['Rg-7167'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000126934', 'ENSG00000169032']",2,,,,,,,,,,
CHEMBL386630,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,Small molecule,True,TESTOSTERONE,4.0,False,True,"['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'Fortesta', 'Intrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%', 'Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'Testoral', 'Testosterone', 'Tostran', 'Vogelxo']","['Android-t', 'Androlan', 'Delatestryl', 'Homosterone', 'Livensa', 'NSC-9700', 'TESTIM', 'Testiculosterone', 'Testosterone', 'Testosterone ciii', 'Virosterone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 7 approved and 29 investigational indications. This drug has a black box warning from the FDA.,['Testosterone'],['DB00624'],"['EFO_0000545', 'HP_0001510', 'EFO_0004234', 'EFO_1001919', 'MONDO_0018555', 'MONDO_0005301', 'EFO_0000660', 'EFO_0003964', 'EFO_0001073', 'EFO_0003884', 'EFO_0003843', 'EFO_0002970', 'EFO_0000195', 'HP_0030016', 'EFO_0005088', 'MONDO_0004992', 'EFO_0000196', 'Orphanet_325690', 'MONDO_0005351', 'MONDO_0008315', 'EFO_0003144', 'EFO_1001006', 'EFO_1001078', 'EFO_1000859', 'EFO_0001645', 'EFO_0001663', 'HP_0003549', 'Orphanet_145', 'EFO_0004714', 'MONDO_0002146', 'GO_0042697', 'MONDO_0018800', 'EFO_1000653', 'HP_0000044', 'EFO_0000765', 'EFO_0002614', 'EFO_0000616']",37.0,['ENSG00000169083'],1,1972.0,,['testosterone'],"['144207887', '17389513', '50085980', '56462804']",['17347'],['https://www.ema.europa.eu/en/medicines/human/EPAR/intrinsa'],,,,
CHEMBL4297296,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1,XAYAKDZVINDZGB-BMVMHAJPSA-N,Small molecule,False,KOS-1584,2.0,False,False,[],"['(e)-9,10-dehydroepothilone d', '(e)-9,10-didehydroepothilone d', '9,10-trans-dehydroepothilone d', 'Dehydelone', 'Kos-1584', 'R-1645', 'R1645']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB05903'],['EFO_0003060'],1.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL75435,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,DKYWVDODHFEZIM-NSHDSACASA-N,Small molecule,False,DEXKETOPROFEN,4.0,False,True,['Keral'],"['(s)-ketoprofen', 'Arveles', 'Dexketoprofen', 'Ketoprofen, (s)-']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 2 investigational indications.,,['DB09214'],"['HP_0002829', 'HP_0003419', 'EFO_0003843', 'HP_0003326', 'EFO_0005755']",5.0,"['ENSG00000073756', 'ENSG00000095303']",2,1994.0,,,"['26754382', '26754383', '56320640']",['76128'],,,,,
CHEMBL1077,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,Small molecule,False,BROMFENAC,4.0,True,True,[],"['Bromfenac', 'ISV-303']","['CHEMBL751', 'CHEMBL3181947']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 7 investigational indications.,['Bromfenac'],['DB00963'],"['HP_0200026', 'MONDO_0005129', 'EFO_0001365', 'MP_0001845', 'MONDO_0001330', 'EFO_0003843', 'MONDO_0005129', 'EFO_0005752', 'MP_0001845', 'EFO_1000906', 'MONDO_0007935', 'EFO_0007141']",12.0,"['ENSG00000073756', 'ENSG00000095303']",2,1997.0,,,['26757971'],['240107'],,,,,
CHEMBL13376,COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1,DGMZLCLHHVYDIS-UHFFFAOYSA-N,Small molecule,False,CLOMETACIN,4.0,True,True,[],"['C 1656', 'C-1656', 'Clometacin', 'Mindolic acid', 'R 3959', 'R-3959']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,,,,"['ENSG00000073756', 'ENSG00000095303']",2,,,,['144206860'],,,,,,
CHEMBL184412,CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1,ZQTNQVWKHCQYLQ-UHFFFAOYSA-N,Small molecule,True,DRONEDARONE,4.0,False,True,[],"['Dronedarone', 'SR-33589', 'SR33589']",['CHEMBL1201729'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for atrial fibrillation and has 4 investigational indications. This drug has a black box warning from the FDA.,['Dronedarone'],['DB04855'],"['EFO_0000275', 'EFO_0000373', 'EFO_0004269', 'EFO_0003911', 'EFO_0000275']",5.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001', 'ENSG00000138622', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000123700']",16,2009.0,,,"['144206559', '170465064']",['50659'],,,,,
CHEMBL2105661,CCNCCS(=O)(=O)NC[C@@]1(c2ccccc2)SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C,YVAFBXLHPINSIK-QHCPKHFHSA-N,Small molecule,False,LITRONESIB,2.0,False,False,[],"['KF 89617', 'KF-89617', 'KF89617', 'LY 2523355', 'LY-2523355', 'LY2523355', 'Litronesib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,['DB11861'],"['EFO_1001951', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000565', 'EFO_0000702', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0008315', 'EFO_0006859', 'MONDO_0007576', 'MONDO_0008170', 'MONDO_0004992']",12.0,['ENSG00000138160'],1,,,,,,,,,,
CHEMBL2105683,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1,JGBUBSOKFSVXKS-LBPRGKRZSA-N,Small molecule,False,NAPROXEN ETEMESIL,2.0,False,False,[],"['LT-NS001', 'MX-1094', 'Naproxen etemesil']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12398'],['MONDO_0005178'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,,,,,,,
CHEMBL2109325,,,Antibody,False,AMG-191,1.0,False,False,[],"['AMG-191', 'Amg-191']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0015974'],1.0,['ENSG00000157404'],1,,,,,,,,,,
CHEMBL3545323,,,Small molecule,False,PWT-33579,1.0,False,False,[],['Pwt-33579'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000198793', 'ENSG00000121879']",2,,,,,,,,,,
CHEMBL3960488,Cn1cc(-c2ccc(=O)n(Cc3cccc(-c4ncc(OCCN5CCOCC5)cn4)c3)n2)cn1,CIUKPBWULKEZMF-UHFFFAOYSA-N,Small molecule,False,EMD-1204831,1.0,False,False,[],['Emd-1204831'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL559478,O=C(Oc1ccc(Br)cc1)N1CCN2CCC1CC2,RXLOZRCLQMJJLC-UHFFFAOYSA-N,Small molecule,False,SSR180711,2.0,False,False,[],"['J2.849.107G', 'SSR-180,711', 'SSR-180711', 'SSR180711C', 'Ssr180711']",['CHEMBL3235499'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004975'],1.0,['ENSG00000175344'],1,,,,['144210561'],,,,,,
CHEMBL1173655,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,ULXXDDBFHOBEHA-CWDCEQMOSA-N,Small molecule,False,AFATINIB,4.0,False,True,"['Gilotrif', 'Giotrif']","['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'Tomtovok', 'Tovok']",['CHEMBL2105712'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for non-small cell lung carcinoma and has 28 investigational indications.,['Afatinib'],['DB08916'],"['EFO_0003869', 'MONDO_0021117', 'EFO_0000616', 'EFO_0000673', 'MONDO_0001657', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001378', 'EFO_0004142', 'HP_0000083', 'EFO_0000707', 'EFO_0003859', 'EFO_0006859', 'EFO_0000702', 'MONDO_0008978', 'MONDO_0007254', 'EFO_0002618', 'EFO_0003863', 'EFO_0009709', 'MONDO_0004992', 'EFO_0004284', 'EFO_0005543', 'EFO_1001956', 'EFO_0000181', 'EFO_0000519', 'EFO_0001421', 'EFO_0005922', 'EFO_0001065', 'EFO_0003060']",29.0,"['ENSG00000146648', 'ENSG00000178568', 'ENSG00000141736']",3,2013.0,,,,['61390'],,,,,
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,AFCGFAGUEYAMAO-UHFFFAOYSA-N,Small molecule,False,ACAMPROSATE,4.0,False,True,[],['Acamprosate'],['CHEMBL2068724'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for alcohol dependence and has 11 investigational indications.,['Acamprosate'],['DB00659'],"['EFO_0003758', 'MONDO_0007079', 'HP_0000360', 'EFO_0002610', 'EFO_0005230', 'HP_0000726', 'EFO_0003756', 'MONDO_0002050', 'EFO_0005203', 'MONDO_0005090', 'MONDO_0010383', 'MONDO_0007079', 'EFO_0004701']",13.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",23,2004.0,,,['50112716'],['51041'],,,,,
CHEMBL1236682,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,RDSACQWTXKSHJT-NSHDSACASA-N,Small molecule,False,REFAMETINIB,2.0,False,False,[],"['BAY 869766', 'BAY 8697661', 'BAY-86-9766', 'BAY-869766', 'BAY-8697661', 'BAY86-9766', 'BAY869766', 'BAY8697661', 'Bay-86-9766', 'RDEA 119', 'RDEA-119', 'Rdea119', 'Refametinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB06309'],"['EFO_0000182', 'MONDO_0003060', 'MONDO_0004992', 'EFO_0000616']",4.0,"['ENSG00000126934', 'ENSG00000169032']",2,,,,,,,,,,
CHEMBL2109338,,,Antibody,False,AMG-729,1.0,False,False,[],['AMG-729'],,Antibody drug with a maximum clinical trial phase of I.,,,,,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL3039544,,,Protein,False,TECEMOTIDE,3.0,False,False,['Stimuvax'],"['BLP-25', 'BLP25', 'BP-1-148', 'Blp 25', 'Blp-25 lipopeptide', 'EMD 531444', 'Emepepimut-s', 'LIPOPEPTIDE BLP-25', 'Tecemotide']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,,"['EFO_0003060', 'EFO_0001378', 'MONDO_0008315', 'MONDO_0008903', 'MONDO_0044937', 'EFO_1000657', 'MONDO_0007254', 'EFO_1001950']",8.0,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL3707275,,,Gene,False,VORETIGENE NEPARVOVEC,4.0,False,True,['Luxturna'],"['AAV-2-HRPE65V2', 'AAV2-hRPE65v2', 'Luxturna', 'SPK-RPE65', 'Voretigene neparvovec', 'Voretigene neparvovec rzyl', 'Voretigene neparvovec-rzyl']",,Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications.,,,"['EFO_0003966', 'HP_0000580', 'MONDO_0018998']",3.0,['ENSG00000116745'],1,2018.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna'],,,,
CHEMBL5314388,CCN1CCC(Oc2c(C#N)ncc3[nH]c4ncccc4c23)CC1,XEZLBMHDUXSICI-UHFFFAOYSA-N,Small molecule,False,RG-7602,1.0,False,False,[],"['GDC-0425', 'RG-7602', 'Rg-7602']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000149554'],1,,,,,,,,,,
CHEMBL5315119,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O,GJMQTRCDSIQEFK-SCDRJROZSA-N,Small molecule,True,UPADACITINIB HEMIHYDRATE,4.0,False,True,['Rinvoq'],['Upadacitinib hydrate'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for rheumatoid arthritis. This drug has a black box warning from the FDA.,,,['EFO_0000685'],1.0,"['ENSG00000105397', 'ENSG00000162434', 'ENSG00000105639', 'ENSG00000096968']",4,2019.0,CHEMBL3622821,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq'],,,,
CHEMBL712,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1,XRCFXMGQEVUZFC-UHFFFAOYSA-N,Small molecule,False,ANISINDIONE,4.0,False,True,['Miradon'],"['Anisindione', 'NSC-759629']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957.,['Anisindione'],['DB01125'],,,['ENSG00000115486'],1,1957.0,,,"['144204923', '14729672', '170465379', '26748631', '50086377']",['133809'],,,,,
CHEMBL856,CCC1(c2ccccc2)C(=O)NCNC1=O,DQMZLTXERSFNPB-UHFFFAOYSA-N,Small molecule,False,PRIMIDONE,4.0,False,True,"['Lepsiral', 'Liskantin', 'Mysoline', 'Neurosyn', 'Primidone']","['Lepimidin', 'NSC-41701', 'Primaclone', 'Primidone', 'Resimatil']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for epilepsy and has 1 investigational indication.,['Primidone'],['DB00794'],"['EFO_0000712', 'EFO_0000474']",2.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",26,1954.0,,['primidone'],"['104171217', '11111659', '11112270', '11113350', '144203789', '144209146', '144213511', '170464846', '17389534', '50104129', '50126364', '56324597', '855864', '90340844']",['8412'],,,,,
CHEMBL2105756,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O,RQXMKRRBJITKRN-UHFFFAOYSA-N,Small molecule,False,TIVOZANIB HYDROCHLORIDE,4.0,False,True,['Fotivda'],"['(tivozanib hydrochloride hydrate', 'AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for renal cell carcinoma and has 2 investigational indications.,,,"['MONDO_0007254', 'EFO_0001421', 'EFO_0000681']",3.0,"['ENSG00000157404', 'ENSG00000113721', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",5,2017.0,CHEMBL1289494,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/fotivda'],,,,
CHEMBL3039525,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,UQRCJCNVNUFYDX-UHFFFAOYSA-N,Small molecule,False,GOLVATINIB,2.0,False,False,[],"['E-7050', 'E7050', 'Golvatinib']",['CHEMBL3039500'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB11977'],"['MONDO_0004992', 'EFO_0000181', 'MONDO_0001056', 'EFO_0000616']",4.0,"['ENSG00000128052', 'ENSG00000105976']",2,,,,,,,,,,
CHEMBL4297302,CCS(=O)(=O)c1ccc(Oc2cc(O[C@@H](C)CO)cc(C(=O)Nc3ccn(C)n3)c2)cn1.CS(=O)(=O)O,PIDNRTWDGDJKSQ-UQKRIMTDSA-N,Small molecule,False,MK-0941,2.0,False,False,[],"['MK0941', 'Mk-0941', 'Mk0941']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005148'],1.0,['ENSG00000106633'],1,,CHEMBL3580737,,,,,,,,
CHEMBL4301162,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1,UBZPNQRBUOBBLN-PWRODBHTSA-O,Small molecule,False,SERDEXMETHYLPHENIDATE,4.0,False,True,[],['Serdexmethylphenidate'],['CHEMBL4298139'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder and has 1 investigational indication.,,,"['EFO_0003888', 'MONDO_0018044']",2.0,"['ENSG00000142319', 'ENSG00000103546']",2,2021.0,,,,,,,,,
CHEMBL4594457,,,Unknown,False,AL-78898A,2.0,False,False,[],"['(trp(me)4)-ac-compstatin', '4(1mew)', 'AL-78898A', 'Al-78898a', 'Compstatin analog 4(1mew)', 'POT-4', 'Pot-4']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0001365', 'EFO_1001492']",2.0,['ENSG00000125730'],1,,,,,,,,,,
CHEMBL5095032,Cl.O=C(N[C@@H]1CN2CCC1CC2)c1n[nH]c2ccccc12,CMRLNEYJEPELSM-BTQNPOSSSA-N,Small molecule,False,FACINICLINE HYDROCHLORIDE,2.0,False,False,[],"['Facinicline hydrochloride', 'MEM 3454', 'MEM-3454', 'MEM3454', 'RG-3487', 'RG3487', 'Rg3487']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0005090', 'MONDO_0004975']",2.0,"['ENSG00000166736', 'ENSG00000186038', 'ENSG00000149305', 'ENSG00000186090', 'ENSG00000178084', 'ENSG00000175344']",6,,CHEMBL2151439,,,,,,,,
CHEMBL52885,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21,OVSKGTONMLKNPZ-UHFFFAOYSA-N,Small molecule,False,ENMD-981693,2.0,False,False,[],"['ENMD 981693', 'ENMD-2076', 'ENMD-981693', 'Enmd-2076 free base', 'Enmd-981693', 'MKC-1', 'Mkc 1', 'R-440', 'RO 31-7453', 'RO-31-7453', 'Ro-317453']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,['DB05608'],"['EFO_1001951', 'EFO_0003060', 'EFO_0002618', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0000616']",6.0,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000087586', 'ENSG00000010810', 'ENSG00000197122', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000136573', 'ENSG00000101336', 'ENSG00000254087', 'ENSG00000111816', 'ENSG00000000938', 'ENSG00000125508', 'ENSG00000122025', 'ENSG00000128052', 'ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",19,,,,,,,,,,
CHEMBL916,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,COKMIXFXJJXBQG-NRFANRHFSA-N,Small molecule,False,TIROFIBAN,4.0,False,True,[],"['Aggrastat', 'Agrastat', 'L-700462', 'MK-383', 'Tirofiban']","['CHEMBL3189072', 'CHEMBL1704']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for myocardial infarction and recurrent thrombophlebitis and has 11 investigational indications.,['Tirofiban'],['DB00775'],"['MONDO_0100096', 'EFO_0004286', 'EFO_0000612', 'EFO_0000712', 'HP_0004419', 'EFO_0001645', 'EFO_0007541', 'EFO_0005672', 'EFO_0009686', 'HP_0002140', 'EFO_0008583', 'EFO_0000612', 'HP_0000083']",13.0,"['ENSG00000259207', 'ENSG00000005961']",2,1998.0,,,,['9605'],,,,,
CHEMBL10316,c1ccc2c(c1)OCC(C1=NCCN1)O2,HPMRFMKYPGXPEP-UHFFFAOYSA-N,Small molecule,False,IDAZOXAN,3.0,False,False,[],"['Dl-idazoxan', 'Idazoxan', 'NSC-759867', 'RX-781094', 'Racemic idazoxan']",['CHEMBL543467'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,['Idazoxan'],['DB12551'],"['MONDO_0002009', 'MONDO_0004975']",2.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,,,,"['104171177', '144203724', '170466595', '26751897', '90341761']",['5862'],,,,,
CHEMBL1200629,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1.[Br-],VEPSYABRBFXYIB-PWXDFCLTSA-M,Small molecule,True,VECURONIUM BROMIDE,4.0,False,True,"['Musculax', 'Norcuron', 'Vecuronium bromide']","['NSC-759184', 'ORG NC 45', 'ORG-NC 45', 'Pancuronium bromide impurity, vecuronium bromide -', 'Vecuronium bromide']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA.,,,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1984.0,CHEMBL1201219,['vecuronium%20bromide'],"['144206024', '170465295']",['9940'],,,,,
CHEMBL1201576,,,Antibody,True,RITUXIMAB,4.0,False,True,"['Mabthera', 'Mabthera rituxan', 'Rituxan', 'Ruxience']","['ABP-798', 'ABP798', 'BI695500', 'Bi 695500', 'Bi-695500', 'Blitzima', 'CT-P10', 'Gp2013', 'HS-006', 'HS-006 (RITUXIMAB BIOSIMILAR)', 'HS006', 'IDEC-102', 'IDEC-C2B8', 'Mk-8808', 'Pf-05280586', 'R-105 IDEC-102', 'RG-105', 'RHCACD20MA', 'Riabni', 'Ritemvia', 'Rituximab', 'Rituximab (genetical recombination)', 'Rituximab (rituxan)', 'Rituximab abbs', 'Rituximab arrx', 'Rituximab biosimilar (amgen)', 'Rituximab biosimilar (celltrion)', 'Rituximab biosimilar (pfizer)', 'Rituximab biosimilar - celltrion', 'Rituximab biosimilar -merck', 'Rituximab pvvr', 'Rituximab-abbs', 'Rituximab-arrx', 'Rituximab-boehringer ingelheim', 'Rituximab-ct-p10', 'Rituximab-pfizer', 'Rituximab-pvvr', 'Ruxience', 'SAIT-101', 'SAIT101', 'Truxima', 'Tuxella', 'Usp mab 001, monoclonal igg1', 'Zuberitamab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 13 approved and 129 investigational indications. This drug has a black box warning from the FDA.,['Rituximab'],,"['MONDO_0002334', 'EFO_0008518', 'EFO_0000309', 'EFO_0003032', 'EFO_0009441', 'Orphanet_365', 'EFO_0007187', 'MONDO_0007915', 'EFO_0003840', 'EFO_0000191', 'EFO_1001938', 'EFO_0009538', 'EFO_0000707', 'EFO_0004244', 'MONDO_0004095', 'EFO_0002617', 'EFO_0004540', 'MONDO_0010602', 'EFO_1000783', 'MONDO_0011382', 'EFO_1000868', 'MONDO_0002462', 'EFO_0000220', 'EFO_1001264', 'MONDO_0001437', 'MONDO_0019391', 'EFO_0003884', 'EFO_0000198', 'EFO_0003898', 'HP_0000093', 'EFO_0000339', 'EFO_0004288', 'MONDO_0044881', 'EFO_0007316', 'EFO_0003144', 'MONDO_0000873', 'MONDO_0004992', 'MONDO_0019338', 'EFO_0000621', 'EFO_0004254', 'EFO_0008522', 'EFO_0000209', 'MONDO_0017719', 'HP_0001871', 'EFO_0000772', 'EFO_1000956', 'EFO_0000729', 'EFO_0004255', 'EFO_0004256', 'EFO_0003086', 'EFO_0000222', 'EFO_0007332', 'EFO_0000095', 'EFO_0000540', 'EFO_0000183', 'EFO_0009562', 'EFO_0004236', 'EFO_0003778', 'EFO_0005297', 'EFO_0000389', 'MONDO_0021117', 'EFO_0002689', 'MONDO_0018906', 'EFO_1002048', 'MONDO_0013730', 'EFO_0008610', 'EFO_0005761', 'EFO_0003780', 'EFO_1000749', 'EFO_0005140', 'MONDO_0000432', 'EFO_0005952', 'EFO_0004826', 'EFO_0000255', 'EFO_0006803', 'EFO_1001161', 'EFO_0004719', 'MONDO_0001718', 'EFO_0004145', 'MONDO_0015760', 'MONDO_0005090', 'EFO_0004289', 'EFO_0000616', 'EFO_1000131', 'MONDO_0000870', 'EFO_0006803', 'MONDO_0015564', 'HP_0001915', 'EFO_1001051', 'MONDO_0016537', 'EFO_0003100', 'MONDO_0005147', 'EFO_0005531', 'EFO_0004599', 'MONDO_0018922', 'MONDO_0008315', 'MONDO_0018904', 'EFO_1001486', 'MONDO_0009348', 'MONDO_0018896', 'EFO_0000565', 'EFO_0007160', 'EFO_0001378', 'HP_0002196', 'EFO_0007498', 'EFO_1000784', 'MONDO_0017276', 'EFO_0003860', 'EFO_1000318', 'EFO_0000096', 'EFO_0000403', 'EFO_1001469', 'EFO_0000574', 'EFO_1000630', 'EFO_0000717', 'MONDO_0044917', 'EFO_0003897', 'MONDO_0020547', 'EFO_0000557', 'EFO_0000699', 'MONDO_0001023', 'EFO_0000094', 'EFO_0004991', 'EFO_0000685', 'EFO_0000384', 'EFO_0009606', 'EFO_0003869', 'EFO_0003929', 'EFO_0001423', 'EFO_0007359', 'EFO_1001779', 'EFO_0007208', 'EFO_1001383', 'EFO_0003818', 'EFO_0001642', 'EFO_0008520', 'MONDO_0005301', 'MONDO_0001549', 'EFO_0000765', 'EFO_0000768', 'EFO_1001466', 'EFO_1001365']",142.0,['ENSG00000156738'],1,1997.0,,"['rituximab', 'rituximab-abbs', 'rituximab-pvvr']",,,['https://www.ema.europa.eu/en/medicines/human/EPAR/ruxience'],,,['4975'],
CHEMBL2093999,C[C@]12CCC(=NOCCN)C[C@@H]1C(=O)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,MPYLDWFDPHRTEG-IFVNMTGRSA-N,Small molecule,False,ISTAROXIME,2.0,False,False,[],"['(E,Z)-Istaroxime', 'Istaroxime', 'PST-2744']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['HP_0031273', 'EFO_0003144', 'EFO_0000373']",3.0,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731', 'ENSG00000174437']",9,,,,,,,,,,
CHEMBL2109334,,,Antibody,False,INEBILIZUMAB,4.0,False,True,['Uplizna'],"['Inebilizumab', 'Inebilizumab cdon', 'MEDI-551', 'MEDI551']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neuromyelitis optica and immune system disease and has 12 investigational indications.,,,"['EFO_0004256', 'EFO_0000095', 'EFO_0000717', 'EFO_0000540', 'EFO_1001993', 'MONDO_0005301', 'MONDO_0017287', 'EFO_0001378', 'MONDO_0004992', 'EFO_0004991', 'EFO_0007332', 'EFO_0000574', 'EFO_0001642', 'EFO_0000403']",14.0,['ENSG00000177455'],1,2020.0,,['inebilizumab-cdon'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/uplizna'],,,,
CHEMBL2109610,,,Antibody,False,HUMIK-BETA-1,1.0,False,False,[],"['HUMIK-BETA-1', 'Humik-beta-1']",,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,,"['MONDO_0019469', 'EFO_0001060', 'EFO_0007316']",3.0,['ENSG00000100385'],1,,,,,,,,,,
CHEMBL3545082,,,Small molecule,False,RG-7376,1.0,False,False,[],"['PLX-5568', 'Rg-7376']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000132155'],1,,,,,,,,,,
CHEMBL660,NC12CC3CC(CC(C3)C1)C2,DKNWSYNQZKUICI-UHFFFAOYSA-N,Small molecule,False,AMANTADINE,4.0,False,True,[],"['Amantadine', 'Amantidine', 'NSC-341865', 'Symadine', 'Symmetrel', 'TCMDC-125869']","['CHEMBL465617', 'CHEMBL1569', 'CHEMBL1445834']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 20 investigational indications.,['Amantadine'],['DB00915'],"['EFO_0003843', 'MONDO_0005090', 'EFO_0000712', 'EFO_0002610', 'MONDO_0002679', 'EFO_0003047', 'MONDO_0004976', 'MONDO_0005301', 'EFO_0007328', 'MONDO_0005090', 'EFO_0000544', 'EFO_1001402', 'EFO_0003888', 'MONDO_0005180', 'MONDO_0043510', 'EFO_0005411', 'MONDO_0005301', 'MONDO_0005148', 'EFO_0004220', 'EFO_0000544', 'EFO_1001175', 'EFO_0004247', 'HP_0001300', 'EFO_0007328', 'EFO_1000860', 'MONDO_0100096', 'MONDO_0043510', 'MONDO_0100096', 'MONDO_0005180', 'EFO_0005411']",30.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,1968.0,,,"['104171100', '11110715', '124879107', '144203619', '170464860', '26755640', '26755641', '50110918', '50110919', '90340894']",['2618'],,,,,
CHEMBL1743022,,,Antibody,False,FRESOLIMUMAB,2.0,False,False,[],"['Fresolimumab', 'GC-1008', 'GC1008', 'GZ-402669', 'GZ402669']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,,"['EFO_0003833', 'EFO_0003060', 'EFO_0000770', 'EFO_0004236', 'EFO_0000768', 'EFO_0000404', 'MONDO_0019019', 'EFO_0000681', 'MONDO_0007254']",9.0,"['ENSG00000119699', 'ENSG00000092969', 'ENSG00000105329']",3,,,,,,,,,,
CHEMBL1801204,COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,KVLFRAWTRWDEDF-IRXDYDNUSA-N,Small molecule,False,AZD-8055,1.0,False,False,[],"['AZ-12600000', 'AZD 8055', 'AZD-8055', 'AZD8055', 'Azd-8055']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications.,,['DB12774'],"['EFO_0000616', 'MONDO_0004992', 'EFO_0002499', 'EFO_0002501', 'EFO_0000574', 'EFO_0000519', 'EFO_0000182']",7.0,['ENSG00000198793'],1,,,,,,,,,,
CHEMBL2347655,CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1,LLXISKGBWFTGEI-FQEVSTJZSA-N,Small molecule,False,FILANESIB,2.0,False,False,[],"['ARRY-520', 'Filanesib']",['CHEMBL3544920'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB06040'],"['EFO_0000222', 'EFO_0001378', 'EFO_0000198', 'EFO_0006475', 'EFO_0000616']",5.0,['ENSG00000138160'],1,,,,,,,,,,
CHEMBL4298045,,,Antibody drug conjugate,False,INDUSATUMAB VEDOTIN,2.0,False,False,[],"['Indusatumab vedotin', 'MLN-0264', 'MLN0264', 'Mln0264', 'TAK-264']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000503', 'MONDO_0004992']",2.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000070019']",16,,,,,,,,,,
CHEMBL4594503,,,Antibody,False,TALQUETAMAB,4.0,False,True,['Talvey'],"['JNJ-63483043', 'JNJ-64407564', 'Talquetamab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for multiple myeloma and has 1 investigational indication.,,,"['EFO_0001378', 'EFO_0001642']",2.0,"['ENSG00000111291', 'ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286']",4,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TALQUETAMAB/relevant/1/'],,,
CHEMBL467084,N[C@@H](Cc1ccccn1)c1ccccc1,FWUQWDCOOWEXRY-ZDUSSCGKSA-N,Small molecule,False,LANICEMINE,2.0,False,False,[],"['AR-R15896AR', 'AZD-6765', 'AZD6765', 'Azd6765', 'Lanicemine']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB11889'],"['MONDO_0002009', 'MONDO_0002050']",2.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL502835,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,XZXHXSATPCNXJR-ZIADKAODSA-N,Small molecule,False,NINTEDANIB,4.0,False,True,"['Ofev', 'Vargatef']","['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']",['CHEMBL3039504'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for idiopathic pulmonary fibrosis and systemic scleroderma and has 47 investigational indications.,,['DB09079'],"['MONDO_0019180', 'EFO_1001331', 'MONDO_0044937', 'EFO_0004244', 'MONDO_0011705', 'EFO_0000222', 'EFO_1001949', 'EFO_0003893', 'MONDO_0011962', 'EFO_0000691', 'EFO_0000503', 'EFO_0001378', 'EFO_1001465', 'EFO_0000768', 'MONDO_0007254', 'EFO_0000681', 'EFO_0000588', 'EFO_0007183', 'EFO_0000571', 'EFO_0009448', 'MONDO_0008903', 'MONDO_0100096', 'EFO_0000616', 'EFO_0008528', 'EFO_0000708', 'EFO_0004284', 'EFO_0000182', 'EFO_0002618', 'EFO_0000717', 'EFO_0000770', 'EFO_0002499', 'EFO_0000519', 'EFO_0001416', 'MONDO_0001235', 'EFO_0000702', 'MONDO_0015277', 'MONDO_0004669', 'MONDO_0002158', 'EFO_0000768', 'MONDO_0008170', 'EFO_1001951', 'EFO_0000717', 'MONDO_0002087', 'EFO_0000673', 'EFO_0004142', 'EFO_0003060', 'EFO_0004243', 'EFO_0000389', 'EFO_0002501']",49.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",9,2014.0,,,,['85164'],,,,,
CHEMBL79,CCN(CC)CC(=O)Nc1c(C)cccc1C,NNJVILVZKWQKPM-UHFFFAOYSA-N,Small molecule,True,LIDOCAINE,4.0,False,True,"['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'Lidoderm', 'Lignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'Xylocaine', 'Xylodase', 'Xylotox', 'Ztlido']","['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'Lidocaine', 'Lidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'Octocaine', 'Solarcaine', 'Xylestesin']","['CHEMBL3278065', 'CHEMBL541521', 'CHEMBL1200409']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 23 approved and 105 investigational indications. This drug has a black box warning from the FDA.,['Lidocaine'],['DB00281'],"['EFO_0003943', 'MONDO_0008903', 'EFO_0004273', 'EFO_0009364', 'EFO_1001097', 'MONDO_0001572', 'EFO_0001074', 'Orphanet_365', 'EFO_0002610', 'HP_0003418', 'EFO_0001663', 'EFO_1000941', 'EFO_0003843', 'MONDO_0005178', 'EFO_0008507', 'EFO_0009688', 'HP_0100543', 'HP_0000989', 'EFO_1001434', 'HP_0003419', 'EFO_1001993', 'EFO_0000555', 'EFO_0005856', 'EFO_0009552', 'EFO_0003878', 'EFO_1001896', 'EFO_0004616', 'HP_0002315', 'EFO_0003958', 'EFO_0007214', 'EFO_1001250', 'EFO_1000249', 'MONDO_0004992', 'EFO_0006346', 'EFO_0005230', 'EFO_0000668', 'EFO_0009660', 'EFO_1001139', 'EFO_1001087', 'EFO_0002970', 'EFO_1001178', 'HP_0003394', 'EFO_1001998', 'MONDO_0007254', 'EFO_0002618', 'EFO_0000712', 'EFO_1001412', 'EFO_0009430', 'EFO_0003917', 'MP_0001845', 'HP_0002315', 'EFO_0001073', 'EFO_0004143', 'EFO_0000546', 'EFO_0009620', 'EFO_0007490', 'MONDO_0004567', 'HP_0001907', 'EFO_0003888', 'EFO_1001951', 'HP_0000360', 'EFO_0010582', 'MONDO_0100096', 'EFO_0000519', 'EFO_0003902', 'EFO_1001898', 'EFO_0000701', 'EFO_0003833', 'EFO_0004142', 'EFO_0009492', 'EFO_0000537', 'EFO_0009619', 'EFO_0006834', 'EFO_0005762', 'EFO_0003100', 'HP_0030834', 'EFO_1001492', 'HP_0000020', 'HP_0100607', 'MONDO_0002258', 'EFO_0005279', 'MP_0001914', 'EFO_0003777', 'EFO_0803321', 'EFO_0003957', 'EFO_1001996', 'EFO_0005687', 'EFO_0003103', 'EFO_0009516', 'EFO_1001219', 'EFO_0000545', 'HP_0012532', 'EFO_0005754', 'EFO_0009552', 'EFO_1001054', 'EFO_0801084', 'HP_0003418', 'EFO_0009846', 'EFO_0000616', 'EFO_0000546', 'EFO_0000400', 'MONDO_0005277', 'HP_0004308', 'EFO_0001069', 'HP_0003326', 'EFO_1001255', 'EFO_1000910', 'EFO_1000781', 'MONDO_0004992', 'EFO_0003843', 'MONDO_0002691', 'EFO_1001904', 'EFO_0004198', 'EFO_1000783', 'EFO_0003901', 'EFO_0000707', 'HP_0000989', 'EFO_0002950', 'EFO_0002950', 'EFO_0001361', 'EFO_1000889', 'HP_0012532', 'EFO_0009582', 'EFO_0007486', 'EFO_0000305', 'MONDO_0005277', 'HP_0012735', 'EFO_0004269', 'EFO_0003854', 'EFO_0000313', 'EFO_1001887', 'EFO_0002496', 'MONDO_0041052']",133.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1948.0,,['lidocaine'],"['104171182', '11111384', '11111385', '144203734', '170464729', '26751483', '26751484', '56422194', '855682', '90340642']",['6456'],,,,,
CHEMBL422872,O=C(O)CSC(CCCc1ccccc1)c1ccc(OCc2ccc3ccccc3n2)cc1,JOIXGLLMSDPZDN-UHFFFAOYSA-N,Small molecule,False,AZD-4769,1.0,False,False,[],"['AZ-12096971', 'AZD-4769', 'AZD4769', 'Azd 4769', 'Azd-4769', 'L-674573', 'L674573']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL4297507,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2,LOWWYYZBZNSPDT-ZBEGNZNMSA-N,Small molecule,False,DELGOCITINIB,3.0,False,False,[],"['Delgocitinib', 'JTE-052', 'JTE-052A', 'LEO 124249', 'LEO 124249A', 'LEO-124249', 'LEO-124249A']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['EFO_0000274', 'HP_0000964', 'EFO_0000676', 'EFO_0004192', 'MONDO_0019558']",5.0,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",4,,,,,,,,,,
CHEMBL4297718,,,Unknown,False,CD40 LIGAND,2.0,False,False,[],"['AMG-950', 'Cd40 ligand', 'Cd40 ligand recombinant', 'Recombinant cd40-ligand', 'Recombinant human cd40 ligand', 'Soluble cd154 recombinant']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000616', 'EFO_0000389']",2.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL4297888,,,Antibody,False,SOTIGALIMAB,2.0,False,False,[],"['APX-005', 'APX-005M', 'APX005M', 'Apx005m', 'EPI-0050', 'Sotigalimab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_0000616', 'EFO_0000756', 'EFO_0002617', 'EFO_1000657', 'MONDO_0008170', 'EFO_1001968', 'MONDO_0007576']",7.0,['ENSG00000101017'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SOTIGALIMAB/relevant/1/'],,,
CHEMBL462018,CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23,URLYINUFLXOMHP-HTVVRFAVSA-N,Small molecule,False,TRICIRIBINE PHOSPHATE,2.0,False,False,[],"['NSC-154020', 'NSC-280594', 'Phosphate salt of tricyclic nucleoside', 'Triciribine', 'Triciribine phosphate', 'Vqd-002']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB14636'],"['MONDO_0004992', 'EFO_0000565', 'MONDO_0008170']",3.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,,,,,,,
CHEMBL809,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,VGKDLMBJGBXTGI-SJCJKPOMSA-N,Small molecule,True,SERTRALINE,4.0,False,True,[],['Sertraline'],['CHEMBL1709'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 approved and 32 investigational indications. This drug has a black box warning from the FDA.,['Sertraline'],['DB01104'],"['MONDO_0002009', 'EFO_0003756', 'EFO_0003047', 'EFO_0004262', 'EFO_0002610', 'EFO_0003761', 'EFO_0007453', 'EFO_0001073', 'HP_0000989', 'EFO_0001358', 'EFO_0000519', 'MONDO_0010383', 'MONDO_0002050', 'EFO_1001917', 'MONDO_0002046', 'EFO_1001917', 'MONDO_0043510', 'EFO_1001892', 'EFO_0005230', 'HP_0002315', 'EFO_0004262', 'EFO_0003890', 'EFO_0003761', 'EFO_0001358', 'EFO_0003758', 'MONDO_0004985', 'EFO_0007211', 'MONDO_0007739', 'MONDO_0007079', 'MONDO_0005090', 'EFO_0004242', 'EFO_0004242', 'EFO_0000222', 'HP_0001249', 'EFO_0004247', 'EFO_0004698', 'EFO_0000198', 'MONDO_0002050', 'EFO_0007228', 'MONDO_0002009', 'HP_0000726']",41.0,['ENSG00000108576'],1,1991.0,,,"['26753299', '29215139', '49665783', '50105682', '50105683', '50105684', '50105685', '90341218']",['9123'],,,,,
CHEMBL1201020,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C.O=P(O)(O)O,CGDDQFMPGMYYQP-UHFFFAOYSA-N,Small molecule,True,DISOPYRAMIDE PHOSPHATE,4.0,False,True,"['Dirythmin', 'Dirythmin-sa', 'Disopyramide phosphate', 'Isomide cr', 'Norpace', 'Norpace cr', 'Rythmodan ret']","['Dirythmin sa', 'Diso-duriles', 'Disopyramide phosphate', 'NSC-756744', 'Rythmodan', 'SC-13957', 'SC-7031 PHOSPHATE']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0004308', 'EFO_0004269', 'EFO_0003144', 'EFO_0000275']",4.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1977.0,CHEMBL517,['disopyramide%20phosphate'],"['50106185', '855629']",['4658'],,,,,
CHEMBL2103883,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,OFZJKCQENFPZBH-UHFFFAOYSA-N,Small molecule,False,AVATROMBOPAG,4.0,False,True,[],"['Akr-501', 'Avatrombopag', 'E-5501', 'E5501', 'YM-301477', 'YM-477']",['CHEMBL2105758'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications.,,['DB11995'],"['HP_0001873', 'EFO_0006927', 'EFO_0007160', 'HP_0001915', 'EFO_0001421', 'MP_0001914', 'HP_0001873', 'MONDO_0002245', 'EFO_0001421']",9.0,['ENSG00000117400'],1,2018.0,,,,,,,,,
CHEMBL2106710,Cl.Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2,OYKZVKWXOWICFI-UHFFFAOYSA-N,Small molecule,False,FADOLMIDINE HYDROCHLORIDE,2.0,False,False,[],"['Fadolmidine hcl', 'Fadolmidine hydrochloride', 'MPV-2426', 'Radolmidine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,,CHEMBL2104262,,,,,,,,
CHEMBL343448,C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,OHRURASPPZQGQM-GCCNXGTGSA-N,Protein,False,ROMIDEPSIN,4.0,False,True,['Istodax'],"['Depsipeptide', 'FK-228', 'FK228', 'FR-901228', 'FR901228', 'NSC-630176', 'Romidepsin']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 36 investigational indications.,,['DB06176'],"['EFO_0006861', 'EFO_0000183', 'EFO_0002499', 'EFO_0000224', 'EFO_0000403', 'EFO_1001951', 'EFO_1001051', 'EFO_0000565', 'EFO_1000785', 'MONDO_0004192', 'EFO_0003032', 'MONDO_0008170', 'EFO_0000569', 'EFO_0000764', 'EFO_1001465', 'EFO_0000255', 'EFO_0003060', 'EFO_1000984', 'EFO_1001469', 'EFO_0000641', 'EFO_0005537', 'EFO_0000180', 'EFO_0000095', 'EFO_0002913', 'EFO_0000574', 'EFO_0001378', 'EFO_0000211', 'EFO_0000616', 'EFO_0002618', 'EFO_0000702', 'MONDO_0001187', 'MONDO_0018906', 'EFO_0000503', 'MONDO_0004992', 'MONDO_0015760', 'EFO_0000756', 'EFO_0000501', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0000430', 'EFO_0002501', 'MONDO_0005184']",42.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,2009.0,,['romidepsin'],['144206460'],['61080'],,,,,
CHEMBL3707354,,,Small molecule,False,ABT-560,-1.0,False,False,[],['Abt-560'],,Small molecule drug.,,,,,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL4297235,,,Unknown,False,OMBIPEPIMUT-S,3.0,False,False,[],"['DSP-7888', 'Ombipepimut-s']",,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0000222', 'EFO_0000198', 'EFO_0000519', 'EFO_1000026']",4.0,['ENSG00000184937'],1,,,,,,,,,,
CHEMBL4650290,,,Antibody,False,GC1118,2.0,False,False,[],"['GC1118', 'Gc1118']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000519', 'EFO_0000503']",2.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL1200382,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1.Cl.O,UEECHQPWQHYEDE-UHFFFAOYSA-N,Small molecule,False,BEPRIDIL HYDROCHLORIDE,4.0,False,True,"['Bepadin', 'Vascor']","['Bepridil hydrochloride', 'Bepridil hydrochloride hydrate', 'CERM 1978', 'CERM-1978', 'Cordium', 'NSC-758390', 'Unicordium']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990.,,,,,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,1990.0,CHEMBL1008,,,['52715'],,,,,
CHEMBL1201234,CNC(C)(C)Cc1ccccc1,RXQCGGRTAILOIN-UHFFFAOYSA-N,Small molecule,False,MEPHENTERMINE,4.0,False,True,[],['Mephentermine'],"['CHEMBL3184799', 'CHEMBL1200996']",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for cardiovascular disease.,['Mephentermine'],['DB01365'],['EFO_0000319'],1.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1951.0,,,['11112475'],['6755'],,,,,
CHEMBL1700,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1.Cl,VIDRYROWYFWGSY-UHFFFAOYSA-N,Small molecule,True,SOTALOL HYDROCHLORIDE,4.0,False,True,"['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'Sotalex', 'Sotalol hydrochloride', 'Sotylize']","['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358', 'Sotalol hcl', 'Sotalol hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for ventricular arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0004308', 'EFO_0003144', 'EFO_0000275']",3.0,"['ENSG00000043591', 'ENSG00000055118', 'ENSG00000169252']",3,1992.0,CHEMBL471,['sotalol%20hydrochloride'],"['144204819', '26719708', '46500431', '50106953']",['9207'],,,,,
CHEMBL4297968,,,Unknown,False,GSK-3174998,2.0,False,False,[],"['GSK-3174998', 'GSK3174998', 'Gsk 3174998', 'Gsk-3174998', 'Gsk3174998']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0001378', 'EFO_0000616']",2.0,['ENSG00000186827'],1,,,,,,,,,,
CHEMBL4594546,,,Antibody,False,TELAZORLIMAB,2.0,False,False,[],"['GBR 830', 'GBR-830', 'GBR830', 'Gbr 830', 'ISB 830', 'ISB-830', 'Telazorlimab']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000274'],1.0,['ENSG00000186827'],1,,,,,,,,,,
CHEMBL96172,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1,XOZIUKBZLSUILX-GIQCAXHBSA-N,Small molecule,False,EPOTHILONE D,2.0,False,False,[],"['(-)-desoxyepothilone b', '12,13-desoxyepothilone b', '12,13-desoxyepothilone b, cis', 'Desoxyepothilone b', 'Epothilone d', 'KOS-862', 'NSC-703147', 'R-1492', 'R1492']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB01873'],"['EFO_0000616', 'EFO_1001951', 'MONDO_0008903', 'MONDO_0008315', 'MONDO_0007254']",5.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,['527930'],['29579'],,,,,
CHEMBL1201774,C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)[nH]c(=O)c2N1,FNKQXYHWGSIFBK-RPDRRWSUSA-N,Small molecule,False,SAPROPTERIN,4.0,False,True,[],"['6r-bh4', 'Dapropterin', 'Daproterin', 'R-thbp', 'Sapropterin', 'Tetrahydrobiopterin']","['CHEMBL1201775', 'CHEMBL1515624']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hyperphenylalaninemia and phenylketonuria and has 20 investigational indications.,['Tetrahydrobiopterin'],['DB00360'],"['MONDO_0010298', 'MONDO_0005090', 'MONDO_0043771', 'EFO_0000537', 'Orphanet_238583', 'EFO_0000181', 'EFO_0003884', 'EFO_0003144', 'EFO_0001645', 'EFO_0003876', 'EFO_0000341', 'EFO_0003884', 'EFO_0003758', 'EFO_0001361', 'MONDO_0004975', 'EFO_0005411', 'MONDO_0043579', 'MONDO_0011382', 'MONDO_0009861', 'EFO_0000666', 'MONDO_0009861', 'EFO_0001422', 'EFO_0000537']",23.0,['ENSG00000171759'],1,2007.0,,,,['59560'],,,,,
CHEMBL2109281,,,Antibody drug conjugate,False,RG-7600,1.0,False,False,[],"['DMOT4039A', 'RG-7600']",,Antibody drug conjugate drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000102854']",16,,,,,,,,,,
CHEMBL2364655,,,Antibody,False,EVOLOCUMAB,4.0,False,True,"['Repatha', 'Repatha sureclick']","['AMG-145', 'Evolocumab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 8 approved and 11 investigational indications.,,,"['EFO_0000712', 'EFO_0000319', 'EFO_0003144', 'MONDO_0018328', 'HP_0003124', 'EFO_0000519', 'EFO_0003060', 'EFO_0008585', 'EFO_0001645', 'HP_0003119', 'MONDO_0008903', 'Orphanet_79211', 'MONDO_0100096', 'EFO_0005672', 'Orphanet_309005', 'EFO_0000612', 'MONDO_0021187', 'HP_0100806', 'EFO_0004911']",19.0,['ENSG00000169174'],1,2015.0,,['evolocumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/repatha'],,,['5000'],
CHEMBL3545063,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.CS(=O)(=O)O,FUKSNUHSJBTCFJ-UHFFFAOYSA-N,Small molecule,False,OSIMERTINIB MESYLATE,4.0,False,True,['Tagrisso'],"['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilate', 'Mereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.,,,"['EFO_0003060', 'MONDO_0008903']",2.0,['ENSG00000146648'],1,2015.0,CHEMBL3353410,['osimertinib%20mesylate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso'],,,,
CHEMBL3833346,,,Oligonucleotide,False,TOFERSEN,4.0,False,True,['Qalsody'],"['BIIB-067', 'BIIB067', 'ISIS-SOD1Rx', 'Tofersen']",,Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for amyotrophic lateral sclerosis.,,,['MONDO_0004976'],1.0,['ENSG00000142168'],1,2023.0,,,,,,,,,
CHEMBL3989724,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl,ZIIJJOPLRSCQNX-UHFFFAOYSA-N,Small molecule,True,FLURAZEPAM HYDROCHLORIDE,4.0,False,True,"['Dalmane', 'Flurazepam hydrochloride']","['Flurazepam', 'Flurazepam dihydrochloride', 'Flurazepam hydrochloride', 'Flurazepam hydrochloride civ', 'NSC-78559', 'RO 5-6901', 'RO-5-6901']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970 and is indicated for insomnia. This drug has a black box warning from the FDA.,,,['EFO_0004698'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1970.0,CHEMBL968,['flurazepam%20hydrochloride'],,,,,,,
CHEMBL3989845,CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,BPQZYOJIXDMZSX-UHFFFAOYSA-N,Small molecule,True,IMIPRAMINE PAMOATE,4.0,False,True,"['Imipramine pamoate', 'Tofranil-pm']",['Imipramine embonate'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973. This drug has a black box warning from the FDA.,,,,,"['ENSG00000108576', 'ENSG00000103546']",2,1973.0,CHEMBL11,['imipramine%20pamoate'],,,,,,,
CHEMBL4297768,,,Oligosaccharide,False,IDRABIOTAPARINUX SODIUM,3.0,False,False,[],['Idrabiotaparinux sodium'],,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0003907', 'MONDO_0000831', 'EFO_0000275']",3.0,['ENSG00000126218'],1,,,,,,,,,,
CHEMBL4650332,O=C([C@H](CO)c1ccccc1)N1CC2=C(C1)CN(S(=O)(=O)c1cnc3c(c1)OCCO3)C2,KZFFYEPYCVDOGE-LJQANCHMSA-N,Small molecule,False,ETAVOPIVAT,2.0,False,False,[],"['Etavopivat', 'FT-4202', 'Ft-4202']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000198', 'MONDO_0011382']",2.0,['ENSG00000143627'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ETAVOPIVAT/relevant/1/'],,,
CHEMBL495727,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,LOLPPWBBNUVNQZ-UHFFFAOYSA-N,Small molecule,False,AT-9283,2.0,False,False,[],"['AT-9283', 'AT9283', 'At 9283', 'At-9283']",['CHEMBL496311'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0001378', 'EFO_0000616', 'EFO_0005952', 'EFO_0000565']",4.0,"['ENSG00000122025', 'ENSG00000097007', 'ENSG00000087586', 'ENSG00000105639', 'ENSG00000178999', 'ENSG00000096968']",6,,,,,,,,,,
CHEMBL5314357,,,Antibody,False,ETARACIZUMAB,2.0,False,False,"['Abegrin', 'Abegrin vitaxin']","['ETARATUZUMAB', 'Etaracizumab', 'HLM60', 'MEDI-522', 'Vitaxin']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,,"['EFO_0000676', 'MONDO_0008315', 'EFO_1001951', 'EFO_0002617', 'EFO_0000685', 'EFO_0000756', 'MONDO_0004992', 'EFO_0000681']",8.0,"['ENSG00000259207', 'ENSG00000138448']",2,,,,,,,,,,
CHEMBL1095032,O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1,GEHAEMCVKDPMKO-HXUWFJFHSA-N,Small molecule,False,LETAXABAN,2.0,False,False,[],"['Letaxaban', 'TAK 442', 'TAK-442', 'TAK442']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB11984'],"['EFO_0004286', 'EFO_0005672']",2.0,['ENSG00000126218'],1,,,,,,,,,,
CHEMBL1255654,CCCCNc1ccc(C(=O)OCCN(C)C)cc1.Cl,PPWHTZKZQNXVAE-UHFFFAOYSA-N,Small molecule,False,TETRACAINE HYDROCHLORIDE,4.0,False,True,"['Anethaine', 'Locan', 'Tetracaine hydrochloride']","['Amethocaine hydrochloride', 'Butethanol', 'Curtacain', 'Dicainum', 'Menonasal', 'NSC-757337', 'Pantocaine', 'Tetocaine', 'Tetraca', 'Tetracaine hcl', 'Tetracaine hydrochloride', 'Tetracaini hydrochloridum']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2016.0,CHEMBL698,['tetracaine%20hydrochloride'],"['11533049', '144203841', '170465190', '26747689', '26747690', '50107143', '50107144', '50107145', '85273695']",,,,,,
CHEMBL1562610,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+],QHJLLDJTVQAFAN-UHFFFAOYSA-M,Small molecule,True,MECLOFENAMATE SODIUM,4.0,False,True,"['Meclodium', 'Meclofenamate sodium', 'Meclomen']","['CL-583.NA SALT', 'Meclofenamate sodium', 'Meclofenamate sodium anhydrous', 'Meclofenamate sodium hydrate', 'Meclofenamic acid sodium', 'NSC-757088', 'Sodium meclofenamate', 'Sodium meclofenamate monohydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 5 approved indications. This drug has a black box warning from the FDA.,,,"['MONDO_0005178', 'HP_0001945', 'EFO_0000685', 'EFO_0002609', 'HP_0100607']",5.0,"['ENSG00000012779', 'ENSG00000073756', 'ENSG00000095303']",3,1980.0,CHEMBL509,['meclofenamate%20sodium'],"['11112978', '144204315', '170464886', '85273783']",['76232'],,,,,
CHEMBL2105763,Cn1cc(CNCC2CCN(c3ncc(C(=O)NO)cn3)CC2)c2ccccc21,PAWIYAYFNXQGAP-UHFFFAOYSA-N,Small molecule,False,QUISINOSTAT,2.0,False,False,[],"['JNJ 26481585', 'JNJ-26481585', 'Quisinostat']",['CHEMBL3039527'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB12985'],"['EFO_0002913', 'MONDO_0008170', 'EFO_0000574']",3.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,,,,,,,,,,
CHEMBL2109583,,,Antibody,False,F16IL2,2.0,False,False,[],"['F16IL2', 'F16il2']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000222', 'EFO_1001471', 'MONDO_0007254', 'EFO_0003060']",4.0,['ENSG00000041982'],1,,,,,,,,,,
CHEMBL2216870,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,IFSDAJWBUCMOAH-HNNXBMFYSA-N,Small molecule,True,IDELALISIB,4.0,False,True,['Zydelig'],"['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,['DB09054'],"['EFO_1001469', 'EFO_0000183', 'MONDO_0005184', 'MONDO_0018906', 'MONDO_0044903', 'EFO_0000095', 'EFO_0005854', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000574', 'EFO_0000403', 'EFO_0000222', 'EFO_0001378', 'MONDO_0000432', 'EFO_1001875', 'EFO_0009441', 'EFO_0000096', 'EFO_0005952', 'EFO_0000220']",19.0,['ENSG00000171608'],1,2014.0,,['idelalisib'],,['82701'],['https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig'],,,,
CHEMBL262075,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,CBIAWPMZSFFRGN-UHFFFAOYSA-N,Small molecule,False,INDIPLON,3.0,False,False,[],"['CL-285489', 'Calenthys', 'Indiplon', 'NBI-34060']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,['Indiplon'],['DB12590'],"['EFO_0004698', 'MONDO_0002050']",2.0,['ENSG00000022355'],1,,,,['174006212'],,,,,,
CHEMBL4110551,COC(=O)NCCCn1nc([C@@H](C)N(C(=O)[C@H]2CNCCO2)C2CC2)c2ccc(C)nc21,GRTDDIZIUSADLD-CRAIPNDOSA-N,Small molecule,False,SPH-3127,3.0,False,False,[],"['SPH-3127', 'SPH3127', 'Sph-3127', 'Sph3127']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0000401', 'EFO_0000729', 'MONDO_0001134', 'EFO_0000537']",4.0,['ENSG00000143839'],1,,,,,,,,,,
CHEMBL4298047,,,Antibody,False,TAFASITAMAB,4.0,False,True,"['Minjuvi', 'Monjuvi', 'Monjuvi (tafasitamab-cxix) for injection']","['MOR-00208', 'MOR00208', 'MOR208', 'Mor-208', 'Mor00208', 'Tafasitamab', 'Tafasitamab cxix', 'XmAb5574', 'Xmab-5574', 'Xmab5574']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 7 investigational indications.,,,"['EFO_0000095', 'EFO_1001469', 'MONDO_0001023', 'EFO_0000574', 'EFO_0000096', 'MONDO_0018906', 'EFO_0000403', 'EFO_0005952', 'EFO_0000616', 'EFO_0000220']",10.0,['ENSG00000177455'],1,2020.0,,['tafasitamab-cxix'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/minjuvi'],,,,
CHEMBL4594566,,,Antibody,False,ONGERICIMAB,3.0,False,False,[],"['JS 002', 'JS-002', 'Js002', 'Ongericimab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0004992', 'Orphanet_79211', 'EFO_0004911', 'HP_0003124', 'MONDO_0021187']",5.0,['ENSG00000169174'],1,,,,,,,,,,
CHEMBL61872,CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3,JACAAXNEHGBPOQ-LLVKDONJSA-N,Small molecule,False,TALAMPANEL,2.0,False,False,[],"['(-)-talampanel', 'GYKI-53773', 'LY-300164', 'Ly300164', 'Talampanel']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,['Talampanel'],['DB04982'],"['EFO_0002499', 'EFO_0002501', 'MONDO_0005180', 'MONDO_0004976', 'EFO_1000158', 'EFO_0000474', 'EFO_0000519', 'EFO_0000630']",8.0,"['ENSG00000120251', 'ENSG00000155511']",2,,,,,['34992'],,,,,
CHEMBL1639,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,UXOWGYHJODZGMF-QORCZRPOSA-N,Small molecule,True,ALISKIREN,4.0,False,True,['Rasilez'],"['Aliskiren', 'SPP-100', 'SPP100']","['CHEMBL559358', 'CHEMBL1667', 'CHEMBL3545059', 'CHEMBL3508698']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA.,['Aliskiren'],['DB09026'],"['EFO_0000537', 'EFO_0000275', 'EFO_0000537', 'EFO_0000400', 'EFO_0003884', 'MONDO_0001134', 'MONDO_0005148', 'EFO_0000712', 'EFO_0000319', 'MONDO_0007947', 'EFO_0000401', 'EFO_0004194', 'EFO_0003144', 'EFO_0000373', 'EFO_0003086', 'EFO_0005672', 'MONDO_0021661', 'EFO_0003914', 'EFO_0003896', 'EFO_0000612']",20.0,['ENSG00000143839'],1,2007.0,,,,['601027'],,,,,
CHEMBL2108280,,,Oligonucleotide,False,CENERSEN,2.0,False,False,[],['Cenersen'],,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000222', 'EFO_0000198']",2.0,['ENSG00000141510'],1,,,,,,,,,,
CHEMBL3989754,CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1.O.O.[Na+],GNMBMOULKUXEQF-UHFFFAOYSA-M,Small molecule,False,FLURBIPROFEN SODIUM,4.0,False,True,"['Ansaid', 'Flurbiprofen sodium', 'Occufen', 'Ocufen', 'Zepolas']","['Flurbiprofen sodium', 'Flurbiprofen sodium anhydrous', 'Flurbiprofen sodium dihydrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986.,,,,,"['ENSG00000073756', 'ENSG00000095303']",2,1986.0,CHEMBL563,['flurbiprofen%20sodium'],,,,,,,
CHEMBL4594254,C(=C/[C@H]1CCNC1)\c1cncnc1,FNEHSHNEXMPCLJ-VWCDRPFISA-N,Small molecule,False,SIMPINICLINE,2.0,False,False,[],"['OC-02', 'Oc-02', 'Simpinicline', 'TC-6499', 'TC-6499-12', 'TC6499', 'Tc-6499']",['CHEMBL4594377'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_1000906', 'EFO_1000948', 'EFO_0000555', 'EFO_1000906']",4.0,"['ENSG00000117971', 'ENSG00000080644', 'ENSG00000160716', 'ENSG00000101204']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SIMPINICLINE/relevant/1/'],,,
CHEMBL4596972,c1cnc2ccc(Nc3nc(NC4CC4)c4nc[nH]c4n3)cc2c1,QUTFBURLXCODBH-UHFFFAOYSA-N,Small molecule,False,PUQUITINIB MESYLATE DIHYDRATE,1.0,False,False,[],"['Puquitinib dimesylate dihydrate', 'Puquitinib mesylate dihydrate', 'Xc-302']",['CHEMBL4545915'],Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000128052', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000113721', 'ENSG00000146648']",11,,,,,,,,,,
CHEMBL587723,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1,OONFNUWBHFSNBT-HXUWFJFHSA-N,Small molecule,False,AEE-788,2.0,False,False,[],"['AEE-788', 'AEE788', 'Aee 788', 'Aee-788', 'GNF-PF-5343', 'NVP-AEE-788', 'NVP-AEE788']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,['AEE788'],['DB12558'],"['MONDO_0004992', 'EFO_0000519', 'EFO_1000158']",3.0,"['ENSG00000128052', 'ENSG00000102755', 'ENSG00000146648', 'ENSG00000141736']",4,,,,,,,,,,
CHEMBL1200413,Cl.c1ccc2c(c1)CCCC2C1=NCCN1,BJORNXNYWNIWEY-UHFFFAOYSA-N,Small molecule,False,TETRAHYDROZOLINE HYDROCHLORIDE,4.0,False,True,['Tyzine'],"['NSC-757339', 'Tetrahydrozoline hydrochloride', 'Tetrahydrozoline nitrate', 'Tetryzoline', 'Tetryzoline hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 2 investigational indications.,,,"['EFO_0000678', 'MP_0001845']",2.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1979.0,CHEMBL1266,,"['170464943', '26747671', '50107052', '56424102', '855698']",,,,,,
CHEMBL1200760,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+],CKMOQBVBEGCJGW-LLIZZRELSA-L,Small molecule,False,BALSALAZIDE DISODIUM,4.0,False,True,"['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']","['BX-661A', 'BX661A', 'Balsalazide disodium', 'Balsalazide disodium anhydrous', 'Balsalazide disodium dihydrate', 'Balsalazide disodium salt dihydrate', 'Balsalazide sodium', 'Balsalazine', 'NSC-760046']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for ulcerative colitis.,,,['EFO_0000729'],1.0,"['ENSG00000012779', 'ENSG00000132170', 'ENSG00000073756', 'ENSG00000095303']",4,2000.0,CHEMBL1201346,['balsalazide%20disodium'],,,,,,,
CHEMBL2108955,,,Antibody,False,EDRECOLOMAB,3.0,False,False,['Panorex'],"['17-1A', 'C-1', 'Edrecolomab', 'MAB-17-1A', 'Mab17-1a']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_1001951', 'EFO_0000616', 'MONDO_0004992']",3.0,['ENSG00000119888'],1,,,,,,,,,,
CHEMBL3039517,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,SYYBDNPGDKKJDU-ZDUSSCGKSA-N,Small molecule,False,RABUSERTIB,2.0,False,False,[],"['IC-83', 'LY-2603618', 'LY2603618', 'Ly-2603618', 'Rabusertib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB11662'],"['EFO_0000616', 'EFO_0003060', 'MONDO_0004992', 'EFO_0003860']",4.0,['ENSG00000149554'],1,,,,,,,,,,
CHEMBL3301625,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,KXBDTLQSDKGAEB-UHFFFAOYSA-N,Small molecule,False,SPEBRUTINIB,2.0,False,False,[],"['AVL-292', 'Btk inhibitor cc-292', 'CC-292', 'Spebrutinib']",['CHEMBL3301600'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB11764'],"['EFO_0000095', 'EFO_0000403', 'EFO_0009441', 'EFO_0000685', 'EFO_0000565']",5.0,['ENSG00000010671'],1,,,,,,,,,,
CHEMBL419667,COc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3[C@](O)(c3ccccc3Cl)[C@@H]2C(=O)N2CCC[C@H]2C(N)=O)cc1OC,CEBYCSRFKCEUSW-NAYZPBBASA-N,Small molecule,False,RELCOVAPTAN,2.0,False,False,[],"['Relcovaptan', 'SR 49059', 'SR49059', 'Sr-49059', 'TDI 0134', 'TDI-0134']",,Small molecule drug with a maximum clinical trial phase of II.,['Relcovaptan'],['DB13929'],,,"['ENSG00000180914', 'ENSG00000166148']",2,,,,['26753276'],,,,,,
CHEMBL4297502,C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC,TUWMKPVJGGWGNL-UHFFFAOYSA-N,Small molecule,False,AVORALSTAT,3.0,False,False,[],"['Avoralstat', 'BCX-4161']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB12120'],['MONDO_0019623'],1.0,['ENSG00000164344'],1,,,,,,,,,,
CHEMBL473159,Oc1cc(O)cc(O)c1,QCDYQQDYXPDABM-UHFFFAOYSA-N,Small molecule,False,PHLOROGLUCINOL,4.0,False,True,"['Spasfon', 'Spasfon-lyoc']","['Benezene-1,3,5-triol', 'Dilospan s', 'NSC-1572', 'Phloroglucin', 'Phloroglucinol', 'Sym-trihydroxybenzene']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for gastrointestinal disease.,['Phloroglucinol'],['DB12944'],['EFO_0010282'],1.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,,,,['29218028'],['16204'],,,,,
CHEMBL565612,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,OAVGBZOFDPFGPJ-UHFFFAOYSA-N,Small molecule,False,SOTRASTAURIN,2.0,False,False,[],"['AEB-071', 'AEB071', 'Aeb-071', 'NVP-AEB071', 'Sotrastaurin']",['CHEMBL2105655'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB12369'],"['EFO_0000403', 'EFO_0000729', 'EFO_0000574', 'EFO_0000676', 'EFO_1001119']",5.0,"['ENSG00000115825', 'ENSG00000163558', 'ENSG00000154229', 'ENSG00000126583', 'ENSG00000163932', 'ENSG00000166501', 'ENSG00000067606', 'ENSG00000171132', 'ENSG00000027075', 'ENSG00000184304', 'ENSG00000065675']",11,,,,['103905056'],['90531'],,,,,
CHEMBL1194,CCCNC(C)C(=O)Nc1ccccc1C,MVFGUOIZUNYYSO-UHFFFAOYSA-N,Small molecule,False,PRILOCAINE,4.0,False,True,[],"['ASTRA-1512', 'ASTRA-1515', 'Citanest', 'NSC-40027', 'Prilocaine', 'Propitocaine']",['CHEMBL1200586'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for pain and has 7 investigational indications.,['Prilocaine'],['DB00750'],"['MONDO_0041052', 'EFO_0002950', 'EFO_0000707', 'EFO_0003843', 'HP_0012532', 'EFO_0803321', 'EFO_0002496', 'EFO_0000701']",8.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1965.0,,['prilocaine'],['90341069'],['8404'],,,,,
CHEMBL1201236,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,TZFNLOMSOLWIDK-JTQLQIEISA-N,Small molecule,False,CARBIDOPA ANHYDROUS,4.0,False,True,[],"['Carbidopa, l- anhydrous']",['CHEMBL1200748'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 23 investigational indications.,['Carbidopa'],['DB00190'],"['EFO_0000712', 'EFO_1001919', 'EFO_0003770', 'EFO_1001402', 'EFO_0002610', 'Orphanet_1764', 'EFO_0000546', 'EFO_0003768', 'MONDO_0018910', 'MONDO_0005301', 'MONDO_0007113', 'HP_0002381', 'EFO_0005252', 'EFO_0005687', 'MONDO_0004979', 'HP_0012532', 'MONDO_0005180', 'HP_0003418', 'EFO_0000537', 'MONDO_0019200', 'EFO_0003888', 'MONDO_0005090', 'EFO_1001175', 'MONDO_0001020', 'EFO_0003843', 'MONDO_0004976', 'EFO_0001365']",27.0,['ENSG00000132437'],1,1975.0,,,"['11113507', '144204461', '26749935', '29215028', '50104417', '50104418', '8139862', '93576631']",['39585'],,,,,
CHEMBL1201608,,,Antibody,True,MUROMONAB-CD3,4.0,False,True,['Orthoclone okt3'],"['Anticd3', 'L04AA02', 'Macs gmp cd3 pure', 'Muromomab', 'Muromonab', 'Muromonab cd3', 'Muromonab-cd3', 'OKT-3', 'OKT3']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for immune system disease and has 9 investigational indications. This drug has a black box warning from the FDA.,['Muromonab-CD3'],,"['MONDO_0002367', 'MONDO_0004992', 'EFO_0000389', 'EFO_0000616', 'EFO_0000756', 'EFO_0000540', 'EFO_1000158', 'EFO_1001249', 'EFO_0003865', 'EFO_0000729']",10.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286']",3,1986.0,,,,,,,,['5177'],
CHEMBL2105629,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,YIHUEPHBPPAAHH-PEPODRRYSA-N,Small molecule,False,VINFLUNINE DITARTRATE,4.0,False,True,['Javlor'],"['BMS-710485', 'F-12158', 'Vinflunine bitartrate', 'Vinflunine ditartrate', 'Vinflunine tartrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009.,,,,,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,2009.0,CHEMBL2110725,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/javlor'],,,,
CHEMBL2386889,Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,GMIZZEXBPRLVIV-SECBINFHSA-N,Small molecule,False,SCH-900776,2.0,False,False,[],"['MK-8776', 'Mk-8776', 'SCH 900776', 'SCH-900776', 'Sch-900776']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB11899'],"['EFO_0000183', 'EFO_0000220', 'EFO_0000222', 'EFO_0000339', 'EFO_0005952']",5.0,['ENSG00000149554'],1,,,,,,,,,,
CHEMBL373742,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,KBZOIRJILGZLEJ-LGYYRGKSSA-N,Protein,False,VASOPRESSIN,4.0,False,True,"['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']","['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressin', 'Vasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']",['CHEMBL2360839'],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for diabetes insipidus and sepsis and has 17 investigational indications.,,,"['MONDO_0003061', 'EFO_0003756', 'EFO_1001255', 'EFO_0003843', 'EFO_0009637', 'MONDO_0001572', 'EFO_0004610', 'EFO_0003758', 'MONDO_0002009', 'MONDO_0005149', 'EFO_0004278', 'EFO_0006834', 'EFO_0003777', 'EFO_0005251', 'EFO_0009492', 'MONDO_0004782', 'EFO_0005207', 'HP_0031273', 'HP_0100806']",19.0,"['ENSG00000126895', 'ENSG00000166148', 'ENSG00000198049']",3,2014.0,,['vasopressin'],"['144206588', '29218064']",['34543'],,,,,
CHEMBL3991932,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,LNMRSSIMGCDUTP-UHFFFAOYSA-N,Small molecule,False,PEXMETINIB,2.0,False,False,[],"['ARRY-614', 'Arry-614', 'Pexmetinib']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000198'],1.0,"['ENSG00000112062', 'ENSG00000120156']",2,,,,,,,,,,
CHEMBL4298088,,,Antibody drug conjugate,False,CETUXIMAB SAROTALOCAN,2.0,False,False,[],"['ASP-1929', 'Cetuximab sarotalocan', 'Cetuximab sarotalocan sodium', 'Cetuximab-IRDye-700DX', 'Cetuximab-irdye 700dx conjugate', 'RM-1929']",,Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000146648'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/CETUXIMAB%20SAROTALOCAN/relevant/1/'],,,
CHEMBL4298119,,,Antibody,False,OLINVACIMAB,2.0,False,False,[],"['Olinvacimab', 'TTAC-0001', 'Tanibirumab', 'Ttac-0001']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0005537', 'MONDO_0007254', 'EFO_0000519']",3.0,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL4594565,,,Protein,False,PABINAFUSP ALFA,3.0,False,False,[],"['JR-141', 'JR141', 'Jr-141', 'Pabinafusp alfa']",,Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['MONDO_0010674'],1.0,"['ENSG00000072274', 'ENSG00000106327']",2,,,,,,,,,,
CHEMBL4650298,,,Unknown,False,PLB1003,1.0,False,False,[],"['PLB1003', 'Plb1003']",,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0003060'],1.0,"['ENSG00000171094', 'ENSG00000143924']",2,,,,,,,,,,
CHEMBL1200787,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl,VBCPVIWPDJVHAN-UHFFFAOYSA-N,Small molecule,False,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,False,True,"['Dibenyline', 'Dibenzyline', 'Phenoxybenzamine hydrochloride']","['Bensylyte hydrochloride', 'Dibenzylin', 'Dibenzyline chloride', 'Dibenzyline hydrochloride', 'Dibenzyran', 'NSC-37448', 'Phenoxybenzamine chloride', 'Phenoxybenzamine hcl', 'Phenoxybenzamine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and is indicated for adrenal gland pheochromocytoma.,,,['EFO_0000239'],1.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1953.0,CHEMBL753,['phenoxybenzamine%20hydrochloride'],"['144208786', '144213295', '17389764', '26747462', '26752311', '50105976', '855636']",['8078'],,,,,
CHEMBL1201168,Cc1cc(C(=O)NNCc2ccccc2)no1,XKFPYPQQHFEXRZ-UHFFFAOYSA-N,Small molecule,True,ISOCARBOXAZID,4.0,False,True,['Marplan'],"['Enerzer', 'Isocarboxazid', 'NSC-169893', 'RO 5-0831', 'RO-5-0831']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for unipolar depression and major depressive disorder and has 1 investigational indication. This drug has a black box warning from the FDA.,['Isocarboxazid'],['DB01247'],"['EFO_0003761', 'MONDO_0002009', 'MONDO_0004975']",3.0,"['ENSG00000189221', 'ENSG00000069535']",2,1959.0,,['isocarboxazid'],"['11112152', '144203887', '56463226']",,,,,,
CHEMBL1256958,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O,YLXIPWWIOISBDD-FVGYRXGTSA-N,Small molecule,False,EPINEPHRINE BITARTRATE,4.0,False,True,"['Bronitin mist', 'Medihaler-epi']","['(-)-Epinephrine Bitartrate', 'Adrenalin tartrate', 'Adrenaline (as tartrate)', 'Adrenaline acid tartrate', 'Adrenaline bitartate', 'Adrenaline bitartrate', 'Epinephrine bitartrate', 'Epinephrine d-bitartrate', 'Epinephrine hydrogen tartrate', 'Epinephrine tartrate', 'Epinephrini hydrogenotartras', 'L-epinephrine hydrogen tartrate', 'NSC-756755']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965 and is indicated for pain.,,,['EFO_0003843'],1.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1965.0,CHEMBL679,['epinephrine%20bitartrate'],"['11532860', '50106283']",,,,,,
CHEMBL1431,CN(C)C(=N)NC(=N)N,XZWYZXLIPXDOLR-UHFFFAOYSA-N,Small molecule,True,METFORMIN,4.0,False,True,[],"['LA-6023', 'Metformin', 'Metformin extended release']","['CHEMBL3094198', 'CHEMBL1703']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 181 investigational indications. This drug has a black box warning from the FDA.,['Metformin'],['DB00331'],"['EFO_0000685', 'EFO_0002617', 'MONDO_0044704', 'EFO_0005537', 'MONDO_0007254', 'EFO_0002618', 'HP_0000842', 'MONDO_0005090', 'EFO_0004214', 'HP_0003124', 'MONDO_0100096', 'MONDO_0010383', 'MONDO_0018906', 'MONDO_0005299', 'EFO_0008522', 'EFO_0000571', 'MONDO_0001941', 'EFO_0001378', 'EFO_0003095', 'MONDO_0010679', 'EFO_0000403', 'EFO_0000182', 'MONDO_0007254', 'EFO_0000673', 'EFO_1001951', 'MP_0001845', 'EFO_0005687', 'MONDO_0018875', 'EFO_1001496', 'EFO_0000432', 'HP_0002745', 'EFO_0000660', 'EFO_0000275', 'EFO_0003914', 'MONDO_0011382', 'MONDO_0021063', 'HP_0003419', 'MONDO_0019391', 'EFO_0001071', 'MONDO_0019353', 'EFO_0004593', 'EFO_0000305', 'EFO_0005411', 'EFO_0003968', 'MONDO_0005148', 'MONDO_0004782', 'EFO_0000673', 'EFO_0000676', 'EFO_0002687', 'EFO_0003884', 'EFO_0000341', 'EFO_0003770', 'EFO_0003060', 'EFO_0000537', 'EFO_0009516', 'EFO_1001121', 'EFO_0000702', 'EFO_0000199', 'EFO_0004208', 'EFO_0004616', 'MONDO_0002158', 'EFO_0002950', 'MONDO_0008315', 'EFO_0000756', 'Orphanet_309005', 'EFO_1001892', 'EFO_0000365', 'MONDO_0021350', 'EFO_1001512', 'EFO_0004265', 'EFO_0009637', 'HP_0100543', 'EFO_0000181', 'EFO_0003767', 'EFO_0000095', 'MONDO_0002108', 'EFO_0000400', 'EFO_0000280', 'EFO_1000043', 'EFO_0004566', 'EFO_0005672', 'MONDO_0004658', 'EFO_0000694', 'MONDO_0011962', 'EFO_1000359', 'EFO_1001492', 'HP_0002910', 'EFO_0008520', 'MONDO_0002009', 'EFO_0004364', 'EFO_0000729', 'EFO_1001459', 'EFO_1000710', 'EFO_0008520', 'EFO_0003144', 'EFO_0001663', 'EFO_0000474', 'EFO_0006859', 'EFO_0004142', 'EFO_0000519', 'EFO_0000196', 'MONDO_0008903', 'MONDO_0019338', 'MONDO_0005180', 'EFO_0000228', 'HP_0001268', 'MONDO_0005178', 'MONDO_0004992', 'EFO_0000195', 'EFO_0001416', 'EFO_0003884', 'EFO_0006859', 'EFO_0001645', 'EFO_0000466', 'EFO_0000313', 'EFO_0003060', 'EFO_0005922', 'EFO_0001054', 'EFO_0001361', 'EFO_0004593', 'EFO_0000707', 'MONDO_0005301', 'Orphanet_733', 'EFO_0000308', 'MONDO_0005277', 'EFO_0000616', 'EFO_1001249', 'HP_0001397', 'HP_0001541', 'MONDO_0020121', 'EFO_0002618', 'EFO_0003963', 'MONDO_0002974', 'MONDO_0008170', 'EFO_0005762', 'MONDO_0008315', 'EFO_0003050', 'EFO_0000571', 'MONDO_0002691', 'EFO_0003863', 'EFO_0000649', 'EFO_0001068', 'MONDO_0005147', 'EFO_0000545', 'EFO_0001378', 'MONDO_0005184', 'EFO_1001207', 'EFO_0000348', 'EFO_1000045', 'EFO_0003940', 'EFO_0003918', 'MONDO_0017975', 'EFO_0003144', 'EFO_0002546', 'EFO_1001901', 'EFO_0000195', 'EFO_0003868', 'EFO_0003876', 'MONDO_0001187', 'EFO_0000199', 'EFO_1000783', 'HP_0012115', 'MONDO_0015229', 'MONDO_0007739', 'EFO_1000657', 'MONDO_0005041', 'EFO_0001663', 'EFO_0000400', 'EFO_0000220', 'EFO_1000286', 'EFO_0000589', 'MONDO_0002087', 'MONDO_0018076', 'MONDO_0021063', 'EFO_0001075', 'EFO_0001073', 'MONDO_0017276', 'MONDO_0004985', 'EFO_0000660', 'EFO_0008522', 'EFO_0000764', 'EFO_0003833', 'EFO_1000632', 'EFO_0001073', 'HP_0001249', 'EFO_0003100', 'EFO_1001465', 'EFO_1001348', 'EFO_0000319', 'EFO_0000616', 'MONDO_0005148', 'EFO_0002614']",192.0,"['ENSG00000198695', 'ENSG00000130414', 'ENSG00000110717', 'ENSG00000212907', 'ENSG00000184983', 'ENSG00000198888', 'ENSG00000165264', 'ENSG00000189043', 'ENSG00000174886', 'ENSG00000099795', 'ENSG00000198763', 'ENSG00000158864', 'ENSG00000198786', 'ENSG00000119421', 'ENSG00000136521', 'ENSG00000198886', 'ENSG00000198840', 'ENSG00000004779', 'ENSG00000125356', 'ENSG00000164258', 'ENSG00000119013', 'ENSG00000109390', 'ENSG00000131495', 'ENSG00000168653', 'ENSG00000115286', 'ENSG00000145494', 'ENSG00000183648', 'ENSG00000213619', 'ENSG00000170906', 'ENSG00000065518', 'ENSG00000166136', 'ENSG00000090266', 'ENSG00000267855', 'ENSG00000151366', 'ENSG00000140990', 'ENSG00000178127', 'ENSG00000023228', 'ENSG00000167792', 'ENSG00000160194', 'ENSG00000128609', 'ENSG00000139180', 'ENSG00000164182', 'ENSG00000178057', 'ENSG00000185633', 'ENSG00000147123', 'ENSG00000123545', 'ENSG00000186010', 'ENSG00000184752', 'ENSG00000137806', 'ENSG00000147684', 'ENSG00000115159']",51,1995.0,,,"['11112469', '137275802', '144212687', '174006543']",['6801'],,,['53'],,
CHEMBL1703,CN(C)C(=N)NC(=N)N.Cl,OETHQSJEHLVLGH-UHFFFAOYSA-N,Small molecule,True,METFORMIN HYDROCHLORIDE,4.0,False,True,"['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850', 'Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'Glumetza', 'Glyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochloride', 'Metsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']","['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404', 'Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochloride', 'NSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 42 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003884', 'EFO_0000571', 'EFO_0008520', 'MONDO_0007254', 'EFO_0002618', 'HP_0000842', 'EFO_0000199', 'MONDO_0005184', 'EFO_0000348', 'EFO_0004208', 'EFO_1001459', 'EFO_0004616', 'EFO_0003144', 'MONDO_0005299', 'MONDO_0002158', 'EFO_0001663', 'EFO_0000195', 'EFO_0003868', 'EFO_0006859', 'MONDO_0008315', 'EFO_1000783', 'EFO_0001378', 'EFO_0000400', 'EFO_1001512', 'MONDO_0002087', 'MP_0001845', 'EFO_0009637', 'EFO_0000432', 'EFO_0000660', 'EFO_0008522', 'EFO_0000466', 'EFO_0003060', 'MONDO_0021063', 'EFO_0004593', 'EFO_0001073', 'EFO_0001071', 'MONDO_0019353', 'EFO_1000043', 'MONDO_0019391', 'EFO_1001465', 'EFO_0000616', 'HP_0001541', 'MONDO_0005148', 'EFO_0000673']",44.0,"['ENSG00000198695', 'ENSG00000130414', 'ENSG00000110717', 'ENSG00000212907', 'ENSG00000184983', 'ENSG00000198888', 'ENSG00000165264', 'ENSG00000189043', 'ENSG00000174886', 'ENSG00000099795', 'ENSG00000198763', 'ENSG00000158864', 'ENSG00000198786', 'ENSG00000119421', 'ENSG00000136521', 'ENSG00000198886', 'ENSG00000198840', 'ENSG00000004779', 'ENSG00000125356', 'ENSG00000164258', 'ENSG00000119013', 'ENSG00000109390', 'ENSG00000131495', 'ENSG00000168653', 'ENSG00000115286', 'ENSG00000145494', 'ENSG00000183648', 'ENSG00000213619', 'ENSG00000170906', 'ENSG00000065518', 'ENSG00000166136', 'ENSG00000090266', 'ENSG00000267855', 'ENSG00000151366', 'ENSG00000140990', 'ENSG00000178127', 'ENSG00000023228', 'ENSG00000167792', 'ENSG00000160194', 'ENSG00000128609', 'ENSG00000139180', 'ENSG00000164182', 'ENSG00000178057', 'ENSG00000185633', 'ENSG00000147123', 'ENSG00000123545', 'ENSG00000186010', 'ENSG00000184752', 'ENSG00000137806', 'ENSG00000147684', 'ENSG00000115159']",51,1995.0,CHEMBL1431,['metformin%20hydrochloride'],"['11532867', '144204049', '170464804', '26749076', '85273756']",['6802'],,,,,
CHEMBL2105738,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,PAFKTGFSEFKSQG-PAASFTFBSA-N,Small molecule,False,GALETERONE,3.0,False,False,[],"['Galeterone', 'TOK 001', 'TOK-001', 'VN 124', 'VN-124', 'VN/124', 'VN/124-1']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB12415'],"['MONDO_0008315', 'EFO_1000359']",2.0,"['ENSG00000169083', 'ENSG00000148795']",2,,,,,,,,,,
CHEMBL3039502,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,SJVQHLPISAIATJ-ZDUSSCGKSA-N,Small molecule,True,DUVELISIB,4.0,False,True,[],"['Duvelisib', 'INK-1197', 'IPI-145']",['CHEMBL5315125'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,['DB11952'],"['EFO_0000574', 'MONDO_0004979', 'EFO_0000095', 'EFO_0000685', 'EFO_0000181', 'EFO_0000574', 'EFO_0000095', 'MONDO_0100096', 'EFO_0000403', 'EFO_1001051', 'EFO_0001421', 'EFO_0000220', 'EFO_1000785', 'MONDO_0018906', 'MONDO_0004992', 'MONDO_0044881', 'EFO_0000096', 'EFO_0000616', 'EFO_0000211', 'EFO_0000756', 'EFO_0000565', 'MONDO_0018906', 'EFO_0005952']",23.0,"['ENSG00000105851', 'ENSG00000171608']",2,2018.0,,['duvelisib'],,,,,,,
CHEMBL4297721,,,Unknown,False,CDX-1140,2.0,False,False,[],"['CDX-1140', 'CDX1140', 'Cdx 1140', 'Cdx-1140']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 19 investigational indications.,,,"['EFO_0005221', 'EFO_0000756', 'EFO_0006859', 'EFO_0003060', 'MONDO_0001056', 'EFO_0000182', 'EFO_0005540', 'EFO_0000305', 'EFO_0000681', 'EFO_0002618', 'MONDO_0007576', 'EFO_1001951', 'EFO_0000616', 'EFO_0002617', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0002158', 'EFO_0000403', 'EFO_1001469']",19.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL4297754,,,Oligonucleotide,False,FITUSIRAN,3.0,False,False,[],"['ALN-57213', 'ALN-AT3SC', 'Aln-at3sc', 'Fitusiran']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['MONDO_0018660', 'MONDO_0010602', 'MONDO_0010604']",3.0,['ENSG00000117601'],1,,,,,,,,,,
CHEMBL4594292,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1.Cl.O,KZVOMLRKFJUTLK-UHFFFAOYSA-N,Small molecule,False,TEPOTINIB HYDROCHLORIDE,4.0,False,True,['Tepmetko'],"['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochloride', 'Tepotinib hydrochloride hydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.,,,"['EFO_0000616', 'EFO_0003060']",2.0,['ENSG00000105976'],1,2021.0,CHEMBL3402762,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko'],['https://searchusan.ama-assn.org/finder/usan/search/TEPOTINIB%20HYDROCHLORIDE/relevant/1/'],,,
CHEMBL488436,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,WJRRGYBTGDJBFX-UHFFFAOYSA-N,Small molecule,False,AZD-5438,1.0,False,False,[],"['AZD-5438', 'Azd 5438', 'Azd-5438']",['CHEMBL454649'],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000170312', 'ENSG00000135446', 'ENSG00000123374', 'ENSG00000164885', 'ENSG00000105810', 'ENSG00000134058', 'ENSG00000250506', 'ENSG00000102225', 'ENSG00000117266', 'ENSG00000132964', 'ENSG00000059758', 'ENSG00000248333', 'ENSG00000138395', 'ENSG00000155111', 'ENSG00000058091', 'ENSG00000136807', 'ENSG00000185324', 'ENSG00000065883', 'ENSG00000156345', 'ENSG00000167258']",20,,,,,,,,,,
CHEMBL1201554,,,Protein,False,ANTITHROMBIN ALFA,4.0,False,True,['Atryn'],"['Antithrombin (recombinant)', 'Antithrombin alfa', 'Antithrombin iii,recombinant', 'Human anti-thrombin-iii', 'KW-3357']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for reduced antithrombin iii activity and has 2 investigational indications.,,,"['EFO_0000668', 'HP_0001976', 'HP_0005521']",3.0,"['ENSG00000180210', 'ENSG00000126218']",2,2006.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/atryn'],,,,
CHEMBL3189072,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O.Cl.O,HWAAPJPFZPHHBC-FGJQBABTSA-N,Small molecule,False,TIROFIBAN HYDROCHLORIDE,4.0,False,True,['Aggrastat'],"['L-700,462', 'L-700462', 'MK-383', 'Tirofiban hcl', 'Tirofiban hydrochloride', 'Tirofiban hydrochloride anhydrous']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998 and is indicated for myocardial infarction.,,,['EFO_0000612'],1.0,"['ENSG00000259207', 'ENSG00000005961']",2,1998.0,CHEMBL916,['tirofiban%20hydrochloride'],"['144206533', '170465092']",['9606'],,,,,
CHEMBL3349001,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,GYCPCOJTCINIFZ-OXJNMPFZSA-N,Small molecule,False,AVN-944,2.0,False,False,[],"['AVN 944', 'AVN944', 'Avn-944', 'Avn944']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0002618'],1.0,"['ENSG00000106348', 'ENSG00000178035']",2,,,,,,,,,,
CHEMBL3545278,CCCCCS(=O)(=O)NC(=O)c1ccc2nc(C)n(Cc3ccc(Cl)cc3Cl)c2c1,UYGZODVVDUIDDQ-UHFFFAOYSA-N,Small molecule,False,ATX08-001,2.0,False,False,[],"['Atx08-001', 'FK-614', 'FK614']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12557'],"['MONDO_0041052', 'EFO_0000400']",2.0,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL3545350,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1,BOVUHBFXPNLTKF-UHFFFAOYSA-N,Small molecule,False,EVT-101,2.0,False,False,[],['Evt-101'],['CHEMBL3545349'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0002050'],1.0,"['ENSG00000176884', 'ENSG00000273079']",2,,,,,,,,,,
CHEMBL5315075,,,Protein,False,SUSOCTOCOG ALFA,4.0,False,True,['Obizur'],"['BAX-802', 'BAX802', 'Susoctocog alfa']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hemorrhage and hemophilia a.,,,"['MP_0001914', 'MONDO_0010602']",2.0,['ENSG00000185010'],1,2015.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/obizur'],,,,
CHEMBL742,CNC1(c2ccccc2Cl)CCCCC1=O,YQEZLKZALYSWHR-UHFFFAOYSA-N,Small molecule,False,KETAMINE,4.0,False,True,['Ketalar'],"['Anaket v', 'Calypsol', 'Clorketam 1000', 'Dl-ketamine', 'Imalgene 1000', 'Ketamine', 'Ketasol 100', 'NSC-70151', 'Narketan', 'PMI-150', 'Tekam', 'Ursotamin', 'Vetaket']",['CHEMBL1714'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 84 investigational indications.,"['Esketamine', 'Ketamine']",['DB01221'],"['EFO_0001358', 'EFO_0003768', 'HP_0012532', 'EFO_0003756', 'EFO_0000713', 'EFO_1001998', 'EFO_0007224', 'MONDO_0007079', 'EFO_0001074', 'EFO_0002460', 'MONDO_0002009', 'EFO_0009854', 'EFO_1001412', 'EFO_0000512', 'EFO_0000546', 'EFO_0004320', 'EFO_1001898', 'EFO_0003890', 'MONDO_0005129', 'HP_0002315', 'EFO_0005279', 'EFO_0009963', 'EFO_0000712', 'EFO_0008526', 'MONDO_0002009', 'EFO_0007191', 'MONDO_0010726', 'EFO_0009513', 'HP_0012378', 'EFO_0003957', 'MONDO_0007079', 'EFO_0007430', 'EFO_0000713', 'MONDO_0011382', 'EFO_0005762', 'HP_0000486', 'EFO_0009552', 'EFO_0004242', 'EFO_1000391', 'EFO_0000474', 'EFO_1001917', 'EFO_0004321', 'EFO_0005323', 'EFO_1000637', 'MONDO_0008903', 'EFO_0007453', 'MONDO_0004992', 'MONDO_0005351', 'EFO_0009267', 'EFO_0004320', 'EFO_0801084', 'MONDO_0004985', 'HP_0012076', 'EFO_0000677', 'MONDO_0002050', 'MONDO_0002038', 'MONDO_0002070', 'HP_0100806', 'EFO_0009854', 'EFO_0003761', 'EFO_0005611', 'EFO_0002610', 'HP_0000360', 'EFO_0003843', 'HP_0100543', 'HP_0000989', 'MONDO_0002050', 'EFO_0007149', 'EFO_0008590', 'MONDO_0007254', 'MONDO_0043510', 'EFO_0009686', 'EFO_0009492', 'EFO_1001210', 'MONDO_0100096', 'EFO_0006834', 'EFO_0002610', 'EFO_0000546', 'EFO_0005611', 'EFO_0003931', 'MONDO_0002258', 'EFO_0009620', 'EFO_0003931', 'HP_0002140', 'MONDO_0004992', 'EFO_0000474', 'MONDO_0005090', 'HP_0000713', 'HP_0100543', 'MONDO_0004985', 'EFO_0003015', 'MONDO_0024417', 'EFO_0000694', 'EFO_1001884']",94.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,1970.0,,,"['144205256', '29215438', '56424156']",['6121'],,,,,
CHEMBL1201162,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl,OSRUSFPMRGDLAG-QMGYSKNISA-N,Small molecule,False,DORZOLAMIDE HYDROCHLORIDE,4.0,False,True,"['Cosopt Pf', 'Dorzolamide hydrochloride', 'Trusopt']","['Dorzolamide (as hydrochloride)', 'Dorzolamide hcl', 'Dorzolamide hydrochloride', 'MK-507']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved indications.,,,"['MONDO_0005041', 'EFO_0004190', 'EFO_1001069']",3.0,['ENSG00000104267'],1,1994.0,CHEMBL218490,['dorzolamide%20hydrochloride'],"['170465119', '56463558']",['4703'],,,,,
CHEMBL1230607,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,HUXYBQXJVXOMKX-UHFFFAOYSA-N,Small molecule,False,PHA-793887,1.0,False,False,[],"['PHA-793887', 'Pha-793887']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB12686'],['EFO_0000616'],1.0,"['ENSG00000170312', 'ENSG00000135446', 'ENSG00000123374', 'ENSG00000164885', 'ENSG00000105810', 'ENSG00000134058', 'ENSG00000250506', 'ENSG00000102225', 'ENSG00000117266', 'ENSG00000132964', 'ENSG00000059758', 'ENSG00000248333', 'ENSG00000138395', 'ENSG00000155111', 'ENSG00000058091', 'ENSG00000136807', 'ENSG00000185324', 'ENSG00000065883', 'ENSG00000156345', 'ENSG00000167258']",20,,,,['137276012'],,,,,,
CHEMBL1334033,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1.O=C(O)/C=C\C(=O)O,JDZOTSLZMQDFLG-BTJKTKAUSA-N,Small molecule,False,PERHEXILINE MALEATE,4.0,True,True,"['Pexid', 'Pexsig']","['NSC-758409', 'Perhexiline maleate', 'Perhexilinum']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974. It was withdrawn in at least one region.,,,,,"['ENSG00000198793', 'ENSG00000205560', 'ENSG00000157184']",3,1974.0,CHEMBL75880,,"['144204948', '170466435', '26748746', '56422147', '855892']",,,,,,
CHEMBL2108375,,,Enzyme,False,DUTEPLASE,2.0,False,False,[],['Duteplase'],,Enzyme drug with a maximum clinical trial phase of II.,,,,,['ENSG00000104368'],1,,,,,,,,,,
CHEMBL2109586,,,Antibody,False,AMG-780,1.0,False,False,[],"['AMG-780', 'Amg 780', 'Amg-780']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000154188', 'ENSG00000091879']",2,,,,,,,,,,
CHEMBL284348,Nc1ccncc1,NUKYPUAOHBNCPY-UHFFFAOYSA-N,Small molecule,False,DALFAMPRIDINE,4.0,False,True,"['Ampyra', 'Ampyra Extended Release', 'Fampridine accord', 'Fampyra']","['Dalfampridine', 'EL-970', 'Fampridine', 'Fampridine (4-aminopyridine)', 'NSC-15041']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for multiple sclerosis and has 16 investigational indications.,['4-Aminopyridine'],['DB06637'],"['EFO_1000632', 'HP_0000083', 'HP_0002140', 'MONDO_0005301', 'EFO_0003918', 'EFO_0008522', 'EFO_0009602', 'EFO_0000712', 'EFO_0003782', 'EFO_0007292', 'EFO_0009490', 'Orphanet_83419', 'EFO_1001919', 'EFO_0004335', 'EFO_0007405', 'EFO_0003929', 'HP_0001257']",17.0,"['ENSG00000053918', 'ENSG00000171385', 'ENSG00000055118', 'ENSG00000177301', 'ENSG00000111262', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000104848', 'ENSG00000185760', 'ENSG00000117013', 'ENSG00000143473', 'ENSG00000182255', 'ENSG00000130037', 'ENSG00000177272', 'ENSG00000151079', 'ENSG00000129159', 'ENSG00000184408', 'ENSG00000182674', 'ENSG00000116396', 'ENSG00000131398', 'ENSG00000158445', 'ENSG00000143105', 'ENSG00000164794', 'ENSG00000140015', 'ENSG00000171126', 'ENSG00000168418', 'ENSG00000168263', 'ENSG00000124134', 'ENSG00000183960', 'ENSG00000166006', 'ENSG00000170745', 'ENSG00000173826', 'ENSG00000162975', 'ENSG00000184611', 'ENSG00000102057', 'ENSG00000026559', 'ENSG00000178342', 'ENSG00000135519', 'ENSG00000156486', 'ENSG00000089558']",40,2010.0,,['dalfampridine'],"['104171097', '11110683', '11113806', '124879040', '124879042', '136964060', '144203616', '144207991', '170466526', '26747141', '26751980', '26751983', '50104658', '8139900', '90341267']",['34385'],['https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord'],,,,
CHEMBL3544945,,,Small molecule,False,SAR-113945,2.0,False,False,[],['Sar-113945'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0005178', 'EFO_0004616']",2.0,['ENSG00000104365'],1,,,,,,,,,,
CHEMBL3545176,,,Small molecule,False,DB959,2.0,False,False,[],"['Db959', 'T3D-959']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004975'],1.0,"['ENSG00000132170', 'ENSG00000112033']",2,,,,,,,,,,
CHEMBL3813842,CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,LGWACEZVCMBSKW-UHFFFAOYSA-N,Small molecule,False,PAXALISIB,2.0,False,False,[],"['G-02441729', 'G02441729', 'GDC-0084', 'GDC0084', 'Paxalisib', 'Rg-7666']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB15186'],"['EFO_0000519', 'EFO_1000158', 'EFO_0000616', 'MONDO_0007254']",4.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PAXALISIB/relevant/1/'],,,
CHEMBL429,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1,SGUAFYQXFOLMHL-UHFFFAOYSA-N,Small molecule,False,LABETALOL,4.0,False,True,[],"['AH-5158A FREE BASE', 'Ibidomide', 'Labetalol', 'Normodyne', 'Normozide', 'SCH-15719W FREE BASE', 'Trandate']",['CHEMBL1200323'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and hypertension and has 10 investigational indications.,['Labetalol'],['DB00598'],"['EFO_0003843', 'EFO_0000319', 'EFO_0000668', 'EFO_0005251', 'EFO_0000537', 'EFO_0002610', 'EFO_0000537', 'EFO_0000712', 'EFO_0005669', 'EFO_0007486', 'EFO_0000668', 'EFO_0003768']",12.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1984.0,,,['90341718'],['6343'],,,['40'],,
CHEMBL4297423,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCCN1CCN(C)CC1)c1nnc(C)n1-2,PKQXLRYFPSZKDU-QFIPXVFZSA-N,Small molecule,False,RO-6870810,1.0,False,False,[],"['(S)-JQ35', 'BET INHIBITOR TEN-010', 'Bet inhibitor ro6870810', 'Jq-35, (s)-', 'RO6870810', 'Rg 6146', 'Ro-6870810', 'Ro6870810']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,['DB15151'],"['EFO_0001378', 'EFO_0000616', 'EFO_0000222', 'EFO_0000198']",4.0,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']",4,,,,,,,,,,
CHEMBL4298198,,,Oligonucleotide,False,VUPANORSEN SODIUM,1.0,False,False,[],"['AKCEA-ANGPTL3-LRx salt', 'ISIS 703802 salt', 'Vupanorsen sodium']",,Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0021187'],1.0,"['ENSG00000132855', 'ENSG00000141505']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/VUPANORSEN%20SODIUM/relevant/1/'],,,
CHEMBL4594350,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,PEMUGDMSUDYLHU-ZEQRLZLVSA-N,Small molecule,False,ADAGRASIB,4.0,False,True,['Krazati'],"['Adagrasib', 'Kras g12c inhibitor mrtx849', 'Krazati', 'MRTX-849', 'MRTX849', 'Mrtx-849', 'Mrtx849']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for neoplasm and non-small cell lung carcinoma and has 5 investigational indications.,,,"['EFO_0000616', 'EFO_0003060', 'EFO_1001951', 'MONDO_0008903', 'EFO_0009709', 'MONDO_0021063', 'EFO_0002618']",7.0,['ENSG00000133703'],1,2022.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ADAGRASIB/relevant/1/'],,,
CHEMBL92401,CC(C)NNC(=O)c1ccncc1,NYMGNSNKLVNMIA-UHFFFAOYSA-N,Small molecule,False,IPRONIAZID,4.0,False,True,['Marsilid'],"['Iproniazid', 'Iproniazide']","['CHEMBL1256361', 'CHEMBL1534878']",Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression.,['Iproniazid'],['DB04818'],['EFO_0003761'],1.0,"['ENSG00000189221', 'ENSG00000069535']",2,,,,"['11111333', '11111334', '50111104', '90341605']",['5958'],,,['62'],,
CHEMBL1200612,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1.Cl,IVHBBMHQKZBJEU-UHFFFAOYSA-N,Small molecule,False,DIBUCAINE HYDROCHLORIDE,4.0,False,True,"['Heavy solution nupercaine', 'Nupercainal', 'Nupercaine']","['Cincaine chloride', 'Cinchocaine hydrochloride', 'Dibucaine hcl', 'Dibucaine hydrochloride', 'NSC-756724']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000183873', 'ENSG00000185313']",2,1982.0,CHEMBL1086,,"['26747981', '26747982', '50107328', '56422129', '855998']",['59735'],,,,,
CHEMBL1200757,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1.[Br-].[Br-],NPIJXCQZLFKBMV-YTGGZNJNSA-L,Small molecule,False,PANCURONIUM BROMIDE,4.0,False,True,"['Mioblock', 'Pancuronium bromide', 'Pavulon']","['Bromurex', 'Mioblock', 'NSC-293162', 'ORG NA 97', 'ORG-NA 97', 'ORG-NA-97', 'Pancuronium bromide']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972.,,,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1972.0,CHEMBL185073,,"['144205586', '50106734']",['7908'],,,,,
CHEMBL1289601,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,WOSKHXYHFSIKNG-UHFFFAOYSA-N,Small molecule,False,LENVATINIB,4.0,False,True,"['Kisplyx', 'Lenvima']","['E-7080', 'ER-203492-00', 'Lenvatinib']","['CHEMBL3527309', 'CHEMBL2105704']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 58 investigational indications.,['Lenvatinib'],['DB09078'],"['EFO_1001961', 'MONDO_0004992', 'MONDO_0002108', 'EFO_1000158', 'MONDO_0002120', 'EFO_0000501', 'MONDO_0007576', 'EFO_0000182', 'EFO_0005221', 'EFO_0000558', 'MONDO_0002367', 'EFO_0000231', 'EFO_1000576', 'EFO_0001421', 'EFO_0000681', 'EFO_1001512', 'EFO_0000349', 'EFO_0005922', 'EFO_0004142', 'EFO_0000228', 'EFO_0000641', 'EFO_0000616', 'EFO_0000574', 'MONDO_0002974', 'EFO_0001061', 'MONDO_0003060', 'MONDO_0008315', 'EFO_1000796', 'EFO_0003891', 'EFO_0000756', 'MONDO_0001056', 'MONDO_0003060', 'MONDO_0004992', 'MONDO_0024477', 'EFO_0002617', 'MONDO_0008170', 'EFO_0003086', 'MONDO_0001528', 'EFO_0000702', 'MONDO_0002108', 'EFO_1001471', 'EFO_0004230', 'EFO_0000637', 'EFO_0003060', 'MONDO_0005184', 'EFO_0000178', 'EFO_0000691', 'EFO_1001961', 'EFO_0000616', 'EFO_0003060', 'EFO_1001901', 'EFO_0000181', 'EFO_0002892', 'EFO_0000681', 'EFO_0008528', 'EFO_0005543', 'EFO_0000503', 'EFO_0000571', 'MONDO_0011962', 'MONDO_0005184', 'EFO_0000588', 'EFO_1001012', 'EFO_1000657', 'MONDO_0007254', 'EFO_1000613']",65.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,2015.0,,,['137276042'],['85994'],,,,,
CHEMBL27810,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,JOATXPAWOHTVSZ-UHFFFAOYSA-N,Small molecule,False,CELIPROLOL,4.0,False,True,[],"['Celiprolol', 'Celiprolol pch']",['CHEMBL1742424'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.,['Celiprolol'],['DB04846'],"['EFO_0000319', 'MONDO_0020066']",2.0,"['ENSG00000043591', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286', 'ENSG00000169252']",5,,,,,,,,,,
CHEMBL403989,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,JMGXJHWTVBGOKG-UHFFFAOYSA-N,Small molecule,False,TG100-801,2.0,False,False,[],"['TG100-801', 'Tg100-801']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB05075'],"['EFO_0009606', 'EFO_0003770', 'EFO_0004683']",3.0,"['ENSG00000066468', 'ENSG00000077782', 'ENSG00000128052', 'ENSG00000102755', 'ENSG00000113721', 'ENSG00000196411', 'ENSG00000010810', 'ENSG00000197122', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000136573', 'ENSG00000101336', 'ENSG00000254087', 'ENSG00000111816', 'ENSG00000000938', 'ENSG00000125508']",16,,,,,,,,,,
CHEMBL4594288,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl.O=C(O)/C=C\C(=O)O,TZNOWAJJWCGILX-HNUXRKMMSA-N,Small molecule,False,LEVAMLODIPINE MALEATE,4.0,False,True,['Conjupri'],"['Amlodipine maleate, s-', 'Levamlodipine maleate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hypertension.,,,['EFO_0000537'],1.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,2019.0,CHEMBL2111097,['levamlodipine%20maleate'],,,,['https://searchusan.ama-assn.org/finder/usan/search/LEVAMLODIPINE%20MALEATE/relevant/1/'],,,
CHEMBL511099,Cc1ccc(C23CNCC2C3)cc1,OFYVIGTWSQPCLF-UHFFFAOYSA-N,Small molecule,False,BICIFADINE,3.0,False,False,[],['Bicifadine'],['CHEMBL544862'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB04889'],"['HP_0003419', 'EFO_1000783']",2.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,,,,,,,,,,
CHEMBL1200879,CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[Na+],KYITYFHKDODNCQ-UHFFFAOYSA-M,Small molecule,True,WARFARIN SODIUM,4.0,False,True,"['Athrombin', 'Coumadin', 'Jantoven', 'Marevan', 'Panwarfin', 'Warfarin sodium']","['Aldocumar', 'Apo-warfarin', 'Prothromadin', 'Sodium warfarin', 'Warfarin sodium', 'Warfarin sodium salt', 'Warfarinum natricum', 'Zoocoumarin sodium salt']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 7 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000712', 'HP_0004936', 'EFO_0003907', 'EFO_0000275', 'EFO_0000612', 'EFO_0000685', 'EFO_0003827', 'HP_0001907', 'EFO_0004239']",9.0,['ENSG00000167397'],1,1954.0,CHEMBL1464,['warfarin%20sodium'],"['144211862', '50085469']",,,,,,
CHEMBL1721885,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,CTNPALGJUAXMMC-PMFHANACSA-N,Small molecule,False,SU-014813,2.0,False,False,[],"['SU-14813', 'Su-014813', 'Su-14813']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000616', 'EFO_0003869']",2.0,"['ENSG00000122025', 'ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",7,,,,['50100117'],,,,,,
CHEMBL197672,C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F,SCVHJVCATBPIHN-SJCJKPOMSA-N,Small molecule,False,EMRICASAN,2.0,False,False,[],"['Emricasan', 'IDN 6556', 'IDN-6556', 'PF 03491390', 'PF-03491390', 'VAY-785', 'VAY785']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB05408'],"['EFO_0010282', 'EFO_0000400', 'MONDO_0100096', 'EFO_1001249', 'EFO_0001422', 'EFO_0004220', 'EFO_0001421', 'EFO_1001345']",8.0,"['ENSG00000196954', 'ENSG00000132906', 'ENSG00000164305', 'ENSG00000137757', 'ENSG00000138794', 'ENSG00000165806', 'ENSG00000064012', 'ENSG00000137752', 'ENSG00000106144', 'ENSG00000003400', 'ENSG00000105141', 'ENSG00000204403']",12,,,,,,,,,,
CHEMBL2103840,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,PIMQWRZWLQKKBJ-SFHVURJKSA-N,Small molecule,False,DINACICLIB,3.0,False,False,[],"['Dinaciclib', 'Mk-7965', 'SCH 727965', 'SCH-727965', 'SCH727965']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,['DB12021'],"['EFO_0006861', 'EFO_0000756', 'EFO_0000222', 'EFO_0000616', 'MONDO_0001023', 'EFO_0000095', 'MONDO_0007254', 'EFO_0001378', 'EFO_0000220']",9.0,"['ENSG00000164885', 'ENSG00000136807', 'ENSG00000170312', 'ENSG00000123374']",4,,,,,,,,,,
CHEMBL2108660,,,Antibody drug conjugate,False,TUCOTUZUMAB CELMOLEUKIN,2.0,False,False,[],"['EMD 273066', 'EMD-273066', 'HUKS-IL2', 'KSA-INTERLEUKIN-2', 'Tucotuzumab celmoleukin']",,Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0008170'],1.0,['ENSG00000119888'],1,,,,,,,,,,
CHEMBL3039521,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@H](NC(=O)c5ccc(NCc6cnc7[nH]c(N)nc(=O)c7n6)cc5)C(=O)O)C(=O)O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,KUZYSQSABONDME-QRLOMCMNSA-N,Unknown,False,VINTAFOLIDE,3.0,False,False,[],"['EC-145', 'EC145', 'Vintafolide']",,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB05168'],"['EFO_0000571', 'EFO_0000616', 'EFO_0003869', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0008170']",6.0,['ENSG00000110195'],1,,,,,,,,,,
CHEMBL4297774,,,Antibody,False,AMIVANTAMAB,4.0,False,True,['Rybrevant'],"['Amivantamab', 'Amivantamab vmjw', 'CNTO-4424', 'CNTO4424', 'JNJ 61186372', 'JNJ-611', 'JNJ-61186372', 'JNJ-6372', 'Jnj 61186372', 'Jnj-61186372']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 3 investigational indications.,,,"['EFO_0000182', 'MONDO_0001056', 'EFO_0003060', 'MONDO_0004669', 'EFO_0000616']",5.0,"['ENSG00000105976', 'ENSG00000146648']",2,2021.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant'],['https://searchusan.ama-assn.org/finder/usan/search/AMIVANTAMAB/relevant/1/'],,,
CHEMBL468,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,UEJJHQNACJXSKW-UHFFFAOYSA-N,Small molecule,True,THALIDOMIDE,4.0,False,True,"['Talidex', 'Thalidomide lipomed', 'Thalomid']","['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17', 'Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847', 'Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'Thalidomide', 'Thalidomide ']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for immune system disease and multiple myeloma and has 85 investigational indications. This drug has a black box warning from the FDA.,['Thalidomide'],['DB01041'],"['EFO_0000519', 'EFO_0005543', 'EFO_1000613', 'EFO_1000158', 'EFO_0004142', 'EFO_0000403', 'EFO_0000191', 'EFO_0003060', 'MONDO_0044903', 'MONDO_0002158', 'EFO_0003843', 'MONDO_0008170', 'EFO_0001065', 'EFO_0000676', 'EFO_0006888', 'MONDO_0002087', 'MONDO_0018364', 'EFO_0000389', 'MONDO_0019472', 'MONDO_0004975', 'EFO_0000182', 'EFO_0000096', 'MONDO_0015564', 'MONDO_0017816', 'EFO_0004268', 'EFO_0000474', 'EFO_0000681', 'EFO_0002430', 'MONDO_0003196', 'EFO_0002939', 'EFO_1001767', 'MONDO_0019438', 'HP_0003073', 'EFO_0006859', 'EFO_0000717', 'MONDO_0002367', 'EFO_0000095', 'EFO_0000765', 'EFO_0005628', 'EFO_0000756', 'EFO_0009441', 'EFO_1001875', 'MONDO_0004992', 'HP_0012735', 'EFO_0000621', 'EFO_0000673', 'MONDO_0018906', 'EFO_1001951', 'EFO_1001996', 'EFO_1001968', 'EFO_0000384', 'EFO_0000729', 'EFO_0000574', 'MONDO_0008903', 'EFO_0000691', 'EFO_0000764', 'MONDO_0019338', 'MONDO_0021063', 'EFO_0005952', 'EFO_0000540', 'MONDO_0100096', 'MONDO_0001056', 'EFO_0000198', 'MONDO_0007254', 'EFO_0005570', 'EFO_0001378', 'EFO_0003898', 'EFO_0000565', 'Orphanet_848', 'EFO_0000183', 'EFO_0000616', 'EFO_0007160', 'EFO_1001901', 'EFO_0007312', 'MONDO_0004976', 'EFO_0000365', 'EFO_0000342', 'EFO_1000045', 'EFO_0000768', 'EFO_1000318', 'MONDO_0019558', 'EFO_0003865', 'MONDO_0002691', 'MONDO_0007576', 'EFO_1001469', 'EFO_0003047', 'MONDO_0008315']",87.0,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']",4,1998.0,,['thalidomide'],"['111716', '11532929', '124881523', '144210897', '170465323', '174007312', '26747126', '26751823', '50104514', '90341724']",['74947'],['https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-lipomed'],,,,
CHEMBL888,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,SDUQYLNIPVEERB-QPPQHZFASA-N,Small molecule,False,GEMCITABINE,4.0,False,True,['Gemzar'],"['Gemcitabine', 'Gemzar', 'LY-188011', 'LY188011', 'NSC-613327']",['CHEMBL1637'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 9 approved and 132 investigational indications.,['Gemcitabine'],['DB00441'],"['EFO_0000182', 'MONDO_0001657', 'EFO_0000255', 'EFO_0000574', 'EFO_0000707', 'EFO_0000681', 'EFO_0006859', 'MONDO_0005184', 'EFO_0008528', 'MONDO_0002367', 'MONDO_0015760', 'EFO_0001075', 'EFO_1001961', 'MONDO_0005575', 'MONDO_0004192', 'EFO_0006861', 'EFO_0006738', 'MONDO_0021117', 'EFO_0001061', 'EFO_0000183', 'MONDO_0005411', 'MONDO_0018906', 'MONDO_0002158', 'EFO_0005537', 'MONDO_0004986', 'EFO_0009708', 'MONDO_0007254', 'MONDO_0002974', 'MONDO_0019472', 'MONDO_0002367', 'EFO_0000565', 'MONDO_0004992', 'EFO_0004252', 'MONDO_0000430', 'EFO_1000359', 'MONDO_0004986', 'MONDO_0001187', 'MONDO_0007576', 'EFO_0002618', 'EFO_0002913', 'EFO_1001469', 'MONDO_0008627', 'EFO_0001075', 'EFO_0003060', 'EFO_0000222', 'EFO_0000616', 'EFO_1000613', 'EFO_0009534', 'MONDO_0002087', 'EFO_0000681', 'MONDO_0011719', 'EFO_1000043', 'EFO_0000096', 'EFO_0003869', 'EFO_0003893', 'MONDO_0008315', 'EFO_0001376', 'MONDO_0011962', 'MONDO_0002087', 'EFO_1001956', 'EFO_0005230', 'EFO_0007532', 'MONDO_0016537', 'MONDO_0021054', 'EFO_0002618', 'EFO_0000403', 'EFO_0000756', 'MONDO_0001056', 'EFO_0000637', 'MONDO_0004192', 'EFO_0000564', 'MONDO_0009348', 'EFO_0000181', 'MONDO_0002691', 'EFO_1001959', 'MONDO_0004992', 'EFO_0005088', 'EFO_0010282', 'MONDO_0008170', 'EFO_0000294', 'EFO_0001378', 'EFO_0006859', 'EFO_0000571', 'EFO_1000026', 'MONDO_0001187', 'EFO_0006475', 'EFO_0000691', 'EFO_0000220', 'EFO_0001416', 'MONDO_0007254', 'MONDO_0005411', 'EFO_0000096', 'EFO_0003050', 'EFO_0003891', 'EFO_0000228', 'MONDO_0011962', 'EFO_0000174', 'EFO_0000770', 'EFO_0003860', 'EFO_1000251', 'EFO_1001951', 'MONDO_0002108', 'EFO_1000292', 'MONDO_0003059', 'EFO_0003863', 'MONDO_0008627', 'EFO_0005952', 'EFO_0000588', 'MONDO_0021063', 'MONDO_0015760', 'EFO_0000305', 'MONDO_0018364', 'MONDO_0003060', 'EFO_0004252', 'EFO_0000305', 'MONDO_0008903', 'EFO_0005537', 'MONDO_0001056', 'EFO_0002939', 'HP_0001907', 'EFO_0000466', 'EFO_1001051', 'EFO_1000657', 'EFO_0000365', 'EFO_0004606', 'EFO_0000313', 'EFO_1000251', 'MONDO_0008315', 'EFO_0003060', 'EFO_1001100', 'EFO_1001968', 'MONDO_0008170', 'EFO_0000183', 'Orphanet_145', 'EFO_0000574', 'EFO_0003032', 'EFO_0008528', 'EFO_0000616', 'EFO_1000359', 'EFO_0000313', 'EFO_0000565', 'EFO_0000211', 'EFO_0000691', 'EFO_1001961', 'MONDO_0019471', 'EFO_0000702', 'EFO_0005221', 'MONDO_0002158', 'EFO_0000514', 'EFO_1001951', 'EFO_0001416', 'EFO_1001469', 'MONDO_0005184', 'EFO_0000708', 'EFO_0000588', 'MONDO_0002974', 'EFO_0001378', 'MONDO_0008903', 'MONDO_0002691']",159.0,"['ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848', 'ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229']",14,1996.0,,,"['124893555', '50113286']",['175901'],,,,,
CHEMBL900,Cc1ccccc1C(OCCN(C)C)c1ccccc1,QVYRGXJJSLMXQH-UHFFFAOYSA-N,Small molecule,False,ORPHENADRINE,4.0,False,True,[],"['Disipal', 'Invagesic', 'Mefenamine', 'Mialgin', 'Norflex', 'Norgesic', 'Orphenadrin', 'Orphenadrine', 'Orphengesic']","['CHEMBL1201023', 'CHEMBL1200395']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for parkinson disease and pain and has 1 investigational indication.,['Orphenadrine'],['DB01173'],"['MONDO_0005180', 'EFO_0003843', 'HP_0003419']",3.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785', 'ENSG00000103546', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000196639']",19,1957.0,,,"['124880989', '174006927', '90341796']",['7789'],,,,,
CHEMBL1200492,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl,DYCKFEBIOUQECE-UHFFFAOYSA-N,Small molecule,True,NEFAZODONE HYDROCHLORIDE,4.0,True,True,"['Dutonin', 'Nefazodone hydrochloride', 'Serzone']","['BMY 13754', 'BMY-13754', 'MJ 13,754-1', 'MJ-13754-1', 'NSC-760344', 'Nefazodone hcl', 'Nefazodone hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for unipolar depression and major depressive disorder. It was withdrawn in at least one region. This drug has a black box warning from the FDA.,,,"['EFO_0003761', 'MONDO_0002009']",2.0,"['ENSG00000147246', 'ENSG00000108576', 'ENSG00000103546', 'ENSG00000102468']",4,1994.0,CHEMBL623,['nefazodone%20hydrochloride'],"['144205288', '144207123', '170465078', '26719737', '49681554']",['7495'],,,,,
CHEMBL1201536,,,Small molecule,False,NICOTINE POLACRILEX,4.0,False,True,"['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']",['Nicotine polacrilex'],,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 investigational indications.,,,"['EFO_0004318', 'MONDO_0002050', 'EFO_0003768']",3.0,"['ENSG00000160716', 'ENSG00000101204']",2,1984.0,CHEMBL3,['nicotine%20polacrilex'],,,,,,,
CHEMBL127516,CCCCOC(=O)c1ccc(N)cc1,IUWVALYLNVXWKX-UHFFFAOYSA-N,Small molecule,False,BUTAMBEN,4.0,True,True,[],"['Butamben', 'Butyl aminobenzoate', 'Butyl p-aminobenzoate', 'Butyl paba', 'NSC-128464', 'P-aminobenzoic acid butyl ester']",['CHEMBL3142541'],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,['Butamben'],['DB11148'],,,"['ENSG00000104321', 'ENSG00000111199']",2,,,,"['104171291', '11112245', '11532999', '144203943', '144207576', '170465735', '17389507']",['3231'],,,,,
CHEMBL2103873,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,JGCMEBMXRHSZKX-UHFFFAOYSA-N,Small molecule,True,MACITENTAN,4.0,False,True,['Opsumit'],"['ACT 064992', 'ACT-064992', 'Macitentan']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.,,['DB08932'],"['EFO_0005207', 'MONDO_0005149', 'EFO_0003144', 'EFO_0000537', 'EFO_0000717', 'EFO_0000519', 'EFO_0000768', 'MONDO_0043839', 'EFO_0001361']",9.0,"['ENSG00000136160', 'ENSG00000151617']",2,2010.0,,['macitentan'],,['76607'],['https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit'],,,,
CHEMBL27759,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,INVTYAOGFAGBOE-UHFFFAOYSA-N,Small molecule,False,ENTINOSTAT,3.0,False,False,[],"['Entinostat', 'MS-27-275', 'MS-275', 'MS-275-27', 'SNDX-275']",['CHEMBL3093129'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 35 investigational indications.,['Entinostat'],['DB11841'],"['MONDO_0001879', 'MONDO_0001325', 'EFO_0000349', 'EFO_0000222', 'EFO_0000756', 'EFO_0002618', 'EFO_0006861', 'MONDO_0008170', 'EFO_0002916', 'EFO_1000657', 'EFO_0000681', 'EFO_0003086', 'EFO_0000673', 'EFO_0000305', 'MONDO_0021063', 'MONDO_0002367', 'MONDO_0002158', 'MONDO_0001528', 'EFO_0000198', 'EFO_1001951', 'EFO_0005537', 'EFO_0003869', 'MONDO_0007254', 'MONDO_0004992', 'MONDO_0002974', 'MONDO_0002087', 'EFO_0000326', 'EFO_0000183', 'MONDO_0001187', 'EFO_1001901', 'EFO_0000616', 'MONDO_0001402', 'EFO_0003060', 'EFO_0000574', 'EFO_1001931']",35.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,,,,"['137275820', '29217590', '529250']",,,,,,
CHEMBL3114577,NCC(=O)Nc1cncc(-c2nn3c(=O)cc(N4CCNCC4)nc3s2)c1,LTVKZVGAALCRFW-UHFFFAOYSA-N,Small molecule,False,ZALUNFIBAN,3.0,False,False,[],"['RUC-4', 'Zalunfiban']",['CHEMBL4802247'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0001645', 'EFO_0008585', 'EFO_0008585']",3.0,"['ENSG00000259207', 'ENSG00000005961']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ZALUNFIBAN/relevant/1/'],,,
CHEMBL31965,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,OMZCMEYTWSXEPZ-UHFFFAOYSA-N,Small molecule,False,CANERTINIB,3.0,False,False,[],"['CI-1033', 'Canertinib']",['CHEMBL545315'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,['Canertinib'],['DB05424'],"['EFO_0003869', 'MONDO_0021117', 'EFO_0003060']",3.0,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568']",3,,,,"['124894124', '144206912', '174006548', '50100094']",['61399'],,,,,
CHEMBL4297627,C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(c3n2)C(=O)N1,OEBIHOVSAMBXIB-SJKOYZFVSA-N,Small molecule,False,SELITRECTINIB,2.0,False,False,[],"['LOXO-195', 'Loxo-195', 'Selitrectinib']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB14896'],['EFO_0000616'],1.0,"['ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']",3,,,,,,,,,,
CHEMBL4650279,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1OCCN1CCOCC1,HIBPKFXWOPYJPZ-UHFFFAOYSA-N,Small molecule,False,TUXOBERTINIB,1.0,False,False,[],"['BDTX-189', 'BDTX189', 'Bdtx-189', 'Bdtx189', 'Tuxobertinib']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000146648', 'ENSG00000141736']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TUXOBERTINIB/relevant/1/'],,,
CHEMBL4650395,,,Antibody,False,GLENZOCIMAB,2.0,False,False,[],"['ACT-017', 'ACT017', 'Glenzocimab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['HP_0002140', 'EFO_0000712', 'MONDO_0005299']",3.0,['ENSG00000088053'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/GLENZOCIMAB/relevant/1/'],,,
CHEMBL52440,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,MKXZASYAUGDDCJ-NJAFHUGGSA-N,Small molecule,False,DEXTROMETHORPHAN,4.0,False,True,[],"['Dextromethorphan', 'Dimetane-DX', 'NSC-751452']","['CHEMBL1201461', 'CHEMBL3989946', 'CHEMBL3989940', 'CHEMBL1201004', 'CHEMBL1256818']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 7 approved and 45 investigational indications.,['Dextromethorphan'],['DB00514'],"['MONDO_0002009', 'EFO_0007486', 'EFO_0000384', 'EFO_0005611', 'EFO_0001068', 'MONDO_0004985', 'MONDO_0004976', 'HP_0012735', 'EFO_0005772', 'EFO_0005762', 'EFO_0002460', 'EFO_0003843', 'MONDO_0008315', 'EFO_0000764', 'EFO_0001062', 'EFO_0003100', 'EFO_0003929', 'MONDO_0010726', 'MONDO_0005180', 'MONDO_0005148', 'MONDO_0005277', 'EFO_0009854', 'HP_0000093', 'MONDO_0004976', 'EFO_0000616', 'MONDO_0005148', 'HP_0100543', 'EFO_0003758', 'EFO_0003890', 'EFO_0002617', 'EFO_0000756', 'EFO_0007214', 'EFO_0007214', 'EFO_0009430', 'MONDO_0044970', 'MONDO_0005271', 'EFO_1000783', 'MONDO_0002009', 'HP_0001945', 'EFO_0003756', 'MONDO_0004975', 'EFO_0009692', 'MONDO_0005090', 'EFO_0000729', 'EFO_0005687', 'EFO_0000616', 'EFO_0009708', 'MONDO_0002050', 'EFO_0000555', 'HP_0002315', 'HP_0001742', 'HP_0012735', 'EFO_0000676', 'EFO_0001663', 'MONDO_0005301']",55.0,"['ENSG00000183454', 'ENSG00000147955']",2,1982.0,,,"['11111057', '50100218']",,,,,,
CHEMBL549,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,WSEQXVZVJXJVFP-UHFFFAOYSA-N,Small molecule,True,CITALOPRAM,4.0,False,True,[],"['Celexa', 'Citadur', 'Citalopram']","['CHEMBL1628605', 'CHEMBL1200781']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA.,['Citalopram'],['DB00215'],"['MONDO_0002050', 'MONDO_0004985', 'HP_0000713', 'EFO_0005230', 'MONDO_0002009', 'MONDO_0005180', 'HP_0031217', 'EFO_0004262', 'EFO_0005672', 'EFO_0003758', 'MONDO_0005090', 'EFO_0000712', 'EFO_0004242', 'MONDO_0002009', 'EFO_0002610', 'EFO_0003756', 'HP_0000726', 'EFO_0000555', 'EFO_0003761', 'EFO_0003761', 'MONDO_0007079', 'MONDO_0002046', 'EFO_0005611']",23.0,['ENSG00000108576'],1,1998.0,,,"['174007166', '50104852', '90340852']",['77397'],,,,,
CHEMBL612,C[C@H](N)Cc1ccccc1,KWTSXDURSIMDCE-QMMMGPOBSA-N,Small molecule,True,DEXTROAMPHETAMINE,4.0,False,True,"['Dexedrine', 'Dextrostat', 'Xelstrym']","['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'Dexamfetamine', 'Dexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'Dextroamphetamine', 'Dextrostat', 'Ferndex', 'NSC-73713', 'Xelstrym']","['CHEMBL1200782', 'CHEMBL287386', 'CHEMBL2106669', 'CHEMBL3544971', 'CHEMBL3989844']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA.,['Dextroamphetamine'],['DB01576'],"['MONDO_0004985', 'EFO_0005611', 'EFO_0000712', 'EFO_0003888', 'EFO_0005543', 'MONDO_0016158', 'MONDO_0016158', 'EFO_0002610', 'EFO_0003888', 'MONDO_0005301', 'MONDO_0005090', 'EFO_0003888', 'EFO_0004701', 'EFO_0003890', 'MONDO_0002277', 'EFO_0001358']",16.0,"['ENSG00000142319', 'ENSG00000103546', 'ENSG00000165646']",3,1955.0,,,['50113060'],['4469'],,,,,
CHEMBL637,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,PNVNVHUZROJLTJ-UHFFFAOYSA-N,Small molecule,True,VENLAFAXINE,4.0,False,True,"['Alventa xl', 'Amphero xl', 'Bonilux xl', 'Depefex xl', 'Efexor', 'Efexor xl', 'Foraven xl', 'Mentaven xl', 'Politid xl', 'Ranfaxine xl', 'Rodomel xl', 'Sunveniz xl', 'Tardcaps xl', 'Tifaxin xl', 'Tonpular xl', 'Trixat xl', 'Vaxalin xl', 'Venaxx xl', 'Venlablue xl', 'Venladex xl', 'Venlalic xl', 'Venlaneo xl', 'Vensir xl', 'Vexarin xl', 'Viepax', 'Viepax xl', 'Winfex xl']","['Efectin', 'Effexor', 'Kanghong', 'NSC-758676', 'Trevilor', 'Velafax', 'Venlafaxine', 'Venlor']","['CHEMBL1201066', 'CHEMBL3133301', 'CHEMBL5095051']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 21 investigational indications. This drug has a black box warning from the FDA.,['Venlafaxine'],['DB00285'],"['MONDO_0005180', 'EFO_0006788', 'MONDO_0002050', 'MONDO_0002009', 'EFO_0006862', 'MONDO_0004985', 'EFO_0009854', 'HP_0000726', 'HP_0031217', 'MONDO_0002009', 'EFO_0005687', 'EFO_0003761', 'MONDO_0004975', 'EFO_0006788', 'EFO_1001892', 'EFO_1001917', 'EFO_0004242', 'EFO_0004262', 'EFO_0000673', 'MONDO_0007254', 'MONDO_0005090', 'EFO_0003843', 'MONDO_0002050', 'EFO_1002014', 'EFO_1001919', 'HP_0030833', 'EFO_0002610', 'EFO_0005230', 'MONDO_0008315', 'EFO_0003918', 'EFO_0005762', 'MONDO_0002009', 'EFO_0003761']",33.0,"['ENSG00000108576', 'ENSG00000103546']",2,1993.0,,,"['144204978', '170465123', '174007175', '26748923', '90341232']",['9943'],,,,,
CHEMBL1200332,CNCCCC1c2ccccc2C=Cc2ccccc21.Cl,OGQDIIKRQRZXJH-UHFFFAOYSA-N,Small molecule,True,PROTRIPTYLINE HYDROCHLORIDE,4.0,False,True,"['Concordin-10', 'Concordin-5', 'Protriptyline hydrochloride', 'Vivactil']","['MK-240', 'NSC-169912', 'Protriptyline hcl', 'Protriptyline hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967 and is indicated for depressive disorder. This drug has a black box warning from the FDA.,,,['MONDO_0002050'],1.0,"['ENSG00000103546', 'ENSG00000108576']",2,1967.0,CHEMBL668,['protriptyline%20hydrochloride'],"['144203795', '170465077', '50106858', '50106859', '56422215', '855990']",['8598'],,,,,
CHEMBL1200609,CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,SHIJTGJXUHTGGZ-RVXRQPKJSA-N,Small molecule,True,PAROXETINE MESYLATE,4.0,False,True,"['Brisdelle', 'Pexeva']","['Mesafem', 'PO-T.MES', 'POT.MES', 'Paroxetine mesilate', 'Paroxetine mesylate', 'Paroxetine methanesulfonate', 'Paroxetine methanesulphonate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_1001917', 'GO_0042697', 'EFO_0006788', 'MONDO_0002009', 'EFO_0004242', 'HP_0031217', 'EFO_0001358', 'EFO_0004262']",8.0,['ENSG00000108576'],1,2003.0,CHEMBL490,['paroxetine%20mesylate'],,,,,,,
CHEMBL1743018,,,Antibody,False,FICLATUZUMAB,2.0,False,False,[],"['AV 299', 'AV-299', 'Ficlatuzumab', 'SCH 900105', 'SCH-900105']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_0000181', 'EFO_0000707', 'EFO_0001378', 'EFO_0000519', 'EFO_0002618', 'EFO_0003060', 'EFO_0000222']",7.0,['ENSG00000019991'],1,,,,,,,,,,
CHEMBL2105740,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+],MDTNUYUCUYPIHE-UHFFFAOYSA-N,Small molecule,False,SITAXENTAN SODIUM,4.0,True,True,['Thelin'],"['Sitaxentan sodium', 'Sitaxsentan sodium salt', 'TBC-11251 SODIUM', 'TBC-11251NA', 'TBC-11251Z']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for pulmonary hypertension and has 1 investigational indication. It was withdrawn in at least one region.,,,"['EFO_1000899', 'MONDO_0005149']",2.0,"['ENSG00000136160', 'ENSG00000151617']",2,2006.0,CHEMBL282724,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/thelin'],,,,
CHEMBL2109283,,,Antibody drug conjugate,False,BICIROMAB BRALLOBARBITAL,1.0,False,False,['Fibriscint'],"['Biciromab brallobarbital', 'T2G1S']",,Antibody drug conjugate drug with a maximum clinical trial phase of I.,,,,,['ENSG00000171564'],1,,,,,,,,,,
CHEMBL2109624,,,Antibody,False,CAPLACIZUMAB,4.0,False,True,['Cablivi'],"['ALX-0081', 'Caplacizumab', 'Caplacizumab yhdp']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications.,,,"['MONDO_0019740', 'MONDO_0018896', 'HP_0004419']",3.0,['ENSG00000110799'],1,2018.0,,['caplacizumab-yhdp'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/cablivi'],,,,
CHEMBL2151437,c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,OCKIPDMKGPYYJS-ZDUSSCGKSA-N,Small molecule,False,AZD0328,2.0,False,False,[],"['AZD-0328', 'AZD0328', 'Azd 0328', 'Azd-0328', 'Azd0328']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12145'],"['MONDO_0004975', 'MONDO_0005090']",2.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL3643413,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,MWKYMZXCGYXLPL-ZDUSSCGKSA-N,Small molecule,False,LENIOLISIB,4.0,False,True,[],"['CDZ-173-NX', 'CDZ173-NX', 'Cdz-173 free base', 'Cdz173 free base', 'Leniolisib']",['CHEMBL3989909'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for inborn error of immunity and has 2 investigational indications.,,,"['MONDO_0015517', 'EFO_0000699', 'MONDO_0003778']",3.0,['ENSG00000171608'],1,2023.0,,,,,,,,,
CHEMBL3989872,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O,DVBUEXCIEIAXPM-PJUQSVSOSA-N,Protein,False,APIMOSTINEL,2.0,False,False,[],"['Apimostinel', 'NRX-1074', 'NRX1074', 'Nrx-1074']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB11784'],"['MONDO_0002009', 'MONDO_0005090']",2.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL4297187,COCCNCCc1cccc(Nc2ncc3c(n2)-c2ccccc2[C@H](c2ccccc2F)C3)c1,KPJDVVCDVBFRMU-AREMUKBSSA-N,Small molecule,False,DERAZANTINIB,2.0,False,False,[],"['ARQ 087', 'ARQ087', 'Arq-087', 'Derazantinib']",['CHEMBL4298156'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB14889'],"['EFO_0000616', 'EFO_0000616', 'EFO_1001961', 'EFO_0000503', 'EFO_0008528']",5.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/DERAZANTINIB/relevant/1/'],,,
CHEMBL4297640,NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O,QLRRJMOBVVGXEJ-XHSDSOJGSA-N,Small molecule,False,VECABRUTINIB,2.0,False,False,[],"['BIIB-062', 'BSK-4841', 'FP-0182', 'FP0182', 'SNS-062', 'Sns-062', 'Vecabrutinib']",['CHEMBL4298148'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication.,,,"['EFO_0000616', 'EFO_0000616']",2.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/VECABRUTINIB/relevant/1/'],,,
CHEMBL2107067,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,UDSFVOAUHKGBEK-CNQKSJKFSA-N,Small molecule,True,TESTOSTERONE UNDECANOATE,4.0,False,True,"['Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'Restandol', 'Restandol testocap', 'Tlando', 'Undestor']","['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011', 'Testosterone 17.beta.-undecylate', 'Testosterone undecanoate', 'Testosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,['DB13946'],"['EFO_1001919', 'EFO_0000681', 'EFO_1001078', 'EFO_0001645', 'EFO_0008572', 'EFO_0009686', 'EFO_1001006', 'EFO_0000616', 'MONDO_0002146', 'MONDO_0018555', 'MONDO_0008315', 'EFO_0004714']",12.0,['ENSG00000169083'],1,2014.0,,['testosterone%20undecanoate'],,,,,,,
CHEMBL3545257,CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O.O=S(=O)(O)c1ccccc1,OKJXJRVWXYRSAN-TXULWXBWSA-N,Small molecule,False,MIROGABALIN BESYLATE,-1.0,False,False,[],"['DS-5565', 'DS5565', 'Ds-5565', 'Mirogabalin', 'Mirogabalin besilate', 'Mirogabalin besylate']",,Small molecule drug.,,,,,"['ENSG00000153956', 'ENSG00000007402']",2,,CHEMBL3545125,,,,,,,,
CHEMBL3707316,,,Small molecule,False,ND0801,2.0,False,False,[],['Nd0801'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003888'],1.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL4065122,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,WNEODWDFDXWOLU-QHCPKHFHSA-N,Small molecule,False,FENEBRUTINIB,3.0,False,False,[],"['Fenebrutinib', 'G-02599853', 'G02599853', 'GDC-0853', 'Gdc-0853', 'RG-7845', 'RG7845', 'RO-7010939', 'RO7010939']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB14785'],"['MONDO_0005301', 'EFO_0003840', 'EFO_0005531', 'EFO_0005809', 'MONDO_0007915', 'EFO_0000685']",6.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/FENEBRUTINIB/relevant/1/'],,,
CHEMBL4650406,,,Antibody,False,LEVILIMAB,3.0,False,False,[],"['BCD-089', 'Bcd-089', 'Levilimab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000685', 'MONDO_0100096']",2.0,['ENSG00000160712'],1,,,,,,,,,,
CHEMBL491473,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,XXJWYDDUDKYVKI-UHFFFAOYSA-N,Small molecule,False,CEDIRANIB,3.0,False,False,['Recentin'],"['AZD-2171', 'AZD2171', 'Azd-2171', 'Cediranib', 'ZD-2171']",['CHEMBL2103798'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 39 investigational indications.,,['DB04849'],"['EFO_1000657', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004992', 'EFO_1001951', 'EFO_0000702', 'EFO_0006861', 'EFO_1001465', 'EFO_0000681', 'EFO_0000222', 'EFO_0003893', 'EFO_0003060', 'MONDO_0002974', 'EFO_0000770', 'MONDO_0002974', 'MONDO_0008903', 'EFO_0000681', 'EFO_0000305', 'EFO_0000673', 'MONDO_0008903', 'EFO_1001951', 'EFO_0003891', 'EFO_0000196', 'EFO_0000588', 'EFO_0000673', 'EFO_0000616', 'EFO_0007143', 'MONDO_0002158', 'EFO_0003833', 'EFO_0000389', 'EFO_0000519', 'EFO_0000349', 'MONDO_0011962', 'MONDO_0001056', 'EFO_0003060', 'EFO_0002892', 'EFO_0000182', 'EFO_0002617', 'MONDO_0007254', 'EFO_0000095', 'MONDO_0008315', 'EFO_0000565', 'EFO_0000519', 'EFO_0009709', 'MONDO_0002087']",45.0,"['ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",6,,,,"['103905340', '137275941']",,,,,,
CHEMBL498,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,RKWGIWYCVPQPMF-UHFFFAOYSA-N,Small molecule,False,CHLORPROPAMIDE,4.0,False,True,"['Chlorpropamide', 'Diabemide', 'Diabinese', 'Glucamide', 'Glymese', 'Melitase']","['Chlorpropamide', 'NSC-44634', 'NSC-626720']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and is indicated for type 2 diabetes mellitus and diabetes mellitus.,['Chlorpropamide'],['DB00672'],"['MONDO_0005148', 'EFO_0000400']",2.0,"['ENSG00000187486', 'ENSG00000006071']",2,1958.0,,,"['11110918', '11110919', '144203653', '144208589', '144213106', '170464898', '17389965', '50103916', '56423142', '855559']",['3650'],,,['80'],,
CHEMBL539697,CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,KSGXQBZTULBEEQ-UHFFFAOYSA-N,Small molecule,True,DABIGATRAN ETEXILATE,4.0,False,True,['Pradaxa'],"['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1', 'Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']",['CHEMBL1615369'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 8 approved and 12 investigational indications. This drug has a black box warning from the FDA.,['Dabigatran'],['DB06695'],"['EFO_0001645', 'HP_0000083', 'EFO_0010726', 'EFO_0000275', 'HP_0001907', 'EFO_0003095', 'EFO_0000712', 'EFO_0003884', 'EFO_0000275', 'EFO_0003827', 'EFO_0000712', 'EFO_0004286', 'EFO_0003907', 'EFO_1000652', 'EFO_0004286', 'HP_0004936', 'HP_0004419', 'HP_0001871', 'MONDO_0000831', 'EFO_0000673']",20.0,['ENSG00000180210'],1,2008.0,,,['170466107'],['70746'],,,,,
CHEMBL1946170,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,FNHKPVJBJVTLMP-UHFFFAOYSA-N,Small molecule,True,REGORAFENIB,4.0,False,True,['Stivarga'],"['BAY 73-4506', 'BAY 73-4506 monohydrate', 'BAY-73-4506', 'BAY-734506', 'Regorafenib', 'Regorafenib anhydrous', 'Regorafenib hydrate', 'Regorafenib monohydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA.,['Regorafenib'],['DB08896'],"['EFO_1001961', 'EFO_0004142', 'EFO_0000222', 'MONDO_0021063', 'EFO_0000616', 'EFO_0000569', 'EFO_0005540', 'EFO_0000691', 'MONDO_0004992', 'MONDO_0007576', 'EFO_0002918', 'EFO_0000365', 'EFO_0000637', 'EFO_0003893', 'EFO_0000756', 'EFO_1001949', 'MONDO_0003060', 'MONDO_0002158', 'EFO_0000182', 'EFO_0000702', 'MONDO_0008170', 'EFO_1000350', 'EFO_0000681', 'EFO_0000519', 'MONDO_0005575', 'EFO_0005221', 'EFO_1001951', 'MONDO_0011719', 'MONDO_0001056', 'EFO_0000389', 'MONDO_0002108', 'EFO_0002618', 'EFO_0009606', 'EFO_0000231', 'EFO_0003968', 'EFO_1001968', 'EFO_1000657', 'EFO_0001075']",38.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000077782', 'ENSG00000165731', 'ENSG00000066468', 'ENSG00000142627', 'ENSG00000120156', 'ENSG00000185386', 'ENSG00000132155', 'ENSG00000111816', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000097007', 'ENSG00000162733', 'ENSG00000198400', 'ENSG00000157764']",18,2012.0,,['regorafenib'],['137275982'],['68647'],['https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga'],,,,
CHEMBL198362,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,KGFYHTZWPPHNLQ-AWEZNQCLSA-N,Small molecule,True,RIVAROXABAN,4.0,False,True,['Xarelto'],"['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 8 approved and 30 investigational indications. This drug has a black box warning from the FDA.,['Rivaroxaban'],['DB06228'],"['HP_0004419', 'EFO_0003964', 'HP_0002140', 'EFO_0009314', 'MONDO_0000831', 'EFO_0000612', 'EFO_0004265', 'EFO_0001378', 'HP_0001907', 'EFO_0001645', 'MONDO_0100096', 'MP_0001914', 'EFO_1000985', 'EFO_0003884', 'EFO_0003777', 'EFO_0004286', 'EFO_0009531', 'HP_0004936', 'EFO_1001161', 'EFO_0003907', 'HP_0000083', 'EFO_0001074', 'EFO_0000712', 'MONDO_0004992', 'HP_0001873', 'EFO_0005672', 'EFO_0000694', 'MONDO_0005148', 'EFO_0001422', 'EFO_0002689', 'EFO_0010680', 'EFO_0000275', 'MONDO_0011382', 'EFO_0000616', 'EFO_0000266', 'EFO_0010726', 'EFO_0000556', 'EFO_0003827']",38.0,['ENSG00000126218'],1,2008.0,,['rivaroxaban'],,['68579'],['https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto'],,,,
CHEMBL2364609,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl,VCMGMSHEPQENPE-ZOWNYOTGSA-N,Small molecule,True,ESKETAMINE HYDROCHLORIDE,4.0,False,True,['Spravato'],"['AM-101', 'Esketamine hydrochloride', 'Ketamine hydrochloride, (s)-', 'Ketamine hydrochloride, s-', 'Ketanest s']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003761', 'MONDO_0002009', 'MONDO_0002050', 'EFO_0003843', 'HP_0000360']",5.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,2019.0,CHEMBL395091,['esketamine%20hydrochloride'],,['60800'],['https://www.ema.europa.eu/en/medicines/human/EPAR/spravato'],,,,
CHEMBL2364611,Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,IVRXNBXKWIJUQB-UHFFFAOYSA-N,Small molecule,False,GALUNISERTIB,2.0,False,False,[],"['Galunisertib', 'LY-2157299', 'LY2157299', 'Ly-2157299']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,['DB11911'],"['EFO_0009708', 'EFO_0005537', 'EFO_0000519', 'EFO_0000616', 'EFO_0005543', 'EFO_0004252', 'EFO_0002618', 'EFO_0000182', 'EFO_1000657', 'EFO_0000198', 'MONDO_0008315', 'EFO_0003860']",12.0,['ENSG00000106799'],1,,,,,,,,,,
CHEMBL3287735,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21,FKSFKBQGSFSOSM-QFIPXVFZSA-N,Small molecule,False,GSK2816126,1.0,False,False,[],['Gsk2816126'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0004992'],1.0,['ENSG00000106462'],1,,,,,,,,,,
CHEMBL3544966,O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1,QDITZBLZQQZVEE-YBEGLDIGSA-N,Small molecule,False,GSK-1059615,1.0,False,False,[],"['GSK-615', 'GSK1059615', 'GSK615', 'Gsk-1059615']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB11962'],['EFO_0000616'],1.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,,,,
CHEMBL3545192,,,Antibody,False,MIRVETUXIMAB,2.0,False,False,[],"['M-9346A', 'M9346A', 'Mirvetuximab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000110195'],1,,,,,,,,,,
CHEMBL3707226,,,Oligonucleotide,False,DEFIBROTIDE SODIUM,4.0,False,True,['Defitelio'],"['Defibrotide sodium', 'JZP-381']",,Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for hepatic veno-occlusive disease.,,,['MONDO_0019514'],1.0,['ENSG00000122194'],1,2013.0,,['defibrotide%20sodium'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio'],,,,
CHEMBL4279455,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,DXOJIXGRFSHVKA-BZVZGCBYSA-N,Small molecule,False,LAROTAXEL,3.0,False,False,[],"['Larotaxel', 'XRP-9881', 'XRP9881', 'Xrp9881']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB12984'],"['EFO_0000294', 'EFO_0003860', 'EFO_0003869', 'MONDO_0007254']",4.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL4297935,,,Unknown,False,RG-7841,1.0,False,False,[],"['Anti-ly6e-vcmmae', 'DLYE-5953A', 'DLYE5953A', 'Dlye5953a', 'RG-7841', 'RG7841', 'Rg 7841', 'Rg-7841']",,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000160932']",16,,,,,,,,,,
CHEMBL4298210,,,Antibody,False,ISCALIMAB,2.0,False,False,[],"['CFZ-533', 'CFZ533', 'Iscalimab', 'NVP-CFZ533']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,,"['EFO_1000710', 'EFO_0000699', 'EFO_0004991', 'EFO_0005761', 'MONDO_0005147', 'EFO_0010134', 'EFO_0004599', 'EFO_0004237', 'EFO_0000685', 'MONDO_0007915']",10.0,['ENSG00000101017'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ISCALIMAB/relevant/1/'],,,
CHEMBL3545402,,,Small molecule,False,XL-820,2.0,False,False,[],['Xl-820'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0011719', 'MONDO_0004992']",2.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000157404']",6,,,,,,,,,,
CHEMBL4297797,,,Unknown,False,NNC0114-0006,2.0,False,False,[],"['NN-8828', 'NN-9828', 'Nnc0114-0006']",,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005147'],1.0,['ENSG00000138684'],1,,,,,,,,,,
CHEMBL4303596,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,KWRYMZHCQIOOEB-LBPRGKRZSA-N,Small molecule,False,AMG-319,2.0,False,False,[],"['AMG319', 'Amg-319', 'J3.391.906I']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0000095', 'EFO_0000181', 'EFO_1001469', 'EFO_0000403', 'MONDO_0004992']",5.0,['ENSG00000171608'],1,,,,,,,,,,
CHEMBL4594492,,,Oligonucleotide,False,REVUSIRAN,3.0,False,False,[],"['AD-51547', 'Revusiran']",,Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0004129'],1.0,['ENSG00000118271'],1,,,,,,,,,,
CHEMBL593430,C[C@H]1CC(CN)(CC(=O)O)C[C@@H]1C,IUVMAUQEZFTTFB-YUMQZZPRSA-N,Small molecule,False,ATAGABALIN,2.0,False,False,[],"['Atagabalin', 'PD 0200390', 'PD-0200,390', 'PD-0200390', 'PD0200390']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,['Atagabalin'],['DB12032'],['EFO_0004698'],1.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,,,,,,,,,,
CHEMBL1201657,,,Oligosaccharide,False,HEPARIN SODIUM,4.0,False,True,"['Heparin lock flush', 'Heparin sodium', 'Heparin sodium preservative free', 'Lipo-hepin', 'Liquaemin lock flush', 'Liquaemin sodium', 'Liquaemin sodium preservative free', 'Multiparin', 'Panheprin', 'Pump-hep', 'Sodium heparin', 'Thrombophob', 'Unihep', 'Uniparin', 'Uniparin fte']","['Crude heparin', 'Crude heparin porcine', 'Heparin sodium', 'Heparin sodium porcine', 'Heparin sodium unfractionated', 'Heparin sodium, porcine', 'Heparinum natricum', 'Liquemin sodium', 'S01XA14']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 5 approved and 52 investigational indications.,,,"['MONDO_0005147', 'HP_0000083', 'EFO_0001645', 'HP_0004936', 'EFO_0003964', 'EFO_0003106', 'HP_0001907', 'EFO_0000668', 'EFO_1000985', 'MONDO_0004992', 'EFO_1001904', 'EFO_0003103', 'EFO_0002950', 'EFO_0000712', 'EFO_0000365', 'EFO_0003033', 'EFO_0004610', 'EFO_0003907', 'EFO_0008507', 'EFO_0000713', 'EFO_0000612', 'MONDO_0002243', 'EFO_0003777', 'EFO_0001073', 'HP_0001919', 'EFO_0000616', 'EFO_1000637', 'EFO_0008585', 'MP_0001914', 'EFO_0006834', 'EFO_0000319', 'HP_0100806', 'EFO_1001129', 'HP_0031273', 'EFO_0000275', 'HP_0004418', 'EFO_0003913', 'EFO_1001375', 'EFO_0003884', 'EFO_0004286', 'EFO_0003827', 'EFO_0000546', 'MONDO_0021148', 'MONDO_0100096', 'EFO_1001951', 'EFO_0000544', 'EFO_0000266', 'EFO_0003060', 'MONDO_0005148', 'EFO_0008583', 'EFO_0000771', 'EFO_1002048', 'EFO_0009516', 'EFO_0000545', 'EFO_0000694', 'MONDO_0000831', 'EFO_0005672']",57.0,['ENSG00000117601'],1,1939.0,,['heparin%20sodium'],,,,,,,
CHEMBL1269025,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,HGVDHZBSSITLCT-JLJPHGGASA-N,Small molecule,True,EDOXABAN,4.0,False,True,['Lixiana'],"['DU-176', 'Edoxaban']","['CHEMBL3542264', 'CHEMBL2105682']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 15 investigational indications. This drug has a black box warning from the FDA.,,['DB09075'],"['EFO_0000275', 'EFO_0004265', 'EFO_0003827', 'EFO_0000712', 'EFO_0008583', 'EFO_0000266', 'EFO_0000694', 'EFO_0009314', 'EFO_0000275', 'HP_0004419', 'MONDO_0100096', 'EFO_0001645', 'MP_0001914', 'EFO_0003907', 'EFO_0000712', 'EFO_0003777', 'MONDO_0000831', 'EFO_0001422', 'EFO_0004286', 'HP_0002140', 'EFO_0004286']",21.0,['ENSG00000126218'],1,2015.0,,,,['85973'],,,,,
CHEMBL1705,Cl.Clc1cccc(Cl)c1NC1=NCCN1,ZNIFSRGNXRYGHF-UHFFFAOYSA-N,Small molecule,True,CLONIDINE HYDROCHLORIDE,4.0,False,True,"['Catapres', 'Catapres p.l.', 'Catapres tts 1', 'Catapres tts 2', 'Catapres tts 3', 'Clonidine hydrochloride', 'Dixarit', 'Duraclon', 'Jenloga', 'Kapvay']","['Clonidine hcl', 'Clonidine hydrochloride', 'Dichloranilino imidazolin', 'NSC-756699', 'ST-155']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for hypertension and attention deficit hyperactivity disorder and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0003843', 'EFO_0000537', 'EFO_0003888']",3.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1974.0,CHEMBL134,['clonidine%20hydrochloride'],"['144211869', '26719783', '50106022']",,,,,,
CHEMBL185073,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1,GVEAYVLWDAFXET-XGHATYIMSA-N,Small molecule,False,PANCURONIUM,4.0,False,True,[],"['Pancuronium', 'Pavulon']",['CHEMBL1200757'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972.,['Pancuronium_bromide'],['DB01337'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1972.0,,,"['50104094', '90341747']",['7907'],,,,,
CHEMBL3545085,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,ALKJNCZNEOTEMP-UHFFFAOYSA-N,Small molecule,False,XL-228,1.0,False,False,[],"['Exel-2280', 'XL228', 'Xl-228']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,,"['MONDO_0004992', 'EFO_0000220', 'EFO_0000574', 'EFO_0000339']",4.0,"['ENSG00000010810', 'ENSG00000197122', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000136573', 'ENSG00000101336', 'ENSG00000254087', 'ENSG00000111816', 'ENSG00000000938', 'ENSG00000125508', 'ENSG00000140443', 'ENSG00000097007']",12,,,,,,,,,,
CHEMBL3545298,,,Small molecule,False,AZD-6918,1.0,False,False,[],['Azd-6918'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0004992'],1.0,"['ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']",3,,,,,,,,,,
CHEMBL3984425,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,XUMALORDVCFWKV-IBGZPJMESA-N,Small molecule,False,EGANELISIB,2.0,False,False,[],"['Eganelisib', 'IPI-549', 'Ipi-549', 'Pi3k-gamma inhibitor ipi-549']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000105851'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/EGANELISIB/relevant/1/'],,,
CHEMBL4298089,,,Antibody,False,CODRITUZUMAB,2.0,False,False,[],"['Codrituzumab', 'GC-33', 'GC33', 'RG-7686', 'RO5137382', 'Ro5137382']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000616', 'EFO_0000182']",2.0,['ENSG00000147257'],1,,,,,,,,,,
CHEMBL5095303,,,Oligonucleotide,False,VUTRISIRAN SODIUM,4.0,False,True,['Amvuttra'],"['ALN-TTRSC02', 'Amvuttra', 'Votrisiran sodium']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for familial amyloid neuropathy and polyneuropathy.,,,"['EFO_0004129', 'EFO_0009562']",2.0,['ENSG00000118271'],1,2022.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra'],,,,
CHEMBL970,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F,WYCLKVQLVUQKNZ-UHFFFAOYSA-N,Small molecule,False,HALAZEPAM,4.0,False,True,['Paxipam'],"['Halazepam', 'Halazepam civ', 'SCH 12041', 'SCH-12041']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and is indicated for anxiety.,['Halazepam'],['DB00801'],['EFO_0005230'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1981.0,,,,,,,,,
CHEMBL1200379,Cl.Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1,OTQYGBJVDRBCHC-UHFFFAOYSA-N,Small molecule,False,APRACLONIDINE HYDROCHLORIDE,4.0,False,True,"['Apraclonidine hydrochloride', 'Iopidine']","['AL-02145', 'AL02145', 'Aplonidine hydrochloride', 'Apraclonidine hcl', 'Apraclonidine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987.,,,,,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1987.0,CHEMBL647,['apraclonidine%20hydrochloride'],"['144204758', '50105753']",['2789'],,,,,
CHEMBL1873475,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,XYFPWWZEPKGCCK-GOSISDBHSA-N,Small molecule,False,IBRUTINIB,4.0,False,True,['Imbruvica'],"['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765', 'PCI-32765-00']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 42 investigational indications.,,['DB09053'],"['EFO_1001469', 'EFO_0007359', 'MONDO_0100096', 'EFO_0000183', 'EFO_0001421', 'EFO_1000560', 'EFO_0000403', 'MONDO_0007576', 'MONDO_0021063', 'EFO_0000220', 'EFO_0000222', 'EFO_1001890', 'EFO_0000096', 'EFO_0001642', 'EFO_0005952', 'EFO_0003060', 'MONDO_0007254', 'EFO_1001264', 'EFO_0001378', 'MONDO_0044881', 'EFO_0000181', 'EFO_1000630', 'EFO_0000574', 'EFO_0000616', 'EFO_0000389', 'EFO_0000198', 'EFO_0009441', 'EFO_0004243', 'MONDO_0008903', 'MONDO_0100053', 'MONDO_0001023', 'EFO_0000309', 'MONDO_0009348', 'EFO_0004289', 'MONDO_0020547', 'EFO_0002616', 'EFO_0000095', 'EFO_0000519', 'MONDO_0008315', 'EFO_0002617', 'MONDO_0018906', 'EFO_1001875', 'MONDO_0004992', 'MONDO_0013730', 'EFO_0000565', 'EFO_1001951', 'EFO_1000956', 'EFO_0000681']",48.0,['ENSG00000010671'],1,2013.0,,['ibrutinib'],['124898784'],['76612'],['https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica'],,,,
CHEMBL2109084,,,Enzyme,False,DESMOTEPLASE,3.0,False,False,[],"['Desmoteplase', 'Dspa desmoteplase', 'RDSPA ALPHA 1']",,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000712', 'HP_0002140']",2.0,['ENSG00000122194'],1,,,,,,,,,,
CHEMBL259972,COc1ccc(-c2noc(CC(=O)O)c2-c2ccc(OC)cc2)cc1,DJEIHHYCDCTAAH-UHFFFAOYSA-N,Small molecule,False,MOFEZOLAC,4.0,False,True,[],['Mofezolac'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994.,,,,,['ENSG00000095303'],1,1994.0,,,"['144206111', '50112817']",,,,,,
CHEMBL3545307,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,QHADVLVFMKEIIP-UHFFFAOYSA-N,Small molecule,False,MERESTINIB,2.0,False,False,[],"['LY-2801653', 'LY2801653', 'Ly-2801653', 'Merestinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB12381'],"['EFO_0000389', 'MONDO_0003060', 'EFO_1001469', 'EFO_0003060', 'EFO_0002618', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0007254']",8.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL3989908,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,DYLUUSLLRIQKOE-UHFFFAOYSA-N,Small molecule,True,ENASIDENIB,4.0,False,True,[],"['AG-221', 'Ag 221', 'CC-90007 Free Base', 'Enasidenib']",['CHEMBL3989931'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,['DB13874'],"['EFO_0000222', 'EFO_0000565', 'MONDO_0044881', 'EFO_0000616', 'EFO_1001779', 'EFO_0001378', 'MONDO_0004992', 'EFO_0001421', 'EFO_0000198', 'EFO_0000222']",10.0,['ENSG00000182054'],1,2017.0,,,,,,,,,
CHEMBL4297549,,,Protein,False,HUMAN C1-ESTERASE INHIBITOR,4.0,False,True,['Cinryze'],"['Berinert', 'C1 inhibitor human', 'C1-inhibitor, plasma derived', 'Cinryze', 'Human c1-esterase inhibitor', 'RVG-19303']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hereditary angioedema and has 5 investigational indications.,,,"['EFO_1002048', 'EFO_0005532', 'EFO_0003884', 'MONDO_0100096', 'MONDO_0019623', 'EFO_0004256']",6.0,"['ENSG00000088926', 'ENSG00000164344', 'ENSG00000182326', 'ENSG00000131187']",4,2011.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze'],,,,
CHEMBL4650293,,,Antibody drug conjugate,False,APRUTUMAB IXADOTIN,1.0,False,False,[],"['Aprutumab ixadotin', 'BAY 1187982', 'BAY-1187982', 'BAY1187982']",,Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0004992'],1.0,"['ENSG00000066468', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL527,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,QYSPLQLAKJAUJT-UHFFFAOYSA-N,Small molecule,True,PIROXICAM,4.0,False,True,"['Brexidol', 'Feldene', 'Feldene 20', 'Feldene p', 'Flamatrol', 'Kentene', 'Larapam', 'Piroflam 10', 'Piroflam 20', 'Piroxicam', 'Pirozip 10', 'Pirozip 20']","['CP-16,171', 'CP-16171', 'NSC-666076', 'Piroxicam']","['CHEMBL2106953', 'CHEMBL1418195']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA.,['Piroxicam'],['DB00554'],"['EFO_0000685', 'EFO_0005752', 'HP_0002829', 'EFO_1001896', 'MONDO_0005178', 'EFO_1001412', 'EFO_0004616', 'EFO_0003843', 'EFO_0005755', 'HP_0003326']",10.0,"['ENSG00000073756', 'ENSG00000095303']",2,1982.0,,['piroxicam'],"['11111641', '11111642', '11113322', '124881135', '144203782', '144207349', '170464817', '26746904', '26751443', '50085963', '50103896', '511550', '856007', '859011']",['8249'],,,,,
CHEMBL1200387,CC(N)Cc1ccccc1.O=C(O)CCCCC(=O)O,OFCJKOOVFDGTLY-UHFFFAOYSA-N,Small molecule,False,AMPHETAMINE ADIPATE,4.0,False,True,[],['Amphetamine adipate'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975.,,,,,"['ENSG00000142319', 'ENSG00000103546']",2,1975.0,CHEMBL405,,,,,,,,
CHEMBL1200412,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@H]2OC(=O)CCc1ccccc1,UBWXUGDQUBIEIZ-QNTYDACNSA-N,Small molecule,False,NANDROLONE PHENPROPIONATE,4.0,False,True,"['Durabolin', 'Nandrolone phenpropionate']","['Nandrolone phenpropionate', 'Nandrolone phenylpropionate', 'Norandrostenolone phenylpropionate', 'Nortestosterone furanpropionate', 'Nortestosterone phenylpropionate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959.,,['DB00984'],,,['ENSG00000169083'],1,1959.0,,,"['144206893', '170465193']",['7468'],,,,,
CHEMBL1200483,CC1NCCOC1c1ccccc1.Cl,VJNXVAVKCZJOFQ-UHFFFAOYSA-N,Small molecule,False,PHENMETRAZINE HYDROCHLORIDE,4.0,False,True,['Preludin'],"['NSC-405728', 'Phenmetraline hydrochloride', 'Phenmetrazine chloride', 'Phenmetrazine hcl', 'Phenmetrazine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000103546', 'ENSG00000142319']",2,1982.0,CHEMBL1201208,,"['144205719', '170465166']",['8068'],,,,,
CHEMBL1743088,,,Antibody,False,VELTUZUMAB,2.0,False,False,[],"['HA20', 'IMMU-106', 'Veltuzumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,,"['EFO_0000220', 'EFO_0005952', 'EFO_0000095', 'EFO_0007160', 'EFO_0000685', 'EFO_0000403', 'EFO_0000574', 'MONDO_0018906', 'MONDO_0000432']",9.0,['ENSG00000156738'],1,,,,,,,,,,
CHEMBL3545183,CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O.Cl,KHQMSZGKHGQUHG-WZDHWKSBSA-N,Protein,False,ETELCALCETIDE HYDROCHLORIDE,4.0,False,True,['Parsabiv'],"['AMG 416', 'Etelcalcetide hydrochloride', 'KAI-4169 HCl', 'Telcalcetide hydrochloride', 'Velcalcetide hydrochloride']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for secondary hyperparathyroidism and chronic kidney disease.,,,"['EFO_1001173', 'EFO_0003884']",2.0,['ENSG00000036828'],1,2016.0,CHEMBL3545184,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv'],,,,
CHEMBL3989410,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+],UHYAQBLOGVNWNT-UHFFFAOYSA-M,Small molecule,False,INDOMETHACIN SODIUM,4.0,False,True,"['Indocin', 'Indomethacin sodium']","['Indometacin sodium', 'Indometacin sodium hydrate', 'Indometacin sodium trihydrate', 'Indomethacin sodium', 'Indomethacin sodium anhydrous', 'Indomethacin sodium salt trihydrate', 'Indomethacin sodium trihydrate', 'Sodium indomethacin', 'Sodium indomethacin trihydrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and has 1 investigational indication.,,,['MP_0001845'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,1985.0,CHEMBL6,,,,,,,,
CHEMBL407,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,OFBIFZUFASYYRE-UHFFFAOYSA-N,Small molecule,True,FLUMAZENIL,4.0,False,True,"['Anexate', 'Flumazenil', 'Flumazepil', 'Mazicon', 'Romazicon']","['Flumazenil', 'Flumazepil', 'Lanexat', 'Mazicon', 'NSC-759193', 'RO 15-1788/000', 'RO-15-1788', 'RO-151788', 'RO-151788000', 'RO-1722', 'RO-41-8157']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 investigational indications. This drug has a black box warning from the FDA.,['Flumazenil'],['DB01205'],"['MONDO_0018044', 'MONDO_0021107', 'EFO_0003890', 'EFO_0004242', 'MONDO_0005180', 'MONDO_0007079', 'EFO_0004698', 'MONDO_0010383', 'EFO_1001884', 'EFO_0005230']",10.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1991.0,,['flumazenil'],"['104171157', '11111184', '11114035', '11532958', '170464960', '26719655', '26752172', '26752173', '50104818', '56422177', '85231047', '90341071']",['5103'],,,,,
CHEMBL4650419,,,Antibody,False,QUAVONLIMAB,3.0,False,False,[],"['MK-1308', 'MK-1308A COMPONENT QUAVONLIMAB', 'Quavonlimab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,,"['EFO_0000616', 'EFO_0000681', 'EFO_0000182', 'EFO_0000756', 'EFO_1001951', 'EFO_0000702', 'EFO_0003060']",7.0,['ENSG00000163599'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/QUAVONLIMAB/relevant/1/'],,,
CHEMBL628,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,Small molecule,False,PENTOXIFYLLINE,4.0,False,True,"['Neotren mr', 'Pentoxifylline', 'Pentoxil', 'Trental', 'Trental 100', 'Trental 400']","['BL 191', 'BL-191', 'C04AD03', 'NSC-637086', 'NSC-758481', 'Oxpentifylline', 'Oxypentifylline', 'Pentoxifylline', 'Pentoxiphyllin']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and has 51 investigational indications.,['Pentoxifylline'],['DB00806'],"['EFO_0000764', 'EFO_1001249', 'EFO_0000278', 'MONDO_0004985', 'MONDO_0021681', 'MONDO_0100096', 'MONDO_0002050', 'MONDO_0010679', 'EFO_0001065', 'EFO_0000545', 'EFO_0004272', 'EFO_0003780', 'EFO_1001346', 'MONDO_0008867', 'EFO_1001345', 'EFO_0003767', 'HP_0001919', 'EFO_0006890', 'EFO_0003928', 'EFO_1001486', 'EFO_0000319', 'EFO_0005046', 'EFO_1000158', 'EFO_0003869', 'EFO_0005774', 'MONDO_0018373', 'MONDO_0002462', 'EFO_0003060', 'EFO_0004255', 'EFO_0000384', 'EFO_0003884', 'EFO_0005044', 'EFO_0004284', 'HP_0001643', 'HP_0001397', 'MONDO_0005090', 'EFO_1000844', 'MONDO_0002009', 'EFO_0007444', 'HP_0040187', 'EFO_0001645', 'EFO_0004259', 'EFO_0005672', 'EFO_0000474', 'HP_0001399', 'EFO_0000401', 'MONDO_0004992', 'EFO_0000546', 'EFO_0001422', 'EFO_1000652', 'EFO_0000220', 'DOID_13406']",52.0,"['ENSG00000170425', 'ENSG00000128271', 'ENSG00000138735', 'ENSG00000065989', 'ENSG00000172572', 'ENSG00000139053', 'ENSG00000185527', 'ENSG00000186642', 'ENSG00000205268', 'ENSG00000115252', 'ENSG00000160191', 'ENSG00000133256', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000156973', 'ENSG00000132915', 'ENSG00000152270', 'ENSG00000095464', 'ENSG00000113231', 'ENSG00000112541', 'ENSG00000123360', 'ENSG00000105650', 'ENSG00000154678', 'ENSG00000073417', 'ENSG00000171408']",25,1984.0,,['pentoxifylline'],"['11111613', '11111614', '124881066', '144203774', '170465384', '26719692', '26747196', '50085870', '50105176', '85231180', '857899', '90341235']",['7986'],,,,,
CHEMBL1341,COC(F)(F)C(Cl)Cl,RFKMCNOHBTXSMU-UHFFFAOYSA-N,Small molecule,False,METHOXYFLURANE,4.0,True,True,"['Metofane', 'Penthrane', 'Pentrane']","['Analgizer', 'Anecotan', 'DA-759', 'Inhalan', 'Methoxiflurane', 'Methoxy flurane', 'Methoxyflurane', 'NSC-110432', 'Penthrox']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 2 investigational indications. It was withdrawn in at least one region.,['Methoxyflurane'],['DB01028'],"['EFO_0003843', 'MONDO_0004992', 'HP_0001945', 'EFO_0000546']",4.0,"['ENSG00000145888', 'ENSG00000109738', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",18,,,,,['6843'],,,,,
CHEMBL2051955,C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,WHXMKTBCFHIYNQ-SECBINFHSA-N,Small molecule,False,LEVOSIMENDAN,3.0,False,False,[],"['(-)-OR-1259', '(r)-simendan', 'Levosimendan', 'NSC-759644', 'OR-1259', 'Simendan, (r)-']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,['DB00922'],"['EFO_0000373', 'MP_0001914', 'HP_0001919', 'EFO_0000712', 'EFO_0003764', 'EFO_0008585', 'EFO_0005207', 'EFO_0001645', 'EFO_0000319', 'EFO_0000694', 'EFO_0003144', 'EFO_0002970', 'MONDO_0004976', 'HP_0031273', 'EFO_0006834']",15.0,"['ENSG00000114854', 'ENSG00000129991', 'ENSG00000118194', 'ENSG00000172572', 'ENSG00000152270']",5,,,,"['144205744', '170466128', '170466129']",['50567'],,,,,
CHEMBL3707357,,,Antibody,False,BROLUCIZUMAB,4.0,False,True,['Beovu'],"['Brolucizumab', 'Brolucizumab dbll', 'ESBA-1008', 'ESBA1008', 'RTH-258', 'RTH258']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for wet macular degeneration and ocular vascular disease and has 3 investigational indications.,,,"['EFO_1001157', 'MONDO_0003005', 'EFO_0004683', 'EFO_0001365', 'EFO_0005753']",5.0,['ENSG00000112715'],1,2019.0,,['brolucizumab-dbll'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/beovu'],,,,
CHEMBL4080062,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12,JNLSTLQFDDAULK-UHFFFAOYSA-N,Small molecule,False,BFH-772,2.0,False,False,[],"['BFH-722', 'BFH-772', 'BFH722', 'BFH772', 'Bfh-772', 'Bfh772']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_1000760'],1.0,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL5314410,C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)N4C[C@H]5CCN(C)[C@H]5C4)cc23)c1,FSXCKIBROURMFT-VGSWGCGISA-N,Small molecule,False,THELIATINIB,2.0,False,False,[],"['HMPL-309', 'Hmpl-309', 'Theliatinib', 'Xiliertinib']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004992'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL1200772,CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[K+],WSHYKIAQCMIPTB-UHFFFAOYSA-M,Small molecule,False,WARFARIN POTASSIUM,4.0,False,True,['Athrombin-k'],"['Potassium warfarin', 'Warfarin potassium', 'Warfarin-potassium']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications.,,,"['EFO_0000275', 'HP_0001907', 'HP_0004936']",3.0,['ENSG00000167397'],1,1982.0,CHEMBL1464,,"['144205190', '170464790']",,,,,,
CHEMBL1201754,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,POGQSBRIGCQNEG-UHFFFAOYSA-N,Small molecule,False,RUFINAMIDE,4.0,False,True,"['Banzel', 'Inovelon', 'Rufinamide']","['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331', 'Rufinamide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 1 investigational indication.,['Rufinamide'],['DB06201'],"['EFO_0003843', 'HP_0001250', 'EFO_0000474', 'MONDO_0016532']",4.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2007.0,,['rufinamide'],"['170465202', '29217641', '50111716', '56320687', '90341717']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon'],,,,
CHEMBL1236962,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CGBJSGAELGCMKE-UHFFFAOYSA-N,Small molecule,False,OMIPALISIB,2.0,False,False,[],"['GSK-2126458', 'GSK2126458', 'Gsk-2126458', 'Omipalisib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB12703'],"['EFO_0000616', 'EFO_0000768', 'MONDO_0004992']",3.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000198793']",9,,,,,,,,,,
CHEMBL2103881,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C,IMYZQPCYWPFTAG-NGZCFLSTSA-N,Small molecule,False,DEXMECAMYLAMINE,3.0,False,False,[],"['Dexmecamylamine', 'NIH-11008', 'TC-5214', 'Tc-5214']",['CHEMBL2105753'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB11807'],"['MONDO_0002009', 'EFO_0003086', 'EFO_0000537', 'EFO_0003890', 'HP_0000975', 'EFO_1000781']",6.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL38,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,SHGAZHPCJJPHSC-YCNIQYBTSA-N,Small molecule,True,TRETINOIN,4.0,False,True,"['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a micro', 'Retin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']","['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'Eudyna', 'Kerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acid', 'Tretinoin']",['CHEMBL2051965'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 35 investigational indications. This drug has a black box warning from the FDA.,"['Retinoic_acid', 'Tretinoin']",['DB00755'],"['EFO_0000621', 'EFO_0002618', 'EFO_0000198', 'EFO_0000231', 'EFO_0007160', 'EFO_0000616', 'EFO_0003060', 'HP_0001065', 'EFO_0000389', 'EFO_0000464', 'EFO_0004268', 'EFO_0000673', 'EFO_0004193', 'MONDO_0002280', 'MONDO_0044881', 'EFO_0001378', 'EFO_0000702', 'EFO_0000574', 'EFO_0003963', 'EFO_0004826', 'EFO_0000222', 'EFO_1000760', 'EFO_0003758', 'MONDO_0004976', 'MONDO_0019289', 'MONDO_0008903', 'EFO_0000224', 'EFO_0003869', 'EFO_0002496', 'EFO_0000756', 'MONDO_0007254', 'EFO_0000707', 'EFO_0000565', 'MONDO_0002367', 'EFO_0003894', 'MONDO_0019098', 'EFO_0004251', 'HP_0003124', 'MONDO_0100096', 'MONDO_0020077']",40.0,"['ENSG00000172819', 'ENSG00000077092', 'ENSG00000131759']",3,1971.0,,['tretinoin'],"['104171346', '124882949', '124882951', '124882956', '124882957', '144204363', '144209528', '144210625', '170465045', '26746936', '29214999', '416403', '50103969', '50103970', '50126361', '50126362', '56422209', '85231340', '855632', '90341365']",['15367'],,,,,
CHEMBL3989690,CCOC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,VCVWXKKWDOJNIT-ZOMKSWQUSA-N,Small molecule,False,TESOFENSINE,2.0,False,False,[],"['NS 2330', 'NS-2330', 'Ns2330', 'Tesofensine']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB06156'],"['EFO_0001073', 'MONDO_0005148', 'MONDO_0008300', 'MONDO_0005180', 'MONDO_0004975']",5.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,,,,,,,,,,
CHEMBL3989914,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1,YRCHYHRCBXNYNU-UHFFFAOYSA-N,Small molecule,False,GLESATINIB,2.0,False,False,[],"['Glesatinib', 'MG-90265', 'MG-90265X', 'MG90265', 'MG90265H9', 'MG90265X', 'MG90265gly', 'MGCD-265', 'MGCD265', 'Mgcd-265']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB06302'],"['EFO_0003060', 'MONDO_0004992']",2.0,"['ENSG00000105976', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000164078', 'ENSG00000120156']",6,,,,,,,,,,
CHEMBL4297385,COC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,PGYDXVBZYKQYCS-VPWBDBDCSA-N,Small molecule,False,NS-2359,2.0,False,False,[],"['GSK-372,475', 'GSK-372475', 'GSK372475', 'Gsk372475', 'NS2359', 'Ns-2359', 'Ns2359']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB05805'],"['EFO_0002610', 'EFO_0003888', 'MONDO_0002050']",3.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,,,,,,,,,,
CHEMBL4297441,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1,LRCZQSDQZJBHAF-PUBGEWHCSA-N,Small molecule,False,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,False,False,[],"['Dha paclitaxel', 'Dha-paclitaxel', 'Paclitaxel docosahexaenoic acid', 'Paclitaxel-dha', 'Taxoprexin']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB05297'],"['EFO_0003060', 'EFO_0000182', 'EFO_0002617']",3.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL4594618,,,Gene,False,BREXUCABTAGENE AUTOLEUCEL,4.0,False,True,['Tecartus'],"['Brexucabtagene autoleucel', 'KTE-X19']",,Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for mantle cell lymphoma and has 4 investigational indications.,,,"['EFO_0001642', 'EFO_0000095', 'EFO_0000220', 'EFO_0000616', 'EFO_1001469']",5.0,['ENSG00000177455'],1,2020.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus'],['https://searchusan.ama-assn.org/finder/usan/search/BREXUCABTAGENE%20AUTOLEUCEL/relevant/1/'],,,
CHEMBL1201336,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,XWLUWCNOOVRFPX-UHFFFAOYSA-N,Small molecule,True,FOSPHENYTOIN,4.0,False,True,[],"['Fosphenytoin', 'Np-06']","['CHEMBL5205794', 'CHEMBL919']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for epilepsy and has 1 investigational indication. This drug has a black box warning from the FDA.,,['DB01320'],"['EFO_0000474', 'EFO_0008526']",2.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1996.0,,,['170465016'],['5165'],,,,,
CHEMBL1742982,,,Protein,False,AFLIBERCEPT,4.0,False,True,"['Eylea', 'Zaltrap']","['ABP-938', 'AVE-0005', 'AVE0005', 'Aflibercept', 'Aflibercept (genetical recombination)', 'Aflibercept beta', 'Aflibercept biosimilar (amgen)', 'Aflibercept recombinant', 'BAY-86-5321', 'BAY-865321', 'BAY86-5321', 'VEGF TRAP', 'Vegf trap-eye']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 13 approved and 36 investigational indications.,,,"['EFO_0007310', 'EFO_0005753', 'EFO_1001951', 'EFO_1000657', 'MONDO_0005041', 'MONDO_0004992', 'MONDO_0005575', 'EFO_1001060', 'EFO_0004207', 'EFO_0004142', 'EFO_0000565', 'EFO_0000616', 'EFO_0010977', 'EFO_1001158', 'EFO_0009606', 'EFO_0004243', 'MONDO_0004986', 'MONDO_0003005', 'EFO_0000681', 'EFO_0000365', 'EFO_0000702', 'EFO_0002499', 'EFO_0002617', 'EFO_0003770', 'EFO_0000641', 'MONDO_0003268', 'EFO_0000574', 'EFO_0003839', 'EFO_0004683', 'EFO_0008626', 'MONDO_0004192', 'EFO_0000756', 'EFO_0000501', 'EFO_0002501', 'EFO_1001465', 'EFO_0003060', 'EFO_0009784', 'EFO_1000880', 'EFO_0005952', 'EFO_1001512', 'EFO_1001466', 'Orphanet_758', 'MONDO_0001576', 'EFO_0000389', 'MONDO_0021063', 'EFO_1001157', 'EFO_0001365', 'EFO_0001378', 'MONDO_0007254']",49.0,"['ENSG00000119630', 'ENSG00000112715']",2,2011.0,,"['aflibercept', 'ziv-aflibercept']",,,['https://www.ema.europa.eu/en/medicines/human/EPAR/eylea'],,,['4916'],
CHEMBL182066,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,GKGRZLGAQZPEHO-UHFFFAOYSA-N,Small molecule,False,RADIPRODIL,2.0,False,False,[],"['RGH-896', 'Radiprodil', 'Rgh-896']",['CHEMBL1802037'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12260'],"['MONDO_0018097', 'EFO_0005762']",2.0,"['ENSG00000176884', 'ENSG00000273079']",2,,,,,,,,,,
CHEMBL4650299,,,Oligosaccharide,False,HEPARIN,4.0,False,True,[],"['B01AB10', 'Heparin', 'Heparin porcine', 'Heparin porcine intestinal mucosa', 'Heparin, porcine']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 2 investigational indications.,,,"['MONDO_0005148', 'MONDO_0100096']",2.0,['ENSG00000117601'],1,2023.0,,,,,,,,,
CHEMBL4650452,,,Unknown,False,BNC-210,2.0,False,False,[],"['BNC-210', 'BNC210', 'Bnc-210', 'Bnc210', 'Iw-2143']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0001358', 'HP_0000713', 'EFO_1001917']",3.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL1200463,O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+],QTAQWNSMRSLSCG-UHFFFAOYSA-M,Small molecule,True,OXAPROZIN POTASSIUM,4.0,False,True,['Daypro alta'],['Oxaprozin potassium'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2002. This drug has a black box warning from the FDA.,,,,,"['ENSG00000073756', 'ENSG00000095303']",2,2002.0,CHEMBL1071,,,,,,,,
CHEMBL14935,O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,ZXFRFPSZAKNPQQ-YTWAJWBKSA-N,Small molecule,False,TEZAMPANEL ANHYDROUS,2.0,False,False,[],"['LY-293,558', 'LY-293558', 'NGX-424', 'NGX424', 'Tezampanel anhydrous']",['CHEMBL3989703'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB06354'],['MONDO_0005277'],1.0,"['ENSG00000171189', 'ENSG00000105737', 'ENSG00000149403', 'ENSG00000164418', 'ENSG00000163873', 'ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",9,,,,,,,,,,
CHEMBL1743049,,,Antibody,False,OLARATUMAB,4.0,False,True,['Lartruvo'],"['IMC-3G3', 'IMC3G3', 'Olaratumab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 8 investigational indications.,,,"['EFO_0000564', 'MONDO_0008315', 'EFO_1001968', 'EFO_0000691', 'EFO_0000519', 'EFO_0003893', 'EFO_0003060', 'MONDO_0011719', 'EFO_0000616', 'EFO_0002618', 'EFO_0009708']",11.0,['ENSG00000134853'],1,2016.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/lartruvo'],,,['5183'],
CHEMBL2079588,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,QFCXANHHBCGMAS-UHFFFAOYSA-N,Small molecule,False,TELATINIB,2.0,False,False,[],"['BAY 57-9352', 'BAY-579352', 'Bay-57-9352', 'Telatinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB15393'],"['EFO_0000616', 'MONDO_0001056']",2.0,"['ENSG00000037280', 'ENSG00000128052', 'ENSG00000113721', 'ENSG00000157404']",4,,,,['124955475'],,,,,,
CHEMBL2109608,,,Antibody,False,L19IL2,3.0,False,False,[],"['L19IL2', 'L19il2']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0002617', 'EFO_0000616', 'EFO_0002618', 'EFO_0000756']",4.0,['ENSG00000115414'],1,,,,,,,,,,
CHEMBL2110737,CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O,HTJGLYIJVSDQAE-VWNXEWBOSA-N,Small molecule,False,CELGOSIVIR,2.0,False,False,[],['Celgosivir'],['CHEMBL2105801'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB06580'],"['EFO_0000764', 'EFO_0004220', 'EFO_0005547']",3.0,"['ENSG00000257335', 'ENSG00000171298', 'ENSG00000090402', 'ENSG00000257743']",4,,,,,,,,,,
CHEMBL2146883,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,BSMCAPRUBJMWDF-KRWDZBQOSA-N,Small molecule,False,COBIMETINIB,4.0,False,True,['Cotellic'],"['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420', 'RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']","['CHEMBL2364607', 'CHEMBL3526209']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 21 investigational indications.,,['DB05239'],"['MONDO_0008170', 'EFO_1001779', 'EFO_0001642', 'EFO_1001956', 'EFO_1000209', 'EFO_0000756', 'EFO_0003060', 'EFO_0000756', 'MONDO_0002898', 'Orphanet_46724', 'EFO_0002892', 'EFO_1001951', 'EFO_0002916', 'EFO_0001378', 'EFO_0000305', 'MONDO_0005184', 'EFO_0000222', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000389', 'EFO_0002617', 'EFO_0000503', 'EFO_0000691', 'EFO_0002617']",25.0,"['ENSG00000169032', 'ENSG00000126934']",2,2015.0,,,,,,,,,
CHEMBL3120215,COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12,JROFGZPOBKIAEW-HAQNSBGRSA-N,Small molecule,False,OSI-027,2.0,False,False,[],"['AEVI-006', 'ASP 7486', 'ASP-7486', 'ASP7486', 'CERC 006', 'CERC-006', 'CERC006', 'OSI-027', 'OSI027', 'Osi 027', 'Osi-027']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12387'],"['EFO_0000574', 'MONDO_0019313']",2.0,['ENSG00000198793'],1,,,,,,,,,,
CHEMBL3137349,,,Antibody,False,BOCOCIZUMAB,3.0,False,False,[],"['Bococizumab', 'PF-04950615', 'RN-316', 'RN316']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0000319', 'EFO_0004911', 'MONDO_0021187', 'HP_0003124']",4.0,['ENSG00000169174'],1,,,,,,,,,,
CHEMBL3545054,,,Small molecule,False,INCB-40093,2.0,False,False,[],"['INCB-040093', 'Incb-40093']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0004992', 'EFO_0000183']",2.0,['ENSG00000171608'],1,,,,,,,,,,
CHEMBL3707353,,,Small molecule,False,RG7893,1.0,False,False,[],"['GDC-0276', 'Rg7893']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000169432'],1,,,,,,,,,,
CHEMBL41355,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,PCOBBVZJEWWZFR-UHFFFAOYSA-N,Small molecule,True,EZOGABINE,4.0,False,True,"['Potiga', 'Trobalt']","['AWD-21360', 'AWD21-360', 'D-23129', 'Ezogabine', 'GKE-841', 'GW-582892X', 'GW582892X', 'Retigabine', 'WAY-143841']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for epilepsy and seizure and has 4 investigational indications. This drug has a black box warning from the FDA.,['Retigabine'],['DB04953'],"['EFO_0000474', 'MONDO_0002009', 'MONDO_0004976', 'MONDO_0002050', 'MONDO_0041052', 'HP_0001250']",6.0,"['ENSG00000053918', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000185760', 'ENSG00000117013']",5,2011.0,,,['174006313'],['68584'],['https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt'],,,,
CHEMBL4594472,,,Unknown,False,EMB-01,2.0,False,False,[],"['Bafisontamab', 'EMB-01', 'Emb-01', 'Emb01', 'Fit-013a']",,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003060'],1.0,"['ENSG00000105976', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL607707,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,WVUNYSQLFKLYNI-AATRIKPKSA-N,Small molecule,False,PELITINIB,2.0,False,False,[],"['EKB-569', 'Pelitinib', 'WAY-EKB-569']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB05524'],"['EFO_1000657', 'EFO_0003060', 'EFO_0000616', 'EFO_0004288']",4.0,['ENSG00000146648'],1,,,,['50100098'],['38927'],,,,,
CHEMBL1201584,,,Antibody,False,ABCIXIMAB,4.0,False,True,['Reopro'],"['Abciximab', 'Abciximab (genetical recombination)', 'C7E3']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for recurrent thrombophlebitis and intermediate coronary syndrome and has 7 investigational indications.,['Abciximab'],,"['EFO_0008583', 'EFO_0003913', 'MONDO_0005299', 'EFO_0000712', 'EFO_0000612', 'HP_0004419', 'EFO_0008585', 'EFO_0002615', 'EFO_1000985']",9.0,"['ENSG00000259207', 'ENSG00000138448', 'ENSG00000005961']",3,1993.0,,,,,,,,['4950'],
CHEMBL1256842,CN1Cc2c(N)cccc2C(c2ccccc2)C1.O=C(O)/C=C\C(=O)O,GEOCVSMCLVIOEV-BTJKTKAUSA-N,Small molecule,False,NOMIFENSINE MALEATE,4.0,True,True,[],"['HOE 984', 'HOE-984', 'Hostalival', 'NSC-289114', 'Nomifensine hydrogen maleate', 'Nomifensine maleate', 'Psicronizer']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. It was withdrawn in at least one region.,,,,,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,1984.0,CHEMBL273575,,"['170466450', '26747597', '26747598', '50106723', '50106724', '50106725', '855660', '93576623']",,,,,,
CHEMBL1742983,,,Antibody,False,ALACIZUMAB PEGOL,2.0,False,False,[],"['Alacizumab pegol', 'CDP-791', 'g165 DFM-PEG']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL190083,C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,SYTBZMRGLBWNTM-SNVBAGLBSA-N,Small molecule,False,TARENFLURBIL,3.0,False,False,[],"['E-7869', 'Flurbiprofen, (r)-', 'MPC-7869', 'R-flurbiprofen', 'Tarenflurbil']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB05289'],"['MONDO_0008315', 'HP_0000726', 'MONDO_0004975']",3.0,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']",6,,,,"['11112562', '11114208', '520769', '520770']",['38666'],,,,,
CHEMBL3301595,N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,SRPXSILJHWNFMK-MEDUHNTESA-N,Small molecule,False,DASOTRALINE,3.0,False,False,[],"['(1r,4s)-trans-norsertraline', 'Dasotraline', 'Norsertraline, (1r,4s)-trans-', 'SEP-225289']",['CHEMBL3301596'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB12305'],"['MONDO_0002009', 'EFO_0005203', 'EFO_0003888']",3.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,,,,,,,,,,
CHEMBL3702854,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,LCFFREMLXLZNHE-GBOLQPHISA-N,Small molecule,False,RILZABRUTINIB,3.0,False,False,[],"['PRN1008', 'Prn-1008', 'Prn1008', 'Rilzabrutinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,,"['EFO_0000274', 'EFO_1001264', 'MP_0001845', 'MONDO_0004979', 'EFO_0005531', 'MONDO_0017287', 'EFO_1000749', 'EFO_0007160', 'EFO_0005809', 'EFO_0004719']",10.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/RILZABRUTINIB/relevant/1/'],,,
CHEMBL4582651,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,GBLBJPZSROAGMF-RWYJCYHVSA-N,Small molecule,False,PRALSETINIB,4.0,False,True,['Gavreto'],"['BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'Pralsetinib', 'X-581238', 'X581238']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved indications.,,,"['MONDO_0015277', 'EFO_0000616', 'MONDO_0004992', 'EFO_0003060']",4.0,"['ENSG00000165731', 'ENSG00000170759', 'ENSG00000108091']",3,2020.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto'],['https://searchusan.ama-assn.org/finder/usan/search/PRALSETINIB/relevant/1/'],,,
CHEMBL16,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,CXOFVDLJLONNDW-UHFFFAOYSA-N,Small molecule,False,PHENYTOIN,4.0,False,True,"['Dilabid', 'Dilantin', 'Dilantin-125', 'Dilantin-30', 'Diphenylhydantoin', 'Hydantol', 'Phentytoin', 'Phenytoin']","['Diphenylhydantoin', 'Epamin', 'Lepitoin', 'NSC-8722', 'Phenytek', 'Phenytex', 'Phenytoin', 'Phenytoinum', 'SM-88 COMPONENT PHENYTOIN', 'Zentropil']","['CHEMBL3274483', 'CHEMBL553532', 'CHEMBL4764504', 'CHEMBL3786353', 'CHEMBL1611']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for epilepsy and seizure and has 17 investigational indications.,['Phenytoin'],['DB00252'],"['EFO_0007405', 'EFO_0005230', 'EFO_0000565', 'EFO_0000474', 'EFO_0002618', 'EFO_0004272', 'EFO_1001996', 'MONDO_0002050', 'HP_0001250', 'MONDO_0005090', 'EFO_0000174', 'EFO_0000621', 'EFO_0000546', 'EFO_0000474', 'HP_0001250', 'HP_0000726', 'EFO_0009562', 'EFO_0000540', 'EFO_0000574', 'MONDO_0011382', 'EFO_0002610']",21.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1953.0,,['phenytoin'],"['11111069', '11532994', '124879886', '124886706', '144204412', '144209497', '144210601', '170464785', '17389903', '26753026', '26753027', '26753028', '50106148', '56423134', '85230999', '90340679', '90341165']",['8107'],,,['26'],,
CHEMBL2103837,O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1,TXEIIPDJKFWEEC-UHFFFAOYSA-N,Small molecule,False,TAFAMIDIS,4.0,False,True,"['Vyndamax', 'Vyndaqel']","['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']",['CHEMBL2105675'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 3 investigational indications.,,['DB11644'],"['EFO_1001875', 'EFO_0000318', 'EFO_0009562', 'EFO_0000318', 'MONDO_0019438', 'EFO_0004129', 'EFO_0004129', 'EFO_1001875']",8.0,['ENSG00000118271'],1,2011.0,,['tafamidis'],,['78538'],,,,,
CHEMBL2108567,,,Antibody,False,TANEZUMAB,3.0,False,False,[],"['PF-04383119', 'PF-4383119', 'RN-624', 'RN624', 'Tanezumab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,,"['EFO_1000786', 'EFO_0000342', 'EFO_1000869', 'EFO_0004616', 'MONDO_0041052', 'HP_0001945', 'EFO_0003830', 'HP_0003419', 'EFO_1000783', 'MONDO_0005178', 'HP_0012532', 'EFO_0001065', 'EFO_0003843']",13.0,['ENSG00000134259'],1,,,,,,,,,,
CHEMBL23293,CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O,WUILNKCFCLNXOK-CFBAGHHKSA-N,Small molecule,False,SALIRASIB,2.0,False,False,[],"['FTS', 'Salirasib']",,Small molecule drug with a maximum clinical trial phase of II.,,['DB12681'],,,"['ENSG00000174775', 'ENSG00000213281', 'ENSG00000133703']",3,,,,"['11111197', '50106301', '50106302', '520931', '85231054']",,,,,,
CHEMBL256997,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,OOUGLTULBSNHNF-UHFFFAOYSA-N,Small molecule,False,ATALUREN,4.0,False,True,['Translarna'],"['Ataluren', 'PTC-124', 'PTC124', 'Translarna']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for duchenne muscular dystrophy and becker muscular dystrophy and has 5 investigational indications.,['Ataluren'],['DB05016'],"['MONDO_0009061', 'MONDO_0010602', 'MONDO_0010679', 'MONDO_0019172', 'MONDO_0010311', 'MONDO_0010604', 'EFO_0000474']",7.0,"['ENSG00000168028', 'ENSG00000177954', 'ENSG00000137154', 'ENSG00000140988', 'ENSG00000149273', 'ENSG00000145425', 'ENSG00000198034', 'ENSG00000129824', 'ENSG00000083845', 'ENSG00000171863', 'ENSG00000142937', 'ENSG00000170889', 'ENSG00000124614', 'ENSG00000142534', 'ENSG00000112306', 'ENSG00000110700', 'ENSG00000164587', 'ENSG00000115268', 'ENSG00000134419', 'ENSG00000105193', 'ENSG00000182774', 'ENSG00000231500', 'ENSG00000105372', 'ENSG00000008988', 'ENSG00000171858', 'ENSG00000186468', 'ENSG00000138326', 'ENSG00000118181', 'ENSG00000197728', 'ENSG00000143947', 'ENSG00000233927', 'ENSG00000213741', 'ENSG00000149806', 'ENSG00000100316', 'ENSG00000174444', 'ENSG00000122406', 'ENSG00000089009', 'ENSG00000147604', 'ENSG00000148303', 'ENSG00000161016', 'ENSG00000163682', 'ENSG00000147403', 'ENSG00000198755', 'ENSG00000142676', 'ENSG00000197958', 'ENSG00000167526', 'ENSG00000142541', 'ENSG00000188846', 'ENSG00000174748', 'ENSG00000265681', 'ENSG00000063177', 'ENSG00000105640', 'ENSG00000108298', 'ENSG00000122026', 'ENSG00000116251', 'ENSG00000125691', 'ENSG00000198242', 'ENSG00000114391', 'ENSG00000161970', 'ENSG00000131469', 'ENSG00000166441', 'ENSG00000108107', 'ENSG00000162244', 'ENSG00000156482', 'ENSG00000071082', 'ENSG00000144713', 'ENSG00000109475', 'ENSG00000136942', 'ENSG00000182899', 'ENSG00000130255', 'ENSG00000241343', 'ENSG00000145592', 'ENSG00000197756', 'ENSG00000172809', 'ENSG00000198918', 'ENSG00000229117', 'ENSG00000089157', 'ENSG00000137818']",78,2014.0,,,"['144206184', '170466862', '85852879', '87334013', '99460885']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/translarna'],,,,
CHEMBL3301607,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,RIJLVEAXPNLDTC-UHFFFAOYSA-N,Small molecule,False,FILGOTINIB,4.0,False,True,[],"['Filgotinib', 'G-146034', 'G146034', 'GLPG0634', 'GS-6034 FREE BASE', 'Glpg-0634']","['CHEMBL3301602', 'CHEMBL4298167']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for rheumatoid arthritis and immune system disease and has 11 investigational indications.,,['DB14845'],"['EFO_0003086', 'EFO_0003767', 'EFO_0003834', 'EFO_0000699', 'MONDO_0007915', 'EFO_0003778', 'EFO_0000384', 'EFO_0000729', 'EFO_0000685', 'EFO_1001231', 'EFO_0000685', 'EFO_0003898', 'EFO_0000540']",13.0,"['ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397', 'ENSG00000105639']",4,2020.0,,,,,,,,,
CHEMBL3707375,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F,JVCPIJKPAKAIIP-UHFFFAOYSA-N,Small molecule,False,AMISELIMOD,2.0,False,False,[],"['2240442', 'Amiselimod']",['CHEMBL3707374'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000729', 'MONDO_0007915', 'EFO_0000384']",6.0,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']",5,,,,,,,,,,
CHEMBL3990032,,,Antibody drug conjugate,False,TELISOTUZUMAB VEDOTIN,3.0,False,False,[],"['ABBV-399', 'ABT-399', 'Abbv 399', 'Abt-700-vcmmae', 'PR-1420682', 'Telisotuzumab vedotin']",,Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0000708', 'EFO_0003060', 'MONDO_0004992']",3.0,"['ENSG00000105976', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL4297852,,,Protein,False,CENEGERMIN,4.0,False,True,['Oxervate'],"['Cenegermin', 'Cenegermin bkbj']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for eye disease and keratitis and has 1 investigational indication.,,,"['EFO_1000906', 'EFO_0003966', 'EFO_0009449']",3.0,"['ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']",3,2017.0,,['cenegermin-bkbj'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/oxervate'],,,,
CHEMBL5314391,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1,DMQYDVBIPXAAJA-VHXPQNKSSA-N,Small molecule,False,XL-999,2.0,False,False,[],"['XL-999', 'Xl 999', 'Xl-999']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_1001951', 'EFO_0000222', 'EFO_0000681', 'EFO_0003060', 'MONDO_0008170', 'MONDO_0004992', 'EFO_0001378']",7.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000157404', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000122025']",11,,,,,,,,,,
CHEMBL833,Clc1ccccc1CN1CCc2sccc2C1,PHWBOXQYWZNQIN-UHFFFAOYSA-N,Small molecule,True,TICLOPIDINE,4.0,False,True,[],"['Ticlopidin-puren', 'Ticlopidine']",['CHEMBL1717'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.,['Ticlopidine'],['DB00208'],"['HP_0004419', 'EFO_0000712', 'EFO_0004265', 'MONDO_0000831', 'EFO_0002615']",5.0,['ENSG00000169313'],1,1991.0,,,"['104171328', '11112786', '124882626', '144204209', '170464698', '26751617', '50085878']",['9588'],,,['146'],,
CHEMBL1120,,,Small molecule,False,BISMUTH SUBSALICYLATE,4.0,False,True,"['Bismukote', 'Corrective Suspension', 'Gastro-Cote', 'Pepto-Bismol']","['Bismuth salicylate', 'Bismuth subsalicylate', 'NSC-759117']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for nausea and diarrhea and has 2 investigational indications.,['Bismuth_subsalicylate'],,"['EFO_0000574', 'HP_0002018', 'EFO_1000961', 'HP_0002014']",4.0,"['ENSG00000073756', 'ENSG00000095303']",2,1996.0,,,"['144205951', '225144280', '29218057']",['261649'],,,,,
CHEMBL1568698,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,PGTVWKLGGCQMBR-FLBATMFCSA-N,Small molecule,False,GANAXOLONE,4.0,False,True,['Ztalmy'],"['CCD 1042', 'CCD-1042', 'DEA NO. 2401', 'Ganaxolone', 'Ztalmy']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 7 investigational indications.,,['DB05087'],"['HP_0001250', 'EFO_0004263', 'MONDO_0010383', 'EFO_0001358', 'MONDO_0001734', 'EFO_0000474', 'MONDO_0018097', 'EFO_0008526', 'EFO_1000877', 'EFO_0004319']",10.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,2022.0,,,"['144205817', '170466317', '29217560', '50111707', '90341411']",,,,,,
CHEMBL2103791,CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12,UAMAIHOEGLEXSV-UHFFFAOYSA-N,Small molecule,False,ADIPIPLON,2.0,False,False,[],"['Adipiplon', 'NG2-73']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB06579'],['EFO_0004698'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL2109480,,,Antibody,False,AHN-12,1.0,False,False,[],"['AHN-12', 'Ahn-12']",,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,,"['EFO_0000565', 'EFO_0000339', 'EFO_0000220', 'EFO_0000222', 'EFO_0000198']",5.0,['ENSG00000081237'],1,,,,,,,,,,
CHEMBL2165326,NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,DKULOVKANLVDEA-UHFFFAOYSA-N,Small molecule,False,APROCITENTAN,3.0,False,False,[],"['ACT-132577', 'Act-132577', 'Aprocitentan', 'Macitentan metabolite m6']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB15059'],"['EFO_0000537', 'EFO_0001421', 'EFO_0003086', 'MONDO_0001134']",4.0,"['ENSG00000136160', 'ENSG00000151617']",2,,,,,['76609'],,['https://searchusan.ama-assn.org/finder/usan/search/APROCITENTAN/relevant/1/'],,,
CHEMBL3402762,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,AHYMHWXQRWRBKT-UHFFFAOYSA-N,Small molecule,False,TEPOTINIB,4.0,False,True,[],"['EMD 1214063', 'EMD-1214063', 'EMD1214063', 'Emd-1214063', 'MSC-2156119', 'MSC-2156119J', 'MSC2156119', 'Tepotinib']",['CHEMBL4594292'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and non-small cell lung carcinoma and has 7 investigational indications.,,['DB15133'],"['EFO_0003833', 'EFO_0000616', 'EFO_0000571', 'EFO_0000616', 'EFO_0001421', 'EFO_0000182', 'EFO_0003060', 'EFO_0004142', 'EFO_0003060']",9.0,['ENSG00000105976'],1,2020.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TEPOTINIB/relevant/1/'],,,
CHEMBL3545000,,,Small molecule,False,MK-2201,1.0,False,False,[],['Mk-2201'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,,,,,,,
CHEMBL1071,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,OFPXSFXSNFPTHF-UHFFFAOYSA-N,Small molecule,True,OXAPROZIN,4.0,False,True,"['Daypro', 'Oxaprozin']","['NSC-310839', 'Oxaprozin', 'WY-21,743', 'WY-21743']",['CHEMBL1200463'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 4 approved indications. This drug has a black box warning from the FDA.,['Oxaprozin'],['DB00991'],"['EFO_0000685', 'MONDO_0005178', 'EFO_0002609', 'EFO_0005755']",4.0,"['ENSG00000073756', 'ENSG00000095303']",2,1992.0,,['oxaprozin'],"['11110656', '11110657', '144203610', '170464987', '26719634', '26747622', '4254158', '455291', '50106813', '50106814', '85230870', '90340983']",['7822'],,,,,
CHEMBL306823,O=C([O-])C(Cl)Cl.[Na+],LUPNKHXLFSSUGS-UHFFFAOYSA-M,Small molecule,False,SODIUM DICHLOROACETATE,4.0,False,True,[],"['CMI X-11S', 'CPC-211', 'DCA', 'Dca sodium', 'NSC-744479', 'Sodium dichloroacetate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications.,,,"['MONDO_0019169', 'EFO_0003777', 'EFO_0001361', 'EFO_1000036', 'EFO_0000519', 'EFO_0000181', 'MONDO_0007254', 'MONDO_0008903']",8.0,"['ENSG00000005882', 'ENSG00000067992', 'ENSG00000004799', 'ENSG00000152256']",4,,,,"['144207122', '144211711', '50112986']",,,,,,
CHEMBL3264002,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,LMMJFBMMJUMSJS-UHFFFAOYSA-N,Small molecule,False,AVUTOMETINIB,2.0,False,False,[],"['Avutometinib', 'CH-5126766', 'CH5126766', 'CKI-27', 'R-7304', 'RG-7304', 'Rg-7304', 'Ro 5126766', 'Ro-5126766', 'VS-6766']",['CHEMBL3264004'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,['DB15254'],"['MONDO_0008170', 'EFO_0000466', 'EFO_0002618', 'EFO_0000616', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0021148', 'EFO_0003060', 'EFO_0001378', 'EFO_0000519']",10.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,,['78825'],,['https://searchusan.ama-assn.org/finder/usan/search/AVUTOMETINIB/relevant/1/'],,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL3545317,,,Antibody,False,REFANEZUMAB,2.0,False,False,[],"['GSK249320', 'Refanezumab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000105695'],1,,,,,,,,,,
CHEMBL3989691,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O.NCCO.NCCO,PLILLUUXAVKBPY-SBIAVEDLSA-N,Small molecule,True,ELTROMBOPAG OLAMINE,4.0,False,True,"['Promacta', 'Promacta kit', 'Revolade']","['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)', 'Eltrombopag olamine', 'SB-497115-GR']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0000198', 'EFO_0006927', 'EFO_0004220', 'EFO_0007160', 'HP_0001873']",5.0,['ENSG00000117400'],1,2008.0,CHEMBL461101,['eltrombopag%20olamine'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/revolade'],,,,
CHEMBL4297674,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,VJPPLCNBDLZIFG-ZDUSSCGKSA-N,Small molecule,False,BRANEBRUTINIB,2.0,False,False,[],"['BMS-986195', 'Bms-986195', 'Branebrutinib']",['CHEMBL4639484'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB15347'],"['MONDO_0002334', 'EFO_0005809', 'EFO_0000274', 'EFO_0000685']",4.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/BRANEBRUTINIB/relevant/1/'],,,
CHEMBL4297879,,,Protein,False,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,False,True,['Respreeza'],"['.alpha.-1 protease inhibitor', '.alpha.1-antitrypsin', '.alpha.1-proteinase inhibitor human', 'Alfa1 antitrypsin', 'Alpha 1-antitrypsin', 'Alpha-1 protease inhibitor', 'Alpha-1 proteinase inhibitor (human)', 'Alpha-1-antiproteinase', 'Alpha-1-antitrypsin', 'Alpha1-proteinase inhibitor', 'Alpha1-proteinase inhibitor (human)', 'Aralast', 'Atc-b02ab02', 'Glassia', 'Human alpha1-proteinase inhibitor', 'Prolastin', 'Prolastin-c', 'Zemaira']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 10 investigational indications.,,,"['MONDO_0020547', 'MP_0001845', 'EFO_0000342', 'EFO_0000341', 'EFO_0003818', 'EFO_0008583', 'MP_0001914', 'Orphanet_60', 'MONDO_0100096', 'MONDO_0009061', 'MONDO_0013730', 'MONDO_0005147', 'EFO_0000508']",13.0,['ENSG00000197561'],1,2015.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza'],,,,
CHEMBL1159,CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C,IVVNZDGDKPTYHK-UHFFFAOYSA-N,Small molecule,False,PINACIDIL ANHYDROUS,4.0,False,True,[],"['(r,s)-pinacidil', 'P-1134', 'Pinacidil anhydrous', 'S-1230']",['CHEMBL1200338'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for hypertension.,['Pinacidil'],['DB06762'],['EFO_0000537'],1.0,"['ENSG00000187486', 'ENSG00000069431']",2,1989.0,,,"['11532877', '124881033', '26749106', '26752206', '50104869', '56463565', '90341497']",,,,,,
CHEMBL1200335,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,VOCBWIIFXDYGNZ-IXKNJLPQSA-N,Small molecule,True,TESTOSTERONE ENANTHATE,4.0,False,True,"['Delatestryl', 'Primoteston depot', 'Testosterone enanthate', 'Xyosted (autoinjector)']","['Androtardyl', 'NSC-17591', 'Testosterone enantate', 'Testosterone enanthate', 'Testosterone enanthate ciii', 'Testosterone heptanoate', 'Testosteroni enantas', 'Xyosted']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,['DB13944'],"['EFO_0000341', 'HP_0000044', 'EFO_1001078', 'EFO_0000673', 'MONDO_0008315', 'EFO_0000196', 'EFO_0000616', 'MONDO_0002146', 'EFO_0007312', 'HP_0001824', 'Orphanet_269']",11.0,['ENSG00000169083'],1,1953.0,,['testosterone%20enanthate'],,['9464'],,,,,
CHEMBL1200432,CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1.Cl,QSRVZCCJDKYRRF-YDALLXLXSA-N,Small molecule,False,METHYLDOPATE HYDROCHLORIDE,4.0,False,True,"['Aldomet', 'Methyldopate hydrochloride']","['Methyldopa l-form ethyl ester hydrochloride', 'Methyldopate hcl', 'Methyldopate hydrochloride', 'NSC-760088']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962.,,,,,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1962.0,CHEMBL1201233,,"['144204076', '170466856']",,,,,,
CHEMBL1201208,CC1NCCOC1c1ccccc1,OOBHFESNSZDWIU-UHFFFAOYSA-N,Small molecule,False,PHENMETRAZINE,4.0,False,True,[],"['Phenmetrazine', 'Preludin', 'Trans-phenmetrazine']",['CHEMBL1200483'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Phenmetrazine'],['DB00830'],,,"['ENSG00000103546', 'ENSG00000142319']",2,1982.0,,,,['8067'],,,,,
CHEMBL1230165,O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,MUOKSQABCJCOPU-UHFFFAOYSA-N,Small molecule,False,SILMITASERTIB,2.0,False,False,[],"['CX 4945', 'CX-4945', 'CX4945', 'Cx-4945', 'Cx-4945 free acid', 'Silmitasertib']",['CHEMBL5305652'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB15408'],"['EFO_0004193', 'EFO_0002939', 'EFO_0005221', 'MONDO_0100096', 'EFO_0001378']",5.0,['ENSG00000101266'],1,,,,['137276036'],,,,,,
CHEMBL2104262,Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2,VTZPAJGVRWKMAG-UHFFFAOYSA-N,Small molecule,False,FADOLMIDINE,2.0,False,False,[],"['Fadolmidine', 'Radolmidine']",['CHEMBL2106710'],Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,,,,,,,,,,
CHEMBL2109575,,,Antibody drug conjugate,False,BIIB-015,1.0,False,False,[],"['BIIB-015', 'Biib-015']",,Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000241186'],1,,,,,,,,,,
CHEMBL2109591,,,Antibody,False,TOL-101,2.0,False,False,[],"['TOL-101', 'TOL101', 'Tol-101']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003884'],1.0,"['ENSG00000211810', 'ENSG00000277734', 'ENSG00000278030', 'ENSG00000211699']",4,,,,,,,,,,
CHEMBL3545042,CC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C,MCECSFFXUPEPDB-UHFFFAOYSA-N,Small molecule,False,SELURAMPANEL,2.0,False,False,[],"['BGG-492', 'BGG492', 'Bgg492', 'Selurampanel']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,['DB12367'],"['MONDO_0015643', 'HP_0001250', 'HP_0001257', 'MONDO_0005277', 'EFO_0000474', 'HP_0000360', 'MONDO_0005301']",7.0,"['ENSG00000171189', 'ENSG00000105737', 'ENSG00000149403', 'ENSG00000164418', 'ENSG00000163873', 'ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",9,,,,,,,,,,
CHEMBL39541,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,OFDNQWIFNXBECV-VFSYNPLYSA-N,Small molecule,False,DOLASTATIN-10,2.0,False,False,[],"['Dolastatin 10', 'Dolastatin-10', 'Dolostatin 10']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,['DB12730'],"['MONDO_0008315', 'EFO_0002618', 'MONDO_0008170', 'EFO_0000574', 'MONDO_0005411', 'EFO_0000198', 'MONDO_0002367', 'EFO_0000565', 'EFO_0000691']",9.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,['67357'],,,,,
CHEMBL4594614,,,Antibody,False,SIBEPRENLIMAB,2.0,False,False,[],"['Sibeprenlimab', 'VIS-649', 'VIS649', 'Vis-649', 'Vis649']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0004194'],1.0,['ENSG00000161955'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SIBEPRENLIMAB/relevant/1/'],,,
CHEMBL460702,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,VNBRGSXVFBYQNN-UHFFFAOYSA-N,Small molecule,False,BMS-777607,2.0,False,False,[],"['ASLAN-002', 'ASLAN002', 'BMS-777607', 'Bms-777607']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12064'],['EFO_0000616'],1.0,['ENSG00000105976'],1,,,,['137276001'],,,,,,
CHEMBL70418,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,CXOXHMZGEKVPMT-UHFFFAOYSA-N,Small molecule,True,CLOBAZAM,4.0,False,True,"['Frisium', 'Onfi', 'Perizam', 'Sympazan', 'Tapclob', 'Urbanyl']","['Clobazam', 'Colbazam', 'H 4723', 'H-4723', 'HR 376', 'HR-376', 'LM 2717', 'LM-2717', 'Mystan', 'NSC-336279', 'Urbadan']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA.,['Clobazam'],['DB00349'],"['EFO_0003843', 'MONDO_0016532', 'HP_0001250', 'HP_0000726', 'EFO_0000474', 'EFO_0005762', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0005090', 'EFO_1000924', 'HP_0003419']",11.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,2005.0,,['clobazam'],['144206161'],['31413'],,,,,
CHEMBL802,Nc1cc(N2CCCCC2)nc(N)[n+]1[O-],ZFMITUMMTDLWHR-UHFFFAOYSA-N,Small molecule,True,MINOXIDIL,4.0,False,True,"['Loniten', 'Lonolox', ""Men's rogaine"", 'Minodyl', 'Minoxidil', 'Minoxidil (for men)', 'Minoxidil (for women)', 'Minoxidil extra strength (for men)', 'Regaine for men', 'Regaine for women', 'Rogaine (for men)', 'Rogaine (for women)', 'Rogaine extra strength (for men)', 'Theroxidil', ""Women's rogaine""]","['Alopexil', 'Alostil', 'Minoxidil', 'Minoximen', 'Mintop', 'NSC-757106', 'Normoxidil', 'Pierminox', 'Prexidil', 'Tricoxidil', 'U-10,858', 'U-10858']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA.,['Minoxidil'],['DB00350'],"['MONDO_0008170', 'EFO_0004191', 'EFO_0000537', 'MONDO_0004907', 'MONDO_0003037']",5.0,"['ENSG00000187486', 'ENSG00000069431']",2,1979.0,,['minoxidil'],"['104171187', '11111457', '11111458', '11113580', '144203744', '170464704', '26751784', '26751785', '46500395', '50104471', '85231134', '90340717']",['6942'],,,,,
CHEMBL862,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,INJOMKTZOLKMBF-UHFFFAOYSA-N,Small molecule,False,GUANFACINE,4.0,False,True,['Intuniv'],"['Guanfacine', 'NSC-759121', 'Tenex']",['CHEMBL1200494'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for attention deficit hyperactivity disorder and hypertension and has 15 investigational indications.,['Guanfacine'],['DB01018'],"['EFO_0004895', 'MONDO_0004975', 'EFO_0003890', 'EFO_0001358', 'EFO_0002610', 'EFO_0004319', 'EFO_1001219', 'EFO_0003768', 'EFO_0007191', 'EFO_0004329', 'EFO_0003888', 'MONDO_0007079', 'EFO_0000712', 'EFO_0000537', 'EFO_0009267', 'MONDO_0001087', 'EFO_0003888', 'EFO_0000537']",18.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1986.0,,,"['104171166', '11111221', '11111222', '11113866', '124880211', '26752038', '90341397']",['5558'],,,,,
CHEMBL1200791,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl,BEEDODBODQVSIM-UHFFFAOYSA-N,Small molecule,False,OXYMETAZOLINE HYDROCHLORIDE,4.0,False,True,"['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine l.r.']","['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochloride', 'Oxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 approved and 3 investigational indications.,,,"['EFO_0005854', 'HP_0001742', 'MONDO_0000728', 'MONDO_0001330', 'HP_0010783', 'EFO_0007486', 'EFO_0007214', 'EFO_0007141', 'EFO_0003956', 'EFO_1000760']",10.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1986.0,CHEMBL762,['oxymetazoline%20hydrochloride'],"['26747607', '26747608', '50106757', '50106758', '50106759', '856146']",['7863'],,,,,
CHEMBL1201206,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1,OWWLUIWOFHMHOQ-XGHATYIMSA-N,Small molecule,False,PIPECURONIUM,4.0,False,True,[],['Pipecuronium'],['CHEMBL1200722'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990.,,['DB01338'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1990.0,,,,['8230'],,,,,
CHEMBL1266,c1ccc2c(c1)CCCC2C1=NCCN1,BYJAVTDNIXVSPW-UHFFFAOYSA-N,Small molecule,False,TETRAHYDROZOLINE,4.0,False,True,[],"['Caltheon', 'Tetrahydrozoline', 'Tetryzoline', 'Tyzine']",['CHEMBL1200413'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for nasal congestion and eye allergy and has 3 investigational indications.,['Tetrahydrozoline'],['DB06764'],"['HP_0001742', 'EFO_1000906', 'EFO_0000678', 'MP_0001845', 'EFO_0005751']",5.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1979.0,,,['90341828'],['28674'],,,,,
CHEMBL2107355,Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,ZJIHMALTJRDNQI-OLALXQGDSA-N,Small molecule,False,MIGALASTAT HYDROCHLORIDE,4.0,False,True,['Galafold'],"['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hcl', 'Migalastat hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for fabry disease.,,,['MONDO_0010526'],1.0,['ENSG00000102393'],1,2016.0,CHEMBL110458,['migalastat%20hydrochloride'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/galafold'],,,,
CHEMBL2109286,,,Antibody drug conjugate,False,COLTUXIMAB RAVTANSINE,2.0,False,False,[],"['Coltuximab ravtansine', 'SAR-3419', 'SAR3419']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0005952', 'EFO_0000403', 'EFO_0000220']",3.0,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL325041,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,GXJABQQUPOEUTA-RDJZCZTQSA-N,Small molecule,False,BORTEZOMIB,4.0,False,True,"['Bortezomib accord', 'Velcade']","['Bortezomib', 'Bortezomib accord', 'Bortezomib hydrate', 'LDP-341', 'NSC-681239', 'PS-341', 'Velcade']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 4 approved and 101 investigational indications.,['Bortezomib'],['DB00188'],"['EFO_1001961', 'EFO_1000158', 'MONDO_0004192', 'MONDO_0002367', 'MONDO_0003175', 'EFO_0000574', 'EFO_0000519', 'EFO_1001226', 'MONDO_0008170', 'MONDO_0017816', 'EFO_0000588', 'EFO_0000096', 'EFO_0000095', 'MONDO_0044917', 'MONDO_0016537', 'MONDO_0008627', 'EFO_0000183', 'EFO_0001378', 'EFO_0003060', 'EFO_0000094', 'EFO_0006859', 'EFO_0005952', 'EFO_0009441', 'EFO_0000339', 'EFO_0000220', 'EFO_0000182', 'MONDO_0018922', 'EFO_0003811', 'EFO_0000681', 'EFO_0000616', 'EFO_0004599', 'MONDO_0020547', 'EFO_0000571', 'MONDO_0019460', 'EFO_0005543', 'EFO_0001642', 'EFO_0003884', 'MONDO_0019471', 'MONDO_0001705', 'EFO_1001365', 'EFO_0007183', 'EFO_1001968', 'EFO_0000209', 'EFO_0000198', 'MONDO_0002974', 'EFO_1001052', 'MONDO_0007254', 'EFO_0000224', 'MONDO_0015277', 'MONDO_0007576', 'EFO_1001875', 'EFO_0000309', 'MONDO_0001056', 'EFO_0000641', 'EFO_0000501', 'MONDO_0019438', 'EFO_0000621', 'EFO_0002618', 'MONDO_0004992', 'EFO_0003032', 'MONDO_0004986', 'EFO_0000222', 'MONDO_0044881', 'EFO_0000191', 'EFO_0004252', 'EFO_1001051', 'MONDO_0009348', 'MONDO_0001187', 'EFO_1000785', 'EFO_0007160', 'EFO_0000305', 'EFO_0007332', 'EFO_0000255', 'EFO_0000403', 'EFO_0003073', 'EFO_0004289', 'EFO_0000231', 'EFO_0001663', 'MONDO_0008315', 'EFO_0006475', 'EFO_0000211', 'EFO_0002428', 'EFO_0004256', 'EFO_1001469', 'MONDO_0018906', 'EFO_0000565', 'EFO_0002501', 'EFO_0000540', 'EFO_1001465', 'EFO_0000756', 'MONDO_0002158', 'MONDO_0002087', 'EFO_0000707', 'EFO_0000691', 'MONDO_0015564', 'EFO_0006738', 'MONDO_0013730', 'MONDO_0016145', 'MONDO_0008903', 'EFO_0002499', 'EFO_0000673', 'EFO_1001951', 'MONDO_0000873', 'MONDO_0005184', 'EFO_0000308']",105.0,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']",38,2003.0,,['bortezomib'],"['124950705', '144206183', '144206225', '170465087', '518755']",['52717'],,,,,
CHEMBL3301582,,,Antibody drug conjugate,False,POLATUZUMAB VEDOTIN,4.0,False,True,['Polivy'],"['ACD-79B-VCMMAE', 'ACD-79BVCMMAE', 'ACD79B-VCMMAE', 'Anti-cd79b adc', 'DCDS-4501A', 'DCDS4501A', 'FCU-2711', 'FCU2711', 'Polatuzumab vedotin', 'Polatuzumab vedotin piiq', 'RG-7596', 'RG7596', 'RO-5541077-000', 'RO-5541077000', 'RO5541077-000']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 6 investigational indications.,,,"['MONDO_0018906', 'EFO_0000574', 'EFO_0000096', 'EFO_1001469', 'EFO_0005952', 'EFO_0000403', 'EFO_0000095', 'MONDO_0004095', 'EFO_0000616']",9.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000007312']",16,2019.0,,['polatuzumab%20vedotin-piiq'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/polivy'],,,,
CHEMBL3544911,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1,DOTGPNHGTYJDEP-UHFFFAOYSA-N,Small molecule,False,PREXASERTIB,2.0,False,False,[],"['LY-2606368', 'LY2606368', 'Ly-2606368', 'Prexasertib']",['CHEMBL5305850'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications.,,['DB12008'],"['EFO_0000616', 'MONDO_0001657', 'EFO_0009708', 'EFO_1001779', 'MONDO_0004992', 'EFO_0000198', 'EFO_0000222', 'EFO_0004284', 'EFO_1000158', 'MONDO_0008170', 'EFO_0004142', 'EFO_0000702', 'EFO_0000708', 'EFO_0002939', 'MONDO_0007254', 'EFO_0003060']",16.0,"['ENSG00000149554', 'ENSG00000183765']",2,,,,,,,,,,
CHEMBL3545080,,,Small molecule,False,RG-7256,1.0,False,False,[],"['PLX-3603', 'Rg-7256', 'Ro-5212054']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000157764'],1,,,,,,,,,,
CHEMBL3989408,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+],VTGPMVCGAVZLQI-UHFFFAOYSA-M,Small molecule,False,IBUPROFEN SODIUM,4.0,False,True,"['Advil', 'Ibuprofen sodium']","['Ibuprofen sodium', 'Ibuprofen sodium dihydrate', 'Sodium ibuprofen dihydrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2012 and has 1 investigational indication.,,,['EFO_0003843'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,2012.0,CHEMBL521,['ibuprofen%20sodium'],,,,,,,
CHEMBL3989927,O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,IXZOHGPZAQLIBH-NRFANRHFSA-N,Small molecule,False,IBERDOMIDE,3.0,False,False,[],"['CC-220', 'Iberdomide']",['CHEMBL3989912'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,['DB12101'],"['EFO_0001378', 'EFO_0003073', 'EFO_0000574', 'MONDO_0018906', 'MONDO_0019338', 'HP_0000083', 'EFO_0005952', 'EFO_0000403', 'EFO_0001378', 'MONDO_0007915', 'EFO_0001421']",11.0,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']",4,,,,,,,,,,
CHEMBL3989937,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.O,COWBUPJEEDYWKD-UHFFFAOYSA-N,Small molecule,False,CAPMATINIB HYDROCHLORIDE,4.0,False,True,['Tabrecta'],"['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrate', 'NVP-INC280-AAA']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for non-small cell lung carcinoma.,,,['EFO_0003060'],1.0,['ENSG00000105976'],1,2020.0,CHEMBL3188267,['capmatinib%20hydrochloride'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta'],,,,
CHEMBL4297458,Cc1nnn(C)c1-c1cnc2c3ccc(C(C)(C)O)cc3n([C@H](c3ccccc3)C3CCOCC3)c2c1,KGERZPVQIRYWRK-GDLZYMKVSA-N,Small molecule,False,EZOBRESIB,1.0,False,False,[],"['BMS-986158', 'Bet inhibitor bms-986158', 'Bms-986158', 'Ezobresib']",['CHEMBL5185824'],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,['DB15435'],"['EFO_0000574', 'EFO_0000616', 'EFO_0001378', 'MONDO_0044903']",4.0,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/EZOBRESIB/relevant/1/'],,,
CHEMBL460291,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C,GKQPCPXONLDCMU-CCEZHUSRSA-N,Small molecule,False,LACIDIPINE,4.0,False,True,"['Caldine', 'Molap', 'Motens']","[""3,3'-iminobispropylamine"", ""3,3'-iminodipropylamine"", '4-azaheptamethylenediamine', ""Dipropylamine, 3,3'-diamino-"", 'Dipropylenetriamine', 'GR 43659X', 'GR-43659X', 'Lacidipine', 'NSC-7773']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications.,,['DB09236'],"['EFO_0000319', 'EFO_0003913', 'EFO_0000537']",3.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,"['144205727', '170465580']",,,,,,
CHEMBL1079593,O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1[C@@H]1CCOc2c(F)cccc21,DBXGGXLBTWZXBB-MRXNPFEDSA-N,Small molecule,False,VS-5584,1.0,False,False,[],"['VS-5584', 'Vs 5584', 'Vs-5584']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0000588', 'EFO_0000574']",2.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000198793']",9,,,,,,,,,,
CHEMBL124660,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,UXXQOJXBIDBUAC-UHFFFAOYSA-N,Small molecule,False,TANDUTINIB,2.0,False,False,[],"['CT 53518', 'CT-53518', 'CT53518', 'MLN-518', 'Mln-0518', 'NSC-759851', 'Tandutinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB05465'],"['EFO_1001465', 'EFO_0002501', 'EFO_0002499', 'EFO_0000222', 'EFO_0000630', 'EFO_0000349', 'EFO_0000198', 'EFO_0000519']",8.0,"['ENSG00000113721', 'ENSG00000157404', 'ENSG00000122025']",3,,,,"['103905342', '124950156', '144206917', '170466826', '50100108']",['90237'],,,,,
CHEMBL1463345,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]21CCC(=O)O1,UJVLDDZCTMKXJK-WNHSNXHDSA-N,Small molecule,False,CANRENONE,4.0,True,True,[],"['Canrenone', 'NSC-261713', 'SC-9376', 'Spironolactone metabolite m1', 'Spironolactone related compound a']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region.,,['DB12221'],['EFO_0000319'],1.0,['ENSG00000151623'],1,,,,"['144205004', '170466206', '49646110']",,,,,,
CHEMBL1480,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,RZTAMFZIAATZDJ-UHFFFAOYSA-N,Small molecule,False,FELODIPINE,4.0,False,True,"['Cabren', 'Cardioplen xl', 'Felodipine', 'Felogen xl', 'Felotens xl', 'Folpik xl', 'Keloc sr', 'Neofel xl', 'Parmid xl', 'Pinefeld xl', 'Plendil', 'Preslow', 'Vascalpha']","['C08CA02', 'Felodipine', 'H 154/82', 'H-154/82', 'NSC-760343']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 4 investigational indications.,['Felodipine'],['DB01023'],"['EFO_0003914', 'EFO_0000400', 'EFO_0000537', 'EFO_0000319', 'MONDO_0005148', 'EFO_0001645', 'HP_0003124']",7.0,"['ENSG00000151623', 'ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",5,1991.0,,['felodipine'],"['124880165', '144203706', '170464849', '17405071', '50106289', '50106290', '85231057', '90340828']",['585948'],,,,,
CHEMBL154,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,CMWTZPSULFXXJA-VIFPVBQESA-N,Small molecule,True,NAPROXEN,4.0,False,True,"['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500', 'Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultra', 'Grenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375', 'Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'Prosaid', 'Rheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'Timpron', 'Timpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']","['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'Naproxen', 'PN400 COMPONENT NAPROXEN', 'RS-3540']",['CHEMBL1200806'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 25 approved and 22 investigational indications. This drug has a black box warning from the FDA.,['Naproxen'],['DB00788'],"['HP_0003418', 'MONDO_0005277', 'EFO_0005856', 'EFO_0010072', 'EFO_0004616', 'MONDO_0007254', 'EFO_0002609', 'MONDO_0002471', 'HP_0003418', 'MONDO_0005178', 'MONDO_0005178', 'MONDO_0005301', 'EFO_0009637', 'EFO_1000786', 'MONDO_0004975', 'EFO_0009454', 'EFO_0007214', 'EFO_0000673', 'EFO_0005755', 'MONDO_0002471', 'EFO_0004607', 'MONDO_0005835', 'HP_0002315', 'MONDO_0005277', 'EFO_1001434', 'MONDO_0003937', 'MP_0001845', 'EFO_0000685', 'MONDO_0004857', 'MONDO_0010870', 'HP_0003326', 'EFO_0004616', 'MONDO_0100096', 'EFO_0003898', 'HP_0003419', 'MONDO_0002258', 'EFO_0000685', 'EFO_0004274', 'EFO_0003843', 'EFO_0003898', 'EFO_0002609', 'MONDO_0004975', 'EFO_0000546', 'HP_0002315', 'EFO_0005757', 'HP_0002829', 'EFO_1000941', 'HP_0100607', 'EFO_0009454', 'EFO_0004274', 'HP_0001945', 'EFO_0005762', 'EFO_0003843', 'EFO_0010072', 'HP_0100607', 'MONDO_0003937', 'HP_0004398', 'EFO_0009846']",58.0,"['ENSG00000073756', 'ENSG00000095303']",2,1976.0,,['naproxen'],"['11112669', '144212270', '26755231', '90341518']",['7476'],,,['73'],,
CHEMBL3039504,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,MMMVNAGRWOJNMW-FJBFXRHMSA-N,Small molecule,False,NINTEDANIB ESYLATE,4.0,False,True,['Ofev'],"['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for idiopathic pulmonary fibrosis and systemic scleroderma.,,,"['EFO_0000768', 'EFO_0000717']",2.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",9,2014.0,CHEMBL502835,['nintedanib%20esylate'],,['85170'],['https://www.ema.europa.eu/en/medicines/human/EPAR/ofev'],,,,
CHEMBL3545337,CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23.Cl.Cl.O,XJYNBZQTAZDMHZ-UHFFFAOYSA-N,Small molecule,False,C-1311,2.0,False,False,['Symadex'],"['C 1311', 'C-1311', 'NSC-645809', 'Xls-002']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000122025', 'ENSG00000131747', 'ENSG00000077097']",3,,CHEMBL338604,,,,,,,,
CHEMBL43064,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,DERZBLKQOCDDDZ-JLHYYAGUSA-N,Small molecule,False,CINNARIZINE,4.0,False,True,"['Marzine r.f.', 'Mylan travel sickness', 'Stugeron', 'Stugeron fte']","['516 MD', '516-MD', 'Aplactan', 'Aplexal', 'Artate', 'Carecin', 'Cerebolan', 'Cerepar', 'Cinaperazine', 'Cinarizine', 'Cinazyn', 'Cinnacet', 'Cinnageron', 'Cinnarizine', 'Cinnipirine', 'Corathiem', 'Denapol', 'Dimitron', 'Eglen', 'Folcodal', 'Giganten', 'Glanil', 'Hilactan', 'Ixertol', 'Katoseran', 'Labyrin', 'Midronal', 'Mitronal', 'NSC-758400', 'Olamin', 'Processine', 'R 1575', 'R 516', 'R-1575', 'R-516', 'Sedatromin', 'Sepan', 'Siptazin', 'Spaderizine', 'Stugeron', 'Stunarone', 'Stutgeron', 'Stutgin']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for vertigo.,['Cinnarizine'],,['HP_0002321'],1.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001', 'ENSG00000196639']",5,,,,"['144203660', '170465920', '50103929', '56422441', '85231348', '855570', '90340734']",['31403'],,,,,
CHEMBL1201222,C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,VOBHXZCDAVEXEY-JSGCOSHPSA-N,Small molecule,True,LISDEXAMFETAMINE,4.0,False,True,[],"['L-lysine-dextroamphetamine', 'Lisdexamfetamine', 'Lisdexamphetamine']",['CHEMBL1201178'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 11 investigational indications. This drug has a black box warning from the FDA.,['Lisdexamfetamine'],['DB01255'],"['EFO_0004701', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0005924', 'EFO_0003888', 'EFO_0002610', 'MONDO_0005301', 'MONDO_0004985', 'EFO_0001073', 'MONDO_0002009', 'MONDO_0002277', 'EFO_0005203', 'EFO_0003890', 'EFO_0005203', 'EFO_0004698', 'EFO_0005204', 'MONDO_0005041', 'EFO_0003888']",18.0,"['ENSG00000165646', 'ENSG00000103546', 'ENSG00000142319']",3,2007.0,,,,,,,,,
CHEMBL135400,CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,GBBSUAFBMRNDJC-UHFFFAOYSA-N,Small molecule,False,ZOPICLONE,4.0,False,True,"['Zileze 3.75', 'Zileze 7.5', 'Zimovane', 'Zimovane ls']","['Amoban', 'Imovane', 'NSC-758463', 'RP 27267', 'RP-27267', 'Zopiclone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 9 investigational indications.,['Zopiclone'],['DB01198'],"['EFO_0005230', 'HP_0000726', 'EFO_0003918', 'EFO_0008568', 'MONDO_0002009', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0004698', 'EFO_0004329']",9.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000011677', 'ENSG00000163288', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",9,,,,"['124881861', '26747152', '866104']",['32315'],,,,,
CHEMBL2107313,CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,JSKFWUPVIZYJMR-UDOAKELVSA-N,Small molecule,False,BECATECARIN,3.0,False,False,[],"['BMS-181176', 'BMY-27557', 'Becatecarin', 'Deae-rebeccamycin', 'NSC-655649', 'XL-119', 'XL119 ']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,['DB06362'],"['MONDO_0002367', 'EFO_0000574', 'EFO_0006861', 'MONDO_0008170', 'EFO_1001951', 'MONDO_0003060', 'MONDO_0008903', 'EFO_0000616', 'EFO_0000702', 'EFO_0000621']",10.0,"['ENSG00000198900', 'ENSG00000131747', 'ENSG00000077097']",3,,,,,,,,,,
CHEMBL2108747,,,Antibody,False,TORALIZUMAB,2.0,False,False,[],"['ANTI-CD154', 'ANTI-CD40L', 'ANTI-GP39', 'E-6040', 'IDEC-131', 'Toralizumab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000102245'],1,,,,,,,,,,
CHEMBL3545208,,,Small molecule,False,AZD3161,1.0,False,False,[],['Azd3161'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0005762'],1.0,['ENSG00000169432'],1,,,,,,,,,,
CHEMBL371064,CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1,LLCRBOWRJOUJAE-UHFFFAOYSA-N,Small molecule,False,BALICATIB,2.0,False,False,[],"['AAE-581', 'AAE581', 'Balicatib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12239'],"['EFO_0003882', 'EFO_0004616']",2.0,['ENSG00000143387'],1,,,,,,,,,,
CHEMBL3989921,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C.O=C(O)/C=C\C(=O)O,VXZCUHNJXSIJIM-MEBGWEOYSA-N,Small molecule,False,NERATINIB MALEATE,4.0,False,True,['Nerlynx'],"['Neratinib maleate', 'Neratinib maleate anhydrous']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for breast cancer and breast carcinoma and has 1 investigational indication.,,,"['MONDO_0007254', 'EFO_0000616', 'EFO_0000305']",3.0,"['ENSG00000141736', 'ENSG00000178568', 'ENSG00000146648']",3,2017.0,CHEMBL180022,['neratinib%20maleate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx'],,,,
CHEMBL4297404,COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,ORZMUVMQJPGFOM-UHFFFAOYSA-N,Small molecule,False,MK-0767,3.0,False,False,[],"['MK 0767', 'Mk-0767', 'Mk0767']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB12055'],"['MONDO_0005148', 'EFO_0000400', 'EFO_0000195']",3.0,"['ENSG00000132170', 'ENSG00000186951']",2,,,,,,,,,,
CHEMBL4650343,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1,DADAEARVGOQWHV-OSYLJGHBSA-N,Small molecule,False,IZENCITINIB,2.0,False,False,[],"['Izencitinib', 'TD-1473', 'TD1473', 'Td-1473']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000729', 'EFO_0003767', 'EFO_0000384']",3.0,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/IZENCITINIB/relevant/1/'],,,
CHEMBL5315071,,,Protein,False,TUROCTOCOG ALFA PEGOL,4.0,False,True,['Esperoct'],['N8-gp'],,Protein drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hemophilia a.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,2019.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct'],,,,
CHEMBL703,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,AXOIZCJOOAYSMI-UHFFFAOYSA-N,Small molecule,True,SUXAMETHONIUM,4.0,False,True,[],"['Anectine', 'Quelicin', 'Succinylcholine', 'Succinylcholine cation', 'Succinylcholine ion', 'Sucostrin', 'Suxamethonium', 'Suxamethonium cation', 'Suxamethonium ion']","['CHEMBL2104486', 'CHEMBL3391771', 'CHEMBL983']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 3 investigational indications. This drug has a black box warning from the FDA.,,['DB00202'],"['EFO_0000712', 'HP_0001662', 'HP_0003326']",3.0,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1952.0,,,"['11111825', '90341285']",['45652'],,,,,
CHEMBL1131,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,IHUNBGSDBOWDMA-AQFIFDHZSA-N,Small molecule,True,ACITRETIN,4.0,False,True,"['Acitretin', 'Neotigason', 'Soriatane']","['Acitretin', 'Etretin', 'RO 10-1670', 'RO 10-1670/000', 'RO-101670000']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for psoriasis vulgaris and psoriasis and has 4 investigational indications. This drug has a black box warning from the FDA.,['Acitretin'],['DB00459'],"['EFO_1001494', 'EFO_0000676', 'MONDO_0002406', 'EFO_0000764', 'EFO_0000756', 'MONDO_0004975']",6.0,"['ENSG00000204231', 'ENSG00000172819', 'ENSG00000143171', 'ENSG00000077092', 'ENSG00000131759', 'ENSG00000186350']",6,1996.0,,['acitretin'],"['144205565', '26756475', '29216416', '49640651']",['50173'],,,,,
CHEMBL2028663,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,BFSMGDJOXZAERB-UHFFFAOYSA-N,Small molecule,False,DABRAFENIB,4.0,False,True,['Tafinlar'],"['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']",['CHEMBL2105729'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 7 approved and 19 investigational indications.,,['DB08912'],"['EFO_1000926', 'EFO_0002892', 'EFO_0003833', 'EFO_0003086', 'EFO_0002892', 'MONDO_0002108', 'EFO_0003060', 'MONDO_0008903', 'MONDO_0002108', 'EFO_0002617', 'EFO_0002617', 'EFO_1000926', 'EFO_0000389', 'MONDO_0100342', 'EFO_0000501', 'EFO_0000756', 'EFO_0000641', 'MONDO_0017795', 'EFO_0000616', 'EFO_0001378', 'MONDO_0004992', 'EFO_0001421', 'EFO_0001378', 'EFO_0006772', 'EFO_0000756', 'EFO_0000389', 'EFO_1000209']",27.0,['ENSG00000157764'],1,2013.0,,,,['75045'],,,,,
CHEMBL2103772,CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1,ODUOJXZPIYUATO-UHFFFAOYSA-N,Small molecule,False,RACECADOTRIL,4.0,False,True,['Hidrasec'],"['Acetorphan', 'NSC-759828', 'Racecadotril', 'Tiorfan', 'Tiorfix']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,['DB11696'],"['HP_0002014', 'EFO_1001306']",2.0,['ENSG00000196549'],1,,,,['174006909'],,,,,,
CHEMBL2108585,,,Gene,False,CONTUSUGENE LADENOVEC,2.0,False,False,[],"['AD5CMV-P53', 'Contusugene ladenovec', 'INGN 201', 'INGN-201']",,Gene drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,,"['EFO_1000158', 'MONDO_0002691', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0007254', 'EFO_0006859', 'MONDO_0004986', 'MONDO_0008170', 'EFO_0003060']",9.0,['ENSG00000141510'],1,,,,,,,,,,
CHEMBL2109263,,,Antibody,False,ING-1,2.0,False,False,[],"['HEMAB', 'ING-1', 'Ing-1']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000228'],1.0,['ENSG00000119888'],1,,,,,,,,,,
CHEMBL2109600,,,Antibody,False,RO-5458640,1.0,False,False,[],"['RG-7212', 'RO-5458640', 'Ro-5458640']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000239697'],1,,,,,,,,,,
CHEMBL3989821,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-],WMIZITXEJNQAQK-GGDSLZADSA-N,Small molecule,False,TUBOCURARINE CHLORIDE,4.0,False,True,"['Jexin', 'Tubarine', 'Tubocurarine chloride']","['Curare', 'NSC-757362', 'Tubaine', 'Tubarine pentahydrate', 'Tubocurarine chloride', 'Tubocurarine chloride anhydrous', 'Tubocurarine chloride, anhydrous', 'Tubocurarini chloridum']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1945.,,,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1945.0,CHEMBL339427,,,,,,,,
CHEMBL3990145,COCCCCn1c(C(=O)N(CC(C)C)[C@@H]2CNC[C@H](C(=O)N3CCOCC3)C2)nc2ccccc21,RHIBAIKQWJNESW-YADHBBJMSA-N,Small molecule,False,IMARIKIREN,2.0,False,False,[],['Imarikiren'],['CHEMBL3969876'],Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000143839'],1,,,,,,,,,,
CHEMBL4297163,,,Oligosaccharide,False,MUPARFOSTAT,3.0,False,False,[],"['Muparfostat', 'PI-88']",['CHEMBL4297162'],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['EFO_0003060', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000756', 'EFO_0000182', 'MONDO_0008315']",6.0,"['ENSG00000112715', 'ENSG00000173083', 'ENSG00000113578', 'ENSG00000138685']",4,,,,,,,,,,
CHEMBL4297185,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,BLIJXOOIHRSQRB-PXYINDEMSA-N,Small molecule,False,DAROLUTAMIDE,4.0,False,True,['Nubeqa'],"['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201', 'Odm-201']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 7 approved and 3 investigational indications.,,['DB12941'],"['EFO_0000616', 'EFO_0001663', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000196', 'MONDO_0004992', 'EFO_0000673', 'MONDO_0021259', 'MONDO_0004669', 'MONDO_0000521']",10.0,['ENSG00000169083'],1,2019.0,,['darolutamide'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa'],,,,
CHEMBL4297440,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O,FSXLOWIFSZNIMV-UHFFFAOYSA-N,Small molecule,False,T-900607,2.0,False,False,[],"['T 900607', 'T-900607', 'T900607']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB12068'],"['EFO_0003893', 'EFO_0005952', 'EFO_0000182', 'MONDO_0001056', 'MONDO_0002691']",5.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL5314383,C[C@@H]1CN(C(=O)CN2CC(C)(C)OC[C@H]2C(=O)Nc2cc(Cl)cc3c2[nH]c2cnccc23)C[C@H](C)O1,BQBAVNBXWBYXIF-DMPWYTOCSA-N,Small molecule,False,MLN-0415,1.0,False,False,[],['Mln-0415'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000104365'],1,,,,,,,,,,
CHEMBL681,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,NPUKDXXFDDZOKR-LLVKDONJSA-N,Small molecule,False,ETOMIDATE,4.0,False,True,"['Amidate', 'Etomidate']","['Etomidate', 'Hypnomidate', 'NSC-759160']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications.,,['DB00292'],"['EFO_0000537', 'EFO_0000712', 'EFO_0009686']",3.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,['etomidate'],['11114097'],['4910'],,,,,
CHEMBL1200585,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,ICMWWNHDUZJFDW-DHODBPELSA-N,Small molecule,True,OXYMETHOLONE,4.0,False,True,"['Anadrol-50', 'Anapolon 50']","['Anadrol', 'Anapolon', 'Anasteron', 'CI-406', 'HMD', 'NSC-26,198', 'NSC-26198', 'Oximetholone', 'Oxymetholone', 'Oxymetholone ciii', 'Pardroyd']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972. This drug has a black box warning from the FDA.,['Oxymetholone'],['DB06412'],,,['ENSG00000169083'],1,1972.0,,,"['144204682', '144207269', '170465403', '17388810']",,,,,,
CHEMBL1201242,CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21,UCEWGESNIULAGX-UHFFFAOYSA-N,Small molecule,False,INDECAINIDE,4.0,False,True,[],['Indecainide'],['CHEMBL1200341'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989.,['Indecainide'],['DB00192'],,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1989.0,,,['170465192'],,,,,,
CHEMBL1276138,O=C(c1ccc2nonc2c1)N1CCCCC1,XFVRBYKKGGDPAJ-UHFFFAOYSA-N,Small molecule,False,FARAMPATOR,2.0,False,False,[],"['CX 691', 'CX-691', 'CX691', 'Farampator', 'ORG 24448', 'ORG-24448', 'SCH-900460']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB15012'],"['MONDO_0002009', 'MONDO_0002050', 'MONDO_0005090']",3.0,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,,,,
CHEMBL258940,CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,FTFRZXFNZVCRSK-UHFFFAOYSA-N,Small molecule,False,FALNIDAMOL,2.0,False,False,[],"['BIBX 1382', 'BIBX-1382', 'Bibx 1382', 'Bibx-1382', 'Bibx1382', 'Falnidamol']",['CHEMBL2136050'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12966'],['EFO_0000616'],1.0,['ENSG00000146648'],1,,,,"['124892343', '26755049']",,,,,,
CHEMBL3545209,,,Small molecule,False,NKTR-171,1.0,False,False,[],['Nktr-171'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,,,,,,,,,,
CHEMBL3545263,,,Small molecule,False,LGX-806,1.0,False,False,[],"['Lgx-806', 'NVP-LGX806']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000157764', 'ENSG00000132155']",2,,,,,,,,,,
CHEMBL3622533,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,JOWXJLIFIIOYMS-UHFFFAOYSA-N,Small molecule,False,FIMEPINOSTAT,2.0,False,False,[],"['CUDC-907', 'CUDC907', 'Cudc 907', 'Cudc-907', 'Fimepinostat']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB11891'],"['MONDO_0002108', 'EFO_0000574']",2.0,"['ENSG00000051382', 'ENSG00000171608', 'ENSG00000121879', 'ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",14,,,,,,,,,,
CHEMBL460785,Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,ZJIHMALTJRDNQI-VFQQELCFSA-N,Small molecule,False,DUVOGLUSTAT HYDROCHLORIDE,2.0,False,False,[],"['1 deoxynojirimycin hydrochloride', '1-deoxynojirimycin hydrochloride', 'AT-2220', 'AT2220', 'Duvoglustat hcl', 'Duvoglustat hydrochloride', 'Moranoline hydrochloride']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['Orphanet_365'],1.0,['ENSG00000171298'],1,,CHEMBL307429,,,,,,,,
CHEMBL553,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,AAKJLRGGTJKAMG-UHFFFAOYSA-N,Small molecule,False,ERLOTINIB,4.0,False,True,['Tarceva'],"['CP-358,774', 'CP-358774', 'CP-35877401', 'Erlotinib', 'OSI-774', 'R-1415', 'RG-1415', 'Ro-508231']","['CHEMBL5220042', 'CHEMBL1079742']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 105 investigational indications.,['Erlotinib'],['DB00530'],"['EFO_0005537', 'EFO_0000632', 'EFO_0002501', 'MONDO_0007576', 'MONDO_0002974', 'MONDO_0004992', 'EFO_0001422', 'EFO_0000616', 'MONDO_0044881', 'EFO_0002429', 'EFO_0000588', 'MONDO_0021117', 'EFO_0000514', 'EFO_0000519', 'EFO_0000305', 'MONDO_0000521', 'EFO_0000681', 'MONDO_0008903', 'EFO_0000182', 'EFO_0004252', 'EFO_0000198', 'EFO_0006859', 'MONDO_0008315', 'MONDO_0002898', 'EFO_0000222', 'EFO_1000657', 'EFO_0003050', 'EFO_0000308', 'EFO_0003868', 'EFO_0000676', 'EFO_0003893', 'EFO_1001951', 'MONDO_0008170', 'MONDO_0018531', 'MONDO_0008903', 'MONDO_0016693', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0016691', 'EFO_0000708', 'EFO_0003060', 'MONDO_0002158', 'MONDO_0003060', 'EFO_0002618', 'MONDO_0002158', 'EFO_0002501', 'EFO_0005577', 'EFO_1000581', 'MONDO_0002898', 'EFO_0000313', 'MONDO_0003060', 'EFO_0003860', 'EFO_1000026', 'EFO_1000158', 'EFO_0000571', 'EFO_1001465', 'MONDO_0021063', 'MONDO_0003478', 'EFO_0000756', 'EFO_0003833', 'MONDO_0007254', 'EFO_0002499', 'EFO_0009708', 'EFO_0000588', 'EFO_0000571', 'MONDO_0021063', 'EFO_0000365', 'MONDO_0007254', 'Orphanet_733', 'EFO_0000691', 'EFO_0001378', 'EFO_0002916', 'EFO_0000519', 'EFO_0000182', 'EFO_0005221', 'EFO_1001901', 'MONDO_0001187', 'EFO_0000707', 'EFO_1000657', 'EFO_1000028', 'MONDO_0004986', 'MONDO_0011962', 'EFO_1001951', 'MONDO_0020634', 'EFO_0010282', 'MONDO_0005411', 'MONDO_0003268', 'EFO_0002618', 'EFO_0000565', 'EFO_0006859', 'EFO_0004220', 'MONDO_0002367', 'EFO_0005567', 'EFO_0000181', 'EFO_1001465', 'EFO_0000616', 'MONDO_0002367', 'EFO_1000359', 'MONDO_0003268', 'EFO_0007243', 'MONDO_0001657', 'MONDO_0002691', 'EFO_0002499', 'MONDO_0044926', 'EFO_0000756', 'EFO_1000158', 'EFO_0000181', 'Orphanet_733', 'EFO_0003060', 'EFO_0000681', 'EFO_0003050', 'MONDO_0008315', 'MONDO_0008170', 'MONDO_0001187', 'EFO_0000349', 'MONDO_0004992', 'EFO_0000308', 'EFO_0000640', 'MONDO_0007576']",119.0,['ENSG00000146648'],1,2004.0,,,"['103905339', '124893165', '124893166', '144205755', '170465434', '26757996', '50100099', '85267493']",['114785'],,,,,
CHEMBL586702,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,HGVNLRPZOWWDKD-UHFFFAOYSA-N,Small molecule,False,ZSTK-474,2.0,False,False,[],"['TCMDC-137004', 'Zstk-474', 'Zstk474']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12904'],['EFO_0000616'],1.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,['90545'],,,,,
CHEMBL940,NCC1(CC(=O)O)CCCCC1,UGJMXCAKCUNAIE-UHFFFAOYSA-N,Small molecule,False,GABAPENTIN,4.0,False,True,"['Gabapentin', 'Gralise', 'Neurontin']","['CI-945', 'DM-1796', 'GOE 3450', 'GOE-3450', 'Gabapentin', 'NSC-742194', 'NSC-759254']",['CHEMBL542620'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 61 investigational indications.,['Gabapentin'],['DB00996'],"['EFO_0005687', 'EFO_1002028', 'HP_0000989', 'EFO_0000512', 'MONDO_0041052', 'MONDO_0011382', 'HP_0003419', 'EFO_0005611', 'HP_0002013', 'EFO_0003756', 'EFO_0007191', 'EFO_0003917', 'EFO_0001422', 'HP_0008419', 'EFO_0005230', 'EFO_1001931', 'MONDO_0002050', 'EFO_0004777', 'EFO_0008507', 'EFO_0005762', 'EFO_0000546', 'HP_0012532', 'HP_0001250', 'EFO_0005323', 'EFO_0003890', 'EFO_0004710', 'MONDO_0007079', 'EFO_0003843', 'EFO_0009267', 'HP_0031217', 'HP_0001337', 'MONDO_0007254', 'EFO_0000764', 'EFO_1001800', 'EFO_0004329', 'EFO_0006859', 'MONDO_0043510', 'EFO_0006510', 'EFO_0003768', 'EFO_0004698', 'EFO_0004143', 'MONDO_0004986', 'EFO_0004263', 'EFO_1001250', 'HP_0000726', 'HP_0000360', 'EFO_1000783', 'EFO_0000474', 'EFO_0009430', 'EFO_0005407', 'EFO_0004888', 'MONDO_0004992', 'EFO_0008568', 'EFO_1001255', 'MONDO_0005090', 'MONDO_0005301', 'EFO_1000971', 'MONDO_0008315', 'MONDO_0002038', 'EFO_0000279', 'EFO_0008533', 'EFO_0004270', 'EFO_0003818', 'EFO_0004273', 'EFO_1001898', 'EFO_0000519']",66.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,1993.0,,['gabapentin'],"['104171164', '11112806', '11113327', '124880194', '144203708', '170464715', '50103936', '855579', '90340599']",['42797'],,,,,
CHEMBL979,CCCC(C)(COC(N)=O)COC(N)=O,NPPQSCRMBWNHMW-UHFFFAOYSA-N,Small molecule,False,MEPROBAMATE,4.0,True,True,"['Amosene', 'Bamate', 'Equanil', 'Mepriam', 'Meprobamate', 'Meprospan', 'Miltown', 'Neuramate', 'Tenavoid', 'Tranmep']","['Meprobamate', 'Meprobamate civ', 'NSC-30418']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for anxiety disorder and anxiety. It was withdrawn in at least one region.,['Meprobamate'],['DB00371'],"['EFO_0006788', 'EFO_0005230']",2.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1955.0,,['meprobamate'],"['144204614', '144207530', '17389535']",,,,,,
CHEMBL1200798,Cl.O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,OHHDIOKRWWOXMT-UHFFFAOYSA-N,Small molecule,True,TRAZODONE HYDROCHLORIDE,4.0,False,True,"['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochloride', 'Trialodine']","['AF-1161', 'NSC-292811', 'Trazodone hcl', 'Trazodone hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['MONDO_0004976', 'MONDO_0002050', 'MONDO_0002009', 'EFO_0003761']",4.0,"['ENSG00000102468', 'ENSG00000147246', 'ENSG00000108576']",3,1981.0,CHEMBL621,['trazodone%20hydrochloride'],"['124891691', '144203837', '144213002', '170465234', '26747679', '50107085', '56423658', '855917']",['9655'],,,,,
CHEMBL1201832,,,Protein,False,ROMIPLOSTIM,4.0,False,True,['Nplate'],"['AMG 531', 'Romiplate', 'Romiplostim']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 12 investigational indications.,['Romiplostim'],,"['MONDO_0010518', 'MONDO_0018896', 'EFO_0000198', 'HP_0001873', 'MP_0001914', 'MONDO_0008170', 'EFO_0000519', 'EFO_0000313', 'HP_0001915', 'MONDO_0004992', 'EFO_0006927', 'EFO_0000574', 'EFO_0007160', 'MONDO_0043768', 'EFO_0005952']",15.0,['ENSG00000117400'],1,2008.0,,['romiplostim'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/nplate'],,,['4996'],
CHEMBL1237123,COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC,GBLRQXKSCRCLBZ-UHFFFAOYSA-N,Small molecule,False,DOXACURIUM,4.0,False,True,[],"['Doxacurium cation', 'Doxacurium ion']",['CHEMBL1237099'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991.,,['DB01135'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1991.0,,,,['4706'],,,,,
CHEMBL1922094,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,YOVVNQKCSKSHKT-HNNXBMFYSA-N,Small molecule,False,APITOLISIB,2.0,False,False,[],"['Apitolisib', 'G-038390', 'G-038390.1', 'GDC-0980', 'GDC-0980.1', 'Gne-390', 'RG-7422', 'RG7422', 'Rg-7422']","['CHEMBL1922103', 'CHEMBL1922106']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,['DB12180'],"['MONDO_0004992', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0007254', 'EFO_0000681', 'EFO_1001512']",6.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,,,,,,
CHEMBL2010872,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3,AEULIVPVIDOLIN-UHFFFAOYSA-N,Small molecule,False,CEP-11981,2.0,False,False,[],"['BOL-303213X', 'CEP-11981', 'CEP11981', 'Cep 11981', 'Cep-11981']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000196', 'MONDO_0004992']",2.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000120156']",4,,,,,,,,,,
CHEMBL2103839,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,BUROJSBIWGDYCN-GAUTUEMISA-N,Small molecule,False,RIDAFOROLIMUS,3.0,False,False,[],"['AP 23573', 'AP-23573', 'AP23573', 'MK-8669', 'MK8669', 'Ridaforolimus']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.,,['DB06233'],"['EFO_0000569', 'MONDO_0008315', 'EFO_0003869', 'EFO_0001378', 'MONDO_0021054', 'EFO_0002430', 'EFO_0000637', 'EFO_1001968', 'EFO_1001465', 'EFO_0000574', 'MONDO_0011962', 'EFO_0003060', 'EFO_0000198', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0007254', 'EFO_0000564', 'EFO_0000565', 'EFO_0000691']",19.0,['ENSG00000198793'],1,,,,,['79700'],,,,,
CHEMBL2105160,C[C@@H](N/C(=N\C#N)Nc1ccc(C#N)cc1)C(C)(C)C,PGYDRGZVXVVZQC-LLVKDONJSA-N,Small molecule,False,NAMINIDIL,2.0,False,False,[],"['BMS-234303', 'BMS-234303-01', 'Naminidil', 'Naminidil, (r)-']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000187486', 'ENSG00000069431', 'ENSG00000006071', 'ENSG00000121361']",4,,,,,,,,,,
CHEMBL2108341,,,Antibody,False,SONTUZUMAB,2.0,False,False,[],"['AS-1402', 'HUHMFG-1', 'Sontuzumab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL282686,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,CXGTZJYQWSUFET-IBGZPJMESA-N,Small molecule,False,TESAGLITAZAR,3.0,False,False,[],"['AR-H-039242', 'AR-H039242XX', 'AZ-242', 'Az-242', 'BR-44608', 'Tesaglitazar']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB06536'],['MONDO_0005148'],1.0,"['ENSG00000186951', 'ENSG00000132170']",2,,,,,,,,,,
CHEMBL3184437,OCc1ccc(Cl)cc1Cl,DBHODFSFBXJZNY-UHFFFAOYSA-N,Small molecule,False,DICHLOROBENZYL ALCOHOL,4.0,False,True,[],"['Dichlorobenzyl alcohol', 'Dybenal', 'NSC-15635', 'Oxiconazole related compound d', 'Rapidosept']",,Small molecule drug with a maximum clinical trial phase of IV.,,['DB13269'],,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,,,,"['144211212', '170465574']",['48220'],,,,,
CHEMBL4105630,C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1,HARRKNSQXBRBGZ-GVKWWOCJSA-N,Small molecule,True,ZURANOLONE,4.0,False,True,['Zurzuvae'],"['S-812217', 'SAGE-217', 'SGE-797', 'Sage-217', 'Zuranolone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for postpartum depression and has 5 investigational indications. This drug has a black box warning from the FDA.,,['DB15490'],"['EFO_0007453', 'MONDO_0002009', 'MONDO_0005180', 'EFO_0003108', 'MONDO_0002050', 'EFO_0004247']",6.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ZURANOLONE/relevant/1/'],,,
CHEMBL435298,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,SYTBZMRGLBWNTM-JTQLQIEISA-N,Small molecule,False,ESFLURBIPROFEN,4.0,False,True,[],"['BTS 24332', 'BTS-24332', 'Esflurbiprofen', 'Flurbiprofen, (s)-']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 investigational indications.,,,"['HP_0002829', 'HP_0003326', 'EFO_0009582']",3.0,"['ENSG00000073756', 'ENSG00000095303']",2,2015.0,,,['47193727'],['42446'],,,,,
CHEMBL5314408,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1,MVWATCATLSSVBH-UHFFFAOYSA-N,Small molecule,False,AZD-0424,1.0,False,False,[],"['AZD0424', 'Azd-0424']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000097007', 'ENSG00000197122']",2,,,,,,,,,,
CHEMBL544,COc1ccc(O)cc1,NWVVVBRKAWDGAB-UHFFFAOYSA-N,Small molecule,False,MEQUINOL,4.0,False,True,[],"['4-hydroxyanisole', '4-methoxyphenol', '4ha', 'BMS-181158', 'Hqmme; hydroxyquinone methyl ether', 'Leucobasal', 'Leucodine b', 'Mechinolum', 'Menthyl anthranilate', 'Mequinol', 'NSC-4960', 'Novo-dermoquinona', 'P-guaiacol', 'P-hydroxyanisole']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999.,['Mequinol'],['DB09516'],,,['ENSG00000077498'],1,1999.0,,,"['144204676', '144209565', '144213193', '170464687', '17389832', '50105587', '71152', '85272557']",['69441'],,,,,
CHEMBL861,CCC1(c2ccccc2)NC(=O)N(C)C1=O,GMHKMTDVRCWUDX-UHFFFAOYSA-N,Small molecule,False,MEPHENYTOIN,4.0,False,True,['Mesantoin'],"['Mephenytoin', 'Methoin', 'NSC-34652']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for epilepsy.,['Mephenytoin'],['DB00532'],['EFO_0000474'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1946.0,,,['56463168'],,,,,,
CHEMBL1079742,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,GTTBEUCJPZQMDZ-UHFFFAOYSA-N,Small molecule,False,ERLOTINIB HYDROCHLORIDE,4.0,False,True,"['Erlotinib hydrochloride', 'Tarceva']","['CP-358', 'CP-358,774-01', 'CP-358774-01', 'Erlotinib hcl', 'Erlotinib hydrochloride', 'OSI-774']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 52 investigational indications.,,,"['EFO_0003060', 'EFO_0005537', 'EFO_0000632', 'EFO_0002501', 'MONDO_0003060', 'EFO_0002618', 'MONDO_0002158', 'EFO_0000691', 'MONDO_0005411', 'MONDO_0007576', 'MONDO_0002974', 'EFO_0005567', 'EFO_0000181', 'EFO_0005221', 'MONDO_0004992', 'MONDO_0002367', 'MONDO_0001187', 'EFO_0001422', 'EFO_0000616', 'MONDO_0003268', 'EFO_0000519', 'EFO_1001465', 'EFO_1000657', 'EFO_0000305', 'MONDO_0021063', 'MONDO_0000521', 'MONDO_0044926', 'MONDO_0004986', 'MONDO_0008903', 'EFO_0000182', 'MONDO_0008315', 'EFO_0006859', 'EFO_1000158', 'MONDO_0002898', 'Orphanet_733', 'MONDO_0011962', 'EFO_0000681', 'EFO_0000756', 'EFO_0003050', 'EFO_0003833', 'EFO_0002499', 'MONDO_0007254', 'EFO_1001951', 'MONDO_0008170', 'EFO_0000588', 'MONDO_0020634', 'EFO_0000308', 'EFO_0000571', 'EFO_0000640', 'EFO_0000365', 'MONDO_0002087', 'MONDO_0002691', 'EFO_0000708']",53.0,['ENSG00000146648'],1,2004.0,CHEMBL553,['erlotinib%20hydrochloride'],['534851'],['53509'],['https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva'],,,,
CHEMBL1083993,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1.Cl,ITPDYQOUSLNIHG-UHFFFAOYSA-N,Small molecule,True,AMIODARONE HYDROCHLORIDE,4.0,False,True,"['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone x', 'Cordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']","['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochloride', 'L-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'Ritmocardyl', 'SK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000275', 'EFO_0004287', 'MONDO_0019438', 'EFO_0005529', 'EFO_0003144', 'EFO_0005306', 'HP_0004308']",7.0,['ENSG00000055118'],1,1985.0,CHEMBL633,['amiodarone%20hydrochloride'],"['144207027', '144210713', '26747445', '50105848', '50105849', '50105850', '552042', '56422901', '855533']",,,,,,
CHEMBL110458,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,LXBIFEVIBLOUGU-DPYQTVNSSA-N,Small molecule,False,MIGALASTAT,4.0,False,True,"['At-1001, gr-181314a', 'Galafold']",['Migalastat'],['CHEMBL2107355'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for fabry disease and has 1 investigational indication.,,['DB05018'],"['MONDO_0010526', 'MONDO_0010526']",2.0,['ENSG00000102393'],1,2016.0,,,['11114003'],,,,,,
CHEMBL1200443,,,Small molecule,False,MERETHOXYLLINE PROCAINE,4.0,False,True,[],"['Merethoxyline procaine', 'Merethoxylline procaine', 'Procaine merethoxylline']",,Small molecule drug with a maximum clinical trial phase of IV.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,,,,,,,,,['4992'],
CHEMBL1743020,,,Antibody,False,FORALUMAB,2.0,False,False,[],"['Foralumab', 'NI-0401', 'TZLS-401']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0000384', 'EFO_0008522', 'EFO_0008520', 'EFO_0004599', 'MONDO_0100096']",5.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286']",3,,,,,,,,,,
CHEMBL2108557,,,Protein,False,TELBERMIN,2.0,False,False,[],"['RH VEGF', 'RH-VEGF', 'RHVEG-F', 'RHVEGF', 'SNN0029', 'Telbermin', 'Vegf-a165', 'Vegf165']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_1001459', 'MONDO_0004976']",2.0,"['ENSG00000102755', 'ENSG00000128052']",2,,,,,,,,,,
CHEMBL4594401,CC1=NN(c2ccc3c(c2)CCCC3)C(=O)/C1=N\Nc1cccc(-c2ccc(C(=O)O)o2)c1O,BDGGFTDRPHKXFC-QYQHSDTDSA-N,Small molecule,False,RAFUTROMBOPAG,3.0,False,False,[],"['Hetrombopag', 'Rafutrombopag', 'SHR-8735', 'SHR8735']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['EFO_0001421', 'EFO_0000198', 'HP_0001915', 'EFO_0007160', 'HP_0001873', 'MONDO_0007254']",6.0,['ENSG00000117400'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL4594448,CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@H](c2ccc(C(=O)O)cc2)C1,RENRQMCACQEWFC-UGKGYDQZSA-N,Small molecule,False,IPTACOPAN,3.0,False,False,[],"['Iptacopan', 'LNP-023', 'LNP023', 'Lnp023', 'NVP-LNP023', 'NVP-LNP023-NX']","['CHEMBL4643495', 'CHEMBL5095401']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,,"['EFO_0004254', 'EFO_0005761', 'MONDO_0100244', 'HP_0000077', 'MONDO_0002462', 'EFO_0001365', 'HP_0000077', 'EFO_0001421', 'MONDO_0100244', 'MONDO_0018904', 'EFO_0004194', 'MONDO_0002462', 'MONDO_0100244', 'MONDO_0016244']",14.0,['ENSG00000243649'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/IPTACOPAN/relevant/1/'],,,
CHEMBL5095451,,,Gene,False,ETRANACOGENE DEZAPARVOVEC,1.0,False,False,[],"['AAV5-hFIXco-Padua', 'AMT-061', 'Etranacogene dezaparvovec', 'Etranacogene dezaparvovec-dlrb', 'Hemgenix']",,Gene drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0010604'],1.0,['ENSG00000101981'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ETRANACOGENE%20DEZAPARVOVEC/relevant/1/'],,,
CHEMBL6,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,CGIGDMFJXJATDK-UHFFFAOYSA-N,Small molecule,True,INDOMETHACIN,4.0,False,True,"['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continus', 'Flexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmon', 'Indo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'Indoderm', 'Indoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 sr', 'Indomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'Ledmecin', 'Maximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'Rimacid', 'Slo-indo', 'Tivorbex']","['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesil', 'Indometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']","['CHEMBL2028292', 'CHEMBL3989410', 'CHEMBL4590319']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 12 approved and 23 investigational indications. This drug has a black box warning from the FDA.,['Indometacin'],['DB00328'],"['MONDO_0003937', 'EFO_0000278', 'EFO_0000199', 'MONDO_0004979', 'EFO_0005755', 'EFO_1001412', 'EFO_0000685', 'EFO_1000652', 'EFO_0010072', 'MONDO_0004975', 'MONDO_0005178', 'MONDO_0100096', 'HP_0002829', 'EFO_1000318', 'EFO_0005252', 'MONDO_0007254', 'EFO_0003843', 'MP_0001914', 'Orphanet_79292', 'EFO_0003898', 'EFO_0003917', 'MP_0001845', 'EFO_0000181', 'MONDO_0024475', 'EFO_0000196', 'EFO_0000342', 'HP_0001643', 'EFO_0000319', 'HP_0003326', 'EFO_0004274', 'EFO_0005752', 'MP_0001845', 'MONDO_0008315', 'EFO_0000389', 'EFO_0000673']",35.0,"['ENSG00000073756', 'ENSG00000095303']",2,1965.0,,['indomethacin'],"['11111328', '11111329', '11113361', '124880453', '124880455', '124880457', '124880458', '144206660', '144208989', '144210586', '170464705', '17389851', '174007200', '26747086', '26747087', '26751593', '50100255', '50104238', '50104239', '50126367', '56422212', '85231093', '856012', '90340917']",['49662'],,,['15'],,
CHEMBL1034,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],KPHWPUGNDIVLNH-UHFFFAOYSA-M,Small molecule,True,DICLOFENAC SODIUM,4.0,False,True,"['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50', 'Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac sr', 'Dexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'Dicloflex', 'Dicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax sr', 'Diclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol ret', 'Diclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100', 'Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xl', 'Enzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'Flamrase', 'Flamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50', 'Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'Mobigel', 'Mobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'Rhumalgan', 'Rhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xl', 'Slofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'Valenac', 'Volraman', 'Volsaid ret 100', 'Volsaid ret 75', 'Voltaren', 'Voltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xr', 'Voltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene ret', 'Voltarol', 'Voltarol 12 hour emulgel p', 'Voltarol active', 'Voltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patch', 'Voltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol ret', 'Voltarol sr']","['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'Delphinac', 'Diclofenac diethylamine', 'Diclofenac diethylamine salt', 'Diclofenac diethylammonium', 'Diclofenac diethylammonium salt', 'Diclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'Diclomax', 'Diclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'Ecofenac', 'Effekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'Neriodin', 'Novapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenac', 'Voldal', 'Xenid']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 5 approved and 16 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0009560', 'EFO_0010072', 'EFO_0002970', 'EFO_0004616', 'EFO_0000649', 'MONDO_0001187', 'EFO_0000685', 'MP_0001914', 'MONDO_0005178', 'MONDO_0002959', 'EFO_0009582', 'EFO_0004272', 'HP_0003419', 'EFO_0004607', 'MP_0001845', 'EFO_0003958', 'HP_0012532', 'EFO_0003843', 'EFO_0004274', 'HP_0011868', 'EFO_0002496']",21.0,"['ENSG00000073756', 'ENSG00000095303']",2,1988.0,CHEMBL139,['diclofenac%20sodium'],"['11111091', '11112998', '144204321', '144210585', '170464642', '26747983', '50106220', '56422389', '85231008', '855544', '90341049']",['4509'],,,,,
CHEMBL1200654,CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N.Cl,PRGUDWLMFLCODA-UHFFFAOYSA-N,Small molecule,False,BENOXINATE HYDROCHLORIDE,4.0,False,True,['Benoxinate hydrochloride'],"['Benoxinate hcl', 'Benoxinate hydrochloride', 'NSC-759847', 'Oxibuprocaine chloride', 'Oxybuprocaine hcl', 'Oxybuprocaine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,CHEMBL1200,['benoxinate%20hydrochloride'],"['144204104', '170464771', '56463336']",['31260'],,,,,
CHEMBL1201662,,,Protein,False,DESIRUDIN,4.0,False,True,"['Iprivask', 'Revasc']","['63-desulfohirudin', '63-desulfohirudin (recombinant)', 'CGP 39393', 'CGP-39393', 'Desirudin', 'Desirudin recombinant', 'Hirudin desirudin', 'Revasc']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved indications.,,,"['EFO_0003907', 'HP_0004419', 'HP_0004936']",3.0,['ENSG00000180210'],1,1997.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/revasc'],,,['2990'],
CHEMBL1201773,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl,JALHGCPDPSNJNY-UHFFFAOYSA-N,Small molecule,True,PRASUGREL HYDROCHLORIDE,4.0,False,True,"['Effient', 'Efient']","['LY640315', 'Prasu doc', 'Prasugrel hcl', 'Prasugrel hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications. This drug has a black box warning from the FDA.,,,"['EFO_0000612', 'EFO_0005672', 'MP_0001914']",3.0,['ENSG00000169313'],1,2009.0,CHEMBL1201772,['prasugrel%20hydrochloride'],"['144207170', '170465441']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/efient'],,,,
CHEMBL1201825,,,Antibody,True,RANIBIZUMAB,4.0,False,True,['Lucentis'],"['BCD-300', 'Byooviz', 'Cimerli', 'FAB-12 VARIANT Y0317', 'FYB-201', 'FYB201', 'PF-582', 'Pf-582 (ranibizumab biosimilar)', 'Pf582', 'QL-1205', 'QL1205', 'RG-3645', 'RHUFAB', 'Ranibizumab', 'Ranibizumab biosimilar pf582', 'Ranibizumab eqrn', 'Ranibizumab nuna', 'Ranibizumab-eqrn', 'Ranibizumab-nuna', 'SB-11', 'SB11 (RANIBIZUMAB BIOSIMILAR)', 'Susvimo']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 8 approved and 23 investigational indications. This drug has a black box warning from the FDA.,['Ranibizumab'],,"['EFO_1001158', 'MONDO_0008380', 'EFO_0004207', 'EFO_0004190', 'EFO_0009606', 'EFO_1000880', 'EFO_1001157', 'EFO_0003770', 'HP_0000545', 'MONDO_0001576', 'EFO_1001060', 'EFO_0010977', 'EFO_0000400', 'EFO_0005753', 'HP_0000573', 'EFO_0001365', 'MONDO_0001941', 'EFO_0000678', 'MONDO_0007935', 'EFO_0003839', 'HP_0000545', 'MONDO_0005041', 'EFO_1000805', 'MONDO_0020204', 'EFO_1000809', 'EFO_0007310', 'MONDO_0008667', 'EFO_0004683', 'EFO_0009784', 'EFO_0005773', 'MONDO_0003005']",31.0,['ENSG00000112715'],1,2006.0,,['ranibizumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis'],,,['4971'],
CHEMBL2108334,,,Protein,False,EPTACOG ALFA (ACTIVATED),4.0,False,True,['Novoseven'],"['Activated recombinant human factor vii', 'Coagulation factor viia (recombinant)', 'Coagulation factor viia recombinant human', 'Eptacog alfa', 'Eptacog alfa (activated)', 'Recombinant activated factor vii']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 5 investigational indications.,,,"['MONDO_0002243', 'MP_0001914', 'MONDO_0010604', 'EFO_0005669', 'EFO_1000025', 'MONDO_0010602', 'MONDO_0100326', 'MONDO_0002244', 'MONDO_0018660', 'EFO_0000551']",10.0,['ENSG00000057593'],1,1996.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven'],,,['5159'],
CHEMBL2109393,,,Antibody,False,RG-7160,2.0,False,False,[],['RG-7160'],,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL770,c1ccc(CC2=NCCN2)cc1,JIVZKJJQOZQXQB-UHFFFAOYSA-N,Small molecule,False,TOLAZOLINE,4.0,False,True,[],"['NSC-35110', 'Priscoline', 'Tolazine', 'Tolazoline']",['CHEMBL1689'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved indications.,['Tolazoline'],['DB00797'],"['HP_0003326', 'HP_0002829', 'EFO_0000319']",3.0,"['ENSG00000196639', 'ENSG00000113749', 'ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",8,1985.0,,,['11112156'],['28502'],,,,,
CHEMBL89598,C=CC(N)CCC(=O)O,PJDFLNIOAUIZSL-UHFFFAOYSA-N,Small molecule,True,VIGABATRIN,4.0,False,True,"['Kigabeq', 'Sabril']","['5-hexenoic acid, 4-amino-', 'CPP-109', 'Gamma vinyl gaba', 'Gamma-vinyl gaba', 'MDL 71,754', 'MDL-71754', 'RMI-71754', 'Vigabatrin', 'Vinyl gamma-aminobutyric acid']",['CHEMBL4303352'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 6 investigational indications. This drug has a black box warning from the FDA.,['Vigabatrin'],['DB01080'],"['MONDO_0001734', 'EFO_0004263', 'EFO_1000877', 'EFO_0004701', 'HP_0011097', 'EFO_0001073', 'MONDO_0007079', 'EFO_0004895', 'MONDO_0100062', 'MONDO_0018097', 'EFO_0002610', 'EFO_0000474']",12.0,['ENSG00000183044'],1,2009.0,,['vigabatrin'],"['104171263', '144203852', '26747129', '26751903', '50104581', '50104582', '50104583', '85231284', '90340732']",['63638'],['https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq'],,,,
CHEMBL2103831,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1,AKFJWRDCWYYTIG-ZDUSSCGKSA-N,Small molecule,False,NAPROXCINOD,3.0,False,False,[],"['AR-P900758XX', 'AZD-3582', 'AZD3582', 'HCT 3012', 'HCT-3012', 'HCT3012', 'Naproxcinod', 'Naproxen-n-butyl nitrate', 'Nitronaproxen']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,['DB06682'],"['MONDO_0005178', 'EFO_1002048', 'EFO_1000786', 'EFO_0001421', 'EFO_0005755']",5.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,,['76254'],,,,,
CHEMBL2103882,O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12,UCEQXRCJXIVODC-PMACEKPBSA-N,Small molecule,False,TIVANTINIB,3.0,False,False,[],"['ARQ 197', 'ARQ-197', 'Arq-197', 'Tivantinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications.,,['DB12200'],"['EFO_0003060', 'EFO_0005537', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000770', 'EFO_0000514', 'MONDO_0002691', 'EFO_0000616', 'EFO_0003860', 'EFO_0000702', 'MONDO_0007576', 'EFO_0000640', 'EFO_0000673', 'MONDO_0001056', 'EFO_0001378', 'EFO_0000181']",16.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL2107339,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O,RPUBHMMISKEXSR-MLCLTIQSSA-N,Small molecule,False,ESMIRTAZAPINE MALEATE,3.0,False,False,[],"['Esmirtazapine maleate', 'Mirtazapine maleate, (s)-', 'ORG 50081', 'ORG-50081', 'Org-50081']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0004698', 'EFO_0008568']",2.0,"['ENSG00000196639', 'ENSG00000147246', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286', 'ENSG00000102468']",6,,CHEMBL1366933,,,,,,,,
CHEMBL274654,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,NHFDRBXTEDBWCZ-ZROIWOOFSA-N,Small molecule,False,ORANTINIB,3.0,False,False,[],"['NSC-702827', 'Orantinib', 'SU-6668', 'Su-6668', 'TSU-68']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,['DB12072'],"['EFO_0001378', 'EFO_1001951', 'EFO_0000182', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0000616', 'EFO_0002618', 'MONDO_0007254', 'MONDO_0001056', 'MONDO_0002367']",10.0,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000128052']",7,,,,['527809'],,,,,,
CHEMBL3813873,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,JGWRKYUXBBNENE-UHFFFAOYSA-N,Small molecule,True,PEXIDARTINIB,4.0,False,True,[],"['CML-261', 'PLX-3397', 'PLX3397', 'Pexidartinib', 'Plx-3397']",['CHEMBL3989973'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for neoplasm and tenosynovial giant cell tumor and has 16 investigational indications. This drug has a black box warning from the FDA.,,['DB12978'],"['EFO_0000183', 'MONDO_0011719', 'MONDO_0008315', 'EFO_0000519', 'EFO_0001421', 'EFO_0000222', 'MONDO_0002171', 'EFO_0000616', 'EFO_1000562', 'EFO_0002617', 'EFO_1001106', 'EFO_0003968', 'EFO_0000685', 'EFO_0000760', 'EFO_0000756', 'EFO_0005537', 'EFO_0000673', 'MONDO_0007254']",18.0,"['ENSG00000182578', 'ENSG00000122025', 'ENSG00000157404']",3,2019.0,,,,,,,,,
CHEMBL3989794,CCOC(=O)[C@H](CCCc1ccccc1)C1(C(=O)N[C@H]2CCc3ccccc3N(CC(=O)O)C2=O)CCCC1,FVWPYVZWVOLAOP-DQEYMECFSA-N,Small molecule,False,DAGLUTRIL,2.0,False,False,[],"['Daglutril', 'SLV-306', 'SLV306']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000537'],1.0,"['ENSG00000196549', 'ENSG00000117298']",2,,,,,,,,,,
CHEMBL404849,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,BFCDFTHTSVTWOG-UHFFFAOYSA-N,Small molecule,False,SULOCTIDIL,4.0,True,True,[],"['Bemperil', 'CP-556S', 'Cerebro', 'Circleton', 'Dulasi', 'Duloctil', 'Euvasal', 'Fluversin', 'Fluvisco', 'Hemoantin', 'Iangene', 'Loctidon', 'Locton', 'MJF 12637', 'MJF-12637', 'Octamet', 'Polivasal', 'Sudil', 'Suloctidil', 'Sulocton', 'Sulodene']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for cardiovascular disease. It was withdrawn in at least one region.,,,['EFO_0000319'],1.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,1979.0,,,"['104171389', '144204409', '170466521', '26748521']",,,,,,
CHEMBL4594301,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21.O=S(=O)(O)c1ccccc1,QMTKNJZIWGTNTE-LMOVPXPDSA-N,Small molecule,True,REMIMAZOLAM BESYLATE,4.0,False,True,['Byfavo'],"['BIPRAZINE PF', 'CNS 7056 besylate', 'CNS 7056B', 'CNS-7056 BESYLATE', 'CNS-7056B', 'GW-502056X', 'GW502056X', 'ONO-2745BS', 'ONO-IN-251', 'RF-10007', 'RF10007', 'Remimazolam besilate', 'Remimazolam besylate', 'SP148.5']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sedation and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0009868', 'EFO_0003843']",2.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,2020.0,CHEMBL4297526,['remimazolam%20besylate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/byfavo'],['https://searchusan.ama-assn.org/finder/usan/search/REMIMAZOLAM%20BESYLATE/relevant/1/'],,,
CHEMBL53292,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1,YYUAYBYLJSNDCX-UHFFFAOYSA-N,Small molecule,False,ISOXICAM,4.0,True,True,[],"['Isoxicam', 'NSC-758436', 'W 8495', 'W-8495']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,['DB08942'],,,"['ENSG00000073756', 'ENSG00000095303']",2,,,,"['11112741', '144204185', '170466334', '26747065', '855966']",['76163'],,,,,
CHEMBL1200715,CC(CNC1CCCCC1)OC(=O)c1ccccc1.Cl,MTFCPNHRBINLRQ-UHFFFAOYSA-N,Small molecule,False,HEXYLCAINE HYDROCHLORIDE,4.0,False,True,['Cyclaine'],"['Hexylcaine HCl', 'Hexylcaine hcl', 'Hexylcaine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,CHEMBL1197,,"['144204007', '170465088', '56463225']",,,,,,
CHEMBL2111112,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,VBHQKCBVWWUUKN-KZNAEPCWSA-N,Small molecule,False,VERNAKALANT,4.0,False,True,[],['Vernakalant'],['CHEMBL2107383'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for atrial fibrillation and cardiac arrhythmia and has 3 investigational indications.,,['DB06217'],"['EFO_0000275', 'EFO_0003911', 'EFO_0000275', 'EFO_0004269', 'EFO_0003911']",5.0,"['ENSG00000171385', 'ENSG00000130037', 'ENSG00000183873', 'ENSG00000162989', 'ENSG00000120457', 'ENSG00000055118']",6,2010.0,,,,,,,,,
CHEMBL2165615,Cc1cnc(NC(=O)c2cc(Oc3cnc(C(=O)N(C)C)nc3)c3cc(C)oc3c2)cn1,MASKQITXHVYVFL-UHFFFAOYSA-N,Small molecule,False,NERIGLIATIN,2.0,False,False,[],"['Nerigliatin', 'PF-04937319', 'Pf-04937319']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB15009'],['MONDO_0005148'],1.0,['ENSG00000106633'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-129']
CHEMBL2396661,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,STUWGJZDJHPWGZ-LBPRGKRZSA-N,Small molecule,False,ALPELISIB,4.0,False,True,"['Piqray', 'Vijoice']","['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 17 investigational indications.,,['DB12015'],"['MONDO_0011962', 'EFO_0001421', 'MONDO_0004992', 'EFO_0000181', 'EFO_1001951', 'MONDO_0007254', 'EFO_0001378', 'EFO_0005922', 'EFO_1001931', 'EFO_0004284', 'EFO_0002618', 'EFO_1000657', 'EFO_0000707', 'EFO_0005537', 'MONDO_0011719', 'MONDO_0044704', 'EFO_0000305', 'MONDO_0001056', 'MONDO_0016642', 'EFO_0000616', 'EFO_0003869', 'MONDO_0008170']",22.0,['ENSG00000121879'],1,2019.0,,['alpelisib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/piqray'],,,,
CHEMBL244243,C[C@@H](NC(=O)[C@@H](CC(=O)N1CCC(N2CCCCC2)CC1)N1C(=O)[C@@H](N2C(=O)OC[C@@H]2c2ccccc2)[C@H]1/C=C/c1ccccc1)c1cccc(C(F)(F)F)c1,ZPKHVQNRKMCYGL-AFAPVMNMSA-N,Small molecule,False,SRX246,2.0,False,False,[],['Srx246'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0001358', 'EFO_0004247', 'EFO_0005230', 'MONDO_0007739']",4.0,['ENSG00000166148'],1,,,,,,,,,,
CHEMBL3545295,,,Small molecule,False,AVE0847,1.0,False,False,[],['Ave0847'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000132170', 'ENSG00000112033']",2,,,,,,,,,,
CHEMBL1201605,,,Antibody,False,DACLIZUMAB,4.0,True,True,"['Zenapax', 'Zinbryta']","['Daclizumab', 'Daclizumab beta', 'RO 24-7375', 'RO-24-7375']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 23 investigational indications. It was withdrawn in at least one region.,['Daclizumab'],,"['EFO_0000198', 'EFO_0001378', 'MONDO_0004979', 'EFO_0000574', 'EFO_0000616', 'MONDO_0001705', 'EFO_0000676', 'HP_0012410', 'EFO_0004683', 'EFO_0000764', 'MONDO_0013730', 'EFO_0000756', 'EFO_0003929', 'MONDO_0018923', 'EFO_0003086', 'MONDO_0005301', 'EFO_0000729', 'EFO_0003884', 'EFO_0000540', 'EFO_0000400', 'HP_0001873', 'EFO_0005297', 'EFO_1001231', 'HP_0001915', 'EFO_0000565', 'MONDO_0005147']",26.0,"['ENSG00000134460', 'ENSG00000147168', 'ENSG00000100385']",3,1997.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta'],,,['4953'],
CHEMBL2105613,CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+],MSRILKIQRXUYCT-UHFFFAOYSA-M,Small molecule,True,DIVALPROEX SODIUM,4.0,False,True,"['Depakote', 'Depakote cp', 'Depakote er', 'Divalproex sodium']","['ABBOTT 50711', 'ABBOTT-50711', 'Divalproex', 'Divalproex sodium', 'Semisodium valproate', 'Valproate semisodium', 'Valproic acid sodium salt (2:1)']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 11 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0007079', 'EFO_0000474', 'HP_0000713', 'HP_0001250', 'EFO_0000616', 'EFO_0000717', 'EFO_0001358', 'HP_0010865', 'EFO_0004247', 'EFO_1000877', 'MONDO_0004975', 'EFO_0003761', 'HP_0002013', 'EFO_0003758', 'MONDO_0005090', 'EFO_0009963', 'MONDO_0004985', 'HP_0000726', 'MONDO_0005277', 'HP_0007359', 'HP_0002121', 'HP_0002039', 'MONDO_0007739']",23.0,['ENSG00000112294'],1,1983.0,CHEMBL109,['divalproex%20sodium'],,['4667'],,,,,
CHEMBL2108570,,,Unknown,True,ABOBOTULINUMTOXINA,4.0,False,True,[],"['Abobotulinumtoxina', 'RTI-150', 'RTI150']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0006346', 'EFO_1001896', 'HP_0003419']",3.0,['ENSG00000132639'],1,2009.0,,['abobotulinumtoxina'],,,,,,,
CHEMBL2109602,,,Antibody,False,IMC-3C5,1.0,False,False,[],"['IMC-3C5', 'Imc-3c5']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000037280'],1,,,,,,,,,,
CHEMBL2219536,COCCO[C@@H]1[C@H](SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cnc4c(N)ncnc43)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2O)[C@@H](COP(=O)(O)S[C@H]2[C@@H](OCCOC)[C@H](n3cc(C)c(N)nc3=O)O[C@@H]2COP(=O)(O)S[C@H]2[C@@H](OCCOC)[C@H](n3cnc4c(=O)[nH]c(N)nc43)O[C@@H]2CO)O[C@H]1n1cc(C)c(N)nc1=O,TZRFSLHOCZEXCC-HIVFKXHNSA-N,Oligonucleotide,True,MIPOMERSEN,4.0,False,True,[],['Mipomersen'],['CHEMBL502097'],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for cardiovascular disease and familial hypercholesterolemia and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0000319', 'EFO_0004911', 'HP_0003124']",3.0,['ENSG00000084674'],1,2013.0,,,,,,,,['4747'],
CHEMBL2323775,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,VMJFTOSOFDEKTM-UHFFFAOYSA-N,Small molecule,False,MK-8033,1.0,False,False,[],"['MK-8033', 'MK8033', 'Mk-8033']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0004992'],1.0,"['ENSG00000164078', 'ENSG00000105976']",2,,,,,,,,,,
CHEMBL3353410,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,DUYJMQONPNNFPI-UHFFFAOYSA-N,Small molecule,False,OSIMERTINIB,4.0,False,True,['Tagrisso'],"['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'Mereletinib', 'Osimertinib']","['CHEMBL4754013', 'CHEMBL4741340', 'CHEMBL3545063', 'CHEMBL4472934', 'CHEMBL4784911']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 11 investigational indications.,,['DB09330'],"['EFO_0000313', 'MONDO_0005575', 'MONDO_0004992', 'EFO_0000707', 'MONDO_0021117', 'EFO_0000571', 'EFO_0000519', 'EFO_0003060', 'MONDO_0008903', 'MONDO_0008903', 'EFO_0003833', 'EFO_0000228', 'EFO_0000616', 'EFO_0003060']",14.0,['ENSG00000146648'],1,2015.0,,,,,,,,,
CHEMBL3989931,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O,ORZHZQZYWXEDDL-UHFFFAOYSA-N,Small molecule,True,ENASIDENIB MESYLATE,4.0,False,True,['Idhifa'],"['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylate', 'Enasidenib methanesulfonate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA.,,,['EFO_0000222'],1.0,['ENSG00000182054'],1,2017.0,CHEMBL3989908,['enasidenib%20mesylate'],,,,,,,
CHEMBL5315122,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1O[C@H]([C@H](O)CO)[C@@H]([C@H](O)CO)O1,QDMRNLRJDHCHLB-DNNBANOASA-N,Small molecule,False,BORTEZOMIB D-MANNITOL,4.0,False,True,['Bortezomib accord'],['Bortezomib d-mannitol ester'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015.,,,,,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']",38,2015.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-accord'],,,,
CHEMBL646,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,JOFWLTCLBGQGBO-UHFFFAOYSA-N,Small molecule,True,TRIAZOLAM,4.0,True,True,"['Halcion', 'Kention', 'Triazolam']","['N05CD05', 'Triazolam', 'Triazolam civ', 'U-33,030', 'U-33030']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for insomnia and has 5 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.,['Triazolam'],['DB00897'],"['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'EFO_0003890', 'MONDO_0005090', 'EFO_0004698']",6.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1978.0,,['triazolam'],"['144206170', '50113071']",['9674'],,,['120'],,
CHEMBL1393,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12,LXMSZDCAJNLERA-ZHYRCANASA-N,Small molecule,True,SPIRONOLACTONE,4.0,False,True,"['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironol', 'Laractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50', 'Spironolactone', 'Spironolactone ceva', 'Spirospare 100', 'Spirospare 25']","['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone ceva', 'Spironolactonum', 'Verospirone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 8 approved and 32 investigational indications. This drug has a black box warning from the FDA.,['Spironolactone'],['DB00421'],"['HP_0001397', 'EFO_0000401', 'EFO_0000537', 'MONDO_0010679', 'EFO_0003894', 'EFO_0000400', 'EFO_1000899', 'EFO_0000275', 'EFO_0008586', 'EFO_0000319', 'EFO_0001422', 'EFO_0000373', 'EFO_0001361', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000266', 'HP_0001919', 'EFO_0000668', 'EFO_0001365', 'EFO_1001249', 'MONDO_0007079', 'EFO_0000612', 'EFO_0000621', 'EFO_0000222', 'EFO_0004255', 'EFO_0000685', 'EFO_0008585', 'EFO_0003144', 'Orphanet_247', 'EFO_0000318', 'MONDO_0001134', 'MONDO_0000088', 'EFO_0003884', 'EFO_0000694', 'MONDO_0100096', 'EFO_0003963', 'HP_0012424', 'EFO_0005669', 'EFO_0000660', 'EFO_1001496']",40.0,['ENSG00000151623'],1,1960.0,,['spironolactone'],"['144206598', '144212471', '26757816', '47193741']",['9241'],['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/spironolactone-ceva'],,,,
CHEMBL189963,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,AHJRHEGDXFFMBM-UHFFFAOYSA-N,Small molecule,False,PALBOCICLIB,4.0,False,True,['Ibrance'],"['PD-0332991', 'Palbociclib']","['CHEMBL2364621', 'CHEMBL3962672']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 45 investigational indications.,,['DB09073'],"['EFO_0008528', 'MONDO_0008170', 'EFO_0003060', 'EFO_1001950', 'EFO_0006318', 'EFO_0001378', 'EFO_0001075', 'EFO_0000349', 'EFO_0000569', 'EFO_0000616', 'EFO_0000182', 'MONDO_0007254', 'EFO_0005952', 'MONDO_0008978', 'EFO_0000574', 'EFO_1000294', 'MONDO_0008315', 'EFO_0000228', 'EFO_0000632', 'EFO_0002626', 'EFO_1000251', 'EFO_0004252', 'MONDO_0005184', 'EFO_0002618', 'EFO_1001469', 'EFO_0000707', 'EFO_0000220', 'EFO_0000305', 'EFO_0000222', 'EFO_0000174', 'EFO_0003085', 'MONDO_0004992', 'EFO_1000045', 'EFO_0000630', 'EFO_0000637', 'Orphanet_145', 'EFO_0000181', 'MONDO_0011962', 'EFO_0003869', 'EFO_0000616', 'MONDO_0100096', 'EFO_0000708', 'EFO_0005922', 'EFO_0003086', 'EFO_0000519', 'EFO_1001512', 'EFO_0006859', 'EFO_0000681', 'EFO_1001968', 'MONDO_0008903', 'EFO_0000756']",51.0,"['ENSG00000110092', 'ENSG00000105810', 'ENSG00000135446']",3,2015.0,,['palbociclib'],"['103905660', '103905661', '137275973']",['85993'],['https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance'],,,,
CHEMBL2029988,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC,DKNUPRMJNUQNHR-UHFFFAOYSA-N,Small molecule,False,CEP-32496,2.0,False,False,[],"['AB-024', 'AC-013773', 'Agerafenib', 'CEP-32496', 'Cep-32496', 'RXDX-105', 'Rxdx 105']",['CHEMBL3309923'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB15068'],['EFO_0000616'],1.0,"['ENSG00000146648', 'ENSG00000157764', 'ENSG00000165731']",3,,,,,,,,,,
CHEMBL2109573,,,Antibody,False,GSK-249320,2.0,False,False,[],"['GSK-249320', 'Gsk-249320']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000712'],1.0,['ENSG00000105695'],1,,,,,,,,,,
CHEMBL4594549,,,Antibody,False,PIMURUTAMAB,2.0,False,False,[],"['HLX-07', 'HLX07', 'Hlx07', 'Pimurutamab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,,"['EFO_1001951', 'EFO_0005922', 'EFO_0003060', 'EFO_0000182', 'EFO_0004252', 'EFO_0000616', 'EFO_0000702', 'EFO_0000181']",8.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL48361,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,YBSJFWOBGCMAKL-UHFFFAOYSA-N,Small molecule,False,DABIGATRAN,3.0,False,False,['Pradaxa'],"['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'Dabigatran', 'Pradaxa (dabigatran)']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,['Dabigatran'],['DB14726'],"['EFO_0000275', 'EFO_0000712', 'Orphanet_136', 'EFO_0000546', 'EFO_1001413', 'EFO_0010680', 'HP_0002140', 'HP_0001907', 'EFO_0004286', 'HP_0000083', 'MP_0001914']",11.0,['ENSG00000180210'],1,,,,['174006835'],['70752'],,,,,
CHEMBL1111,COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,OUJTZYPIHDYQMC-LJQANCHMSA-N,Small molecule,True,AMBRISENTAN,4.0,False,True,"['Ambrisentan mylan', 'Letairis', 'Volibris']","['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760A', 'LU-208075']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.,['Ambrisentan'],['DB06403'],"['MONDO_0004933', 'EFO_0001361', 'EFO_0000768', 'EFO_0000537', 'EFO_1000782', 'MONDO_0100096', 'EFO_0004264', 'MONDO_0011382', 'MONDO_0004979', 'MONDO_0005149']",10.0,"['ENSG00000136160', 'ENSG00000151617']",2,2007.0,,['ambrisentan'],"['144205520', '170465143']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/ambrisentan-mylan'],,,,
CHEMBL1201013,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+],ZJEFYLVGGFISGT-VRZXRVJBSA-L,Small molecule,False,OLSALAZINE SODIUM,4.0,False,True,['Dipentum'],"['Ads', 'Azodisal sodium', 'CJ 91B', 'CJ-91B', 'Disodium azodisalicylate', 'Olsalazine disodium salt', 'Olsalazine sodium', 'Sodium azodisalicylate', 'Sodium olsalazine']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for ulcerative colitis.,,,['EFO_0000729'],1.0,"['ENSG00000012779', 'ENSG00000132170', 'ENSG00000073756', 'ENSG00000095303']",4,1990.0,CHEMBL425,['olsalazine%20sodium'],,,,,,,
CHEMBL1565476,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,MPHPHYZQRGLTBO-UHFFFAOYSA-N,Small molecule,False,APAZONE,4.0,False,True,"['Rheumox', 'Rheumox 600']","['AHR-3018', 'Apazone', 'Apazone dihydrate', 'Azapropazone', 'Azapropazone dihydrate', 'Cinnopropazone', 'MI-85', 'MI-85DI', 'NSC-102824', 'Prolixan']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease.,,,['EFO_0005755'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,"['144204120', '56463151']",['38010'],,,,,
CHEMBL1567,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,LBWFXVZLPYTWQI-IPOVEDGCSA-N,Small molecule,True,SUNITINIB MALATE,4.0,False,True,"['Sunitinib malate', 'Sutent']","['PHA-290940AD', 'SU-010398', 'SU-011248 L-MALATE SALT', 'SU010398', 'SU011248 L-MALATE SALT', 'Sunitinib l-malate', 'Sunitinib malate', 'Sutent']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 50 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000514', 'EFO_0000222', 'MONDO_0003268', 'MONDO_0002158', 'EFO_1000984', 'MONDO_0002367', 'EFO_0006861', 'EFO_0000349', 'EFO_1000576', 'EFO_0002499', 'MONDO_0044926', 'EFO_0000641', 'EFO_0000501', 'EFO_0002618', 'EFO_0000640', 'MONDO_0004192', 'EFO_0007331', 'MONDO_0008315', 'EFO_1001951', 'EFO_0000632', 'EFO_0002617', 'EFO_0000681', 'MONDO_0015277', 'EFO_0000588', 'EFO_0003865', 'EFO_0000095', 'EFO_0000673', 'EFO_0000182', 'EFO_1001465', 'MONDO_0018364', 'EFO_1001968', 'EFO_0000220', 'EFO_0000403', 'EFO_1000045', 'EFO_0003897', 'EFO_0003869', 'EFO_0002938', 'MONDO_0011719', 'MONDO_0002691', 'EFO_0000702', 'EFO_1001901', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0007576', 'MONDO_0007254', 'MONDO_0004986', 'EFO_0000519', 'EFO_0001378', 'EFO_0006352', 'MONDO_0002087', 'MONDO_0008667', 'EFO_0000616', 'MONDO_0008903', 'EFO_0000558', 'EFO_0007416']",56.0,"['ENSG00000165731', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000157404', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000182578', 'ENSG00000122025']",9,2006.0,CHEMBL535,['sunitinib%20malate'],,,,,,,
CHEMBL295698,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,Small molecule,True,LEVOKETOCONAZOLE,4.0,False,True,"['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'Panfungol', 'Recorlev', 'Xolegel']","['(-)-(2s,4r)-ketoconazole', '2s,4r ketoconazole', '2s,4r-ketoconazole', 'COR-003', 'COR003', 'DIO-902', 'Ketoconazole, (2s,4r)-', 'Levoketoconazole', 'Nizoral', 'Normocort', 'R-41400']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,['DB05667'],"['EFO_0005539', 'MONDO_0005148', 'EFO_0003099', 'EFO_1000797', 'EFO_1001110']",5.0,"['ENSG00000160882', 'ENSG00000179142', 'ENSG00000140459', 'ENSG00000148795']",4,2021.0,,,"['11111347', '11112822', '124882653', '124882654']",['47518'],,,,,
CHEMBL3137317,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O,RWIVSVMMGFFZIJ-VWDRLOGHSA-N,Small molecule,True,SONIDEGIB PHOSPHATE,4.0,False,True,['Odomzo'],"['Erismodegib phosphate', 'Sonidegib diphosphate', 'Sonidegib phosphate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for basal cell carcinoma. This drug has a black box warning from the FDA.,,,['EFO_0004193'],1.0,['ENSG00000128602'],1,2015.0,CHEMBL2105737,['sonidegib%20phosphate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/odomzo'],,,,
CHEMBL3545100,,,Small molecule,False,ASP7991,2.0,False,False,[],['Asp7991'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_1001173'],1.0,['ENSG00000036828'],1,,,,,,,,,,
CHEMBL3545184,CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,ANIAZGVDEUQPRI-ZJQCGQFWSA-N,Protein,False,VELCALCETIDE,4.0,False,True,['Parsabiv'],"['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'Telcalcetide', 'Velcalcetide']",['CHEMBL3545183'],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 1 investigational indication.,,['DB12865'],"['EFO_1001173', 'EFO_0003884', 'EFO_0005754', 'EFO_0003884', 'EFO_1001173']",5.0,['ENSG00000036828'],1,2016.0,,['etelcalcetide'],,,,,,,
CHEMBL3653256,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1,AGBSXNCBIWWLHD-FQEVSTJZSA-N,Small molecule,False,SIREMADLIN,2.0,False,False,[],"['HDM-201', 'HDM201', 'Hdm 201', 'NVP-HDM 201', 'Siremadlin']",['CHEMBL5095424'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_0001421', 'EFO_0000616', 'MONDO_0044903', 'EFO_0000616', 'EFO_0000569', 'EFO_1001968', 'EFO_0000222']",7.0,"['ENSG00000141510', 'ENSG00000135679']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SIREMADLIN/relevant/1/'],,,
CHEMBL43,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,XCPGHVQEEXUHNC-UHFFFAOYSA-N,Small molecule,False,AMSACRINE,4.0,False,True,[],"['Acridinylanisidide', 'Amekrin', 'Amsacrine', 'Amsidil', 'Amsidine', 'CI-880', 'Lamasine', 'M-AMSA', 'NCI-249992', 'NSC-156303', 'NSC-249992', 'SN-11841', 'SN-21429']","['CHEMBL1256655', 'CHEMBL3229103', 'CHEMBL540070']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for neoplasm and has 3 investigational indications.,['Amsacrine'],['DB00276'],"['EFO_0000222', 'EFO_0000616', 'EFO_0000565', 'EFO_0000198']",4.0,"['ENSG00000131747', 'ENSG00000077097']",2,1987.0,,,"['11110803', '137181', '50110958']",['2687'],,,,,
CHEMBL496102,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,HEAIZQNMNCHNFD-UHFFFAOYSA-N,Small molecule,False,AMG-208,2.0,False,False,[],"['AMG-208', 'Amg 208', 'Amg-208', 'Amg208']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB08079'],"['MONDO_0008315', 'MONDO_0004992']",2.0,['ENSG00000105976'],1,,,,['174006590'],['90626'],,,,,
CHEMBL5314402,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc(F)cc(F)c1,UAKZGMMGIMKFMV-RBUKOAKNSA-N,Small molecule,False,TC-6987,2.0,False,False,[],"['TC-6987', 'Tc-6987']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0005148', 'MONDO_0004979']",2.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL2109284,,,Antibody,False,CMB-401,1.0,False,False,[],"['CMB-401', 'HCTMO1-CALICHEAMICIN']",,Antibody drug with a maximum clinical trial phase of I.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL3218576,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,PZBCKZWLPGJMAO-UHFFFAOYSA-N,Small molecule,False,COPANLISIB,4.0,False,True,[],"['BAY 80-6946', 'BAY-80-6946', 'BAY80-6946', 'Bay-80-6946', 'Copanlisib']",['CHEMBL3545068'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 26 investigational indications.,,['DB12483'],"['EFO_0000403', 'EFO_0000616', 'EFO_0000403', 'MONDO_0018906', 'EFO_0001378', 'EFO_0005537', 'EFO_0000574', 'MONDO_0018906', 'EFO_0000305', 'EFO_0000305', 'MONDO_0007254', 'EFO_1001469', 'EFO_0000220', 'EFO_0005221', 'EFO_0000183', 'EFO_0000096', 'EFO_0003060', 'EFO_0008528', 'HP_0000083', 'EFO_0000616', 'EFO_0000096', 'EFO_0005952', 'EFO_0000707', 'MONDO_0021063', 'EFO_0004606', 'EFO_0007532', 'MONDO_0008315', 'EFO_1001051', 'EFO_1001469', 'EFO_0000095']",30.0,"['ENSG00000121879', 'ENSG00000171608']",2,2017.0,,,,,,,,,
CHEMBL3990038,,,Antibody,False,FLOTETUZUMAB,2.0,False,False,[],"['Flotetuzumab', 'MGD-006', 'MGD006', 'RES-234', 'RES234', 'S-80880', 'S80880']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000222'],1.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000185291']",4,,,,,,,,,,
CHEMBL4101807,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,FWCVZAQENIZVMY-UHFFFAOYSA-N,Small molecule,False,VOXELOTOR,4.0,False,True,['Oxbryta'],"['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 4 investigational indications.,,['DB14975'],"['EFO_0003086', 'EFO_0004272', 'MONDO_0002280', 'EFO_0001421', 'EFO_0000768', 'EFO_0004610', 'MONDO_0011382']",7.0,"['ENSG00000206172', 'ENSG00000188536', 'ENSG00000244734']",3,2019.0,,['voxelotor'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta'],,,,
CHEMBL4297181,CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,ACCFLVVUVBJNGT-AWEZNQCLSA-N,Small molecule,False,SAMOTOLISIB,2.0,False,False,[],"['LY 3023414', 'LY-3023414', 'LY3023414', 'Ly-3023414', 'Samotolisib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,['DB12167'],"['EFO_0003869', 'MONDO_0008315', 'EFO_0005952', 'EFO_0009708', 'EFO_0004142', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0005184', 'EFO_0000588', 'MONDO_0011962', 'EFO_0003060']",11.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SAMOTOLISIB/relevant/1/'],,,
CHEMBL4298197,,,Oligonucleotide,False,VUPANORSEN,2.0,False,False,[],"['AKCEA-ANGPTL3-LRx', 'ISIS 703802', 'ISIS-703802', 'Vupanorsen']",,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0020088', 'MONDO_0018328', 'MONDO_0021187']",3.0,"['ENSG00000141505', 'ENSG00000132855']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/VUPANORSEN/relevant/1/'],,,
CHEMBL448,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,WEXRUCMBJFQVBZ-UHFFFAOYSA-N,Small molecule,False,PENTOBARBITAL,4.0,True,True,['Nembutal'],"['Mebubarbital', 'Mebumal', 'NSC-28708', 'Pentobarbital', 'Pentobarbital calcium', 'Pentobarbital cii', 'Pentobarbitone']",['CHEMBL971'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for insomnia and has 4 investigational indications. It was withdrawn in at least one region.,['Pentobarbital'],['DB00312'],"['EFO_0003890', 'EFO_0008526', 'EFO_0004698', 'EFO_0003777', 'MONDO_0043510']",5.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1973.0,,,"['144205108', '26750091']",['7983'],,,,,
CHEMBL4594584,,,Unknown,False,"ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT",4.0,False,True,['Adynovi'],"['Adynovate', 'Adynovi', 'Antihemophilic factor, pegylated (mw 20000) human sequence recombinant', 'Pegylated recombinant factor viii', 'Pegylated rfviii', 'Rurioctocog alfa pegol']",,Unknown drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for hemophilia a.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,2018.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi'],,,,
CHEMBL553025,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,GBABOYUKABKIAF-IELIFDKJSA-N,Small molecule,True,VINORELBINE,4.0,False,True,[],"['NSC-760087', 'Navelbin', 'Vinorelbine', 'Vinorelbine Base']",['CHEMBL538943'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for cancer and neoplasm and has 52 investigational indications. This drug has a black box warning from the FDA.,,['DB00361'],"['EFO_0000437', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0021063', 'EFO_0004284', 'EFO_0002918', 'MONDO_0004992', 'EFO_1000895', 'EFO_0003869', 'EFO_0000313', 'EFO_0000770', 'EFO_0003050', 'EFO_1000026', 'EFO_0003032', 'EFO_0000571', 'EFO_0000437', 'MONDO_0007254', 'EFO_0000313', 'MONDO_0002367', 'MONDO_0021117', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000621', 'EFO_0000616', 'EFO_0005537', 'EFO_0005952', 'EFO_0000248', 'EFO_1000158', 'EFO_0003869', 'EFO_0000403', 'EFO_0001071', 'MONDO_0008903', 'MONDO_0002158', 'EFO_0000389', 'EFO_0000248', 'EFO_0002617', 'EFO_0000571', 'EFO_0003060', 'EFO_0000211', 'EFO_0000691', 'EFO_0000691', 'EFO_0001378', 'EFO_0006861', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0009348', 'EFO_0000183', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0008903', 'EFO_0000183', 'EFO_0000702', 'MONDO_0001187', 'EFO_0005922', 'EFO_0000565', 'EFO_1000294', 'EFO_0001416', 'MONDO_0001402', 'MONDO_0011962', 'EFO_0005952', 'EFO_0000574', 'MONDO_0007254']",64.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1994.0,,,"['124893200', '29217724', '50111727']",['480999'],,,,,
CHEMBL744,Nc1nc2ccc(OC(F)(F)F)cc2s1,FTALBRSUTCGOEG-UHFFFAOYSA-N,Small molecule,False,RILUZOLE,4.0,False,True,"['Exservan', 'Rilutek', 'Riluzole', 'Riluzole zentiva', 'Teglutik', 'Tiglutik kit']","['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'Riluzole', 'Tiglutik']",['CHEMBL1531817'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for amyotrophic lateral sclerosis and has 22 investigational indications.,['Riluzole'],['DB00740'],"['MONDO_0004976', 'EFO_0001358', 'EFO_0003100', 'MONDO_0007739', 'MONDO_0005301', 'MONDO_0004985', 'HP_0002196', 'MONDO_0002050', 'EFO_0000275', 'MONDO_0007254', 'MONDO_0019037', 'MONDO_0008458', 'EFO_1001919', 'MONDO_0002009', 'EFO_1001050', 'EFO_0003756', 'EFO_0008522', 'EFO_0008525', 'EFO_0000389', 'MONDO_0016163', 'MONDO_0000437', 'MONDO_0004975', 'EFO_0004242']",23.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1995.0,,['riluzole'],"['104171227', '11111723', '11113346', '124881305', '144203803', '170464928', '26751529', '50104104', '85231207', '855844', '90341557']",['8863'],['https://www.ema.europa.eu/en/medicines/human/EPAR/riluzole-zentiva'],,,,
CHEMBL817,Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1,OUDSBRTVNLOZBN-UHFFFAOYSA-N,Small molecule,False,TOLAZAMIDE,4.0,False,True,"['Tolazamide', 'Tolinase']","['NSC-70762', 'Tolazamide', 'U-17835']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and is indicated for diabetes mellitus and type 2 diabetes mellitus.,['Tolazamide'],['DB00839'],"['EFO_0000400', 'MONDO_0005148']",2.0,"['ENSG00000187486', 'ENSG00000006071']",2,1966.0,,,"['11111870', '124881598', '144203832', '144208705', '144210734', '170465136', '26747047', '26751566', '50104182', '56422126', '85231252', '855941']",['9613'],,,,,
CHEMBL101,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,VYMDGNCVAMGZFE-UHFFFAOYSA-N,Small molecule,False,PHENYLBUTAZONE,4.0,True,True,"['Antadol', 'Azolid', 'Butacote', 'Butaject', 'Butazolidin', 'Elmedal', 'Equiphar', 'Phenylbutazone', 'Pro-Bute']","['Ambene', 'Artrizin', 'Bizolin', 'Butadion', 'Butadiona', 'Butapirazol', 'Butatron', 'Butoz', 'Buzon', 'Diphebuzol', 'Diphenylbutazone', 'Ecobutazone', 'Equipalazone', 'Exrheudon n', 'Fenibutazona', 'Fenibutol', 'Fenylbutazon', 'Flexazone', 'G-13871', 'Intrabutazone', 'Intrazone', 'Mepha-butazon', 'NSC-25134', 'Phebuzine', 'Phenylbutazone', 'Phenyzene', 'R-3-ZON', 'Robizone-v', 'Shigrodin', 'Tevcodyne', 'Uzone', 'Zolaphen']",['CHEMBL3137687'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved indications. It was withdrawn in at least one region.,['Phenylbutazone'],['DB00812'],"['EFO_0005755', 'HP_0003326', 'HP_0002829']",3.0,"['ENSG00000073756', 'ENSG00000095303']",2,1980.0,,,"['104171220', '104171221', '11111674', '144203793', '144203794', '144209007', '144213080', '170465040', '17389760', '26747057', '26751573', '50104199', '56436656', '85231197', '855958', '90341773']",['48574'],,,['11'],,
CHEMBL1075,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,FUBVWMNBEHXPSU-UHFFFAOYSA-N,Small molecule,True,MORICIZINE,4.0,False,True,[],"['EN-313', 'EN-313 FREE BASE', 'Ethmozine', 'Moracizine', 'Moricizine']",['CHEMBL1200334'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for cardiac arrhythmia and has 1 investigational indication. This drug has a black box warning from the FDA.,['Moracizine'],['DB00680'],"['EFO_0000275', 'EFO_0004269']",2.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1990.0,,,"['11112721', '174006664', '50086819']",['6997'],,,,,
CHEMBL1215331,N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl,XNULRSOGWPFPBL-REWPJTCUSA-N,Small molecule,False,PF-03882845,1.0,False,False,[],"['PF-3882845', 'Pf-03882845']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,['DB11814'],"['EFO_0000401', 'MONDO_0005148']",2.0,['ENSG00000151623'],1,,,,,,,,,,
CHEMBL1257015,COc1ccc(C(=O)NCc2cccnc2)cc1C(=O)NCc1cccnc1,KYWCWBXGRWWINE-UHFFFAOYSA-N,Small molecule,False,PICOTAMIDE,4.0,False,True,[],"['G-137', 'NSC-304384', 'Picotamide']",['CHEMBL1317747'],Small molecule drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis.,,['DB13327'],['HP_0004419'],1.0,"['ENSG00000006638', 'ENSG00000059377']",2,,,,"['11111675', '50106897', '85231198', '90341089']",,,,,,
CHEMBL2103842,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,UWXSAYUXVSFDBQ-CYBMUJFWSA-N,Small molecule,False,VARLITINIB,2.0,False,False,[],"['AR-00334543', 'ARRY-334543', 'ARRY-543', 'ASLAN-001', 'ASLAN001', 'Varlitinib']",['CHEMBL2105679'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB05944'],"['EFO_0000182', 'MONDO_0001056', 'EFO_0000616', 'EFO_0005221', 'MONDO_0003060', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0002618']",8.0,"['ENSG00000141736', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL2178100,CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@@]1(CO)c1ccccc1,VAJGULUVTFDTAS-GOSISDBHSA-N,Small molecule,False,GLPG0492,1.0,False,False,[],"['(-)-GLPG-0492', 'DT-200', 'G 100192', 'GLPG0492', 'Glpg-0492', 'Glpg0492']",,Small molecule drug with a maximum clinical trial phase of I.,,['DB12461'],,,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL356388,CCOC(=O)c1cnc2c(cnn2CC)c1NN=C(C)C,OPQRBXUBWHDHPQ-UHFFFAOYSA-N,Small molecule,False,ETAZOLATE,2.0,False,False,[],"['EHT-0202', 'Etazolate', 'SQ-20009']",['CHEMBL1256671'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,['Etazolate'],,['MONDO_0004975'],1.0,['ENSG00000166206'],1,,,,"['11111137', '11113501', '124880016', '90341463']",,,,,,
CHEMBL3905910,CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO,MRPGRAKIAJJGMM-OCCSQVGLSA-N,Small molecule,False,VORUCICLIB,2.0,False,False,[],"['P-1446', 'P1446a-05', 'Voruciclib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB15157'],"['EFO_0000756', 'EFO_0000095', 'MONDO_0004992', 'MONDO_0044881']",4.0,['ENSG00000135446'],1,,,,,,,,,,
CHEMBL41,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,Small molecule,True,FLUOXETINE,4.0,False,True,[],"['Fluoxetin ratiopharm', 'Fluoxetine', 'Fluval', 'NSC-283480', 'NSC-758685', 'Prozac', 'Sarafem', 'Symbyax']",['CHEMBL1201082'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 5 approved and 37 investigational indications. This drug has a black box warning from the FDA.,['Fluoxetine'],['DB00472'],"['HP_0002140', 'EFO_0004262', 'MONDO_0002050', 'MONDO_0024290', 'EFO_0003768', 'HP_0011868', 'MONDO_0005147', 'EFO_1001917', 'EFO_1001050', 'EFO_0001361', 'HP_0000726', 'HP_0100543', 'EFO_0001073', 'MONDO_0021632', 'EFO_0000694', 'EFO_0000712', 'EFO_0003948', 'MONDO_0004985', 'EFO_0003761', 'MONDO_0002009', 'EFO_0003758', 'EFO_0003761', 'MONDO_0005090', 'EFO_0002610', 'MONDO_0100096', 'EFO_0005230', 'MONDO_0002009', 'EFO_0005687', 'MONDO_0004985', 'EFO_0009854', 'EFO_0008623', 'EFO_0000546', 'EFO_0004242', 'EFO_0007328', 'EFO_0009963', 'EFO_0008522', 'EFO_0001358', 'EFO_0000474', 'EFO_0005669', 'MONDO_0002050', 'EFO_0007191', 'EFO_0004242']",42.0,['ENSG00000108576'],1,1987.0,,,"['104171153', '144203695', '170465374', '26751973', '26755310', '50104648', '90341619']",['86990'],,,,,
CHEMBL4297744,,,Unknown,False,ELX-02,2.0,False,False,[],"['ELX-02', 'Elx-02', 'Exaluren', 'NB-124']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0000508', 'MONDO_0009061', 'MONDO_0016239', 'EFO_0003086', 'MONDO_0018965']",5.0,"['ENSG00000168028', 'ENSG00000177954', 'ENSG00000137154', 'ENSG00000140988', 'ENSG00000149273', 'ENSG00000145425', 'ENSG00000198034', 'ENSG00000129824', 'ENSG00000083845', 'ENSG00000171863', 'ENSG00000142937', 'ENSG00000170889', 'ENSG00000124614', 'ENSG00000142534', 'ENSG00000112306', 'ENSG00000110700', 'ENSG00000164587', 'ENSG00000115268', 'ENSG00000134419', 'ENSG00000105193', 'ENSG00000182774', 'ENSG00000231500', 'ENSG00000105372', 'ENSG00000008988', 'ENSG00000171858', 'ENSG00000186468', 'ENSG00000138326', 'ENSG00000118181', 'ENSG00000197728', 'ENSG00000143947', 'ENSG00000233927', 'ENSG00000213741', 'ENSG00000149806', 'ENSG00000100316', 'ENSG00000174444', 'ENSG00000122406', 'ENSG00000089009', 'ENSG00000147604', 'ENSG00000148303', 'ENSG00000161016', 'ENSG00000163682', 'ENSG00000147403', 'ENSG00000198755', 'ENSG00000142676', 'ENSG00000197958', 'ENSG00000167526', 'ENSG00000142541', 'ENSG00000188846', 'ENSG00000174748', 'ENSG00000265681', 'ENSG00000063177', 'ENSG00000105640', 'ENSG00000108298', 'ENSG00000122026', 'ENSG00000116251', 'ENSG00000125691', 'ENSG00000198242', 'ENSG00000114391', 'ENSG00000161970', 'ENSG00000131469', 'ENSG00000166441', 'ENSG00000108107', 'ENSG00000162244', 'ENSG00000156482', 'ENSG00000071082', 'ENSG00000144713', 'ENSG00000109475', 'ENSG00000136942', 'ENSG00000182899', 'ENSG00000130255', 'ENSG00000241343', 'ENSG00000145592', 'ENSG00000197756', 'ENSG00000172809', 'ENSG00000198918', 'ENSG00000229117', 'ENSG00000089157', 'ENSG00000137818']",78,,,,,,,,,,
CHEMBL4297876,,,Antibody,False,ZALIFRELIMAB,2.0,False,False,[],"['AGEN1884', 'Agen-1884', 'Agen1884', 'Ugn-301', 'Zalifrelimab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,,"['MONDO_0004992', 'EFO_0000294', 'EFO_0003060', 'EFO_1000026', 'EFO_0000616', 'EFO_0003968', 'EFO_1001968', 'MONDO_0005184', 'MONDO_0002974']",9.0,['ENSG00000163599'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ZALIFRELIMAB/relevant/1/'],,,
CHEMBL451,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,ANTSCNMPPGJYLG-UHFFFAOYSA-N,Small molecule,True,CHLORDIAZEPOXIDE,4.0,False,True,"['Clopoxide', 'Librelease', 'Libritabs', 'Librium', 'Sarlib', 'Trakipeal', 'Zeisin']","['A-Poxide', 'Chlordiazachel', 'Chlordiazepoxide', 'Chlordiazepoxide civ', 'Clopoxide', 'Librium', 'Lygen']",['CHEMBL1200703'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.,['Chlordiazepoxide'],['DB00475'],"['EFO_0005230', 'EFO_0006788', 'MONDO_0007079', 'EFO_0004777', 'MONDO_0002009']",5.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1960.0,,['chlordiazepoxide'],"['144205120', '144205121', '49648393']",['3611'],,,,,
CHEMBL4594455,,,Unknown,False,AGS-16C3F,2.0,False,False,[],"['ADC AGS-16C3F', 'AGS-16C3F', 'Ags-16c3f', 'Ags-16c3f (anti-enpp3 antibody)']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000349', 'EFO_0000681']",2.0,"['ENSG00000154269', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL661,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,VREFGVBLTWBCJP-UHFFFAOYSA-N,Small molecule,True,ALPRAZOLAM,4.0,False,True,"['Alprazolam', 'Niravam', 'Xanax', 'Xanax xr']","['Alprazolam', 'Alprazolam civ', 'NSC-760140', 'U 31,889', 'U-31,889', 'U-31889']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.,['Alprazolam'],['DB00404'],"['EFO_0006788', 'MONDO_0005147', 'EFO_0003890', 'EFO_0000474', 'EFO_1001917', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0005090', 'EFO_1001892', 'HP_0001250', 'EFO_0004262', 'EFO_0001358', 'HP_0000726', 'MONDO_0005277', 'EFO_1001884', 'MONDO_0004979']",16.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1981.0,,['alprazolam'],"['144205245', '26719699', '29215419']",['2611'],,,,,
CHEMBL1200644,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],XEKSTYNIJLDDAZ-JASSWCPGSA-D,Oligosaccharide,True,FONDAPARINUX SODIUM,4.0,False,True,"['Arixtra', 'Fondaparinux sodium']","['Fondaparin sodium', 'Fondaparinux sodium', 'Fondaparinux sodium for assay', 'Fondaparinux sodium identification', 'IC-851589', 'ORG 31540', 'ORG-31540', 'Quixidar', 'SR 90107A', 'SR-90107A']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0001907', 'HP_0004936', 'HP_0000083', 'EFO_0000612', 'EFO_0003907', 'EFO_0004286', 'EFO_1000985', 'EFO_0003827']",8.0,['ENSG00000117601'],1,2001.0,CHEMBL1201202,['fondaparinux%20sodium'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra'],,,,
CHEMBL1201244,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,YXRDKMPIGHSVRX-OOJCLDBCSA-N,Small molecule,False,ROCURONIUM,4.0,False,True,[],"['Rocuronium', 'Rocuronium cation', 'Rocuronium ion']",['CHEMBL1200648'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 11 investigational indications.,['Rocuronium_bromide'],['DB00728'],"['EFO_0009492', 'EFO_0007490', 'EFO_0003843', 'EFO_0010581', 'EFO_0003931', 'EFO_0009492', 'HP_0003326', 'EFO_0003086', 'HP_0003418', 'MONDO_0008315', 'EFO_0002618', 'MONDO_0021117']",12.0,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1994.0,,,['50112687'],['8884'],,,,,
CHEMBL1714,CNC1(c2ccccc2Cl)CCCCC1=O.Cl,VCMGMSHEPQENPE-UHFFFAOYSA-N,Small molecule,False,KETAMINE HYDROCHLORIDE,4.0,False,True,"['Anaket-V', 'Ketalar', 'Ketamine hydrochloride', 'Ketanest', 'Ketavet', 'Vetalar']","['CI-581', 'CL 369', 'CL-369', 'CN-52,372-2', 'CN-52372-2', 'CN-523722', 'Ketamine (as hydrochloride)', 'Ketamine hcl', 'Ketamine hydrochloride', 'Ketamine hydrochloride ciii', 'Ketamini hydrochloridum', 'Special k', 'Vetalar']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 24 investigational indications.,,,"['EFO_0000546', 'EFO_0003931', 'EFO_0000713', 'MONDO_0007079', 'EFO_0007430', 'MONDO_0002009', 'EFO_0009854', 'EFO_0005611', 'EFO_0002610', 'HP_0000360', 'EFO_1000391', 'MONDO_0004992', 'EFO_0004321', 'HP_0000989', 'EFO_0000474', 'HP_0000713', 'MONDO_0002050', 'HP_0100543', 'MONDO_0005351', 'EFO_0004320', 'EFO_0009963', 'EFO_0003015', 'MONDO_0004985', 'EFO_1001884']",24.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,1970.0,CHEMBL742,['ketamine%20hydrochloride'],,['650657'],,,,,
CHEMBL1743000,,,Antibody drug conjugate,False,CITATUZUMAB BOGATOX,2.0,False,False,[],"['Citatuzumab bogatox', 'VB6-845']",,Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000119888'],1,,,,,,,,,,
CHEMBL2109249,,,Antibody,False,AMG-557,2.0,False,False,[],"['AMG-557', 'Amg-557', 'MEDI-5872', 'Medi 5872', 'Prezalumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['MONDO_0007915', 'EFO_0000699', 'EFO_0003834', 'EFO_0000676']",4.0,['ENSG00000160223'],1,,,,,,,,,,
CHEMBL2109621,,,Antibody,False,ABITUZUMAB,2.0,False,False,[],"['ALD403', 'Abituzumab', 'DI 17E6', 'DI-17E6', 'DI17E6', 'EMD 525797', 'EMD-525797']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['MONDO_0008170', 'EFO_0004244', 'EFO_0000717', 'MONDO_0008315', 'EFO_1001951']",5.0,"['ENSG00000138448', 'ENSG00000115221', 'ENSG00000082781', 'ENSG00000259207', 'ENSG00000150093', 'ENSG00000105855']",6,,,,,,,,,,
CHEMBL232201,CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1,CZCHIEJNWPNBDE-UHFFFAOYSA-N,Small molecule,False,BENZIODARONE,4.0,True,True,[],"['Amplivix', 'Benziodarone', 'L 2329', 'L-2329', 'NSC-82133']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region.,['Benziodarone'],['DB13277'],['EFO_0000319'],1.0,['ENSG00000198668'],1,,,,"['144205346', '170465852', '29216089']",,,,['130'],,
CHEMBL2326966,N=C(N)NCCC[C@H](NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)[O-],SVNJBEMPMKWDCO-KCHLEUMXSA-N,Small molecule,False,SF-1126,2.0,False,False,[],"['SF 1126', 'SF-1126', 'SF-1126 INNER SALT', 'Sf-1126']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000181', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000621']",4.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,,,,,,
CHEMBL3545237,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C,CKAXZOYFIHQCBN-UQOAMHMYSA-N,Small molecule,False,HE3235,1.0,False,False,['Apotone'],"['Apoptone', 'HE-3235', 'He 3235', 'He3235']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0008315'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL4297873,,,Protein,False,"ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT",4.0,False,True,['Advate'],"['Advate', 'Antihemophilic factor, human recombinant', 'BAY 14-2222', 'BAY 81-8973', 'BAY W 6240', 'BAY-14-2222', 'BAY-81-8973', 'BAY-W-6240', 'BAY81-8973', 'Bay81-8973', 'Factor viii (rdna)', 'Factor viii octocog alfa', 'Factor viii, recombinant', 'Octocog alfa']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for hemophilia a and has 1 investigational indication.,,,"['MONDO_0010602', 'Orphanet_903']",2.0,['ENSG00000185010'],1,2004.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/advate'],,,,
CHEMBL4650321,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1,MZPVEMOYADUARK-UHFFFAOYSA-N,Small molecule,False,ORELABRUTINIB,3.0,False,False,['Innobruka'],"['ICP-022', 'ICP022', 'Icp-022', 'Orelabrutinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,,"['EFO_0001421', 'MONDO_0018906', 'EFO_1001469', 'EFO_0007160', 'MONDO_0007915', 'EFO_0000616', 'EFO_0000403', 'EFO_0003929', 'EFO_0009441', 'EFO_0000095', 'EFO_0000183', 'EFO_0000096', 'MONDO_0004992']",13.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ORELABRUTINIB/relevant/1/'],,,
CHEMBL4802239,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.O=C(O)CCC(=O)O,YXYAEUMTJQGKHS-UHFFFAOYSA-N,Small molecule,True,MOBOCERTINIB SUCCINATE,4.0,False,True,['Exkivity'],[],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for non-small cell lung carcinoma. This drug has a black box warning from the FDA.,,,['EFO_0003060'],1.0,['ENSG00000146648'],1,2021.0,CHEMBL4650319,,,,,,,,
CHEMBL1097279,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(Cl)(Cl)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Na+].[Na+].[Na+].[Na+],COWWROCHWNGJHQ-OPKBHZIBSA-J,Small molecule,False,CANGRELOR TETRASODIUM,4.0,False,True,"['Kengreal', 'Kengrexal']","['AR-C69931MX', 'Cangrelor tetrasodium', 'Cangrelor tetrasodium salt', 'Kengrexal']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for myocardial infarction and recurrent thrombophlebitis.,,,"['EFO_0000612', 'HP_0004419']",2.0,['ENSG00000169313'],1,2015.0,CHEMBL334966,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal'],,,,
CHEMBL1200338,CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C.O,AFJCNBBHEVLGCZ-UHFFFAOYSA-N,Small molecule,False,PINACIDIL,4.0,False,True,['Pindac'],"['NSC-759588', 'Pinacidil', 'Pinacidil hydrate', 'Pinacidil monohydrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for hypertension.,['Pinacidil'],,['EFO_0000537'],1.0,"['ENSG00000187486', 'ENSG00000069431']",2,1989.0,CHEMBL1159,,"['144204505', '170465261', '56462991']",['34923'],,,,,
CHEMBL1201346,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1,IPOKCKJONYRRHP-FMQUCBEESA-N,Small molecule,False,BALSALAZIDE,4.0,False,True,[],['Balsalazide'],['CHEMBL1200760'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for ulcerative colitis.,,['DB01014'],['EFO_0000729'],1.0,"['ENSG00000132170', 'ENSG00000073756', 'ENSG00000095303', 'ENSG00000012779']",4,2000.0,,,"['144205805', '170465305', '26758056']",['267413'],,,,,
CHEMBL1201577,,,Antibody,True,CETUXIMAB,4.0,False,True,['Erbitux'],"['ABP-494', 'C-225', 'C225', 'CMAB-009', 'CMAB009', 'Cetuximab', 'Cetuximab (genetical recombination)', 'Cetuximab biosimilar (abp-494)', 'IMC-225', 'IMC-C225', 'MOAB C225']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 13 approved and 61 investigational indications. This drug has a black box warning from the FDA.,['Cetuximab'],,"['MONDO_0001056', 'EFO_0005950', 'EFO_0007535', 'EFO_0000571', 'MONDO_0002974', 'EFO_0000519', 'EFO_0009430', 'EFO_0000616', 'MONDO_0007576', 'EFO_0004284', 'EFO_1001931', 'EFO_0004252', 'MONDO_0002358', 'EFO_0002916', 'MONDO_0008315', 'EFO_1001949', 'EFO_0000231', 'MONDO_0021074', 'EFO_0001061', 'EFO_0002938', 'EFO_1001951', 'EFO_0000503', 'EFO_0003897', 'MONDO_0021355', 'EFO_0004142', 'EFO_0005922', 'EFO_0003817', 'MONDO_0004992', 'MONDO_0001187', 'EFO_1000657', 'EFO_0001378', 'MONDO_0021364', 'EFO_0000182', 'MONDO_0002691', 'EFO_0003871', 'EFO_0003835', 'MONDO_0007254', 'EFO_0000673', 'MONDO_0044926', 'EFO_0003060', 'MONDO_0005575', 'MONDO_0008978', 'MONDO_0001879', 'EFO_0006352', 'MONDO_0044704', 'EFO_0004198', 'EFO_0000181', 'MONDO_0021310', 'EFO_0009708', 'EFO_0002618', 'EFO_0000365', 'MONDO_0002087', 'MONDO_0100342', 'EFO_0003869', 'EFO_0000707', 'EFO_1001100', 'MONDO_0005184', 'MONDO_0008903', 'MONDO_0011962', 'EFO_1000251', 'MONDO_0001657', 'EFO_0006859', 'MONDO_0008170', 'EFO_0002499', 'MONDO_0002038', 'EFO_0000313', 'MONDO_0021063', 'EFO_0000691', 'EFO_0003891', 'EFO_0000228', 'EFO_1001998', 'EFO_0003868', 'EFO_0005221', 'EFO_1001950']",74.0,['ENSG00000146648'],1,2004.0,,['cetuximab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux'],,,['4954'],
CHEMBL1611,O=C1N=C([O-])NC1(c1ccccc1)c1ccccc1.[Na+],FJPYVLNWWICYDW-UHFFFAOYSA-M,Small molecule,True,PHENYTOIN SODIUM,4.0,False,True,"['Dilantin', 'Diphenylan sodium', 'Extended phenytoin sodium', 'Pentran', 'Phenytek', 'Phenytex', 'Phenytoin sodium', 'Prompt phenytoin sodium']","['5,5-diphenylhydantoin sodium salt', 'Antisacer', 'Diphenylhydantoin sodium', 'NSC-757274', 'Phenytoin Sodium', 'Phenytoin sodium', 'Phenytoin sodium extended', 'Phenytoin sodium for injection', 'Phenytoin sodium salt', 'Phenytoin sodium, extended', 'Phenytoin sodium, prompt', 'Phenytoin sodium,extended', 'Phenytoin sodium,prompt', 'Phenytoinum natricum', 'Tacosal']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and is indicated for seizure and epilepsy. This drug has a black box warning from the FDA.,,,"['HP_0001250', 'EFO_0000474']",2.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1956.0,CHEMBL16,['phenytoin%20sodium'],"['11112021', '144212655', '14742085', '26757853', '50106089', '85231301', '855788']",,,,,,
CHEMBL1742994,,,Antibody drug conjugate,True,BRENTUXIMAB VEDOTIN,4.0,False,True,['Adcetris'],"['Brentuximab vedotin', 'Brentuximab vedotin brentuximab', 'CAC-10', 'CAC10', 'CAC10-VCMMAE', 'Cac10-1006(4)', 'Cac10-vcmmae(4)', 'Monoclonal antibody sgn-30', 'SGN-35', 'Sgn 30']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0007359', 'MONDO_0019473', 'MONDO_0009348', 'EFO_0000095', 'EFO_0002913', 'EFO_0000616', 'EFO_0001642', 'EFO_0000565', 'EFO_1000785', 'MONDO_0013730', 'EFO_0000096', 'EFO_0000764', 'EFO_1001051', 'MONDO_0019471', 'MONDO_0018906', 'EFO_0000211', 'EFO_0000514', 'EFO_0000222', 'EFO_0003032', 'EFO_0000574', 'MONDO_0007915', 'EFO_0000183', 'EFO_0000403', 'EFO_0000588', 'EFO_0000404', 'EFO_0005952']",26.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000120949']",16,2011.0,,['brentuximab%20vedotin'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris'],,,['4964'],
CHEMBL235668,N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,QQHMKNYGKVVGCZ-UHFFFAOYSA-N,Small molecule,False,TIPIRACIL,4.0,False,True,[],"['MA-1', 'TPI (freebase)', 'Tipiracil']",['CHEMBL65375'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 20 investigational indications.,,['DB09343'],"['EFO_0004252', 'EFO_0000365', 'MONDO_0001187', 'MONDO_0044937', 'EFO_0003869', 'EFO_1001951', 'EFO_1001949', 'EFO_0005221', 'EFO_1000657', 'EFO_0000616', 'EFO_0000365', 'MONDO_0021063', 'EFO_0002618', 'EFO_0000708', 'MONDO_0001056', 'MONDO_0005575', 'EFO_0003860', 'EFO_0004142', 'MONDO_0007254', 'EFO_0000702', 'EFO_1000657']",21.0,['ENSG00000025708'],1,2015.0,,,,,,,,,
CHEMBL29919,Nc1cnc(-c2cc(Cl)cc(Cl)c2Cl)c(N)n1,NNXUYJFHOVCRSM-UHFFFAOYSA-N,Small molecule,False,ELPETRIGINE,2.0,False,False,[],"['Elpetrigine', 'JZP-4']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000141837', 'ENSG00000136531', 'ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001', 'ENSG00000153253', 'ENSG00000148408']",8,,,,,,,,,,
CHEMBL4163691,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1,LZMJNVRJMFMYQS-UHFFFAOYSA-N,Small molecule,False,POSELTINIB,2.0,False,False,[],"['HM71224', 'Hm-71224', 'LY3337641', 'Ly3337641', 'Poseltinib']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000685'],1.0,['ENSG00000010671'],1,,,,,,,,,,
CHEMBL461101,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,XDXWLKQMMKQXPV-QYQHSDTDSA-N,Small molecule,True,ELTROMBOPAG,4.0,False,True,['Revolade'],"['Eltrombopag', 'SB497115']","['CHEMBL461805', 'CHEMBL461806', 'CHEMBL3989691']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 22 investigational indications. This drug has a black box warning from the FDA.,['Eltrombopag'],['DB06210'],"['EFO_0000198', 'EFO_0001421', 'MONDO_0010518', 'HP_0001915', 'EFO_0006927', 'EFO_0000637', 'EFO_0001422', 'EFO_0006927', 'EFO_0000565', 'EFO_0007160', 'EFO_0007160', 'HP_0001873', 'EFO_0004599', 'EFO_0001378', 'EFO_0000095', 'MONDO_0002245', 'EFO_0000616', 'EFO_0003047', 'EFO_0004220', 'EFO_0000198', 'EFO_0000574', 'MONDO_0019391', 'EFO_0004220', 'MP_0001914', 'EFO_0004272', 'EFO_0000222', 'HP_0001873']",27.0,['ENSG00000117400'],1,2008.0,,,,['85010'],,,,,
CHEMBL967,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,SEQDDYPDSLOBDC-UHFFFAOYSA-N,Small molecule,True,TEMAZEPAM,4.0,False,True,"['Kentepam', 'Normison', 'Restoril', 'Temaz', 'Temazepam']","['(rs)-temazepam', 'NSC-246303', 'Temazepam', 'Temazepam civ', 'WY-3917']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for insomnia and has 5 investigational indications. This drug has a black box warning from the FDA.,['Temazepam'],['DB00231'],"['EFO_0005230', 'EFO_0004698', 'EFO_0000341', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090']",6.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1981.0,,['temazepam'],"['144205223', '144207242', '29215382']",['9435'],,,,,
CHEMBL1200377,CC(N)Cc1ccccc1.NC(CC(=O)O)C(=O)O,DYOBNLAYPQSBLB-UHFFFAOYSA-N,Small molecule,False,AMPHETAMINE ASPARTATE,4.0,False,True,[],"['Amfetamine aspartate', 'Amphetamine aspartate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996 and has 1 investigational indication.,,,['EFO_0003888'],1.0,"['ENSG00000103546', 'ENSG00000142319']",2,1996.0,CHEMBL405,['amphetamine%20aspartate'],,,,,,,
CHEMBL1589,CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,VGZSUPCWNCWDAN-UHFFFAOYSA-N,Small molecule,False,ACETOHEXAMIDE,4.0,False,True,"['Acetohexamide', 'Dimelor', 'Dymelor']","['33006', 'Acetohexamide', 'NSC-759128']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for diabetes mellitus and has 1 investigational indication.,['Acetohexamide'],['DB00414'],"['MONDO_0005129', 'EFO_0000400']",2.0,"['ENSG00000187486', 'ENSG00000006071']",2,1964.0,,,"['11110689', '11112460', '144203618', '144209220', '144213052', '170465411', '17390067', '50105548', '56463352']",['28052'],,,,,
CHEMBL1743063,,,Antibody,False,RILOTUMUMAB,3.0,False,False,[],"['AMG 102', 'AMG-102', 'Rilotumumab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,,"['EFO_0000702', 'MONDO_0100342', 'EFO_0000681', 'EFO_0000708', 'EFO_0000588', 'MONDO_0001056', 'MONDO_0008315', 'EFO_1001465']",8.0,['ENSG00000019991'],1,,,,,,,,,,
CHEMBL1822792,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,JGEBLDKNWBUGRZ-HXUWFJFHSA-N,Small molecule,False,MK-2461,2.0,False,False,[],"['MK-2461', 'Mk-2461']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0004992', 'EFO_0000616']",2.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL1852688,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,QADPYRIHXKWUSV-UHFFFAOYSA-N,Small molecule,False,INFIGRATINIB,4.0,False,True,[],"['BGJ-398', 'BGJ398', 'Bgj-398', 'Infigratinib', 'MVP-BGJ398', 'NVP-BGJ398']",['CHEMBL1834657'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 12 investigational indications.,,['DB11886'],"['EFO_0001668', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0044704', 'MONDO_0004992', 'MONDO_0007037', 'EFO_0005221', 'EFO_1002027', 'EFO_0000519', 'EFO_0005221', 'EFO_0000616', 'MONDO_0001187', 'EFO_1001961', 'MONDO_0011719', 'EFO_0000756', 'EFO_0001061']",16.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,2021.0,,,,['63451'],,['https://searchusan.ama-assn.org/finder/usan/search/INFIGRATINIB/relevant/1/'],,,
CHEMBL2043437,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,SFNSLLSYNZWZQG-VQIMIIECSA-N,Small molecule,True,GLASDEGIB,4.0,False,True,[],"['Glasdegib', 'PF-04449913', 'PF-4449913']","['CHEMBL4297534', 'CHEMBL2043440']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,['DB11978'],"['EFO_0000519', 'MONDO_0020547', 'MONDO_0004992', 'EFO_0000198', 'EFO_0000222', 'EFO_1001968', 'EFO_0000222', 'EFO_0000616']",8.0,['ENSG00000128602'],1,2018.0,,,,,,,,,
CHEMBL232202,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,BJRNKVDFDLYUGJ-RMPHRYRLSA-N,Small molecule,False,ARBUTIN,2.0,False,False,[],"['Arbutin', 'Arbutinum', 'Arbutoside', 'NSC-4036', 'Ursin']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,['Arbutin'],['DB11217'],['EFO_0003963'],1.0,['ENSG00000077498'],1,,,,"['144205062', '144212745', '170465722', '93576640']",['18305'],,,,,
CHEMBL3678076,CCCCOc1cccc(CCNCC(=O)N(C)C)c1,GRHBODILPPXVKN-UHFFFAOYSA-N,Small molecule,False,EVENAMIDE,2.0,False,False,[],"['Evenamide', 'Nw-3509']",['CHEMBL4286909'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005090'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,,,,,,,,,,
CHEMBL3707320,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl,GYABBVHSRIHYJR-UHFFFAOYSA-N,Small molecule,False,ALECTINIB HYDROCHLORIDE,4.0,False,True,['Alecensa'],[],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for non-small cell lung carcinoma.,,,['EFO_0003060'],1.0,"['ENSG00000171094', 'ENSG00000165731', 'ENSG00000143924']",3,2015.0,CHEMBL1738797,['alectinib%20hydrochloride'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa'],,,,
CHEMBL3907479,Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1,BEMNJULZEQTDJY-UHFFFAOYSA-N,Small molecule,False,FGFR INHIBITOR DEBIO 1347,2.0,False,False,[],['Fgfr inhibitor debio 1347'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12903'],"['MONDO_0007254', 'EFO_0000616']",2.0,"['ENSG00000077782', 'ENSG00000068078', 'ENSG00000066468']",3,,,,,,,,,,
CHEMBL4297945,,,Unknown,False,EFMOROCTOCOG ALFA,4.0,False,True,['Elocta'],"['Efmoroctocog alfa', 'Efraloctocog alfa', 'Elocta', 'Eloctate']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hemophilia a and hemophilia.,,,"['MONDO_0010602', 'MONDO_0018660']",2.0,['ENSG00000185010'],1,2015.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/elocta'],,,,
CHEMBL4303201,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,KSMZEXLVHXZPEF-UHFFFAOYSA-N,Small molecule,False,CATEQUENTINIB,3.0,False,False,[],"['AL 3818', 'AL-3818', 'AL3818', 'Al-3818', 'Anlotinib', 'Catequentinib']",['CHEMBL5314570'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 60 investigational indications.,,,"['MONDO_0021117', 'EFO_0003108', 'EFO_0002618', 'EFO_0003860', 'MONDO_0004992', 'EFO_0004252', 'EFO_0000564', 'EFO_0000756', 'MONDO_0011962', 'EFO_0000333', 'MONDO_0005575', 'EFO_0001378', 'EFO_1001512', 'EFO_0003869', 'EFO_1001951', 'EFO_0000174', 'MONDO_0002367', 'EFO_0000616', 'EFO_1000657', 'EFO_0000616', 'EFO_0005221', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0024503', 'MONDO_0008170', 'MONDO_0020547', 'EFO_0007143', 'EFO_0003818', 'EFO_0000707', 'MONDO_0015277', 'EFO_0003060', 'EFO_0000403', 'EFO_1001968', 'EFO_0000691', 'EFO_0003820', 'MONDO_0008903', 'EFO_1000359', 'EFO_0000313', 'EFO_1001972', 'MONDO_0002108', 'MONDO_0003060', 'EFO_0000574', 'MONDO_0011719', 'EFO_0001376', 'MONDO_0002912', 'EFO_0002916', 'HP_0001410', 'MONDO_0100342', 'MONDO_0007576', 'EFO_0005537', 'EFO_0000681', 'EFO_0001071', 'EFO_0000702', 'MONDO_0002974', 'MONDO_0001056', 'EFO_0000621', 'EFO_0005922', 'EFO_0000588', 'EFO_0000519', 'EFO_0000181']",60.0,"['ENSG00000128052', 'ENSG00000037280', 'ENSG00000157404', 'ENSG00000113721']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/CATEQUENTINIB/relevant/1/'],,,
CHEMBL592054,Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1,ULVDFHLHKNJICZ-QCWLDUFUSA-N,Small molecule,False,IMIGLITAZAR,3.0,False,False,[],"['Imiglitazar', 'TAK-559', 'Tak-559']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB12511'],['EFO_0000400'],1.0,"['ENSG00000132170', 'ENSG00000186951']",2,,,,,,,,,,
CHEMBL92,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,Small molecule,True,DOCETAXEL ANHYDROUS,4.0,False,True,[],"['Bind 014', 'CKD-810', 'Cabazitaxel metabolite (rp56976)', 'Docetaxel accord', 'Docetaxel kabi', 'Docetaxel mylan', 'Docetaxel teva', 'Docetaxel teva pharma', 'Docetaxel winthrop', 'Docetaxel, anhydrous', 'NSC-628503', 'RP-56976', 'Rp56976', 'Taxotere']",['CHEMBL3545252'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 20 approved and 96 investigational indications. This drug has a black box warning from the FDA.,['Docetaxel'],['DB01248'],"['MONDO_0011719', 'HP_0002039', 'EFO_0000313', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0004281', 'MONDO_0021117', 'EFO_0007355', 'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'EFO_0000181', 'MONDO_0004986', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000673', 'MONDO_0001528', 'EFO_0000432', 'HP_0004326', 'EFO_0001416', 'MONDO_0003060', 'EFO_0009708', 'EFO_0006859', 'EFO_0004230', 'MONDO_0008903', 'EFO_1001951', 'MONDO_0008315', 'MONDO_0005271', 'MONDO_0000521', 'MONDO_0002038', 'EFO_0003869', 'MONDO_0021310', 'EFO_1000043', 'MONDO_0005575', 'EFO_0003891', 'MONDO_0004192', 'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'Orphanet_145', 'EFO_0001376', 'EFO_1000984', 'EFO_0005537', 'EFO_0003817', 'EFO_0000616', 'MONDO_0001325', 'MONDO_0002120', 'EFO_0000174', 'EFO_0000565', 'EFO_0000574', 'EFO_0000178', 'EFO_0003860', 'EFO_0007362', 'EFO_0005570', 'EFO_0002916', 'MONDO_0021063', 'EFO_0005088', 'EFO_0000503', 'EFO_0002938', 'EFO_0000571', 'EFO_0006352', 'EFO_0000707', 'EFO_0003897', 'MONDO_0002158', 'EFO_0000466', 'EFO_0003060', 'EFO_0002428', 'EFO_0000756', 'EFO_0000198', 'EFO_0000199', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0003865', 'EFO_0000702', 'MONDO_0002367', 'EFO_0001663', 'EFO_0000637', 'EFO_0002618', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0018364', 'EFO_0008528', 'EFO_0000305', 'EFO_0003893', 'EFO_0006911', 'EFO_0004284', 'HP_0012378', 'MONDO_0007254', 'MONDO_0001056', 'EFO_0000228', 'MONDO_0011962', 'EFO_0000691', 'EFO_0000196', 'MONDO_0007576', 'EFO_0000564', 'EFO_0005950', 'MONDO_0001475', 'EFO_1000601', 'MONDO_0021355', 'MONDO_0004669', 'EFO_0000182', 'EFO_0000708', 'EFO_0001075', 'EFO_0005577', 'MONDO_0003199', 'EFO_1001100', 'EFO_1001931', 'EFO_1001214', 'EFO_0004252', 'EFO_0003859', 'EFO_1000595', 'EFO_0001378', 'MONDO_0001402']",116.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1996.0,,,"['124950708', '144206334', '144206639', '170464919', '494081']",['4672'],,,,,
CHEMBL1684984,CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,JEGHXKRHKHPBJD-UHFFFAOYSA-N,Small molecule,False,IZORLISIB,2.0,False,False,[],"['CH-5132799', 'CH5132799', 'Ch 5132799', 'Izorlisib', 'PA-799', 'PA799', 'Pa-799']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB13051'],['EFO_0000616'],1.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL2109326,,,Antibody,False,MIK-BETA-1,1.0,False,False,[],"['MIK-BETA-1', 'Mik-beta-1']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000565'],1.0,['ENSG00000100385'],1,,,,,,,,,,
CHEMBL2364968,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,ZQLJWTRXKINMIN-BEJKIDSHSA-N,Unknown,False,ERGOLOID,4.0,False,True,[],[],['CHEMBL2311030'],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for cardiovascular disease and has 2 investigational indications.,,,"['EFO_0004718', 'EFO_0000319', 'MONDO_0010383']",3.0,"['ENSG00000149295', 'ENSG00000151577', 'ENSG00000169676', 'ENSG00000069696', 'ENSG00000184845', 'ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000135312', 'ENSG00000178394']",13,1953.0,,,,,,,,,
CHEMBL4297422,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@@H]1C(=O)Nc2ccccc2-c2ccccc21,OJPLJFIFUQPSJR-INIZCTEOSA-N,Small molecule,False,RG-4733,2.0,False,False,[],"['RO 4929097', 'RO-4929097', 'Rg 4733', 'Rg-4733', 'Ro4929097']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications.,,['DB11870'],"['EFO_0000365', 'EFO_1000251', 'MONDO_0021063', 'EFO_0000616', 'EFO_0000756', 'EFO_0000673', 'EFO_0001075', 'EFO_0001378', 'EFO_0002501', 'EFO_0000349', 'EFO_0005537', 'EFO_1001465', 'EFO_0000389', 'EFO_1000657', 'EFO_0006861', 'EFO_0002499', 'MONDO_0007254', 'EFO_0003060']",18.0,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']",6,,,,,,,,,,
CHEMBL4297508,CC(C)C[C@@H](C(=O)Nc1ccn(C[C@@H](O)CO)n1)N1CC(Oc2ccccc2Cl)=CC1=O,HMUMWSORCUWQJO-QAPCUYQASA-N,Small molecule,False,DORZAGLIATIN,3.0,False,False,[],"['Dorzagliatin', 'HMS-5552', 'HMS5552', 'Hms5552', 'RO-5305552', 'RO5305552', 'Sinogliatin']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB15123'],"['HP_0001952', 'MONDO_0005148', 'EFO_0000400']",3.0,['ENSG00000106633'],1,,,,,,,,,,
CHEMBL101253,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,YCOYDOIWSSHVCK-UHFFFAOYSA-N,Small molecule,False,VATALANIB,3.0,False,False,[],"['BAY-86-5127', 'CGP-79787', 'K-222584', 'NVP-PTK787', 'PTK-787', 'PTK787', 'Ptk-787', 'Vatalanib', 'Vatalanib succinate', 'ZK-222584', 'ZK222584']","['CHEMBL75232', 'CHEMBL2142861']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications.,['Vatalanib'],['DB04879'],"['MONDO_0008667', 'EFO_0002618', 'MONDO_0002087', 'EFO_1000158', 'EFO_0001378', 'EFO_0000588', 'EFO_1000657', 'MONDO_0011962', 'MONDO_0002367', 'EFO_0002430', 'EFO_0004288', 'EFO_0000691', 'EFO_0000519', 'EFO_0000222', 'EFO_0000339', 'MONDO_0002974', 'EFO_0000403', 'EFO_0000389', 'EFO_0000756', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0003869', 'EFO_0009708', 'EFO_0000616', 'MONDO_0008315', 'EFO_0003060', 'MONDO_0002158', 'EFO_0001365', 'EFO_1001901', 'MONDO_0004992']",30.0,"['ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000182578', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",7,,,,"['103905548', '104171421', '144206361', '170466113', '50100112']",['90620'],,,,,
CHEMBL1200560,CC(=O)O.N=C(N)N/N=C/c1c(Cl)cccc1Cl,MCSPBPXATWBACD-GAYQJXMFSA-N,Small molecule,False,GUANABENZ ACETATE,4.0,False,True,"['Guanabenz acetate', 'Wytensin']","['Guanabenz acetate', 'Guanabenz monoacetate', 'NSC-757044', 'WY-8678', 'WY-8678 ACETATE']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1982.0,CHEMBL420,,['50106405'],,,,,,
CHEMBL12610,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,CNBGNNVCVSKAQZ-UHFFFAOYSA-N,Small molecule,False,BENZYDAMINE,4.0,False,True,[],"['Apo-benzydamine', 'Benzindamine', 'Benzydamine']",['CHEMBL1528134'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 2 investigational indications.,['Benzydamine'],['DB09084'],"['EFO_1001904', 'HP_0003326', 'EFO_0009688', 'EFO_1001904', 'EFO_0005755', 'HP_0002829', 'EFO_0005757']",7.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,"['11112291', '160657813']",,,,,,
CHEMBL1738697,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12,LGXVKMDGSIWEHL-UHFFFAOYSA-N,Small molecule,False,PF-00337210,1.0,False,False,[],"['Pf-00337210', 'Pf-337210']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL2103761,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,VXMOONUMYLCFJD-DHLKQENFSA-N,Small molecule,False,BARNIDIPINE,2.0,False,False,[],"['Barnidipine', 'Barnidipine hydrochloride', 'Mepirodipine', 'Vasexten']",['CHEMBL2356712'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB09227'],['EFO_0000319'],1.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,,,,,,,
CHEMBL2108667,,,Antibody drug conjugate,True,YTTRIUM Y 90 IBRITUMOMAB TIUXETAN,4.0,False,True,[],"['(90)y-ibritumomab tiuxetan', '90y ibritumomab tiuxetan', '90y-ibritumomab', 'Ibritumomab tiuxetan y-90', 'Ibritumomab tiuxetan yttrium y-90', 'Yttrium y 90 ibritumomab tiuxetan', 'Yttrium y-90 ibritumomab tiuxetan']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 17 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0013730', 'EFO_0000183', 'EFO_0001378', 'EFO_0003032', 'EFO_0000191', 'EFO_0009441', 'EFO_1001365', 'EFO_0000403', 'EFO_0000565', 'EFO_0000309', 'EFO_1001469', 'MONDO_0000873', 'EFO_0000574', 'EFO_0000095', 'EFO_0005952', 'EFO_0000096', 'MONDO_0018906']",17.0,['ENSG00000156738'],1,2002.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin'],,,,
CHEMBL2109265,,,Antibody,False,MOC31-PE,1.0,False,False,[],"['MOC31-PE', 'Moc31-pe']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000313'],1.0,['ENSG00000119888'],1,,,,,,,,,,
CHEMBL2109592,,,Antibody,False,MEDI-500,3.0,False,False,[],"['MEDI-500', 'Medi-500', 'T10B9']",,Antibody drug with a maximum clinical trial phase of III.,,,,,"['ENSG00000211810', 'ENSG00000277734', 'ENSG00000278030', 'ENSG00000211699']",4,,,,,,,,,,
CHEMBL2143592,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,PDYXPCKITKHFOZ-UHFFFAOYSA-N,Small molecule,False,BMS-794833,1.0,False,False,[],['Bms-794833'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000105976', 'ENSG00000128052']",2,,,,['137276020'],,,,,,
CHEMBL230011,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,UJIAQDJKSXQLIT-UHFFFAOYSA-N,Small molecule,False,TG100-115,2.0,False,False,[],"['TG100-115', 'Tg100-115']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB05552'],['EFO_0000612'],1.0,"['ENSG00000105851', 'ENSG00000171608']",2,,,,,,,,,,
CHEMBL3137301,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,PYNXFZCZUAOOQC-UTKZUKDTSA-N,Small molecule,False,SACUBITRIL,4.0,False,True,[],"['AHU-377', 'AHU377', 'Sacubitril']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for heart failure and congestive heart failure and has 11 investigational indications.,,['DB09292'],"['EFO_0003144', 'EFO_0007148', 'EFO_0000612', 'EFO_0008583', 'MONDO_0001134', 'EFO_0004265', 'MONDO_0005149', 'EFO_0000538', 'MONDO_0100096', 'EFO_0000537', 'EFO_0000373', 'EFO_0008585', 'EFO_0005529']",13.0,['ENSG00000196549'],1,2015.0,,['sacubitril'],,,,,,,
CHEMBL4297258,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C,GHKOONMJXNWOIW-UHFFFAOYSA-N,Small molecule,False,FIRMONERTINIB,3.0,False,False,[],"['AST-2818', 'AST2818', 'Alflutinib', 'Firmonertinib', 'Furmonertinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0003060', 'MONDO_0008903', 'EFO_0000571', 'EFO_0000616']",4.0,['ENSG00000146648'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-129']
CHEMBL441,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,IUJDSEJGGMCXSG-UHFFFAOYSA-N,Small molecule,False,THIOPENTAL,4.0,False,True,[],"['Thiopental', 'Thiopental ciii']",['CHEMBL738'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 5 investigational indications.,,['DB00599'],"['EFO_0006834', 'EFO_0008526', 'HP_0000486', 'EFO_1001454', 'MONDO_0043510']",5.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,,['29215503'],['102166'],,,,,
CHEMBL452,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,DGBIGWXXNGSACT-UHFFFAOYSA-N,Small molecule,True,CLONAZEPAM,4.0,False,True,"['Clonazepam', 'Klonopin', 'Klonopin rapidly disintegrating', 'Rivotril']","['Clonazepam', 'Clonazepam civ', 'NSC-179913', 'RO 5-4023', 'RO-5-4023', 'RO-54023', 'Ravotril', 'Rivatril']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA.,['Clonazepam'],['DB01068'],"['EFO_0000474', 'EFO_0003843', 'EFO_0004262', 'EFO_0005230', 'HP_0001250', 'EFO_0008526', 'EFO_1000850', 'EFO_0007262', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0007191', 'HP_0000726', 'EFO_0007462', 'EFO_1000924', 'EFO_0005762']",15.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1975.0,,['clonazepam'],,['3756'],,,,,
CHEMBL1200690,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,BJFIDCADFRDPIO-DZCXQCEKSA-N,Protein,False,LYPRESSIN,4.0,False,True,['Diapid'],"['8-l-lysinevasopressin', 'L-8', 'Lypressin', 'Lysine vasopressin', 'Vasopressin pig', 'Vasopressin, 8-l-lysine']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.,,['DB14642'],,,"['ENSG00000126895', 'ENSG00000166148', 'ENSG00000198049']",3,1982.0,,,"['144206455', '144206977']",,,,,,
CHEMBL1272,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,FAEKWTJYAYMJKF-QHCPKHFHSA-N,Small molecule,False,REPAGLINIDE,4.0,False,True,"['Enyglid', 'Novonorm', 'Prandin', 'Repaglinide', 'Repaglinide krka']","['A10BX02', 'AG-EE 623 ZW', 'AG-EE-623-ZW', 'AG-EE-623ZW', 'AGEE-623ZW', 'NSC-759893', 'Prandin', 'Repaglinide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 12 investigational indications.,['Repaglinide'],['DB00912'],"['MONDO_0044970', 'EFO_0001068', 'EFO_0000616', 'EFO_0000400', 'EFO_0001645', 'HP_0003124', 'MONDO_0005148', 'MONDO_0011719', 'MONDO_0008315', 'EFO_0003914', 'MONDO_0009061', 'MONDO_0005180', 'EFO_0000685', 'EFO_0000537']",14.0,"['ENSG00000187486', 'ENSG00000006071']",2,1997.0,,['repaglinide'],"['11112894', '144204272', '26719812', '49648522']",['8805'],['https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-krka'],,,,
CHEMBL1743047,,,Antibody,True,NECITUMUMAB,4.0,False,True,['Portrazza'],"['11F8', 'IMC-11F8', 'Necitumumab', 'Portrazza']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and non-small cell lung carcinoma and has 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000708', 'EFO_0000707', 'EFO_0000616', 'EFO_0003060', 'EFO_0009708']",5.0,['ENSG00000146648'],1,2015.0,,['necitumumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/portrazza'],,,['5071'],
CHEMBL1751,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,LTMHDMANZUZIPE-PUGKRICDSA-N,Small molecule,False,DIGOXIN,4.0,False,True,"['Digamex', 'Digoxin', 'Digoxin pediatric', 'Lanoxicaps', 'Lanoxin', 'Lanoxin pediatric', 'Lanoxin-125', 'Lanoxin-pg', 'Vanoxin']","['Digoxin', 'Digoxinum', 'Dynamos', 'Fargoxin', 'Lanocardin', 'Mapluxin', 'NSC-95100', 'Natigoxin', 'Rougoxin', 'Stillacor-', 'Toloxin', 'Vanoxin']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 34 investigational indications.,['Digoxin'],['DB00390'],"['EFO_1000359', 'EFO_1001249', 'EFO_0006911', 'MONDO_0002009', 'EFO_0000616', 'EFO_0003047', 'EFO_0000400', 'EFO_0000222', 'MP_0001845', 'EFO_0001062', 'MONDO_0008667', 'EFO_0000764', 'EFO_0003890', 'MONDO_0001134', 'EFO_0000474', 'EFO_0000685', 'EFO_0000373', 'EFO_0001073', 'EFO_0000558', 'EFO_0006859', 'EFO_0003869', 'MONDO_0002050', 'EFO_0003060', 'EFO_0007328', 'HP_0004755', 'EFO_0000198', 'EFO_0000544', 'EFO_0000275', 'EFO_0003144', 'EFO_0000756', 'MONDO_0008315', 'MONDO_0019623', 'EFO_0000319', 'EFO_0002496', 'MONDO_0005148', 'EFO_0003843', 'MONDO_0007254', 'EFO_0004239']",38.0,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731']",8,1975.0,,['digoxin'],"['11533002', '144204576', '144208876', '144213367', '17389540', '26752810', '49718191', '50105460', '56422204']",['4551'],,,,,
CHEMBL2109065,,,Protein,False,DROTRECOGIN ALFA (ACTIVATED),4.0,True,True,['Xigris'],"['Activated protein c', 'Drotrecogin alfa', 'Drotrecogin alfa (activated)', 'Drotrecogin alfa activated', 'Drotrecogin alfa, activated', 'Drotrecogin-alfa', 'LY-203638', 'LY203638']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 7 investigational indications. It was withdrawn in at least one region.,,,"['EFO_0005251', 'EFO_0006834', 'HP_0100806', 'EFO_0003827', 'HP_0002140', 'EFO_0000712', 'HP_0004419', 'EFO_0003884', 'MONDO_0100130', 'EFO_1001373']",10.0,"['ENSG00000198734', 'ENSG00000185010']",2,2001.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/xigris'],,,,
CHEMBL2109630,,,Antibody,False,BC8 131I,2.0,False,False,[],"['BC8', 'Bc8 131i']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000081237'],1,,,,,,,,,,
CHEMBL3989949,NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl,GFHAXPJGXSQLPT-VIFPVBQESA-N,Small molecule,False,CENOBAMATE,4.0,False,True,"['Ontozry', 'Xcopri']","['Cenobamate', 'YKP-3089', 'YKP3089']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 2 investigational indications.,,['DB06119'],"['EFO_0000474', 'HP_0001250', 'EFO_0001421', 'EFO_0004263', 'HP_0007359']",5.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",26,2020.0,,['cenobamate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry'],,,,
CHEMBL4297229,,,Unknown,True,PRABOTULINUMTOXIN A,4.0,False,True,['Jeuveau'],"['ABP 450', 'ABP-450', 'ABP450', 'Botulinum toxin type a complex', 'DWP-450', 'DWP450', 'Prabotulinumtoxin a', 'Prabotulinumtoxina', 'Prabotulinumtoxina xvfs']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for skin aging and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0005422', 'MONDO_0005277', 'HP_0000473']",3.0,['ENSG00000132639'],1,2019.0,,['prabotulinumtoxina-xvfs'],,,,,,,
CHEMBL4297536,,,Oligonucleotide,False,PATISIRAN SODIUM,4.0,False,True,['Onpattro'],[],,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved indications.,,,"['MONDO_0018634', 'EFO_0004129', 'EFO_0009562', 'EFO_1001875']",4.0,['ENSG00000118271'],1,2018.0,,['patisiran%20sodium'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/onpattro'],,,,
CHEMBL4594214,CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC3=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O,BPKIMPVREBSLAJ-QTBYCLKRSA-N,Protein,False,ZICONOTIDE,4.0,False,True,[],"['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 2 investigational indications.,,,"['EFO_0003843', 'HP_0001945']",2.0,['ENSG00000148408'],1,2004.0,,,,,,,,,
CHEMBL5315078,,,Unknown,False,EPTACOG BETA (ACTIVATED),4.0,False,True,['Cevenfacta'],[],,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hemophilia b and hemophilia a.,,,"['MONDO_0010604', 'MONDO_0010602']",2.0,['ENSG00000057593'],1,2022.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/cevenfacta'],,,,
CHEMBL941,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,KTUFNOKKBVMGRW-UHFFFAOYSA-N,Small molecule,False,IMATINIB,4.0,False,True,[],"['Glamox', 'Gleevec', 'Imatinib', 'NSC-743414', 'NSC-759854', 'STI-571']","['CHEMBL2386595', 'CHEMBL1642']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for chronic myelogenous leukemia and has 110 investigational indications.,['Imatinib'],['DB00619'],"['EFO_0004288', 'EFO_0006861', 'MONDO_0002108', 'EFO_0000717', 'EFO_0000760', 'EFO_1001361', 'MONDO_0005575', 'EFO_0003106', 'EFO_0003032', 'EFO_0001361', 'MONDO_0011934', 'EFO_0000756', 'MONDO_0004979', 'MONDO_0004643', 'EFO_0007328', 'EFO_0000181', 'EFO_0000685', 'MONDO_0008978', 'EFO_0004198', 'EFO_0000717', 'EFO_0000220', 'MONDO_0005301', 'MONDO_0018975', 'MONDO_0005147', 'EFO_1001465', 'MONDO_0002108', 'EFO_0000702', 'EFO_0002429', 'HP_0001880', 'MONDO_0013730', 'EFO_0000588', 'EFO_0009907', 'EFO_1000729', 'MONDO_0100096', 'EFO_0000339', 'MONDO_0004992', 'EFO_0002617', 'MONDO_0021063', 'MONDO_0005149', 'MONDO_0011962', 'MONDO_0009937', 'EFO_0000691', 'MONDO_0008170', 'EFO_1000657', 'EFO_1000895', 'MONDO_0008903', 'MONDO_0007254', 'EFO_0000641', 'MONDO_0100096', 'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715', 'EFO_0000313', 'EFO_0009907', 'EFO_0000209', 'MONDO_0007254', 'EFO_1000613', 'EFO_0000756', 'MONDO_0001056', 'EFO_1001471', 'MONDO_0018076', 'EFO_1000359', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000333', 'EFO_0000768', 'EFO_0003060', 'EFO_0004683', 'EFO_0001361', 'MONDO_0000870', 'EFO_0006859', 'EFO_0000519', 'EFO_0000497', 'EFO_0000094', 'EFO_0005952', 'EFO_0001422', 'EFO_0000616', 'MONDO_0011382', 'MONDO_0011719', 'MONDO_0008315', 'EFO_0002087', 'EFO_0007444', 'EFO_0000339', 'MONDO_0004992', 'MONDO_0005149', 'MONDO_0044881', 'EFO_1000158', 'EFO_1001951', 'MONDO_0002367', 'MONDO_0002087', 'MONDO_0000873', 'MONDO_0013730', 'EFO_0000519', 'MONDO_0011719', 'MONDO_0011705', 'MONDO_0002158', 'EFO_0000503', 'EFO_1001467', 'EFO_0000712', 'EFO_1001814', 'EFO_1001467', 'EFO_0000673', 'EFO_0000658', 'EFO_1000576', 'EFO_0000691', 'EFO_1001993', 'EFO_0002430', 'EFO_0000365', 'EFO_0000222', 'EFO_0004610', 'EFO_0001376', 'EFO_0003956', 'MONDO_0044917', 'EFO_0002428', 'EFO_0000616', 'MONDO_0020547', 'EFO_0000565', 'EFO_0005952', 'EFO_1001919', 'EFO_0004289', 'EFO_0000220', 'EFO_0000349', 'MONDO_0000873', 'EFO_0000565', 'EFO_0000574', 'EFO_0003897', 'EFO_0000222']",127.0,"['ENSG00000097007', 'ENSG00000186716', 'ENSG00000113721', 'ENSG00000157404']",4,2001.0,,,"['103905596', '124892207', '124892208', '124892209', '26755316', '29215405', '50100104']",['45783'],,,,,
CHEMBL193,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],HYIMSNHJOBLJNT-UHFFFAOYSA-N,Small molecule,False,NIFEDIPINE,4.0,False,True,"['Adalat', 'Adalat a.r.', 'Adalat cc', 'Adalat ic', 'Adalat la 20', 'Adalat la 30', 'Adalat la 60', 'Adalat ret', 'Adalate lp', 'Adanif xl', 'Adipine mr 10', 'Adipine mr 20', 'Adipine xl', 'Afeditab cr', 'Angiopine 10', 'Angiopine 40 la', 'Angiopine 5', 'Angiopine mr 10', 'Angiopine mr 20', 'Calanif', 'Calchan mr 10', 'Calchan mr 20', 'Calcilat', 'Cardilate mr', 'Coracten sr', 'Coracten xl', 'Coroday mr', 'Fortipine la40', 'Genalat 10 ret', 'Genalat 20 ret', 'Hypolar ret 10', 'Hypolar ret 20', 'Hypolar xl 30', 'Kentipine', 'Kentipine mr 10', 'Kentipine mr 20', 'Neozipine xl', 'Nife-wolff', 'Nifedipine', 'Nifedipress mr 10', 'Nifedipress mr 20', 'Nifedotard 20 mr', 'Nifelease', 'Nifensar xl', 'Nifopress mr', 'Nifopress ret', 'Nimodrel mr 10', 'Nimodrel mr 20', 'Nimodrel xl', 'Nivaten ret', 'Procardia', 'Procardia xl', 'Slofedipine xl 30', 'Slofedipine xl 60', 'Tensipine mr 10', 'Tensipine mr 20', 'Unipine xl', 'Valni 20 ret', 'Valni xl', 'Vasad']","['BAY A 1040', 'BAY-A-1040', 'Coracten', 'NSC-757242', 'Nifedipine', 'Nifedipine hydrochloride', 'Nifedipine slow release', 'Nifedipinum']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 15 investigational indications.,['Nifedipine'],['DB01115'],"['MONDO_0018479', 'HP_0000093', 'EFO_1001145', 'EFO_0000401', 'EFO_0003917', 'EFO_1001375', 'EFO_0003890', 'EFO_0004263', 'EFO_0009660', 'EFO_0007442', 'HP_0012390', 'MONDO_0005149', 'EFO_0000668', 'EFO_0003884', 'EFO_0004225', 'EFO_0000319', 'EFO_0000537', 'EFO_0004253']",18.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1981.0,,['nifedipine'],"['104171202', '11111548', '11111549', '11113899', '124880908', '124880909', '124880910', '124880913', '144203763', '144207502', '170465006', '17388858', '26747150', '26747151', '26752059', '26752060', '50100293', '50104712', '50104713', '50104714', '85231157', '90341123']",['7565'],,,['91'],,
CHEMBL2104986,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1,CVASBKDYSQKLSO-UHFFFAOYSA-N,Small molecule,False,TEDATIOXETINE,2.0,False,False,[],"['LU AA24530', 'LU-AA24530', 'LUAA24530', 'Lu aa24530', 'Tedatioxetine']",['CHEMBL2107377'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12641'],['MONDO_0002009'],1.0,"['ENSG00000166736', 'ENSG00000186038', 'ENSG00000149305', 'ENSG00000186090', 'ENSG00000178084', 'ENSG00000147246', 'ENSG00000142319', 'ENSG00000103546', 'ENSG00000102468', 'ENSG00000120907', 'ENSG00000108576']",11,,,,,,,,,,
CHEMBL2105728,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,DYNHJHQFHQTFTP-UHFFFAOYSA-N,Small molecule,False,CRENOLANIB,3.0,False,False,[],"['ARO 002', 'ARO-002', 'CP 868596', 'CP-868,596', 'CP-868596', 'Crenolanib']",['CHEMBL2146086'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,['DB11832'],"['EFO_0005543', 'EFO_1000026', 'MONDO_0011719', 'EFO_0000616', 'EFO_0000222', 'EFO_0000222', 'EFO_0000503', 'MONDO_0011719', 'EFO_0000519']",9.0,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000122025']",3,,,,,,,,,,
CHEMBL2108072,,,Enzyme,False,PAMITEPLASE,2.0,False,False,[],"['Pamiteplase', 'Solinase']",,Enzyme drug with a maximum clinical trial phase of II.,,,,,['ENSG00000104368'],1,,,,,,,,,,
CHEMBL2108735,,,Oligonucleotide,False,DRISAPERSEN,3.0,False,False,[],"['Drisapersen', 'GSK-2402968', 'GSK-2402968A', 'GSK2402968', 'GSK2402968A', 'Gsk 2402968a', 'H51AON23', 'PRO-051', 'PRO051']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['MONDO_0020121', 'MONDO_0010679']",2.0,['ENSG00000198947'],1,,,,,,,,,,
CHEMBL222460,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO,QESHSZWKJULSAR-UHFFFAOYSA-N,Small molecule,False,BMS-223131,2.0,False,False,[],['Bms-223131'],,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000156113'],1,,,,,,,,,,
CHEMBL23,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,HSUGRBWQSSZJOP-RTWAWAEBSA-N,Small molecule,False,DILTIAZEM,4.0,False,True,[],"['Cardizem', 'Dilt-CD', 'Diltiazem', 'Diltiazem extended release', 'Diltzac', 'Ditiaz', 'Surazem', 'Tiamate', 'Tiazac']","['CHEMBL1697', 'CHEMBL1200805']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 approved and 25 investigational indications.,['Diltiazem'],['DB00343'],"['EFO_0004888', 'EFO_0002687', 'EFO_0000701', 'MONDO_0000831', 'EFO_1001375', 'EFO_0000195', 'HP_0003124', 'EFO_0003890', 'EFO_0000537', 'EFO_0000537', 'EFO_0009660', 'EFO_0000538', 'EFO_0003144', 'EFO_0000275', 'EFO_1001951', 'EFO_0009552', 'EFO_0007328', 'EFO_0004225', 'EFO_0001645', 'EFO_0003914', 'MONDO_0004992', 'HP_0012390', 'EFO_0000319', 'EFO_0000275', 'MONDO_0005148', 'EFO_0005251', 'HP_0012390', 'MONDO_0100096', 'EFO_0000764', 'EFO_0003913', 'HP_0002019']",31.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1982.0,,,"['11113366', '144204449', '170464699', '26751609', '26751610', '50104266', '50104267', '50104268', '50104269', '90341257']",['101278'],,,['92'],,
CHEMBL3137345,,,Antibody,False,DULIGOTUZUMAB,2.0,False,False,[],"['Duligotumab', 'Duligotuzumab', 'MEHD-7945A', 'MEHD7945A', 'RG-7597', 'RG7597']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000616', 'EFO_1001951', 'EFO_0006859']",3.0,"['ENSG00000065361', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL3545110,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,RHXHGRAEPCAFML-UHFFFAOYSA-N,Small molecule,False,RIBOCICLIB,4.0,False,True,[],"['LEE-011', 'LEE-011A', 'LEE011', 'LEE011A', 'Lee-011', 'NVP-LEE011', 'Ribociclib']","['CHEMBL4468983', 'CHEMBL3707266']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 34 investigational indications.,,['DB11730'],"['MONDO_0002158', 'MONDO_0007254', 'EFO_0003085', 'EFO_0000616', 'MONDO_0044903', 'EFO_0000569', 'EFO_0000519', 'EFO_0002499', 'EFO_0000182', 'EFO_0005701', 'EFO_0000220', 'EFO_1001968', 'EFO_0000574', 'EFO_0000313', 'EFO_0000181', 'EFO_0000305', 'EFO_0001075', 'EFO_0000196', 'MONDO_0004992', 'EFO_1001901', 'EFO_0002626', 'EFO_0003869', 'EFO_0000305', 'EFO_1001100', 'EFO_0000756', 'EFO_0000616', 'EFO_0003859', 'EFO_1000251', 'EFO_0003869', 'MONDO_0002601', 'EFO_0003086', 'EFO_0005220', 'EFO_1000026', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0008170', 'MONDO_0007254', 'EFO_0000621']",38.0,"['ENSG00000135446', 'ENSG00000105810']",2,2017.0,,,,,,,,,
CHEMBL4297560,,,Antibody,False,GATIPOTUZUMAB,2.0,False,False,[],['Gatipotuzumab'],,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL4297581,,,Oligonucleotide,False,TOMINERSEN,3.0,False,False,[],"['ISIS-443139 FREE ACID', 'Ionis httrx', 'Isis 443139', 'RG-6042 FREE ACID', 'RG6042', 'RG6042 FREE ACID', 'Rg6042', 'Ro7234292', 'Tominersen']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['EFO_0006835', 'MP_0001845', 'MONDO_0015492', 'MONDO_0007739', 'EFO_1000710']",5.0,['ENSG00000197386'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TOMINERSEN/relevant/1/'],,,
CHEMBL4594605,,,Unknown,False,OMFILOCTOCOG ALFA,3.0,False,False,[],"['Omfiloctocog alfa', 'SCT-800', 'SCT800', 'Sct800']",,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,,,,,,,,,,
CHEMBL5095492,C=CC(=O)Nc1cc(C#CC(C)(C)N2CCN(C)CC2)cc2ncnc(Nc3ccc(F)c(Cl)c3)c12,JZDDKMMYGMSSFH-UHFFFAOYSA-N,Small molecule,False,MP-412,1.0,False,False,[],[],['CHEMBL5095024'],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['MONDO_0004992', 'EFO_0000616']",2.0,"['ENSG00000141736', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL604710,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1,VCPMZDWBEWTGNW-UHFFFAOYSA-N,Small molecule,False,Z160,2.0,False,False,[],"['MK-6721', 'MK6721', 'NMED-160', 'NP-118809', 'Z-160', 'Z160']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12743'],"['MONDO_0002959', 'MONDO_0041052']",2.0,['ENSG00000148408'],1,,,,,,,,,,
CHEMBL633,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,Small molecule,True,AMIODARONE,4.0,False,True,[],"['Amiodarone', 'Cordarone', 'L-3428', 'Pacerone', 'SKF 33134-A']",['CHEMBL1083993'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 16 investigational indications. This drug has a black box warning from the FDA.,['Amiodarone'],['DB01118'],"['EFO_0004269', 'EFO_0004287', 'EFO_0007243', 'EFO_0000373', 'HP_0004755', 'MONDO_0100096', 'EFO_0001645', 'EFO_0000275', 'EFO_0005306', 'EFO_0003911', 'MONDO_0019438', 'EFO_0005529', 'EFO_0000612', 'EFO_0009492', 'EFO_0004287', 'EFO_0004278', 'EFO_0003144', 'EFO_0005306', 'HP_0004308', 'EFO_0000275', 'HP_0004308', 'EFO_0000318']",22.0,['ENSG00000055118'],1,1985.0,,,"['104171110', '11110784', '11110785', '124879287', '144203634', '170464920', '26751596', '26751597', '50100172', '90341282']",['2663'],,,['33'],,
CHEMBL1228,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O,HFHZKZSRXITVMK-UHFFFAOYSA-N,Small molecule,False,OXYPHENBUTAZONE ANHYDROUS,4.0,True,True,"['Oxyphenbutazone', 'Tandearil']","['Californit', 'Crovaril', 'Flogitolo', 'Flogoril', 'Frabel', 'G-27202', 'NSC-526053', 'Neo-farmadol', 'Oxalid', 'Oxyphenbutazone', 'RO-04-4410', 'Rapostan', 'Reozon', 'Suganril', 'Visubutina']",['CHEMBL3989676'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 approved indications.,['Oxyphenbutazone'],['DB03585'],"['EFO_0005752', 'EFO_0005755', 'HP_0002829', 'HP_0003326']",4.0,"['ENSG00000073756', 'ENSG00000095303']",2,1960.0,,,"['144203965', '170465310', '26748182', '56463172']",['76258'],,,,,
CHEMBL1297,CC(C(=O)O)c1cccc(Oc2ccccc2)c1,RDJGLLICXDHJDY-UHFFFAOYSA-N,Small molecule,True,FENOPROFEN,4.0,False,True,['Progesic'],"['53858', 'Fenoprofen', 'LILLY-53858', 'NSC-757813', 'Nalfon']","['CHEMBL2068720', 'CHEMBL2103736', 'CHEMBL138241']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved indications. This drug has a black box warning from the FDA.,['Fenoprofen'],['DB00573'],"['MONDO_0005178', 'EFO_0000685', 'EFO_0005755']",3.0,"['ENSG00000073756', 'ENSG00000095303']",2,1976.0,,,,['5004'],,,,,
CHEMBL1738797,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,KDGFLJKFZUIJMX-UHFFFAOYSA-N,Small molecule,False,ALECTINIB,4.0,False,True,['Alecensa'],"['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802', 'RO5424802']",['CHEMBL3707320'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 19 investigational indications.,,['DB11363'],"['EFO_0001421', 'EFO_0000756', 'EFO_0000641', 'MONDO_0004992', 'EFO_0001642', 'EFO_0000691', 'EFO_0003032', 'EFO_0005221', 'EFO_0003826', 'EFO_0003893', 'EFO_0004142', 'EFO_0003833', 'EFO_0000326', 'MONDO_0021117', 'EFO_1000849', 'EFO_0000616', 'EFO_0003860', 'EFO_1001901', 'EFO_0003060', 'EFO_0000519', 'EFO_0003060', 'EFO_0004284']",22.0,"['ENSG00000171094', 'ENSG00000165731', 'ENSG00000143924']",3,2015.0,,,['174006440'],,,,,,
CHEMBL2107759,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C,GJQWFXNJAXOCBV-XVGNUGADSA-N,Small molecule,False,MILATAXEL,2.0,False,False,[],"['MAC-321', 'Milataxel']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0003060', 'EFO_0004288', 'EFO_1000657', 'EFO_0000588']",4.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL333021,c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,VOYMOBPSYVKQGF-UHFFFAOYSA-N,Small molecule,False,L-21649,1.0,False,False,[],['L-21649'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,,,,,,,,,,
CHEMBL4297789,,,Unknown,False,MT-3724,2.0,False,False,[],['Mt-3724'],,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0005952', 'EFO_0000403', 'EFO_0004289', 'EFO_0000095']",4.0,"['ENSG00000156738', 'ENSG00000168028', 'ENSG00000177954', 'ENSG00000137154', 'ENSG00000140988', 'ENSG00000149273', 'ENSG00000145425', 'ENSG00000198034', 'ENSG00000129824', 'ENSG00000083845', 'ENSG00000171863', 'ENSG00000142937', 'ENSG00000170889', 'ENSG00000124614', 'ENSG00000142534', 'ENSG00000112306', 'ENSG00000110700', 'ENSG00000164587', 'ENSG00000115268', 'ENSG00000134419', 'ENSG00000105193', 'ENSG00000182774', 'ENSG00000231500', 'ENSG00000105372', 'ENSG00000008988', 'ENSG00000171858', 'ENSG00000186468', 'ENSG00000138326', 'ENSG00000118181', 'ENSG00000197728', 'ENSG00000143947', 'ENSG00000233927', 'ENSG00000213741', 'ENSG00000149806', 'ENSG00000100316', 'ENSG00000174444', 'ENSG00000122406', 'ENSG00000089009', 'ENSG00000147604', 'ENSG00000148303', 'ENSG00000161016', 'ENSG00000163682', 'ENSG00000147403', 'ENSG00000198755', 'ENSG00000142676', 'ENSG00000197958', 'ENSG00000167526', 'ENSG00000142541', 'ENSG00000188846', 'ENSG00000174748', 'ENSG00000265681', 'ENSG00000063177', 'ENSG00000105640', 'ENSG00000108298', 'ENSG00000122026', 'ENSG00000116251', 'ENSG00000125691', 'ENSG00000198242', 'ENSG00000114391', 'ENSG00000161970', 'ENSG00000131469', 'ENSG00000166441', 'ENSG00000108107', 'ENSG00000162244', 'ENSG00000156482', 'ENSG00000071082', 'ENSG00000144713', 'ENSG00000109475', 'ENSG00000136942', 'ENSG00000182899', 'ENSG00000130255', 'ENSG00000241343', 'ENSG00000145592', 'ENSG00000197756', 'ENSG00000172809', 'ENSG00000198918', 'ENSG00000229117', 'ENSG00000089157', 'ENSG00000137818']",79,,,,,,,,,,
CHEMBL4594334,,,Oligonucleotide,False,EPLONTERSEN,3.0,False,False,[],"['AKCEA-TTR-LRx', 'Akcea ttr lrx', 'Akcea-ttr-lrx', 'Eplontersen', 'ION-682884', 'ION-682884 FREE ACID', 'IONIS-TTR-LRx', 'ISIS-682884 FREE ACID', 'Ion-ttr-lrx']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0004129', 'EFO_1001875']",2.0,['ENSG00000118271'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/EPLONTERSEN/relevant/1/'],,,
CHEMBL545315,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl,JZZFDCXSFTVOJY-UHFFFAOYSA-N,Small molecule,False,CANERTINIB DIHYDROCHLORIDE,3.0,False,False,[],"['CI-1033', 'Canertinib dihydrochloride', 'Canertinib hydrochloride', 'PD-0183805', 'PD-0183805-002B', 'PD-183805', 'SN-26606']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0003869', 'MONDO_0021117', 'EFO_0003060']",3.0,"['ENSG00000178568', 'ENSG00000141736', 'ENSG00000146648']",3,,CHEMBL31965,,,,,,,,
CHEMBL806,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,MKXKFYHWDHIYRV-UHFFFAOYSA-N,Small molecule,True,FLUTAMIDE,4.0,False,True,"['Chimax', 'Drogenil', 'Eulexin', 'Flutamide']","['Flutamide', 'NSC-215876', 'SCH 13521', 'SCH-13521']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA.,['Flutamide'],['DB00499'],"['EFO_0000616', 'EFO_0000196', 'EFO_0000313', 'MONDO_0008170', 'EFO_0000673', 'MONDO_0008315', 'EFO_0000660', 'EFO_0001663']",8.0,['ENSG00000169083'],1,1989.0,,['flutamide'],"['104171162', '11111202', '11111203', '11532925', '124880151', '124880153', '144203705', '144209367', '144210854', '170464921', '17388997', '174007322', '26747365', '26747366', '26753014', '26753015', '49675006', '50105597', '50105598', '50105599', '50105600', '85231055', '90341271']",['5132'],,,['44'],,
CHEMBL1709,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21.Cl,BLFQGGGGFNSJKA-XHXSRVRCSA-N,Small molecule,True,SERTRALINE HYDROCHLORIDE,4.0,False,True,"['Aremis', 'Besitron', 'Lustral', 'Sertraline hydrochloride', 'Zoloft']","['CP-51,974-1', 'CP-51974-1', 'NSC-746308', 'NSC-758948', 'Sertraline (as hydrochloride)', 'Sertraline hcl', 'Sertraline hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0002050', 'EFO_1001917', 'EFO_0001358', 'EFO_0004262', 'MONDO_0007739', 'MONDO_0002009', 'EFO_0003761', 'HP_0002315', 'EFO_0004242', 'HP_0001249']",10.0,['ENSG00000108576'],1,1991.0,CHEMBL809,['sertraline%20hydrochloride'],"['144204750', '170465121', '26719805', '26753298', '26753614', '49681568']",['9124'],,,,,
CHEMBL20,CC(=O)Nc1nnc(S(N)(=O)=O)s1,BZKPWHYZMXOIDC-UHFFFAOYSA-N,Small molecule,True,ACETAZOLAMIDE,4.0,False,True,"['Acetazolamide', 'Diamox', 'Diamox sr', 'Eytazox']","['Acetamox', 'Acetazolamide', 'Acetazolamidum', 'Atenezo', 'Defiltran', 'Didoc', 'Diuriwas', 'Donmox', 'Edemox', 'Glaupax', 'L 579486', 'NSC-145177', 'Nephramide', 'Phonurit']","['CHEMBL1200814', 'CHEMBL542496']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 8 approved and 22 investigational indications. This drug has a black box warning from the FDA.,['Acetazolamide'],['DB00819'],"['MONDO_0005301', 'EFO_0002617', 'MONDO_0005147', 'EFO_0003086', 'Orphanet_37553', 'MONDO_0005041', 'EFO_1000961', 'EFO_1001065', 'HP_0012532', 'HP_0002104', 'MONDO_0008315', 'EFO_0009373', 'MONDO_0005090', 'EFO_0005252', 'EFO_0008526', 'MONDO_0003005', 'EFO_1001132', 'EFO_0000182', 'EFO_1000782', 'EFO_0001361', 'MONDO_0005041', 'EFO_0007231', 'EFO_0003144', 'EFO_0000702', 'MONDO_0001744', 'HP_0001250', 'EFO_0000712', 'EFO_0003918', 'EFO_0000373', 'MONDO_0001744', 'HP_0001250', 'EFO_0000474', 'EFO_0009373', 'EFO_1001010']",34.0,"['ENSG00000167434', 'ENSG00000074410', 'ENSG00000133742', 'ENSG00000104267']",4,1953.0,,['acetazolamide'],"['11110757', '144208757', '144213090', '170464692', '26747033', '26751551', '50104152', '855900']",['27690'],,,['108'],,
CHEMBL2104793,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1.Cl,MWRACNBZNVAJHE-UHFFFAOYSA-N,Small molecule,False,PYROVALERONE HYDROCHLORIDE,4.0,True,True,[],"['Centroton', 'F 1983', 'F-1983', 'Pyrovalerone hcl', 'Pyrovalerone hydrochloride', 'SP-1059', 'Thymergix']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,,,,"['ENSG00000142319', 'ENSG00000103546']",2,,CHEMBL201960,,,,,,,,
CHEMBL2105233,C=CCC1(CC(C)O)C(=O)NC(=O)NC1=O,VNLMRPAWAMPLNZ-UHFFFAOYSA-N,Small molecule,False,PROXIBARBAL,4.0,True,True,[],"['Axeen', 'Centralgol', 'HH-184', 'Hydroxydial', 'Ipronal', 'Proxibarbal']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,['DB13253'],,,"['ENSG00000002726', 'ENSG00000189221']",2,,,,,,,,,,
CHEMBL4297845,,,Unknown,False,TRU-015,2.0,False,False,[],"['Pf-5212374', 'Tru-015']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0007915', 'EFO_0000574', 'EFO_0000685']",3.0,['ENSG00000156738'],1,,,,,,,,,,
CHEMBL4298002,,,Antibody,False,ICHORCUMAB,2.0,False,False,[],"['Ichorcumab', 'JNJ-375', 'JNJ-64179375', 'JNJ-9375', 'Jnj-64179375']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000180210'],1,,,,,,,,,,
CHEMBL5315093,,,Unknown,False,AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA CDNA SEQUENCE,4.0,False,True,['Strimvelis'],[],,Unknown drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for severe combined immunodeficiency.,,,['MONDO_0015974'],1.0,['ENSG00000196839'],1,2016.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis'],,,,
CHEMBL558,Cc1cccc(C)c1OCC(C)N,VLPIATFUUWWMKC-UHFFFAOYSA-N,Small molecule,True,MEXILETINE,4.0,False,True,[],"['(rs)-mexiletine', 'Dl-mexiletine', 'Mexiletine']",['CHEMBL1200606'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 10 investigational indications. This drug has a black box warning from the FDA.,['Mexiletine'],['DB00379'],"['MONDO_0016107', 'MONDO_0016120', 'EFO_0004278', 'EFO_0000612', 'MONDO_0015626', 'HP_0004308', 'EFO_0004287', 'MONDO_0011728', 'EFO_0004269', 'HP_0012532', 'Orphanet_273', 'EFO_0009387', 'EFO_0000555']",13.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1985.0,,,['90341048'],['6916'],,,['103'],,
CHEMBL1200749,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl,SIEYLFHKZGLBNX-NTISSMGPSA-N,Small molecule,False,LEVOBUPIVACAINE HYDROCHLORIDE,4.0,False,True,"['Chirocaine', 'Levobupivac']","['Bupivacaine (-)-form hydrochloride', 'CHIROCAINE', 'Levobupivacaine hcl', 'Levobupivacaine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 2 investigational indications.,,,"['EFO_0003843', 'EFO_0002950']",2.0,['ENSG00000007314'],1,1999.0,CHEMBL1201193,,"['144205259', '170465452']",['31772'],,,,,
CHEMBL1364551,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1.Cl.Cl,GNUCGROXDZMCJI-UHFFFAOYSA-N,Small molecule,False,MINAPRINE HYDROCHLORIDE,4.0,True,True,['Cantor'],"['30038-CB', '30038CB', 'Minaprine dihydrochloride', 'Minaprine hcl', 'Minaprine hydrochloride', 'NSC-305742']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,,,,"['ENSG00000149295', 'ENSG00000184845', 'ENSG00000168539', 'ENSG00000135914', 'ENSG00000102468', 'ENSG00000147246', 'ENSG00000087085', 'ENSG00000189221']",8,,CHEMBL278819,,"['144204908', '170466172', '26748498']",['51040'],,,,,
CHEMBL1795072,,,Protein,True,ZICONOTIDE ACETATE,4.0,False,True,['Prialt'],['Ziconotide acetate'],,Protein drug with a maximum clinical trial phase of IV that was first approved in 2004. This drug has a black box warning from the FDA.,,,,,['ENSG00000148408'],1,2004.0,,['ziconotide%20acetate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/prialt'],,,,
CHEMBL2109355,,,Antibody,False,DUSIGITUMAB,2.0,False,False,[],"['Dusigitumab', 'MEDI-573', 'MEDI573']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0007254', 'MONDO_0004992', 'EFO_0000182']",3.0,"['ENSG00000167244', 'ENSG00000017427']",2,,,,,,,,,,
CHEMBL2151572,O=C(N[C@H]1CN2CCC1CC2)c1cc2cccc(Cl)c2s1,SSRDSYXGYPJKRR-ZDUSSCGKSA-N,Small molecule,False,ENCENICLINE,3.0,False,False,[],"['EVP-6124', 'Encenicline', 'Evp-6124', 'MT-4666', 'MT4666']",['CHEMBL3137323'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,['DB11726'],"['HP_0000726', 'EFO_0005411', 'HP_0100543', 'EFO_0003086', 'MONDO_0004975', 'MONDO_0005090', 'EFO_0001421', 'MONDO_0005090', 'MONDO_0004975']",9.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL240163,C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,XAGMUUZPGZWTRP-ZETCQYMHSA-N,Small molecule,False,PAZUFLOXACIN,3.0,False,False,[],"['Pazufloxacin', 'T-3761']",['CHEMBL3764913'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB11774'],"['EFO_0004992', 'EFO_0000771', 'EFO_1000829']",3.0,"['ENSG00000131747', 'ENSG00000077097']",2,,,,"['144206084', '170465985', '26719888', '49681761', '50112787']",,,,,,
CHEMBL3137352,,,Antibody,False,RALPANCIZUMAB,2.0,False,False,[],"['PF-05335810', 'RN-317', 'RN317', 'Ralpancizumab']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['HP_0003124'],1.0,['ENSG00000169174'],1,,,,,,,,,,
CHEMBL3989987,,,Oligonucleotide,False,PATISIRAN,4.0,False,True,[],"['ALN-18328', 'ALN-TTR02', 'Genz-438027', 'Patisiran', 'SAR-438037']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.,,,"['EFO_0004129', 'EFO_1000783', 'EFO_1001875']",3.0,['ENSG00000118271'],1,,,,,,,,,,
CHEMBL501,CC(N)Cc1ccccc1.O=S(=O)(O)O,SOFQDLYSFOWTJX-UHFFFAOYSA-N,Small molecule,True,AMPHETAMINE SULFATE,4.0,False,True,"['Amphetamine sulfate', 'Evekeo', 'Evekeo odt']","['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine Sulfate', 'Amphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfate', 'Dl-amphetamine sulphate', 'NSC-170999']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0001073', 'MONDO_0016158', 'EFO_0003888', 'EFO_0002610']",4.0,"['ENSG00000103546', 'ENSG00000142319']",2,1960.0,CHEMBL405,['amphetamine%20sulfate'],,,,,,,
CHEMBL5314386,Cc1c(O)ccc2c1OC[C@@H](c1ccc(O)cc1)[C@H]2c1ccc(O)cc1,QVCAATSEPLQVBX-FPOVZHCZSA-N,Small molecule,False,ME-344,1.0,False,False,[],"['Me 344', 'Me-344']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,,"['EFO_0000305', 'EFO_0000616', 'EFO_1001951']",3.0,"['ENSG00000198695', 'ENSG00000130414', 'ENSG00000110717', 'ENSG00000212907', 'ENSG00000184983', 'ENSG00000198888', 'ENSG00000165264', 'ENSG00000189043', 'ENSG00000174886', 'ENSG00000099795', 'ENSG00000198763', 'ENSG00000158864', 'ENSG00000198786', 'ENSG00000119421', 'ENSG00000136521', 'ENSG00000198886', 'ENSG00000198840', 'ENSG00000004779', 'ENSG00000125356', 'ENSG00000164258', 'ENSG00000119013', 'ENSG00000109390', 'ENSG00000131495', 'ENSG00000168653', 'ENSG00000115286', 'ENSG00000145494', 'ENSG00000183648', 'ENSG00000213619', 'ENSG00000170906', 'ENSG00000065518', 'ENSG00000166136', 'ENSG00000090266', 'ENSG00000267855', 'ENSG00000151366', 'ENSG00000140990', 'ENSG00000178127', 'ENSG00000023228', 'ENSG00000167792', 'ENSG00000160194', 'ENSG00000128609', 'ENSG00000139180', 'ENSG00000164182', 'ENSG00000178057', 'ENSG00000185633', 'ENSG00000147123', 'ENSG00000123545', 'ENSG00000186010', 'ENSG00000184752', 'ENSG00000137806', 'ENSG00000147684']",50,,,,,,,,,,
CHEMBL592445,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,DWZAEMINVBZMHQ-UHFFFAOYSA-N,Small molecule,False,GEDATOLISIB,3.0,False,False,[],"['Gedatolisib', 'PF-05212384', 'PKI-587']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,['DB11896'],"['EFO_0000198', 'MONDO_0004992', 'EFO_0005537', 'EFO_0004230', 'EFO_0003060', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000616']",8.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,,,,,,
CHEMBL108,NC(=O)N1c2ccccc2C=Cc2ccccc21,FFGPTBGBLSHEPO-UHFFFAOYSA-N,Small molecule,True,CARBAMAZEPINE,4.0,False,True,"['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'Epimaz', 'Epimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol Xr', 'Tegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'Teril', 'Teril ret', 'Timonil 200 ret', 'Timonil 400 ret']","['Biston', 'Carbamazepine', 'Carbamazepine anhydrous', 'Carbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883', 'GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'Neurotol', 'Neurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA.,['Carbamazepine'],['DB00564'],"['EFO_0000764', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0015643', 'MONDO_0005090', 'EFO_0009963', 'EFO_0006911', 'MONDO_0100096', 'HP_0000726', 'HP_0001250', 'EFO_0004263', 'EFO_0002610', 'MONDO_0005180', 'MONDO_0004985', 'EFO_1001219', 'EFO_0000474', 'EFO_0004197']",17.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1968.0,,['carbamazepine'],"['11110939', '11110940', '124879629', '144203655', '144209471', '144210515', '170464712', '17389547', '26751576', '50104203', '56314829', '56422193', '855967', '90341617']",['3387'],,,['18'],,
CHEMBL1201604,,,Antibody,True,TOSITUMOMAB,4.0,False,True,['Bexxar'],['Tositumomab'],,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 investigational indications. This drug has a black box warning from the FDA.,['Tositumomab'],,"['EFO_0000574', 'EFO_0005952', 'MONDO_0018906', 'EFO_0000096', 'EFO_1001469', 'EFO_0000095']",6.0,['ENSG00000156738'],1,2003.0,,,,,,,,,
CHEMBL1551724,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N,RTRQQBHATOEIAF-UUOKFMHZSA-N,Small molecule,False,ACADESINE,3.0,False,False,[],"['Acadesine', 'GP-1-110', 'NSC-105823']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB04944'],"['EFO_0000319', 'EFO_0000095']",2.0,"['ENSG00000162409', 'ENSG00000131791', 'ENSG00000181929', 'ENSG00000106617', 'ENSG00000111725', 'ENSG00000132356', 'ENSG00000115592']",7,,,,"['124893186', '144205104', '170465608', '29217492']",['28498'],,,,,
CHEMBL2001019,OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,PDMUGYOXRHVNMO-UHFFFAOYSA-N,Small molecule,False,PF-04217903,1.0,False,False,[],"['MET TYROSINE KINASE INHIBITOR PF-04217903', 'PF-04217903', 'PF-4217903', 'Pf-04217903']",['CHEMBL2170804'],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB12848'],['EFO_0000616'],1.0,['ENSG00000105976'],1,,,,"['103905666', '137276005']",,,,,,
CHEMBL2219421,O=C(O)c1ccc(/C=C/S(=O)(=O)Cc2ccc(Cl)cc2)cc1,KBEKQQJUNVQLDZ-MDZDMXLPSA-N,Small molecule,False,RECILISIB,2.0,False,False,['Ex-rad'],"['ON 01210', 'ON 01210.Na', 'ON01210', 'On-01210', 'Recilisib']",['CHEMBL2219410'],Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,,,,
CHEMBL281872,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,YBTGTVGEKMZEQX-UHFFFAOYSA-N,Small molecule,False,ZD-4190,1.0,False,False,[],['ZD-4190'],['CHEMBL3544937'],Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL3545134,,,Small molecule,False,LY-2780301,1.0,False,False,[],['Ly-2780301'],,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0000574', 'EFO_0009708']",2.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208', 'ENSG00000175634', 'ENSG00000108443']",5,,,,,,,,,,
CHEMBL3659497,CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1,AYOOGWWGECJQPI-NSHDSACASA-N,Small molecule,False,AZD-7451,1.0,False,False,[],"['Azd-7451', 'Utatrectinib']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000519'],1.0,"['ENSG00000140538', 'ENSG00000148053', 'ENSG00000198400']",3,,,,,,,,,,
CHEMBL3678958,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21,WSOHOUHPUOAXIN-UHFFFAOYSA-N,Small molecule,False,RUSERONTINIB,3.0,False,False,[],"['Ruserontinib', 'SKLB-1028', 'Sklb 1028', 'Sklb1028']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000222', 'EFO_0000616']",2.0,"['ENSG00000146648', 'ENSG00000122025', 'ENSG00000097007']",3,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-127']
CHEMBL370805,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C,ZPUCINDJVBIVPJ-LJISPDSOSA-N,Small molecule,True,COCAINE,4.0,False,True,[],"['(r)-(-)-cocaine', 'Benzoylmethylecgonine', 'Cocaine', 'Cocainum', 'IDS-NC-004', 'Neurocaine', 'RX-0041', 'RX0041']",['CHEMBL529437'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 investigational indications. This drug has a black box warning from the FDA.,,['DB00907'],"['EFO_0005800', 'EFO_0005611', 'MONDO_0005271', 'EFO_0002610', 'EFO_0002610']",5.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2017.0,,,,['27958'],,,,,
CHEMBL3833330,,,Antibody,False,CINPANEMAB,2.0,False,False,[],"['BIIB-054', 'BIIB054', 'Cinpanemab', 'Ni-202']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005180'],1.0,['ENSG00000145335'],1,,,,,,,,,,
CHEMBL3989820,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O,VXRDAMSNTXUHFX-UHFFFAOYSA-N,Small molecule,True,ZOLPIDEM TARTRATE,4.0,False,True,"['Ambien', 'Ambien cr', 'Edluar', 'Intermezzo', 'Stilnoct', 'Tovalt odt', 'Zolpidem tartrate', 'Zolpimist']","['Ivadal', 'Myslee', 'Niotal', 'SL 80.0750-23N', 'SL-80.0750', 'SL-80.0750-23N', 'Stilnox', 'Tovalt', 'Zolpidem hemitartrate', 'Zolpidem tartrate', 'Zolpidem tartrate civ']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for insomnia and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0004698', 'EFO_0001073', 'EFO_0008568']",3.0,"['ENSG00000022355', 'ENSG00000113327', 'ENSG00000163288']",3,1992.0,CHEMBL911,['zolpidem%20tartrate'],,,,,,,
CHEMBL5095050,CCCCCCCCCCCCOS(=O)(=O)O.CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,XTLZVNMZICNQBB-UHFFFAOYSA-N,Small molecule,False,FINGOLIMOD LAURYL SULFATE,4.0,False,True,['Tascenso odt'],['Tascenso'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021.,,,,,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']",5,2021.0,CHEMBL314854,,,,,,,,
CHEMBL5170587,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F,OPSIVAKKLQRWKC-VXGBXAGGSA-N,Small molecule,False,VK5211,2.0,False,False,[],"['LGD-4033', 'Ligandrol', 'Vk 5211', 'Vk-5211', 'Vk5211']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003964'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL844,Brc1c(NC2=NCCN2)ccc2nccnc12,XYLJNLCSTIOKRM-UHFFFAOYSA-N,Small molecule,False,BRIMONIDINE,4.0,False,True,[],"['AGN-190342 FREE BASE', 'Brimonidine', 'NSC-318825', 'UK-14304', 'UK-1430418 FREE BASE']","['CHEMBL1200389', 'CHEMBL2062257']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 14 investigational indications.,['Brimonidine'],['DB00484'],"['EFO_0003770', 'EFO_1000906', 'EFO_1001069', 'MONDO_0021698', 'MONDO_0001330', 'EFO_0004190', 'EFO_0000537', 'EFO_1001893', 'MONDO_0001330', 'MONDO_0005041', 'EFO_0003822', 'HP_0000951', 'EFO_1000879', 'MONDO_0005041', 'HP_0010783', 'EFO_1000760', 'EFO_1000906', 'HP_0031284', 'EFO_1001069', 'EFO_0005751', 'EFO_0007141', 'EFO_1000760', 'EFO_0004190']",23.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1996.0,,,"['104171261', '11111939', '11113354', '144203850', '170464941', '26751556', '50104157', '85231282', '855898', '90340645']",['3175'],,,,,
CHEMBL1201421,,,Unknown,False,PEGAPTANIB SODIUM,4.0,False,True,['Macugen'],"['EYE-001', 'EYE001', 'EYEOO1', 'NX-1838', 'NX1838', 'Pegaptanib na', 'Pegaptanib sodium']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for wet macular degeneration and has 6 investigational indications.,,,"['MONDO_0007935', 'MONDO_0003005', 'EFO_1001157', 'EFO_0001365', 'EFO_0004683', 'MONDO_0008667', 'EFO_0009606']",7.0,['ENSG00000112715'],1,2004.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/macugen'],,,,
CHEMBL1631540,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,ANGUXJDGJCHGOG-UHFFFAOYSA-N,Small molecule,False,GSK163090,2.0,False,False,[],"['GSK163090', 'Gsk163090']",['CHEMBL3215829'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0002050', 'MONDO_0002009']",2.0,"['ENSG00000178394', 'ENSG00000179546', 'ENSG00000108576', 'ENSG00000135312']",4,,,,,,,,,,
CHEMBL1889140,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl,NDNSIBYYUOEUSV-RSAXXLAASA-N,Small molecule,False,ROPIVACAINE HYDROCHLORIDE,4.0,False,True,"['Naropin', 'Ropivacaine hydrochloride']","['Ropivacaine hcl', 'Ropivacaine hydrochloride', 'Ropivacaine hydrochloride hydrate', 'Ropivacaine hydrochloride monohydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for pain and has 6 investigational indications.,,,"['EFO_0009676', 'EFO_0003931', 'EFO_0003843', 'EFO_0006859', 'HP_0000023', 'MONDO_0005178', 'HP_0001822']",7.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1996.0,CHEMBL1077896,['ropivacaine%20hydrochloride'],"['144205774', '170465120', '49681555']",['60803'],,,,,
CHEMBL217092,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,OUKYUETWWIPKQR-UHFFFAOYSA-N,Small molecule,False,SARACATINIB,3.0,False,False,[],"['AZ-10353926', 'AZD-0530', 'AZD0530', 'Azd-0530', 'Saracatinib']",['CHEMBL2105677'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.,,['DB11805'],"['MONDO_0021063', 'EFO_0006861', 'EFO_0000637', 'MONDO_0011705', 'EFO_0000616', 'MONDO_0007606', 'EFO_0000365', 'MONDO_0008315', 'MONDO_0002158', 'EFO_1000581', 'EFO_0002618', 'MONDO_0007254', 'EFO_0004329', 'MONDO_0008170', 'MONDO_0007079', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000756', 'EFO_1000657', 'MONDO_0004975']",20.0,"['ENSG00000097007', 'ENSG00000197122']",2,,,,"['137275842', '164339484']",,,,,,
CHEMBL253371,CCN(CCCc1ccccc1)CCCc1ccccc1,ZPFXAOWNKLFJDN-UHFFFAOYSA-N,Small molecule,False,ALVERINE,4.0,False,True,[],"['Alverine', 'Phenpropamine']",['CHEMBL1408594'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and has 1 investigational indication.,['Alverine'],['DB01616'],"['EFO_0010282', 'EFO_0000666']",2.0,"['ENSG00000178394', 'ENSG00000101076']",2,,,,"['50103849', '50104229', '50104230']",['518413'],,,,,
CHEMBL3182621,Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,RWEVIPRMPFNTLO-UHFFFAOYSA-N,Small molecule,False,AZD-8330,1.0,False,False,[],"['ARRY-424704', 'ARRY-704', 'AZD-8330', 'Azd 8330', 'Azd-8330', 'Azd8330']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB06061'],['MONDO_0004992'],1.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,['174006482'],,,,,,
CHEMBL329123,CCCc1c(OCCCOc2cc(O)c(-c3ccc(F)cc3)cc2CC)cccc1Oc1ccccc1C(=O)O,YFIZRWPXUYFCSN-UHFFFAOYSA-N,Small molecule,False,ETALOCIB,2.0,False,False,[],"['Etalocib', 'LY-193111', 'LY-293111', 'LY293111', 'Ly-293111', 'Ly293111', 'VML 295']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,['Etalocib'],['DB12850'],"['EFO_0002618', 'EFO_0000616', 'EFO_0003060']",3.0,"['ENSG00000213903', 'ENSG00000132170']",2,,,,,,,,,,
CHEMBL3559672,,,Unknown,False,RAUWOLFIA SERPENTINA,4.0,False,True,"['Hiwolfia', 'Hyserpin', 'Koglucoid', 'Raudixin', 'Rauserpin', 'Rauval', 'Rauwolfia serpentina', 'Wolfina']","['Rauvolfia serpentina root', 'Rauwolfia alkaloids', 'Rauwolfia alkaloids, whole root', 'Rauwolfia serpentina', 'Rauwolfia serpentina alseroxylon']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for hypertension and has 1 investigational indication.,,,"['EFO_0003777', 'EFO_0000537']",2.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1954.0,,,,,,,,,
CHEMBL4650323,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1,KOEUOFPEZFUWRF-LJQANCHMSA-N,Small molecule,False,TOLEBRUTINIB,3.0,False,False,[],"['PRN-2246', 'PRN2246', 'SAR-442168', 'SAR442168', 'Sar442168', 'Tolebrutinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0003086', 'EFO_0008520', 'EFO_0008522', 'MONDO_0005301']",4.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TOLEBRUTINIB/relevant/1/'],,,
CHEMBL94657,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,QXRSDHAAWVKZLJ-PVYNADRNSA-N,Small molecule,False,PATUPILONE,3.0,False,False,[],"['(-)-epothilone b', 'EPO 906', 'EPO 906A', 'EPO-906', 'EPO-906A', 'EPO906', 'EPO906A', 'Epithilone b', 'Epo b', 'Epothilone b', 'GNF-PF-193', 'Patupilone']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,['DB03010'],"['MONDO_0008170', 'EFO_0000182', 'EFO_0003865', 'EFO_0004243', 'MONDO_0004992', 'EFO_0000673', 'EFO_0000756', 'MONDO_0007254', 'EFO_0003869', 'EFO_0003060', 'EFO_0000616', 'MONDO_0002158', 'MONDO_0008315', 'EFO_0000519', 'EFO_0004288', 'EFO_1001100', 'MONDO_0021063']",17.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,"['50125842', '520207']",['31550'],,,,,
CHEMBL1201460,,,Oligosaccharide,True,DALTEPARIN SODIUM,4.0,False,True,"['Fragmin', 'Low liquemine']","['.alpha.-heparin', 'B01AB04', 'Boxol', 'Dalteparin', 'Dalteparin sodium', 'FR-860', 'Fragmine', 'HEPARIN FRAGMENT KABI 2165', 'KABI-2165', 'Low-liquemine']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0002618', 'EFO_0000712', 'EFO_0001378', 'HP_0001907', 'EFO_1000954', 'MONDO_0043510', 'MONDO_0011382', 'MONDO_0008903', 'HP_0004419', 'EFO_0004286', 'EFO_0000681', 'MONDO_0007254', 'EFO_1001951', 'MONDO_0008315', 'HP_0004936', 'MONDO_0008170', 'EFO_0009315', 'EFO_0002950', 'EFO_1000158', 'MONDO_0019514', 'EFO_0003884', 'MONDO_0100096', 'EFO_1001459', 'EFO_0006834', 'EFO_0003907']",25.0,['ENSG00000117601'],1,1994.0,,['dalteparin%20sodium'],,,,,,,
CHEMBL1255582,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1,KXSUAWAUCNFBQJ-UHFFFAOYSA-N,Small molecule,False,FIPAMEZOLE,2.0,False,False,[],['Fipamezole'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB06585'],['MONDO_0005180'],1.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,,,,,,,,,,
CHEMBL1257,FC(F)OC(F)(F)C(F)Cl,JPGQOUSTVILISH-UHFFFAOYSA-N,Small molecule,False,ENFLURANE,4.0,False,True,"['Enflurane', 'Ethrane']","['ANESTHETIC COMPOUND NO. 347', 'Alyrane', 'Anesthetic Compound No. 347', 'Compound 347', 'Efrane', 'Enflurane', 'Methylflurether', 'NSC-115944', 'Ohio 347', 'R-E-235CA2']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972.,['Enflurane'],['DB00228'],,,"['ENSG00000082482', 'ENSG00000145888', 'ENSG00000109738', 'ENSG00000186795', 'ENSG00000169427', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000171303', 'ENSG00000100433']",23,1972.0,,,"['144207364', '50112675']",['4792'],,,,,
CHEMBL1484,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,Small molecule,False,NICARDIPINE,4.0,False,True,[],"['Nicardipine', 'Nicardipine (stn)', 'Perpidine']",['CHEMBL1200326'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for cardiovascular disease and hypertension and has 12 investigational indications.,['Nicardipine'],['DB00622'],"['EFO_1000994', 'EFO_0000713', 'EFO_0000319', 'EFO_0009846', 'EFO_0001645', 'EFO_0000668', 'EFO_0005669', 'EFO_0003833', 'EFO_0000319', 'EFO_0000712', 'EFO_0000537', 'EFO_0000537', 'EFO_0004282', 'EFO_0003843']",14.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1988.0,,,"['104171201', '124880905', '144203762', '170465173', '26755701', '26755702', '50111158', '50111159', '90340664']",['7550'],,,,,
CHEMBL150894,CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCO)Cc1ccccc1-4)C(=O)NC3,MLIFNJABMANKEU-UHFFFAOYSA-N,Small molecule,False,CEP-5214,1.0,False,False,[],"['CEP-5214', 'CEP5214', 'Cep-5214']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,,,,,,,,,,
CHEMBL1829433,Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1,SMFXSYMLJDHGIE-UHFFFAOYSA-N,Small molecule,False,AZD-4877,2.0,False,False,[],"['AZD-4877', 'AZD4877', 'Azd 4877', 'Azd-4877']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB11671'],"['EFO_0000222', 'EFO_0005952', 'EFO_0000616', 'EFO_0000574', 'EFO_0000313']",5.0,['ENSG00000138160'],1,,,,,,,,,,
CHEMBL201960,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1,SWUVZKWCOBGPTH-UHFFFAOYSA-N,Small molecule,False,PYROVALERONE,4.0,True,True,[],"['J8.659B', 'Pyrovalerone']",['CHEMBL2104793'],Small molecule drug with a maximum clinical trial phase of IV.,['Pyrovalerone'],,,,"['ENSG00000142319', 'ENSG00000103546']",2,,,,,,,,,,
CHEMBL2103852,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC,JXONINOYTKKXQQ-CQSZACIVSA-N,Small molecule,False,CROLIBULIN,2.0,False,False,[],"['Crolibulin', 'EPC 2407', 'EPC-2407', 'EPC2407']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12925'],"['MONDO_0004992', 'MONDO_0002108']",2.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL2108222,,,Unknown,False,ALOXIPRIN,4.0,False,True,['Palaprin fte'],"['Alaprin', 'Aloxiprin', 'Paloxin', 'Polyoxyaluminium acetylsalicylate', 'Polyoxyaluminum acetylsalicylate', 'Superpyrin']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved indications.,,,"['HP_0001945', 'HP_0004419', 'EFO_0003843']",3.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,,,,,,['4760'],
CHEMBL2108767,,,Antibody,False,RUPLIZUMAB,3.0,False,False,['Antova'],"['BG-9588', 'BG9588', 'HU-5C8', 'Ruplizumab', 'hu5c8']",,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0005761'],1.0,['ENSG00000102245'],1,,,,,,,,,,
CHEMBL2165191,Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,IRTDIKMSKMREGO-OAHLLOKOSA-N,Small molecule,False,AZD-6482,2.0,False,False,[],"['AZD-6482', 'AZD6482', 'Azd 6482', 'Azd-6482']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB14980'],['HP_0002140'],1.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,,,,
CHEMBL3286830,C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,IIXWYSCJSQVBQM-LLVKDONJSA-N,Small molecule,False,LORLATINIB,4.0,False,True,"['Lorbrena', 'Lorviqua']","['Lorlatinib', 'PF-06463922']",['CHEMBL4539157'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 5 investigational indications.,,['DB12130'],"['EFO_0003032', 'EFO_0000621', 'EFO_0003060', 'EFO_0003086', 'EFO_0001421', 'EFO_0000502', 'EFO_0000574', 'EFO_0000616', 'MONDO_0004992']",9.0,"['ENSG00000171094', 'ENSG00000143924']",2,2018.0,,['lorlatinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua'],,,,
CHEMBL3833386,,,Cell,False,GALINPEPIMUT-S,3.0,False,False,[],"['Galinpepimut-s', 'SLS-001']",,Cell drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0000222'],1.0,['ENSG00000184937'],1,,,,,,,,,,
CHEMBL4650338,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1,DNPOFZXZJJDQLB-MRXNPFEDSA-N,Small molecule,False,EDRALBRUTINIB,2.0,False,False,[],"['Edralbrutinib', 'SHR-1459', 'SHR1459', 'Shr1459', 'TG-1701', 'TG1701', 'Tg 1701', 'Tg-1701']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_0000096', 'EFO_0004256', 'EFO_0004289', 'EFO_0003086', 'EFO_0000095', 'EFO_0000616', 'EFO_0005809']",7.0,['ENSG00000010671'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/EDRALBRUTINIB/relevant/1/'],,,
CHEMBL146506,C/C(=C\c1ccc(OCCN2CCOCC2)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C,OUQPTBCOEKUHBH-LSDHQDQOSA-N,Small molecule,False,MOFAROTENE,2.0,False,False,[],"['Mofarotene', 'RO 40-8757', 'Ro-408757']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000204231', 'ENSG00000172819', 'ENSG00000143171', 'ENSG00000077092', 'ENSG00000131759', 'ENSG00000186350']",6,,,,,,,,,,
CHEMBL285674,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,CDCHDCWJMGXXRH-UHFFFAOYSA-N,Small molecule,True,ESTAZOLAM,4.0,False,True,"['Estazolam', 'Eurodin', 'Prosom']","['ABBOTT-47631', 'Estazolam', 'Estazolam civ', 'NSC-290818']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for insomnia and has 1 investigational indication. This drug has a black box warning from the FDA.,['Estazolam'],['DB01215'],"['EFO_0008568', 'EFO_0004698']",2.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1990.0,,['estazolam'],"['144206162', '50113063']",['4858'],,,,,
CHEMBL3039529,C#Cc1cnc2nc(O)n(C(CC)CC)c2n1,RSQGZEAXODVTOL-UHFFFAOYSA-N,Small molecule,False,TIRASEMTIV,3.0,False,False,[],"['CK-2017357', 'CK2017357', 'Tirasemtiv']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB12209'],"['EFO_0003876', 'EFO_0004265', 'EFO_0004991', 'MONDO_0004976']",4.0,"['ENSG00000130598', 'ENSG00000130595', 'ENSG00000101470']",3,,,,,,,,,,
CHEMBL3544937,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1.Cl,IOFHDGSCWJNVRZ-UHFFFAOYSA-N,Small molecule,False,ZD-4190,1.0,False,False,[],['Zd-4190'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000128052'],1,,CHEMBL281872,,,,,,,,
CHEMBL3545076,Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1,FYXRSVDHGLUMHB-UHFFFAOYSA-N,Small molecule,False,LY-2584702,1.0,False,False,[],"['LY 2584702', 'LY2584702', 'Ly-2584702']","['CHEMBL3911801', 'CHEMBL3909070']",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,['DB12690'],"['EFO_0000681', 'MONDO_0004992', 'EFO_0003060', 'EFO_1001901', 'EFO_0009708']",5.0,['ENSG00000108443'],1,,,,,,,,,,
CHEMBL363295,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,UISARWKNNNHPGI-UHFFFAOYSA-N,Small molecule,False,TERODILINE,4.0,True,True,[],['Terodiline'],['CHEMBL539770'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for urinary incontinence and polyuria.,['Terodiline'],['DB13725'],"['HP_0000020', 'HP_0000103']",2.0,"['ENSG00000133019', 'ENSG00000180720', 'ENSG00000168539', 'ENSG00000181072', 'ENSG00000184984', 'ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",31,1986.0,,,,,,,,,
CHEMBL459,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,CJCSPKMFHVPWAR-JTQLQIEISA-N,Small molecule,False,METHYLDOPA,4.0,False,True,"['Aldomet', 'Dopamet', 'Lederdopa', 'Medomet', 'Metalpha 250', 'Metalpha 500', 'Methyldopa']","['(-)-.alpha.-methyldopa', '(s)-(-)-.alpha.-methyldopa', '.alpha.-methyl-l-dopa', 'Alpha-methyldopa', 'Anhydrous methyldopa', 'BAYER-1440L', 'J9.247I', 'L-.alpha.-methyldopa', 'MK-351', 'Methyldopa', 'Methyldopa (levorotatory)', 'Methyldopa anhydrous', 'Methyldopa hydrate', 'Methyldopa sesquihydrate', 'Methyldopa, anhydrous', 'NSC-169916', 'NSC-760080']","['CHEMBL4063475', 'CHEMBL1591707']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and is indicated for hypertension and has 2 investigational indications.,['Methyldopa'],['DB00968'],"['EFO_0000668', 'EFO_0000537', 'MONDO_0005147']",3.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1962.0,,['methyldopa'],"['11113581', '124886927', '144209808', '50104474', '8139902', '90341702']",['61058'],,,['56'],,
CHEMBL4594293,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O,JWEQLWMZHJSMEC-AFJTUFCWSA-N,Small molecule,False,ACALABRUTINIB MALEATE,4.0,False,True,['Calquence'],"['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrous', 'Calquence maleate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for chronic lymphocytic leukemia and mantle cell lymphoma.,,,"['EFO_0000095', 'EFO_1001469']",2.0,['ENSG00000010671'],1,2022.0,CHEMBL3707348,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ACALABRUTINIB%20MALEATE/relevant/1/'],,,
CHEMBL4594417,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1,KCBJGVDOSBKVKP-UHFFFAOYSA-N,Small molecule,False,PRUXELUTAMIDE,3.0,False,False,[],"['Gt-0918', 'Gt0918', 'Proxalutamide', 'Pruxelutamide']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['MONDO_0100096', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000694']",4.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL5314406,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1,MAFACRSJGNJHCF-UHFFFAOYSA-N,Small molecule,False,4SC-203,1.0,False,False,[],"['4sc 203', '4sc-203']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000222'],1.0,"['ENSG00000122025', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",4,,,,,,,,,,
CHEMBL1087,Cc1cccc(C)c1NC(=O)C1CCCCN1C,INWLQCZOYSRPNW-UHFFFAOYSA-N,Small molecule,False,MEPIVACAINE,4.0,False,True,[],"[""1-methyl-2',6'-pipecoloxylidide"", ""2',6'-pipecoloxylidide, 1-methyl-"", 'APF-135', 'Carbocaine', 'Carboplyin dental', 'Dl-mepivacaine', 'Mepisv', 'Mepivacaine', 'Polocaine', 'Polocaine-Mpf', 'Tevacaine']",['CHEMBL1200440'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 investigational indications.,['Mepivacaine'],['DB00961'],"['MONDO_0004001', 'EFO_0004616', 'EFO_1000786', 'EFO_0003843']",4.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1960.0,,,,['6759'],,,,,
CHEMBL1200648,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1.[Br-],OYTJKRAYGYRUJK-FMCCZJBLSA-M,Small molecule,False,ROCURONIUM BROMIDE,4.0,False,True,"['Esmeron', 'Rocuronium bromide', 'Zemuron']","['ORG 9426', 'ORG-9426', 'Rocuronium bromide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 investigational indications.,,,"['EFO_0007490', 'EFO_0009492', 'HP_0003418']",3.0,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1994.0,CHEMBL1201244,['rocuronium%20bromide'],['144205990'],['8885'],,,,,
CHEMBL1201180,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1,DCERVXIINVUMKU-UHFFFAOYSA-N,Small molecule,True,DICLOFENAC EPOLAMINE,4.0,False,True,"['Flector', 'Flector Patch', 'Licart']","['Diclofenac epolamine', 'Diclofenac epolaminum']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for sprain and pain and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0007254', 'EFO_0009582', 'EFO_0003843', 'EFO_1000652']",4.0,"['ENSG00000073756', 'ENSG00000095303']",2,2007.0,CHEMBL139,['diclofenac%20epolamine'],,['48296'],,,,,
CHEMBL18,CCOc1ccc2nc(S(N)(=O)=O)sc2c1,OUZWUKMCLIBBOG-UHFFFAOYSA-N,Small molecule,False,ETHOXZOLAMIDE,4.0,False,True,"['Cardrase', 'Ethamide']","['Ethoxzolamide', 'NSC-10679']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Ethoxzolamide'],['DB00311'],,,"['ENSG00000104267', 'ENSG00000168748', 'ENSG00000133742', 'ENSG00000164879', 'ENSG00000131686', 'ENSG00000074410', 'ENSG00000118298', 'ENSG00000107159', 'ENSG00000167434', 'ENSG00000185015', 'ENSG00000169239', 'ENSG00000174990']",12,1982.0,,,"['144204399', '170465083', '56422188', '855751']",['101096'],,,,,
CHEMBL1947204,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,MVZGYPSXNDCANY-UHFFFAOYSA-N,Small molecule,False,ALLITINIB,2.0,False,False,[],"['ALL-3', 'AST-1306', 'Allitinib', 'Als 1306', 'Ast 1306', 'Ast-1306', 'Ast1306']",['CHEMBL4779286'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0008903'],1.0,"['ENSG00000141736', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL2103736,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2],LZPBLUATTGKZBH-UHFFFAOYSA-L,Small molecule,True,FENOPROFEN CALCIUM,4.0,False,True,"['Fenoprofen calcium', 'Nalfon']","['69323', 'Fenoprofen calcium', 'Fenoprofen calcium salt dihydrate', 'Fenopron', 'Fepron', 'Feprona', 'Nalgesic']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for osteoarthritis and rheumatoid arthritis. This drug has a black box warning from the FDA.,,,"['MONDO_0005178', 'EFO_0000685']",2.0,"['ENSG00000073756', 'ENSG00000095303']",2,1976.0,CHEMBL1297,['fenoprofen%20calcium'],,['5005'],,,,,
CHEMBL2109528,,,Antibody,False,FASINUMAB,3.0,False,False,[],"['Fasinumab', 'REGN-475', 'REGN475', 'SAR-164877', 'SAR164877']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,,"['HP_0003418', 'EFO_1000786', 'HP_0011868', 'EFO_0004616', 'HP_0003419', 'MONDO_0005178', 'HP_0002027']",7.0,['ENSG00000134259'],1,,,,,,,,,,
CHEMBL2109589,,,Antibody,False,L19TNFA,2.0,False,False,[],"['L19TNFA', 'L19tnfa']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_1001951'],1.0,['ENSG00000115414'],1,,,,,,,,,,
CHEMBL3545165,O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1,IJUMFEAYOMCXAQ-UHFFFAOYSA-N,Small molecule,False,AFACIFENACIN,2.0,False,False,[],"['Afacifenacin', 'NS-986', 'Smp-986']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_1000781'],1.0,"['ENSG00000133019', 'ENSG00000180720', 'ENSG00000168539', 'ENSG00000181072', 'ENSG00000184984', 'ENSG00000168356', 'ENSG00000185313']",7,,,,,,,,,,
CHEMBL3545279,Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N.Cl.Cl,WFIOHOJEIMQCEG-UHFFFAOYSA-N,Small molecule,False,EFATUTAZONE HYDROCHLORIDE,2.0,False,False,[],"['CS-7017', 'Efatutazone dihydrochloride', 'Efatutazone hydrochloride', 'Inolitazone dihydrochloride', 'RS5444']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000132170'],1,,CHEMBL3545280,,,,,,,,
CHEMBL431651,CCCOc1ccc2c(c1)[C@@H](c1ccc(OC)cc1OCCO)[C@H](C(=O)O)[C@H]2c1ccc2c(c1)OCO2,GLCKXJLCYIJMRB-UPRLRBBYSA-N,Small molecule,False,ENRASENTAN,2.0,False,False,[],"['Enrasentan', 'SB-217242', 'Sb-217242']",,Small molecule drug with a maximum clinical trial phase of II.,,['DB06460'],,,"['ENSG00000136160', 'ENSG00000151617']",2,,,,,,,,,,
CHEMBL46618,COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1,PFGVNLZDWRZPJW-OPAMFIHVSA-N,Small molecule,False,OTAMIXABAN,3.0,False,False,[],"['FXV-673', 'Fxv673', 'Otamixaban', 'RPR-130673', 'RPR130673', 'XRP-0673', 'XRP0673']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,['Otamixaban'],['DB06635'],"['EFO_0003086', 'EFO_0001421', 'EFO_0001645', 'EFO_0005672']",4.0,['ENSG00000126218'],1,,,,,,,,,,
CHEMBL492,CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C,VTUSIVBDOCDNHS-UHFFFAOYSA-N,Small molecule,False,ETIDOCAINE,4.0,False,True,[],"['Etidocaine', 'W-19053', 'W-19053 [AS HYDROCHLORIDE]']",['CHEMBL1200597'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976.,['Etidocaine'],['DB08987'],,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1976.0,,,['144206521'],['4904'],,,,,
CHEMBL526,CC(C)c1cccc(C(C)C)c1O,OLBCVFGFOZPWHH-UHFFFAOYSA-N,Small molecule,False,PROPOFOL,4.0,False,True,"['Diprivan', 'Disoprivan', 'Propofol', 'Rapinovet']","['Disoprofol', 'Fresofol', 'ICI 35,868', 'ICI 35-868', 'ICI-35868', 'ICI35,868', 'Lipuro', 'NSC-5105', 'Phenol, 2,6-bis(1-methylethyl)', 'Propofol']","['CHEMBL356637', 'CHEMBL154232']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 55 investigational indications.,['Propofol'],['DB00818'],"['HP_0000989', 'EFO_0000713', 'EFO_0003918', 'EFO_0003870', 'EFO_0004259', 'EFO_0004888', 'EFO_0004698', 'EFO_0001074', 'EFO_0003855', 'EFO_0005251', 'EFO_0007355', 'EFO_0006834', 'HP_0011110', 'MONDO_0002009', 'HP_0003418', 'EFO_0002618', 'EFO_0003884', 'MONDO_0002050', 'EFO_0003917', 'EFO_0002687', 'HP_0000713', 'EFO_0009267', 'EFO_0004273', 'MONDO_0007576', 'EFO_1001210', 'EFO_0000662', 'MONDO_0043510', 'EFO_0001073', 'EFO_0001422', 'EFO_0003869', 'EFO_0009854', 'EFO_0000537', 'HP_0100806', 'EFO_0000616', 'EFO_0000712', 'HP_0031273', 'HP_0002093', 'EFO_0007490', 'EFO_0003843', 'MONDO_0005277', 'HP_0000486', 'EFO_0000546', 'EFO_0000565', 'EFO_0000694', 'EFO_1000644', 'MONDO_0004992', 'MP_0001845', 'EFO_1002048', 'EFO_0008526', 'EFO_1000637', 'EFO_1001951', 'EFO_0003777', 'EFO_1001454', 'EFO_0001645', 'MONDO_0021117']",55.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1989.0,,['propofol'],"['104171149', '11111121', '11111122', '124879991', '144203685', '144208569', '144213542', '170464994', '17389856', '26747380', '47193694', '50105615', '90341256']",['44915'],,,,,
CHEMBL547,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,SHGAZHPCJJPHSC-XFYACQKRSA-N,Small molecule,True,ISOTRETINOIN,4.0,False,True,"['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'Isotrex', 'Myorisan', 'Roaccutane', 'Sotret', 'Zenatane']","['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156', 'PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-form', 'Retinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for acne and has 47 investigational indications. This drug has a black box warning from the FDA.,['Isotretinoin'],['DB00982'],"['MONDO_0100096', 'EFO_0000632', 'EFO_0000180', 'EFO_0000616', 'EFO_0000565', 'EFO_1001051', 'EFO_0000544', 'EFO_0002501', 'MONDO_0008315', 'EFO_0000464', 'EFO_0000339', 'EFO_0001378', 'MONDO_0002974', 'EFO_1000309', 'MONDO_0008903', 'MONDO_0003268', 'EFO_1000760', 'EFO_0004236', 'EFO_0000519', 'EFO_1001465', 'EFO_0000403', 'EFO_0007512', 'EFO_0000198', 'MONDO_0002367', 'EFO_0000309', 'EFO_0002499', 'EFO_0003833', 'EFO_0000183', 'EFO_0000621', 'EFO_1000690', 'EFO_0002496', 'EFO_1001006', 'EFO_1000158', 'MONDO_0000870', 'MONDO_0000873', 'EFO_0000502', 'MONDO_0007254', 'EFO_0000681', 'EFO_0002939', 'EFO_0000222', 'EFO_0006859', 'EFO_1000910', 'EFO_0000224', 'EFO_0000279', 'MONDO_0004975', 'MONDO_0019269', 'EFO_0003894', 'MONDO_0006058']",48.0,"['ENSG00000172819', 'ENSG00000077092', 'ENSG00000131759']",3,1982.0,,['isotretinoin'],"['144207291', '26747659', '26753641', '26753642', '26753643', '26753644', '47193696', '50106981', '90341473']",['6067'],,,,,
CHEMBL1200396,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,SIEYLFHKZGLBNX-UHFFFAOYSA-N,Small molecule,True,BUPIVACAINE HYDROCHLORIDE,4.0,False,True,"['Bupivac hcl', 'Bupivacaine hydrochloride', 'Bupivacaine hydrochloride kit', 'Bupivacaine hydrochloride preservative free', 'Marcain', 'Marcaine', 'Marcaine hydrochloride', 'Marcaine hydrochloride preservative free', 'Sensorcaine', 'Xaracoll']","['AH-2250', 'Bupivacaine hcl', 'Bupivacaine hydrochloride', 'Bupivacaine hydrochloride hydrate', 'Bupivacaine hydrochloride monohydrate', 'Bupivacaine hydrochloride rs', 'Bupivacaini hydrochloridum', 'Carbostesin', 'LAC-43', 'NSC-758631', 'WIN 11,318', 'WIN-11318', 'Xaracoll']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for pain and has 16 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0031217', 'MONDO_0002087', 'EFO_0004616', 'MONDO_0005277', 'MONDO_0007254', 'HP_0000023', 'MONDO_0041052', 'HP_0012532', 'EFO_0009552', 'HP_0000175', 'EFO_1001087', 'EFO_0000546', 'EFO_0003843', 'EFO_0000764', 'MONDO_0004992', 'MONDO_0002959', 'HP_0001822']",17.0,['ENSG00000007314'],1,1972.0,CHEMBL1098,['bupivacaine%20hydrochloride'],"['26748842', '56463371']",['31322'],,,,,
CHEMBL1200833,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1.Cl,VKFAUCPBMAGVRG-UHFFFAOYSA-N,Small molecule,False,DIPIVEFRIN HYDROCHLORIDE,4.0,False,True,"['Akpro', 'Dipivefrin hydrochloride', 'Propine']","['Dipivefrin hcl', 'Dipivefrin hydrochloride', 'Dipivefrine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980.,,,,,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1980.0,CHEMBL1201262,,"['144204226', '56463529']",['4647'],,,,,
CHEMBL1230609,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,CXQHYVUVSFXTMY-UHFFFAOYSA-N,Small molecule,False,FORETINIB,2.0,False,False,[],"['EXEL-2880', 'Foretinib', 'GSK-089', 'GSK-1363089', 'GSK-1363089G', 'GSK089', 'GSK1363089G', 'Gsk-1363089', 'Gsk1363089', 'XL-880', 'XL880']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,['DB12307'],"['MONDO_0007254', 'EFO_0000182', 'EFO_0005950', 'MONDO_0008903', 'EFO_0000616', 'EFO_0000681', 'MONDO_0004992']",7.0,"['ENSG00000122025', 'ENSG00000157404', 'ENSG00000120156', 'ENSG00000105976', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",9,,,,['137275948'],,,,,,
CHEMBL1743052,,,Antibody drug conjugate,False,OPORTUZUMAB MONATOX,3.0,False,False,"['Proxinium', 'Proxinium, Vicinium', 'Vicineum', 'Vicinium']","['4D5MOCB-ETA', 'Oportuzumab monatox', 'VB4-845', 'XD60E5X7FI']",,Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0000294', 'MONDO_0001187', 'EFO_0000616']",3.0,['ENSG00000119888'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/OPORTUZUMAB%20MONATOX/relevant/1/'],,,
CHEMBL1769,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC.Cl,GITPCGSPKUQZTE-UHFFFAOYSA-N,Small molecule,False,PROPOXYCAINE HYDROCHLORIDE,4.0,False,True,[],"['NSC-760044', 'Propoxycaine HCl', 'Propoxycaine hcl', 'Propoxycaine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,CHEMBL1195,,"['144204013', '56463554']",,,,,,
CHEMBL3039556,,,Oligonucleotide,False,APATORSEN,2.0,False,False,[],"['Apatorsen', 'OGX-427']",,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0000708', 'MONDO_0008315', 'EFO_0000616', 'EFO_0002618', 'MONDO_0001187', 'EFO_0003060']",6.0,['ENSG00000106211'],1,,,,,,,,,,
CHEMBL4303214,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,BALLNEJQLSTPIO-UHFFFAOYSA-N,Small molecule,False,FRUQUINTINIB,4.0,False,True,['Fruzaqla'],"['Fruquintinib', 'HMPL-013', 'HMPL013', 'Hmpl-013']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 16 investigational indications.,,,"['EFO_0002618', 'EFO_1001968', 'EFO_0000616', 'EFO_1001951', 'EFO_1000657', 'MONDO_0001056', 'EFO_0003897', 'MONDO_0007254', 'EFO_0001421', 'MONDO_0011962', 'EFO_0003060', 'MONDO_0021063', 'EFO_0000365', 'MONDO_0008903', 'EFO_0003086', 'EFO_0005922', 'MONDO_0004992', 'EFO_0000681', 'EFO_0004142']",19.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/FRUQUINTINIB/relevant/1/'],,,
CHEMBL4650827,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C,FRVSRBKUQZKTOW-YOCNBXQISA-N,Small molecule,False,REVUMENIB,2.0,False,False,[],['Revumenib'],['CHEMBL4650278'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0000565', 'EFO_0000222', 'EFO_0000220', 'EFO_1001951', 'EFO_0000222', 'EFO_0000616']",6.0,"['ENSG00000133895', 'ENSG00000118058']",2,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL1079,Clc1ccc2nsnc2c1NC1=NCCN1,XFYDIVBRZNQMJC-UHFFFAOYSA-N,Small molecule,False,TIZANIDINE,4.0,False,True,[],"['Tizanidine', 'Zanaflex']",['CHEMBL1200329'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for spasticity and has 7 investigational indications.,['Tizanidine'],['DB00697'],"['EFO_0003843', 'HP_0001257', 'EFO_0000756', 'MONDO_0043510', 'MONDO_0100431', 'HP_0001257', 'MONDO_0005475', 'MONDO_0002959']",8.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1996.0,,,"['144205429', '170465419', '26754628', '29216212', '29216213', '90340638']",['63629'],,,,,
CHEMBL1200436,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,QSLJIVKCVHQPLV-PEMPUTJUSA-N,Small molecule,True,OXANDROLONE,4.0,False,True,"['Anavar', 'Oxandrin', 'Oxandrolone']","['Lonavar', 'NSC-67068', 'Oxandrolone', 'Oxandrolone ciii', 'Provitar', 'SC 11585', 'SC-11585', 'Vasorome']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 9 investigational indications. This drug has a black box warning from the FDA.,['Oxandrolone'],['DB00621'],"['EFO_1001006', 'MONDO_0019391', 'EFO_0007067', 'EFO_0000616', 'EFO_0000546', 'EFO_0008572', 'EFO_1001250', 'EFO_0009516', 'MONDO_0019499']",9.0,['ENSG00000169083'],1,1964.0,,['oxandrolone'],,['7820'],,,,,
CHEMBL1201134,CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1,WGFOBBZOWHGYQH-MXHNKVEKSA-N,Small molecule,False,LUBIPROSTONE,4.0,False,True,['Amitiza'],"['Lubiprostone', 'RU-0211']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 2 investigational indications.,['Lubiprostone'],['DB01046'],"['MONDO_0002203', 'HP_0002019', 'EFO_0000555', 'EFO_0000764', 'EFO_0003095', 'HP_0012532']",6.0,['ENSG00000114859'],1,2006.0,,['lubiprostone'],['144206539'],,,,,,
CHEMBL1206232,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,WDOGQTQEKVLZIJ-WAYWQWQTSA-N,Small molecule,False,FOSBRETABULIN,3.0,False,False,[],"['Combretastatin a-4 phosphate', 'Combretastatin a4 phosphate', 'Fosbretabulin', 'Phosbretabulin']","['CHEMBL2105643', 'CHEMBL1972559', 'CHEMBL289351', 'CHEMBL263994']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,['DB12577'],"['MONDO_0002108', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000616', 'EFO_0004683', 'EFO_1001901', 'MONDO_0004992', 'MONDO_0008170', 'EFO_1001901', 'EFO_0006859']",10.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL1521,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,HUNXMJYCHXQEGX-UHFFFAOYSA-N,Small molecule,True,ZALEPLON,4.0,False,True,"['Sonata', 'Zaleplon']","['CL 284,846', 'CL-284846', 'L-846', 'L846', 'LJC 10846', 'LJC-10846', 'LJC10846', 'SKP-1041', 'ZAL-846', 'Zaleplon', 'Zaleplon civ', 'Zerene']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for insomnia and has 4 investigational indications. This drug has a black box warning from the FDA.,['Zaleplon'],['DB00962'],"['EFO_0004698', 'EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090']",5.0,"['ENSG00000022355', 'ENSG00000113327', 'ENSG00000163288']",3,1999.0,,['zaleplon'],"['144205425', '170465168', '26719706', '29216208']",['10102'],['https://www.ema.europa.eu/en/medicines/human/EPAR/sonata'],,,,
CHEMBL1614701,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,CYOHGALHFOKKQC-UHFFFAOYSA-N,Small molecule,False,SELUMETINIB,4.0,False,True,[],"['ARRY-142886', 'ARRY-886', 'AZD-6244', 'AZD6244', 'Azd-6244', 'Selumetinib']",['CHEMBL2105684'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 48 investigational indications.,,['DB11689'],"['EFO_0000389', 'EFO_0003144', 'EFO_0000272', 'EFO_0000501', 'EFO_0000403', 'EFO_0001075', 'EFO_0009254', 'EFO_0003060', 'EFO_1001956', 'MONDO_0018975', 'MONDO_0002367', 'MONDO_0001187', 'EFO_0000756', 'EFO_0000365', 'EFO_0008514', 'MONDO_0018975', 'MONDO_0007254', 'MONDO_0003060', 'EFO_0000558', 'EFO_0002617', 'EFO_0000339', 'EFO_1001951', 'EFO_0000228', 'EFO_1001950', 'EFO_0000220', 'EFO_0001378', 'EFO_0002618', 'EFO_1000251', 'MONDO_0004992', 'EFO_0000503', 'EFO_0005221', 'EFO_0002618', 'MONDO_0016691', 'EFO_0000707', 'EFO_0005537', 'EFO_0000616', 'EFO_0000182', 'EFO_1001968', 'EFO_0004606', 'EFO_0000708', 'EFO_0000760', 'EFO_0000641', 'EFO_0000389', 'MONDO_0005411', 'EFO_0004142', 'EFO_0000658', 'EFO_1000657', 'EFO_1001512', 'MONDO_0021063', 'EFO_0002617', 'MONDO_0002108', 'MONDO_0018531', 'MONDO_0008903']",53.0,"['ENSG00000169032', 'ENSG00000126934']",2,2020.0,,,"['144206913', '170466898', '174006431']",['90227'],,,,,
CHEMBL17350,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,QEMSVZNTSXPFJA-HNAYVOBHSA-N,Small molecule,False,TRAXOPRODIL,2.0,False,False,[],"['CP-101,606', 'CP-101606', 'Cp-101,606', 'Traxoprodil']",['CHEMBL3989673'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,['Traxoprodil'],,"['MONDO_0005180', 'MONDO_0002009', 'EFO_0000712']",3.0,"['ENSG00000176884', 'ENSG00000273079']",2,,,,,,,,,,
CHEMBL20684,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,URCVCIZFVQDVPM-UHFFFAOYSA-N,Small molecule,False,ABT-751,2.0,False,False,[],"['Abt-751', 'E 7010', 'E-7010', 'NSC-742134']",['CHEMBL1830238'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB12254'],"['EFO_0000681', 'EFO_1001951', 'EFO_0001642', 'EFO_0000621', 'MONDO_0008315', 'MONDO_0007254', 'MONDO_0000870', 'EFO_0003060']",8.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000258947', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000173213']",10,,,,,,,,,,
CHEMBL2109494,,,Antibody,False,A27.15,1.0,False,False,[],['A27.15'],,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,,"['EFO_0000198', 'EFO_0000565', 'EFO_0001378', 'EFO_0002428']",4.0,['ENSG00000072274'],1,,,,,,,,,,
CHEMBL2110954,CC1(C)CC(C)(C)CC(C)(N)C1,OGZQTTHDGQBLBT-UHFFFAOYSA-N,Small molecule,False,NERAMEXANE,3.0,False,False,[],['Neramexane'],['CHEMBL2106798'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB04926'],"['MONDO_0004975', 'HP_0000360', 'HP_0000360']",3.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785', 'ENSG00000174343', 'ENSG00000129749']",9,,,,,,,,,,
CHEMBL3586573,CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21,GMYLVKUGJMYTFB-UHFFFAOYSA-N,Small molecule,False,CC-115,2.0,False,False,[],['Cc-115'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,['DB12740'],"['EFO_0009708', 'EFO_0000095', 'EFO_0000181', 'EFO_0000519', 'EFO_0000637', 'MONDO_0008315']",6.0,"['ENSG00000253729', 'ENSG00000198793']",2,,,,,,,,,,
CHEMBL454,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,UZVHFVZFNXBMQJ-UHFFFAOYSA-N,Small molecule,False,BUTALBITAL,4.0,False,True,[],"['Alisobumal', 'Allylbarbituric acid', 'Butalbital', 'Butalbital ciii', 'Itobarbital', 'Tetrallobarbital']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and is indicated for migraine disorder.,['Butalbital'],['DB00241'],['MONDO_0005277'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1983.0,,['butalbital'],,['102524'],,,,,
CHEMBL529437,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C.Cl,PIQVDUKEQYOJNR-VZXSFKIWSA-N,Small molecule,True,COCAINE HYDROCHLORIDE,4.0,False,True,"['Goprelto', 'Numbrino']","['Cocaine hcl', 'Cocaine hydrochloride', 'Cocaine hydrochloride cii', 'Cocaine muriate', 'Cocainum muriaticum', 'MCV 4526', 'NIH 8211', 'NSC-25263', 'RX-0041-002']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and has 1 investigational indication. This drug has a black box warning from the FDA.,,,['EFO_0002610'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2017.0,CHEMBL370805,['cocaine%20hydrochloride'],['144206436'],['613010'],,,,,
CHEMBL569,CCN(CC)CCOC(=O)c1ccc(N)cc1,MFDFERRIHVXMIY-UHFFFAOYSA-N,Small molecule,False,PROCAINE,4.0,False,True,[],"['NSC-169497', 'Novocain', 'Procaine']",['CHEMBL1200841'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for hemorrhoid and has 2 investigational indications.,['Procaine'],['DB00721'],"['EFO_0000764', 'EFO_0003102', 'EFO_0009552']",3.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1954.0,,,"['11111696', '11111697', '90341175']",['8430'],,,,,
CHEMBL1059,CC(C)C[C@H](CN)CC(=O)O,AYXYPKUFHZROOJ-ZETCQYMHSA-N,Small molecule,False,PREGABALIN,4.0,False,True,"['Alzain', 'Axalid', 'Lecaent', 'Lyrica', 'Lyrica cr', 'Pregabalin', 'Pregabalin mylan', 'Rewisca']","['CI-1008', 'NSC-759256', 'PD-144723', 'Pregabalin', 'Pregabalin mylan', 'Pregabalin sandoz', 'Pregabalin sandoz gmbh', 'Pregabalin zentiva', 'Vronogabic', 'YNP-1807']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 9 approved and 45 investigational indications.,['Pregabalin'],['DB00230'],"['EFO_1000783', 'HP_0002018', 'EFO_0006510', 'EFO_1000877', 'MONDO_0005277', 'HP_0002069', 'EFO_0000400', 'MONDO_0007079', 'EFO_0009558', 'EFO_0002950', 'EFO_0006788', 'EFO_1001892', 'EFO_0000474', 'HP_0012532', 'EFO_1000906', 'EFO_0000342', 'HP_0012735', 'HP_0000726', 'EFO_0003108', 'EFO_1001998', 'EFO_0003931', 'EFO_0009846', 'EFO_0009430', 'EFO_0004270', 'HP_0000989', 'EFO_0005230', 'HP_0008419', 'EFO_0005762', 'EFO_0005687', 'HP_0007359', 'EFO_0004149', 'MONDO_0004892', 'EFO_0003100', 'MONDO_0002959', 'HP_0001250', 'MONDO_0005090', 'MONDO_0002050', 'EFO_1000781', 'EFO_0000707', 'EFO_0003830', 'MONDO_0007254', 'MONDO_0005178', 'EFO_0007191', 'EFO_0004257', 'EFO_1001919', 'EFO_1001884', 'EFO_0004698', 'EFO_1001931', 'EFO_0003768', 'EFO_0005611', 'MONDO_0041052', 'EFO_0000555', 'EFO_0003843', 'EFO_0004263']",54.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,2004.0,,['pregabalin'],['144205028'],['64356'],['https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-mylan'],,,,
CHEMBL1095,CCN1C(=O)NC(c2ccccc2)C1=O,SZQIFWWUIBRPBZ-UHFFFAOYSA-N,Small molecule,False,ETHOTOIN,4.0,False,True,['Peganone'],"['Accenon', 'Ethotoin', 'NSC-760074']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for seizure and epilepsy.,['Ethotoin'],['DB00754'],"['HP_0001250', 'EFO_0000474']",2.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1957.0,,,"['144203934', '56463534']",['4888'],,,,,
CHEMBL1200556,CC(=O)O.N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,MLSVJHOYXJGGTR-IFHOVBQLSA-N,Protein,True,DESMOPRESSIN ACETATE,4.0,False,True,"['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'Desmomelt', 'Desmopressin acetate', 'Desmopressin acetate (needs no refrigeration)', 'Desmopressin acetate preservative free', 'Desmospray', 'Desmotabs', 'Minirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'Octostim', 'Presinex', 'Stimate', 'Stimate (needs no refrigeration)']","['Anhydrous desmopressin acetate', 'Desmopressin acetate', 'Desmopressin acetate anhydrous', 'Desmopressin acetate hydrate', 'Desmopressin acetate trihydrate']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0009505', 'EFO_0005669', 'HP_0000863', 'MONDO_0024290', 'EFO_0000537', 'MONDO_0004782', 'HP_0001742', 'MONDO_0024574', 'HP_0031364', 'MP_0001914']",10.0,"['ENSG00000126895', 'ENSG00000166148', 'ENSG00000198049']",3,1978.0,CHEMBL1429,['desmopressin%20acetate'],,,,,,,
CHEMBL1743032,,,Antibody,False,INTETUMUMAB,2.0,False,False,[],"['CNTO 095', 'CNTO 95', 'CNTO-095', 'CNTO-95', 'Intetumumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000756', 'EFO_0000673']",2.0,"['ENSG00000138448', 'ENSG00000082781', 'ENSG00000259207']",3,,,,,,,,,,
CHEMBL1834657,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O,GUQNHCGYHLSITB-UHFFFAOYSA-N,Small molecule,False,INFIGRATINIB PHOSPHATE,4.0,False,True,['Truseltiq'],"['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cholangiocarcinoma and intrahepatic cholangiocarcinoma and has 1 investigational indication.,,,"['EFO_0000616', 'EFO_0005221', 'EFO_1001961']",3.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,2021.0,CHEMBL1852688,,,,,['https://searchusan.ama-assn.org/finder/usan/search/INFIGRATINIB%20PHOSPHATE/relevant/1/'],,,
CHEMBL2108730,,,Antibody,True,SARILUMAB,4.0,False,True,['Kevzara'],"['REG-N88', 'REGN-88', 'REGN88', 'SAR-153191', 'SAR153191', 'Sarilumab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for immune system disease and rheumatoid arthritis and has 14 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000694', 'EFO_1001231', 'EFO_0000540', 'EFO_0000685', 'EFO_0008518', 'MONDO_0100096', 'MONDO_0016586', 'EFO_0002609', 'EFO_0003106', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0007328', 'EFO_1001361', 'EFO_1001209', 'EFO_0003898', 'EFO_0000756']",16.0,['ENSG00000160712'],1,2017.0,,['sarilumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara'],,,,
CHEMBL2109257,,,Antibody,False,IMC-1C11,1.0,False,False,[],['IMC-1C11'],,Antibody drug with a maximum clinical trial phase of I.,,,,,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL261244,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21.[Na+].[Na+],MKQKPLQMNCXTJE-VEZQGTPESA-L,Small molecule,False,REGRELOR DISODIUM,2.0,False,False,[],"['INS-50589', 'INS50589', 'Regrelor disodium']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0001645', 'EFO_0000319']",2.0,['ENSG00000169313'],1,,CHEMBL1162175,,,,,,,,
CHEMBL3544917,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O,GIBQQARAXHVEGD-BSOLPCOYSA-N,Protein,False,RAPASTINEL,3.0,False,False,[],"['GLYX-13', 'Rapastinel', 'Rapastinelum', 'Tppt-amide']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB11801'],"['MONDO_0002009', 'EFO_0004242']",2.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL3644672,COc1c(OC[C@H](O)CN2CCOCC2)ccc2c1N=C(NC(=O)c1cccnc1C)N1CCN=C21,JGNRMIWLBBNSMU-QGZVFWFLSA-N,Small molecule,False,BAY-1082439,1.0,False,False,[],"['BAY1082439', 'Bay 1082439', 'Bay-1082439']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000121879', 'ENSG00000051382']",2,,,,,,,,,,
CHEMBL3989869,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1,KYJWUPZPSXZEPG-NTISSMGPSA-N,Small molecule,False,UMBRALISIB TOSYLATE,4.0,False,True,['Ukoniq'],"['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202', 'Umbralisib tosylate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for marginal zone b-cell lymphoma and follicular lymphoma and has 13 investigational indications.,,,"['MONDO_0044903', 'MONDO_0001056', 'EFO_1000630', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0007576', 'EFO_1001469', 'EFO_1001951', 'EFO_0002618', 'EFO_0000183', 'MONDO_0011719', 'EFO_0000403', 'EFO_1000657', 'EFO_0002429', 'EFO_0000211']",15.0,"['ENSG00000097007', 'ENSG00000213923', 'ENSG00000171608']",3,2021.0,CHEMBL3948730,,,,,,,,
CHEMBL421,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,NCEXYHBECQHGNR-QZQOTICOSA-N,Small molecule,False,SULFASALAZINE,4.0,False,True,"['Azulfidine', 'Azulfidine EN', 'Azulfidine en-tabs', 'Colizine', 'S.a.s.-500', 'Salazopyrin', 'Salazopyrin e.c.', 'Salazopyrin-en', 'Salazosulfapyridine', 'Salicylazosulfapyridine', 'Sulfasalazine', 'Ucine']","['Azulfidine', 'Benzosulfa', 'NSC-203730', 'NSC-667219', 'SAS-500', 'Salazosulfapyridine', 'Salicylazosulfapyridine', 'Sulfasalazine', 'Sulfasalazinum', 'Sulfasalazopyridine', 'Sulphasalazine']","['CHEMBL3765414', 'CHEMBL2311115']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 11 investigational indications.,['Sulfasalazine'],['DB00795'],"['EFO_0000222', 'EFO_0000685', 'EFO_0006911', 'MONDO_0004565', 'EFO_0004268', 'EFO_0003917', 'EFO_0003898', 'EFO_0003778', 'EFO_0000519', 'EFO_0002609', 'EFO_0001361', 'EFO_0003102', 'EFO_0004149', 'EFO_0000729']",14.0,"['ENSG00000012779', 'ENSG00000073756', 'ENSG00000095303']",3,1950.0,,['sulfasalazine'],"['144204588', '144208437', '144210859', '170464716', '17389737', '26747277']",['9334'],,,['34'],,
CHEMBL5314801,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O,AJBMORBNKXNZSF-COSHMZDQSA-N,Oligosaccharide,False,IDRAPARINUX,3.0,False,False,[],"['SR 34006', 'SR-34006', 'Sr34006']",['CHEMBL5314374'],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0003907', 'EFO_0003827', 'EFO_0003827', 'EFO_0000275']",4.0,['ENSG00000126218'],1,,,,,,,,,,
CHEMBL1229517,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,GPXBXXGIAQBQNI-UHFFFAOYSA-N,Small molecule,False,VEMURAFENIB,4.0,False,True,['Zelboraf'],"['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426', 'RO-5185426', 'Vemurafenib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 16 investigational indications.,['Vemurafenib'],['DB08881'],"['EFO_0000616', 'EFO_0000326', 'EFO_0001642', 'MONDO_0002108', 'EFO_1000209', 'EFO_1000956', 'EFO_0000756', 'MONDO_0002898', 'EFO_0000222', 'HP_0100727', 'EFO_0002892', 'EFO_0000365', 'MONDO_0004992', 'EFO_0002618', 'EFO_0002617', 'EFO_0003060', 'EFO_0001378', 'EFO_0000574', 'EFO_0000389', 'EFO_1000318', 'EFO_1001951']",21.0,['ENSG00000157764'],1,2011.0,,['vemurafenib'],,['63637'],['https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf'],,,,
CHEMBL3545189,,,Antibody,False,LANADELUMAB,4.0,False,True,['Takhzyro'],"['DX-2930', 'Lanadelumab', 'Lanadelumab flyo', 'Lanadelumab-flyo', 'SHP-643', 'Tak-743']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for hereditary angioedema and has 4 investigational indications.,,,"['EFO_0000546', 'EFO_0005532', 'EFO_0005251', 'MONDO_0019623', 'MONDO_0100096']",5.0,['ENSG00000164344'],1,2018.0,,['landelumab-flyo'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro'],,,,
CHEMBL3707183,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O,ZHNFLHYOFXQIOW-AHSOWCEXSA-N,Small molecule,True,QUINIDINE SULFATE,4.0,False,True,"['Cin-quin', 'Quinicardine', 'Quinidex', 'Quinidine sulfate', 'Quinora']","['AVP-786 COMPONENT QUINIDINE SULFATE', 'NSC-10004', 'QUINIDINE SULFATE COMPONENT OF AVP-786', 'Quinidex extentabs', 'Quinidine sulfate', 'Quinidine sulfate anhydrous', 'Quinidine sulfate dihydrate', 'Quinidine sulfate hydrate', 'Quinidine sulphate', 'Quinidine sulphate anhydrous', 'Quinidine sulphate dihydrate', 'Quinidine, sulfate (2:1) (salt)', 'Quinidini sulfas']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003758', 'MONDO_0004976']",2.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1962.0,CHEMBL1294,['quinidine%20sulfate'],,,,,,,
CHEMBL5314411,C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)N4CCN(CC)CC4)cc23)c1,DQAZPZIYEOGZAF-UHFFFAOYSA-N,Small molecule,False,EPITINIB,1.0,False,False,[],"['Epitinib', 'HMPL-813', 'Hmpl-813']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0000519', 'EFO_0000616']",2.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL94081,C=CCOc1ccc(CC(=O)O)cc1Cl,ARHWPKZXBHOEEE-UHFFFAOYSA-N,Small molecule,False,ALCLOFENAC,4.0,True,True,[],"['Alclofenac', 'W 7320']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease. It was withdrawn in at least one region.,['Alclofenac'],['DB13167'],['EFO_0005755'],1.0,['ENSG00000095303'],1,,,,"['144205279', '29215481']",['31183'],,,,,
CHEMBL1068,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,CTRLABGOLIVAIY-UHFFFAOYSA-N,Small molecule,False,OXCARBAZEPINE,4.0,False,True,"['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']","['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'Oxcarbazepine', 'SPN-804']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for epilepsy and seizure and has 10 investigational indications.,['Oxcarbazepine'],['DB00776'],"['MONDO_0005090', 'HP_0000713', 'EFO_0005230', 'HP_0000726', 'MONDO_0004992', 'MONDO_0002050', 'EFO_0005762', 'EFO_0000474', 'MONDO_0005301', 'EFO_0003015', 'HP_0001250', 'EFO_0004263']",12.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2000.0,,['oxcarbazepine'],"['144204534', '170464811', '174006287', '26719673', '26747194', '50085868', '866068']",['7824'],,,,,
CHEMBL1265,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,LZCDAPDGXCYOEH-UHFFFAOYSA-N,Small molecule,False,ADAPALENE,4.0,False,True,"['Adapalene', 'Differin']","['Adapalene', 'CD 271', 'CD-271', 'Differin']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for acne and has 2 investigational indications.,['Adapalene'],['DB00210'],"['EFO_0007375', 'EFO_0000701', 'EFO_0003894']",3.0,"['ENSG00000172819', 'ENSG00000077092', 'ENSG00000131759']",3,1996.0,,['adapalene'],"['144205789', '170464674', '174006867', '26758039']",['31174'],,,,,
CHEMBL1294,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,LOUPRKONTZGTKE-LHHVKLHASA-N,Small molecule,True,QUINIDINE,4.0,False,True,[],"['(8r,9s)-quinidine', '.beta.-quinidine', 'Conquinine', 'Kinidin', 'Pitayine', 'Quinidine']","['CHEMBL2068675', 'CHEMBL3707183', 'CHEMBL1435413', 'CHEMBL1200437', 'CHEMBL2165709']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 16 investigational indications. This drug has a black box warning from the FDA.,,['DB00908'],"['EFO_0001068', 'EFO_0004278', 'HP_0004308', 'EFO_0004287', 'HP_0002019', 'EFO_0000275', 'MONDO_0100096', 'EFO_0004269', 'MONDO_0004976', 'EFO_1001413', 'MONDO_0002050', 'EFO_0000612', 'MONDO_0004976', 'MONDO_0005277', 'MONDO_0002009', 'MONDO_0005301', 'EFO_1001249', 'EFO_0003758', 'EFO_0004197']",19.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1950.0,,,"['17389531', '56320931', '56320932']",['28593'],,,,,
CHEMBL1546,CC(N)Cc1ccc(O)cc1,GIKNHHRFLCDOEU-UHFFFAOYSA-N,Small molecule,False,HYDROXYAMPHETAMINE,4.0,False,True,[],"['Dl-4-hydroxyamphetamine', 'Dl-p-hydroxyamphetamine', 'Hydroxyamfetamine', 'Hydroxyamphetamine', 'NSC-170995', 'Norveritol', 'P-hydroxyamphetamine', 'Phenol, p-(2-aminopropyl)-', 'Pulsoton', 'Racemic p-hydroxyamphetamine']",['CHEMBL1200705'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969.,['Hydroxyamfetamine'],['DB09352'],,,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1969.0,,,,,,,,,
CHEMBL2108568,,,Protein,False,TREBANANIB,3.0,False,False,[],"['AMG 386', 'AMG-386', 'Trebananib']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,,"['MONDO_0008170', 'EFO_0000673', 'EFO_1001465', 'EFO_0000632', 'MONDO_0002158', 'EFO_0008528', 'EFO_0000616', 'EFO_0003060', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0002087', 'EFO_1000158', 'EFO_0000681', 'EFO_0003968']",14.0,"['ENSG00000091879', 'ENSG00000154188']",2,,,,,,,,,,
CHEMBL24828,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,UHTHHESEBZOYNR-UHFFFAOYSA-N,Small molecule,True,VANDETANIB,4.0,False,True,"['Caprelsa', 'Zactima']","['GNF-PF-2188', 'NSC-744325', 'NSC-760766', 'Vandetanib', 'ZD-64', 'ZD-6474', 'ZD6474']",['CHEMBL533849'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 7 approved and 41 investigational indications. This drug has a black box warning from the FDA.,['Vandetanib'],['DB05294'],"['EFO_0000588', 'MONDO_0008627', 'EFO_1001951', 'MONDO_0100342', 'EFO_0009708', 'EFO_0000349', 'EFO_0000641', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0001663', 'EFO_0000182', 'EFO_0007535', 'MONDO_0002367', 'EFO_0000702', 'MONDO_0008903', 'EFO_1000026', 'EFO_0003060', 'EFO_0003869', 'EFO_0002501', 'EFO_1000657', 'EFO_0002916', 'MONDO_0011719', 'EFO_0000519', 'MONDO_0001187', 'EFO_0003897', 'MONDO_0008170', 'EFO_0001378', 'MONDO_0002108', 'EFO_0006859', 'EFO_1000158', 'MONDO_0004992', 'EFO_0002499', 'MONDO_0015277', 'EFO_0000501', 'EFO_0000222', 'MONDO_0004192', 'MONDO_0001056', 'EFO_0002618', 'MONDO_0002087', 'EFO_0000630', 'MONDO_0002158', 'EFO_0000616', 'EFO_0000181', 'EFO_1001465', 'EFO_0000621', 'EFO_0002892', 'EFO_0003841', 'EFO_0000365']",48.0,"['ENSG00000142627', 'ENSG00000133216', 'ENSG00000145242', 'ENSG00000116106', 'ENSG00000070886', 'ENSG00000080224', 'ENSG00000135333', 'ENSG00000182580', 'ENSG00000044524', 'ENSG00000154928', 'ENSG00000196411', 'ENSG00000146904', 'ENSG00000106123', 'ENSG00000183317', 'ENSG00000197122', 'ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568', 'ENSG00000065361', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000120156', 'ENSG00000165731', 'ENSG00000101213']",25,2011.0,,['vandetanib'],"['103905338', '124893338', '144206064', '170465617', '50100123', '50112766']",['49960'],['https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa'],,,,
CHEMBL1089,NNCCc1ccccc1,RMUCZJUITONUFY-UHFFFAOYSA-N,Small molecule,True,PHENELZINE,4.0,False,True,[],"['Nardil', 'Phenelzine']",['CHEMBL1200895'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for unipolar depression and has 2 investigational indications. This drug has a black box warning from the FDA.,['Phenelzine'],['DB00780'],"['EFO_0003761', 'EFO_0000673', 'MONDO_0007254']",3.0,"['ENSG00000189221', 'ENSG00000069535']",2,1961.0,,,"['11111653', '11111654', '174006798', '50111200', '90341694']",['8060'],,,,,
CHEMBL1259,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3,JFXBEKISTKFVAB-AJQTZOPKSA-N,Small molecule,False,METOCURINE,4.0,False,True,[],"['Dimethyl tubocurarine', 'Dimethyltubocurarine', 'Dimethyltubocurarinium', 'Metocurine', 'Metocurine cation', 'Metocurine ion']","['CHEMBL1739', 'CHEMBL2105841']",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Metocurine'],['DB01336'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1982.0,,,,['6900'],,,,,
CHEMBL2105643,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO,FIDMEHCRMLKKPZ-YSMBQZINSA-N,Small molecule,False,FOSBRETABULIN TROMETHAMINE,2.0,False,False,['Zybrestat'],['Fosbretabulin tromethamine'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0008170', 'EFO_1001901']",2.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,CHEMBL1206232,,,,,,,,
CHEMBL2109253,,,Antibody,False,HOKT3,3.0,False,False,[],"['HOKT3', 'Hokt3']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0003778', 'MONDO_0005147']",2.0,['ENSG00000198851'],1,,,,,,,,,,
CHEMBL2133806,Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1,JRWCBEOAFGHNNU-UHFFFAOYSA-N,Small molecule,False,JNJ-38877605,1.0,False,False,[],"['JNJ-38877605', 'Jnj-38877605']",['CHEMBL5275126'],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB13113'],['EFO_0000616'],1.0,['ENSG00000105976'],1,,,,['137276033'],,,,,,
CHEMBL3301588,,,Antibody,False,TAREXTUMAB,2.0,False,False,[],"['OMP-59R5', 'Tarextumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000702', 'EFO_0002618', 'EFO_0000616']",3.0,"['ENSG00000074181', 'ENSG00000134250']",2,,,,,,,,,,
CHEMBL3545040,CC(C)(C)OC(=O)NCCN1CC2CN(C[C@H](O)COc3ccc(C#N)cc3)CC(C1)O2,JRHUUZPSMQIWBQ-PELRDEGISA-N,Small molecule,False,AZD7009,2.0,False,False,[],['Azd7009'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000275'],1.0,"['ENSG00000055118', 'ENSG00000183873']",2,,,,,,,,,,
CHEMBL3545432,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,MBOMYENWWXQSNW-AWEZNQCLSA-N,Small molecule,False,IXAZOMIB CITRATE,4.0,False,True,['Ninlaro'],"['Ixazomib citrate', 'MLN-9708', 'MLN9708']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for multiple myeloma and has 14 investigational indications.,,,"['EFO_0000220', 'MONDO_0019438', 'EFO_0009441', 'EFO_0000222', 'EFO_0000558', 'EFO_0000574', 'MONDO_0004992', 'EFO_0006738', 'MONDO_0007254', 'EFO_0000519', 'MONDO_0000873', 'MONDO_0020547', 'EFO_0001378', 'EFO_1001469', 'EFO_0006475']",15.0,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']",38,2015.0,,['ixazomib%20citrate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro'],,,,
CHEMBL4298090,,,Protein,False,SIMLUKAFUSP ALFA,2.0,False,False,[],"['FAP-IL-2V', 'FAP-IL2V FP RO6874281', 'FAP-IL2v', 'RG-7461', 'RG7461', 'RO-6874281', 'RO6874281', 'Ro6874281', 'Simlukafusp alfa']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000681', 'EFO_0002617', 'EFO_0000616']",3.0,"['ENSG00000078098', 'ENSG00000147168', 'ENSG00000100385']",3,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SIMLUKAFUSP%20ALFA/relevant/1/'],,,
CHEMBL452076,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)C1c1cccc([N+](=O)[O-])c1,KJEBULYHNRNJTE-DHZHZOJOSA-N,Small molecule,False,CILNIDIPINE,3.0,False,False,[],"['Atelec', 'Cilnidipine', 'Cinalong', 'FRC-8653', 'Siscard']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB09232'],"['EFO_0000319', 'EFO_1001496', 'EFO_0000537']",3.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,"['144205554', '170465867', '26755677', '50111041', '90341030']",['31399'],,,,,
CHEMBL99946,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN,GJJFMKBJSRMPLA-DZGCQCFKSA-N,Small molecule,True,LEVOMILNACIPRAN,4.0,False,True,['Fetzima'],"['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'Levomilnacipran', 'Milnacipran, (1s,2r)-']",['CHEMBL2105732'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,['DB08918'],"['MONDO_0002009', 'EFO_0005687', 'EFO_0003761', 'EFO_0003768', 'EFO_0003761', 'MONDO_0002009', 'HP_0002140']",7.0,"['ENSG00000108576', 'ENSG00000103546']",2,2013.0,,,,,,,,,
CHEMBL276520,c1ccc2c(CCC3CCNCC3)c[nH]c2c1,SADQVAVFGNTEOD-UHFFFAOYSA-N,Small molecule,False,INDALPINE,4.0,True,True,[],"['Indalpine', 'LM-5008']",['CHEMBL2362557'],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,['Indalpine'],['DB08953'],,,['ENSG00000108576'],1,,,,,,,,,,
CHEMBL3545083,COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,XLSYZSRXVVCHLS-UHFFFAOYSA-N,Small molecule,False,RGB-286638,1.0,False,False,[],"['RGB 286638', 'Rgb-286638']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0001642'],1.0,"['ENSG00000170312', 'ENSG00000164885', 'ENSG00000136807', 'ENSG00000123374', 'ENSG00000134058', 'ENSG00000135446']",6,,,,,,,,,,
CHEMBL3545368,CC(O)C(=O)O.Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,XVDWNSFFSMWXJJ-ASTDGNLGSA-N,Small molecule,True,PANOBINOSTAT LACTATE,4.0,False,True,['Farydak'],"['Panobinostat lactate', 'Panobinostat lactate anhydrous']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for multiple myeloma. This drug has a black box warning from the FDA.,,,['EFO_0001378'],1.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,2015.0,CHEMBL483254,['panobinostat%20lactate'],,['85991'],['https://www.ema.europa.eu/en/medicines/human/EPAR/farydak'],,,,
CHEMBL3545372,,,Antibody drug conjugate,False,SOFITUZUMAB VEDOTIN,2.0,False,False,[],"['Anti-MUC16 ADC', 'DMUC-5754A', 'DMUC5754A', 'RG-7458', 'Sofituzumab vedotin']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0008170', 'EFO_0002618']",2.0,"['ENSG00000181143', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL4297684,,,Protein,False,ABICIPAR PEGOL,3.0,False,False,[],"['AGN-150998', 'Abicipar pegol', 'Agn-150998', 'MP-0112', 'MP-0260', 'MP0112', 'Mp0112', 'P7FHD7AG35', 'Vegf-a binding darpin']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['EFO_0004683', 'EFO_0005753', 'MONDO_0003005', 'EFO_0009606', 'EFO_0001365']",5.0,['ENSG00000112715'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ABICIPAR%20PEGOL/relevant/1/'],,,
CHEMBL49642,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,SOLIIYNRSAWTSQ-UHFFFAOYSA-N,Small molecule,False,INDIBULIN,2.0,False,False,[],"['D-24851', 'Indibulin', 'ZIO-301']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB06169'],"['EFO_0000616', 'MONDO_0004992', 'MONDO_0007254']",3.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,['174007308'],,,,,,
CHEMBL727,Nc1nc2[nH]cnc2c(=S)[nH]1,WYWHKKSPHMUBEB-UHFFFAOYSA-N,Small molecule,False,THIOGUANINE,4.0,False,True,"['Lanvis', 'Tabloid', 'Thioguanine']","['NSC-752', 'NSC-76504', 'Thioguanine', 'Thioguanine anhydrous', 'Thioguanine hemihydrate', 'Thioguanine, anhydrous', 'Tioguanine', 'Tioguanine hemihydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and is indicated for neoplasm and has 26 investigational indications.,['Tioguanine'],['DB00352'],"['EFO_0000183', 'EFO_0003027', 'EFO_0000198', 'EFO_0000519', 'EFO_0000209', 'MONDO_0001657', 'EFO_0000565', 'EFO_0003811', 'EFO_0003025', 'MONDO_0000873', 'EFO_0003833', 'EFO_0004251', 'EFO_0000574', 'EFO_1000318', 'EFO_0005952', 'EFO_0003029', 'EFO_0000616', 'MONDO_0000870', 'EFO_0000220', 'EFO_0000222', 'EFO_0000223', 'EFO_0000218', 'EFO_0004289', 'EFO_0003802', 'EFO_0000221', 'EFO_1001779', 'MONDO_0044917']",27.0,"['ENSG00000106348', 'ENSG00000178035']",2,1966.0,,,"['144204586', '144206735', '144209599', '144210595', '170464908', '174007001', '26748270', '538243', '57260104', '57264437']",['9555'],,,,,
CHEMBL1200425,C#CCN(C)Cc1ccccc1.Cl,BCXCABRDBBWWGY-UHFFFAOYSA-N,Small molecule,False,PARGYLINE HYDROCHLORIDE,4.0,False,True,['Eutonyl'],"['A-19120', 'MO-911', 'NSC-43798', 'Pargyline hcl', 'Pargyline hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000189221', 'ENSG00000069535']",2,1982.0,CHEMBL673,,"['144203792', '144212995', '170465066', '50106924', '56422872', '855526']",,,,,,
CHEMBL1200781,Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,WIHMBLDNRMIGDW-UHFFFAOYSA-N,Small molecule,True,CITALOPRAM HYDROBROMIDE,4.0,False,True,"['Celexa', 'Cipramil', 'Citalopram hydrobromide', 'Paxoran']","['Citalopram (as hydrobromide)', 'Citalopram hbr', 'Citalopram hydrobromide', 'LU 10-171-B', 'LU-10-171-B', 'NSC-758684']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for unipolar depression and major depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0031217', 'EFO_0004262', 'EFO_0003758', 'EFO_0003761', 'MONDO_0002009']",5.0,['ENSG00000108576'],1,1998.0,CHEMBL549,['citalopram%20hydrobromide'],"['26719710', '29215151', '46500388', '50106010', '50106011']",,,,,,
CHEMBL1201505,,,Unknown,False,"FIBRINOLYSIN, HUMAN",4.0,False,True,[],"['Fibrinolysin', 'Fibrinolysin (human)', 'Fibrinolysin human', 'Fibrinolysin, human', 'Plasmin', 'Plasmin (bos taurus)', 'Plasmin (bovine)', 'Plasmin (human)', 'Plasmin bovine', 'Thrombolysin.']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for recurrent thrombophlebitis and has 2 investigational indications.,['Fibrinolysin'],,"['HP_0004419', 'MONDO_0020673', 'HP_0002140']",3.0,"['ENSG00000171560', 'ENSG00000171564', 'ENSG00000171557']",3,1964.0,,,,,,,,,
CHEMBL1717,Cl.Clc1ccccc1CN1CCc2sccc2C1,MTKNGOHFNXIVOS-UHFFFAOYSA-N,Small molecule,True,TICLOPIDINE HYDROCHLORIDE,4.0,False,True,"['Ticlid', 'Ticlopidine hydrochloride', 'Tiklid']","['4-C-32', '53-32C', 'Ipaton', 'NSC-759165', 'Ticlopidine hcl', 'Ticlopidine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for stroke and thrombotic disease. This drug has a black box warning from the FDA.,,,"['EFO_0000712', 'MONDO_0000831']",2.0,['ENSG00000169313'],1,1991.0,CHEMBL833,['ticlopidine%20hydrochloride'],['865815'],['9589'],,,,,
CHEMBL1983268,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,HAYYBYPASCDWEQ-UHFFFAOYSA-N,Small molecule,False,ENTRECTINIB,4.0,False,True,['Rozlytrek'],"['Entrectinib', 'NMS-E628', 'RXDX-101', 'Rxdx-101']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 5 investigational indications.,,['DB11986'],"['MONDO_0004992', 'EFO_0001642', 'EFO_0000326', 'EFO_0003060', 'EFO_0000389', 'EFO_0000616', 'EFO_0000222', 'EFO_0000553']",8.0,"['ENSG00000047936', 'ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538', 'ENSG00000171094']",5,2019.0,,['entrectinib'],['103905026'],,['https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek'],,,,
CHEMBL2041933,NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,IAYGCINLNONXHY-LBPRGKRZSA-N,Small molecule,False,AZD-7762,1.0,False,False,[],"['AZD-7762', 'AZD7762', 'Azd 7762', 'Azd-7762']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,['DB12242'],"['EFO_0000616', 'MONDO_0004992']",2.0,['ENSG00000149554'],1,,,,['124950686'],,,,,,
CHEMBL3414621,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,NSQSAUGJQHDYNO-UHFFFAOYSA-N,Small molecule,False,TAZEMETOSTAT,4.0,False,True,[],"['E-7438', 'E7438', 'EPZ-6438', 'EPZ6438', 'Tazemetostat']",['CHEMBL4594260'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 19 investigational indications.,,['DB12887'],"['EFO_0005952', 'EFO_0000222', 'MONDO_0001187', 'EFO_0000181', 'EFO_0000702', 'EFO_0000616', 'MONDO_0018906', 'EFO_0000196', 'MONDO_0015760', 'MONDO_0018906', 'EFO_0002913', 'EFO_0000403', 'EFO_0000096', 'EFO_0000574', 'EFO_0000691', 'EFO_0008528', 'EFO_0001378', 'MONDO_0008315', 'MONDO_0017387', 'EFO_0000616', 'EFO_0000588', 'EFO_0003060']",22.0,['ENSG00000106462'],1,2020.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TAZEMETOSTAT/relevant/1/'],,,
CHEMBL3545057,CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O,HPMZBILYSWLILX-UMDUKNJSSA-N,Small molecule,False,ACETYLDIGITOXIN,4.0,False,True,['Acylanid'],"['Acetyldigitoxin', 'Acetyldigitoxins .alpha.-form']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease.,,['DB00511'],['EFO_0000319'],1.0,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731']",8,1982.0,,,,['53773'],,,,,
CHEMBL3545068,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21.Cl.Cl,STGQPVQAAFJJFX-UHFFFAOYSA-N,Small molecule,False,COPANLISIB HYDROCHLORIDE,4.0,False,True,['Aliqopa'],"['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDE', 'BAY-84-1236', 'Copanlisib hydrochloride', 'Copanlisib hydrochloride hydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for follicular lymphoma and neoplasm of mature b-cells and has 8 investigational indications.,,,"['EFO_0005537', 'MONDO_0018906', 'EFO_0000305', 'EFO_1001051', 'EFO_1001469', 'EFO_0000616', 'EFO_0000096', 'EFO_0000403', 'EFO_0001378', 'EFO_0000183']",10.0,"['ENSG00000121879', 'ENSG00000171608']",2,2017.0,CHEMBL3218576,['copanlisib%20dihydrochloride'],,,,,,,
CHEMBL4297584,CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,HDXDQPRPFRKGKZ-INIZCTEOSA-N,Small molecule,False,TENALISIB,2.0,False,False,[],['Tenalisib'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,['DB15295'],"['EFO_0000211', 'EFO_0000574', 'MONDO_0007254', 'EFO_0001642', 'EFO_0000095', 'MONDO_0009348', 'EFO_0005952']",7.0,"['ENSG00000105851', 'ENSG00000171608']",2,,,,,,,,,,
CHEMBL4297886,,,Protein,False,ASUNERCEPT,3.0,False,False,[],"['APG-101', 'APG101', 'Apg101', 'Apocept', 'Asinercept', 'Asunercept', 'CAN-008']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0000519', 'MONDO_0100096', 'EFO_0000198']",3.0,['ENSG00000117560'],1,,,,,,,,,,
CHEMBL4298098,,,Antibody drug conjugate,False,TUSAMITAMAB RAVTANSINE,3.0,False,False,[],"['Maytansin-loaded anti-ceacam5 mab', 'SAR-408701', 'SAR408701', 'Sar 408701', 'Sar-408701', 'Sar408701', 'Tusamitamab ravtansine']",,Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0003060', 'EFO_0000616']",2.0,"['ENSG00000105388', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TUSAMITAMAB%20RAVTANSINE/relevant/1/'],,,
CHEMBL866,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2,HPNSFSBZBAHARI-RUDMXATFSA-N,Small molecule,True,MYCOPHENOLIC ACID,4.0,False,True,"['Mycophenolic acid', 'Myfortic']","['68618', 'Mycophenolate', 'Mycophenolate mofetil impurity, mycophenolic acid-', 'Mycophenolic acid', 'NSC-129185', 'RS-61443 [AS MOFETIL]']",['CHEMBL2106643'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for immune system disease and multiple sclerosis and has 18 investigational indications. This drug has a black box warning from the FDA.,['Mycophenolic_acid'],['DB01024'],"['EFO_0005140', 'EFO_0004255', 'EFO_0005761', 'HP_0001871', 'MONDO_0007915', 'EFO_0000717', 'EFO_0000384', 'EFO_1002048', 'EFO_0003884', 'MONDO_0005147', 'EFO_0004599', 'EFO_0000699', 'EFO_0003086', 'EFO_0000540', 'EFO_1000906', 'EFO_1000986', 'MONDO_0005301', 'EFO_0000222', 'EFO_0003884', 'EFO_0004599', 'MONDO_0013730', 'EFO_0005761']",22.0,"['ENSG00000106348', 'ENSG00000178035']",2,2004.0,,,"['11112696', '11112697', '11114111', '124882524', '124882525', '124882528', '124882529', '124882530', '144204161', '170465182', '26747168', '26752207', '26752208', '420202', '47193743', '50104875', '85148364']",['168396'],,,,,
CHEMBL1201201,CN[C@@H](C)Cc1ccccc1,MYWUZJCMWCOHBA-VIFPVBQESA-N,Small molecule,True,METHAMPHETAMINE,4.0,False,True,[],"['(s)-phenylmethylaminopropane', 'J6.362B', 'Metamfetamine', 'Methamphetamine', 'NSC-25115']",['CHEMBL1200952'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and is indicated for attention deficit hyperactivity disorder and has 2 investigational indications. This drug has a black box warning from the FDA.,['Methamphetamine'],['DB01577'],"['EFO_0003888', 'EFO_0004701', 'EFO_0004242', 'EFO_0003888']",4.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,1943.0,,,,['6809'],,,,,
CHEMBL1232583,COc1ccc(S(=O)(=O)n2cc(CCC(=O)O)c3cc(OC)ccc32)cc1,YMPALHOKRBVHOJ-UHFFFAOYSA-N,Small molecule,False,INDEGLITAZAR,2.0,False,False,[],"['Indeglitazar', 'PPM-204']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB07724'],['EFO_0000400'],1.0,"['ENSG00000132170', 'ENSG00000186951', 'ENSG00000112033']",3,,,,,,,,,,
CHEMBL1561,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,IBAQFPQHRJAVAV-ULAWRXDQSA-N,Small molecule,False,MIGLITOL,4.0,False,True,"['Diastabol', 'Glyset', 'Miglitol']","['BAY M 1099', 'BAY-M-1099', 'Miglitol', 'NSC-758702']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 1 investigational indication.,['Miglitol'],['DB00491'],"['MONDO_0005148', 'MONDO_0005147', 'EFO_0000400']",3.0,"['ENSG00000171298', 'ENSG00000257335']",2,1996.0,,['miglitol'],"['144204989', '170465326', '26719889', '49681630']",['6935'],,,,,
CHEMBL2105664,CC(OC(=O)c1ccc(Cc2c(O)c3ccccc3oc2=O)cc1)(C(F)(F)F)C(F)(F)F,QFLNTQDOVCLQKW-UHFFFAOYSA-N,Small molecule,False,TECARFARIN,3.0,False,False,[],"['ATI-5923', 'Tecarfarin']",['CHEMBL2105676'],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB12823'],['EFO_0000275'],1.0,['ENSG00000167397'],1,,,,,,,,,,
CHEMBL3545330,c1cnc(NCc2ccc(CNc3ncccn3)cc2)nc1,PXZXYRKDDXKDTK-UHFFFAOYSA-N,Small molecule,False,MSX-122,1.0,False,False,[],"['Msx 122', 'Msx-122']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB12715'],['EFO_0000616'],1.0,['ENSG00000121966'],1,,,,,,,,,,
CHEMBL3545427,,,Small molecule,False,CM-082,3.0,False,False,[],['Cm-082'],,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,,"['EFO_0001365', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000616', 'EFO_0000681', 'EFO_0000702']",7.0,"['ENSG00000122025', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113721']",4,,,,,,,,,,
CHEMBL3707400,,,Small molecule,False,INDANTADOL,2.0,False,False,[],"['Chf-3381 free base', 'Chf3381', 'Indantadol', 'V3381']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_1000783', 'HP_0012735', 'EFO_0005762', 'EFO_0003843']",4.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785', 'ENSG00000189221']",8,,,,,,,,,,
CHEMBL4650393,,,Antibody,False,EPCORITAMAB,4.0,False,True,['Epkinly'],"['Epcoritamab', 'Epcoritamab-bysp', 'Epkinly', 'GEN-3013', 'GEN3013']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for diffuse large b-cell lymphoma and has 6 investigational indications.,,,"['EFO_0000095', 'EFO_0000403', 'EFO_1001469', 'MONDO_0018906', 'EFO_0005952', 'EFO_0000096', 'EFO_0000616']",7.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000156738']",4,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/EPCORITAMAB/relevant/1/'],,,
CHEMBL471,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,ZBMZVLHSJCTVON-UHFFFAOYSA-N,Small molecule,True,SOTALOL,4.0,False,True,[],"['Betapace', 'C07AA07', 'Darob mite', 'Dl-sotalol', 'MJ-1999', 'Sorine', 'Sotalol']",['CHEMBL1700'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for ventricular arrhythmia and cardiovascular disease and has 6 investigational indications. This drug has a black box warning from the FDA.,['Sotalol'],['DB00489'],"['HP_0004308', 'EFO_0004278', 'EFO_0000319', 'EFO_0000275', 'EFO_0000612', 'EFO_0004287', 'EFO_0003144', 'EFO_0000275', 'EFO_0005306']",9.0,"['ENSG00000043591', 'ENSG00000055118', 'ENSG00000169252']",3,1992.0,,,"['144203812', '26751989']",['63622'],,,,,
CHEMBL1201550,,,Protein,True,DENILEUKIN DIFTITOX,4.0,False,True,['Ontak'],"['DAB(SUB 389)IL2', 'DAB-389IL2', 'DAB389 IL2', 'DAB389IL2', 'Denileukin', 'Denileukin diftitox', 'E-7272', 'E-7777', 'E7272', 'E7777', 'LY-335348', 'LY335348']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for neoplasm and cutaneous t-cell lymphoma and has 20 investigational indications. This drug has a black box warning from the FDA.,"['Denileukin_diftitox', 'Resimmune']",,"['EFO_0000574', 'MONDO_0002367', 'MONDO_0013730', 'EFO_0006861', 'EFO_1000043', 'EFO_0000211', 'EFO_0000222', 'EFO_1000251', 'EFO_0000389', 'EFO_0005952', 'EFO_0002618', 'EFO_0000095', 'EFO_0000209', 'EFO_0000466', 'MONDO_0002087', 'EFO_0001378', 'MONDO_0008170', 'EFO_0000565', 'EFO_0000616', 'MONDO_0002158', 'EFO_0002913', 'EFO_0000756']",22.0,"['ENSG00000167658', 'ENSG00000134460', 'ENSG00000147168', 'ENSG00000100385']",4,1999.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/DENILEUKIN%20DIFTITOX/relevant/1/'],,['5087'],
CHEMBL1419,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,UNAANXDKBXWMLN-UHFFFAOYSA-N,Small molecule,False,SIBUTRAMINE,4.0,True,True,['Reductil'],"['Butramin', 'Cf-alli', 'Medaria', 'Racemic sibutramine', 'Sibutramine']","['CHEMBL3989830', 'CHEMBL1200765']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for obesity and has 1 investigational indication. It was withdrawn in at least one region.,['Sibutramine'],['DB01105'],"['EFO_0001073', 'EFO_0001073']",2.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,1997.0,,,"['174007250', '49732001']",['9137'],,,,,
CHEMBL3301574,,,Cell,True,TISAGENLECLEUCEL,4.0,False,True,['Kymriah'],"['CART-19', 'CART19', 'CTL-019', 'CTL019', 'Car.cd19-redirected t cells', 'Kymriah', 'Tisagenlecleucel', 'Tisagenlecleucel-t']",,Cell drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for b-cell acute lymphoblastic leukemia and diffuse large b-cell lymphoma and has 13 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000094', 'EFO_0000403', 'EFO_0002618', 'EFO_0000183', 'EFO_0000096', 'EFO_0001378', 'EFO_0005952', 'MONDO_0000873', 'EFO_0000222', 'EFO_0000565', 'EFO_0000220', 'MONDO_0018906', 'EFO_0000574', 'EFO_0000094', 'EFO_0000095']",15.0,['ENSG00000177455'],1,2018.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah'],,,,
CHEMBL3707401,,,Small molecule,False,MK-8777,2.0,False,False,[],"['Mk-8777', 'Org-26576']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0003888', 'MONDO_0002050']",2.0,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,,,,
CHEMBL3948730,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,IUVCFHHAEHNCFT-INIZCTEOSA-N,Small molecule,False,UMBRALISIB,4.0,False,True,[],"['RP-5264', 'RP5264', 'TGR-1202 FREE BASE', 'TGR-1202 base', 'Tgr 1202', 'Umbralisib']",['CHEMBL3989869'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 19 investigational indications.,,['DB14989'],"['EFO_0000095', 'EFO_0000183', 'MONDO_0044903', 'MONDO_0001056', 'EFO_0000095', 'EFO_1000630', 'MONDO_0018906', 'MONDO_0007576', 'EFO_1001469', 'EFO_1001469', 'EFO_0002618', 'EFO_1001951', 'EFO_0000183', 'MONDO_0011719', 'EFO_0000403', 'EFO_0000616', 'EFO_1000657', 'EFO_0002429', 'EFO_0000096', 'EFO_0000403', 'EFO_0009441', 'EFO_0000211', 'MONDO_0018906']",23.0,"['ENSG00000213923', 'ENSG00000171608', 'ENSG00000097007']",3,2021.0,,,,,,,,,
CHEMBL4650215,C[C@H](Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O,SGEUNORSOZVTOL-CABZTGNLSA-N,Small molecule,False,INAVOLISIB,3.0,False,False,[],"['GDC-0077', 'GDC0077', 'Gdc-0077', 'Inavolisib', 'RG-6114', 'RG6114', 'RO-7113755', 'RO7113755']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0007254', 'MONDO_0011962', 'MONDO_0008170', 'EFO_0000616', 'MONDO_0004992']",5.0,['ENSG00000121879'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/INAVOLISIB/relevant/1/'],,,
CHEMBL477772,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,CUIHSIWYWATEQL-UHFFFAOYSA-N,Small molecule,True,PAZOPANIB,4.0,False,True,['Votrient'],"['GW786034', 'NSC-752782', 'Pazopanib']",['CHEMBL1201733'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 66 investigational indications. This drug has a black box warning from the FDA.,['Pazopanib'],['DB06589'],"['EFO_1001465', 'EFO_0000182', 'MONDO_0004986', 'EFO_0005543', 'MONDO_0002087', 'EFO_0003016', 'EFO_0007143', 'EFO_0000681', 'MONDO_0011719', 'MONDO_0015277', 'EFO_1001465', 'EFO_0003869', 'MONDO_0008903', 'EFO_1000613', 'MONDO_0008170', 'MONDO_0004192', 'MONDO_0002158', 'MONDO_0019297', 'MONDO_0004986', 'MONDO_0000521', 'EFO_0003893', 'EFO_1001968', 'EFO_0000637', 'EFO_0000691', 'MONDO_0001056', 'MONDO_0008315', 'EFO_0000333', 'EFO_0002618', 'MONDO_0008667', 'EFO_0003968', 'EFO_0000564', 'MONDO_0002367', 'MONDO_0007254', 'EFO_1001100', 'EFO_0000616', 'EFO_0000519', 'MONDO_0011934', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0019180', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000574', 'EFO_0000702', 'EFO_0000222', 'EFO_0000501', 'EFO_0002892', 'MONDO_0001187', 'MONDO_0001187', 'EFO_0000181', 'EFO_0000349', 'EFO_0000349', 'EFO_0003968', 'MONDO_0002087', 'MONDO_0008315', 'EFO_0000588', 'EFO_0001663', 'EFO_0009606', 'EFO_0000691', 'EFO_0000641', 'MONDO_0002974', 'EFO_0000365', 'EFO_0000616', 'EFO_0000640', 'MONDO_0002158', 'EFO_0000681', 'EFO_1000880', 'MONDO_0016238', 'EFO_1001968', 'MONDO_0008903', 'EFO_0000756', 'EFO_0000569', 'EFO_0000673', 'EFO_0000514', 'EFO_0000676', 'EFO_1001901', 'EFO_0000335', 'EFO_0000389', 'MONDO_0008170']",79.0,"['ENSG00000113263', 'ENSG00000182578', 'ENSG00000077782', 'ENSG00000182866', 'ENSG00000068078', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853']",11,2009.0,,,"['103905642', '144206725', '170465625', '50100102']",['71219'],,,,,
CHEMBL5314390,CO[C@]1(COC(=O)CCNC(=O)C(N)CCCCN)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4.Cl.Cl,PBEVPBFDKPJIOM-RHIKYVLPSA-N,Small molecule,False,CEP-2563 DIHYDROCHLORIDE,1.0,False,False,[],"['Cep-2563', 'KT-8391']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000165731', 'ENSG00000122025', 'ENSG00000113721', 'ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538', 'ENSG00000115825', 'ENSG00000163558', 'ENSG00000154229', 'ENSG00000126583', 'ENSG00000163932', 'ENSG00000166501', 'ENSG00000067606', 'ENSG00000171132', 'ENSG00000027075', 'ENSG00000184304', 'ENSG00000065675']",17,,CHEMBL5316170,,,,,,,,
CHEMBL598797,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,PLIVFNIUGLLCEK-UHFFFAOYSA-N,Small molecule,False,CUDC-101,1.0,False,False,[],"['CUDC-101', 'Cudc 101', 'Cudc-101']","['CHEMBL3922781', 'CHEMBL3957601', 'CHEMBL3983283', 'CHEMBL3913031']",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications.,,['DB12174'],"['EFO_0000616', 'EFO_0006859', 'EFO_0003060', 'MONDO_0002691', 'MONDO_0001056', 'MONDO_0007254', 'MONDO_0004992']",7.0,"['ENSG00000146648', 'ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429', 'ENSG00000141736']",13,,,,['137276021'],,,,,,
CHEMBL608533,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,BMGQWWVMWDBQGC-IIFHNQTCSA-N,Small molecule,False,MIDOSTAURIN,4.0,False,True,['Rydapt'],"['CGP 41251', 'CGP-41251', 'Midostaurin', 'NSC-656576', 'NVP-PKC412', 'PKC 412', 'PKC-412', 'Pkc-412']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 6 investigational indications.,['Midostaurin'],['DB06595'],"['EFO_0000220', 'EFO_0001421', 'EFO_1000131', 'EFO_0009001', 'EFO_0000616', 'MONDO_0016586', 'EFO_0007359', 'EFO_0000198', 'EFO_0000565', 'EFO_0000222', 'EFO_1000657']",11.0,"['ENSG00000122025', 'ENSG00000128052', 'ENSG00000115825', 'ENSG00000163558', 'ENSG00000154229', 'ENSG00000126583', 'ENSG00000163932', 'ENSG00000166501', 'ENSG00000067606', 'ENSG00000171132', 'ENSG00000027075', 'ENSG00000184304', 'ENSG00000065675', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000157404']",16,2017.0,,['midostaurin'],['124950161'],['63452'],['https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt'],,,,
CHEMBL652,O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,DJBNUMBKLMJRSA-UHFFFAOYSA-N,Small molecule,True,FLECAINIDE,4.0,False,True,[],"['Flecainide', 'NSC-719273', 'THN-102 COMPONENT FLECAINIDE']","['CHEMBL4591096', 'CHEMBL1200822']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for cardiac arrhythmia and ventricular arrhythmia and has 3 investigational indications. This drug has a black box warning from the FDA.,['Flecainide'],['DB01195'],"['EFO_0004269', 'EFO_0000275', 'Orphanet_247', 'HP_0004308', 'EFO_0003843', 'EFO_0000275']",6.0,['ENSG00000183873'],1,1985.0,,,"['104171159', '124880129', '144203702', '170464874', '26752195']",['75984'],,,,,
CHEMBL673,C#CCN(C)Cc1ccccc1,DPWPWRLQFGFJFI-UHFFFAOYSA-N,Small molecule,False,PARGYLINE,4.0,False,True,[],"['Eutonyl', 'Eutron', 'Pargyline']",['CHEMBL1200425'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for hypertension.,['Pargyline'],['DB01626'],['EFO_0000537'],1.0,"['ENSG00000189221', 'ENSG00000069535']",2,1982.0,,,"['11111668', '11111669', '90340843']",['7930'],,,,,
CHEMBL1922235,COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1,IJNIQYINMSGIPS-UHFFFAOYSA-N,Small molecule,False,DAREXABAN,3.0,False,False,[],"['Darexaban', 'Tanexaban', 'YM-150', 'YM150']","['CHEMBL1922345', 'CHEMBL3527359']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB12289'],"['EFO_0004286', 'EFO_0000275', 'HP_0001907', 'EFO_0005672']",4.0,['ENSG00000126218'],1,,,,,,,,,,
CHEMBL2104449,CC(=O)N(O)CC1=C(n2ccccc2=O)c2cc(C(F)(F)F)ccc2OC1(C)C,FXRJKZVWFJSKGI-UHFFFAOYSA-N,Small molecule,False,SARAKALIM,2.0,False,False,[],"['RS-91309', 'Sarakalim']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000187486', 'ENSG00000069431', 'ENSG00000006071', 'ENSG00000121361']",4,,,,,,,,,,
CHEMBL2108658,,,Antibody,False,TREMELIMUMAB,4.0,False,True,['Imjudo'],"['CP-675,206', 'CP-675206', 'PF-06753388', 'TICILIMUMAB', 'Tremelimumab', 'Tremelimumab (genetical recombination)', 'Tremelimumab actl']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 56 investigational indications.,,,"['EFO_0002617', 'EFO_0000514', 'EFO_0000501', 'MONDO_0008315', 'EFO_0000691', 'EFO_0000181', 'EFO_0000349', 'MONDO_0004992', 'EFO_0003863', 'MONDO_0008903', 'EFO_0000503', 'EFO_0001075', 'MONDO_0001187', 'EFO_0000681', 'EFO_0001378', 'MONDO_0002158', 'EFO_0000702', 'EFO_0000764', 'EFO_0005221', 'EFO_0001642', 'EFO_0000305', 'EFO_0003060', 'MONDO_0007576', 'EFO_0005537', 'EFO_1001100', 'EFO_0000403', 'MONDO_0008170', 'MONDO_0003060', 'EFO_0000365', 'MONDO_0003001', 'EFO_0000182', 'EFO_0003891', 'MONDO_0002108', 'EFO_0000198', 'EFO_0000756', 'EFO_0008528', 'EFO_0004142', 'MONDO_0044704', 'EFO_0000199', 'EFO_0000673', 'EFO_0000574', 'EFO_1000251', 'EFO_0000616', 'EFO_0000389', 'MONDO_0021148', 'EFO_0000641', 'MONDO_0005184', 'MONDO_0007254', 'EFO_0000708', 'EFO_1001961', 'EFO_0004284', 'EFO_0000519', 'EFO_0002618', 'EFO_0000588', 'MONDO_0001056', 'EFO_1001951', 'EFO_1001968', 'EFO_0005220', 'MONDO_0003002']",59.0,['ENSG00000163599'],1,2022.0,,,,,,,,,
CHEMBL2109171,,,Protein,False,DIBOTERMIN ALFA,4.0,False,True,['Inductos'],"['Dibotermin', 'Dibotermin alfa', 'Inductos', 'Nebotermin', 'Rhbmp-2']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for bone disease and tibia fracture and has 4 investigational indications.,,,"['EFO_0004260', 'HP_0000689', 'EFO_0003931', 'EFO_0003957', 'EFO_0003944', 'MONDO_0005178']",6.0,"['ENSG00000115170', 'ENSG00000138696', 'ENSG00000114739', 'ENSG00000204217', 'ENSG00000121989', 'ENSG00000107779']",6,2002.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/inductos'],,,['5024'],
CHEMBL2220486,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,CUDVHEFYRIWYQD-UHFFFAOYSA-N,Small molecule,False,LUCITANIB,2.0,False,False,[],"['AL-3810', 'Al-3810', 'CO-3810', 'E-3810', 'Lucitanib', 'S 80881', 'S-80881']",['CHEMBL2180605'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,['DB11845'],"['EFO_0000702', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254', 'MONDO_0021148', 'EFO_0003060']",6.0,"['ENSG00000066468', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000077782']",5,,,,,['65209'],,,,,
CHEMBL235191,CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1,VAZAPHZUAVEOMC-UHFFFAOYSA-N,Small molecule,False,TACEDINALINE,3.0,False,False,[],"['CI-994', 'GOE 5549', 'GOE-5549', 'PD 123654', 'PD-123654', 'Tacedinaline']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB12291'],"['EFO_0001378', 'MONDO_0008903', 'EFO_0002618']",3.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,,,,,['90195'],,,,,
CHEMBL3,CN1CCC[C@H]1c1cccnc1,SNICXCGAKADSCV-JTQLQIEISA-N,Small molecule,False,NICOTINE,4.0,False,True,"['Habitrol', 'Nicabate', 'Nicoderm cq', 'Nicopass', 'Nicopatch', 'Nicorette invisi', 'Nicotine', 'Nicotinell classic', 'Nicotinell support', 'Nicotinell tts 10', 'Nicotinell tts 20', 'Nicotinell tts 30', 'Nicotrol', 'Nicotrol Inhaler', 'Nicotrol NS', 'Niquitin', 'Niquitin clr', 'Niquitin minis cherry', 'Niquitin minis mint', 'Niquitin minis orange', 'Niquitin mint', 'Niquitin pre-quit', 'Niquitin strips mint', 'Prostep', 'Stoppers', 'Stubit']",['Nicotine'],"['CHEMBL3137669', 'CHEMBL1448280', 'CHEMBL3989563', 'CHEMBL151515', 'CHEMBL3182465', 'CHEMBL225057', 'CHEMBL1201536']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for nicotine dependence and has 30 investigational indications.,['Nicotine'],['DB00184'],"['HP_0100543', 'MONDO_0002050', 'MONDO_0005180', 'EFO_0003768', 'EFO_0004329', 'EFO_0002610', 'MONDO_0004647', 'MONDO_0019338', 'MONDO_0004938', 'EFO_0003888', 'EFO_0000691', 'EFO_0003144', 'MONDO_0005090', 'EFO_0000341', 'MONDO_0008903', 'MONDO_0100096', 'EFO_0000313', 'EFO_0001072', 'MONDO_0002050', 'EFO_0004319', 'EFO_0000694', 'MONDO_0018076', 'DOID_13406', 'EFO_0004888', 'EFO_0000546', 'EFO_0004318', 'EFO_0004318', 'MONDO_0002974', 'EFO_0007191', 'EFO_0003768', 'EFO_0003768']",31.0,"['ENSG00000160716', 'ENSG00000101204']",2,1984.0,,['nicotine'],"['144209012', '144210494', '17389805', '26752744', '26752745', '26752746', '50105392', '50105393', '56314824', '90341453']",['17688'],,,,,
CHEMBL3133037,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C,POERAARDVFVDLO-QGZVFWFLSA-N,Small molecule,False,LEQ506,1.0,False,False,[],"['LEQ-506', 'LEQ506', 'Leq 506', 'Leq506', 'NVP-LEQ506', 'Nvp-leq-506']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,['DB12857'],"['EFO_0004193', 'EFO_0002939']",2.0,['ENSG00000128602'],1,,,,,,,,,,
CHEMBL4297183,CN1Cc2cc(Cl)ccc2-n2c(nnc2[C@H]2CC[C@H](Oc3ccccn3)CC2)C1,GMPZPHGHNDMRKL-RZDIXWSQSA-N,Small molecule,False,BALOVAPTAN,3.0,False,False,[],"['Balovaptan', 'RG-7314', 'RG7314', 'RO-5285119', 'RO5285119', 'Rg7314']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB14823'],"['HP_0002140', 'EFO_0001358', 'EFO_0003756']",3.0,['ENSG00000166148'],1,,,,,,,,,,
CHEMBL4297555,,,Unknown,False,RESIMMUNE,2.0,False,False,[],"['A-dmdt390-bisfv(ucht1)', 'LAX-699', 'Resimmune']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_1001051', 'EFO_0005592', 'EFO_1000785', 'EFO_0000756']",4.0,"['ENSG00000167658', 'ENSG00000198851']",2,,,,,,,,,,
CHEMBL705,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,Small molecule,False,ALITRETINOIN,4.0,False,True,"['Panretin', 'Toctino']","['9-cis retinoic acid', '9-cis-retinoic acid', 'AGN 192013', 'AGN-192013', 'AGN192013', 'ALRT-1057', 'ALRT1057', 'Alitretinoin', 'BAL-4079', 'LG-100057', 'LG100057', 'LGD-1057', 'LGD1057', 'NSC-659772', 'Panretin', 'Retinoic acid 9-cis-form']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 5 investigational indications.,['Alitretinoin'],['DB00523'],"['HP_0000964', 'EFO_1000706', 'EFO_0003834', 'EFO_0000676', 'EFO_1000726', 'EFO_0000558', 'MONDO_0007254', 'EFO_0000616']",8.0,"['ENSG00000204231', 'ENSG00000172819', 'ENSG00000143171', 'ENSG00000077092', 'ENSG00000131759', 'ENSG00000186350']",6,1999.0,,['alitretinoin'],"['144212512', '26755228', '26755229', '26755230']",['50648'],['https://www.ema.europa.eu/en/medicines/human/EPAR/panretin'],,,,
CHEMBL1201752,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,FABUFPQFXZVHFB-PVYNADRNSA-N,Small molecule,True,IXABEPILONE,4.0,False,True,"['Ixempra', 'Ixempra kit']","['Azaepothilone b', 'BMS 247550-01', 'BMS-247550', 'BMS-247550-01', 'Ixabepilone', 'Ixempra', 'NSC-747973']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 38 investigational indications. This drug has a black box warning from the FDA.,['Ixabepilone'],['DB04845'],"['EFO_0000756', 'MONDO_0004992', 'MONDO_0004192', 'EFO_0000182', 'EFO_0003897', 'EFO_1001465', 'EFO_1001968', 'EFO_0005221', 'EFO_1000613', 'MONDO_0005411', 'MONDO_0007254', 'EFO_0006861', 'MONDO_0044926', 'EFO_0000305', 'EFO_0007532', 'EFO_1001469', 'MONDO_0011962', 'MONDO_0004986', 'EFO_0000403', 'EFO_0000349', 'EFO_0000565', 'EFO_0000309', 'MONDO_0008903', 'EFO_0002499', 'EFO_0000681', 'EFO_0003869', 'MONDO_0018906', 'EFO_0000673', 'EFO_0000616', 'MONDO_0002158', 'EFO_0002938', 'EFO_0002618', 'EFO_0003871', 'EFO_0003032', 'EFO_0000574', 'EFO_0003060', 'EFO_0006859', 'MONDO_0002087', 'MONDO_0008170', 'EFO_0007535', 'EFO_0006352', 'EFO_1001951', 'MONDO_0008315']",43.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,2007.0,,,,['63605'],,,,,
CHEMBL1693,CCN(CC)C(C)C(=O)c1ccccc1.Cl,ICFXZZFWRWNZMA-UHFFFAOYSA-N,Small molecule,False,DIETHYLPROPION HYDROCHLORIDE,4.0,False,True,"['Apisate', 'Diethylpropion hydrochloride', 'Tenuate', 'Tenuate dospan', 'Tepanil', 'Tepanil ten-tab']","['Amfepramone hydrochloride', 'Anorex', 'D03801', 'Diethylpropion HCl', 'Diethylpropion hcl', 'Diethylpropion hydrochloride', 'Diethylpropion hydrochloride civ', 'Dobesin', 'Moderatan', 'Prefamone', 'Regenon']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for obesity.,,,['EFO_0001073'],1.0,"['ENSG00000103546', 'ENSG00000142319']",2,1959.0,CHEMBL1194666,['diethylpropion%20hydrochloride'],['170464650'],['643703'],,,,,
CHEMBL2108041,,,Antibody,False,OCRELIZUMAB,4.0,False,True,['Ocrevus'],"['2H7', 'Ocrelizumab', 'PR-070769', 'PR070769', 'R-1594', 'RG-1594']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 4 investigational indications.,,,"['MONDO_0005301', 'EFO_0003929', 'EFO_0003840', 'EFO_0005952', 'EFO_0000540', 'MONDO_0007915', 'EFO_0008520', 'EFO_0000685', 'EFO_0007332']",9.0,['ENSG00000156738'],1,2017.0,,['ocrelizumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus'],,,,
CHEMBL4297182,COCCN1C(=O)O[C@@]2(C[C@H]3O[C@]2(C)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)C1=O,SHWPFRVVBIKGAT-LYWBODIJSA-N,Small molecule,False,PEGCANTRATINIB,2.0,False,False,[],"['CT-327', 'CT327', 'Ct-327', 'Pegcantratinib', 'SNA-120', 'Sna-120']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000676', 'EFO_0000274', 'EFO_0005762', 'EFO_1001494']",4.0,['ENSG00000198400'],1,,,,,,,,,,
CHEMBL522038,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N\O)cc1)C1CCCCC1,ZXIBCJHYVWYIKI-PZJWPPBQSA-N,Small molecule,False,XIMELAGATRAN,4.0,True,True,[],"['Exanta', 'H 376/95', 'Ximelagatran']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 2 investigational indications. It was withdrawn in at least one region.,['Ximelagatran'],['DB04898'],"['HP_0001907', 'HP_0004419', 'EFO_0000275']",3.0,['ENSG00000180210'],1,,,,['144207182'],['65172'],,,,,
CHEMBL796,COC(=O)C(c1ccccc1)C1CCCCN1,DUGOZIWVEXMGBE-UHFFFAOYSA-N,Small molecule,True,METHYLPHENIDATE,4.0,False,True,"['Concerta', 'Cotempla xr-odt', 'Daytrana']","['Concerta', 'Methylin', 'Methylphenidate', 'Methylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']",['CHEMBL1722'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome and has 36 investigational indications. This drug has a black box warning from the FDA.,['Methylphenidate'],['DB00422'],"['HP_0000726', 'EFO_0009267', 'MONDO_0005180', 'EFO_0008568', 'EFO_0001642', 'MONDO_0008315', 'MONDO_0004992', 'EFO_0003768', 'MONDO_0007079', 'EFO_0003840', 'MONDO_0011184', 'MONDO_0011382', 'MONDO_0004992', 'EFO_0001663', 'MONDO_0002050', 'EFO_0005252', 'EFO_0005203', 'EFO_0007625', 'EFO_0003890', 'MONDO_0005090', 'HP_0012378', 'MONDO_0043510', 'EFO_0001358', 'MONDO_0004985', 'EFO_0003833', 'EFO_0004701', 'EFO_0002610', 'MONDO_0002050', 'HP_0012378', 'EFO_0003888', 'MONDO_0004975', 'EFO_0005323', 'EFO_0003888', 'EFO_0004216', 'HP_0012532', 'MONDO_0016158', 'MONDO_0005301', 'EFO_0003929', 'EFO_0003768', 'EFO_0005611', 'MONDO_0002009', 'EFO_0003843']",42.0,"['ENSG00000142319', 'ENSG00000103546']",2,1955.0,,['methylphenidate'],,['84276'],,,,,
CHEMBL98,O=C(CCCCCCC(=O)Nc1ccccc1)NO,WAEXFXRVDQXREF-UHFFFAOYSA-N,Small molecule,False,VORINOSTAT,4.0,False,True,['Zolinza'],"['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852', 'Suberoylanilide hydroxamic acid', 'Vorinostat']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 85 investigational indications.,['Vorinostat'],['DB02546'],"['EFO_1001951', 'MONDO_0004992', 'EFO_0002913', 'EFO_0000691', 'MONDO_0008903', 'EFO_0000220', 'EFO_0000096', 'EFO_0000191', 'EFO_0003828', 'EFO_0006352', 'EFO_1000026', 'MONDO_0004975', 'EFO_0000616', 'MONDO_0015760', 'EFO_0004198', 'EFO_1001830', 'EFO_0000574', 'EFO_1001110', 'EFO_0000621', 'MONDO_0002158', 'EFO_0000641', 'EFO_0003833', 'MONDO_0003268', 'EFO_0007535', 'MONDO_0007254', 'MONDO_0005090', 'EFO_0000309', 'MONDO_0011382', 'EFO_0000365', 'EFO_0000222', 'EFO_0000565', 'MONDO_0019460', 'EFO_0000764', 'EFO_0000224', 'EFO_1001380', 'MONDO_0008315', 'EFO_0003060', 'MONDO_0001657', 'EFO_0005774', 'EFO_0000349', 'EFO_0002429', 'EFO_0000180', 'EFO_0002939', 'EFO_0000211', 'MONDO_0007576', 'EFO_0000198', 'EFO_0000519', 'EFO_1000785', 'EFO_0003893', 'EFO_0000479', 'EFO_0000339', 'MONDO_0015277', 'EFO_1001968', 'MONDO_0018364', 'EFO_0002618', 'EFO_0003869', 'MONDO_0044926', 'EFO_1000657', 'EFO_0000183', 'EFO_0000702', 'EFO_1001465', 'EFO_0002938', 'EFO_1001469', 'EFO_0004289', 'MONDO_0018906', 'EFO_1000309', 'MONDO_0001879', 'EFO_0000756', 'EFO_0000588', 'MONDO_0002087', 'EFO_0001378', 'EFO_0000681', 'MONDO_0021063', 'MONDO_0008170', 'MONDO_0000873', 'EFO_0000095', 'MONDO_0002691', 'EFO_0002501', 'EFO_0000673', 'MONDO_0001056', 'EFO_0000384', 'EFO_0000770', 'EFO_0000403', 'EFO_0002499', 'EFO_0005952', 'MONDO_0004986', 'EFO_1001051', 'EFO_0006861', 'MONDO_0000870']",89.0,"['ENSG00000116478', 'ENSG00000094631', 'ENSG00000171720', 'ENSG00000196591']",4,2006.0,,['vorinostat'],"['104171411', '124893442', '144206158', '144207172', '170465180', '49645508', '50113029']",['45716'],,,,,
CHEMBL1981592,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O,VBUWHHLIZKOSMS-RIWXPGAOSA-N,Protein,False,AVIPTADIL,3.0,False,False,"['Samiairtm', 'Samiviptm', 'Samivirtm', 'Zyesami']","['Aviptadil', 'Aviptadil acetate', 'Vip human vip']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['MONDO_0100096', 'EFO_0004610', 'EFO_1000637', 'MONDO_0100096']",4.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,,,,['124893751'],,,['https://searchusan.ama-assn.org/finder/usan/search/AVIPTADIL/relevant/1/'],,,
CHEMBL206468,OC[C@H]1CNC[C@@H](O)[C@@H]1O,QPYJXFZUIJOGNX-HSUXUTPPSA-N,Small molecule,False,AFEGOSTAT,2.0,False,False,[],"['Afegostat', 'Isofagomine']",['CHEMBL2105671'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB04545'],['MONDO_0018150'],1.0,['ENSG00000177628'],1,,,,['85267413'],,,,,,
CHEMBL2105719,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1.O,BSPLGGCPNTZPIH-IPZCTEOASA-N,Small molecule,False,DACOMITINIB,4.0,False,True,['Vizimpro'],"['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydrate', 'PF-00299804-03']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 7 investigational indications.,,,"['MONDO_0008903', 'EFO_0000616', 'MONDO_0001657', 'EFO_1001951', 'EFO_1001094', 'EFO_0000707', 'EFO_0001421', 'EFO_0000181', 'MONDO_0004992', 'EFO_0003060']",10.0,"['ENSG00000146648', 'ENSG00000178568', 'ENSG00000141736']",3,2018.0,CHEMBL2110732,['dacomitinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro'],,,,
CHEMBL2107762,CCCN(c1ccncc1F)n1cc(C)c2ccccc21,BTDHTARYCBHHPJ-UHFFFAOYSA-N,Small molecule,False,NERISPIRDINE,2.0,False,False,[],"['HP-184', 'HP184', 'Nerispirdine', 'Nerispirdine hydrochloride']",['CHEMBL3585642'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12714'],"['MONDO_0005301', 'EFO_1001919']",2.0,"['ENSG00000053918', 'ENSG00000171385', 'ENSG00000055118', 'ENSG00000177301', 'ENSG00000111262', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000104848', 'ENSG00000185760', 'ENSG00000117013', 'ENSG00000143473', 'ENSG00000182255', 'ENSG00000130037', 'ENSG00000177272', 'ENSG00000151079', 'ENSG00000129159', 'ENSG00000184408', 'ENSG00000182674', 'ENSG00000116396', 'ENSG00000131398', 'ENSG00000158445', 'ENSG00000143105', 'ENSG00000164794', 'ENSG00000140015', 'ENSG00000171126', 'ENSG00000168418', 'ENSG00000168263', 'ENSG00000124134', 'ENSG00000183960', 'ENSG00000166006', 'ENSG00000170745', 'ENSG00000173826', 'ENSG00000162975', 'ENSG00000184611', 'ENSG00000102057', 'ENSG00000026559', 'ENSG00000178342', 'ENSG00000135519', 'ENSG00000156486', 'ENSG00000089558', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",50,,,,,,,,,,
CHEMBL2109527,,,Antibody,False,MEDI-578,1.0,False,False,[],"['MEDI-578', 'Medi-578']",,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0003843', 'MONDO_0005178']",2.0,['ENSG00000134259'],1,,,,,,,,,,
CHEMBL288441,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,UBPYILGKFZZVDX-UHFFFAOYSA-N,Small molecule,False,BOSUTINIB,4.0,False,True,['Bosulif'],"['Bosutinib', 'SK-606', 'SKI-606']","['CHEMBL2095206', 'CHEMBL2131134']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for myeloid leukemia and chronic myelogenous leukemia and has 21 investigational indications.,['Bosutinib'],['DB06616'],"['EFO_0000222', 'MONDO_0002974', 'MONDO_0004643', 'EFO_1000131', 'EFO_0002618', 'EFO_0000616', 'EFO_1001496', 'MONDO_0002087', 'EFO_1000581', 'MONDO_0007254', 'EFO_0000519', 'EFO_0000339', 'EFO_0003060', 'EFO_0000565', 'MONDO_0001187', 'MONDO_0002586', 'HP_0000726', 'EFO_0000220', 'EFO_0000305', 'EFO_0000588', 'MONDO_0004976', 'MONDO_0008170', 'EFO_0000339']",23.0,"['ENSG00000197122', 'ENSG00000097007', 'ENSG00000101336', 'ENSG00000186716', 'ENSG00000254087']",5,2012.0,,,['124950167'],['39112'],,,,,
CHEMBL3039538,,,Protein,False,TRENONACOG ALFA,3.0,False,False,['Ixinity[tm]'],"['IB-1001', 'IB1001', 'Trenonacog alfa']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0010006', 'MONDO_0008840', 'MONDO_0018982', 'MONDO_0010604', 'MONDO_0010100']",5.0,['ENSG00000101981'],1,,,,,,,,,,
CHEMBL4650426,,,Protein,False,PEGENZILEUKIN,2.0,False,False,[],"['Il-2 variant thor-707', 'Pegenzileukin', 'SAR-444245', 'SAR444245', 'THOR-707', 'THOR707', 'Thor 707', 'Thor-707']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0009708', 'EFO_0001378', 'MONDO_0009348', 'EFO_0000181', 'EFO_0000403', 'EFO_0000616']",6.0,"['ENSG00000147168', 'ENSG00000100385']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PEGENZILEUKIN/relevant/1/'],,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL68117,CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC,XZAFZXJXZHRNAQ-STQMWFEESA-N,Small molecule,False,VOSAROXIN,3.0,False,False,[],"['AG-7352', 'SNS-595', 'SPC-595', 'Vosaroxin']",['CHEMBL543336'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,['DB11999'],"['EFO_0000565', 'EFO_0000220', 'EFO_0003060', 'EFO_0000702', 'EFO_0000339', 'EFO_0000616', 'EFO_0000198', 'EFO_0000222']",8.0,"['ENSG00000131747', 'ENSG00000077097']",2,,,,,,,,,,
CHEMBL945,N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,XSDQTOBWRPYKKA-UHFFFAOYSA-N,Small molecule,True,AMILORIDE,4.0,False,True,[],"['Amiclaran', 'Amiloride', 'Hydro-Ride', 'Midamor']","['CHEMBL1201085', 'CHEMBL1398126', 'CHEMBL540851']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.,['Amiloride'],['DB00594'],"['EFO_0000537', 'MONDO_0009061', 'EFO_0000319', 'EFO_0008519', 'EFO_0003144', 'EFO_0000373', 'EFO_0003888', 'EFO_0001645', 'EFO_0007405', 'EFO_0004269', 'EFO_0008522', 'MONDO_0005475', 'MONDO_0009061', 'EFO_0000537', 'HP_0011096']",15.0,"['ENSG00000111319', 'ENSG00000168447', 'ENSG00000166828']",3,1981.0,,,"['104171108', '11110775', '11113372', '124879259', '124879263', '144203631', '170465124', '26751628', '26751629', '49645530', '90341609']",['2639'],,,,,
CHEMBL984,COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2.[Cl-].[Cl-],WMSYWJSZGVOIJW-ONUALHDOSA-L,Small molecule,False,MIVACURIUM CHLORIDE,4.0,False,True,"['Mivacron', 'Mivacurium chloride']","['BW B109OU DICHLORIDE', 'BW-1090U DICHLORIDE', 'BW-B109OU', 'BW-B109OU DICHLORIDE', 'BWB109OU', 'MIVACURIUM CHLORIDE', 'Mivacurium chloride', 'mivacurium']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and has 1 investigational indication.,['Mivacurium_chloride'],,['HP_0001410'],1.0,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1992.0,CHEMBL1182833,,['144206026'],,,,,,
CHEMBL1201048,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)[C@H](C)C[C@]4(C)[C@H]3CC[C@]12C,NOTIQUSPUUHHEH-UXOVVSIBSA-N,Small molecule,False,DROMOSTANOLONE PROPIONATE,4.0,False,True,"['Drolban', 'Masteril']","['32379', 'Dromostanolone propionate', 'Drostanolone propionate', 'Masterid', 'Masteron', 'NSC-12198', 'NSC-1298', 'Permastril']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,['DB14655'],,,['ENSG00000169083'],1,1982.0,,,,['31523'],,,,,
CHEMBL1201217,CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1,BZEWSEKUUPWQDQ-UHFFFAOYSA-N,Small molecule,False,DYCLONINE,4.0,False,True,[],['Dyclonine'],['CHEMBL1200478'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Dyclonine'],['DB00645'],,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,,,"['11112403', '50100427']",['4724'],,,,,
CHEMBL2403108,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,VERWOWGGCGHDQE-UHFFFAOYSA-N,Small molecule,False,CERITINIB,4.0,False,True,['Zykadia'],"['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NX', 'NVP-LDK378-NX']","['CHEMBL4476089', 'CHEMBL4468931', 'CHEMBL4542506']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 10 investigational indications.,,['DB09063'],"['EFO_0000756', 'EFO_0003032', 'MONDO_0004992', 'EFO_0003060', 'EFO_0001421', 'EFO_0000389', 'EFO_1001968', 'EFO_0000519', 'MONDO_0015798', 'EFO_0000621', 'EFO_0005221', 'MONDO_0002108', 'EFO_0000616']",13.0,"['ENSG00000171094', 'ENSG00000143924', 'ENSG00000181163']",3,2014.0,,['ceritinib'],,['78432'],['https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia'],,,,
CHEMBL253969,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1,HXHAJRMTJXHJJZ-UHFFFAOYSA-N,Small molecule,False,OSI-632,2.0,False,False,[],"['CP-547,632', 'CP-547632', 'CP-632', 'Cp-547,632', 'OSI-632', 'Osi-632', 'PAN 90806', 'PAN-90806', 'PAN90806']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,['DB12962'],"['MONDO_0021117', 'MONDO_0002158', 'EFO_0003770', 'EFO_0001365', 'MONDO_0008170', 'MONDO_0002087']",6.0,['ENSG00000128052'],1,,,,"['103905622', '137275944']",,,,,,
CHEMBL3137336,Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl,AXTAPYRUEKNRBA-JTQLQIEISA-N,Small molecule,False,UPROSERTIB,2.0,False,False,[],"['Akt inhibitor gsk-2141795', 'Akt inhibitor gsk2141795', 'GSK-2141795C', 'GSK2141795', 'GSK2141795C', 'Gsk-2141795', 'Uprosertib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,['DB11969'],"['EFO_0000222', 'EFO_0001378', 'EFO_0000756', 'EFO_0000616', 'MONDO_0002974', 'MONDO_0004992', 'EFO_0005537']",7.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,,,,,,,
CHEMBL3545243,,,Small molecule,False,AS-703988,1.0,False,False,[],"['As-703988', 'MSC-2015103B']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,,,,,,,
CHEMBL3589904,COc1ccc(Cl)c(-c2ccc(NC(=O)c3ccnn3C)nc2N)c1,ZRJGMDIPCQOGNI-UHFFFAOYSA-N,Small molecule,False,PF-04531083,2.0,False,False,[],"['PF-4531083', 'Pf-04531083']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12468'],"['HP_0012532', 'EFO_0010072']",2.0,['ENSG00000185313'],1,,,,,,,,,,
CHEMBL3707250,,,Small molecule,False,CP-601927,2.0,False,False,[],"['CP-601,927', 'Cp-601927']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0002009'],1.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL4871106,NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(Cl)c(C(F)(F)F)c3)ncnc12,HXAUJHZZPCBFPN-QGZVFWFLSA-N,Small molecule,False,MSC-2363318A,1.0,False,False,[],"['M-2698', 'M2698', 'MSC-2363318A', 'MSC2363318A', 'Msc-2363318a']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000117020', 'ENSG00000142208', 'ENSG00000175634', 'ENSG00000108443']",4,,,,,,,,,,
CHEMBL1201233,CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1,SVEBYYWCXTVYCR-LBPRGKRZSA-N,Small molecule,False,METHYLDOPATE,4.0,False,True,[],['Methyldopate'],['CHEMBL1200432'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962.,,,,,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1962.0,,,,,,,,,
CHEMBL14762,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,Small molecule,False,SELICICLIB,2.0,False,False,[],"['AL-39256', 'CYC-202', 'Cyc-202', 'NSC-701554', 'R-roscovitine', 'Roscovitin', 'Roscovitine', 'Seliciclib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,['Seliciclib'],['DB06195'],"['MONDO_0009061', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000616', 'EFO_1001110']",5.0,"['ENSG00000170312', 'ENSG00000123374', 'ENSG00000164885', 'ENSG00000136807', 'ENSG00000134058']",5,,,,"['124891685', '26753649', '26753650', '50100113', '50107006', '527377']",['45307'],,,,,
CHEMBL1743028,,,Antibody drug conjugate,False,GLEMBATUMUMAB VEDOTIN,2.0,False,False,[],"['CDX-011', 'CR-011-VCMMAE', 'Glembatumumab vedotin']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000637', 'EFO_0000756', 'EFO_0000708', 'MONDO_0007254']",4.0,"['ENSG00000136235', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL2105758,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1.O=C(O)/C=C\C(=O)O,MISPBGHDNZYFNM-BTJKTKAUSA-N,Small molecule,False,AVATROMBOPAG MALEATE,4.0,False,True,['Doptelet'],"['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for thrombocytopenia and liver disease.,,,"['HP_0001873', 'EFO_0001421']",2.0,['ENSG00000117400'],1,2018.0,CHEMBL2103883,['avatrombopag%20maleate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet'],,,,
CHEMBL254328,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,GZOSMCIZMLWJML-VJLLXTKPSA-N,Small molecule,False,ABIRATERONE,4.0,False,True,['Zytiga'],"['Abiraterone', 'CB 7598', 'CB-7598', 'NSC-741232']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 4 investigational indications.,['Abiraterone'],['DB05812'],"['MONDO_0004992', 'EFO_0001663', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000673', 'EFO_0000196']",6.0,"['ENSG00000145545', 'ENSG00000277893', 'ENSG00000128039', 'ENSG00000169083', 'ENSG00000148795']",5,,,,,['68642'],,,,,
CHEMBL3545224,Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NCC2CCC(CNCCCNC3CCCCC3)CC2)n1,QLVSJMZJSABWRX-UHFFFAOYSA-N,Small molecule,False,BURIXAFOR,2.0,False,False,[],"['Burixafor', 'Tg-0054']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000183', 'EFO_0005952', 'EFO_0001378', 'MONDO_0008315']",4.0,['ENSG00000121966'],1,,,,,,,,,,
CHEMBL3701238,C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,KEIPNCCJPRMIAX-HNNXBMFYSA-N,Small molecule,False,FUTIBATINIB,4.0,False,True,['Lytgobi'],"['Fgfr-in-1', 'Futibatinib', 'TAS-120', 'Tas 120', 'Tas-120']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 5 investigational indications.,,['DB15149'],"['EFO_0000182', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0003891', 'EFO_1001968', 'EFO_0005221', 'EFO_0000616', 'EFO_0003060']",8.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,2022.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/FUTIBATINIB/relevant/1/'],,,
CHEMBL520733,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21,PKXWXXPNHIWQHW-RCBQFDQVSA-N,Small molecule,False,SEMAGACESTAT,3.0,False,False,[],"['LY-450139', 'LY450139', 'Semagacestat']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,['Semagacestat'],['DB12463'],['MONDO_0004975'],1.0,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']",6,,,,,,,,,,
CHEMBL968,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,SAADBVWGJQAEFS-UHFFFAOYSA-N,Small molecule,True,FLURAZEPAM,4.0,False,True,[],"['Dalmane', 'Flurazepam', 'Insumin']",['CHEMBL3989724'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for insomnia and has 5 investigational indications. This drug has a black box warning from the FDA.,['Flurazepam'],['DB00690'],"['EFO_0004698', 'EFO_0005230', 'EFO_0004698', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090']",6.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1970.0,,,"['144205754', '170465018', '26757995']",,,,,,
CHEMBL1076903,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,JQSHBVHOMNKWFT-DTORHVGOSA-N,Small molecule,False,VARENICLINE,4.0,False,True,[],"['CP-526,555', 'CP-526555', 'Varenicline']","['CHEMBL5303393', 'CHEMBL5316216']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for nicotine dependence and eye disease and has 21 investigational indications.,['Varenicline'],,"['MONDO_0007079', 'EFO_0002610', 'EFO_0004319', 'MONDO_0008903', 'EFO_0005672', 'MONDO_0002491', 'Orphanet_98757', 'EFO_0004329', 'MONDO_0004992', 'EFO_0007191', 'EFO_1000906', 'EFO_0003768', 'MONDO_0007079', 'EFO_0001071', 'MONDO_0100339', 'EFO_0003890', 'EFO_0004319', 'EFO_0004701', 'EFO_0003966', 'EFO_0003768', 'MONDO_0005180', 'EFO_0005411', 'MONDO_0005090', 'EFO_1000906', 'MONDO_0004975']",25.0,"['ENSG00000160716', 'ENSG00000101204']",2,2006.0,,,,['84500'],,,,,
CHEMBL1201284,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,VDHAWDNDOKGFTD-MRXNPFEDSA-N,Small molecule,False,CINACALCET,4.0,False,True,[],"['AMG 073', 'AMG-073', 'AMG073', 'Cinacalcet', 'KRN-1493', 'KRN1493']",['CHEMBL1200776'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 8 investigational indications.,['Cinacalcet'],['DB01012'],"['EFO_1001173', 'EFO_1001152', 'HP_0003072', 'EFO_0003884', 'EFO_0000673', 'EFO_0003884', 'EFO_0005754', 'EFO_0008506', 'EFO_0001072', 'MONDO_0024300', 'EFO_1001173', 'EFO_0008519', 'EFO_0000313', 'EFO_0008506', 'EFO_1000456']",15.0,['ENSG00000036828'],1,2004.0,,,"['124893630', '50125742']",['48390'],,,,,
CHEMBL1201666,,,Protein,False,LEPIRUDIN,4.0,False,True,['Refludan'],"['Hirudin lepirudin', 'Lepirudin', 'Lepirudin Recombinant', 'Lepirudin recombinant']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 1 investigational indication.,['Lepirudin'],,"['HP_0001873', 'HP_0004419', 'MONDO_0000831', 'HP_0001907', 'MONDO_0008903']",5.0,['ENSG00000180210'],1,1997.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/refludan'],,,['2995'],
CHEMBL1237132,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,KPBZROQVTHLCDU-UHFFFAOYSA-N,Small molecule,False,CLEVIDIPINE,4.0,False,True,['Cleviprex'],"['Clevidepine', 'Clevidepine butyrate', 'Clevidipine']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for cardiovascular disease and has 5 investigational indications.,,['DB04920'],"['EFO_1001031', 'EFO_0000319', 'EFO_0004264', 'EFO_0000537', 'EFO_0004273', 'EFO_0000712']",6.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,2008.0,,['clevidipine'],['170466066'],,,,,,
CHEMBL1580,OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,FPVKHBSQESCIEP-JQCXWYLXSA-N,Small molecule,True,PENTOSTATIN,4.0,False,True,"['Nipent', 'Pentostatin']","['CI-825', 'Deoxycoformycin', 'NSC-218321', 'Nipent', 'PD 81565', 'PD-81565', 'Pentostatin', 'YK-176']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA.,['Pentostatin'],['DB00552'],"['EFO_0000616', 'EFO_0000574', 'MONDO_0013730', 'EFO_0000565', 'MONDO_0004992', 'MONDO_0002367', 'EFO_0004599', 'MONDO_0011382', 'EFO_0000095', 'EFO_1000956', 'EFO_0006927', 'MONDO_0002280', 'MONDO_0020547']",13.0,['ENSG00000196839'],1,1991.0,,['pentostatin'],"['124893765', '144206967']",,,,,,
CHEMBL17,NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1,GJQPMPFPNINLKP-UHFFFAOYSA-N,Small molecule,False,DICHLORPHENAMIDE,4.0,False,True,"['Daranide', 'Keveyis', 'Oratrol']","['Dichlorphenamide', 'Diclofenamide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and is indicated for glaucoma and has 3 investigational indications.,['Diclofenamide'],['DB01144'],"['MONDO_0008223', 'MONDO_0008195', 'MONDO_0008224', 'MONDO_0005041']",4.0,"['ENSG00000167434', 'ENSG00000074410', 'ENSG00000104267', 'ENSG00000133742']",4,1958.0,,['dichlorphenamide'],"['11112264', '144203952', '56463645']",['101085'],,,,,
CHEMBL2109413,,,Antibody,False,AS-1409,1.0,False,False,[],"['AS-1409', 'As-1409', 'HUBC1-HUIL12']",,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0000756', 'EFO_0000681']",2.0,['ENSG00000115414'],1,,,,,,,,,,
CHEMBL3142541,CCCCOC(=O)c1ccc(N)cc1.CCCCOC(=O)c1ccc(N)cc1.O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1,ATAGSVCDFKGYPE-UHFFFAOYSA-N,Small molecule,False,BUTAMBEN PICRATE,4.0,True,True,[],"['ABBOTT-34842', 'Butamben picrate']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,,,,"['ENSG00000111199', 'ENSG00000104321']",2,,CHEMBL127516,,,['86300'],,,,,
CHEMBL3545097,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,GYLDXIAOMVERTK-UHFFFAOYSA-N,Small molecule,False,SAPANISERTIB,2.0,False,False,[],"['CB-228', 'INK-128', 'INK128', 'Ink-128', 'MLN-0128', 'MLN0128', 'Mln-0128', 'Sapanisertib', 'TAK-228']",['CHEMBL3943182'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 25 investigational indications.,,['DB11836'],"['MONDO_0008315', 'EFO_0000616', 'EFO_0007416', 'EFO_1001968', 'EFO_0004230', 'EFO_0000182', 'EFO_0000681', 'EFO_1000251', 'MONDO_0007254', 'EFO_0000519', 'EFO_1001471', 'EFO_0001378', 'EFO_0000708', 'EFO_1000045', 'MONDO_0004992', 'EFO_0003060', 'EFO_1000043', 'EFO_0000209', 'EFO_0000466', 'EFO_0007532', 'MONDO_0002108', 'EFO_0000574', 'EFO_0009441', 'EFO_1001465', 'EFO_0003869']",25.0,['ENSG00000198793'],1,,,,,,,,,,
CHEMBL3545125,CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O,FTBQORVNHOIASH-CKYFFXLPSA-N,Small molecule,False,MIROGABALIN,3.0,False,False,[],"['A-200-0700', 'A200-0700', 'Mirogabalin']",['CHEMBL3545257'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB11825'],"['EFO_1000783', 'EFO_0005687', 'MONDO_0041052', 'EFO_0005762']",4.0,"['ENSG00000153956', 'ENSG00000007402']",2,,,,,,,,,,
CHEMBL4298004,,,Antibody,False,VOPRATELIMAB,2.0,False,False,[],"['Anti-icos agonist mab jtx-2011', 'JTX-2011', 'Jtx 2011', 'Jtx-2011', 'Vopratelimab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0003060', 'MONDO_0004992', 'EFO_0000616']",3.0,['ENSG00000163600'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/VOPRATELIMAB/relevant/1/'],,,
CHEMBL482967,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,GPSZYOIFQZPWEJ-UHFFFAOYSA-N,Small molecule,False,CYC-116,1.0,False,False,[],"['CYC-116', 'Cyc 116', 'Cyc-116']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000128052', 'ENSG00000178999', 'ENSG00000105146', 'ENSG00000087586']",4,,,,"['103904403', '137276048']",,,,,,
CHEMBL1201775,C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1.Cl.Cl,RKSUYBCOVNCALL-NTVURLEBSA-N,Small molecule,False,SAPROPTERIN DIHYDROCHLORIDE,4.0,False,True,"['Kuvan', 'Sapropterin dipharma']","['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588', 'SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochloride', 'Sapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hyperphenylalaninemia and phenylketonuria and has 9 investigational indications.,,,"['EFO_0003876', 'MONDO_0005090', 'EFO_0000537', 'EFO_0001361', 'EFO_0005411', 'MONDO_0011382', 'Orphanet_238583', 'MONDO_0009861', 'EFO_0000181', 'EFO_0003884', 'EFO_0001645']",11.0,['ENSG00000171759'],1,2007.0,CHEMBL1201774,['sapropterin%20dihydrochloride'],['144205335'],['32120'],['https://www.ema.europa.eu/en/medicines/human/EPAR/sapropterin-dipharma'],,,,
CHEMBL1523964,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O,CAVQBDOACNULDN-KHFUBBAMSA-N,Small molecule,False,EPHEDRINE SULFATE,4.0,False,True,"['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plus']","['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for asthma and hypotension.,,,"['MONDO_0004979', 'EFO_0005251']",2.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,2016.0,CHEMBL211456,['ephedrine%20sulfate'],['50106282'],,,,,,
CHEMBL187927,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3,SUPRUPHAEXPGPF-QWHCGFSZSA-N,Small molecule,False,DIANICLINE,3.0,False,False,[],"['Dianicline', 'SSR-591813', 'SSR591813']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB12125'],['EFO_0003768'],1.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL2109391,,,Antibody,False,MDX-447,2.0,False,False,[],"['EMD-82633', 'MDX-447', 'Mdx-447']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_1000158'],1.0,"['ENSG00000150337', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL2179529,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1,GTUIQNHJSXQMKW-UHFFFAOYSA-N,Small molecule,False,AZD1446,2.0,False,False,[],"['AZD-1446', 'AZD1446 HCL', 'Azd 1446', 'Azd1446', 'Azd1446 free base', 'TC-6683', 'TC6683', 'TC6683 HCL']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['HP_0100543', 'MONDO_0004975', 'EFO_0003888']",3.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL254219,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,WDJUZGPOPHTGOT-XUDUSOBPSA-N,Small molecule,False,DIGITOXIN,4.0,False,True,"['Crystodigin', 'Digimerck', 'Nativelle digitaline']","['CRYSTODIGIN', 'Cristapurat', 'Digitalin, crystalline', 'Digitophyllin', 'Digitoxin', 'Digitoxinum', 'Digitoxoside', 'Glucodigin', 'Lanatoxin', 'NSC-7529', 'Purpurid', 'Tradigal']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 1 investigational indication.,['Digitoxin'],['DB01396'],"['EFO_0000319', 'MONDO_0009061']",2.0,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731']",8,1982.0,,,"['11533060', '144205212', '144212586', '170464713', '26754428', '26754429']",['28544'],,,,,
CHEMBL3545247,,,Small molecule,False,CAL-263,1.0,False,False,[],['Cal-263'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0005854'],1.0,"['ENSG00000171608', 'ENSG00000105851']",2,,,,,,,,,,
CHEMBL3545291,CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1,IURMHZBQEYNQOH-UHFFFAOYSA-N,Small molecule,False,JNJ-39393406,2.0,False,False,[],['Jnj-39393406'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB11867'],"['MONDO_0002050', 'EFO_0004319', 'MONDO_0005090']",3.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL3785909,COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(-c5cnn(C)c5)cn34)c(=O)c2c1,DWHXUGDWKAIASB-CQSZACIVSA-N,Small molecule,False,AMG-337,2.0,False,False,[],"['AMG 337', 'Amg-337']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB15639'],"['EFO_0000616', 'EFO_0003897', 'EFO_0008498', 'MONDO_0004992']",4.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL4297589,CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1,FYXHWMQPCJOJCH-GMAHTHKFSA-N,Small molecule,False,SELATOGREL,3.0,False,False,[],"['ACT-246475', 'Act-246475', 'Selatogrel']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB15163'],"['EFO_0001421', 'EFO_0008583', 'EFO_0001645']",3.0,['ENSG00000169313'],1,,,,,,,,,,
CHEMBL43452,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,UVSMNLNDYGZFPF-UHFFFAOYSA-N,Small molecule,True,POMALIDOMIDE,4.0,False,True,"['Imnovid', 'Imnovid (previously pomalidomide celgene)', 'Pomalyst']","['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for multiple myeloma and immune system disease and has 28 investigational indications. This drug has a black box warning from the FDA.,['Pomalidomide'],['DB08910'],"['EFO_0003073', 'EFO_0009441', 'EFO_0005952', 'MONDO_0019180', 'MONDO_0015564', 'MONDO_0017816', 'EFO_0002618', 'EFO_0002430', 'EFO_0006475', 'EFO_0000717', 'EFO_0002939', 'EFO_0002429', 'EFO_0004251', 'EFO_0000616', 'EFO_0000702', 'EFO_0001378', 'EFO_0000403', 'EFO_0000540', 'EFO_0000558', 'EFO_0004244', 'MONDO_0008315', 'EFO_1001968', 'EFO_0000183', 'EFO_0000309', 'MONDO_0019438', 'MONDO_0013730', 'EFO_0009448', 'EFO_0006738', 'MONDO_0044903', 'MONDO_0011382']",30.0,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']",4,2013.0,,['pomalidomide'],['174007398'],['72690'],['https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid'],,,,
CHEMBL4594331,,,Protein,False,DAZODALIBEP,2.0,False,False,[],"['Dazodalibep', 'MEDI-4920', 'MEDI4920', 'Medi 4920', 'VIB-4920', 'VIB4920', 'Vib4920']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0007160', 'EFO_0005809', 'EFO_0000685', 'EFO_0005761', 'EFO_0000699']",5.0,['ENSG00000102245'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/DAZODALIBEP/relevant/1/'],,,
CHEMBL686,Cc1cccc(Nc2ccccc2C(=O)O)c1C,HYYBABOKPJLUIN-UHFFFAOYSA-N,Small molecule,True,MEFENAMIC ACID,4.0,False,True,"['Contraflam', 'Dysman-250', 'Dysman-500', 'Mefenamic acid', 'Meflam 250', 'Meflam 500', 'Mendys', 'Opustan 250', 'Opustan 500', 'Ponstan', 'Ponstan fte', 'Ponstel']","['CI-473', 'CN-35355', 'Gardan', 'INF-3355', 'J2.344B', 'M01AG01', 'Mefenamate', 'Mefenamic acid', 'Mefenaminic acid', 'Mephenamic acid', 'Mephenaminic acid', 'NSC-94437']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for rheumatic disease and dysmenorrhea and has 3 investigational indications. This drug has a black box warning from the FDA.,['Mefenamic_acid'],['DB00784'],"['EFO_0003843', 'EFO_0005755', 'EFO_0000400', 'HP_0100607', 'MP_0001914']",5.0,"['ENSG00000073756', 'ENSG00000095303']",2,1967.0,,['mefenamic%20acid'],"['104171280', '11112163', '124882006', '144203895', '144212300', '170464813', '26746974', '26751493', '56422190', '855723']",['6717'],,,['84'],,
CHEMBL1200733,FC(F)OC(F)C(F)(F)F,DPYMFVXJLLWWEU-UHFFFAOYSA-N,Small molecule,False,DESFLURANE,4.0,False,True,['Suprane'],"['Desflurane', 'I-653']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 2 investigational indications.,['Desflurane'],['DB01189'],"['EFO_0005323', 'EFO_1002048']",2.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000145888', 'ENSG00000109738', 'ENSG00000169427', 'ENSG00000082482', 'ENSG00000186795', 'ENSG00000100433', 'ENSG00000171303']",23,1992.0,,['desflurane'],,['4445'],,,,,
CHEMBL1642,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,YLMAHDNUQAMNNX-UHFFFAOYSA-N,Small molecule,False,IMATINIB MESYLATE,4.0,False,True,"['Gleevec', 'Glivec', 'Imatinib accord', 'Imatinib mesylate']","['Gleevec', 'Imatinib (as mesilate)', 'Imatinib accord', 'Imatinib medac', 'Imatinib mesilate', 'Imatinib mesylate', 'Imatinib methane sulfonate', 'Imatinib methanesulfonate', 'NSC-716051', 'QTI-571', 'QTI571', 'Qti571', 'STI 571', 'STI-571', 'STI571']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for chronic myelogenous leukemia and has 77 investigational indications.,,,"['EFO_0006861', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000333', 'EFO_0000768', 'EFO_0003060', 'EFO_0000760', 'EFO_1001361', 'EFO_0004683', 'EFO_0001361', 'MONDO_0011934', 'MONDO_0004979', 'MONDO_0000870', 'EFO_0006859', 'EFO_0000094', 'EFO_0005952', 'EFO_0000616', 'EFO_0004198', 'MONDO_0011382', 'MONDO_0011719', 'MONDO_0008315', 'EFO_0000717', 'EFO_0000339', 'EFO_0000220', 'MONDO_0004992', 'MONDO_0002367', 'MONDO_0002087', 'EFO_1000158', 'EFO_1001951', 'MONDO_0018975', 'MONDO_0005147', 'MONDO_0005301', 'EFO_0000519', 'EFO_1001465', 'MONDO_0002108', 'MONDO_0011705', 'MONDO_0002158', 'EFO_0000702', 'EFO_0002429', 'HP_0001880', 'MONDO_0013730', 'EFO_0000588', 'EFO_0009907', 'EFO_1000729', 'EFO_0000503', 'EFO_1001467', 'EFO_1001814', 'EFO_0000673', 'EFO_0000658', 'EFO_1001993', 'MONDO_0021063', 'MONDO_0005149', 'EFO_0002430', 'MONDO_0011962', 'MONDO_0009937', 'EFO_0000222', 'EFO_0000691', 'MONDO_0008170', 'EFO_0001376', 'EFO_1000657', 'MONDO_0044917', 'EFO_0002428', 'MONDO_0020547', 'MONDO_0100096', 'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715', 'EFO_0000313', 'EFO_0004289', 'MONDO_0000873', 'EFO_0000209', 'MONDO_0007254', 'EFO_0000565', 'EFO_1000613', 'EFO_0000574', 'EFO_0000756', 'MONDO_0001056', 'EFO_1001471']",78.0,"['ENSG00000097007', 'ENSG00000186716', 'ENSG00000113721', 'ENSG00000157404']",4,2001.0,CHEMBL941,['imatinib%20mesylate'],"['144205237', '170465393', '49681833']",['31690'],['https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord'],,,,
CHEMBL1743077,,,Antibody,False,TENATUMOMAB,2.0,False,False,[],"['ST-2146', 'Tenatumomab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000041982'],1,,,,,,,,,,
CHEMBL2103826,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O,DWLTUUXCVGVRAV-XWRHUKJGSA-N,Protein,False,DAVUNETIDE,2.0,False,False,[],"['AL-108', 'AL-208', 'Davunetide']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB12613'],"['HP_0100543', 'MONDO_0019037', 'MONDO_0005090']",3.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL2105527,CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21,IQWYAQCHYZHJOS-UHFFFAOYSA-N,Small molecule,False,TETRAZEPAM,4.0,True,True,[],"['CB 4261', 'CB-4261', 'Myolastan', 'Tetrazepam']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,['DB13324'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL2109337,,,Antibody,False,MDX-1342,1.0,False,False,[],"['MDX-1342', 'Mdx-1342']",,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0000685', 'EFO_0000095']",2.0,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL292376,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1,ZVQUCWXZCKWZBP-CQSZACIVSA-N,Small molecule,False,TECALCET,2.0,False,False,[],['Tecalcet'],['CHEMBL2107572'],Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000036828'],1,,,,,,,,,,
CHEMBL4297788,,,Antibody,False,MOSUNETUZUMAB,4.0,False,True,['Lunsumio'],"['BTCT-4465A', 'BTCT4465A', 'Mosunetuzumab', 'Mosunetuzumab axgb', 'Mosunetuzumab-axgb', 'RG-7828', 'RG7828', 'RO-7030816', 'RO7030816']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for follicular lymphoma and neoplasm of mature b-cells and has 6 investigational indications.,,,"['EFO_0005952', 'MONDO_0002334', 'EFO_0000183', 'MONDO_0007915', 'EFO_0000403', 'MONDO_0018906', 'EFO_0000096', 'EFO_0000095']",8.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000156738']",4,2022.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/lunsumio'],['https://searchusan.ama-assn.org/finder/usan/search/MOSUNETUZUMAB/relevant/1/'],,,
CHEMBL4298005,,,Unknown,False,MITIGLINIDE CALCIUM DIHYDRATE,3.0,False,False,[],"['Glufast', 'KAD-1229', 'Kad-1229', 'Mitiglinide calcium dihydrate', 'Mitiglinide calcium hydrate', 'Mitiglinide calcium salt dihydrate', 'S-21403']",,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['MONDO_0005148'],1.0,"['ENSG00000187486', 'ENSG00000006071']",2,,,,,,,,,,
CHEMBL49120,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,IFPPYSWJNWHOLQ-UHFFFAOYSA-N,Small molecule,False,PD-0166285,1.0,False,False,[],"['PD-0166285', 'TCMDC-140940']",['CHEMBL3545196'],Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000077782', 'ENSG00000197122', 'ENSG00000146648', 'ENSG00000113721']",4,,,,"['103905313', '137275855', '307078458']",,,,,,
CHEMBL591,C#CC(O)(/C=C/Cl)CC,ZEHYJZXQEQOSON-AATRIKPKSA-N,Small molecule,False,ETHCHLORVYNOL,4.0,False,True,"['Ethchlorvynol', 'Placidyl']","['Alvinol', 'Arvynol', 'Ethchlorvynol', 'Ethchlorvynol civ', 'NSC-30372', 'Normoson', 'Nostel', 'Roeridorm', 'Serenesil', 'Serensil']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.,['Ethchlorvynol'],['DB00189'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1961.0,,,,,,,,,
CHEMBL1200464,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N.Cl,BFUUJUGQJUTPAF-UHFFFAOYSA-N,Small molecule,False,PROPARACAINE HYDROCHLORIDE,4.0,False,True,"['Alcaine', 'Kainair', 'Ophthaine', 'Ophthetic', 'Paracaine', 'Proparacaine hydrochloride']","['Ak-taine', 'NSC-759896', 'Proparacaine hcl', 'Proparacaine hydrochloride', 'Proxymetacaine', 'Proxymetacaine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1953.0,CHEMBL1196,['proparacaine%20hydrochloride'],"['144207096', '170465400', '56320661']",,,,,,
CHEMBL1200705,Br.CC(N)Cc1ccc(O)cc1,RZCJLMTXBMNRAD-UHFFFAOYSA-N,Small molecule,False,HYDROXYAMPHETAMINE HYDROBROMIDE,4.0,False,True,['Paredrine'],"['Hydroxyamfetamine hbr', 'Hydroxyamfetamine hydrobromide', 'Hydroxyamphetamine hbr', 'Hydroxyamphetamine hydrobromide', 'Hyroxyamfetamine hydrobromide', 'NSC-61065', 'Oxamphetamine hydrobromide', 'Phenol, 4-(2-aminopropyl)-, hbr']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969.,,,,,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1969.0,CHEMBL1546,['hydroxyamphetamine%20hydrobromide'],"['124752968', '124752971', '144205040', '26749172']",,,,,,
CHEMBL1200841,CCN(CC)CCOC(=O)c1ccc(N)cc1.Cl,HCBIBCJNVBAKAB-UHFFFAOYSA-N,Small molecule,False,PROCAINE HYDROCHLORIDE,4.0,False,True,"['Novocain', 'Pasconeural n', 'Procaine hydrochloride']","['Anestil', 'Enpro', 'Jenacaine', 'Medaject', 'NSC-757280', 'Naucaine', 'Neocaine', 'Omnicain', 'Planocaine', 'Procaine hcl', 'Procaine hydrochloride', 'Procaini hydrochloridum', 'Rocain', 'SP-01A', 'SP01A', 'Sp01a', 'Syntocain']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954 and has 1 investigational indication.,,,['EFO_0000764'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1954.0,CHEMBL569,,"['144203799', '144212431', '170464937', '50085977', '50106847']",['8431'],,,,,
CHEMBL1201593,,,Enzyme,False,ALTEPLASE,4.0,False,True,"['Actilyse', 'Actilyse cathflo', 'Activase', 'Cathflo activase']","['Alteplase', 'Alteplase (genetical recombination)', 'Alteplase for injection', 'Alteplase, recombinant', 'Alteplase,recombinant', 'Ec 3.4.21.68', 'RT-PA', 'Tissue plasminogen activator alteplase']",,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 28 investigational indications.,,,"['EFO_0009680', 'EFO_1000637', 'EFO_0001365', 'MONDO_0000831', 'EFO_0003966', 'EFO_0003907', 'EFO_0000616', 'MONDO_0005299', 'EFO_0000712', 'MONDO_0100096', 'HP_0004418', 'EFO_0000618', 'EFO_0003827', 'MONDO_0002679', 'EFO_0000713', 'EFO_0003913', 'EFO_1001375', 'HP_0000573', 'HP_0004419', 'EFO_0003144', 'EFO_1001753', 'EFO_1001154', 'EFO_1001157', 'HP_0002140', 'EFO_0009661', 'EFO_0000694', 'MP_0001914', 'EFO_0000612', 'EFO_0000544', 'EFO_0003030', 'EFO_0005669', 'MONDO_0020673', 'EFO_0003097', 'EFO_0000373', 'MONDO_0004992', 'HP_0000016']",36.0,['ENSG00000104368'],1,1996.0,,['alteplase'],,,,,,['5141'],
CHEMBL2109264,,,Antibody,False,SOLITOMAB,2.0,False,False,[],"['MT110', 'Solitomab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000119888']",4,,,,,,,,,,
CHEMBL3545135,,,Small molecule,False,NV-128,1.0,False,False,[],['Nv-128'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000198695', 'ENSG00000130414', 'ENSG00000110717', 'ENSG00000212907', 'ENSG00000184983', 'ENSG00000198888', 'ENSG00000165264', 'ENSG00000189043', 'ENSG00000174886', 'ENSG00000099795', 'ENSG00000198763', 'ENSG00000158864', 'ENSG00000198786', 'ENSG00000119421', 'ENSG00000136521', 'ENSG00000198886', 'ENSG00000198840', 'ENSG00000004779', 'ENSG00000125356', 'ENSG00000164258', 'ENSG00000119013', 'ENSG00000109390', 'ENSG00000131495', 'ENSG00000168653', 'ENSG00000115286', 'ENSG00000145494', 'ENSG00000183648', 'ENSG00000213619', 'ENSG00000170906', 'ENSG00000065518', 'ENSG00000166136', 'ENSG00000090266', 'ENSG00000267855', 'ENSG00000151366', 'ENSG00000140990', 'ENSG00000178127', 'ENSG00000023228', 'ENSG00000167792', 'ENSG00000160194', 'ENSG00000128609', 'ENSG00000139180', 'ENSG00000164182', 'ENSG00000178057', 'ENSG00000185633', 'ENSG00000147123', 'ENSG00000123545', 'ENSG00000186010', 'ENSG00000184752', 'ENSG00000137806', 'ENSG00000147684']",50,,,,,,,,,,
CHEMBL3984441,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C,VQYYQSZNRVQLIS-UHFFFAOYSA-N,Small molecule,False,NINGETINIB,2.0,False,False,[],"['CT-053 FREE BASE', 'CT-053-PTSA FREE BASE', 'CT053PTSA FREE BASE', 'Ningetinib']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003060'],1.0,"['ENSG00000153208', 'ENSG00000167601', 'ENSG00000105976', 'ENSG00000122025', 'ENSG00000128052']",5,,,,,,,,,,
CHEMBL4297636,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O,IEKGSKLKBICCHQ-BDOJOPHNSA-N,Small molecule,False,PLOCABULIN,2.0,False,False,[],"['J3.348.355D', 'PM-060184', 'PM060184', 'Plocabulin', 'Pm 060184', 'Pm060184']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB13137'],"['MONDO_0005575', 'EFO_0000616']",2.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL4594539,,,Protein,False,TRENIBOTULINUMTOXINE,3.0,False,False,[],"['AGN-151586', 'BoNT/E', 'Bontoxilysin-e', 'Botulinum neurotoxin type e', 'Botulinum toxin type e', 'EB-001', 'Eb-001', 'Trenibotulinumtoxine']",,Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0003843'],1.0,['ENSG00000132639'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TRENIBOTULINUMTOXINE/relevant/1/'],,,
CHEMBL506569,CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,JAYAGJDXJIDEKI-PTGWOZRBSA-N,Small molecule,False,LANATOSIDE C,4.0,False,True,['Cedilanid'],"['Allocor', 'Celadigal', 'Cetosanol', 'Digilanogen c', 'Isolanid', 'Isolanide', 'Lanatigen c', 'Lanatoside c', 'Lanatoside c jp 17', 'Lanimerck', 'NSC-119991', 'NSC-7533']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease.,['Lanatoside_C'],['DB13467'],['EFO_0000319'],1.0,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731']",8,,,,['144204914'],,,,,,
CHEMBL1201065,C=CCC1(C(C)CCC)C(=O)[N-]C(=S)NC1=O.[Na+],LYZGJWXNOGIVQA-UHFFFAOYSA-M,Small molecule,False,THIAMYLAL SODIUM,4.0,False,True,['Surital'],"['NSC-759558', 'Sodium thiamylal', 'Thiamylal sodium', 'Thiamylal sodium salt']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,CHEMBL440,,"['144205070', '26749789']",,,,,,
CHEMBL1201836,,,Antibody,True,OFATUMUMAB,4.0,False,True,"['Arzerra', 'Kesimpta']","['2F2', 'GSK-1841157', 'GSK1841157', 'GSKI841157', 'HUMAX-CD20', 'HUMAX-CD20 2F2', 'HUMAX-CD20, 2F2', 'HUMAX-CD20-2F2', 'Ofatumumab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 22 investigational indications. This drug has a black box warning from the FDA.,['Ofatumumab'],,"['EFO_0004255', 'MONDO_0005301', 'EFO_0000574', 'EFO_0004256', 'MONDO_0020547', 'EFO_0003929', 'MONDO_0001023', 'EFO_0000183', 'EFO_1000749', 'EFO_0000756', 'EFO_1001469', 'EFO_0000565', 'EFO_0000685', 'EFO_0000540', 'EFO_0009441', 'EFO_0004289', 'EFO_0000309', 'EFO_0000403', 'MONDO_0018906', 'MONDO_0004992', 'MONDO_0000873', 'MONDO_0000870', 'EFO_0000616', 'EFO_0000765', 'EFO_0000095', 'EFO_0004719', 'EFO_0005952', 'EFO_0000220']",28.0,['ENSG00000156738'],1,2009.0,,['ofatumumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta'],,,['4951'],
CHEMBL2181929,CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(c2ccc(F)cc2)C1=O,AZNHWXAFPBYFGH-UHFFFAOYSA-N,Small molecule,False,MT-3995,2.0,False,False,[],"['Apararenone', 'MT-3995', 'Mt-3995']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB15024'],"['EFO_0000401', 'EFO_1001249']",2.0,['ENSG00000151623'],1,,,,,,,,,,
CHEMBL220491,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,HCRKCZRJWPKOAR-JTQLQIEISA-N,Small molecule,False,BRINZOLAMIDE,4.0,False,True,['Azopt'],"['AL-4862', 'Azopt', 'Brinzolamide', 'NSC-760050']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 1 investigational indication.,['Brinzolamide'],['DB01194'],"['EFO_0004190', 'EFO_0009784', 'MONDO_0005041', 'EFO_1001069']",4.0,['ENSG00000104267'],1,1998.0,,['brinzolamide'],"['170464926', '56463043']",['3176'],['https://www.ema.europa.eu/en/medicines/human/EPAR/azopt'],,,,
CHEMBL277474,Cc1cc(=O)n(-c2ccccc2)n1C,VEQOALNAAJBPNY-UHFFFAOYSA-N,Small molecule,False,ANTIPYRINE,4.0,False,True,[],"['Antipyrin', 'Antipyrine', 'Antipyrinum', 'NSC-7945', 'Phenazon', 'Phenazone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for fever and pain and has 3 investigational indications.,['Phenazone'],['DB01435'],"['MONDO_0004979', 'HP_0001945', 'HP_0100607', 'EFO_0004992', 'EFO_0003843']",5.0,['ENSG00000095303'],1,,,,"['104171279', '11112159', '144203893', '144208798', '144213343', '170465510', '26753718', '56320742']",['31225'],,,,,
CHEMBL3301611,Nc1ccncc1N.O=P(O)(O)O,KAICRBBQCRKMPO-UHFFFAOYSA-N,Small molecule,False,AMIFAMPRIDINE PHOSPHATE,4.0,False,True,"['Firdapse', 'Firdapse (previously zenas)']","['3,4-DAPP', 'Amifampridine phosphate', 'DAPP', 'Zenas']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for lambert-eaton myasthenic syndrome and myasthenia gravis and has 4 investigational indications.,,,"['EFO_0008525', 'EFO_0004991', 'MONDO_0015263', 'EFO_0020094', 'EFO_0004991', 'EFO_0009851']",6.0,"['ENSG00000053918', 'ENSG00000171385', 'ENSG00000055118', 'ENSG00000177301', 'ENSG00000111262', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000104848', 'ENSG00000185760', 'ENSG00000117013', 'ENSG00000143473', 'ENSG00000182255', 'ENSG00000130037', 'ENSG00000177272', 'ENSG00000151079', 'ENSG00000129159', 'ENSG00000184408', 'ENSG00000182674', 'ENSG00000116396', 'ENSG00000131398', 'ENSG00000158445', 'ENSG00000143105', 'ENSG00000164794', 'ENSG00000140015', 'ENSG00000171126', 'ENSG00000168418', 'ENSG00000168263', 'ENSG00000124134', 'ENSG00000183960', 'ENSG00000166006', 'ENSG00000170745', 'ENSG00000173826', 'ENSG00000162975', 'ENSG00000184611', 'ENSG00000102057', 'ENSG00000026559', 'ENSG00000178342', 'ENSG00000135519', 'ENSG00000156486', 'ENSG00000089558']",40,2009.0,CHEMBL354077,['amifampridine%20phosphate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse'],,,,
CHEMBL3545046,,,Small molecule,False,GSK2849466,1.0,False,False,[],['Gsk2849466'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['HP_0004326'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL4297883,,,Antibody,False,IVUXOLIMAB,3.0,False,False,[],"['Anti-ox40 antibody pf-04518600', 'Ivuxolimab', 'PF-04518600', 'PF-8600', 'PF04518600', 'Pf-04518600', 'Pf04518600']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,,"['MONDO_0018906', 'EFO_0000349', 'MONDO_0004992', 'EFO_0000222', 'EFO_0005537', 'EFO_0000616', 'EFO_0000196']",7.0,['ENSG00000186827'],1,,,,,,,,,,
CHEMBL4297919,,,Unknown,False,PAROXETINE HYDROCHLORIDE HEMIHYDRATE,3.0,False,False,[],"['BRL29060A', 'Brl29060a', 'Paroxetine hydrochloride', 'Paroxetine hydrochloride hemihydrate', 'Paroxetine hydrochloride hydrate']",,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_1001917'],1.0,['ENSG00000108576'],1,,,,,,,,,,
CHEMBL4297938,,,Antibody drug conjugate,False,LIFASTUZUMAB VEDOTIN,2.0,False,False,[],"['DNIB-0600A', 'DNIB0600A', 'Dnib0600a', 'Lifastuzumab vedotin', 'NAPI3B', 'RG-7599']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0003060', 'MONDO_0008170']",2.0,"['ENSG00000157765', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL535,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,WINHZLLDWRZWRT-ATVHPVEESA-N,Small molecule,True,SUNITINIB,4.0,False,True,"['Sunitinib accord', 'Sutent']","['NSC-736511', 'NSC-750690', 'SU-011248', 'SU-11248', 'SU011248', 'Sunitinib', 'Sutent']","['CHEMBL3109278', 'CHEMBL3542310', 'CHEMBL1567']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 8 approved and 86 investigational indications. This drug has a black box warning from the FDA.,['Sunitinib'],['DB01268'],"['EFO_0000222', 'EFO_0000313', 'MONDO_0003268', 'EFO_0000181', 'EFO_0005221', 'EFO_0000228', 'MONDO_0002367', 'EFO_1000251', 'EFO_0002499', 'EFO_0006861', 'EFO_0000349', 'EFO_1000045', 'MONDO_0001056', 'EFO_0000702', 'EFO_1000581', 'EFO_0000641', 'EFO_0000640', 'MONDO_0004192', 'MONDO_0044926', 'EFO_0003869', 'EFO_0007331', 'EFO_0000673', 'EFO_0000514', 'EFO_0002617', 'MONDO_0015277', 'EFO_0000294', 'EFO_0000095', 'EFO_1001901', 'EFO_0000673', 'EFO_0000220', 'EFO_0000403', 'MONDO_0002367', 'EFO_1000045', 'EFO_0003869', 'EFO_0003897', 'MONDO_0011719', 'MONDO_0002691', 'EFO_0000702', 'EFO_0003833', 'EFO_0003897', 'EFO_0003060', 'MONDO_0007254', 'EFO_0004142', 'EFO_0000519', 'EFO_0008528', 'EFO_0006352', 'EFO_0001378', 'EFO_0000182', 'MONDO_0008170', 'EFO_0002618', 'MONDO_0002087', 'EFO_0000756', 'MONDO_0007254', 'MONDO_0008667', 'EFO_0000239', 'EFO_0000616', 'EFO_0007416', 'EFO_0000558', 'MONDO_0008667', 'MONDO_0008903', 'EFO_0000514', 'EFO_0000222', 'EFO_0000640', 'EFO_0000519', 'MONDO_0002158', 'EFO_0004243', 'MONDO_0007576', 'EFO_0000349', 'EFO_0003060', 'MONDO_0002158', 'EFO_1001951', 'EFO_1000984', 'MONDO_0001187', 'EFO_1000796', 'MONDO_0008903', 'EFO_0000616', 'EFO_0003863', 'EFO_1000576', 'EFO_1001465', 'EFO_0002618', 'EFO_0000196', 'EFO_0000501', 'MONDO_0008315', 'EFO_1001951', 'EFO_0000632', 'EFO_0003865', 'MONDO_0002087', 'EFO_0000588', 'EFO_0000681', 'EFO_0007243', 'EFO_0004252', 'EFO_0000637', 'EFO_0000691', 'HP_0001541', 'EFO_0000182', 'EFO_1001465', 'MONDO_0018364', 'EFO_1001968', 'EFO_0007143', 'EFO_0002938', 'EFO_1001968', 'MONDO_0008315', 'EFO_1001901', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0007416', 'MONDO_0011719', 'EFO_0000681', 'MONDO_0004992', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0002892', 'EFO_1000576', 'EFO_0002617']",114.0,"['ENSG00000165731', 'ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000037280', 'ENSG00000102755', 'ENSG00000128052', 'ENSG00000182578', 'ENSG00000122025']",9,2006.0,,,"['124893176', '26758053', '50100120']",['38940'],['https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord'],,,,
CHEMBL1086,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,PUFQVTATUTYEAL-UHFFFAOYSA-N,Small molecule,False,DIBUCAINE,4.0,False,True,[],"['Cinchocaine', 'Dibucaine', 'NSC-159055']",['CHEMBL1200612'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved indications.,['Cinchocaine'],['DB00527'],"['EFO_0003958', 'EFO_0009552', 'HP_0000989']",3.0,"['ENSG00000185313', 'ENSG00000183873']",2,1982.0,,,"['11112228', '144203932', '170464829', '50100394', '50100395', '56424123', '855529']",['247956'],,,,,
CHEMBL1200597,CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C.Cl,LMWQQUMMGGIGJQ-UHFFFAOYSA-N,Small molecule,False,ETIDOCAINE HYDROCHLORIDE,4.0,False,True,['Duranest'],"['Duranest hydrochloride', 'Etidocaine hcl', 'W-19053']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1976.0,CHEMBL492,,,,,,,,
CHEMBL282724,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,PHWXUGHIIBDVKD-UHFFFAOYSA-N,Small molecule,False,SITAXENTAN,4.0,True,True,[],"['IPI-1040', 'Sitaxentan', 'Sitaxsentan', 'TBC-11251']",['CHEMBL2105740'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for hypertension and pulmonary hypertension and has 6 investigational indications. It was withdrawn in at least one region.,['Sitaxentan'],['DB06268'],"['MONDO_0005149', 'EFO_0000537', 'HP_0000093', 'EFO_1000899', 'EFO_0001361', 'MONDO_0004979', 'EFO_0003884', 'MONDO_0005149']",8.0,"['ENSG00000136160', 'ENSG00000151617']",2,2006.0,,,['170465720'],,,,,,
CHEMBL3623290,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,MXDSJQHFFDGFDK-CYBMUJFWSA-N,Small molecule,False,AZD-3759,2.0,False,False,[],"['AZD3759', 'Azd 3759', 'Azd-3759', 'Azd3759', 'Zorifertinib']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB14795'],['EFO_0003060'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL4650333,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC,JHJNPOSPVGRIAN-SFHVURJKSA-N,Small molecule,False,SERALUTINIB,2.0,False,False,[],"['GB-002', 'GB002', 'Gb002', 'PK-10571', 'Seralutinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0001361', 'MONDO_0005149']",2.0,"['ENSG00000182578', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000157404']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SERALUTINIB/relevant/1/'],,,
CHEMBL93747,O=C1NC(=O)C(Cc2ccc3cc(OCc4ccccc4F)ccc3c2)S1,PKWDZWYVIHVNKS-UHFFFAOYSA-N,Small molecule,False,NETOGLITAZONE,2.0,False,False,[],"['MCC 555', 'MCC555', 'Mcc-555', 'Netoglitazone', 'PGX-510', 'RWJ-241947']",,Small molecule drug with a maximum clinical trial phase of II.,,['DB09199'],,,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL1256841,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,NOIIUHRQUVNIDD-UHFFFAOYSA-N,Small molecule,False,NIALAMIDE,4.0,True,True,[],"['NSC-124514', 'Nialamide', 'Niamid']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression. It was withdrawn in at least one region.,,['DB04820'],['EFO_0003761'],1.0,"['ENSG00000189221', 'ENSG00000069535']",2,,,,"['11111522', '11111523', '144203759', '170466097', '50104074', '56422110', '85231151', '855800', '90341025']",,,,,,
CHEMBL139,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,DCOPUUMXTXDBNB-UHFFFAOYSA-N,Small molecule,True,DICLOFENAC,4.0,False,True,"['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'Zorvolex', 'Zorvolex capsules']","['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acid', 'Diclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'Solaraze', 'Voltaren', 'Voltaren-XR']","['CHEMBL1201180', 'CHEMBL3350449', 'CHEMBL1034', 'CHEMBL1200804']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 16 approved and 35 investigational indications. This drug has a black box warning from the FDA.,['Diclofenac'],['DB00586'],"['MP_0001845', 'EFO_1000786', 'EFO_0000685', 'MONDO_0005277', 'EFO_0009582', 'EFO_0003898', 'EFO_0004607', 'HP_0100607', 'HP_0003326', 'EFO_0010072', 'EFO_0004616', 'MONDO_0001187', 'EFO_1000652', 'EFO_0004616', 'EFO_1001139', 'EFO_0003843', 'EFO_0000649', 'MP_0001845', 'MONDO_0005178', 'EFO_0003843', 'EFO_0004274', 'EFO_0009582', 'EFO_1000720', 'EFO_0000685', 'MONDO_0007254', 'EFO_1001412', 'EFO_0003843', 'EFO_0010072', 'MONDO_0005277', 'MONDO_0005129', 'EFO_0003931', 'EFO_1001366', 'EFO_0000545', 'MONDO_0005178', 'EFO_0000685', 'MONDO_0005178', 'EFO_0010072', 'HP_0003419', 'EFO_0004272', 'EFO_0000546', 'EFO_0003843', 'EFO_0002496', 'EFO_0002496', 'EFO_0009582', 'MONDO_0002050', 'EFO_0009560', 'EFO_0000616', 'EFO_0002970', 'EFO_0000649', 'EFO_0009454', 'MP_0001914', 'HP_0002829', 'MONDO_0002959', 'MONDO_0002887', 'EFO_0004193', 'HP_0100607', 'EFO_0005755', 'EFO_0003958', 'HP_0012532', 'EFO_0005752', 'EFO_0000313', 'HP_0011868', 'EFO_0003827']",63.0,"['ENSG00000073756', 'ENSG00000095303']",2,1988.0,,['diclofenac'],['24424557'],['47381'],,,['19'],,
CHEMBL2103824,CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,BJBCSGQLZQGGIQ-QGZVFWFLSA-N,Small molecule,False,ARHALOFENATE,2.0,False,False,[],"['Arhalofenate', 'CB-102', 'CB102', 'JNJ-39659100', 'M-102', 'M102', 'MBX-102']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB11811'],"['EFO_0004274', 'MONDO_0005148']",2.0,"['ENSG00000197891', 'ENSG00000132170']",2,,,,,,,,,,
CHEMBL2105737,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,VZZJRYRQSPEMTK-CALCHBBNSA-N,Small molecule,True,SONIDEGIB,4.0,False,True,[],"['Erismodegib', 'LDE 225', 'LDE-225', 'LDE225', 'NVP-LDE 225', 'NVP-LDE-225', 'NVP-LDE225', 'Sonidegib']",['CHEMBL3137317'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for basal cell carcinoma and neoplasm and has 14 investigational indications. This drug has a black box warning from the FDA.,,['DB09143'],"['EFO_0004193', 'EFO_0002618', 'EFO_0004193', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000182', 'EFO_0001378', 'MONDO_0007254', 'EFO_0003869', 'MONDO_0007576', 'MONDO_0008170', 'EFO_0001421', 'MONDO_0005341', 'EFO_0002939', 'MONDO_0013730', 'EFO_0000565']",16.0,['ENSG00000128602'],1,2015.0,,,,,,,,,
CHEMBL2205230,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1,ZADWXQMNNVICKB-UHFFFAOYSA-N,Small molecule,False,TAK-441,1.0,False,False,[],['Tak-441'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0004193'],1.0,['ENSG00000128602'],1,,,,,,,,,,
CHEMBL2448612,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O,CJMJLDQKTOJACI-SEUSHGJOSA-N,Small molecule,True,ERGOTAMINE TARTRATE,4.0,False,True,"['Cafergot', 'Ergomar', 'Ergostat', 'Femergin', 'Gynergen', 'Lingraine', 'Medihaler ergotamine', 'Migril', 'Wigrettes']","['Ergotamine bitartrate', 'Ergotamine d-tartrate', 'Ergotamine tartrate', 'Ergotamini tartras', 'Gotamine tartrate', 'NSC-41869']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for migraine disorder and headache. This drug has a black box warning from the FDA.,,,"['MONDO_0005277', 'HP_0002315']",2.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000179546']",7,1948.0,CHEMBL442,['ergotamine%20tartrate'],,,,,,,
CHEMBL3039553,,,Oligonucleotide,False,APATORSEN SODIUM,-1.0,False,False,[],"['Apatorsen sodium', 'OGX-427']",,Oligonucleotide drug.,,,,,['ENSG00000106211'],1,,,,,,,,,,
CHEMBL3306803,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12,HOIIHACBCFLJET-SFTDATJTSA-N,Small molecule,True,LUMATEPERONE,4.0,False,True,[],"['ITI 007', 'ITI-007', 'ITI-722', 'ITI007', 'Lumateperone']",['CHEMBL3233142'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for schizophrenia and psychosis and has 5 investigational indications. This drug has a black box warning from the FDA.,,['DB06077'],"['MONDO_0002009', 'MONDO_0005090', 'HP_0012076', 'EFO_0005407', 'MONDO_0004975', 'MONDO_0004985', 'MONDO_0005090']",7.0,"['ENSG00000108576', 'ENSG00000102468', 'ENSG00000149295']",3,2019.0,,,,,,,,,
CHEMBL3663929,C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,QKDCLUARMDUUKN-XMMPIXPASA-N,Small molecule,False,NAQUOTINIB,3.0,False,False,[],"['ASP-8273', 'ASP8273', 'Naquotinib']",['CHEMBL3707350'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB12036'],"['EFO_0003060', 'EFO_0000616', 'EFO_0003060']",3.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL4204794,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,DWYRIWUZIJHQKQ-SANMLTNESA-N,Small molecule,False,AVAPRITINIB,4.0,False,True,"['Ayvakit', 'Ayvakyt']","['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 3 investigational indications.,,['DB15233'],"['EFO_0000326', 'EFO_0007359', 'EFO_0000616', 'MONDO_0011719', 'MONDO_0016586', 'MONDO_0004992']",6.0,"['ENSG00000157404', 'ENSG00000134853']",2,2020.0,,['avapritinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt'],,,,
CHEMBL4297813,,,Unknown,False,PRI-724,2.0,False,False,[],"['(S,S)-ICG-001', 'Foscenvivint', 'PRI-724', 'PRI724', 'Pri-724']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000616', 'EFO_0000365', 'EFO_0000222', 'EFO_0000339']",4.0,"['ENSG00000005339', 'ENSG00000168036']",2,,,,,,,,,,
CHEMBL580,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,DIWRORZWFLOCLC-UHFFFAOYSA-N,Small molecule,True,LORAZEPAM,4.0,False,True,"['Abbloraz', 'Ativan', 'Loraz', 'Lorazepam', 'Lorazepam intensol', 'Lorazepam preservative free', 'Loreev xr', 'Temesta']","['Lorazepam', 'Lorazepam civ', 'NSC-289758', 'WY-4036']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA.,['Lorazepam'],['DB00186'],"['EFO_0009267', 'EFO_0003761', 'EFO_0005411', 'MONDO_0002009', 'EFO_0008526', 'HP_0000713', 'MONDO_0007079', 'HP_0000726', 'EFO_0002610', 'EFO_0009692', 'EFO_0000474', 'EFO_0004701', 'EFO_0003890', 'EFO_0005230', 'EFO_0001064', 'MONDO_0005090', 'MONDO_0004900', 'EFO_0004777', 'MONDO_0004975', 'EFO_0006788', 'EFO_1000690', 'MONDO_0002050', 'HP_0001250', 'EFO_0004242', 'EFO_1000924', 'EFO_0003843', 'EFO_1001146']",27.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1977.0,,['lorazepam'],"['144205222', '29215381']",,,,,,
CHEMBL70972,CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,ZBVKEHDGYSLCCC-UHFFFAOYSA-N,Small molecule,False,SERATRODAST,4.0,False,True,[],"['A-73001', 'AA-2414', 'ABBOTT 73001', 'ABBOTT-73001', 'ABT-001', 'Bronica', 'NSC-759640', 'Seratrodast']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication.,,['DB06739'],['HP_0006536'],1.0,['ENSG00000006638'],1,1995.0,,,"['144206327', '170465940', '50125893']",,,,,,
CHEMBL1201288,O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,OZOMQRBLCMDCEG-VIZOYTHASA-N,Small molecule,True,DANTROLENE,4.0,False,True,[],"['2-methylbenzoic acid anilide', 'BAS-305', 'BAS-3050', 'BAS-3050F', 'Bebenil', 'Dantrolene', 'F-368', 'Mebenil', 'NSC-227402', 'NSC-26404', 'O-methylbenzanilide', 'O-toluanilide', 'SHA-458100']","['CHEMBL2067986', 'CHEMBL928']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 7 investigational indications. This drug has a black box warning from the FDA.,['Dantrolene'],['DB01219'],"['EFO_0000712', 'EFO_1001919', 'EFO_0020003', 'MONDO_0005301', 'EFO_1000632', 'HP_0001257', 'EFO_0005306', 'EFO_0000546', 'HP_0001945', 'EFO_1001340', 'MONDO_0018105', 'MONDO_0005301', 'HP_0001945']",13.0,"['ENSG00000198838', 'ENSG00000196218']",2,1974.0,,,"['26756482', '26756773']",,,,['119'],,
CHEMBL1743078,,,Antibody,False,TEPLIZUMAB,4.0,False,True,['Tzield'],"['HOKT3-GAMMA-1 (ALA-ALA)', 'HUMANIZED OKT3', 'Humanzied OKT3', 'MGA-031', 'MGA031', 'Teplizumab', 'Teplizumab mzwv', 'Teplizumab-mzwv', 'Tzield', 'hOKT3 gamma 1 (Ala-Ala)']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for type 1 diabetes mellitus and has 2 investigational indications.,,,"['EFO_0002546', 'MONDO_0005147', 'EFO_0000676']",3.0,['ENSG00000198851'],1,2022.0,,,,,,,,,
CHEMBL2103743,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,SYIKUFDOYJFGBQ-YLAFAASESA-N,Small molecule,True,TOFACITINIB CITRATE,4.0,False,True,"['Xeljanz', 'Xeljanz xr']","['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for psoriatic arthritis and rheumatoid arthritis and has 4 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0019558', 'EFO_0003778', 'EFO_0003898', 'MONDO_0007915', 'EFO_0000274', 'EFO_0000685']",6.0,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",4,2012.0,CHEMBL221959,['tofacitinib%20citrate'],,['71197'],['https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz'],,,,
CHEMBL2109348,,,Antibody,False,LFB-R603,1.0,False,False,[],"['LFB-R603', 'Lfb-r603']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000095'],1.0,['ENSG00000156738'],1,,,,,,,,,,
CHEMBL2311030,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O,PBKVEOSEPXMKDN-LZHUFOCISA-N,Unknown,False,ERGOLOID MESYLATES,4.0,False,True,"['Alkergot', 'Circanol', 'Deapril-st', 'Ergoloid mesylates', 'Gerimal', 'Hydergine', 'Hydergine lc', 'Hydrogenated ergot alkaloids']","['Co-dergocrine mesilate', 'Co-dergocrine mesylate', 'Codergocrine mesilate', 'Dihydroergotoxine mesilate', 'Dihydroergotoxine mesylate', 'Dihydroergotoxine methanesulfonate', 'Dihydrogenated ergot alkaloids', 'Ergoloid mesilates', 'Ergoloid mesylates', 'Hydrogenated ergot alkaloids']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for cardiovascular disease and has 2 investigational indications.,,,"['EFO_0004718', 'EFO_0000319', 'MONDO_0010383']",3.0,"['ENSG00000149295', 'ENSG00000151577', 'ENSG00000169676', 'ENSG00000069696', 'ENSG00000184845', 'ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000135312', 'ENSG00000178394']",13,1953.0,CHEMBL2364968,['ergoloid%20mesylates'],,,,,,['5035'],
CHEMBL3545261,,,Antibody,False,BRONTICTUZUMAB,2.0,False,False,[],"['Brontictuzumab', 'OMP-52M51']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000616', 'MONDO_0004992']",2.0,['ENSG00000148400'],1,,,,,,,,,,
CHEMBL4297599,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O,PVPJTBAEAQVTPN-HRAQMCAYSA-N,Small molecule,False,ASPACYTARABINE,2.0,False,False,[],"['Aspacytarabine', 'Astarabine', 'BST-236', 'Bst-236']",['CHEMBL4802250'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000198', 'EFO_0000222', 'EFO_0000198', 'EFO_0000220', 'EFO_0000222']",5.0,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229']",11,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ASPACYTARABINE/relevant/1/'],,,
CHEMBL4297764,,,Unknown,False,HETROMBOPAG OLAMINE,3.0,False,False,[],"['Hetrombopag diolamine', 'Hetrombopag ethanolamine', 'Hetrombopag olamine', 'Rafutrombopag olamine', 'SHR-8735 OLAMINE', 'SHR8735 OLAMINE']",,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0007160', 'EFO_0006927', 'HP_0001915']",3.0,['ENSG00000117400'],1,,,,,,,,,,
CHEMBL5314409,CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1.Cl,GECUEJGEJLAXQA-UHFFFAOYSA-N,Small molecule,False,GSK-2269557,2.0,False,False,[],"['GSK-2269557', 'GSK2269557', 'Gsk-2269557', 'Nemiralisib hydrochloride']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000341', 'MONDO_0004979']",2.0,['ENSG00000171608'],1,,CHEMBL2216859,,,,,,,,
CHEMBL76688,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1,BTGNGJJLZOIYID-UHFFFAOYSA-N,Small molecule,False,SIVELESTAT,3.0,False,False,[],"['LY-544349', 'LY544349', 'ONO-5046', 'Sivelestat']","['CHEMBL3182314', 'CHEMBL2107493']",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,['Sivelestat'],['DB12863'],['EFO_0000694'],1.0,['ENSG00000197561'],1,,,,,,,,,,
CHEMBL1200778,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl,BIFMNMPSIYHKDN-FJXQXJEOSA-N,Small molecule,False,DEXRAZOXANE HYDROCHLORIDE,4.0,False,True,"['Dexrazoxane hydrochloride', 'Savene', 'Totect', 'Zinecard']","['ADR-529 HYDROCHLORIDE', 'Cardioxan', 'Dexrazoxane hcl', 'Dexrazoxane hydrochloride', 'ICRF-187 HYDROCHLORIDE', 'Razoxane hydrochloride, (s)-', 'Savene']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 11 investigational indications.,,,"['EFO_0000318', 'EFO_0000691', 'MONDO_0000870', 'EFO_1000984', 'EFO_0000621', 'EFO_0000574', 'EFO_0000502', 'EFO_0000565', 'MONDO_0007254', 'EFO_0000222', 'EFO_0000209', 'EFO_0000616', 'EFO_1000158']",13.0,"['ENSG00000131747', 'ENSG00000077097']",2,1995.0,CHEMBL1738,,,['50224'],['https://www.ema.europa.eu/en/medicines/human/EPAR/savene'],,,,
CHEMBL1207366,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1,XDKRVNKVAKCFGW-FOCLMDBBSA-N,Small molecule,False,GW468816,2.0,False,False,[],"['GW468816', 'Gw-468816', 'Gw468816']",['CHEMBL400007'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003768'],1.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL1980391,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,UOVCGJXDGOGOCZ-UHFFFAOYSA-N,Small molecule,False,RG-1530,1.0,False,False,[],"['R-1530', 'RG-1530', 'Rg-1530']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000066468', 'ENSG00000142731', 'ENSG00000077782', 'ENSG00000122025', 'ENSG00000087586', 'ENSG00000113721']",9,,,,['103905607'],,,,,,
CHEMBL2108080,,,Oligosaccharide,False,PARNAPARIN SODIUM,3.0,False,False,[],"['Fluxum', 'Lowepa', 'Minidalton', 'OP 21-23', 'OP-21-23', 'OP-2123', 'Parnaparin sodium', 'Tromboparin']",,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['HP_0004418', 'EFO_0000545']",2.0,['ENSG00000117601'],1,,,,,,,,,,
CHEMBL2108581,,,Antibody,False,CATUMAXOMAB,4.0,False,True,['Removab'],['Catumaxomab'],,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 7 investigational indications.,,,"['MONDO_0008170', 'EFO_1000251', 'MONDO_0004992', 'HP_0001541', 'MONDO_0001187', 'EFO_1001100', 'EFO_0003897', 'EFO_0000294', 'EFO_0000503', 'EFO_0000616']",10.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000119888']",4,2009.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/removab'],,,,
CHEMBL427216,Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,BOVGTQGAOIONJV-UHFFFAOYSA-N,Small molecule,False,GLICLAZIDE,4.0,False,True,"['Bilxona', 'Dacadis mr', 'Diaglyk', 'Diamicron', 'Diamicron mr', 'Edicil', 'Glimil', 'Nazdol mr', 'Vamju', 'Vitile xl', 'Ziclaseg', 'Zicron', 'Zicron pr']","['Gliclazide', 'Glimicron', 'J3.151H', 'NSC-758673', 'S-1702', 'S-852', 'SE 1702', 'SE-1702']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 2 investigational indications.,['Gliclazide'],['DB01120'],"['EFO_0000474', 'EFO_0000400', 'MONDO_0005148']",3.0,"['ENSG00000187486', 'ENSG00000006071']",2,,,,"['144204141', '170465698', '26748918', '26748919', '26748920', '49646130']",['31654'],,,,,
CHEMBL429317,Cc1cc(/C(=C/Nc2ccc(Cl)cc2)C(=O)Nc2ccc(Cl)cc2)on1,VMAKIACTLSBBIY-BOPFTXTBSA-N,Small molecule,False,AVL-3288,1.0,False,False,[],"['Anvylic-3288', 'Avl-3288', 'CCMI', 'UCI-4083', 'XY-4083']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0005411', 'MONDO_0005090']",2.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL4583691,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1,UEPXBTCUIIGYCY-UHFFFAOYSA-N,Small molecule,False,LXH254,2.0,False,False,[],"['LXH-254', 'LXH254', 'Lxh 254', 'Lxh254', 'Naporafenib', 'PAN-RAF INHIBITOR LXH254']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0003060', 'EFO_0000756']",2.0,"['ENSG00000132155', 'ENSG00000157764']",2,,,,,,,,,,
CHEMBL5315069,,,Protein,False,DAMOCTOCOG ALFA PEGOL,4.0,False,True,['Jivi'],[],,Protein drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for hemophilia a.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,2018.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/jivi'],,,,
CHEMBL597,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,MRBDMNSDAVCSSF-UHFFFAOYSA-N,Small molecule,False,PHENTOLAMINE,4.0,False,True,[],"['Phentolamin', 'Phentolamine']","['CHEMBL1204146', 'CHEMBL1200873']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and is indicated for adrenal gland pheochromocytoma and cardiovascular disease and has 6 investigational indications.,['Phentolamine'],['DB00692'],"['MONDO_0008315', 'EFO_0000239', 'EFO_0000319', 'EFO_0001073', 'EFO_0001073', 'HP_0001943', 'HP_0011499', 'EFO_0000319', 'MONDO_0001330']",9.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1952.0,,,"['104171285', '11112200', '124882050', '124882053', '144203915', '170464866', '26751465', '26751466', '26751467', '50085867', '50100389', '50100390', '50103967', '860967', '90341742']",['8081'],,,,,
CHEMBL1201066,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.Cl,QYRYFNHXARDNFZ-UHFFFAOYSA-N,Small molecule,True,VENLAFAXINE HYDROCHLORIDE,4.0,False,True,"['Effexor', 'Effexor xr', 'Venlafaxine hydrochloride']","['NSC-745751', 'Venlafaxine (as hydrochloride)', 'Venlafaxine hcl', 'Venlafaxine hydrochloride', 'WY-45,030', 'WY-45030']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 20 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0005180', 'MONDO_0002009', 'EFO_0006862', 'MONDO_0004985', 'EFO_0009854', 'HP_0000726', 'HP_0031217', 'EFO_0005687', 'EFO_0003761', 'MONDO_0004975', 'EFO_0006788', 'EFO_1001892', 'EFO_1001917', 'EFO_0004242', 'EFO_0004262', 'EFO_0000673', 'MONDO_0007254', 'MONDO_0005090', 'EFO_0003843', 'MONDO_0002050', 'EFO_1001919', 'EFO_1002014', 'HP_0030833', 'EFO_0002610', 'EFO_0005230', 'MONDO_0008315', 'EFO_0003918', 'EFO_0005762']",28.0,"['ENSG00000103546', 'ENSG00000108576']",2,1993.0,CHEMBL637,['venlafaxine%20hydrochloride'],"['144212825', '49681556']",['9944'],,,,,
CHEMBL129857,COc1cccc2nc(-c3cccs3)nc(NN3C(=O)C=C(C)C3=O)c12,GZGLPBNOIFLLRE-UHFFFAOYSA-N,Small molecule,False,AS-602868,1.0,False,False,[],"['As-602868', 'SPC-839']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000122025', 'ENSG00000104365']",2,,,,"['137275813', '26755375']",,,,,,
CHEMBL15677,O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl,IDKAXRLETRCXKS-UHFFFAOYSA-N,Small molecule,False,FENCLOFENAC,4.0,True,True,[],"['Fenclofenac', 'R 67408', 'R-67408', 'RX 67408', 'RX-67408']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978. It was withdrawn in at least one region.,['Fenclofenac'],,,,"['ENSG00000073756', 'ENSG00000095303']",2,1978.0,,,['144206863'],,,,,,
CHEMBL1614,C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1,OBATZBGFDSVCJD-LALPQLPRSA-N,Small molecule,False,DESLANOSIDE,4.0,False,True,['Cedilanid-d'],"['Deacetylanatoside c', 'Desacetyl-lanatoside c', 'Deslanoside']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease.,['Deslanoside'],['DB01078'],['EFO_0000319'],1.0,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731']",8,1982.0,,,"['144205224', '170465236']",['31468'],,,,,
CHEMBL1743060,,,Antibody,False,RADRETUMAB,2.0,False,False,[],['Radretumab'],,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000115414'],1,,,,,,,,,,
CHEMBL334966,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O,PAEBIVWUMLRPSK-IDTAVKCVSA-N,Small molecule,False,CANGRELOR,4.0,False,True,[],"['AR-C69931XX', 'Cangrelor']",['CHEMBL1097279'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for myocardial infarction and recurrent thrombophlebitis and has 6 investigational indications.,,['DB06441'],"['EFO_0005672', 'HP_0004419', 'HP_0002140', 'EFO_0000556', 'EFO_0008585', 'EFO_0001645', 'EFO_0000612', 'HP_0004419']",8.0,['ENSG00000169313'],1,2015.0,,['cangrelor'],,,,,,,
CHEMBL3545092,,,Small molecule,False,CR 1447,2.0,False,False,[],['Cr 1447'],,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000169083', 'ENSG00000140009']",2,,,,,,,,,,
CHEMBL3545420,CCNCc1cncc(-c2ccc3c(c2)/C(=C2/N=c4cc(F)cc(F)c4=N2)NN3)c1C,RBOKLZGCVRXGEP-XTQSDGFTSA-N,Small molecule,False,AG-24322,1.0,False,False,[],"['AG-024322', 'Ag 024322', 'Ag-24322']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0005952'],1.0,"['ENSG00000123374', 'ENSG00000135446', 'ENSG00000170312']",3,,,,,,,,,,
CHEMBL3990034,,,Gene,False,FIDANACOGENE ELAPARVOVEC,3.0,False,False,[],"['Aav8 hfix19', 'Fidanacogene elaparvovec', 'PF-06838435', 'Raav-spark100-hfix-padua', 'SPK 101', 'SPK-1001', 'SPK-9001', 'SPK-FIX Padua', 'Spark 101']",,Gene drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['MONDO_0010604'],1.0,['ENSG00000101981'],1,,,,,,,,,,
CHEMBL4071161,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SEJLPXCPMNSRAM-GOSISDBHSA-N,Small molecule,False,TIRABRUTINIB,4.0,False,True,['Velexbru'],"['GS-4059', 'Gs-4059', 'ONO-4059', 'ONO-4059(FREE BASE)', 'Ono-4059', 'Tirabrutinib']",['CHEMBL5314600'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 6 investigational indications.,,['DB15227'],"['EFO_0000616', 'EFO_0000616', 'EFO_0000685', 'EFO_0000699', 'EFO_0000095', 'EFO_0005531', 'MONDO_0004992']",7.0,['ENSG00000010671'],1,2020.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TIRABRUTINIB/relevant/1/'],,,
CHEMBL4594271,N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1,UXNXMBYCBRBRFD-UHFFFAOYSA-N,Small molecule,False,BEROTRALSTAT,4.0,False,True,[],"['BCX-7353', 'BCX7353', 'Bcx7353', 'Berotralstat']",['CHEMBL4594272'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hereditary angioedema and has 1 investigational indication.,,,"['EFO_0005532', 'MONDO_0019623', 'MONDO_0019623']",3.0,['ENSG00000164344'],1,2020.0,,,,,,,,,
CHEMBL631,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,JWHAUXFOSRPERK-UHFFFAOYSA-N,Small molecule,True,PROPAFENONE,4.0,False,True,[],"['GNF-Pf-4594', 'Propafenon hexal', 'Propafenone', 'Rythmol']",['CHEMBL1201063'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.,['Propafenone'],['DB01182'],"['HP_0004308', 'EFO_0000275', 'EFO_0004278', 'EFO_0000612', 'EFO_0003144', 'EFO_0004287', 'EFO_0004269', 'EFO_0000275']",8.0,"['ENSG00000169252', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000043591']",12,1989.0,,,"['104171212', '124881115', '144203779', '170464755', '26752315', '26752316', '50105251', '50105252', '90341088']",['63619'],,,,,
CHEMBL1615374,Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,RPZBRGFNBNQSOP-UHFFFAOYSA-N,Small molecule,True,VILAZODONE HYDROCHLORIDE,4.0,False,True,['Viibryd'],"['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hcl', 'Vilazodone hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2011 and is indicated for unipolar depression. This drug has a black box warning from the FDA.,,,['EFO_0003761'],1.0,"['ENSG00000108576', 'ENSG00000178394']",2,2011.0,CHEMBL439849,['vilazodone%20hydrochloride'],,['70705'],,,,,
CHEMBL1963502,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1,XRYJULCDUUATMC-CYBMUJFWSA-N,Small molecule,False,PKI-166,1.0,False,False,[],"['CGP-75166', 'NVP-PKI166', 'PKI-166', 'Pki 166', 'Pki-166']",['CHEMBL1914653'],Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL2364651,,,Antibody,False,TOVETUMAB,2.0,False,False,[],"['MEDI-575', 'Tovetumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0003060', 'MONDO_0004992', 'EFO_0000519']",3.0,['ENSG00000134853'],1,,,,,,,,,,
CHEMBL3989861,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O,YETWCSLOYUZBLK-JITBQSAISA-N,Small molecule,True,DESVENLAFAXINE FUMARATE,4.0,False,True,[],"['Desvenlafaxine fumarate anhydrous', 'O-desmethylvenlafaxine fumarate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for unipolar depression. This drug has a black box warning from the FDA.,,,['EFO_0003761'],1.0,"['ENSG00000103546', 'ENSG00000108576']",2,2013.0,CHEMBL1118,,,,,,,,
CHEMBL5315076,,,Protein,False,ALBUTREPENONACOG ALFA,4.0,False,True,['Idelvion'],"['CSL-654', 'Csl654']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for hemophilia b.,,,['MONDO_0010604'],1.0,['ENSG00000101981'],1,2016.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/idelvion'],,,,
CHEMBL571,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,DKYWVDODHFEZIM-UHFFFAOYSA-N,Small molecule,True,KETOPROFEN,4.0,False,True,"['Actron', 'Alrheumat', 'Axorid', 'Fenoket 200', 'Jomethid xl', 'Ketocid 200', 'Ketonal', 'Ketoprofen', 'Ketotard 200 xl', 'Ketovail', 'Ketozip 200 xl', 'Larafen', 'Larafen cr', 'Nexcede', 'Orudis', 'Orudis 100', 'Orudis kt', 'Oruvail', 'Oruvail 100', 'Oruvail 150', 'Oruvail 200', 'Oruvail im', 'Powergel', 'Tiloket', 'Tiloket cr', 'Valket 200 retard']","['(rs)-ketoprofen', '19583RP', 'Actron ketoprofen', 'Aneol', 'Capisten', 'Hydratropic acid, m-benzoyl-', 'IDEA-033', 'Iso-k', 'Ketoprofen', 'Ketorin', 'NSC-758144', 'R.P. 19,583', 'R.P. 19583', 'RP-19583', 'RU-4733', 'Sector']","['CHEMBL4650345', 'CHEMBL341922']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 approved and 14 investigational indications. This drug has a black box warning from the FDA.,['Ketoprofen'],['DB01009'],"['EFO_0000685', 'EFO_0000649', 'EFO_0000546', 'HP_0003326', 'MONDO_0005178', 'EFO_0002970', 'EFO_1001412', 'HP_0003419', 'MONDO_0005277', 'EFO_0000512', 'HP_0100607', 'MONDO_0002471', 'HP_0002829', 'EFO_0003843', 'EFO_0005755', 'EFO_0009582', 'EFO_0004888', 'MONDO_0004857', 'EFO_0004616', 'MP_0001845', 'EFO_0004253']",21.0,"['ENSG00000073756', 'ENSG00000095303']",2,1986.0,,['ketoprofen'],"['11532908', '144204145', '144208045', '170465449', '26747548', '50086520', '50106498', '85231099', '857801', '90341309']",['6128'],,,,,
CHEMBL601719,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,KTEIFNKAUNYNJU-GFCCVEGCSA-N,Small molecule,False,CRIZOTINIB,4.0,False,True,['Xalkori'],"['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 18 investigational indications.,['Crizotinib'],['DB08865'],"['EFO_1001951', 'EFO_1000026', 'EFO_0000707', 'MONDO_0008903', 'MONDO_0011962', 'EFO_0000571', 'EFO_0000228', 'EFO_0000222', 'MONDO_0007254', 'EFO_0001378', 'MONDO_0001056', 'EFO_0003060', 'MONDO_0015798', 'MONDO_0004992', 'EFO_0000519', 'EFO_0003086', 'MONDO_0007039', 'EFO_0003032', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000640', 'EFO_0000403']",22.0,"['ENSG00000171094', 'ENSG00000181163', 'ENSG00000105976', 'ENSG00000143924']",4,2011.0,,['crizotinib'],,['64310'],['https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori'],,,,
CHEMBL1200527,COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1,XXZSQOVSEBAPGS-UHFFFAOYSA-L,Small molecule,False,ATRACURIUM BESYLATE,4.0,False,True,"['Atracurium Besilate', 'Atracurium besylate', 'Atracurium besylate preservative free', 'Tracrium', 'Tracrium preservative free']","['Atracurium besilate', 'Atracurium besylate', 'Atracurium dibesylate', 'BW 33A', 'BW-33A', 'NSC-760047']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983.,,['DB00732'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1983.0,CHEMBL1360,['atracurium%20besylate'],"['144204341', '174006843']",['2915'],,,,,
CHEMBL18116,Cc1cccc(N2CC(CO)OC2=O)c1,MXUNKHLAEDCYJL-UHFFFAOYSA-N,Small molecule,False,TOLOXATONE,4.0,False,True,[],"['Humoryl', 'Toloxatone']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and has 1 investigational indication.,['Toloxatone'],['DB09245'],['EFO_0003761'],1.0,['ENSG00000189221'],1,1984.0,,,,,,,,,
CHEMBL2105717,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,ONIQOQHATWINJY-UHFFFAOYSA-N,Small molecule,True,CABOZANTINIB,4.0,False,True,"['Cabometyx', 'Cometriq']","['BMS-907351', 'BMS-907351 FREE BASE', 'Cabozantinib', 'XL-184', 'XL-184 FREE BASE', 'XL184']",['CHEMBL2103868'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 9 approved and 61 investigational indications. This drug has a black box warning from the FDA.,,['DB08875'],"['EFO_0000519', 'EFO_0001075', 'MONDO_0004992', 'EFO_0000501', 'EFO_1001949', 'EFO_0000640', 'EFO_0001421', 'EFO_0003968', 'EFO_0000239', 'EFO_0000640', 'EFO_0000313', 'EFO_0000616', 'EFO_1001512', 'EFO_0007532', 'EFO_0000681', 'EFO_0003060', 'MONDO_0007254', 'EFO_1001968', 'MONDO_0002974', 'EFO_0003060', 'EFO_0005220', 'EFO_1001951', 'EFO_0000326', 'EFO_0000272', 'EFO_0000616', 'EFO_0000673', 'EFO_1000796', 'EFO_1001465', 'EFO_0000389', 'MONDO_0002120', 'MONDO_0002108', 'EFO_0000182', 'EFO_0004243', 'EFO_0002618', 'EFO_1000251', 'EFO_0000305', 'EFO_1000657', 'MONDO_0011719', 'EFO_0008528', 'EFO_0004252', 'EFO_0000349', 'EFO_0000681', 'EFO_0000641', 'EFO_0000222', 'EFO_0002617', 'EFO_1000613', 'MONDO_0004669', 'MONDO_0001187', 'EFO_0000637', 'EFO_0000519', 'EFO_1001465', 'EFO_0003016', 'EFO_0000756', 'EFO_0000641', 'EFO_0000182', 'EFO_0002892', 'EFO_0001378', 'MONDO_0002108', 'MONDO_0008315', 'EFO_0000637', 'MONDO_0004986', 'EFO_0000707', 'MONDO_0002367', 'EFO_0000349', 'MONDO_0016642', 'MONDO_0004992', 'EFO_0000501', 'EFO_0003863', 'EFO_0000335', 'EFO_0008524', 'EFO_0000673', 'EFO_1001901', 'MONDO_0015277', 'EFO_0002499', 'EFO_1001961']",75.0,"['ENSG00000128052', 'ENSG00000105976']",2,2012.0,,,['137276008'],['72317'],,,,,
CHEMBL2110732,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,LVXJQMNHJWSHET-AATRIKPKSA-N,Small molecule,False,DACOMITINIB ANHYDROUS,4.0,False,True,[],"['Dacomitinib anhydrous', 'Pf-00299804']",['CHEMBL2105719'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 16 investigational indications.,,['DB11963'],"['MONDO_0008903', 'EFO_0000616', 'MONDO_0008903', 'EFO_0003060', 'EFO_0004284', 'EFO_1001951', 'MONDO_0001657', 'EFO_0009708', 'EFO_0000707', 'MONDO_0004992', 'EFO_0000181', 'EFO_0000519', 'EFO_0000616', 'EFO_0003833', 'EFO_1001094', 'EFO_0000313', 'EFO_0001421', 'EFO_0003060', 'EFO_0000181', 'EFO_0005570']",20.0,"['ENSG00000178568', 'ENSG00000141736', 'ENSG00000146648']",3,2018.0,,,,,,,,,
CHEMBL304087,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,JBPUGFODGPKTDW-SFHVURJKSA-N,Small molecule,False,MERIMEPODIB,2.0,False,False,[],"['Merimepodib', 'VI-21,497', 'VI-21497', 'VX-497']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB04862'],['MONDO_0100096'],1.0,['ENSG00000106348'],1,,,,,,,,,,
CHEMBL314854,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,KKGQTZUTZRNORY-UHFFFAOYSA-N,Small molecule,False,FINGOLIMOD,4.0,False,True,['Gilenya'],"['FTY-720', 'Fingolimod']","['CHEMBL5095050', 'CHEMBL544665', 'CHEMBL3526818']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for immune system disease and multiple sclerosis and has 18 investigational indications.,['Fingolimod'],['DB08868'],"['EFO_0008520', 'EFO_0002499', 'MONDO_0010726', 'EFO_1000868', 'HP_0000083', 'EFO_0000540', 'MONDO_0005090', 'EFO_1001231', 'MONDO_0004979', 'EFO_0000712', 'EFO_0007405', 'MONDO_0100096', 'EFO_0003840', 'EFO_0003929', 'EFO_0000519', 'MONDO_0004976', 'MONDO_0005301', 'EFO_0000305', 'EFO_0003929', 'MONDO_0005301']",20.0,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']",5,2010.0,,,,['63115'],,,,,
CHEMBL4297905,,,Antibody,False,OSOCIMAB,2.0,False,False,[],"['BAY 1213790', 'BAY-1213790', 'Bay1213790', 'Osocimab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000088926'],1,,,,,,,,,,
CHEMBL469,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,OZWKMVRBQXNZKK-UHFFFAOYSA-N,Small molecule,True,KETOROLAC,4.0,False,True,[],['Ketorolac'],['CHEMBL1201124'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 6 approved and 39 investigational indications. This drug has a black box warning from the FDA.,['Ketorolac'],['DB00465'],"['EFO_0003777', 'EFO_0005755', 'EFO_0003869', 'HP_0003418', 'EFO_0003843', 'HP_0011110', 'EFO_1001178', 'EFO_0008571', 'EFO_1001250', 'HP_0002315', 'EFO_0000649', 'EFO_0000668', 'MONDO_0003005', 'EFO_0004616', 'EFO_1001158', 'MP_0001845', 'HP_0200026', 'EFO_0000546', 'EFO_0009676', 'HP_0002015', 'EFO_1001412', 'EFO_0004273', 'MONDO_0005129', 'EFO_0003843', 'MONDO_0005277', 'HP_0002027', 'MONDO_0005184', 'EFO_1000859', 'EFO_1001139', 'MONDO_0005277', 'EFO_1001412', 'EFO_1000652', 'HP_0012532', 'MP_0001845', 'EFO_0009444', 'HP_0003418', 'MONDO_0002087', 'EFO_0005752', 'MONDO_0005129', 'HP_0000616', 'EFO_0005854', 'MONDO_0008170', 'EFO_0004253', 'EFO_0004253', 'EFO_0003770', 'MONDO_0002158', 'MONDO_0002367']",47.0,"['ENSG00000073756', 'ENSG00000095303']",2,1989.0,,,"['174007295', '90341692']",['76223'],,,,,
CHEMBL761,c1ccc2c(CC3=NCCN3)cccc2c1,CNIIGCLFLJGOGP-UHFFFAOYSA-N,Small molecule,False,NAPHAZOLINE,4.0,False,True,[],"['Nafazair', 'Nafazolin', 'Naphazoline']",['CHEMBL1706'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 7 investigational indications.,['Naphazoline'],['DB06711'],"['EFO_0007214', 'EFO_0000678', 'MP_0001845', 'EFO_0007141', 'EFO_0000616', 'HP_0001742', 'EFO_0007328', 'EFO_0003822', 'EFO_0003956', 'EFO_0005751', 'EFO_0007214', 'EFO_0007486', 'HP_0001742']",13.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1971.0,,,"['11112411', '26751615']",,,,,,
CHEMBL969,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,MWQCHHACWWAQLJ-UHFFFAOYSA-N,Small molecule,False,PRAZEPAM,4.0,False,True,"['Centrax', 'Demetrin', 'Prazepam']","['NSC-277179', 'Prazepam', 'Prazepam civ', 'W 4020', 'W-4020']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for anxiety.,['Prazepam'],['DB01588'],['EFO_0005230'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,,"['144206168', '144207274', '50113069']",['8362'],,,,,
CHEMBL1089636,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,GBVKRUOMSUTVPW-AHNVSIPUSA-N,Protein,False,ANG1005,3.0,False,False,[],"['ANG-1005', 'ANG1005', 'Ang1005', 'Paclitaxel trevatide']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['MONDO_0100342', 'EFO_0000616', 'EFO_0000519', 'EFO_0003833']",4.0,"['ENSG00000123384', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL1200969,C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)Nc3cc(C(F)(F)F)ccc3C(F)(F)F)CC[C@@H]12,JWJOTENAMICLJG-QWBYCMEYSA-N,Small molecule,False,DUTASTERIDE,4.0,False,True,"['Avodart', 'Dutasteride']","['Avolve', 'Duastride', 'Dutasteride', 'GG-745', 'GI 198745', 'GI-198745', 'NSC-740477', 'NSC-759880']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 8 investigational indications.,['Dutasteride'],['DB01126'],"['EFO_0001663', 'MONDO_0002146', 'MONDO_0004976', 'EFO_0000284', 'EFO_0003830', 'MONDO_0010735', 'MONDO_0004907', 'EFO_0004191', 'MONDO_0100096', 'EFO_0000673', 'MONDO_0008315']",11.0,"['ENSG00000145545', 'ENSG00000277893', 'ENSG00000128039']",3,2001.0,,['dutasteride'],['144205752'],['521033'],,,,,
CHEMBL1201101,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,HPFVBGJFAYZEBE-ZLQWOROUSA-N,Small molecule,False,TESTOSTERONE CYPIONATE,4.0,False,True,"['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'Testosterone cypionate']","['Depo-Testadiol', 'NSC-9157', 'Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionate', 'Testosterone cyclopentylpropionate', 'Testosterone cypionate', 'Testosterone cypionate ciii']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 3 approved and 5 investigational indications.,,['DB13943'],"['EFO_0000673', 'EFO_0000616', 'EFO_0004714', 'MONDO_0002146', 'MONDO_0008315', 'EFO_1001078', 'EFO_1000783', 'EFO_0000196']",8.0,['ENSG00000169083'],1,1978.0,,['testosterone%20cypionate'],,['9463'],,,,,
CHEMBL123292,C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1,YPHMISFOHDHNIV-FSZOTQKASA-N,Small molecule,False,CYCLOHEXIMIDE,2.0,False,False,[],"['Cicloheximide', 'Cycloheximide', 'GNF-Pf-5118', 'NSC-171', 'NSC-185', 'TCMDC-125838', 'U-4527']",,Small molecule drug with a maximum clinical trial phase of II.,['Cycloheximide'],,,,"['ENSG00000168028', 'ENSG00000177954', 'ENSG00000137154', 'ENSG00000140988', 'ENSG00000149273', 'ENSG00000145425', 'ENSG00000198034', 'ENSG00000129824', 'ENSG00000083845', 'ENSG00000171863', 'ENSG00000142937', 'ENSG00000170889', 'ENSG00000124614', 'ENSG00000142534', 'ENSG00000112306', 'ENSG00000110700', 'ENSG00000164587', 'ENSG00000115268', 'ENSG00000134419', 'ENSG00000105193', 'ENSG00000182774', 'ENSG00000231500', 'ENSG00000105372', 'ENSG00000008988', 'ENSG00000171858', 'ENSG00000186468', 'ENSG00000138326', 'ENSG00000118181', 'ENSG00000197728', 'ENSG00000143947', 'ENSG00000233927', 'ENSG00000213741', 'ENSG00000149806', 'ENSG00000100316', 'ENSG00000174444', 'ENSG00000122406', 'ENSG00000089009', 'ENSG00000147604', 'ENSG00000148303', 'ENSG00000161016', 'ENSG00000163682', 'ENSG00000147403', 'ENSG00000198755', 'ENSG00000142676', 'ENSG00000197958', 'ENSG00000167526', 'ENSG00000142541', 'ENSG00000188846', 'ENSG00000174748', 'ENSG00000265681', 'ENSG00000063177', 'ENSG00000105640', 'ENSG00000108298', 'ENSG00000122026', 'ENSG00000116251', 'ENSG00000125691', 'ENSG00000198242', 'ENSG00000114391', 'ENSG00000161970', 'ENSG00000131469', 'ENSG00000166441', 'ENSG00000108107', 'ENSG00000162244', 'ENSG00000156482', 'ENSG00000071082', 'ENSG00000144713', 'ENSG00000109475', 'ENSG00000136942', 'ENSG00000182899', 'ENSG00000130255', 'ENSG00000241343', 'ENSG00000145592', 'ENSG00000197756', 'ENSG00000172809', 'ENSG00000198918', 'ENSG00000229117', 'ENSG00000089157', 'ENSG00000137818']",78,,,,"['103076162', '124883128', '124883129', '144207129', '144208356', '144213954', '170466349', '17389082', '17389083', '26752000', '50104677', '56463698', '67121']",['27641'],,,,,
CHEMBL1236107,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,BCZUAADEACICHN-UHFFFAOYSA-N,Small molecule,False,SGX-523,1.0,False,False,[],"['SGX-523', 'SGX523', 'Sgx-523']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB06314'],['MONDO_0004992'],1.0,['ENSG00000105976'],1,,,,"['137276007', '174006581']",['90624'],,,,,
CHEMBL2105729,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O,YKGMKSIHIVVYKY-UHFFFAOYSA-N,Small molecule,False,DABRAFENIB MESYLATE,4.0,False,True,['Tafinlar'],"['Dabrafenib mesilate', 'Dabrafenib mesylate', 'GSK-2118436 METHANESULFONATE SALT', 'GSK-2118436B', 'GSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALT', 'GSK2118436B', 'GSK2118436B, METHANE SULFONATE SALT', 'METHANE SULFONATE SALT']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 2 investigational indications.,,,"['EFO_1000926', 'EFO_0002892', 'MONDO_0002108', 'EFO_0001378', 'EFO_0000756', 'EFO_0000389', 'EFO_0002617']",7.0,['ENSG00000157764'],1,2013.0,CHEMBL2028663,['dabrafenib%20mesylate'],,['75048'],['https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar'],,,,
CHEMBL2219776,,,Oligonucleotide,False,CENERSEN SODIUM,2.0,False,False,[],"['Cenersen sodium', 'EL-625', 'EL625', 'OL(1)P53']",,Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000095'],1.0,['ENSG00000141510'],1,,,,,,,,,,
CHEMBL25202,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,MUTNCGKQJGXKEM-UHFFFAOYSA-N,Small molecule,False,TAMIBAROTENE,4.0,False,True,[],"['AM-80', 'Am80', 'Amnoid', 'INNO-507', 'NSC-608000', 'OP-01', 'RR-110', 'SY-1425', 'Sy-1425', 'TM-411', 'TOS-80T', 'Tamibarotene']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 8 investigational indications.,['Tamibarotene'],['DB04942'],"['EFO_0000224', 'MONDO_0004975', 'EFO_0007527', 'EFO_0002618', 'EFO_0000198', 'EFO_0005761', 'EFO_0000222', 'EFO_0000384']",8.0,"['ENSG00000131759', 'ENSG00000077092']",2,2005.0,,,"['144206278', '170465883', '485050', '50125822']",['32181'],,['https://searchusan.ama-assn.org/finder/usan/search/TAMIBAROTENE/relevant/1/'],,,
CHEMBL3188386,Cc1cc(-c2ncc(CC(=O)Nc3ccc(-c4cnccn4)cn3)cc2C)ccn1,XXYGTCZJJLTAGH-UHFFFAOYSA-N,Small molecule,False,WNT-974,2.0,False,False,[],"['LGK-974', 'LGK974', 'Lgk974', 'WNT-974', 'WNT974', 'Wnt-974', 'Wnt974']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12561'],['EFO_0000707'],1.0,['ENSG00000102312'],1,,,,['174006720'],['78030'],,,,,
CHEMBL4297600,NC(=O)c1ccn(-c2cnc(NC[C@]3(c4ncccc4F)C[C@H](F)C3)nc2)c1,MQXWPWOCXGARRK-HJGJAMNPSA-N,Small molecule,False,RELDESEMTIV,3.0,False,False,[],"['CK-2127107', 'Ck-2127107', 'Reldesemtiv']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB15256'],"['MONDO_0004976', 'EFO_0000341', 'EFO_0008525']",3.0,"['ENSG00000130598', 'ENSG00000130595', 'ENSG00000101470']",3,,,,,,,,,,
CHEMBL5316167,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1,GBXJAPBXPROFPY-GOSISDBHSA-N,Small molecule,False,ARQ-736 FREE ACID,1.0,False,False,[],[],['CHEMBL5314407'],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000157764', 'ENSG00000132155']",2,,,,,,,,,,
CHEMBL848,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,GOTYRUGSSMKFNF-UHFFFAOYSA-N,Small molecule,True,LENALIDOMIDE,4.0,False,True,['Revlimid'],"['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 6 approved and 82 investigational indications. This drug has a black box warning from the FDA.,['Lenalidomide'],['DB00480'],"['MONDO_0018906', 'MONDO_0100342', 'EFO_1000657', 'EFO_0000180', 'EFO_1001779', 'MONDO_0002280', 'MONDO_0002158', 'EFO_0003758', 'EFO_1001951', 'MONDO_0044903', 'MONDO_0004992', 'EFO_1001469', 'MONDO_0002367', 'EFO_0000681', 'EFO_0000621', 'EFO_0000095', 'EFO_0006475', 'HP_0004326', 'EFO_0000673', 'MONDO_0004095', 'EFO_1001115', 'EFO_0000479', 'EFO_0000182', 'MONDO_0001187', 'EFO_0000616', 'MONDO_0008170', 'EFO_1001465', 'EFO_0000384', 'MONDO_0021063', 'EFO_0004142', 'EFO_0000403', 'EFO_0000209', 'MONDO_0002087', 'EFO_0002892', 'EFO_0000183', 'EFO_1000630', 'MONDO_0005184', 'EFO_0000222', 'EFO_1001938', 'MONDO_0019471', 'EFO_1001998', 'EFO_0000191', 'EFO_0004272', 'MONDO_0008315', 'EFO_0003060', 'MONDO_0017816', 'EFO_0000294', 'EFO_0002499', 'MONDO_0001023', 'EFO_0000540', 'EFO_0000339', 'EFO_0000756', 'EFO_0000574', 'EFO_0002430', 'EFO_0003841', 'MONDO_0044881', 'EFO_1000026', 'EFO_0000707', 'EFO_0009708', 'EFO_0002618', 'MONDO_0019438', 'EFO_0000196', 'EFO_0002913', 'MONDO_0015760', 'EFO_0000096', 'EFO_0006738', 'MONDO_0002691', 'EFO_0000764', 'MONDO_0004192', 'MONDO_0013730', 'EFO_1000158', 'EFO_0003073', 'EFO_0000558', 'EFO_0000769', 'EFO_0000198', 'EFO_0004251', 'EFO_0000211', 'MONDO_0002959', 'EFO_0001378', 'EFO_0009441', 'EFO_0005952', 'EFO_0000309', 'MONDO_0006412', 'EFO_0002429', 'EFO_0000565', 'EFO_0000220', 'MONDO_0000430', 'HP_0001871']",88.0,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']",4,2005.0,,['lenalidomide'],"['124893327', '124893328', '144206045', '170465201']",['63791'],['https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid'],,,,
CHEMBL1242,Nc1ccc(/N=N/c2ccccc2)c(N)n1,QPFYXYFORQJZEC-FOCLMDBBSA-N,Small molecule,False,PHENAZOPYRIDINE,4.0,False,True,[],"['NSC-145895', 'Phenazopyridine']",['CHEMBL1201022'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 investigational indications.,['Phenazopyridine'],['DB01438'],"['EFO_0003103', 'EFO_0003843', 'HP_0000016', 'EFO_0003901']",4.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1987.0,,,['104171363'],,,,,,
CHEMBL1742986,,,Protein,False,ATACICEPT,3.0,False,False,[],"['Atacicept', 'TACI-FC5', 'TACI-IG']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['MONDO_0007915', 'EFO_0005761', 'EFO_0004194', 'EFO_0007405', 'EFO_0000685', 'MONDO_0005301']",6.0,"['ENSG00000102524', 'ENSG00000161955']",2,,,,,,,,,,
CHEMBL1909286,CC(COc1ccccc1)NN,QNEXFJFTGQBXBJ-UHFFFAOYSA-N,Small molecule,False,PHENOXYPROPAZINE,4.0,True,True,[],"['Fenoxypropazine', 'Phenoxypropazine']",['CHEMBL4303424'],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,['Phenoxypropazine'],['DB09251'],,,"['ENSG00000189221', 'ENSG00000069535']",2,,,,['144206870'],,,,,,
CHEMBL2109412,,,Antibody,False,L19SIP 131I,2.0,False,False,[],"['L19SIP', 'L19sip 131i']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004992'],1.0,['ENSG00000115414'],1,,,,,,,,,,
CHEMBL2109635,,,Antibody drug conjugate,False,SAR-566658,2.0,False,False,[],"['SAR-566658', 'SAR566658', 'Sar 566658', 'Sar-566658', 'huDS6-DM4']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0007254', 'EFO_0000616']",2.0,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL3039543,,,Antibody,False,ULOCUPLUMAB,2.0,False,False,[],"['BMS-936564', 'MDX-1338', 'Ulocuplumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['MONDO_0018906', 'EFO_0000222', 'EFO_0000565', 'EFO_0000616', 'EFO_0009441', 'EFO_0001378', 'EFO_0000095']",7.0,['ENSG00000121966'],1,,,,,,,,,,
CHEMBL3544983,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,HVXKQKFEHMGHSL-QKDCVEJESA-N,Small molecule,False,TESEVATINIB,3.0,False,False,[],"['EXEL-7647', 'KD-019', 'KD-020', 'KD019', 'Tesevatinib', 'XL647', 'Xl-647']",['CHEMBL3544982'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,['DB11973'],"['MONDO_0007254', 'MONDO_0009889', 'EFO_0003060', 'EFO_1001496', 'EFO_0000519', 'EFO_0003833', 'MONDO_0004992']",7.0,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000196411']",3,,,,,,,,,,
CHEMBL3622821,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,WYQFJHHDOKWSHR-MNOVXSKESA-N,Small molecule,True,UPADACITINIB,4.0,False,True,[],"['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrous']","['CHEMBL3707269', 'CHEMBL5315119']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for rheumatoid arthritis and has 12 investigational indications. This drug has a black box warning from the FDA.,,['DB15091'],"['EFO_0000274', 'EFO_0003778', 'EFO_0000540', 'EFO_0000384', 'EFO_1000710', 'EFO_0002609', 'EFO_0000685', 'EFO_1001209', 'EFO_0000729', 'EFO_0004208', 'EFO_0000685', 'MONDO_0007915', 'EFO_0003898']",13.0,"['ENSG00000105397', 'ENSG00000162434', 'ENSG00000105639', 'ENSG00000096968']",4,2019.0,,['upadacitinib'],,,,,,,
CHEMBL4297574,,,Oligonucleotide,False,TEPRASIRAN,3.0,False,False,[],"['I5-NP', 'I5NP', 'QPI-1002', 'Qpi-1002', 'Teprasiran']",,Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['HP_0001919'],1.0,['ENSG00000141510'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TEPRASIRAN/relevant/1/'],,,
CHEMBL471498,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,WPGGHFDDFPHPOB-BBWFWOEESA-N,Small molecule,False,MITIGLINIDE,3.0,False,False,[],['Mitiglinide'],['CHEMBL1603301'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,['Mitiglinide'],['DB01252'],"['EFO_0000400', 'MONDO_0005148']",2.0,"['ENSG00000187486', 'ENSG00000006071']",2,,,,,,,,,,
CHEMBL574737,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,PBCZSGKMGDDXIJ-KRUBCLEUSA-N,Small molecule,False,UCN-01,2.0,False,False,[],"['7-hydroxystaurosporine', 'KRX-0601', 'KW-2401', 'NSC-638850', 'UCN-01', 'UCN-02', 'Ucn 01', 'Ucn-01']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 43 investigational indications.,,,"['MONDO_0002158', 'EFO_1001013', 'EFO_0000756', 'EFO_1001512', 'EFO_0003025', 'EFO_0000209', 'MONDO_0007254', 'MONDO_0004669', 'EFO_0003027', 'MONDO_0002087', 'EFO_0000198', 'MONDO_0002367', 'EFO_0007535', 'EFO_0000224', 'MONDO_0011719', 'EFO_1000407', 'MONDO_0008315', 'MONDO_0003196', 'MONDO_0044926', 'EFO_0003060', 'EFO_0000339', 'EFO_0002938', 'MONDO_0002537', 'MONDO_0018364', 'EFO_0005537', 'MONDO_0002974', 'EFO_0004193', 'MONDO_0001879', 'EFO_0000616', 'EFO_0006352', 'EFO_0000221', 'MONDO_0001056', 'MONDO_0007576', 'EFO_0003028', 'EFO_0000702', 'MONDO_0005411', 'EFO_0000218', 'EFO_0000574', 'MONDO_0008170', 'EFO_0002618', 'EFO_0000223', 'EFO_0000673', 'EFO_0000565']",43.0,"['ENSG00000115825', 'ENSG00000163558', 'ENSG00000154229', 'ENSG00000126583', 'ENSG00000163932', 'ENSG00000166501', 'ENSG00000067606', 'ENSG00000171132', 'ENSG00000027075', 'ENSG00000184304', 'ENSG00000065675', 'ENSG00000105810', 'ENSG00000140992', 'ENSG00000149554', 'ENSG00000123374', 'ENSG00000135446']",16,,,,,,,,,,
CHEMBL814,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,CJOFXWAVKWHTFT-XSFVSMFZSA-N,Small molecule,True,FLUVOXAMINE,4.0,False,True,[],"['Fluvoxamine', 'N06AB08']",['CHEMBL1409'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.,['Fluvoxamine'],['DB00176'],"['EFO_1001916', 'EFO_0000694', 'EFO_1001917', 'MONDO_0100096', 'EFO_0003758', 'EFO_0004262', 'EFO_0005230', 'MONDO_0005090', 'EFO_0004242', 'EFO_0000616', 'EFO_0003761', 'EFO_0004242', 'HP_0000726', 'MONDO_0002050', 'MONDO_0100096', 'EFO_1001892', 'EFO_0000694', 'EFO_1002014']",18.0,['ENSG00000108576'],1,1994.0,,,"['104171369', '144204388', '170464809', '26751469', '50103976', '90340960']",['5138'],,,,,
CHEMBL87992,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21,QIALRBLEEWJACW-INIZCTEOSA-N,Small molecule,False,ESLICARBAZEPINE ACETATE,4.0,False,True,"['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']","['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetate', 'SEP - 0002093', 'SEP-0002093']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for seizure and epilepsy and has 8 investigational indications.,,['DB09119'],"['MONDO_0041052', 'EFO_0005762', 'EFO_1000877', 'EFO_0005687', 'HP_0001250', 'EFO_0000474', 'EFO_0009963', 'EFO_0004263', 'MONDO_0005277', 'EFO_1000783']",10.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2009.0,,['eslicarbazepine%20acetate'],"['29217508', '90341297']",['87016'],['https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix'],,,,
CHEMBL1201129,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,XAUDJQYHKZQPEU-KVQBGUIXSA-N,Small molecule,False,DECITABINE,4.0,False,True,"['Dacogen', 'Decitabine']","[""2'-deoxy-5-azacytidine"", 'DAC', 'Decitabine', 'NSC-127716']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 7 approved and 54 investigational indications.,['Decitabine'],['DB01262'],"['EFO_0000096', 'EFO_0000224', 'EFO_0000403', 'EFO_0000326', 'EFO_0000220', 'MONDO_0011382', 'MONDO_0003660', 'MONDO_0007254', 'EFO_0000198', 'EFO_0002913', 'EFO_1000131', 'MONDO_0000870', 'EFO_0000621', 'EFO_0003869', 'MONDO_0004643', 'EFO_1001996', 'EFO_0003811', 'EFO_1001830', 'MONDO_0003659', 'EFO_0000756', 'EFO_0007160', 'MONDO_0019472', 'EFO_0000183', 'EFO_0000641', 'EFO_0002428', 'EFO_0004251', 'EFO_0003060', 'EFO_0004599', 'MONDO_0008170', 'EFO_0002617', 'EFO_0005537', 'MONDO_0013730', 'EFO_0000681', 'EFO_0000501', 'EFO_0001663', 'HP_0001915', 'MONDO_0002158', 'EFO_0000196', 'EFO_0000180', 'EFO_0000211', 'MONDO_0002280', 'EFO_0005952', 'EFO_0000565', 'EFO_0006859', 'EFO_0000616', 'EFO_1001779', 'EFO_0000339', 'EFO_0001642', 'HP_0001873', 'EFO_0000222', 'MONDO_0004992', 'MONDO_0002087', 'EFO_0000389', 'EFO_0002939', 'MONDO_0000430', 'EFO_0001378', 'EFO_0000574', 'EFO_0005922', 'EFO_0000309', 'EFO_1001469', 'MONDO_0100096']",61.0,"['ENSG00000130816', 'ENSG00000119772']",2,2006.0,,['decitabine'],"['144205864', '170465126', '47211573', '56324652', '57260149']",['50131'],['https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen'],,,,
CHEMBL1201179,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,XNRVGTHNYCNCFF-UHFFFAOYSA-N,Small molecule,True,LAPATINIB DITOSYLATE,4.0,False,True,"['Tykerb', 'Tyverb']","['GW-572016F', 'GW572016F', 'Lapatinib', 'Lapatinib ditoluenesulfonate monohydrate', 'Lapatinib ditosylate', 'Lapatinib ditosylate anhydrous', 'Lapatinib ditosylate monohydrate', 'Lapatinib tosilate', 'Lapatinib tosilate hydrate', 'Tycerb']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 15 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0002892', 'MONDO_0008315', 'EFO_0002938', 'MONDO_0044926', 'EFO_0000616', 'EFO_1001465', 'EFO_0000305', 'MONDO_0004986', 'MONDO_0001187', 'EFO_1000294', 'EFO_1000158', 'EFO_1001512', 'EFO_0000574', 'EFO_0006859', 'MONDO_0007254', 'EFO_0002618', 'EFO_0006861', 'EFO_0003869', 'EFO_0006352']",19.0,"['ENSG00000146648', 'ENSG00000141736']",2,2007.0,CHEMBL554,['lapatinib%20ditosylate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb'],,,,
CHEMBL1201574,,,Unknown,True,ONABOTULINUMTOXINA,4.0,False,True,"['Botox', 'Botox Cosmetic', 'Botox/botox cosmetic']","['Bontoxilysin', 'Botulin', 'Botulinum neurotoxin', 'Botulinum toxin', 'Botulinum toxin type a purified neurotoxin complex', 'Onabotulinumtoxina', 'RTI-150', 'RTI150']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 104 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0005279', 'EFO_1001896', 'EFO_1001887', 'HP_0030834', 'EFO_0003897', 'EFO_1001434', 'EFO_1001466', 'MONDO_0011728', 'EFO_0009550', 'EFO_0005422', 'EFO_1001993', 'Orphanet_93955', 'EFO_0008521', 'MONDO_0005180', 'HP_0012532', 'HP_0000565', 'HP_0002307', 'EFO_0003899', 'EFO_0001073', 'MONDO_0043839', 'EFO_0000618', 'HP_0003419', 'HP_0012390', 'HP_0001347', 'HP_0000020', 'HP_0000016', 'EFO_1000781', 'EFO_1000999', 'EFO_0004212', 'EFO_0009523', 'HP_0000473', 'EFO_1000657', 'EFO_1000391', 'EFO_0005762', 'EFO_1000948', 'HP_0000726', 'EFO_1001054', 'EFO_0003877', 'EFO_0004234', 'MONDO_0005178', 'MONDO_0005301', 'MONDO_0043510', 'EFO_0009453', 'HP_0001257', 'EFO_0004270', 'EFO_0009619', 'HP_0002315', 'HP_0000989', 'EFO_0003894', 'HP_0010992', 'EFO_0004616', 'MONDO_0004001', 'EFO_0000275', 'EFO_1001250', 'EFO_0007159', 'EFO_0002618', 'EFO_1000632', 'HP_0000486', 'EFO_1001092', 'MONDO_0000485', 'MONDO_0002050', 'EFO_0002970', 'EFO_0000284', 'EFO_0004143', 'EFO_0004273', 'HP_0001337', 'EFO_0002916', 'MONDO_0002471', 'HP_0009926', 'EFO_0004269', 'EFO_1001866', 'EFO_1001219', 'HP_0012228', 'EFO_0005306', 'EFO_0009846', 'EFO_0009625', 'EFO_0004191', 'EFO_1000850', 'EFO_0000546', 'HP_0000975', 'MONDO_0041052', 'EFO_0003911', 'EFO_0006865', 'EFO_0009430', 'MONDO_0005277', 'EFO_0003830', 'HP_0003549', 'EFO_0003108', 'HP_0000011', 'EFO_0000712', 'EFO_0007507', 'EFO_1001919', 'EFO_0006346', 'HP_0001605', 'MONDO_0002009', 'EFO_0008507', 'EFO_0803321', 'EFO_1001909', 'EFO_1001494', 'EFO_1001145', 'HP_0032252', 'EFO_0001074', 'EFO_0003843', 'EFO_1000906', 'MONDO_0002507']",105.0,['ENSG00000132639'],1,1991.0,,['onabotulinumtoxina'],,,,,,,
CHEMBL1214124,N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,PRMWGUBFXWROHD-UHFFFAOYSA-N,Small molecule,True,PERAMPANEL,4.0,False,True,['Fycompa'],"['E-2007', 'E2007', 'ER-155055-90', 'Perampanel']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA.,['Perampanel'],['DB08883'],"['EFO_0001358', 'HP_0002069', 'EFO_0004263', 'EFO_0003108', 'MONDO_0004985', 'EFO_0007262', 'EFO_0009430', 'HP_0001250', 'MONDO_0004976', 'MONDO_0800207', 'MONDO_0002009', 'MONDO_0005277', 'MONDO_0005180', 'EFO_0000474', 'MONDO_0007079', 'HP_0000473', 'MONDO_0016532', 'EFO_1000783']",18.0,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,2012.0,,['perampanel'],,['71013'],['https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa'],,,,
CHEMBL1258006,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2o1,OXKRFEWMSWPKKV-GHTZIAJQSA-N,Small molecule,False,BRADANICLINE,2.0,False,False,[],"['ATA-101', 'Bradanicline', 'TC 5619', 'TC-5619']",['CHEMBL3137311'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB06090'],"['MONDO_0005090', 'EFO_0003888', 'HP_0012735']",3.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL2016893,Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1,IKBSEBRGSVFUHM-UHFFFAOYSA-N,Small molecule,False,XL-418,1.0,False,False,[],"['XL418', 'Xl-418']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0004992'],1.0,"['ENSG00000175634', 'ENSG00000108443', 'ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",5,,,,,,,,,,
CHEMBL2104993,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,YQNWZWMKLDQSAC-UHFFFAOYSA-N,Small molecule,True,VORTIOXETINE,4.0,False,True,['Brintellix'],"['LU AA21004', 'LU-AA21004', 'LUAA21004', 'Vortioxetine']","['CHEMBL5314578', 'CHEMBL2107387', 'CHEMBL3260563', 'CHEMBL2204360']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for unipolar depression and major depressive disorder and has 10 investigational indications. This drug has a black box warning from the FDA.,,['DB09068'],"['MONDO_0004985', 'EFO_0003761', 'EFO_0003761', 'MONDO_0002009', 'EFO_0003888', 'MONDO_0002050', 'EFO_0001421', 'EFO_0005203', 'EFO_0003761', 'EFO_0006788', 'EFO_1001892', 'MONDO_0002009']",12.0,"['ENSG00000108576', 'ENSG00000166736', 'ENSG00000178394']",3,2013.0,,,,['76016'],,,,,
CHEMBL3218578,COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,BMMXYEBLEBULND-UHFFFAOYSA-N,Small molecule,False,BGT-226,2.0,False,False,[],"['BGT-226', 'NVP-BGT226']",['CHEMBL3545096'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0016063', 'MONDO_0007254', 'MONDO_0004992']",3.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,['71967'],,,,,
CHEMBL3545252,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O,XCDIRYDKECHIPE-QHEQPUDQSA-N,Small molecule,True,DOCETAXEL,4.0,False,True,"['Docefrez', 'Docetaxel', 'Docetaxel zentiva (previously docetaxel winthrop)', 'Taxceus', 'Taxotere']","['Docetaxel', 'Docetaxel (as trihydrate)', 'Docetaxel hydrate', 'Docetaxel trihydrate', 'RP 56976', 'RP-56976', 'XRP6976']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 20 approved and 96 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0011719', 'HP_0002039', 'EFO_0000313', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0004281', 'MONDO_0021117', 'EFO_0007355', 'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'EFO_0000181', 'MONDO_0004986', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000673', 'MONDO_0001528', 'EFO_0000432', 'HP_0004326', 'EFO_0001416', 'MONDO_0003060', 'EFO_0009708', 'EFO_0006859', 'EFO_0004230', 'MONDO_0008903', 'EFO_1001951', 'MONDO_0008315', 'MONDO_0005271', 'MONDO_0000521', 'MONDO_0002038', 'EFO_0003869', 'MONDO_0021310', 'EFO_1000043', 'MONDO_0005575', 'EFO_0003891', 'MONDO_0004192', 'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'Orphanet_145', 'EFO_0001376', 'EFO_1000984', 'EFO_0005537', 'EFO_0003817', 'EFO_0000616', 'MONDO_0001325', 'MONDO_0002120', 'EFO_0000174', 'EFO_0000565', 'EFO_0000574', 'EFO_0000178', 'EFO_0003860', 'EFO_0007362', 'EFO_0005570', 'EFO_0002916', 'MONDO_0021063', 'EFO_0005088', 'EFO_0000503', 'EFO_0002938', 'EFO_0000571', 'EFO_0006352', 'EFO_0000707', 'EFO_0003897', 'MONDO_0002158', 'EFO_0000466', 'EFO_0003060', 'EFO_0002428', 'EFO_0000756', 'EFO_0000198', 'EFO_0000199', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0003865', 'EFO_0000702', 'MONDO_0002367', 'EFO_0001663', 'EFO_0000637', 'EFO_0002618', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0018364', 'EFO_0008528', 'EFO_0000305', 'EFO_0003893', 'EFO_0006911', 'EFO_0004284', 'HP_0012378', 'MONDO_0007254', 'MONDO_0001056', 'EFO_0000228', 'MONDO_0011962', 'EFO_0000691', 'EFO_0000196', 'MONDO_0007576', 'EFO_0000564', 'EFO_0005950', 'MONDO_0001475', 'EFO_1000601', 'MONDO_0021355', 'MONDO_0004669', 'EFO_0000182', 'EFO_0000708', 'EFO_0001075', 'EFO_0005577', 'MONDO_0003199', 'EFO_1001100', 'EFO_1001931', 'EFO_1001214', 'EFO_0004252', 'EFO_0003859', 'EFO_1000595', 'EFO_0001378', 'MONDO_0001402']",116.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1996.0,CHEMBL92,['docetaxel'],,['59809'],['https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop'],,,,
CHEMBL405130,COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC,HOZUXBLMYUPGPZ-UHFFFAOYSA-N,Small molecule,False,WHI-P131,1.0,False,False,[],"['JANEX-1', 'Janex 1', 'WHI-P131', 'Whi-p131']",['CHEMBL555201'],Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000105639'],1,,,,,,,,,,
CHEMBL411907,C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C,QIUASFSNWYMDFS-NILGECQDSA-N,Small molecule,False,SONOLISIB,2.0,False,False,[],"['PX-866', 'Px-866', 'Sonolisib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB12601'],"['MONDO_0004992', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000519']",4.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,['65345'],,,,,
CHEMBL41306,CSc1cccc(N(C)C(=N)Nc2cc(SC)ccc2Cl)c1,JHVHEDNLONERHY-UHFFFAOYSA-N,Small molecule,False,CNS-5161,-1.0,False,False,[],"['Cns 5161', 'Cns-5161']",['CHEMBL1079972'],Small molecule drug.,,['DB05824'],,,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL4594357,,,Antibody,False,IANALUMAB,3.0,False,False,[],"['Ianalumab', 'NVP-VAY736', 'VAY-736', 'VAY736', 'Vay736']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,,"['EFO_0000768', 'EFO_0005809', 'EFO_0000699', 'EFO_0005676', 'EFO_1001264', 'EFO_0000685', 'MONDO_0018906', 'MONDO_0005301', 'EFO_1001469', 'EFO_1000630', 'EFO_0000616', 'EFO_0007160', 'EFO_0000095', 'MONDO_0007915', 'EFO_0000403', 'EFO_0004719', 'EFO_0005761']",17.0,['ENSG00000159958'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/IANALUMAB/relevant/1/'],,,
CHEMBL61780,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO,TUYWTLTWNJOZNY-UHFFFAOYSA-N,Small molecule,False,TEZOSENTAN,3.0,False,False,['Veletri'],"['ACT-050089', 'Ro 61-0612', 'Ro-610612', 'Tezosentan']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,['Tezosentan'],['DB06558'],"['EFO_0001361', 'EFO_0003144']",2.0,"['ENSG00000136160', 'ENSG00000151617']",2,,,,,,,,,,
CHEMBL655,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,DDLIGBOFAVUZHB-UHFFFAOYSA-N,Small molecule,True,MIDAZOLAM,4.0,False,True,"['Midazolam in 0.8% sodium chloride', 'Midazolam in 0.9% sodium chloride', 'Nayzilam']","['Midazolam', 'Midazolam civ', 'USL-261', 'USL261']","['CHEMBL2106922', 'CHEMBL1200420']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 112 investigational indications. This drug has a black box warning from the FDA.,['Midazolam'],['DB00683'],"['EFO_0009686', 'EFO_0005741', 'MONDO_0043510', 'HP_0000083', 'EFO_1001413', 'EFO_1001884', 'EFO_0000685', 'EFO_0003929', 'EFO_0001073', 'MONDO_0002050', 'MONDO_0004992', 'EFO_0009854', 'EFO_0000544', 'EFO_0000384', 'EFO_0007157', 'EFO_0006834', 'EFO_0004272', 'EFO_0008525', 'MONDO_0002009', 'EFO_1002048', 'EFO_0007328', 'HP_0000989', 'EFO_0003869', 'MONDO_0002009', 'EFO_0003914', 'EFO_0009708', 'EFO_0003103', 'EFO_0003890', 'MONDO_0004985', 'EFO_1000049', 'MONDO_0005148', 'MONDO_0005148', 'EFO_0000616', 'EFO_0005251', 'EFO_1001494', 'EFO_1001454', 'EFO_0003144', 'HP_0030833', 'EFO_0003060', 'EFO_0003854', 'EFO_0000701', 'EFO_0000545', 'EFO_0004242', 'EFO_0000546', 'EFO_0006911', 'EFO_0009267', 'EFO_0005230', 'EFO_0001422', 'EFO_0000756', 'MONDO_0044970', 'MONDO_0011719', 'EFO_0000537', 'HP_0002140', 'EFO_0000095', 'HP_0001250', 'HP_0012532', 'EFO_0004888', 'EFO_0003015', 'MONDO_0018076', 'MONDO_0011382', 'EFO_1001884', 'EFO_0003768', 'EFO_0000676', 'HP_0001623', 'EFO_0000662', 'EFO_1001328', 'HP_0011110', 'MONDO_0002050', 'EFO_1001249', 'MONDO_0005129', 'EFO_0001378', 'EFO_0004320', 'MONDO_0007606', 'EFO_1001454', 'EFO_0002617', 'EFO_0003931', 'EFO_0009513', 'EFO_0003047', 'EFO_0000588', 'MONDO_0007254', 'HP_0100806', 'EFO_0004220', 'MONDO_0004975', 'MONDO_0005180', 'EFO_0002610', 'MONDO_0004976', 'EFO_0000274', 'HP_0012076', 'EFO_0000274', 'EFO_0003758', 'MONDO_0100096', 'EFO_0000713', 'EFO_0001068', 'EFO_0003863', 'HP_0003419', 'EFO_0000764', 'EFO_0000616', 'EFO_0000319', 'EFO_0008526', 'HP_0000726', 'EFO_0000222', 'EFO_0003843', 'EFO_0004239', 'EFO_0005411', 'EFO_0000618', 'EFO_0000474', 'EFO_0008526', 'MONDO_0005090', 'MONDO_0004985', 'EFO_0005952', 'EFO_0005762', 'EFO_0000729', 'MP_0001914', 'MONDO_0018076', 'EFO_0001065', 'MONDO_0008315', 'EFO_0001358', 'EFO_0000673', 'HP_0000023', 'HP_0012735']",120.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1985.0,,['midazolam'],['50113067'],['6931'],,,,,
CHEMBL821,N=C(N)N,ZRALSGWEFCBTJO-UHFFFAOYSA-N,Small molecule,False,GUANIDINE,4.0,False,True,[],['Guanidine'],"['CHEMBL1200728', 'CHEMBL3187576']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 3 approved and 2 investigational indications.,['Guanidine'],['DB00536'],"['EFO_0009708', 'EFO_0008524', 'EFO_1001901', 'HP_0001324', 'EFO_0004991']",5.0,"['ENSG00000053918', 'ENSG00000171385', 'ENSG00000055118', 'ENSG00000177301', 'ENSG00000111262', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000104848', 'ENSG00000185760', 'ENSG00000117013', 'ENSG00000143473', 'ENSG00000182255', 'ENSG00000130037', 'ENSG00000177272', 'ENSG00000151079', 'ENSG00000129159', 'ENSG00000184408', 'ENSG00000182674', 'ENSG00000116396', 'ENSG00000131398', 'ENSG00000158445', 'ENSG00000143105', 'ENSG00000164794', 'ENSG00000140015', 'ENSG00000171126', 'ENSG00000168418', 'ENSG00000168263', 'ENSG00000124134', 'ENSG00000183960', 'ENSG00000166006', 'ENSG00000170745', 'ENSG00000173826', 'ENSG00000162975', 'ENSG00000184611', 'ENSG00000102057', 'ENSG00000026559', 'ENSG00000178342', 'ENSG00000135519', 'ENSG00000156486', 'ENSG00000089558']",40,1939.0,,,,['42820'],,,,,
CHEMBL944,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl.Cl,SZKQYDBPUCZLRX-UHFFFAOYSA-N,Small molecule,False,CHLOROPROCAINE HYDROCHLORIDE,4.0,False,True,"['Ampres', 'Chloroprocaine hydrochloride', 'Clorotekal', 'Nesacaine', 'Nesacaine-mpf']","['Chloroprocaine HCl', 'Chloroprocaine hcl', 'Chloroprocaine hydrochloride', 'Chlorprocaine chloride', 'Iheezo']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and has 1 investigational indication.,,,['EFO_0003843'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1955.0,CHEMBL1179047,['chloroprocaine%20hydrochloride'],['144206478'],['3637'],,,,,
CHEMBL1275868,CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1,ZKFQEACEUNWPMT-UHFFFAOYSA-N,Small molecule,False,AZELNIDIPINE,3.0,False,False,[],"['Azelnidipine', 'Calblock']",,Small molecule drug with a maximum clinical trial phase of III.,,['DB09230'],,,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,"['144205993', '170465756', '174006618', '50112690']",,,,,,
CHEMBL2108356,,,Protein,False,PEGDINETANIB,2.0,False,False,[],"['Angiocept', 'BMS-844203', 'CT-322', 'Ct-322', 'Pegdinetanib', 'VEGFR-2 INHIBITOR PEPTIDE CT-322']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0003060', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000519', 'EFO_0000365']",5.0,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL2109259,,,Antibody,False,IGN-101,3.0,False,False,[],['IGN-101'],,Antibody drug with a maximum clinical trial phase of III.,,,,,['ENSG00000119888'],1,,,,,,,,,,
CHEMBL270995,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1,LTEJRLHKIYCEOX-OCCSQVGLSA-N,Small molecule,False,BRIVANIB ALANINATE,3.0,False,False,[],"['BMS-582664', 'BMS-582664-02', 'Brivanib alaninate', 'Brivanib l-alanine ester']",['CHEMBL3526472'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,['DB11865'],"['MONDO_0004992', 'EFO_0000182', 'EFO_0000681', 'EFO_0000616', 'EFO_1001951']",5.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",7,,,,,,,,,,
CHEMBL3184799,CNC(C)(C)Cc1ccccc1.CNC(C)(C)Cc1ccccc1.O=S(=O)(O)O,DNKCFBJMFIUNRS-UHFFFAOYSA-N,Small molecule,False,MEPHENTERMINE SULFATE,4.0,False,True,['Wyamine sulfate'],"['Mephentermine sulfate', 'Mephentermine sulfate dihydrate', 'Mephentermine sulphate', 'Mephine', 'NSC-758424', 'Wyamine', 'Wyamine sulphate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951.,,,,,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1951.0,CHEMBL1201234,,"['144204052', '170465271']",,,,,,
CHEMBL425,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O,QQBDLJCYGRGAKP-FOCLMDBBSA-N,Small molecule,False,OLSALAZINE,4.0,False,True,[],"['C. i. mordant yellow 5', 'Dipentum', 'Olsalazine']",['CHEMBL1201013'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for ulcerative colitis and has 1 investigational indication.,,['DB01250'],"['EFO_0003898', 'EFO_0000729']",2.0,"['ENSG00000012779', 'ENSG00000132170', 'ENSG00000073756', 'ENSG00000095303']",4,1990.0,,,['50125747'],,,,,,
CHEMBL4297892,,,Antibody drug conjugate,False,ANVATABART OPADOTIN,2.0,False,False,[],"['ARX-788', 'ARX788', 'ARX788 ADC', 'Anvatabart opadotin', 'Anvatabart opafidotin', 'Arx 788', 'Arx-788', 'Arx788']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0000616', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0003968', 'EFO_0003869', 'EFO_0005537']",6.0,"['ENSG00000141736', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ANVATABART%20OPADOTIN/relevant/1/'],,,['https://www.who.int/publications/m/item/inn-pl-127']
CHEMBL4594272,Cl.Cl.N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1,XFZLBLTUANGZBD-UHFFFAOYSA-N,Small molecule,False,BEROTRALSTAT HYDROCHLORIDE,4.0,False,True,['Orladeyo'],"['BCX7353.2HCl', 'Berotralstat dihydrochloride', 'Berotralstat hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hereditary angioedema and has 1 investigational indication.,,,"['EFO_0005532', 'MONDO_0019623']",2.0,['ENSG00000164344'],1,2020.0,CHEMBL4594271,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo'],['https://searchusan.ama-assn.org/finder/usan/search/BEROTRALSTAT%20HYDROCHLORIDE/relevant/1/'],,,
CHEMBL1237022,,,Antibody,True,TOCILIZUMAB,4.0,False,True,"['Actemra', 'Actemra roactemra', 'Roactemra']","['ATLIZUMAB', 'Actemra', 'BAT-1806', 'BAT1806', 'Bat1806', 'MRA', 'MSB-11456', 'MSB11456', 'R-1569', 'RG-1569', 'RHPM-1', 'RO-4877533', 'Tocilizumab', 'Tocilizumab biosimilar (bat-1806)', 'Tocilizumab biosimilar (msb11456)']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 6 approved and 67 investigational indications. This drug has a black box warning from the FDA.,['Tocilizumab'],,"['EFO_0000616', 'EFO_1001513', 'EFO_0000565', 'MONDO_0000845', 'EFO_0000540', 'EFO_0000095', 'EFO_1000926', 'EFO_0000222', 'EFO_0000702', 'EFO_0007328', 'EFO_0000094', 'EFO_0003818', 'EFO_0008586', 'EFO_0003780', 'EFO_0000685', 'EFO_1000986', 'EFO_1001469', 'EFO_0000474', 'EFO_0004256', 'HP_0001945', 'EFO_0008518', 'EFO_0007135', 'EFO_0008528', 'EFO_0004991', 'EFO_1000637', 'EFO_1001165', 'MONDO_0007915', 'EFO_0007541', 'EFO_0000519', 'EFO_0003106', 'MONDO_0005147', 'MONDO_0007254', 'MONDO_0015564', 'EFO_0001378', 'EFO_1001119', 'EFO_1001231', 'EFO_0000717', 'EFO_1001951', 'EFO_0000673', 'EFO_1001148', 'EFO_0000403', 'EFO_0000764', 'EFO_0000694', 'EFO_1001806', 'MONDO_0013730', 'EFO_0002609', 'EFO_0003060', 'MONDO_0002009', 'EFO_0000756', 'MONDO_0004976', 'EFO_0000220', 'EFO_0003898', 'EFO_0000398', 'EFO_1001209', 'MONDO_0008170', 'EFO_0000182', 'MONDO_0044881', 'EFO_1001857', 'MONDO_0005090', 'MONDO_0018088', 'EFO_0002618', 'EFO_0000574', 'EFO_1001466', 'EFO_0001361', 'EFO_0004599', 'EFO_0000096', 'MONDO_0001187', 'EFO_0005952', 'MONDO_0018906', 'EFO_0003884', 'MONDO_0100096', 'EFO_0009730', 'MONDO_0015540']",73.0,['ENSG00000160712'],1,2005.0,,['tocilizumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra'],,,['4933'],
CHEMBL2108752,,,Unknown,False,PEGAPTANIB OCTASODIUM,3.0,False,False,[],['Pegaptanib octasodium'],,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0004683'],1.0,['ENSG00000112715'],1,,,,,,,,,['4905'],
CHEMBL2109205,,,Protein,False,COAGULATION FACTOR IX RECOMBINANT HUMAN,4.0,False,True,"['Benefix', 'Rixubis']","['Coagulation factor ix recombinant human', 'Factor ix,recombinant', 'Nonacog alfa', 'Nonacog gamma', 'Recombinant factor ix']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for hemophilia b.,,,['MONDO_0010604'],1.0,['ENSG00000101981'],1,1997.0,,,,,"['https://www.ema.europa.eu/en/medicines/human/EPAR/benefix', 'https://www.ema.europa.eu/en/medicines/human/EPAR/rixubis']",,,['5163'],
CHEMBL2109390,,,Antibody,False,MAB-425,2.0,False,False,[],"['MAB-425', 'Mab-425']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000326'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL2109449,,,Antibody,False,MEDI-570,1.0,False,False,[],"['MEDI-570', 'Medi 570', 'Medi-570']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0007915'],1.0,['ENSG00000163600'],1,,,,,,,,,,
CHEMBL3545147,,,Small molecule,False,IMD-2560,1.0,False,False,[],['Imd-2560'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000104365'],1,,,,,,,,,,
CHEMBL3545359,,,Small molecule,False,ARRY-300,1.0,False,False,[],"['Arry-300', 'MET-300']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL3707266,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1.O=C(O)CCC(=O)O,NHANOMFABJQAAH-UHFFFAOYSA-N,Small molecule,False,RIBOCICLIB SUCCINATE,4.0,False,True,['Kisqali'],"['Birociclib', 'LEE-011-BBA', 'LEE011-BBA', 'Ribociclib succinate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved indications.,,,"['EFO_0000305', 'EFO_0003869', 'EFO_0000616', 'MONDO_0007254']",4.0,"['ENSG00000135446', 'ENSG00000105810']",2,2017.0,CHEMBL3545110,['ribociclib%20succinate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali'],,,,
CHEMBL3989988,,,Antibody,False,MODOTUXIMAB,3.0,False,False,[],"['1024 DS', '1024-DS', 'Modotuximab', 'Zatuximab']",,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL406381,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,VPBYZLCHOKSGRX-UHFFFAOYSA-N,Small molecule,False,KRN-633,1.0,False,False,[],"['K00589A', 'KRN-633', 'KRN633', 'Krn-633']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,,,,['174006598'],,,,,,
CHEMBL1201583,,,Antibody,False,BEVACIZUMAB,4.0,False,True,"['Avastin', 'Mvasi']","['12-IGG1', 'AVA-1', 'Abp-215', 'Alymsys', 'BAT-1706', 'BEVZ-92', 'BEVZ92', 'BI 695502', 'BI695502', 'BS-503A', 'Bat 1706', 'Bat1706', 'Bevacizumab', 'Bevacizumab (avastin)', 'Bevacizumab adcd', 'Bevacizumab awwb', 'Bevacizumab beta', 'Bevacizumab biosimilar (abp-215)', 'Bevacizumab biosimilar (amgen)', 'Bevacizumab biosimilar (fkb-238)', 'Bevacizumab biosimilar (pfizer)', 'Bevacizumab bvzr', 'Bevacizumab maly', 'Bevacizumab-adcd', 'Bevacizumab-awwb', 'Bevacizumab-bvzr', 'Bevacizumab-maly', 'Bevax', 'Bi-695502', 'Bs-503', 'Byvasda', 'CHS-5217', 'CT-16', 'CT-P16', 'CT-P16 (BIOSIMILAR OF BEVACIZUMAB)', 'Ct p16', 'Ct-16', 'Ct-p16', 'FKB-238', 'Fkb 238', 'Fkb238', 'HLX-04', 'HLX04', 'Hlx 04', 'Ibi-305', 'Ibi305', 'LY 01008', 'LY-01008', 'MB-02', 'Mvasi', 'Oyavas', 'PF-06439535', 'Pf-06439535', 'Q-1101', 'Q1101', 'R-435', 'RG-435', 'RHUMAB-', 'RHUMAB-VEGF', 'RO-4876646', 'Usp mab 002, monoclonal igg1', 'Vegzelma', 'Zirabev']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 29 approved and 174 investigational indications.,['Bevacizumab'],,"['MONDO_0001056', 'MONDO_0005184', 'EFO_0003050', 'EFO_1000613', 'EFO_0000174', 'EFO_1000796', 'EFO_0006859', 'EFO_0003828', 'MONDO_0002158', 'MONDO_0008903', 'HP_0009588', 'MONDO_0004992', 'EFO_0003016', 'EFO_1000052', 'MONDO_0002363', 'EFO_0007224', 'MONDO_0018364', 'MONDO_0100342', 'EFO_0002893', 'EFO_0001061', 'EFO_0002618', 'EFO_1000783', 'EFO_1001100', 'EFO_0003869', 'EFO_0009708', 'EFO_0003106', 'EFO_0003884', 'EFO_0009637', 'EFO_0000182', 'EFO_0008528', 'EFO_0004243', 'MONDO_0003060', 'EFO_0003060', 'EFO_1001187', 'MONDO_0001187', 'EFO_0000756', 'EFO_0000698', 'EFO_1000158', 'EFO_0000349', 'MONDO_0011719', 'MONDO_0001280', 'EFO_0000770', 'MONDO_0020634', 'EFO_1000657', 'MONDO_0003005', 'EFO_0009606', 'EFO_0000630', 'EFO_1001231', 'EFO_0000571', 'EFO_0005537', 'EFO_1001465', 'EFO_0000678', 'HP_0001541', 'EFO_0000095', 'EFO_1000895', 'EFO_1000984', 'MONDO_0024677', 'EFO_0005577', 'EFO_0000305', 'EFO_0002087', 'EFO_0000632', 'EFO_0001416', 'EFO_0002892', 'MONDO_0001576', 'EFO_0000198', 'EFO_1000581', 'EFO_0000694', 'EFO_0000673', 'EFO_0000564', 'MONDO_0018906', 'MONDO_0009937', 'EFO_0000588', 'MONDO_0011962', 'EFO_1001951', 'MONDO_0044903', 'EFO_0000707', 'MONDO_0008315', 'EFO_0000365', 'EFO_1001949', 'EFO_0009448', 'MONDO_0002087', 'MONDO_0003268', 'MONDO_0002691', 'EFO_0003833', 'EFO_0005543', 'EFO_0000503', 'EFO_0004212', 'EFO_0002499', 'EFO_0004284', 'EFO_0002617', 'EFO_1001111', 'EFO_0005753', 'EFO_0004264', 'MONDO_0044937', 'MP_0001914', 'EFO_0000335', 'MONDO_0005575', 'EFO_0000640', 'MONDO_0002989', 'MONDO_0002108', 'EFO_0007532', 'MONDO_0019472', 'EFO_0000519', 'EFO_1001961', 'MONDO_0007254', 'EFO_0000574', 'EFO_0001376', 'EFO_0000248', 'EFO_0001365', 'EFO_1000043', 'EFO_0000621', 'EFO_0001642', 'EFO_0001065', 'MONDO_0002120', 'EFO_0004683', 'EFO_0000183', 'EFO_0000348', 'EFO_0002916', 'EFO_0002918', 'EFO_0006772', 'EFO_0002939', 'EFO_0000569', 'EFO_0005773', 'EFO_0000313', 'MONDO_0016700', 'EFO_0000339', 'EFO_1001471', 'EFO_0005952', 'EFO_1000809', 'EFO_0000096', 'EFO_0007143', 'EFO_0007416', 'EFO_0005221', 'EFO_1001158', 'EFO_0000272', 'MP_0001845', 'EFO_0001075', 'EFO_1001469', 'EFO_1001968', 'EFO_0009784', 'EFO_1000475', 'EFO_1000026', 'EFO_1001157', 'MONDO_0008170', 'EFO_0000232', 'EFO_0000514', 'EFO_0004252', 'EFO_0003839', 'MONDO_0001657', 'EFO_0005567', 'MONDO_0021632', 'MONDO_0016642', 'EFO_0000389', 'EFO_0000681', 'MONDO_0005041', 'EFO_1000028', 'EFO_0000228', 'EFO_0000558', 'EFO_0000403', 'EFO_0004251', 'EFO_1000823', 'MONDO_0018271', 'EFO_0010282', 'MONDO_0100096', 'EFO_0000466', 'MONDO_0018092', 'MONDO_0008667', 'EFO_0001378', 'EFO_0006861', 'EFO_1001901', 'EFO_0003893', 'EFO_0003770', 'EFO_1001512', 'EFO_1001513', 'EFO_0000691', 'EFO_1000251', 'MONDO_0007576', 'EFO_0000565', 'EFO_0004142', 'EFO_0000178', 'MONDO_0005835', 'MONDO_0019297', 'EFO_0003860', 'MONDO_0007935', 'MONDO_0021063', 'EFO_0004256', 'HP_0000545', 'EFO_0003968', 'EFO_0000196', 'EFO_0000760', 'MONDO_0019180', 'MONDO_0002974', 'EFO_0000702', 'EFO_0008626', 'EFO_0000181', 'MONDO_0002367', 'MONDO_0005411', 'EFO_0004288', 'EFO_0002501', 'EFO_0000616', 'MONDO_0043510', 'EFO_1000880', 'EFO_0000326']",203.0,['ENSG00000112715'],1,2004.0,,"['bevacizumab', 'bevacizumab-awwb', 'bevacizumab-bvzr']",,,['https://www.ema.europa.eu/en/medicines/human/EPAR/mvasi'],,,['4956'],
CHEMBL1428,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,Small molecule,True,NIMODIPINE,4.0,False,True,"['Nimodipine', 'Nimotop', 'Nymalize']","['Admon', 'BAY E 9736', 'BAY-E-9736', 'NSC-758476', 'Nemotan', 'Nimodipine', 'Nimodipine ap', 'Periplum']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for cardiovascular disease and has 10 investigational indications. This drug has a black box warning from the FDA.,['Nimodipine'],['DB00393'],"['EFO_0002610', 'EFO_0003763', 'EFO_0000712', 'EFO_0008546', 'EFO_0003870', 'EFO_0000319', 'HP_0009588', 'MONDO_0005090', 'EFO_0009846', 'EFO_0000545', 'EFO_0000713']",11.0,"['ENSG00000151623', 'ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",5,1988.0,,['nimodipine'],"['104171194', '124880812', '124880816', '144203753', '170466561', '26747118', '26747119', '26747120', '26751792', '26751793', '50104485', '50104486', '50104487', '85231145', '90340912']",['7575'],,,,,
CHEMBL2103869,O=C(O)[C@@H]1C[C@H]2C[C@@H](Oc3cccc(Cl)c3-c3nnn[nH]3)CC[C@H]2CN1,LAKQPSQCICNZII-NOHGZBONSA-N,Small molecule,False,DASOLAMPANEL,2.0,False,False,[],"['Dasolampanel', 'NGX426']",['CHEMBL3088054'],Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000171189', 'ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",5,,,,,,,,,,
CHEMBL2103884,COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1,SWZXEVABPLUDIO-WSZYKNRRSA-N,Small molecule,False,OPROZOMIB,2.0,False,False,[],"['ONX 0912', 'ONX-0912', 'Oprozomib', 'Pr-047']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB11991'],"['EFO_0000616', 'EFO_0000182', 'MONDO_0004992', 'EFO_0009441', 'EFO_0001378']",5.0,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']",38,,,,,,,,,,
CHEMBL2106468,CCN(CC)C(=O)CNC(=O)c1cc(OC)c(OC)c(OC)c1,NLRFFZRHTICQBO-UHFFFAOYSA-N,Small molecule,False,TRICETAMIDE,1.0,False,False,[],"['R-548', 'Tricetamide']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000105639', 'ENSG00000162434']",2,,,,,,,,,,
CHEMBL2109388,,,Antibody,False,FUTUXIMAB,3.0,False,False,[],"['992 DS', '992-DS', 'Futuximab', 'SYM-004', 'Sym004']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['MONDO_0100342', 'EFO_0000616', 'EFO_0000707', 'EFO_0003060']",4.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL2110725,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,NMDYYWFGPIMTKO-KLCPSUAYSA-N,Small molecule,False,VINFLUNINE,4.0,False,True,[],['Vinflunine'],['CHEMBL2105629'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 15 investigational indications.,,['DB11641'],"['MONDO_0001056', 'MONDO_0004992', 'EFO_0008528', 'EFO_0000702', 'EFO_1001094', 'MONDO_0007254', 'EFO_0000616', 'EFO_0003060', 'MONDO_0002038', 'MONDO_0008903', 'EFO_1000601', 'MONDO_0001187', 'MONDO_0004986', 'EFO_0003863', 'MONDO_0008315']",15.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,2009.0,,,,['90241'],,,,,
CHEMBL281398,CC(C)(C)N/C(=N\C#N)Nc1cccc(/C(=C\CCCC(=O)O)c2cccnc2)c1,XUTLOCQNGLJNSA-RGVLZGJSSA-N,Small molecule,False,TERBOGREL,2.0,False,False,[],"['BIBV 308 SE', 'BIBV-308-SE', 'BIBV-308SE', 'Terbogrel']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,['Terbogrel'],['DB12204'],['EFO_0001361'],1.0,"['ENSG00000059377', 'ENSG00000006638']",2,,,,,,,,,,
CHEMBL3787344,Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,IOMMMLWIABWRKL-WUTDNEBXSA-N,Small molecule,False,NAZARTINIB,2.0,False,False,[],"['EGF-816', 'EGF816', 'Egf816', 'NVP-EGF816-NX', 'Nazartinib']","['CHEMBL4297222', 'CHEMBL3984979']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000616', 'MONDO_0008903', 'EFO_1000849', 'EFO_0003060']",4.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL3989844,C[C@H](N)Cc1ccccc1.O=C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O,VHKVKWTWHZUFIA-DGOKBZBKSA-N,Small molecule,False,DEXTROAMPHETAMINE SACCHARATE,4.0,False,True,[],"['D-amphetamine saccharate', 'Dexamfetamine hemisaccharate', 'Dexamfetamine saccharate', 'Dexamfetaphine saccharate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome.,,,"['EFO_0003888', 'MONDO_0016158']",2.0,"['ENSG00000142319', 'ENSG00000165646', 'ENSG00000103546']",3,1996.0,CHEMBL612,['dextroamphetamine%20saccharate'],,,,,,,
CHEMBL4297615,CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,Small molecule,False,PARSACLISIB,3.0,False,False,[],"['INCB-050465', 'INCB050465', 'Incb050465', 'Parsaclisib']",['CHEMBL4298155'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.,,['DB14867'],"['EFO_0000574', 'EFO_0000211', 'MONDO_0000430', 'EFO_0004719', 'MONDO_0007254', 'EFO_0000616', 'EFO_1001264', 'EFO_0000756', 'MONDO_0011962', 'EFO_0000095', 'EFO_0000403', 'EFO_0004251', 'EFO_0000616', 'MONDO_0018906', 'MONDO_0004992', 'EFO_1001469', 'EFO_0000096', 'EFO_0000699']",18.0,['ENSG00000171608'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PARSACLISIB/relevant/1/'],,,
CHEMBL1743053,,,Antibody,False,OTELIXIZUMAB,3.0,False,False,[],"['CHAGLY CD3', 'CHAGLYCD-3', 'ChAglyCD', 'Chaglycd3', 'Otelixizumab', 'TRX-4', 'TRX4']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['MONDO_0005147', 'EFO_1001466', 'EFO_0000685']",3.0,['ENSG00000198851'],1,,,,,,,,,,
CHEMBL2146102,CN[C@@H](C)[C@H](O)c1ccccc1.Cl,BALXUFOVQVENIU-GNAZCLTHSA-N,Small molecule,False,EPHEDRINE HYDROCHLORIDE,4.0,False,True,"['Amesec', 'Asmapax', 'Bronchipax', 'C.a.m.', 'Do-do', 'Ephed hcl', 'Ephed in nor saline', 'Expurhin', 'Franol', 'Haymine', 'Rezipres', 'Secron', 'Tabasan', 'Taumasthman', 'Tedral', 'Tedral sa']","['(-)-ephedrine hydrochloride', 'Ephedrine hcl', 'Ephedrine hydrochloride', 'Ephedrini hydrochloridum', 'L-ephedrine hydrochloride', 'NSC-759611']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 5 approved indications.,,,"['HP_0001742', 'EFO_0005251', 'EFO_0007214', 'EFO_0003956', 'MONDO_0004979']",5.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,2021.0,CHEMBL211456,,"['144204863', '170465509']",,,,,,
CHEMBL278819,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1,LDMWSLGGVTVJPG-UHFFFAOYSA-N,Small molecule,False,MINAPRINE,4.0,True,True,[],"['AGR-1240', 'Brantur', 'CB-30038', 'Cantor', 'Minaprine']","['CHEMBL536932', 'CHEMBL1364551']",Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression. It was withdrawn in at least one region.,['Minaprine'],['DB00805'],['EFO_0003761'],1.0,"['ENSG00000168539', 'ENSG00000149295', 'ENSG00000184845', 'ENSG00000135914', 'ENSG00000102468', 'ENSG00000147246', 'ENSG00000087085', 'ENSG00000189221']",8,,,,['11112706'],['51038'],,,,,
CHEMBL338604,CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23,CUNDRHORZHFPLY-UHFFFAOYSA-N,Small molecule,False,C-1311,2.0,False,False,[],['NSC-645809'],"['CHEMBL3545337', 'CHEMBL2002951']",Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000122025', 'ENSG00000131747', 'ENSG00000077097']",3,,,,,,,,,,
CHEMBL3545401,,,Small molecule,False,X-82,2.0,False,False,[],['X-82'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0001365', 'EFO_0000228', 'EFO_0003860', 'EFO_0000616']",4.0,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",5,,,,,,,,,,
CHEMBL3580737,CCS(=O)(=O)c1ccc(Oc2cc(O[C@@H](C)CO)cc(C(=O)Nc3ccn(C)n3)c2)cn1,KJSGTWFWVTYPFZ-AWEZNQCLSA-N,Small molecule,False,MK-0941,2.0,False,False,[],[],['CHEMBL4297302'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005148'],1.0,['ENSG00000106633'],1,,,,,,,,,,
CHEMBL4297593,CONC(=N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)c2cc(Cl)cc(OC(F)F)c2)cc1,XSNMGLZVFNDDPW-ZWKOTPCHSA-N,Small molecule,False,ATECEGATRAN METOXIL,2.0,False,False,[],"['AZD-0837', 'AZD0837', 'Atecegatran fexenetil', 'Atecegatran metoxil', 'Azd 0837', 'Azd0837']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12507'],['EFO_0000275'],1.0,['ENSG00000180210'],1,,,,,,,,,,
CHEMBL4650214,CN1CCC(c2ccccc2CC(C)(C)Nc2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,WPFUFWIHMYZXSF-UHFFFAOYSA-N,Small molecule,False,ZANDELISIB,3.0,False,False,[],"['ACC-524', 'ME-401', 'Me-401', 'PW-143', 'PWT-143', 'PWT143', 'Pwt-143', 'Zandelisib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,,"['EFO_0000096', 'EFO_0000403', 'EFO_0004289', 'MONDO_0004992', 'EFO_1001469', 'MONDO_0018906', 'EFO_0000095']",7.0,['ENSG00000171608'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ZANDELISIB/relevant/1/'],,,
CHEMBL640,CCN(CC)CCNC(=O)c1ccc(N)cc1,REQCZEXYDRLIBE-UHFFFAOYSA-N,Small molecule,True,PROCAINAMIDE,4.0,False,True,[],"['NSC-27461', 'Novocainamide', 'Procainamide', 'Procan', 'Procanbid', 'Procapan', 'Pronestyl', 'Pronestyl-SR', 'Sp 100 (pharmaceutical)']",['CHEMBL605'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 5 investigational indications. This drug has a black box warning from the FDA.,['Procainamide'],['DB01035'],"['EFO_0004278', 'HP_0004308', 'EFO_0000612', 'EFO_0004269', 'EFO_0003144', 'EFO_0004287', 'EFO_0000275', 'EFO_0000275', 'EFO_0004269']",9.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1950.0,,,"['11111690', '11111691', '144203797', '170464952', '26751611', '90340905']",['8428'],,,,,
CHEMBL11,CN(C)CCCN1c2ccccc2CCc2ccccc21,BCGWQEUPMDMJNV-UHFFFAOYSA-N,Small molecule,True,IMIPRAMINE,4.0,False,True,[],"['Antideprin', 'Berkomine', 'Cristalia', 'Imipramine', 'Janimine', 'Melipramine', 'NSC-169866', 'ORG-2463', 'Pramine', 'Presamine', 'Sermonil', 'Tofranil', 'Tofranil-PM', 'Trimipramine maleate impurity, imipramine-']","['CHEMBL3989845', 'CHEMBL1692']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA.,['Imipramine'],['DB00458'],"['MONDO_0002050', 'HP_0100749', 'EFO_0003761', 'EFO_0000519', 'EFO_0005230', 'EFO_0009687', 'EFO_0004278', 'EFO_0003948', 'MONDO_0024290', 'EFO_0004287', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0008623', 'HP_0010992', 'MONDO_0007254', 'HP_0000726', 'EFO_0000612', 'EFO_0002496', 'HP_0003419', 'EFO_0010282']",20.0,"['ENSG00000108576', 'ENSG00000103546']",2,1959.0,,,"['104171178', '11111330', '11111331', '124880469', '144203725', '170464777', '26751600', '50100256', '50104254', '90341377']",['47499'],,,['69'],,
CHEMBL1200776,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl,QANQWUQOEJZMLL-PKLMIRHRSA-N,Small molecule,False,CINACALCET HYDROCHLORIDE,4.0,False,True,"['Mimpara', 'Sensipar']","['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDE', 'Cinacalcet hcl', 'Cinacalcet hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 1 investigational indication.,,,"['EFO_1001173', 'HP_0003072', 'EFO_0000673', 'EFO_0000313', 'EFO_0003884', 'EFO_1000456', 'EFO_0008506']",7.0,['ENSG00000036828'],1,2004.0,CHEMBL1201284,['cinacalcet%20hydrochloride'],"['144206207', '170465336']",['48391'],['https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara'],,,,
CHEMBL1201262,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,OCUJLLGVOUDECM-UHFFFAOYSA-N,Small molecule,False,DIPIVEFRIN,4.0,False,True,[],"['DPE', 'Dipivalyl epinephrine', 'Dipivefrin', 'Dipivefrine']",['CHEMBL1200833'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for glaucoma.,['Dipivefrine'],['DB00449'],['MONDO_0005041'],1.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1980.0,,,,['4646'],,,,,
CHEMBL1201513,,,Oligosaccharide,False,HEPARIN CALCIUM,4.0,False,True,"['Calciparine', 'Uniparin ca']","['Ecasolv', 'Heparin calcium', 'Heparin calcium salt', 'Heparinum calcicum']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 2 investigational indications.,,,"['EFO_1000954', 'EFO_1000965']",2.0,['ENSG00000117601'],1,1982.0,,,,,,,,,
CHEMBL1722,COC(=O)C(c1ccccc1)C1CCCCN1.Cl,JUMYIBMBTDDLNG-UHFFFAOYSA-N,Small molecule,True,METHYLPHENIDATE HYDROCHLORIDE,4.0,False,True,"['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xl', 'Jornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cd', 'Metadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochloride', 'Quillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin la', 'Ritalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']","['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HCl', 'Methylphenidate hcl', 'Methylphenidate hydrochloride', 'Methylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'Quillichew', 'Quillivant', 'SPD-544', 'SPD544']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and has 10 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003888', 'MONDO_0005090', 'EFO_0008568', 'EFO_0004216', 'MONDO_0004992', 'HP_0012378', 'EFO_0003840', 'MONDO_0011184', 'EFO_0003929', 'EFO_0003768', 'MONDO_0002050']",11.0,"['ENSG00000103546', 'ENSG00000142319']",2,1955.0,CHEMBL796,['methylphenidate%20hydrochloride'],"['144204737', '144207507', '17389819']",['31836'],,,,,
CHEMBL1743048,,,Antibody,True,OBINUTUZUMAB,4.0,False,True,['Gazyvaro'],"['AFUTUZUMAB', 'Afutuzumab', 'GA-101', 'GA101', 'Gazyva', 'HUMAB CD20', 'HUMAB<CD20>', 'HUMABCD20', 'Obinutuzumab', 'R-7159', 'RG-7159', 'RO 5072759', 'RO 5072759 HUMAB<CD20>', 'RO-5072759', 'RO-5072759 HUMAB<CD20>', 'Ro5072759']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0005761', 'MONDO_0001023', 'EFO_1000956', 'EFO_0004255', 'EFO_1001469', 'EFO_0005952', 'EFO_1001951', 'EFO_0008528', 'MONDO_0004992', 'EFO_0000574', 'MONDO_0018906', 'EFO_0000565', 'EFO_0009441', 'EFO_0000403', 'MONDO_0007915', 'EFO_0003060', 'MONDO_0013730', 'EFO_1001051', 'EFO_0004236', 'EFO_0003086', 'EFO_0003884', 'EFO_0000309', 'EFO_0000095', 'EFO_0000096', 'EFO_0000183', 'EFO_0000220', 'EFO_0000616']",27.0,['ENSG00000156738'],1,2013.0,,['obinutuzumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro'],,,['4983'],
CHEMBL346631,CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCOC(=O)CN(C)C)Cc1ccccc1-4)C(=O)NC3,UHEBDUAFKQHUBV-UHFFFAOYSA-N,Small molecule,False,CEP-7055,1.0,False,False,[],"['CEP-7055', 'Cep-7055']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,,,,,,,,,,
CHEMBL3545159,,,Small molecule,False,R-333,2.0,False,False,[],['R-333'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0007915'],1.0,"['ENSG00000165025', 'ENSG00000105639']",2,,,,,,,,,,
CHEMBL3990033,,,Oligonucleotide,False,INCLISIRAN,3.0,False,False,[],"['ALN-60212', 'ALN-PCSSC', 'ALN-PSCsc', 'Inclisiran', 'Leqvio']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,,"['HP_0003124', 'EFO_0005672', 'EFO_0004911', 'EFO_0003086', 'EFO_0000319', 'EFO_0003914', 'EFO_0001645', 'MONDO_0021187', 'MONDO_0018328']",9.0,['ENSG00000169174'],1,,,,,,,,,,
CHEMBL4297750,,,Antibody,False,FARICIMAB,4.0,False,True,['Vabysmo'],"['Faricimab', 'Faricimab svoa', 'Faricimab-svoa', 'RG7716', 'RG77161', 'RO-6867461', 'RO6867461', 'Rg-7716', 'Ro6867461', 'Vabysmo', 'Y8ha1i28d3']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 5 approved and 3 investigational indications.,,,"['HP_0000478', 'EFO_0009606', 'MONDO_0007935', 'EFO_0010977', 'EFO_0001365', 'EFO_0005753', 'MONDO_0003005', 'EFO_0004683']",8.0,"['ENSG00000091879', 'ENSG00000112715']",2,2022.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo'],['https://searchusan.ama-assn.org/finder/usan/search/FARICIMAB/relevant/1/'],,,
CHEMBL4303404,Cc1noc2c1-c1ccccc1C(c1ccc(Cl)cc1)=N[C@H]2CC(N)=O,GCWIQUVXWZWCLE-INIZCTEOSA-N,Small molecule,False,PELABRESIB,3.0,False,False,[],"['CPI-0610', 'CPI-232', 'CPI-267232', 'Cpi 0610', 'Cpi-0610', 'Cpi-0610 anhydrous', 'Pelabresib', 'Pelabresib anhydrous', 'Pelabresib monohydrate']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0044903', 'EFO_0002430', 'EFO_0002431', 'EFO_0000574', 'EFO_0001378']",5.0,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PELABRESIB/relevant/1/'],,,
CHEMBL517427,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,FAIIFDPAEUKBEP-UHFFFAOYSA-N,Small molecule,False,NILVADIPINE,3.0,False,False,[],"['CL 287,389', 'CL-287,389', 'CL-287389', 'Dl-nilvadipine', 'Escor', 'FK 235', 'FK-235', 'FR-34235', 'Nilvadipine', 'Nivadil', 'Nivadip', 'Nivadipine', 'SK&F 102,362', 'SKF-102362']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,['Nilvadipine'],['DB06712'],"['MONDO_0004975', 'EFO_0000319']",2.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,"['144205992', '50112689']",,,,,,
CHEMBL1190,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,MTCUAOILFDZKCO-UHFFFAOYSA-N,Small molecule,False,DECAMETHONIUM,4.0,False,True,[],"['Decamethonium', 'Decamethonium cation', 'Decamethonium ion', 'Syncurine']",['CHEMBL1134'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,['DB01245'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1982.0,,,"['11111046', '11111047', '26756594', '90341654']",['41934'],,,,,
CHEMBL1697,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl,HDRXZJPWHTXQRI-BHDTVMLSSA-N,Small molecule,False,DILTIAZEM HYDROCHLORIDE,4.0,False,True,"['Adizem-60', 'Adizem-sr', 'Adizem-xl', 'Angiozem 60', 'Angiozem cr 120', 'Angiozem cr 90', 'Angitil sr 120', 'Angitil sr 180', 'Angitil sr 90', 'Angitil xl 240', 'Angitil xl 300', 'Anoheal', 'Bi-carzem sr', 'Bi-carzem xl', 'Britiazim', 'Calazem', 'Calcicard', 'Calcicard cr', 'Cardizem', 'Cardizem cd', 'Cardizem la', 'Cardizem sr', 'Cartia xt', 'Dilacor xr', 'Dilcardia sr', 'Dilcardia xl', 'Dilt-cd', 'Diltiazem hydrochloride', 'Diltiazem hydrochloride in dextrose 5%', 'Diltzac', 'Dilzem sr 120', 'Dilzem sr 60', 'Dilzem sr 90', 'Dilzem xl 120', 'Dilzem xl 180', 'Dilzem xl 240', 'Disogram sr', 'Horizem sr 120', 'Horizem sr 60', 'Horizem sr 90', 'Kentiazem', 'Kenzem sr', 'Optil', 'Optil sr 120', 'Optil sr 180', 'Optil sr 90', 'Optil xl 240', 'Optil xl 300', 'Retalzem 60', 'Slozem', 'Slozem 120', 'Slozem 180', 'Slozem 240', 'Taztia xt', 'Tiamex', 'Tiazac', 'Tildiem', 'Tildiem la 200', 'Tildiem la 300', 'Tildiem ret 120', 'Tildiem ret 90', 'Uard 120xl', 'Uard 180xl', 'Uard 240xl', 'Uard 300xl', 'Viazem xl', 'Zemret 180 xl', 'Zemret 240 xl', 'Zemret 300 xl', 'Zemtard 120 xl', 'Zemtard 180 xl', 'Zemtard 240 xl', 'Zemtard 300 xl', 'Zildil sr']","['Adizem', 'Altiazem', 'CRD-401', 'Cartia', 'Deltazen', 'Diladel', 'Dilpral', 'Dilrene', 'Diltiazem hcl', 'Diltiazem hydrochloride', 'Dilzem', 'Dilzene', 'Masdil', 'NSC-759576', 'RG 83606', 'RG-83606', 'Taztia', 'Zilden']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 6 investigational indications.,,,"['HP_0012390', 'EFO_0000537', 'EFO_0003144', 'EFO_0000275', 'EFO_0000701', 'EFO_1001951', 'EFO_0003913', 'EFO_0004225', 'HP_0002019', 'EFO_0000764']",10.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1982.0,CHEMBL23,['diltiazem%20hydrochloride'],"['50106088', '56422509', '855699']",['645509'],,,,,
CHEMBL472,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,Small molecule,False,GLYBURIDE,4.0,False,True,"['Amglidia', 'Calabren', 'Daonil', 'Diabeta', 'Diabetamide 2.5', 'Diabetamide 5', 'Euglucon', 'Gliken', 'Glyburide', 'Glyburide (micronized)', 'Glynase', 'Glynase Prestab', 'Lederglib', 'Libanil', 'Malix', 'Micronase', 'Semi-daonil']","['Cirara', 'Glibenclamide', 'Glibenclamidum', 'Glybenclamide', 'Glyburide', 'HB 419', 'HB-419', 'NSC-759618', 'U-26,45', 'U-26,452', 'U-26452']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 7 investigational indications.,['Glibenclamide'],['DB01016'],"['EFO_1001919', 'HP_0002140', 'MONDO_0005148', 'EFO_0000712', 'MONDO_0005147', 'EFO_0004593', 'EFO_0000400', 'MONDO_0043510', 'EFO_0003913']",9.0,"['ENSG00000187486', 'ENSG00000006071']",2,1984.0,,['glyburide'],"['11111219', '11112597', '11113353', '144203709', '144211075', '170464964', '26747031', '26747032', '26751550', '50100249', '50104148', '50104149', '50104150', '50126365', '56422139', '85231061', '855894']",['5441'],['https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia'],,['42'],,
CHEMBL1020,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1,UPSPUYADGBWSHF-UHFFFAOYSA-N,Small molecule,True,TOLMETIN,4.0,False,True,[],"['MCN-2559', 'Tolectin', 'Tolmetin']","['CHEMBL1556918', 'CHEMBL1200613', 'CHEMBL1437585']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 5 approved indications. This drug has a black box warning from the FDA.,['Tolmetin'],['DB00500'],"['HP_0002829', 'HP_0003326', 'EFO_0005755', 'EFO_0000685', 'MONDO_0005178']",5.0,"['ENSG00000073756', 'ENSG00000095303']",2,1976.0,,,,['71941'],,,,,
CHEMBL1237099,COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-],APADFLLAXHIMFU-UHFFFAOYSA-L,Small molecule,False,DOXACURIUM CHLORIDE,4.0,False,True,['Nuromax'],"['BW A938U DICHLORIDE', 'BW-A938U', 'Doxacurium chloride', 'Doxacurium chloride, meso-', 'Meso doxacurium chloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991.,,,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1991.0,CHEMBL1237123,,,,,,,,
CHEMBL1267,CC(O)c1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,OXVFDZYQLGRLCD-UHFFFAOYSA-N,Small molecule,False,LERIGLITAZONE,3.0,False,False,[],"['Hydroxypioglitazone', 'Leriglitazone', 'MIN-102', 'Min-102']",['CHEMBL4298170'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB15021'],"['Orphanet_43', 'MONDO_0100339', 'Orphanet_43', 'MONDO_0018544']",4.0,['ENSG00000132170'],1,,,,,['82937'],,['https://searchusan.ama-assn.org/finder/usan/search/LERIGLITAZONE/relevant/1/'],,,
CHEMBL18442,c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,YIQPUIGJQJDJOS-UHFFFAOYSA-N,Small molecule,False,PLERIXAFOR,4.0,False,True,['Mozobil'],"['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloride', 'Plerixafor octahydrochloride', 'SID 791']","['CHEMBL1788331', 'CHEMBL2311028', 'CHEMBL554014', 'CHEMBL2088494', 'CHEMBL2373140', 'CHEMBL2311089']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 30 investigational indications.,['Plerixafor'],['DB06809'],"['MONDO_0003783', 'EFO_0001378', 'EFO_0000095', 'EFO_0000222', 'MONDO_0000870', 'EFO_0000198', 'MONDO_0015760', 'EFO_1001311', 'EFO_1001996', 'EFO_0000717', 'EFO_0000565', 'MONDO_0018305', 'MONDO_0001475', 'EFO_0002618', 'EFO_0000403', 'EFO_0000220', 'MONDO_0011382', 'EFO_0000691', 'EFO_1001465', 'EFO_0003086', 'MONDO_0019391', 'MONDO_0018906', 'EFO_1001469', 'MONDO_0044881', 'MONDO_0019460', 'EFO_0000574', 'EFO_0000220', 'EFO_0000616', 'EFO_0006859', 'EFO_0005952', 'EFO_1001459', 'EFO_0000183', 'MONDO_0005147', 'Orphanet_848', 'EFO_1000654', 'EFO_0004599']",36.0,['ENSG00000121966'],1,2008.0,,['plerixafor'],"['174007494', '29217477']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil'],,,,
CHEMBL2104753,COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1,XMSXOLDPMGMWTH-UHFFFAOYSA-N,Small molecule,False,RIVOGLITAZONE,3.0,False,False,[],"['CS-011', 'DE-101', 'R 106056', 'R-106056', 'Rivoglitazone']","['CHEMBL3526906', 'CHEMBL3527103', 'CHEMBL3526905']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB09200'],"['EFO_1000906', 'MONDO_0005148']",2.0,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL447,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O,KQPKPCNLIDLUMF-UHFFFAOYSA-N,Small molecule,False,SECOBARBITAL,4.0,True,True,[],"['(rs)-secobarbital', 'Evronal', 'Hypotrol', 'Immenox', 'Meballymal', 'Quinalbarbital', 'Secobarbital', 'Secobarbital cii', 'Secobarbital sodium free acid', 'Secobarbitone', 'Somatarax']",['CHEMBL1200903'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950.,['Secobarbital'],['DB00418'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1950.0,,,,['9073'],,,,,
CHEMBL473417,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,BPQMGSKTAYIVFO-UHFFFAOYSA-N,Small molecule,True,VISMODEGIB,4.0,False,True,['Erivedge'],"['GDC-0449', 'NSC-747691', 'NSC-755986', 'Vismodegib']","['CHEMBL4129312', 'CHEMBL4125998', 'CHEMBL4127241']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 4 approved and 22 investigational indications. This drug has a black box warning from the FDA.,,['DB08828'],"['MONDO_0007254', 'MONDO_0008170', 'EFO_0000702', 'EFO_0002618', 'EFO_0002939', 'MONDO_0008315', 'MONDO_0003684', 'EFO_0000222', 'EFO_1001465', 'EFO_0005537', 'MONDO_0004992', 'MONDO_0005184', 'EFO_0000768', 'EFO_0000616', 'EFO_0000673', 'EFO_0003897', 'MONDO_0044903', 'MONDO_0020547', 'EFO_0004193', 'MONDO_0005341', 'EFO_0000326', 'MONDO_0007187', 'EFO_0001378', 'EFO_0000519', 'EFO_1001041', 'MONDO_0016642']",26.0,['ENSG00000128602'],1,2012.0,,['vismodegib'],,['66903'],['https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge'],,,,
CHEMBL497939,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1,ANJTVLIZGCUXLD-DTWKUNHWSA-N,Small molecule,False,CYTISINICLINE,3.0,False,False,['Tabex'],"['6039 Sopharma', 'Baptitoxine', 'Cytisine', 'Cytisinicline', 'Cytiton', 'NSC-407282', 'Sophorine', 'Ulexine']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,['Cytisine'],['DB09028'],"['EFO_0004319', 'EFO_0003768', 'EFO_0003086']",3.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,"['11112361', '11114058', '26752181', '477069', '56463106']",['4055'],,,,,
CHEMBL1200606,Cc1cccc(C)c1OCC(C)N.Cl,NFEIBWMZVIVJLQ-UHFFFAOYSA-N,Small molecule,True,MEXILETINE HYDROCHLORIDE,4.0,False,True,"['Mexiletine hydrochloride', 'Mexitil', 'Mexitil p.l.', 'Namuscla']","['KO 1173 CL', 'KO-1173', 'KO-1173 CL', 'KO-1173-CL', 'Katen', 'Mexiletine hcl', 'Mexiletine hydrochloride', 'NSC-758639']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for myotonic syndrome and ventricular arrhythmia and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['MONDO_0016120', 'HP_0004308', 'EFO_0009387']",3.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1985.0,CHEMBL558,['mexiletine%20hydrochloride'],"['144204800', '144204801', '170464740', '26732616', '26747574', '50106611']",['6917'],['https://www.ema.europa.eu/en/medicines/human/EPAR/namuscla'],,,,
CHEMBL1201141,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O,IHHXIUAEPKVVII-ZSCHJXSPSA-N,Small molecule,False,IBUPROFEN LYSINE,4.0,False,True,"['Feminax express', 'Ibuprofen lysine', 'Neoprofen', 'Nurofen advance', 'Nurofen max strgth mig pain', 'Nurofen migraine pain', 'Nurofen tension headache']","['Arfen', 'Dolormin', 'Ibuprofen l-lysine', 'Ibuprofen lysinate', 'Ibuprofen lysine', 'Imbun', 'Lisiprofen', 'Saren', 'Solufenum', 'Soluphene']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006 and is indicated for patent ductus arteriosus.,,,['HP_0001643'],1.0,"['ENSG00000073756', 'ENSG00000095303']",2,2006.0,CHEMBL521,['ibuprofen%20lysine'],,,,,,,
CHEMBL1201619,,,Unknown,False,APROTININ,4.0,True,True,['Trasylol'],"['Aprotinin', 'Aprotinin (bovine)', 'Aprotinin (synthetic)', 'Aprotinin biosynthetic', 'Aprotinin bovine', 'Aprotinin concentrated solution', 'BAYER A 128', 'BAYER-A-128', 'BAYERA-128', 'Bovine aprotinin', 'Fibrinolysis inhibitor', 'RIKER 52G', 'RIKER-52G', 'RP 9921', 'RP-9921']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for hemorrhage and has 2 investigational indications. It was withdrawn in at least one region.,['Aprotinin'],,"['MONDO_0007254', 'EFO_0000278', 'MP_0001914']",3.0,"['ENSG00000122194', 'ENSG00000164344']",2,1993.0,,,,,,,,['4839'],
CHEMBL2103875,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,LIRYPHYGHXZJBZ-UHFFFAOYSA-N,Small molecule,False,TRAMETINIB,4.0,False,True,['Mekinist'],"['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212', 'Tmt212', 'Trametinib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 42 investigational indications.,,['DB08911'],"['EFO_0002618', 'MONDO_0011719', 'MONDO_0008315', 'EFO_1000926', 'MONDO_0015523', 'EFO_0000196', 'EFO_1000657', 'EFO_0000182', 'EFO_0000222', 'MONDO_0004976', 'MONDO_0100342', 'EFO_0000565', 'MONDO_0008903', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000756', 'EFO_0001378', 'MONDO_0017795', 'EFO_0002617', 'EFO_1001968', 'EFO_0005221', 'EFO_1001951', 'MONDO_0021063', 'EFO_1000209', 'HP_0100727', 'EFO_0003868', 'MONDO_0002974', 'MONDO_0005184', 'EFO_1000849', 'EFO_1000760', 'MONDO_0007254', 'EFO_0000571', 'MONDO_0001056', 'EFO_0005537', 'EFO_0000616', 'EFO_0000389', 'EFO_0000501', 'EFO_0000641', 'MONDO_0002108', 'MONDO_0016642', 'EFO_0000365', 'EFO_0006772']",42.0,"['ENSG00000126934', 'ENSG00000169032']",2,2013.0,,,['137276024'],['75998'],,,,,
CHEMBL2111097,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl,HTIQEAQVCYTUBX-KRWDZBQOSA-N,Small molecule,False,LEVAMLODIPINE,4.0,False,True,[],"['Amlodipine, (s)-', 'Levamlodipine', 'S-amlodipine']","['CHEMBL2107350', 'CHEMBL4594288']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for cardiovascular disease and hypertension and has 2 investigational indications.,,['DB09237'],"['EFO_0000537', 'EFO_0000537', 'EFO_0000319', 'EFO_0000537']",4.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,2019.0,,,,['53796'],,,,,
CHEMBL2387080,Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,BEUQXVWXFDOSAQ-UHFFFAOYSA-N,Small molecule,False,TASELISIB,3.0,False,False,[],"['GDC-0032', 'RG-7604', 'Taselisib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB12108'],"['MONDO_0008903', 'EFO_0000708', 'EFO_0005952', 'MONDO_0007254', 'EFO_0005537', 'EFO_0001378']",6.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,,,,
CHEMBL3940890,Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F,WBFUHHBPNXWNCC-UHFFFAOYSA-N,Small molecule,False,ACORAMIDIS,3.0,False,False,[],"['AG-10', 'AG10', 'Acoramidis']",['CHEMBL4650226'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0004129', 'EFO_1001875', 'EFO_0004129']",3.0,['ENSG00000118271'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ACORAMIDIS/relevant/1/'],,,
CHEMBL4297762,,,Oligonucleotide,False,GOLODIRSEN,4.0,False,True,['Vyondys 53'],"['Golodirsen', 'NG-12-0163', 'SRP-4053']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for duchenne muscular dystrophy and muscular dystrophy.,,,"['MONDO_0010679', 'MONDO_0020121']",2.0,['ENSG00000198947'],1,2019.0,,['golodirsen'],,,,['https://searchusan.ama-assn.org/finder/usan/search/GOLODIRSEN/relevant/1/'],,,
CHEMBL451930,CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,UUSZLLQJYRSZIS-LXNNNBEUSA-N,Small molecule,False,PLITIDEPSIN,3.0,False,False,[],"['Aplidine', 'Plitidepsin']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,['DB04977'],"['MONDO_0008315', 'EFO_0000616', 'MONDO_0044903', 'EFO_0000574', 'EFO_0001378', 'EFO_0003085', 'MONDO_0100096']",7.0,['ENSG00000101210'],1,,,,,['90205'],,,,,
CHEMBL490029,CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,STWITCBWQHTJFJ-XMMPIXPASA-N,Small molecule,False,MK-0533,2.0,False,False,[],"['MK-0533', 'MK0533', 'Mk-0533']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB15242'],['MONDO_0005148'],1.0,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL623,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,VRBKIVRKKCLPHA-UHFFFAOYSA-N,Small molecule,True,NEFAZODONE,4.0,True,True,[],['Nefazodone'],['CHEMBL1200492'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for unipolar depression and major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA.,['Nefazodone'],['DB01149'],"['EFO_0007191', 'EFO_0002610', 'EFO_0003761', 'MONDO_0002009', 'EFO_0003761']",5.0,"['ENSG00000147246', 'ENSG00000108576', 'ENSG00000103546', 'ENSG00000102468']",4,1994.0,,,"['29217604', '49666410', '50111710']",['7494'],,,,,
CHEMBL11662,O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1,SHZKQBHERIJWAO-AATRIKPKSA-N,Small molecule,False,OZAGREL,4.0,False,True,[],"['KCT-0809', 'Ozagrel', 'Ozagrel sodium']","['CHEMBL1715705', 'CHEMBL542549']",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and has 1 investigational indication.,['Ozagrel'],['DB12017'],['EFO_1000906'],1.0,['ENSG00000059377'],1,1988.0,,,,,,,,,
CHEMBL1200334,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2.Cl,GAQAKFHSULJNAK-UHFFFAOYSA-N,Small molecule,True,MORICIZINE HYDROCHLORIDE,4.0,False,True,['Ethmozine'],"['Moracizine hydrochloride', 'Moricizine hcl', 'Moricizine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. This drug has a black box warning from the FDA.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1990.0,CHEMBL1075,,"['144204173', '170465141', '24840971', '856698']",['60937'],,,,,
CHEMBL1201573,,,Protein,True,OPRELVEKIN,4.0,False,True,['Neumega'],"['Interleukin-11 (2-178)', 'Oprelvekin']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for thrombocytopenia and neoplasm and has 7 investigational indications. This drug has a black box warning from the FDA.,['Oprelvekin'],,"['Orphanet_903', 'EFO_0000191', 'EFO_0000095', 'EFO_0000339', 'MONDO_0018906', 'MONDO_0010602', 'EFO_0009441', 'HP_0001873', 'EFO_0000616']",9.0,['ENSG00000137070'],1,1997.0,,,,,,,,['5026'],
CHEMBL1395,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,GCKMFJBGXUYNAG-HLXURNFRSA-N,Small molecule,False,METHYLTESTOSTERONE,4.0,False,True,"['Android 10', 'Android 25', 'Android 5', 'Metandren', 'Methitest', 'Methyltestosterone', 'Oreton', 'Oreton methyl', 'Perandren', 'Plex hormone', 'Potensan fte', 'Testovis', 'Testred', 'Virilon']","['17-methyltestosterone', 'CDB-110', 'L 589.372', 'L-589.372', 'L-589372', 'Methyltestosterone', 'Methyltestosterone ciii', 'NSC-139965', 'NSC-9701', 'Oxandrolone impurity, methyltestosterone-', 'RU 24400', 'RU-24400', 'U-2842']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 1 investigational indication.,['Methyltestosterone'],['DB06710'],"['GO_0042697', 'MONDO_0007254', 'MONDO_0002146', 'EFO_1001078']",4.0,['ENSG00000169083'],1,1973.0,,['methyltestosterone'],"['144206712', '144206713', '144214019', '170464631', '17388912', '26719668', '56463771']",['27436'],,,['41'],,
CHEMBL2219422,Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,AFJRDFWMXUECEW-LBPRGKRZSA-N,Small molecule,False,AFURESERTIB,2.0,False,False,[],"['ASB-183', 'ASB183', 'Afuresertib', 'GSK-2110183', 'GSK-2110183C', 'GSK2110183', 'GSK2110183C', 'Gsk-2110183']",['CHEMBL2219423'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,['DB11648'],"['MONDO_0008170', 'MONDO_0008315', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0004992', 'EFO_1000318']",7.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,,,,,,,
CHEMBL397420,CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,VABCILAOYCMVPS-UHFFFAOYSA-N,Small molecule,False,ACENOCOUMAROL,4.0,False,True,['Sinthrome'],"['Acenocoumarin', 'Acenocoumarol', 'Mini-sintrom', 'NSC-760052', 'Nicoumalone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 3 investigational indications.,['Acenocoumarol'],['DB01418'],"['EFO_0003827', 'EFO_0000275', 'EFO_0000756', 'HP_0004419']",4.0,['ENSG00000167397'],1,,,,"['144203981', '170465636']",['53766'],,,,,
CHEMBL4303729,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12,YYACLQUDUDXAPA-MRXNPFEDSA-N,Small molecule,False,PLIXORAFENIB,2.0,False,False,[],"['FORE-8394', 'FORE8394', 'PLX8394', 'Plixorafenib', 'Plx 8394', 'Plx-8394']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,,"['EFO_0003060', 'EFO_0000756', 'MONDO_0004992', 'HP_0100727', 'EFO_0005221', 'EFO_1000956', 'MONDO_0002108', 'EFO_1001951', 'EFO_0000616']",9.0,['ENSG00000157764'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-128']
CHEMBL4594511,,,Oligonucleotide,False,VUTRISIRAN,4.0,False,True,['Amvuttra'],"['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for familial amyloid neuropathy and polyneuropathy and has 1 investigational indication.,,,"['EFO_1001875', 'EFO_0004129', 'EFO_0009562']",3.0,['ENSG00000118271'],1,2022.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/VUTRISIRAN/relevant/1/'],,,
CHEMBL1095097,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,JUKPWJGBANNWMW-VWBFHTRKSA-N,Small molecule,False,EPLERENONE,4.0,False,True,"['Eplerenone', 'Inspra']","['Eplerenone', 'SC-66110', 'SC-6611O']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 10 investigational indications.,['Eplerenone'],['DB00700'],"['EFO_0000401', 'EFO_0003884', 'EFO_0000612', 'EFO_0008519', 'EFO_0000275', 'MONDO_0010679', 'EFO_0009784', 'EFO_0003144', 'MONDO_0005148', 'EFO_0000537', 'EFO_0000318', 'EFO_0000319', 'MONDO_0007254', 'EFO_0000712', 'MONDO_0001134', 'EFO_0000373']",16.0,['ENSG00000151623'],1,2002.0,,['eplerenone'],"['144205299', '170465283', '26754514']",['31547'],,,,,
CHEMBL1289926,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,RITAVMQDGBJQJZ-FMIVXFBMSA-N,Small molecule,False,AXITINIB,4.0,False,True,['Inlyta'],"['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 37 investigational indications.,['Axitinib'],['DB06626'],"['EFO_0004142', 'MONDO_0004669', 'EFO_0000673', 'EFO_0000198', 'EFO_0000616', 'MONDO_0011719', 'MONDO_0011962', 'MONDO_0002367', 'EFO_1001951', 'EFO_0009708', 'EFO_0003860', 'EFO_0003060', 'EFO_1001465', 'EFO_0003841', 'EFO_0000231', 'EFO_1001968', 'EFO_0003865', 'EFO_0000681', 'EFO_0004198', 'EFO_1000131', 'EFO_0000222', 'EFO_1001513', 'EFO_0004252', 'EFO_0000640', 'EFO_0000313', 'MONDO_0005184', 'EFO_0000181', 'EFO_0000349', 'EFO_0000770', 'EFO_1000796', 'EFO_0002890', 'EFO_0003869', 'EFO_0004243', 'EFO_0007143', 'EFO_0003891', 'MONDO_0008315', 'EFO_0000756', 'EFO_0000519', 'MONDO_0016238', 'MONDO_0004992', 'MONDO_0001056', 'EFO_0001065', 'EFO_0000182']",43.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,2012.0,,['axitinib'],"['124950168', '144207146', '170466656']",['66910'],['https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta'],,,,
CHEMBL1616951,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)O,PBKZPPIHUVSDNM-WNHSNXHDSA-N,Small molecule,False,CANRENOATE,4.0,False,True,[],['Canrenoic acid'],['CHEMBL1371200'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.,,['DB09015'],"['EFO_0000319', 'EFO_0008585']",2.0,['ENSG00000151623'],1,,,,,['50156'],,,,,
CHEMBL2109478,,,Antibody,False,DAPIROLIZUMAB PEGOL,3.0,False,False,[],"['CDP-7657', 'CDP7657', 'Cdp-7657', 'Dapirolizumab pegol']",,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['MONDO_0007915'],1.0,['ENSG00000102245'],1,,,,,,,,,,
CHEMBL221959,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,UJLAWZDWDVHWOW-YPMHNXCESA-N,Small molecule,True,TOFACITINIB,4.0,False,True,[],"['550', 'CP 690550', 'CP- 690 550', 'CP-690', 'CP-690,550', 'CP-690,550 FREE BASE', 'CP-690-550', 'CP-690550', 'CP-690550 FREE BASE', 'CP690,550', 'CP690550', 'Cp-690 free base', 'Tofacitinib']",['CHEMBL2103743'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for psoriatic arthritis and rheumatoid arthritis and has 38 investigational indications. This drug has a black box warning from the FDA.,['Tofacitinib'],['DB08895'],"['MONDO_0019472', 'EFO_0003778', 'EFO_0000274', 'EFO_0003884', 'EFO_0000398', 'MONDO_0019338', 'MONDO_0018305', 'EFO_0000783', 'EFO_0000274', 'EFO_1001857', 'EFO_1000704', 'EFO_0003921', 'EFO_0000546', 'EFO_0008518', 'MONDO_0007915', 'EFO_0003898', 'EFO_0000699', 'EFO_0002609', 'EFO_1000906', 'EFO_0003778', 'EFO_0000676', 'MONDO_0100096', 'EFO_0003834', 'EFO_0000729', 'EFO_0003106', 'EFO_0000685', 'EFO_0004991', 'EFO_0001064', 'MONDO_0019558', 'EFO_1001494', 'EFO_0000685', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872', 'MONDO_0007915', 'EFO_0004192', 'EFO_0000717', 'EFO_0003898', 'EFO_0000540', 'EFO_0003086']",40.0,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",4,2012.0,,,"['124939204', '50100095']",['71200'],,,,,
CHEMBL315985,NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21,BMPDWHIDQYTSHX-AWEZNQCLSA-N,Small molecule,False,ESLICARBAZEPINE,4.0,False,True,"['Erelib', 'Pazzul', 'Stedesa']","['(s)-licarbazepine', 'BIA 2-194', 'BIA-2-194', 'BIA-2194', 'CGP-13751', 'Eslicarbazepine', 'Licarbazepine, (s)-']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for epilepsy.,,['DB14575'],['EFO_0000474'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,,,,,,,,,,
CHEMBL3545013,,,Small molecule,False,APN1125,1.0,False,False,[],['Apn1125'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0005090'],1.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL4297739,,,Oligonucleotide,False,DANVATIRSEN,2.0,False,False,[],"['AZD 9150', 'AZD-9150', 'AZD9150', 'Azd9150', 'Danvatirsen', 'ISIS-481464', 'ISIS-STAT3RX']",,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_0000182', 'EFO_0000403', 'EFO_0000616', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0001187', 'EFO_0000181']",7.0,['ENSG00000168610'],1,,,,,,,,,,
CHEMBL4594260,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,UQRICAQPWZSJNF-UHFFFAOYSA-N,Small molecule,False,TAZEMETOSTAT HYDROBROMIDE,4.0,False,True,['Tazverik'],"['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDE', 'EZ-438', 'EZ438', 'Tazemetostat hydrobromide', 'Tazemetostat monohydrobromide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sarcoma and follicular lymphoma and has 3 investigational indications.,,,"['EFO_0000691', 'MONDO_0008315', 'EFO_0000702', 'EFO_0000616', 'MONDO_0018906']",5.0,['ENSG00000106462'],1,2020.0,CHEMBL3414621,['tazemetostat%20hydrobromide'],,,,['https://searchusan.ama-assn.org/finder/usan/search/TAZEMETOSTAT%20HYDROBROMIDE/relevant/1/'],,,
CHEMBL4650319,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,AZSRSNUQCUDCGG-UHFFFAOYSA-N,Small molecule,True,MOBOCERTINIB,4.0,False,True,[],"['AP-32788', 'AP32788', 'Mobocertinib', 'TAK-788', 'Tak-788']",['CHEMBL4802239'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003086', 'EFO_0001421', 'EFO_0003060', 'EFO_0000616', 'EFO_0003060']",5.0,['ENSG00000146648'],1,2021.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/MOBOCERTINIB/relevant/1/'],,,
CHEMBL533,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,ALOBUEHUHMBRLE-UHFFFAOYSA-N,Small molecule,True,IBUTILIDE,4.0,False,True,[],['Ibutilide'],"['CHEMBL3187455', 'CHEMBL2355456']",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for cardiac arrhythmia. This drug has a black box warning from the FDA.,['Ibutilide'],['DB00308'],['EFO_0004269'],1.0,['ENSG00000055118'],1,1995.0,,,,['5856'],,,,,
CHEMBL605,CCN(CC)CCNC(=O)c1ccc(N)cc1.Cl,ABTXGJFUQRCPNH-UHFFFAOYSA-N,Small molecule,True,PROCAINAMIDE HYDROCHLORIDE,4.0,False,True,"['Biocoryl', 'Novocainamid', 'Procainamide hydrochloride', 'Procan', 'Procan sr', 'Procanbid', 'Procapan', 'Pronestyl', 'Pronestyl-sr']","['Amidoprocaine', 'Cardiorytmin', 'NSC-757279', 'Procainamide HCl', 'Procainamide hcl', 'Procainamide hydrochloride', 'Procainamidi hydrochloridum']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0004308', 'EFO_0004269', 'EFO_0003144', 'EFO_0000275']",4.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1950.0,CHEMBL640,['procainamide%20hydrochloride'],"['144210053', '26747643', '50106886', '56423113', '855728']",['8429'],,,,,
CHEMBL654,CN1CCN2c3ncccc3Cc3ccccc3C2C1,RONZAEMNMFQXRA-UHFFFAOYSA-N,Small molecule,True,MIRTAZAPINE,4.0,False,True,"['Mirtazapine', 'Remeron', 'Remeron soltab', 'Zispin']","['6-azamianserin', 'Avanza', 'Mirataz', 'Mirtazapin', 'Mirtazapine', 'Mirtazapine anhydrous', 'Norset', 'ORG 3770', 'ORG-3770', 'Promyrtil', 'Rexer']",['CHEMBL5315116'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 19 investigational indications. This drug has a black box warning from the FDA.,['Mirtazapine'],['DB00370'],"['HP_0004326', 'HP_0002039', 'EFO_0005687', 'EFO_0002610', 'MONDO_0002050', 'EFO_0004240', 'EFO_0004888', 'MONDO_0005090', 'HP_0000726', 'MONDO_0002491', 'MONDO_0007079', 'EFO_0005230', 'MONDO_0005351', 'HP_0001824', 'EFO_0003761', 'MONDO_0002009', 'EFO_0003890', 'EFO_0004698', 'EFO_0003918', 'EFO_0004701', 'EFO_0000326', 'EFO_0006911', 'EFO_0003756']",23.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286', 'ENSG00000147246', 'ENSG00000102468']",5,1996.0,,['mirtazapine'],"['144204516', '29215050', '49648465']",['6950'],,,,,
CHEMBL738,CCCC(C)C1(CC)C(=O)[N-]C(=S)NC1=O.[Na+],AWLILQARPMWUHA-UHFFFAOYSA-M,Small molecule,False,THIOPENTAL SODIUM,4.0,False,True,"['Intraval', 'Intraval sod', 'Penthiobarbital', 'Pentothal', 'Thiomebumal', 'Thionembutal', 'Thiopentone', 'Trapanal']","['Farmotal', 'Hypnostan', 'Leopental', 'NSC-759557', 'Nesdonal', 'Penthiobarbital sodium', 'Ravonal', 'Sodium pentothal', 'Sodium thiopental', 'Thiomebumal sodium', 'Thiopental Sodium', 'Thiopental sodium', 'Thiopentalum natricum', 'Thiopentobarbitone sodium', 'Thiopentone', 'Thiopentone sodium', 'Trapanal']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.,['Sodium_thiopental'],,['EFO_1001454'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,CHEMBL441,,"['144205294', '170464734', '26749790']",['9561'],,,,,
CHEMBL939,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,XGALLCVXEZPNRQ-UHFFFAOYSA-N,Small molecule,False,GEFITINIB,4.0,False,True,['Iressa'],"['Gefitinib', 'Iressa', 'NSC-759856', 'ZD-1839', 'ZD1839']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 45 investigational indications.,['Gefitinib'],['DB00317'],"['EFO_0000514', 'EFO_0000702', 'EFO_0000182', 'EFO_0000222', 'EFO_0003869', 'MONDO_0001187', 'EFO_0003060', 'EFO_0000708', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000196', 'EFO_0000616', 'EFO_1000158', 'MONDO_0002367', 'MONDO_0004992', 'EFO_0000313', 'EFO_0000681', 'EFO_0004252', 'EFO_0003859', 'EFO_0000588', 'EFO_0002618', 'EFO_0000571', 'EFO_1001951', 'EFO_0000691', 'EFO_0000181', 'MONDO_0004192', 'MONDO_0002158', 'MONDO_0004669', 'EFO_0001071', 'EFO_0000308', 'EFO_0000707', 'EFO_0000519', 'MONDO_0021117', 'EFO_0006861', 'EFO_0000621', 'MONDO_0002898', 'MONDO_0002087', 'EFO_1000251', 'MONDO_0002974', 'MONDO_0007576', 'MONDO_0008903', 'EFO_0006859', 'EFO_1001100', 'EFO_1001465', 'EFO_0000178', 'EFO_0004284', 'EFO_0003897', 'MONDO_0008170']",48.0,['ENSG00000146648'],1,2003.0,,['gefitinib'],"['103905343', '103905344', '124892204', '124892206', '137275808', '144205236', '170464828', '29215403', '50100103']",['49668'],['https://www.ema.europa.eu/en/medicines/human/EPAR/iressa'],,,,
CHEMBL1201827,,,Antibody,True,PANITUMUMAB,4.0,False,True,['Vectibix'],"['ABX-EGF', 'Abenix', 'E7.6.3', 'L01xc08', 'Panitumumab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 27 investigational indications. This drug has a black box warning from the FDA.,['Panitumumab'],,"['EFO_0000707', 'MONDO_0007576', 'EFO_1000657', 'EFO_0001075', 'EFO_0006859', 'EFO_1000852', 'MONDO_0008170', 'EFO_0000503', 'EFO_0000681', 'EFO_0000365', 'MONDO_0021063', 'MONDO_0008903', 'EFO_0000313', 'EFO_0005922', 'EFO_1000251', 'EFO_0002618', 'MONDO_0005575', 'EFO_0005221', 'MONDO_0002158', 'MONDO_0002974', 'EFO_0000616', 'MONDO_0008315', 'MONDO_0002367', 'EFO_0005537', 'MONDO_0004992', 'MONDO_0001187', 'EFO_0004142', 'EFO_1001951', 'EFO_0000181', 'EFO_1001512', 'MONDO_0007254', 'EFO_0002916', 'EFO_0003060']",33.0,['ENSG00000146648'],1,2006.0,,['panitumumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix'],,,['4955'],
CHEMBL1336,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,MLDQJTXFUGDVEO-UHFFFAOYSA-N,Small molecule,False,SORAFENIB,4.0,False,True,['Nexavar'],"['BAY 43-9006', 'BAY-43-9006', 'Sorafenib']","['CHEMBL1200485', 'CHEMBL4297490', 'CHEMBL1760433']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 7 approved and 112 investigational indications.,['Sorafenib'],['DB00398'],"['MONDO_0004192', 'EFO_0000691', 'EFO_0000673', 'EFO_0001061', 'EFO_0000198', 'EFO_1001968', 'EFO_0000756', 'MONDO_0018531', 'EFO_0000641', 'EFO_0004212', 'MONDO_0008170', 'EFO_0000365', 'MONDO_0008903', 'EFO_0008524', 'EFO_0000756', 'MONDO_0008170', 'EFO_0000691', 'EFO_0003060', 'EFO_0001361', 'EFO_1001968', 'EFO_1001465', 'EFO_0003833', 'EFO_0000574', 'MONDO_0000831', 'EFO_1000657', 'EFO_0002499', 'MONDO_0002108', 'EFO_0000588', 'EFO_1001469', 'EFO_0000501', 'EFO_0000313', 'EFO_1000796', 'EFO_0000702', 'MONDO_0002691', 'EFO_1001052', 'MONDO_0044937', 'EFO_0003891', 'EFO_0000666', 'EFO_0000095', 'EFO_0001378', 'EFO_0000224', 'EFO_0000196', 'MONDO_0008315', 'EFO_0002618', 'MONDO_0004992', 'EFO_0003833', 'EFO_0000519', 'EFO_0002499', 'EFO_0000640', 'EFO_0000565', 'EFO_0000221', 'MONDO_0007576', 'MONDO_0011719', 'EFO_0009907', 'EFO_0000558', 'EFO_1001465', 'EFO_0000621', 'EFO_0000702', 'EFO_1000158', 'EFO_0000681', 'EFO_0000095', 'MONDO_0001187', 'EFO_1001901', 'MONDO_0002087', 'EFO_1001346', 'EFO_0000222', 'EFO_1000657', 'EFO_0000501', 'EFO_0003865', 'EFO_0003893', 'MONDO_0015277', 'MONDO_0001187', 'EFO_0000403', 'EFO_0003841', 'MONDO_0002691', 'EFO_0000335', 'EFO_0000637', 'MONDO_0011719', 'EFO_0000349', 'EFO_0006352', 'EFO_0006861', 'EFO_0002501', 'EFO_0000389', 'MONDO_0007254', 'MONDO_0002367', 'MONDO_0004992', 'EFO_0004142', 'EFO_0002918', 'EFO_0000224', 'EFO_0007535', 'EFO_1000292', 'MONDO_0008315', 'EFO_0000220', 'EFO_0000228', 'EFO_0000222', 'MONDO_0008903', 'EFO_0002618', 'EFO_0000616', 'MONDO_0001056', 'EFO_1000613', 'EFO_0003860', 'EFO_0000616', 'EFO_1000359', 'MONDO_0021063', 'EFO_0005221', 'EFO_0002618', 'MONDO_0044926', 'EFO_0002938', 'EFO_0000707', 'EFO_0000673', 'MONDO_0001056', 'EFO_0000339', 'MONDO_0004986', 'EFO_0000641', 'EFO_0003060', 'EFO_0004284', 'EFO_0001421', 'EFO_0000182', 'MONDO_0007254', 'EFO_0002501', 'MONDO_0002108', 'EFO_0000222', 'EFO_1001951', 'MONDO_0002108', 'EFO_0000182', 'EFO_0000519', 'EFO_0000588', 'MONDO_0002367', 'EFO_0003086', 'EFO_0002892', 'EFO_0003060', 'EFO_0004252', 'EFO_0000616', 'EFO_0000681', 'EFO_0005088', 'EFO_1001513', 'EFO_0000637', 'EFO_0001378', 'EFO_0003871', 'EFO_0002892', 'EFO_0004252', 'EFO_0003032', 'EFO_0000182', 'EFO_0000220', 'MONDO_0002158']",145.0,"['ENSG00000157764', 'ENSG00000122025', 'ENSG00000132155', 'ENSG00000113721', 'ENSG00000165731', 'ENSG00000157404', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",9,2005.0,,,"['103904444', '124893321', '124893323', '50100118', '50112741']",['50924'],,,,,
CHEMBL1371200,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)[O-].[K+],JTZQCHFUGHIPDF-RYVBEKKQSA-M,Small molecule,False,CANRENOATE POTASSIUM,4.0,False,True,"['Soldactone', 'Spiroctan-m']","['Canrenoate potassium', 'Canrenone free acid potassium salt', 'Kanrenol', 'NSC-757789', 'Potassium canrenoate', 'SC-14266']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.,,,"['EFO_0000319', 'EFO_0008585']",2.0,['ENSG00000151623'],1,,CHEMBL1616951,,"['144204351', '56463334']",,,,,,
CHEMBL2108345,,,Oligonucleotide,False,TRABEDERSEN,3.0,False,False,[],"['A-12009 FREE ACID', 'Trabedersen']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000519', 'EFO_0002499']",2.0,['ENSG00000092969'],1,,,,,,,,,,
CHEMBL2331680,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1,RGJOJUGRHPQXGF-INIZCTEOSA-N,Small molecule,False,RG-7603,1.0,False,False,[],"['GDC-0349', 'Rg-7603']",['CHEMBL2331681'],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB13072'],['EFO_0005952'],1.0,['ENSG00000198793'],1,,,,,,,,,,
CHEMBL272980,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,HRNLUBSXIHFDHP-UHFFFAOYSA-N,Small molecule,False,MOCETINOSTAT,2.0,False,False,[],"['MGCD-0103', 'MGCD0103', 'Mocetinostat']",['CHEMBL481122'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications.,['Mocetinostat'],['DB11830'],"['EFO_0000574', 'EFO_0000183', 'EFO_0003060', 'MONDO_0018906', 'EFO_0008528', 'EFO_0000222', 'EFO_0000565', 'EFO_0000095', 'EFO_0000616', 'EFO_0000198', 'EFO_0002918', 'EFO_0000199', 'EFO_0000564', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0008903']",16.0,"['ENSG00000196591', 'ENSG00000171720', 'ENSG00000116478', 'ENSG00000147099', 'ENSG00000163517']",5,,,,['137276026'],,,,,,
CHEMBL307429,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,LXBIFEVIBLOUGU-JGWLITMVSA-N,Small molecule,False,DUVOGLUSTAT,2.0,False,False,[],"['1 deoxynojirimycin', '1,5-dideoxy-1,5-imino-', '1,5-dideoxy-1,5-imino-d-glucitol', '1-deoxynojirimycin', 'Bay-h-5595', 'D-1-deoxynojirimycin', 'Deoxynojirimycin', 'Duvoglustat', 'Moranolin', 'Moranoline', 'Nojirimycin, 1-deoxy-']",['CHEMBL460785'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB03206'],['Orphanet_365'],1.0,['ENSG00000171298'],1,,,,['26752140'],['44369'],,,,,
CHEMBL5314374,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],MVPQUSQUURLQKF-MCPDASDXSA-E,Oligosaccharide,False,IDRAPARINUX SODIUM,3.0,False,False,[],"['Idraparinux nonasodium salt', 'Idraparinux sodium', 'ORG-34006', 'SANORG-34006', 'SANORG34006']",,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0003907', 'EFO_0003827', 'EFO_0000275']",3.0,['ENSG00000126218'],1,,CHEMBL5314801,,,,,,,,
CHEMBL762,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,WYWIFABBXFUGLM-UHFFFAOYSA-N,Small molecule,False,OXYMETAZOLINE,4.0,False,True,[],"['Nasacon', 'Ocuclear', 'Operil', 'Oxymetazoline']",['CHEMBL1200791'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 8 approved and 10 investigational indications.,['Oxymetazoline'],['DB00935'],"['EFO_0009523', 'MONDO_0000728', 'EFO_0003956', 'MONDO_0001330', 'HP_0010783', 'HP_0001742', 'EFO_0007141', 'EFO_0007214', 'EFO_0005252', 'HP_0010783', 'EFO_0005854', 'EFO_1000760', 'HP_0001742', 'EFO_0005751', 'EFO_0005854', 'MONDO_0001330', 'EFO_0007486', 'EFO_0007214', 'EFO_0003956', 'EFO_1000760']",20.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1986.0,,,"['104171207', '11111570', '11111571', '11113337', '124880976', '124880979', '144203768', '170464916', '26751491', '26751492', '50100299', '50104031', '90341671']",['7862'],,,,,
CHEMBL1200728,Cl.N=C(N)N,PJJJBBJSCAKJQF-UHFFFAOYSA-N,Small molecule,False,GUANIDINE HYDROCHLORIDE,4.0,False,True,['Guanidine hydrochloride'],"['Guanidine HCl', 'Guanidine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 3 approved indications.,,,"['EFO_0008524', 'HP_0001324', 'EFO_0004991']",3.0,"['ENSG00000053918', 'ENSG00000171385', 'ENSG00000055118', 'ENSG00000177301', 'ENSG00000111262', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000104848', 'ENSG00000185760', 'ENSG00000117013', 'ENSG00000143473', 'ENSG00000182255', 'ENSG00000130037', 'ENSG00000177272', 'ENSG00000151079', 'ENSG00000129159', 'ENSG00000184408', 'ENSG00000182674', 'ENSG00000116396', 'ENSG00000131398', 'ENSG00000158445', 'ENSG00000143105', 'ENSG00000164794', 'ENSG00000140015', 'ENSG00000171126', 'ENSG00000168418', 'ENSG00000168263', 'ENSG00000124134', 'ENSG00000183960', 'ENSG00000166006', 'ENSG00000170745', 'ENSG00000173826', 'ENSG00000162975', 'ENSG00000184611', 'ENSG00000102057', 'ENSG00000026559', 'ENSG00000178342', 'ENSG00000135519', 'ENSG00000156486', 'ENSG00000089558']",40,1939.0,CHEMBL821,,,['32735'],,,,,
CHEMBL1592101,,,Small molecule,False,BISMUTH SUBGALLATE,4.0,False,True,[],"['Basic bismuth gallate', 'Bismuth subgallate', 'Gallic acid bismuth basic salt']",,Small molecule drug with a maximum clinical trial phase of IV and is indicated for flatulence.,,,['EFO_0009669'],1.0,['ENSG00000131187'],1,,,,"['144205941', '29218038']",['31292'],,,,,
CHEMBL1657,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,OGQICQVSFDPSEI-UHFFFAOYSA-N,Small molecule,False,TAZAROTENE,4.0,False,True,"['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']","['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 3 investigational indications.,['Tazarotene'],['DB00799'],"['EFO_0003894', 'EFO_0009259', 'Orphanet_183469', 'EFO_1001494', 'EFO_0000701', 'EFO_0002913', 'EFO_0000676']",7.0,"['ENSG00000172819', 'ENSG00000077092', 'ENSG00000131759']",3,1997.0,,['tazarotene'],"['144206075', '170464671', '174006350', '50112778']",['32184'],,,,,
CHEMBL289351,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+],VXNQMUVMEIGUJW-XNOMRPDFSA-L,Small molecule,False,FOSBRETABULIN DISODIUM,2.0,False,False,[],"['CA 4P', 'CA-4DP', 'CA4DP', 'Fosbretabulin disodium', 'Fosbretabulin disodium salt']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000616', 'EFO_0004683', 'MONDO_0004992', 'EFO_0006859']",4.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,CHEMBL1206232,,,,,,,,
CHEMBL4297579,,,Gene,False,VALOCTOCOGENE ROXAPARVOVEC,4.0,False,True,['Roctavian'],"['BMN-270', 'BMN270', 'Valoctocogene roxaparvovec']",,Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and has 1 investigational indication.,,,['MONDO_0010602'],1.0,['ENSG00000101981'],1,2022.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0'],,,,
CHEMBL4297850,,,Antibody,False,XENTUZUMAB,2.0,False,False,[],"['BI 836845', 'BI-836845', 'Bi 836845', 'Xentuzumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0000616', 'EFO_0000673', 'EFO_0003869', 'MONDO_0008315', 'EFO_0003060']",5.0,"['ENSG00000167244', 'ENSG00000017427']",2,,,,,,,,,,
CHEMBL4650349,O=C(c1ccc(F)cc1)c1ccccc1N[C@@H](Cc1ccc(OCCn2c3ccccc3c3ccccc32)cc1)C(=O)O,QNLWMPLUWMWDMQ-YTTGMZPUSA-N,Small molecule,False,CHIGLITAZAR,3.0,False,False,[],"['CS 038', 'CS-038', 'Carfloglitazar, (s)-', 'Chiglitazar']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0003086', 'EFO_0001421', 'EFO_1001249', 'MONDO_0005148']",4.0,"['ENSG00000132170', 'ENSG00000186951', 'ENSG00000112033']",3,,,,,,,,,,
CHEMBL90555,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,OGWKCGZFUXNPDA-XQKSVPLYSA-N,Small molecule,True,VINCRISTINE,4.0,False,True,[],"['22-oxovincaleukoblastine', 'Leucristine', 'Leurocristine', 'Oncotcs', 'Tecnocris', 'Vincaleukoblastine, 22-oxo-', 'Vincristin', 'Vincristine', 'Vinkristin']",['CHEMBL501867'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for neoplasm and has 90 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000174', 'MONDO_0009348', 'MONDO_0000870', 'EFO_0000248', 'EFO_0000220', 'MONDO_0008380', 'EFO_1000292', 'MONDO_0015760', 'EFO_0000094', 'EFO_0000183', 'MONDO_0016717', 'EFO_0000616', 'EFO_1001469', 'EFO_0000183', 'EFO_0002939', 'EFO_0004289', 'EFO_0000255', 'EFO_0000502', 'EFO_0003833', 'EFO_0000211', 'EFO_0002918', 'EFO_0005952', 'EFO_0000096', 'MONDO_0008903', 'EFO_1000131', 'EFO_0000180', 'EFO_0005235', 'EFO_0000502', 'EFO_1000292', 'EFO_1000635', 'EFO_0002499', 'EFO_0000209', 'EFO_1001951', 'MONDO_0008380', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0015540', 'EFO_0000095', 'MONDO_0002974', 'MONDO_0044881', 'EFO_1000796', 'EFO_0007160', 'MONDO_0003478', 'HP_0001871', 'EFO_0002939', 'MONDO_0000873', 'EFO_0000574', 'MONDO_0018271', 'MONDO_0019004', 'EFO_0003833', 'EFO_0000309', 'EFO_0000222', 'EFO_0000437', 'EFO_0000272', 'EFO_1001469', 'EFO_0000309', 'EFO_0000211', 'EFO_0000094', 'MONDO_0000873', 'EFO_0009254', 'EFO_0004289', 'MONDO_0044917', 'MONDO_0018975', 'MONDO_0000432', 'EFO_0006859', 'EFO_1001365', 'EFO_0000198', 'EFO_0000558', 'EFO_0000248', 'EFO_0000437', 'EFO_0001378', 'EFO_0000565', 'EFO_0003032', 'EFO_0000519', 'MONDO_0004095', 'EFO_0000220', 'EFO_1000158', 'EFO_0000756', 'EFO_0000565', 'EFO_1001042', 'EFO_0009708', 'EFO_0000621', 'MONDO_0002367', 'EFO_0003032', 'EFO_0000616', 'MONDO_0016700', 'EFO_0001378', 'MONDO_0019004', 'EFO_0000621', 'MONDO_0001657', 'MONDO_0000430', 'EFO_0000403', 'EFO_0000574', 'EFO_0000702', 'EFO_0000637', 'MONDO_0000870', 'EFO_0000209', 'EFO_1000318', 'MONDO_0018944', 'MONDO_0015564', 'EFO_0005952', 'EFO_0000313', 'EFO_0000691', 'EFO_1000158', 'EFO_0000588', 'EFO_0000403', 'MONDO_0009348', 'MONDO_0006058', 'EFO_0000222', 'EFO_1001365', 'EFO_1001830', 'EFO_0009441', 'MONDO_0018906', 'EFO_0000691', 'MONDO_0019471', 'EFO_0000096', 'EFO_0000765', 'EFO_0002918', 'EFO_0000174', 'MONDO_0044917']",120.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1963.0,,,"['124892473', '144205620', '170465186']",['28445'],,,,,
CHEMBL1196,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N,KCLANYCVBBTKTO-UHFFFAOYSA-N,Small molecule,False,PROPARACAINE,4.0,False,True,[],"['Alcaine', 'Kainair', 'Ophthaine', 'Ophthetic', 'Paracaine', 'Proparacaine', 'Proxymetacaine']",['CHEMBL1200464'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and has 1 investigational indication.,['Proxymetacaine'],['DB00807'],['EFO_0003843'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1953.0,,,"['11112907', '124882712', '174006303']",['8485'],,,,,
CHEMBL1200814,CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+],MRSXAJAOWWFZJJ-UHFFFAOYSA-M,Small molecule,False,ACETAZOLAMIDE SODIUM,4.0,False,True,"['Acetazolamide sodium', 'Diamox']","['Acetazolamide Sodium', 'Acetazolamide sodium', 'Acetazolamide sodium salt', 'Sodium acetazolamide', 'Vetamox']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 4 approved indications.,,,"['MONDO_0001744', 'EFO_0009373', 'MONDO_0005041', 'HP_0001250']",4.0,"['ENSG00000167434', 'ENSG00000074410', 'ENSG00000133742', 'ENSG00000104267']",4,1990.0,CHEMBL20,,,['31163'],,,,,
CHEMBL121,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,YASAKCUCGLMORW-UHFFFAOYSA-N,Small molecule,True,ROSIGLITAZONE,4.0,True,True,['Avandia'],"['Avandamet', 'Avandaryl', 'Avandia', 'BRL-49653', 'Gaudil', 'NSC-758698', 'Rezult', 'Rosiglitazone', 'Rosiglizole', 'Rosvel', 'TDZ-01']","['CHEMBL843', 'CHEMBL1704605']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 43 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.,['Rosiglitazone'],['DB00412'],"['MONDO_0004992', 'HP_0001952', 'EFO_1001373', 'EFO_0000400', 'MONDO_0007254', 'MONDO_0004979', 'HP_0003124', 'MONDO_0005148', 'EFO_0000691', 'EFO_1001051', 'EFO_0001068', 'EFO_0000616', 'EFO_0003914', 'EFO_0006911', 'MONDO_0005148', 'EFO_0003914', 'HP_0100543', 'EFO_0004236', 'Orphanet_309005', 'EFO_1001110', 'EFO_0000195', 'EFO_0007444', 'EFO_0000764', 'EFO_0000373', 'EFO_0004272', 'EFO_0000589', 'EFO_0002614', 'EFO_1000785', 'HP_0002745', 'EFO_0000685', 'EFO_0004234', 'EFO_0000764', 'EFO_0000729', 'EFO_1000158', 'EFO_0001065', 'EFO_0001645', 'EFO_1001249', 'EFO_0000400', 'EFO_0002546', 'EFO_1001121', 'EFO_1000783', 'EFO_0003095', 'MONDO_0004975', 'EFO_0000537', 'EFO_0006859', 'EFO_0000673', 'EFO_0002614']",47.0,['ENSG00000132170'],1,1999.0,,,"['144204987', '170465417', '174007204', '26748954']",['50122'],,,,,
CHEMBL1697737,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,CHBRHODLKOZEPZ-UHFFFAOYSA-N,Small molecule,False,CLOTIAZEPAM,4.0,False,True,['Clozan'],['Clotiazepam'],,Small molecule drug with a maximum clinical trial phase of IV and is indicated for anxiety.,,['DB01559'],['EFO_0005230'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL188462,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1,RPCVIAXDAUMJJP-PZBABLGHSA-N,Small molecule,False,ISPRONICLINE,2.0,False,False,[],"['AZD-3480', 'Azd3480', 'Ispronicline', 'TC-01734', 'TC-1734']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0001072', 'MONDO_0005090', 'MONDO_0004975', 'EFO_0003888']",4.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL2108361,,,Enzyme,False,AMEDIPLASE,2.0,False,False,[],['Amediplase'],,Enzyme drug with a maximum clinical trial phase of II.,,,,,['ENSG00000122194'],1,,,,,,,,,,
CHEMBL2109526,,,Antibody,False,PG-110,1.0,False,False,[],"['PG-110', 'Pg-110']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0004616'],1.0,['ENSG00000134259'],1,,,,,,,,,,
CHEMBL3183409,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,HJBWBFZLDZWPHF-UHFFFAOYSA-N,Small molecule,False,APALUTAMIDE,4.0,False,True,['Erleada'],"['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']","['CHEMBL4082191', 'CHEMBL4105484', 'CHEMBL4100200', 'CHEMBL4062002']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 2 investigational indications.,,['DB11901'],"['EFO_0000196', 'EFO_0000616', 'EFO_0000673', 'MONDO_0004992', 'EFO_0001421', 'EFO_0001663', 'EFO_0003826', 'MONDO_0008315']",8.0,['ENSG00000169083'],1,2018.0,,['apalutamide'],['174007290'],,['https://www.ema.europa.eu/en/medicines/human/EPAR/erleada'],,,,
CHEMBL3989519,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O,ZOMBFZRWMLIDPX-UHFFFAOYSA-N,Small molecule,False,DOXAPRAM HYDROCHLORIDE,4.0,False,True,"['Dopram', 'Doxapram hydrochloride', 'Stimulexin']","['AHR-619', 'Doxapram hcl', 'Doxapram hydrochloride', 'Doxapram hydrochloride hydrate', 'Doxapram hydrochloride monohydrate', 'NSC-170958', 'NSC-760347', 'Stimulexin']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for lung disease and has 1 investigational indication.,,,"['EFO_0004262', 'EFO_0003818']",2.0,"['ENSG00000171303', 'ENSG00000169427']",2,1965.0,CHEMBL1754,['doxapram%20hydrochloride'],,,,,,,
CHEMBL3989970,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F,JYIUNVOCEFIUIU-GHMZBOCLSA-N,Small molecule,False,MAVELERTINIB,2.0,False,False,[],"['Egfr t790m inhibitor pf-06747775', 'Mavelertinib', 'PF-06747775']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003060'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL6966,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,SGTNSNPWRIOYBX-UHFFFAOYSA-N,Small molecule,False,VERAPAMIL,4.0,False,True,[],"['CP-16,533-1', 'CP-16533-1', 'CP-165331', 'Calan', 'Covera-HS', 'D-365', 'Iproveratril', 'Isoptin', 'NSC-272306NA', 'Tarka', 'Verapamil', 'Verapamil slow release', 'Verelan']","['CHEMBL1280', 'CHEMBL1707604', 'CHEMBL483787']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 16 investigational indications.,['Verapamil'],['DB00661'],"['HP_0004308', 'EFO_0004616', 'MONDO_0005148', 'MP_0001914', 'EFO_0000384', 'EFO_0000275', 'MONDO_0100096', 'EFO_0003843', 'EFO_0003890', 'EFO_0000319', 'EFO_0004269', 'EFO_0000319', 'EFO_1001413', 'EFO_0000400', 'EFO_0003144', 'EFO_0000183', 'EFO_0000275', 'HP_0002140', 'MONDO_0004985', 'MONDO_0005147', 'EFO_0000537']",21.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1981.0,,,"['104171262', '124881789', '124881790', '124881792', '124881795', '144203851', '170464904', '174316170', '26751825', '50104518', '50104519', '50104520', '90340771']",['77733'],,,,,
CHEMBL1174,N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O,CZKPOZZJODAYPZ-LROMGURASA-N,Protein,False,EPTIFIBATIDE,4.0,False,True,"['Eptifibatide', 'Eptifibatide accord', 'Integrilin']","['Eptifibatide', 'Integrelin']",['CHEMBL4068311'],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 9 investigational indications.,['Eptifibatide'],,"['MONDO_0011382', 'EFO_0000612', 'EFO_0000319', 'EFO_0001645', 'EFO_0000712', 'HP_0002140', 'EFO_0005672', 'EFO_0008583', 'EFO_0006834', 'EFO_0003106', 'HP_0004419', 'EFO_0008585', 'EFO_0004277']",13.0,"['ENSG00000259207', 'ENSG00000005961']",2,1998.0,,['eptifibatide'],"['144206056', '170465043']",['291902'],['https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord'],,,,
CHEMBL1201735,Br.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,WSTCENNATOVXKQ-UHFFFAOYSA-N,Small molecule,True,BUPROPION HYDROBROMIDE,4.0,False,True,['Aplenzin'],"['BVF-033', 'Bupropion hbr', 'Bupropion hydrobromide']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and is indicated for unipolar depression. This drug has a black box warning from the FDA.,,,['EFO_0003761'],1.0,"['ENSG00000142319', 'ENSG00000103546']",2,2008.0,CHEMBL894,['bupropion%20hydrobromide'],,,,,,,
CHEMBL1278146,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,GKEYKDOLBLYGRB-LGMDPLHJSA-N,Small molecule,False,FAMITINIB,3.0,False,False,[],"['Famitinib', 'SHR-1020', 'SHR1020', 'Shr-1020']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,['DB11741'],"['MONDO_0024503', 'EFO_0003869', 'EFO_0003060', 'EFO_0000756', 'EFO_0004252', 'EFO_0005537', 'EFO_0002618', 'EFO_0000681', 'EFO_0001071', 'EFO_0005922', 'EFO_1001961', 'MONDO_0002974', 'MONDO_0011719', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000365']",17.0,"['ENSG00000157404', 'ENSG00000128052', 'ENSG00000122025', 'ENSG00000037280', 'ENSG00000102755', 'ENSG00000113721', 'ENSG00000134853']",7,,,,,,,,,,
CHEMBL166863,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O,IJWPAFMIFNSIGD-UHFFFAOYSA-N,Small molecule,False,POLMACOXIB,3.0,False,False,[],"['CG-100649', 'CG100649', 'Polmacoxib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB12399'],"['EFO_1000786', 'MONDO_0005178', 'EFO_0005755', 'EFO_0004616']",4.0,"['ENSG00000073756', 'ENSG00000104267', 'ENSG00000133742']",3,,,,,,,,,,
CHEMBL1712842,CC(=O)O.CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1,COBIOCPXKOZHSU-UHFFFAOYSA-N,Small molecule,False,MEPAZINE ACETATE,4.0,True,True,[],"['Mepazine acetate', 'NND 1964', 'Pecazine acetate']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,,,,['ENSG00000172175'],1,,CHEMBL395110,,['49645132'],,,,,,
CHEMBL1743089,,,Antibody,False,VESENCUMAB,2.0,False,False,[],"['MNRP-1685A', 'MNRP1685A', 'RG-7347', 'Vesencumab']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0004992'],1.0,['ENSG00000099250'],1,,,,,,,,,,
CHEMBL2108250,,,Enzyme,False,ANISTREPLASE,4.0,False,True,['Eminase'],"['APSAC', 'Anistreplase', 'BRL 26921', 'BRL-26921']",,Enzyme drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis.,,,['HP_0004419'],1.0,['ENSG00000122194'],1,,,,,,,,,,
CHEMBL2108319,,,Protein,False,SIMOCTOCOG ALFA,4.0,False,True,['Vihuma'],"['Human-cl rh fviii', 'Nuwiq', 'Simoctocog alfa']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia a.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,2017.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/vihuma'],,,,
CHEMBL2108403,,,Antibody,False,EPITUMOMAB,2.0,False,False,[],['Epitumomab'],,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL395110,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1,CBHCDHNUZWWAPP-UHFFFAOYSA-N,Small molecule,False,MEPAZINE,4.0,True,True,[],"['III-2318', 'Lacumin', 'Mepasin', 'Mepazin', 'Mepazine base', 'Meprazine', 'Mesapin', 'Nothiazine', 'P-391', 'Pacatal', 'Pacatal base', 'Pacatol', 'Pakatal', 'Paxital', 'Pecatal', 'Pecazine']",['CHEMBL1712842'],Small molecule drug with a maximum clinical trial phase of IV.,,,,,['ENSG00000172175'],1,,,,"['144205395', '29216162']",,,,,,
CHEMBL4298192,,,Oligonucleotide,False,SUVODIRSEN,2.0,False,False,[],"['BMTR0139', 'Suvodirsen', 'WLS-4176', 'WV-3473', 'WVE-210201', 'Wve-210201']",,Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0010679'],1.0,['ENSG00000198947'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SUVODIRSEN/relevant/1/'],,,
CHEMBL4535757,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,NXQKSXLFSAEQCZ-SFHVURJKSA-N,Small molecule,False,SOTORASIB,4.0,False,True,"['Lumakras', 'Lumykras']","['AMG-510', 'AMG510', 'Kras g12c inhibitor 9', 'Kras mutant-targeting amg 510', 'Sotorasib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 8 investigational indications.,,,"['EFO_0000571', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001075', 'EFO_1001512', 'EFO_0001421', 'EFO_1000251', 'EFO_0002618', 'EFO_0000365', 'EFO_0000616']",10.0,['ENSG00000133703'],1,2021.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras'],['https://searchusan.ama-assn.org/finder/usan/search/SOTORASIB/relevant/1/'],,,
CHEMBL494089,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,KGPGFQWBCSZGEL-ZDUSSCGKSA-N,Small molecule,False,GSK-690693,1.0,False,False,[],"['GSK 690693', 'GSK690693', 'Gsk-690693']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB12745'],['MONDO_0004992'],1.0,"['ENSG00000142875', 'ENSG00000072062', 'ENSG00000165059', 'ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208', 'ENSG00000115825', 'ENSG00000163558', 'ENSG00000154229', 'ENSG00000126583', 'ENSG00000163932', 'ENSG00000166501', 'ENSG00000067606', 'ENSG00000171132', 'ENSG00000027075', 'ENSG00000184304', 'ENSG00000065675']",17,,,,,['90677'],,,,,
CHEMBL1200703,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1.Cl,DMLFJMQTNDSRFU-UHFFFAOYSA-N,Small molecule,True,CHLORDIAZEPOXIDE HYDROCHLORIDE,4.0,False,True,"['A-poxide', 'Chlordiazachel', 'Chlordiazepoxide hydrochloride', 'Librium', 'Lygen', 'Tropium']","['Chlordiazepoxide hcl', 'Chlordiazepoxide hydrochloride', 'Clopoxide chloride', 'NSC-115748', 'RO 5-0690', 'RO-5-0690']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1960.0,CHEMBL451,['chlordiazepoxide%20hydrochloride'],,['3612'],,,,,
CHEMBL266510,COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(C(F)(F)F)ccc21,ULYONBAOIMCNEH-HNNXBMFYSA-N,Small molecule,False,FLINDOKALNER,3.0,False,False,[],"['BMS-204352', 'BMS-204352-01', 'Flindokalner']",,Small molecule drug with a maximum clinical trial phase of III.,,,,,"['ENSG00000184156', 'ENSG00000117013', 'ENSG00000185760', 'ENSG00000156113', 'ENSG00000075043']",5,,,,,,,,,,
CHEMBL3545385,,,Small molecule,False,WX-037,1.0,False,False,[],['Wx-037'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,,,,
CHEMBL4297534,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O,VJCVKWFBWAVYOC-UIXXXISESA-N,Small molecule,True,GLASDEGIB MALEATE,4.0,False,True,['Daurismo'],"['Glasdegib maleate', 'PF-04449913 MALEATE']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA.,,,['EFO_0000222'],1.0,['ENSG00000128602'],1,2018.0,CHEMBL2043437,['glasdegib%20maleate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo'],,,,
CHEMBL517,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,UVTNFZQICZKOEM-UHFFFAOYSA-N,Small molecule,True,DISOPYRAMIDE,4.0,False,True,[],"['(rs)-disopyramide', 'Dicorantil', 'Disopyramide', 'Dl-disopyramide', 'H-3292', 'Isorythm', 'Lispine', 'Norpace', 'Ritmilen', 'Rythmodan p', 'SC-7031', 'Searle-703']",['CHEMBL1201020'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.,['Disopyramide'],['DB00280'],"['HP_0004308', 'EFO_0004269', 'EFO_0000275', 'EFO_0004269', 'EFO_0003144', 'EFO_0000275']",6.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1977.0,,,"['144204278', '170464947', '174006632', '50106174', '85148360', '85231006', '90340571', '90341382']",['4657'],,,['102'],,
CHEMBL1201248,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC,YXSLJKQTIDHPOT-LJCJQEJUSA-N,Small molecule,False,CISATRACURIUM,4.0,False,True,['Nimbex'],"['Cisatracurium', 'Cisatracurium cation', 'Cisatracurium ion']",['CHEMBL1200641'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication.,['Cisatracurium_besilate'],['DB00565'],['EFO_1000637'],1.0,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1995.0,,,,,,,,,
CHEMBL1201772,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,DTGLZDAWLRGWQN-UHFFFAOYSA-N,Small molecule,True,PRASUGREL,4.0,False,True,['Efient'],"['LY-640315', 'NSC-759625', 'Prasugrel']",['CHEMBL1201773'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA.,['Prasugrel'],['DB06209'],"['EFO_0003777', 'EFO_0000612', 'EFO_0000612', 'MONDO_0004979', 'EFO_0008585', 'MP_0001914', 'EFO_0003884', 'EFO_0000275', 'EFO_0000764', 'EFO_0003106', 'HP_0004419', 'MONDO_0011382', 'EFO_0007328', 'EFO_0005672', 'EFO_0001645', 'MONDO_0100096', 'EFO_0005672']",17.0,['ENSG00000169313'],1,2009.0,,,"['124899264', '174006898']",['87723'],,,,,
CHEMBL1234354,COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1,XDLYKKIQACFMJG-WKILWMFISA-N,Small molecule,False,PF-04691502,2.0,False,False,[],"['PF-04691502', 'PF-4691502', 'Pf-04691502']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB11974'],"['EFO_0003869', 'MONDO_0007254', 'MONDO_0004992']",3.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,,,,,,
CHEMBL1683544,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O,QAMYWGZHLCQOOJ-WRNBYXCMSA-N,Small molecule,False,ERIBULIN MESYLATE,4.0,False,True,['Halaven'],"['E-7389', 'E7389', 'Eribulin (as mesylate)', 'Eribulin mesilate', 'Eribulin mesylate', 'Eribulin monomethanesulfonate', 'Halaven']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 4 approved and 18 investigational indications.,,,"['EFO_0003060', 'EFO_0000616', 'MONDO_0001187', 'EFO_0000569', 'MONDO_0004992', 'EFO_0008528', 'MONDO_0004669', 'EFO_0006859', 'EFO_0000574', 'EFO_0000637', 'EFO_1001968', 'MONDO_0004192', 'EFO_0000673', 'EFO_0006861', 'MONDO_0021632', 'EFO_0000305', 'EFO_1000613', 'EFO_0003869', 'MONDO_0002974', 'MONDO_0007254', 'EFO_0005537', 'MONDO_0008315']",22.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,2010.0,CHEMBL1683590,['eribulin%20mesylate'],,['70710'],['https://www.ema.europa.eu/en/medicines/human/EPAR/halaven'],,,,
CHEMBL2107873,,,Protein,False,VONICOG ALFA,4.0,False,True,['Veyvondi'],"['BAX 111', 'BAX-111', 'Von willebrand factor (recombinant)', 'Vonicog alfa', 'Vonvendi']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for von willebrand disease.,,,['Orphanet_903'],1.0,['ENSG00000110799'],1,2018.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi'],,,['5173'],
CHEMBL2108278,,,Oligonucleotide,False,ETEPLIRSEN,4.0,False,True,['Exondys 51'],"['AVI-4658', 'Eteplirsen']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for duchenne muscular dystrophy and muscular dystrophy.,,,"['MONDO_0010679', 'MONDO_0020121']",2.0,['ENSG00000198947'],1,2016.0,,['eteplirsen'],,,,,,['5182'],
CHEMBL2110900,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,USRHYDPUVLEVMC-FQEVSTJZSA-N,Small molecule,False,DAPOXETINE,4.0,False,True,[],"['Dapoxetine', 'Kutub', 'LY-210448']",['CHEMBL2106574'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.,,['DB04884'],"['EFO_0004714', 'EFO_0803321', 'EFO_0004234']",3.0,['ENSG00000108576'],1,,,,['170466555'],,,,,,
CHEMBL2304041,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O,BFZKMNSQCNVFGM-UCEYFQQTSA-N,Small molecule,False,SAGOPILONE,2.0,False,False,[],"['BAY86-5302', 'DE-03757', 'Sagopilone', 'ZK 219477', 'ZK-219477', 'ZK-EPO', 'Zk219477']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,['DB12391'],"['EFO_0000519', 'MONDO_0007254', 'EFO_0003893', 'EFO_1000158', 'EFO_0003060', 'EFO_0000616', 'EFO_0000756', 'EFO_0003869', 'EFO_0000702', 'MONDO_0008315']",10.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL2402737,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,TVTXCJFHQKSQQM-LJQIRTBHSA-N,Small molecule,False,IDASANUTLIN,3.0,False,False,[],"['Idasanutlin', 'RG-7388', 'RG7388', 'RO-5503781', 'RO5503781']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,['DB12325'],"['EFO_0001378', 'EFO_0000403', 'EFO_1001951', 'MONDO_0018906', 'MONDO_0007254', 'EFO_0000616', 'EFO_0002429', 'EFO_0000222', 'EFO_0000519', 'EFO_0000479', 'EFO_0005952']",11.0,"['ENSG00000141510', 'ENSG00000135679']",2,,,,,,,,,,
CHEMBL3039513,CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,ASUGUQWIHMTFJL-QGZVFWFLSA-N,Small molecule,False,DECERNOTINIB,2.0,False,False,[],"['Adelatinib', 'Decernotinib', 'VRT-831509', 'VX-509']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12566'],['EFO_0000685'],1.0,['ENSG00000105639'],1,,,,,,,,,,
CHEMBL3544913,NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1,JESCETIFNOFKEU-SJORKVTESA-N,Small molecule,False,VIXOTRIGINE,3.0,False,False,[],"['BIIB-074', 'BIIB074', 'CNV-1014802', 'CNV1014802', 'GSK-1014802', 'GSK1014802', 'Raxatrigine', 'Vixotrigine']",['CHEMBL3544912'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB11706'],"['MONDO_0004985', 'MONDO_0016028', 'MONDO_0002959', 'EFO_1001219', 'EFO_1000783', 'EFO_0005762']",6.0,['ENSG00000169432'],1,,,,,,,,,,
CHEMBL3545154,C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,LPFWVDIFUFFKJU-UHFFFAOYSA-N,Small molecule,False,POZIOTINIB,3.0,False,False,[],"['HM 781-36', 'HM 781-36B', 'HM-781-36', 'HM-781-36B', 'HM781-36B', 'Hm-781-36b', 'NOV-1201', 'NOV-120101', 'Poziotinib']",['CHEMBL5095402'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,['DB12114'],"['MONDO_0001056', 'EFO_0000616', 'EFO_0004284', 'EFO_0005922', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000616', 'EFO_0000571', 'MONDO_0004992']",9.0,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568', 'ENSG00000065361']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/POZIOTINIB/relevant/1/'],,,
CHEMBL3545199,,,Small molecule,False,RG-7741,1.0,False,False,[],"['GDC-0575', 'Rg-7741']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000574'],1.0,['ENSG00000149554'],1,,,,,,,,,,
CHEMBL4297986,,,Unknown,False,COAGULATION FACTOR IX HUMAN,4.0,False,True,['Nonafact'],"['Coagulation factor ix human', 'Human coagulation factor ix']",,Unknown drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for hemophilia b.,,,['MONDO_0010604'],1.0,['ENSG00000101981'],1,2001.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/nonafact'],,,,
CHEMBL4298024,,,Protein,False,BINTRAFUSP ALFA,3.0,False,False,[],"['8L9YQ2N6PA', 'Bintrafusp alfa', 'M-7824', 'M7824', 'MSB-0011359C', 'MSB0011359C', 'Msb0011359c']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 32 investigational indications.,,,"['MONDO_0001879', 'MONDO_0001325', 'EFO_0003869', 'EFO_0000196', 'EFO_0000588', 'EFO_0000702', 'MONDO_0007254', 'MONDO_0002974', 'EFO_1001968', 'EFO_0000181', 'MONDO_0008315', 'MONDO_0001528', 'EFO_0003863', 'MONDO_0008903', 'EFO_1000581', 'EFO_0000305', 'EFO_0000365', 'EFO_1001961', 'MONDO_0008170', 'EFO_0001416', 'EFO_0005537', 'MONDO_0001056', 'EFO_0002618', 'EFO_0005221', 'EFO_0000616', 'EFO_0003060', 'EFO_0002916', 'EFO_0001663', 'MONDO_0001402', 'MONDO_0021063', 'EFO_1001931', 'EFO_0000558']",32.0,"['ENSG00000120217', 'ENSG00000105329', 'ENSG00000092969', 'ENSG00000119699']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/BINTRAFUSP%20ALFA/relevant/1/'],,,
CHEMBL521,CC(C)Cc1ccc(C(C)C(=O)O)cc1,HEFNNWSXXWATRW-UHFFFAOYSA-N,Small molecule,True,IBUPROFEN,4.0,False,True,"['Aches-n-pain', 'Advil', 'Advil liqui-gels', 'Advil migraine liqui-gels', 'Anadin joint pain', 'Anadin liquifast', 'Anadin period pain relief', 'Anadin ultra', 'Apsifen', 'Apsifen-f', 'Arthrofen 200', 'Arthrofen 400', 'Arthrofen 600', 'Brufen ret', 'Caldolor', 'Cap-profen', ""Children's advil"", ""Children's advil-flavored"", ""Children's elixsure"", ""Children's ibuprofen"", ""Children's motrin"", 'Co-op', 'Codafen continus', 'Cuprofen for child', 'Cuprofen plus', 'Deep relief', 'Ebufac', 'Femafen', 'Fenbid', 'Fenbid fte', 'Fenpaed', 'Feverfen', 'Fleximex', 'Ibu-slo', 'Ibu-tab', 'Ibu-tab 200', 'Ibucalm', 'Ibuderm', 'Ibufac', 'Ibugel', 'Ibugel fte', 'Ibular', 'Ibuleve', 'Ibumed', 'Ibumetin', 'Ibumousse', 'Ibuprin', 'Ibuprofen', 'Ibuprohm', 'Ibuspray', 'Ibutime', 'Inabrin', ""Infant's advil"", 'Inoven', 'Isisfen', 'Junifen', 'Junior strength advil', 'Junior strength ibuprofen', 'Junior strength motrin', 'Lidifen', 'Lidifen-f', 'Lobufen', 'Mandafen', 'Manorfen', 'Maxa-gesic', 'Medipren', 'Midol', 'Midol liquid gels', 'Migrafen', 'Motrin', 'Motrin ib', 'Motrin migraine pain', 'Novaprin', 'Nuprin', 'Nurofen 400', 'Nurofen back pain sr', 'Nurofen child', 'Nurofen for child', 'Nurofen plus', 'Nurofen recovery', 'Nurofen sinus', 'Nurofen solb', 'Orbifen', 'Pacifene', 'Paxofen', 'Pedea', 'Pediatric advil', 'Phensic', 'Phor pain', 'Phorpain', 'Phorpain max strgh', 'Profen', 'Proflex', 'Proflex sr', 'Relcofen', 'Rimafen', 'Rufen', 'Seclodin', 'Suspren', 'Tab-profen']","['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01', 'NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']","['CHEMBL4594450', 'CHEMBL5201530', 'CHEMBL3989408', 'CHEMBL1201141', 'CHEMBL1241153']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 21 approved and 61 investigational indications. This drug has a black box warning from the FDA.,['Ibuprofen'],['DB01050'],"['EFO_0002609', 'EFO_0009582', 'EFO_0007328', 'EFO_1000652', 'EFO_0003931', 'HP_0003326', 'MONDO_0002009', 'EFO_0000546', 'HP_0012228', 'EFO_0003869', 'HP_0004398', 'EFO_0009615', 'EFO_0005252', 'HP_0003419', 'EFO_0002970', 'MONDO_0004975', 'HP_0002315', 'EFO_1001158', 'EFO_0000685', 'EFO_0009516', 'EFO_0009846', 'EFO_0001068', 'EFO_0003917', 'EFO_0005854', 'EFO_0000537', 'EFO_1000632', 'EFO_0003843', 'MONDO_0024290', 'EFO_0006803', 'EFO_0005279', 'EFO_0003938', 'EFO_0000649', 'HP_0001643', 'EFO_0007214', 'EFO_0004263', 'EFO_0003918', 'EFO_0003843', 'EFO_0004209', 'MONDO_0002367', 'EFO_0003958', 'HP_0001945', 'HP_0100543', 'EFO_0010072', 'EFO_0003944', 'EFO_0000706', 'EFO_0004616', 'EFO_0005856', 'MONDO_0007254', 'EFO_1000843', 'EFO_0000464', 'MONDO_0019091', 'EFO_1000637', 'EFO_1001139', 'MONDO_0005301', 'MP_0001914', 'HP_0012532', 'EFO_0000544', 'MONDO_0005147', 'EFO_0006834', 'EFO_0000668', 'MONDO_0005277', 'EFO_0003843', 'MONDO_0002258', 'HP_0030833', 'MONDO_0010679', 'HP_0003418', 'EFO_0005755', 'EFO_1000782', 'HP_0001643', 'EFO_0007486', 'EFO_0000764', 'EFO_1000854', 'MONDO_0005178', 'MONDO_0100342', 'EFO_0009610', 'MONDO_0009291', 'EFO_1001216', 'EFO_0005757', 'EFO_0000319', 'HP_0100607', 'MONDO_0018076', 'MONDO_0018305', 'HP_0002829']",83.0,"['ENSG00000073756', 'ENSG00000095303']",2,1974.0,,['ibuprofen'],"['104171175', '124880372', '124880375', '138460', '144203721', '144208582', '144213146', '170464979', '174007269', '26747223', '26747224', '26752326', '50105276', '50105277', '50105278', '56422436', '85231082', '855602', '90341584']",['5855'],['https://www.ema.europa.eu/en/medicines/human/EPAR/pedea'],,['72'],,
CHEMBL1750,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,WDDPHFBMKLOVOX-AYQXTPAHSA-N,Small molecule,False,CLOFARABINE,4.0,False,True,"['Clolar', 'Evoltra']","['Clofarabine', 'Clolar', 'NSC-759857']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 17 investigational indications.,['Clofarabine'],['DB00631'],"['MONDO_0017198', 'EFO_0000574', 'MONDO_0000873', 'EFO_0000220', 'EFO_1001779', 'MONDO_0015760', 'EFO_0000222', 'MONDO_0013730', 'EFO_1000318', 'EFO_0000095', 'EFO_0005803', 'EFO_0000183', 'EFO_0001378', 'EFO_0005952', 'EFO_0000198', 'EFO_0000096', 'EFO_0004289', 'EFO_0000339', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000224', 'EFO_0000616']",22.0,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229', 'ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848']",14,2004.0,,['clofarabine'],"['144205735', '170465145']",['681569'],['https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra'],,,,
CHEMBL2109637,,,Antibody,False,HUHMFG1,2.0,False,False,[],"['AS-1402', 'AS1402', 'HUHMFG1', 'Huhmfg1', 'MOAB HuHMFG1', 'R1550', 'Therex', 'humanized IgG1 monoclonal antibody', 'humanized human milk fat globule-1 monoclonal antibody']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000305', 'MONDO_0007254']",2.0,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL3301589,,,Antibody drug conjugate,True,ENFORTUMAB VEDOTIN,4.0,False,True,['Padcev'],"['AGS-22CE', 'AGS-22M6E', 'AGS-22ME', 'AGS-22MSE', 'ASG-22ME', 'Asg-22ce', 'Enfortumab vedotin', 'Enfortumab vedotin ejfv']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_1000601', 'MONDO_0004180', 'EFO_0000616', 'MONDO_0004992', 'EFO_0003863', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0008528', 'MONDO_0005184']",9.0,"['ENSG00000143217', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,2019.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/padcev'],,,,
CHEMBL339427,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,JFJZZMVDLULRGK-URLMMPGGSA-O,Small molecule,False,TUBOCURARINE,4.0,False,True,[],"['D-tubocurarine', 'Tubocurarine', 'Tubocurarine cation', 'Tubocurarine ion']","['CHEMBL292280', 'CHEMBL3989821', 'CHEMBL1687']",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1945.,,['DB01199'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1945.0,,,['26756599'],['9774'],,,,,
CHEMBL3544992,,,Antibody,False,DENINTUZUMAB,-1.0,False,False,[],"['Denintuzumab', 'HBU-12', 'hBU12']",,Antibody drug.,,,,,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL3545366,CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,RGHYDLZMTYDBDT-UHFFFAOYSA-N,Small molecule,False,VOXTALISIB,2.0,False,False,[],"['SAR-245409', 'SAR245409', 'Voxtalisib', 'XL-765', 'XL765']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,['DB12400'],"['EFO_0003060', 'MONDO_0007254', 'MONDO_0003268', 'EFO_0000756', 'EFO_0000574', 'EFO_0000095', 'EFO_0000616', 'EFO_1001469', 'EFO_1001951', 'EFO_0000519', 'MONDO_0004992', 'MONDO_0008170']",12.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,,,,,,,,,
CHEMBL3590187,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,GPNHMOZDMYNCPO-PDUMRIMRSA-N,Small molecule,False,CLASCOTERONE,4.0,False,True,"['Breezula', 'Winlevi']","['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionate', 'Cortodoxone 17.alpha.-propionate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for acne and has 1 investigational indication.,,['DB12499'],"['EFO_0004191', 'EFO_0003894']",2.0,['ENSG00000169083'],1,2020.0,,,,,,,,,
CHEMBL3989830,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1.Cl.O,KFNNPQDSPLWLCX-UHFFFAOYSA-N,Small molecule,False,SIBUTRAMINE HYDROCHLORIDE,4.0,True,True,['Meridia'],"['BTS 54524', 'BTS-54524', 'NSC-758928', 'Sibutramine hcl', 'Sibutramine hydrochloride', 'Sibutramine hydrochloride civ', 'Sibutramine hydrochloride hydrate', 'Sibutramine hydrochloride monohydrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and has 1 investigational indication. It was withdrawn in at least one region.,,,['EFO_0001073'],1.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,1997.0,CHEMBL1419,,,,,,,,
CHEMBL420,N=C(N)N/N=C/c1c(Cl)cccc1Cl,WDZVGELJXXEGPV-YIXHJXPBSA-N,Small molecule,False,GUANABENZ,4.0,False,True,[],"['Guanabenz', 'NSC-68982', 'WY-8678']",['CHEMBL1200560'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.,['Guanabenz'],,['EFO_0003929'],1.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1982.0,,,"['26751943', '50104618', '50104619', '90341577']",['5553'],,,,,
CHEMBL4297223,O.O.O.O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1.O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1.O=S(=O)(O)O,DMRIPASJCJRBMV-UHFFFAOYSA-N,Small molecule,False,MITAPIVAT SULFATE,4.0,False,True,['Pyrukynd'],"['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrate', 'Mitapivat sulfate', 'Pyrukynd']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved indications.,,,"['MONDO_0003689', 'MONDO_0002280', 'EFO_0000508']",3.0,['ENSG00000143627'],1,2022.0,CHEMBL4299940,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd'],,,,
CHEMBL461522,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,LVWZTYCIRDMTEY-UHFFFAOYSA-N,Small molecule,False,METAMIZOLE,4.0,True,True,[],"['Metamizole', 'Methamizole-']","['CHEMBL487894', 'CHEMBL3989803']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 4 investigational indications.,,['DB04817'],"['HP_0100806', 'MONDO_0005277', 'EFO_0003843', 'HP_0001945', 'EFO_1001463', 'HP_0012532']",6.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,,['62088'],,,,,
CHEMBL571209,Cn1cc(C[C@@H](N)C(=O)O)c2ccccc21,ZADWXFSZEAPBJS-SNVBAGLBSA-N,Small molecule,False,INDOXIMOD,2.0,False,False,[],"['1-methyltryptophan, d-', 'D-1-methyltryptophan', 'D-1MT', 'Indoximod', 'N-1-methyl-d-tryptophan', 'NLG-8189', 'NSC-721782']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,['DB12827'],"['EFO_0000756', 'EFO_1000028', 'MONDO_0007254', 'EFO_0002617', 'EFO_0002939', 'EFO_0003060', 'EFO_0000222', 'EFO_0000616', 'EFO_1001465', 'EFO_0000196']",10.0,"['ENSG00000198793', 'ENSG00000141564', 'ENSG00000167965']",3,,,,['536240'],,,,,,
CHEMBL807,CC12CC3CC(C)(C1)CC(N)(C3)C2,BUGYDGFZZOZRHP-UHFFFAOYSA-N,Small molecule,False,MEMANTINE,4.0,False,True,[],"['D-145', 'DRG-0267', 'Memantine', 'NSC-757843', 'Namenda']","['CHEMBL1882685', 'CHEMBL1699']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and dementia and has 51 investigational indications.,['Memantine'],['DB01043'],"['HP_0012167', 'EFO_0000326', 'MONDO_0005180', 'MONDO_0004985', 'MONDO_0004975', 'EFO_0009386', 'MONDO_0004992', 'EFO_0005611', 'EFO_0003890', 'EFO_0003758', 'MONDO_0004976', 'MONDO_0007079', 'HP_0100543', 'EFO_0007328', 'MONDO_0005090', 'MONDO_0002050', 'MONDO_0017276', 'EFO_0003757', 'MONDO_0002009', 'EFO_0000519', 'HP_0002140', 'MONDO_0005277', 'EFO_0003833', 'MONDO_0011382', 'HP_0001268', 'EFO_0005411', 'MONDO_0002046', 'EFO_0001073', 'EFO_0004699', 'MONDO_0002491', 'EFO_1001801', 'EFO_0004240', 'MONDO_0004681', 'MONDO_0007739', 'MONDO_0007915', 'EFO_0005407', 'EFO_0005230', 'EFO_0003768', 'MONDO_0010383', 'HP_0000726', 'EFO_0003843', 'EFO_0003758', 'HP_0000726', 'MONDO_0004976', 'EFO_0004329', 'MONDO_0004975', 'EFO_0004242', 'HP_0012228', 'MONDO_0005301', 'EFO_0004190', 'EFO_1001465', 'EFO_0005762', 'EFO_0003756', 'EFO_0002610', 'EFO_0005687']",55.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,2003.0,,,"['104171191', '144203750', '170464999', '26751885', '50104569', '90341818']",['64312'],,,,,
CHEMBL1201420,,,Enzyme,False,UROKINASE,4.0,False,True,"['Abbokinase', 'Kinlytic', 'Ukidan']","['Kinase (enzyme-activating), uro-', 'Urinary plasminogen activator', 'Urokinase']",,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for recurrent thrombophlebitis and has 6 investigational indications.,['Urokinase'],,"['EFO_0008585', 'EFO_0000712', 'EFO_0003827', 'EFO_0003097', 'EFO_0009680', 'EFO_0000544', 'HP_0004419']",7.0,['ENSG00000122861'],1,2007.0,,,,,,,,['5109'],
CHEMBL1201454,,,Unknown,False,ALSEROXYLON,4.0,False,True,"['Rautensin', 'Rauwiloid']",['Alseroxylon'],,Unknown drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Alseroxylon'],,,,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1982.0,,,,,,,,,
CHEMBL13280,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,PPTYJKAXVCCBDU-UHFFFAOYSA-N,Small molecule,False,FLUNITRAZEPAM,4.0,True,True,['Rohypnol'],"['Flunitrazepam', 'N05CD03', 'RO 5-4200', 'RO-5-4200', 'RO-54200']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,['Flunitrazepam'],['DB01544'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL2103851,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,FOFDIMHVKGYHRU-UHFFFAOYSA-N,Small molecule,False,AMUVATINIB,2.0,False,False,[],"['Amuvatinib', 'HPK 56', 'HPK-56', 'HPK56', 'MP 470', 'MP-470', 'MP470']","['CHEMBL4071984', 'CHEMBL4061772', 'CHEMBL4092757', 'CHEMBL2105685', 'CHEMBL4063359', 'CHEMBL4099995', 'CHEMBL4085000']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12742'],"['EFO_0000616', 'EFO_0000702']",2.0,"['ENSG00000122025', 'ENSG00000105976', 'ENSG00000134853', 'ENSG00000157404']",4,,,,['137276002'],,,,,,
CHEMBL2109477,,,Antibody,False,SELICRELUMAB,2.0,False,False,[],"['CP 870,893', 'CP-870,893', 'CP-870893', 'RG-7876', 'RG7876', 'RO-7009789', 'Selicrelumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0000616', 'EFO_1001951', 'EFO_0000096', 'EFO_0003860', 'EFO_0000756', 'MONDO_0007254']",6.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL2109534,,,Antibody,False,PF-03732010,1.0,False,False,[],"['P-cadherin antagonist pf-03732010', 'PF-03732010', 'PF03732010', 'Pf-03732010']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000062038'],1,,,,,,,,,,
CHEMBL2151570,c1cc2cc(-c3ccc(O[C@H]4CN5CCC4CC5)nn3)ccc2[nH]1,LUKNJAQKVPBDSC-SFHVURJKSA-N,Small molecule,False,ABT-107,1.0,False,False,[],"['ABT-PR1', 'Abt-107', 'Abt-107 free base']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL37676,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,SEBPXHSZHLFWRL-UHFFFAOYSA-N,Small molecule,False,APC-100,1.0,False,False,[],"['2,2,5,7,9-pentamethyl-6-chromanol', 'APC-100', 'Apc-100', 'Chromane c1', 'NSC-226236']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB13111'],['MONDO_0008315'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL4297804,,,Unknown,False,PF-06263507,1.0,False,False,[],['Pf-06263507'],,Unknown drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000146242', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL4298092,,,Antibody,False,GLOFITAMAB,4.0,False,True,['Columvi'],"['Columvi', 'Glofitamab', 'Glofitamab-gxbm', 'RG-6026', 'RG6026', 'RO-7082859', 'RO7082859', 'Ro7082859']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for diffuse large b-cell lymphoma and has 6 investigational indications.,,,"['EFO_0000403', 'EFO_0000574', 'EFO_0000096', 'EFO_1001469', 'EFO_0005952', 'EFO_0000616', 'MONDO_0018906']",7.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000156738']",4,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/GLOFITAMAB/relevant/1/'],,,
CHEMBL4298138,C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1,FIKPXCOQUIZNHB-WDEREUQCSA-N,Small molecule,False,REPOTRECTINIB,4.0,False,True,['Augtyro'],"['Repotrectinib', 'TPX-0005', 'TRX-0005']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 investigational indications.,,,"['EFO_0003060', 'MONDO_0004992', 'EFO_0000616']",3.0,"['ENSG00000047936', 'ENSG00000148053', 'ENSG00000124145', 'ENSG00000019582', 'ENSG00000198400', 'ENSG00000140538']",6,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/REPOTRECTINIB/relevant/1/'],,,
CHEMBL4594497,,,Oligonucleotide,False,SEPOFARSEN,2.0,False,False,[],"['EW9I3PJC3R', 'QR-110', 'QR-110 FREE ACID', 'Qr-110', 'Sepofarsen']",,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0018998', 'EFO_0003966']",2.0,['ENSG00000198707'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SEPOFARSEN/relevant/1/'],,,
CHEMBL554,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,BCFGMOOMADDAQU-UHFFFAOYSA-N,Small molecule,True,LAPATINIB,4.0,False,True,['Tyverb'],"['GSK-572016', 'GW-2016', 'GW-572016', 'GW-572016X', 'GW572016', 'Lapatinib']","['CHEMBL1201179', 'CHEMBL3526325', 'CHEMBL1076241', 'CHEMBL1201183']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 47 investigational indications. This drug has a black box warning from the FDA.,['Lapatinib'],['DB01259'],"['EFO_0000228', 'MONDO_0008315', 'EFO_0006859', 'MONDO_0044926', 'EFO_0005774', 'EFO_0005543', 'EFO_1000478', 'EFO_1001465', 'MONDO_0004986', 'EFO_0000707', 'MONDO_0004986', 'EFO_1001951', 'EFO_1000294', 'MONDO_0004992', 'EFO_1001512', 'EFO_1000158', 'MONDO_0007254', 'EFO_0005922', 'MONDO_0007576', 'EFO_0002618', 'EFO_0003869', 'EFO_0005950', 'EFO_0003884', 'EFO_1001968', 'MONDO_0011962', 'MONDO_0001056', 'EFO_0000181', 'EFO_0000365', 'EFO_0006352', 'EFO_0002892', 'EFO_0002938', 'EFO_0003869', 'EFO_0000616', 'EFO_1000294', 'EFO_0002618', 'EFO_0000305', 'MONDO_0002974', 'MONDO_0002087', 'EFO_0000305', 'EFO_0000616', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0003060', 'EFO_0000574', 'MONDO_0008170', 'EFO_0006859', 'EFO_0006318', 'EFO_0000756', 'MONDO_0007254', 'EFO_0006861', 'EFO_0000681', 'MONDO_0001657']",52.0,"['ENSG00000146648', 'ENSG00000141736']",2,2007.0,,,"['103905567', '103905568', '144206058', '170465125', '50100107']",['49603'],,,,,
CHEMBL572284,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO,IXWNTLSTOZFSCM-YVACAVLKSA-N,Small molecule,False,OMBRABULIN,3.0,False,False,[],"['AC7700', 'AVE-8062', 'AVE8062', 'Ave8062', 'Ombrabulin']",['CHEMBL585539'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB12882'],"['EFO_0000691', 'EFO_0000616', 'EFO_0003060', 'MONDO_0008170']",4.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL1277072,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2,MCTXSDCWFQAGFS-UEXNTNOUSA-N,Small molecule,False,HENATINIB,1.0,False,False,[],['Henatinib'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB13019'],['MONDO_0004992'],1.0,['ENSG00000128052'],1,,,,,,,,,,
CHEMBL1366933,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,RONZAEMNMFQXRA-MRXNPFEDSA-N,Small molecule,False,ESMIRTAZAPINE,3.0,False,False,[],"['(s)-6-azamianserin', '(s)-mirtazapine', '(s)-org 3770', 'Esmirtazapine', 'Mirtazapine, (s)-', 'ORG-44-20']",['CHEMBL2107339'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB06678'],"['EFO_0004698', 'EFO_0004698', 'EFO_0008568']",3.0,"['ENSG00000147246', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286', 'ENSG00000102468', 'ENSG00000196639']",6,,,,['11114267'],,,,,,
CHEMBL1464,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,PJVWKTKQMONHTI-UHFFFAOYSA-N,Small molecule,True,WARFARIN,4.0,False,True,[],"['NSC-59813', 'Warfarin']","['CHEMBL1200879', 'CHEMBL1200772']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 9 approved and 60 investigational indications. This drug has a black box warning from the FDA.,['Warfarin'],['DB00682'],"['EFO_0000275', 'HP_0004419', 'EFO_0003764', 'EFO_0006911', 'EFO_0003875', 'EFO_0002950', 'HP_0004936', 'EFO_0000685', 'EFO_0003929', 'EFO_0004286', 'EFO_0002689', 'EFO_0003827', 'MONDO_0002009', 'EFO_0000275', 'EFO_0000319', 'EFO_1001161', 'HP_0001907', 'EFO_0004616', 'EFO_0003911', 'EFO_0000712', 'EFO_0000274', 'EFO_0000574', 'EFO_0003907', 'EFO_0004277', 'EFO_0000612', 'EFO_0009708', 'EFO_1001249', 'HP_0002140', 'EFO_0000612', 'EFO_0001073', 'HP_0001907', 'HP_0004936', 'EFO_0004239', 'EFO_0003914', 'EFO_0000384', 'HP_0004936', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000712', 'HP_0004418', 'EFO_0000685', 'EFO_0001422', 'MONDO_0001134', 'EFO_0004211', 'MONDO_0004992', 'EFO_0001361', 'EFO_0003907', 'EFO_0000673', 'EFO_0003777', 'EFO_0000275', 'MP_0001914', 'MONDO_0005149', 'EFO_0000756', 'EFO_0000266', 'MONDO_0005180', 'EFO_0003144', 'HP_0001907', 'EFO_0000474', 'EFO_0000400', 'EFO_0000768', 'MONDO_0000831', 'MONDO_0004975', 'EFO_0000676', 'EFO_1000781', 'HP_0001873', 'EFO_0000729', 'MONDO_0002679', 'EFO_1001375', 'EFO_0001642', 'EFO_0002618', 'MONDO_0005148', 'EFO_0003827']",72.0,['ENSG00000167397'],1,1954.0,,,"['144206736', '144209380', '144210849', '174006926', '26748308', '26754489']",['87732'],,,,,
CHEMBL1643,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,IWUCXVSUMQZMFG-AFCXAGJDSA-N,Small molecule,True,RIBAVIRIN,4.0,False,True,"['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'Ribavirin', 'Ribofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']","['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartners', 'Ribavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 20 investigational indications. This drug has a black box warning from the FDA.,['Ribavirin'],['DB00811'],"['EFO_0001422', 'EFO_0000764', 'EFO_0006890', 'EFO_0000616', 'HP_0012115', 'HP_0001873', 'MONDO_0100096', 'EFO_0000222', 'EFO_0007299', 'EFO_0004220', 'EFO_0000694', 'EFO_0003047', 'EFO_0007328', 'EFO_0007338', 'EFO_1001413', 'MONDO_0002050', 'EFO_0004197', 'EFO_0007332', 'MONDO_0005147', 'MONDO_0007254', 'EFO_0000544', 'EFO_0004239', 'EFO_0007304', 'EFO_0000763']",24.0,['ENSG00000106348'],1,1985.0,,['ribavirin'],"['144203810', '144208165', '170464657', '17389529', '50105410', '50105411', '50105412', '50105413', '8139972', '90341426']",['63580'],['https://www.ema.europa.eu/en/medicines/human/EPAR/rebetol'],,,,
CHEMBL2180604,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,DZFZXPPHBWCXPQ-UHFFFAOYSA-N,Small molecule,False,TAK-593,1.0,False,False,[],"['TAK 593', 'TAK-593', 'Tak-593']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB13093'],['EFO_0000616'],1.0,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",5,,,,,,,,,,
CHEMBL3707355,,,Small molecule,False,AZD8108,1.0,False,False,[],['Azd8108'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL4297399,O=C(Nc1ncc(SCCN2CCCC2)s1)[C@]1(c2ccc(S(=O)(=O)C3CC3)cc2)C[C@H]1C1CCCCC1,QIIVJLHCZUTGSD-CUBQBAPOSA-N,Small molecule,False,LY-2608204,2.0,False,False,[],"['Globalagliatin', 'LY2608204', 'Ly-2608204', 'Ly2608204', 'Sy-004']",['CHEMBL5095182'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12284'],"['MONDO_0005148', 'HP_0003074']",2.0,['ENSG00000106633'],1,,,,,,,,,,
CHEMBL4802262,,,Gene,False,ATIDARSAGENE AUTOTEMCEL,4.0,False,True,['Libmeldy'],"['Atidarsagene autotemcel', 'OTL-200']",,Gene drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for metachromatic leukodystrophy.,,,['MONDO_0018868'],1.0,['ENSG00000100299'],1,2020.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy'],['https://searchusan.ama-assn.org/finder/usan/search/ATIDARSAGENE%20AUTOTEMCEL/relevant/1/'],,,
CHEMBL573352,C#C[C@@]1(O)[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@@H]1O,JFIWEPHGRUDAJN-DYUFWOLASA-N,Small molecule,False,TAS-106,2.0,False,False,[],"[""2'-C-Ethynylcytidine"", ""3'-C-Ethynylcytidine"", 'Tas 106', 'Tas-106']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB06656'],"['MONDO_0004992', 'EFO_0006859']",2.0,"['ENSG00000068654', 'ENSG00000181222', 'ENSG00000148606']",3,,,,,,,,,,
CHEMBL1079175,NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,ULDXWLCXEDXJGE-UHFFFAOYSA-N,Small molecule,False,MK-2206,2.0,False,False,[],"['MK-2206', 'MK2206', 'Mk-2206']",['CHEMBL4635254'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 24 investigational indications.,,,"['MONDO_0008903', 'EFO_0000756', 'EFO_0005221', 'MONDO_0011962', 'EFO_0001663', 'EFO_0000308', 'EFO_0000403', 'MONDO_0005411', 'MONDO_0021063', 'EFO_0000681', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000095', 'EFO_0004252', 'EFO_0000305', 'EFO_0003060', 'EFO_0000181', 'EFO_0006861', 'EFO_1000657', 'EFO_0000182', 'EFO_0000616', 'EFO_0003050', 'EFO_0005537', 'MONDO_0100342']",24.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,"['124897541', '124897542', '144206919', '170466896']",['67271'],,,,,
CHEMBL1166,CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,KXNPVXPOPUZYGB-IOVMHBDKSA-N,Small molecule,False,ARGATROBAN,4.0,False,True,"['Acova', 'Argatroban', 'Argatroban in dextrose', 'Argatroban in sodium chloride']","['Argatroban', 'Argatroban anhydrous', 'Argatroban hydrate', 'Argatroban monohydrate', 'Argipidine', 'DK-7419', 'GN-1600', 'GN1600', 'MCI-9038', 'MD-805']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 3 investigational indications.,['Argatroban'],['DB00278'],"['HP_0004419', 'HP_0002140', 'HP_0001873', 'EFO_1000985', 'MONDO_0002243', 'MONDO_0000831']",6.0,['ENSG00000180210'],1,2000.0,,['argatroban'],,,,,,,
CHEMBL1200802,C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O,BJVVMKUXKQHWJK-UHFFFAOYSA-N,Small molecule,False,TALBUTAL,4.0,False,True,['Lotusate'],['Talbutal'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Talbutal'],['DB00306'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,,['170465408'],,,,,,
CHEMBL1201439,,,Antibody,True,BASILIXIMAB,4.0,False,True,['Simulect'],"['Basiliximab', 'CHI-621', 'SDZ-CHI-621']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for kidney transplant and immune system disease and has 21 investigational indications. This drug has a black box warning from the FDA.,['Basiliximab'],,"['EFO_0003086', 'MONDO_0013730', 'EFO_0000183', 'EFO_1000794', 'EFO_0004236', 'EFO_0000616', 'MONDO_0018923', 'EFO_0003884', 'MONDO_0019472', 'EFO_0010134', 'EFO_1001226', 'EFO_1001231', 'EFO_0002687', 'EFO_0000544', 'EFO_0000464', 'EFO_0004599', 'EFO_0000729', 'EFO_0001378', 'EFO_0000540', 'MONDO_0005147', 'MONDO_0004976', 'EFO_0000222', 'EFO_0000519']",23.0,"['ENSG00000134460', 'ENSG00000147168', 'ENSG00000100385']",3,1998.0,,['basiliximab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/simulect'],,,['4940'],
CHEMBL1614766,O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,FIMYFEGKMOCQKT-UHFFFAOYSA-N,Small molecule,False,RO-4987655,1.0,False,False,[],"['CH-4987655', 'RO4987655', 'Ro 4987655', 'Ro-4987655']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB12933'],['EFO_0000616'],1.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,,,,,,,
CHEMBL1743038,,,Antibody,False,LUCATUMUMAB,2.0,False,False,[],"['CHIR-12.12', 'HCD-122', 'HCD122', 'Lucatumumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_0005952', 'MONDO_0018906', 'EFO_0001378', 'EFO_0000183', 'EFO_0000095']",5.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL2216859,CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1,MCIDWGZGWVSZMK-UHFFFAOYSA-N,Small molecule,False,NEMIRALISIB,2.0,False,False,[],"['GSK-2269557', 'GSK-2269557 FREE BASE', 'GSK-2269557A', 'GSK2269557A', 'Nemiralisib']","['CHEMBL5314409', 'CHEMBL4297193']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000341', 'EFO_0000341', 'MONDO_0004979']",3.0,['ENSG00000171608'],1,,,,,,,,,,
CHEMBL3545141,,,Small molecule,False,RP-6530,1.0,False,False,[],['Rp-6530'],,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0000574', 'EFO_0002913']",2.0,"['ENSG00000105851', 'ENSG00000171608']",2,,,,,,,,,,
CHEMBL4298101,,,Antibody drug conjugate,False,LADIRATUZUMAB VEDOTIN,2.0,False,False,[],"['Ladiratuzumab vedotin', 'SGN-LIV1A', 'Sgn-liv1a']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0003968', 'EFO_0003869', 'EFO_0005537', 'MONDO_0007254']",4.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000141424']",16,,,,,,,,,,
CHEMBL4298189,,,Gene,False,ELADOCAGENE EXUPARVOVEC,4.0,False,True,['Upstaza'],"['AGIL-AADC', 'Eladocagene exuparvovec']",,Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for inborn disorder of amino acid metabolism.,,,['MONDO_0004736'],1.0,['ENSG00000132437'],1,2022.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza'],['https://searchusan.ama-assn.org/finder/usan/search/ELADOCAGENE%20EXUPARVOVEC/relevant/1/'],,,
CHEMBL4594460,,,Antibody,False,TEGOPRUBART,2.0,False,False,[],"['AT-1501', 'At-1501', 'Tegoprubart']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['MONDO_0004976', 'EFO_0004194', 'EFO_0005809', 'MONDO_0005147']",4.0,['ENSG00000102245'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-128']
CHEMBL4802163,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1,VQIIUJSNIKEMCK-MHZLTWQESA-N,Small molecule,False,NEZULCITINIB,2.0,False,False,[],"['Nezulcitinib', 'TD-0903', 'THRX-136377', 'Td-0903']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0100096', 'EFO_0004610']",2.0,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/NEZULCITINIB/relevant/1/'],,,
CHEMBL1097999,CCNc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\[C@@H](C)[C@H](C)OC2=O,MWUFVYLAWAXDHQ-HMNLTAHHSA-N,Small molecule,False,E-6201,2.0,False,False,[],"['E-6201', 'E6201', 'ER-806201']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB11687'],"['EFO_1001494', 'EFO_0000616', 'EFO_0000676']",3.0,"['ENSG00000169032', 'ENSG00000095015']",2,,,,,,,,,,
CHEMBL1201461,,,Small molecule,False,DEXTROMETHORPHAN POLISTIREX,4.0,False,True,"['Delsym', 'Dextromethorphan polistirex']","['Dextromethorphan polistirex', 'NSC-751452']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.,,,['EFO_0003756'],1.0,"['ENSG00000183454', 'ENSG00000147955']",2,1982.0,CHEMBL52440,['dextromethorphan%20polistirex'],,,,,,,
CHEMBL1742998,,,Antibody drug conjugate,False,CANTUZUMAB RAVTANSINE,2.0,False,False,[],"['Cantuzumab ravtansine', 'HUC242-DM4', 'IMGN-242', 'IMGN242']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0002618', 'MONDO_0001056', 'EFO_0000365']",3.0,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL2108967,,,Antibody,False,LERDELIMUMAB,3.0,False,False,['Trabio'],"['CAT-152', 'Lerdelimumab', 'TRABIO']",,Antibody drug with a maximum clinical trial phase of III.,,,,,['ENSG00000092969'],1,,,,,,,,,,
CHEMBL312443,Oc1noc2c1CCNC2,ZXRVKCBLGJOCEE-UHFFFAOYSA-N,Small molecule,False,GABOXADOL,3.0,False,False,[],"['Gaboxadol', 'LU 02-030', 'LU-02-030', 'LU-02030', 'MK-0928', 'NSC-759585']",['CHEMBL1255746'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,['Gaboxadol'],['DB06554'],"['MONDO_0010383', 'MONDO_0007113', 'EFO_0004698', 'MONDO_0002009']",4.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000011677', 'ENSG00000163288', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",9,,,,"['104171241', '11111836', '11111837', '11113715', '170466512', '90341079']",['34373'],,,,,
CHEMBL3301612,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,CMJCXYNUCSMDBY-ZDUSSCGKSA-N,Small molecule,False,ENCORAFENIB,4.0,False,True,['Braftovi'],"['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818', 'NVP-LGX818-NXA']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 8 approved and 10 investigational indications.,,['DB11718'],"['MONDO_0004992', 'EFO_0000365', 'EFO_1001951', 'EFO_0000756', 'EFO_0002617', 'EFO_0009259', 'EFO_0002618', 'EFO_1000657', 'EFO_1000956', 'EFO_0001378', 'EFO_0000389', 'EFO_0004142', 'EFO_0003060', 'EFO_0002892', 'EFO_0003891', 'EFO_1001949', 'MONDO_0005184', 'EFO_0000616']",18.0,['ENSG00000157764'],1,2018.0,,['encorafenib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi'],,,,
CHEMBL3545333,CN1C(=O)C(F)=C[C@]2(C)C3CC[C@@]4(C)C(CC[C@@H]4C(=O)NCc4nc5ncccc5[nH]4)C3CCC12,GBEUKTWTUSPHEE-PAWGCEJPSA-N,Small molecule,False,MK-0773,2.0,False,False,[],"['Mk-0773', 'PF-05314882']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_1000653'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL4297236,,,Gene,False,LISOCABTAGENE MARALEUCEL,3.0,False,False,[],"['Breyanzi', 'JCAR-017', 'JCAR017', 'Lisocabtagene maraleucel']",,Gene drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['MONDO_0018906', 'EFO_0000095', 'EFO_1001469', 'EFO_0000220', 'EFO_0005952', 'EFO_0000403']",6.0,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL4298193,,,Oligonucleotide,False,SUVODIRSEN SODIUM,1.0,False,False,[],"['BMTR0139 SODIUM', 'Suvodirsen sodium', 'WLS-4176 SODIUM', 'WV3473']",,Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0010679'],1.0,['ENSG00000198947'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/SUVODIRSEN%20SODIUM/relevant/1/'],,,
CHEMBL1743037,,,Antibody drug conjugate,False,LORVOTUZUMAB MERTANSINE,2.0,False,False,[],"['HUN901-DM1, BB-10901', 'IMGN-901', 'Lorvotuzumab mertansine']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,,"['MONDO_0006058', 'EFO_0000702', 'EFO_0000565', 'EFO_0002918', 'EFO_0000760', 'EFO_0001378', 'EFO_0001376', 'EFO_0000621']",8.0,"['ENSG00000149294', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL3707380,,,Small molecule,False,RG6029,1.0,False,False,[],"['GDC-0310', 'Rg6029']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000169432'],1,,,,,,,,,,
CHEMBL476960,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,FZNCGRZWXLXZSZ-CIQUZCHMSA-N,Small molecule,False,VOGLIBOSE,4.0,False,True,[],"['A-71100', 'AO-128', 'Voglibose']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 2 investigational indications.,['Voglibose'],['DB04878'],"['MONDO_0005148', 'EFO_0000400']",2.0,"['ENSG00000257335', 'ENSG00000171298', 'ENSG00000090402', 'ENSG00000257743']",4,1994.0,,,"['144205773', '170465993']",,,,,,
CHEMBL677,C[C@H](N)[C@H](O)c1ccc(O)c(O)c1,GEFQWZLICWMTKF-CDUCUWFYSA-N,Small molecule,False,LEVONORDEFRIN,4.0,False,True,[],"['(-)-cobefrin', 'BA 2818', 'BA-2818', 'Corbadrine', 'L-.alpha.-methylnoradrenaline', 'L-nordefrin', 'L-norephedrine, 3,4-dihydroxy-', 'Levonordefrin', 'NSC-757084', 'Neo-Cobefrin', 'Nordefrin', 'Nordefrin (-)-form', 'Nordefrin, l-']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.,['Levonordefrin'],['DB06707'],,,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1960.0,,,"['11111073', '11112447', '144205604', '170464794']",['10304'],,,,,
CHEMBL146095,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,GWOFUCIGLDBNKM-UHFFFAOYSA-N,Small molecule,False,GLAFENINE,4.0,True,True,[],"['Glafenin', 'Glafenine', 'Glaphenine', 'Glycerylaminophenaquine', 'NSC-757808', 'R 1707', 'R-1707']",['CHEMBL1572751'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for fever and pain. It was withdrawn in at least one region.,,,"['HP_0001945', 'EFO_0003843']",2.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,['26748455'],['31653'],,,,,
CHEMBL2103799,CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1,SDDSJMXGJNWMJY-BRHAQHMBSA-N,Small molecule,False,COBIPROSTONE,2.0,False,False,[],"['Cobiprostone', 'RU-8811', 'SPI-8811']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB05514'],"['EFO_0004607', 'EFO_0000666', 'EFO_1001904']",3.0,['ENSG00000114859'],1,,,,,,,,,,
CHEMBL2103847,CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO,FWFGIHPGRQZWIW-SQNIBIBYSA-N,Small molecule,False,TOSEDOSTAT,2.0,False,False,[],"['CHR 2797', 'CHR-2797', 'CHR2797', 'Tosedostat']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB11781'],"['EFO_0000616', 'EFO_0000198', 'EFO_0000222', 'EFO_0003060', 'EFO_0002618']",5.0,"['ENSG00000166825', 'ENSG00000141279', 'ENSG00000176393', 'ENSG00000164024', 'ENSG00000113441', 'ENSG00000123992', 'ENSG00000138792', 'ENSG00000108039', 'ENSG00000002549', 'ENSG00000111142', 'ENSG00000122121', 'ENSG00000164308', 'ENSG00000164307', 'ENSG00000172901', 'ENSG00000148120', 'ENSG00000172878', 'ENSG00000215440', 'ENSG00000142327', 'ENSG00000196236']",19,,,,,,,,,,
CHEMBL2108025,,,Protein,False,DEPELESTAT,2.0,False,False,[],"['DX-890', 'Depelestat']",,Protein drug with a maximum clinical trial phase of II.,,,,,['ENSG00000197561'],1,,,,,,,,,,
CHEMBL3186011,COCC1(CO)C(=O)C2CCN1CC2,BGBNULCRKBVAKL-UHFFFAOYSA-N,Small molecule,False,EPRENETAPOPT,3.0,False,False,[],"['APR-246', 'Apr 246', 'Apr-246', 'Eprenetapopt', 'PRIMA-1Met']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB11684'],"['EFO_0000756', 'EFO_0000198', 'EFO_1001469', 'MONDO_0008170', 'EFO_0002916', 'EFO_0000616']",6.0,['ENSG00000141510'],1,,,,['174007096'],,,['https://searchusan.ama-assn.org/finder/usan/search/EPRENETAPOPT/relevant/1/'],,,
CHEMBL3707348,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,WDENQIQQYWYTPO-IBGZPJMESA-N,Small molecule,False,ACALABRUTINIB,4.0,False,True,['Calquence'],"['ACP-196', 'Acalabrutinib', 'Acp-196']",['CHEMBL4594293'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 20 investigational indications.,,['DB11703'],"['MONDO_0001023', 'MONDO_0018906', 'EFO_0000565', 'EFO_0000095', 'EFO_1001469', 'EFO_0000519', 'EFO_0001378', 'EFO_0000181', 'EFO_0009441', 'EFO_0003060', 'EFO_1001469', 'MONDO_0020547', 'MONDO_0100096', 'MONDO_0044881', 'EFO_1001890', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000096', 'EFO_0000095', 'EFO_0000574', 'EFO_0000685', 'EFO_0002618', 'MONDO_0008170', 'EFO_0005741', 'EFO_0005952', 'EFO_0000403']",26.0,['ENSG00000010671'],1,2017.0,,['acalabrutinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/calquence'],,,,
CHEMBL4297778,,,Antibody drug conjugate,False,LONCASTUXIMAB TESIRINE,4.0,False,True,['Zynlonta'],"['ADCT-402', 'ADCT-402 TESIRINE', 'Adct-402 tesirine', 'Loncastuximab tesirine']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 7 investigational indications.,,,"['EFO_1001938', 'EFO_0000309', 'EFO_1001469', 'EFO_0009441', 'EFO_0000096', 'EFO_0000616', 'EFO_0000220', 'MONDO_0018906', 'EFO_0005952', 'EFO_0000403']",10.0,['ENSG00000177455'],1,2021.0,,,,,,,,,
CHEMBL445,CNCCC=C1c2ccccc2CCc2ccccc21,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,Small molecule,True,NORTRIPTYLINE,4.0,False,True,"['Allegron', 'Aventyl', 'Motipress', 'Motival']","['Desitriptilina', 'Lumbeck', 'NCI-169453', 'NSC-757234', 'Noramitriptyline', 'Nortrilen', 'Nortriptyline', 'Pamelor', 'Sesaval']",['CHEMBL1201156'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for unipolar depression and depressive disorder and has 13 investigational indications. This drug has a black box warning from the FDA.,['Nortriptyline'],['DB00540'],"['EFO_0005230', 'EFO_1000948', 'EFO_0003948', 'MONDO_0005090', 'EFO_0000676', 'MONDO_0002009', 'EFO_0008533', 'EFO_0005279', 'EFO_0003761', 'EFO_0008524', 'HP_0000726', 'EFO_0000676', 'EFO_0000555', 'MONDO_0002050', 'EFO_0003761', 'EFO_0003768', 'EFO_0000274']",17.0,"['ENSG00000103546', 'ENSG00000108576']",2,1964.0,,,"['11110653', '11110654', '124878449', '152146160', '26747092', '26747093', '4253930', '50100156', '50104257', '50104258', '90340759']",['7640'],,,,,
CHEMBL898,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,HUPFGZXOMWLGNK-UHFFFAOYSA-N,Small molecule,True,DIFLUNISAL,4.0,False,True,"['Diflunisal', 'Dolobid', 'Dolobid 500']","['Diflunisal', 'NSC-756728']",['CHEMBL4745456'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA.,['Diflunisal'],['DB00861'],"['MONDO_0005148', 'HP_0001945', 'EFO_0003843', 'MONDO_0005178', 'EFO_0000685', 'EFO_0004129']",6.0,"['ENSG00000073756', 'ENSG00000095303']",2,1982.0,,['diflunisal'],"['11112675', '124882514', '144204149', '170464956', '26746997', '855794']",['39669'],,,,,
CHEMBL1085699,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1,ANEBWFXPVPTEET-UHFFFAOYSA-N,Small molecule,False,MANIDIPINE 6300,3.0,False,False,[],"['Artedil', 'Franidipine', 'Manidipine', 'Manidipine 6300', 'Manidipine hydrochloride']",['CHEMBL2362693'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB09238'],"['EFO_0000319', 'EFO_0000537']",2.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,"['174006297', '50112746']",,,,,,
CHEMBL1201156,CNCCC=C1c2ccccc2CCc2ccccc21.Cl,SHAYBENGXDALFF-UHFFFAOYSA-N,Small molecule,True,NORTRIPTYLINE HYDROCHLORIDE,4.0,False,True,"['Aventyl', 'Aventyl hydrochloride', 'Nortriptyline hydrochloride', 'Pamelor', 'Psychostyl']","['38489', 'NSC-169453', 'Nortriptyline hcl', 'Nortriptyline hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for unipolar depression and has 4 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003761', 'EFO_0008524', 'EFO_1000948', 'EFO_0000676', 'EFO_0000274']",5.0,"['ENSG00000103546', 'ENSG00000108576']",2,1964.0,CHEMBL445,['nortriptyline%20hydrochloride'],"['144203599', '50106715', '50106716', '562776', '56423135', '855575']",,,,,,
CHEMBL1236924,O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl,NMRWDFUZLLQSBN-UHFFFAOYSA-N,Small molecule,False,INT131,2.0,False,False,[],"['AMG-131', 'CHS-131', 'INT-131', 'Ibrigampar', 'Int131', 'T-0903131', 'T0903131', 'T131']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB05490'],"['EFO_0003929', 'MONDO_0005148']",2.0,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL1256818,Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O,STTADZBLEUMJRG-IKNOHUQMSA-N,Small molecule,False,DEXTROMETHORPHAN HYDROBROMIDE,4.0,False,True,"['Beecham coughcaps', 'Brontyl', 'Contac coughcaps', 'Delsym', 'Franolyn dry', 'Franolyn sed', 'Tussabron', 'Tuxium']","['Dextromethorphan Hydrobromide Monohydrate', 'Dextromethorphan hydrobromide', 'NSC-756723']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 7 approved and 8 investigational indications.,,,"['EFO_0007214', 'EFO_0007486', 'MONDO_0005271', 'MONDO_0004976', 'MONDO_0002009', 'HP_0001945', 'EFO_0003843', 'EFO_0000616', 'MONDO_0002050', 'HP_0002315', 'HP_0001742', 'HP_0012735', 'MONDO_0005277', 'EFO_0001663', 'MONDO_0005148']",15.0,"['ENSG00000183454', 'ENSG00000147955']",2,1984.0,CHEMBL52440,['dextromethorphan%20hydrobromide'],"['11112982', '26732619', '49731998']",,,,,,
CHEMBL2142592,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1,SZBGQDXLNMELTB-UHFFFAOYSA-N,Small molecule,False,TALADEGIB,2.0,False,False,[],"['LY-2940680', 'LY2940680', 'Taladegib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB12550'],"['EFO_0000768', 'EFO_0009708', 'EFO_0000702', 'MONDO_0004992', 'EFO_0000616']",5.0,['ENSG00000128602'],1,,,,['137276014'],,,,,,
CHEMBL2364607,O=C(O)/C=C/C(=O)O.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,RESIMIUSNACMNW-BXRWSSRYSA-N,Small molecule,False,COBIMETINIB FUMARATE,4.0,False,True,['Cotellic'],"['Cobimetinib fumarate', 'Cobimetinib hemifumarate', 'Gdc-0973 hemifumarate', 'Xl-518 hemifumarate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for melanoma and metastatic melanoma.,,,"['EFO_0000756', 'EFO_0002617']",2.0,"['ENSG00000169032', 'ENSG00000126934']",2,2015.0,CHEMBL2146883,['cobimetinib%20fumarate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic'],,,,
CHEMBL3301610,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,UZWDCWONPYILKI-UHFFFAOYSA-N,Small molecule,False,ABEMACICLIB,4.0,False,True,"['Verzenio', 'Verzenios']","['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']","['CHEMBL4290012', 'CHEMBL4560869', 'CHEMBL4534140', 'CHEMBL4474565']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 6 approved and 48 investigational indications.,,['DB12001'],"['EFO_0000616', 'EFO_0000182', 'EFO_0003060', 'EFO_0004284', 'EFO_0000588', 'MONDO_0008903', 'EFO_0002618', 'MONDO_0008170', 'EFO_0009708', 'EFO_0000702', 'EFO_0000305', 'EFO_0000349', 'MONDO_0008315', 'EFO_0000632', 'MONDO_0001187', 'EFO_0005701', 'EFO_0003825', 'EFO_0005543', 'MONDO_0100342', 'EFO_0000181', 'EFO_0001378', 'EFO_0003869', 'MONDO_0011962', 'EFO_1001951', 'EFO_0005537', 'EFO_0000574', 'MONDO_0002108', 'EFO_0003085', 'EFO_0006861', 'EFO_1001469', 'EFO_0000637', 'EFO_0002918', 'EFO_0005952', 'EFO_0000196', 'EFO_0000174', 'EFO_0001075', 'EFO_0000673', 'MONDO_0004992', 'MONDO_0005184', 'EFO_0000389', 'MONDO_0003060', 'EFO_1000294', 'MONDO_0007254', 'EFO_0003833', 'EFO_0000756', 'EFO_1000045', 'EFO_1000026', 'EFO_0000558', 'EFO_0000621', 'EFO_0000519', 'EFO_0003968', 'EFO_1001331', 'MONDO_0016642', 'MONDO_0018975']",54.0,"['ENSG00000105810', 'ENSG00000135446']",2,2017.0,,['abemaciclib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios'],,,,
CHEMBL4297736,,,Antibody drug conjugate,False,PRALUZATAMAB RAVTANSINE,2.0,False,False,[],"['Anti-cd166-dm4 cx-2009', 'CX-2009', 'Cx 2009', 'Cx-2009', 'Praluzatamab ravtansine']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0007254', 'EFO_0000616']",2.0,"['ENSG00000170017', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PRALUZATAMAB%20RAVTANSINE/relevant/1/'],,,
CHEMBL4650405,,,Protein,False,LERODALCIBEP,3.0,False,False,[],['Lerodalcibep'],,Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['MONDO_0018328', 'EFO_0004911', 'HP_0003124', 'EFO_0000319']",4.0,['ENSG00000169174'],1,,,,,,,,,,
CHEMBL467888,C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,HWLLYFXDDGGHOE-BCSUUIJWSA-N,Small molecule,False,LGD-2941,1.0,False,False,[],"['LGD-122941', 'LGD122941', 'Lgd-2941']",,Small molecule drug with a maximum clinical trial phase of I.,,['DB05234'],,,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL1201022,Cl.Nc1ccc(/N=N/c2ccccc2)c(N)n1,QQBPIHBUCMDKFG-GEEYTBSJSA-N,Small molecule,False,PHENAZOPYRIDINE HYDROCHLORIDE,4.0,False,True,"['Pyridium', 'Uropyrine']","['NC 150', 'NC-150', 'NSC-1879', 'Phenazopyridine hcl', 'Phenazopyridine hydrochloride', 'W 1655', 'W-1655']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and has 1 investigational indication.,,,['EFO_0003103'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1987.0,CHEMBL1242,,"['17389769', '26748196', '26752976']",,,,,,
CHEMBL1429,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,NFLWUMRGJYTJIN-PNIOQBSNSA-N,Protein,True,DESMOPRESSIN,4.0,False,True,[],"['Desmopressin', 'H01BA02', 'Ser-120', 'Ser120']",['CHEMBL1200556'],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,['DB00035'],"['MONDO_0004782', 'EFO_0005669', 'EFO_1000781', 'MP_0001914', 'EFO_1001412', 'MONDO_0024290', 'MONDO_0004782', 'MONDO_0007254', 'HP_0001742', 'MONDO_0024574', 'HP_0031364', 'MP_0001914', 'MONDO_0024290', 'EFO_0009505', 'HP_0000863', 'MONDO_0008315', 'EFO_0000537', 'EFO_0007344']",18.0,"['ENSG00000126895', 'ENSG00000166148', 'ENSG00000198049']",3,1978.0,,,,['4450'],,,,,
CHEMBL2109374,,,Antibody,False,TRC-093,1.0,False,False,[],"['MT-293', 'TRC-093', 'TRC093', 'Trc-093']",,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['MONDO_0004992', 'EFO_0009708']",2.0,['ENSG00000081052'],1,,,,,,,,,,
CHEMBL2109539,,,Antibody,False,RG-7652,2.0,False,False,[],['RG-7652'],,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000169174'],1,,,,,,,,,,
CHEMBL223360,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,MPVGZUGXCQEXTM-UHFFFAOYSA-N,Small molecule,False,LINIFANIB,3.0,False,False,[],"['A-741439', 'ABT-869', 'AL-39324', 'Linifanib', 'RG-3635']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,,"['EFO_0000681', 'EFO_1000657', 'EFO_0000365', 'EFO_0003060', 'MONDO_0021063', 'EFO_0000616', 'EFO_0001365', 'EFO_0001065', 'EFO_0000182', 'MONDO_0007254']",10.0,"['ENSG00000182578', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000122025']",7,,,,"['103904340', '137275904', '50100086']",,,,,,
CHEMBL3544971,C[C@H](N)Cc1ccccc1.C[C@H](N)Cc1ccccc1.O=S(=O)(O)O,PYHRZPFZZDCOPH-QXGOIDDHSA-N,Small molecule,True,DEXTROAMPHETAMINE SULFATE,4.0,False,True,"['Dexampex', 'Dexedrine', 'Dextroamphetamine sulfate', 'Dextrostat', 'Ferndex']","['Amphetamine sulfate, dextro', 'D-amphetamine hemisulfate salt', 'Dexamfetamine sulfate', 'Dexamphetamine sulfate', 'Dexamphetamine sulphate', 'Dextroamphetamine sulfate', 'Dextroamphetamine sulfate cii', 'Dextroamphetamine sulphate', 'NSC-27104']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome. This drug has a black box warning from the FDA.,,,"['EFO_0003888', 'MONDO_0016158']",2.0,"['ENSG00000103546', 'ENSG00000165646', 'ENSG00000142319']",3,1960.0,CHEMBL612,['dextroamphetamine%20sulfate'],,['51064'],,,,,
CHEMBL3545236,,,Small molecule,False,BPI-9016,1.0,False,False,[],"['BPI-9016M', 'Bpi-9016']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_0003060', 'EFO_0000616']",2.0,"['ENSG00000167601', 'ENSG00000105976']",2,,,,,,,,,,
CHEMBL4297517,CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O,RLCLASQCAPXVLM-NSHDSACASA-N,Small molecule,True,MAVACAMTEN,4.0,False,True,['Camzyos'],"['Camzyos', 'MYK-461', 'Mavacamten', 'Myk-461', 'SAR-439152']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hypertrophic cardiomyopathy and cardiovascular disease and has 1 investigational indication. This drug has a black box warning from the FDA.,,['DB14921'],"['EFO_0000538', 'EFO_0003144', 'EFO_0000319']",3.0,"['ENSG00000092054', 'ENSG00000197616', 'ENSG00000078814', 'ENSG00000160808', 'ENSG00000111245', 'ENSG00000106631', 'ENSG00000198336']",7,2022.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/MAVACAMTEN/relevant/1/'],,,
CHEMBL4650296,,,Unknown,False,BOS-589,2.0,False,False,[],"['BOS-589', 'Bos-589', 'GSK3352589']",,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000555'],1.0,['ENSG00000165731'],1,,,,,,,,,,
CHEMBL473,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,IXTMWRCNAAVVAI-UHFFFAOYSA-N,Small molecule,True,DOFETILIDE,4.0,False,True,"['Dofetilide', 'Tikosyn']","['Dofetilide', 'UK-68,798', 'UK-68798']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA.,['Dofetilide'],['DB00204'],"['EFO_0003911', 'EFO_0004269', 'EFO_0003144', 'HP_0001657', 'HP_0004308', 'EFO_0000275']",6.0,['ENSG00000055118'],1,1999.0,,['dofetilide'],"['144205731', '170465418', '26757968']",['4681'],['https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn'],,,,
CHEMBL592374,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl,BSMNRYCSBFHEMQ-KCJUWKMLSA-N,Small molecule,False,AMITIFADINE,2.0,False,False,[],"['Amitifadine', 'DOV 21947', 'DOV-21,947', 'DOV-21947', 'EB1010']",['CHEMBL1818442'],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,['Amitifadine'],['DB05964'],['MONDO_0002009'],1.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,,,,,,,,,,
CHEMBL595,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,HYAFETHFCAUJAY-UHFFFAOYSA-N,Small molecule,True,PIOGLITAZONE,4.0,False,True,[],"['AD-4833', 'Actos', 'Duetact', 'Glustin', 'Pioglitazone', 'U-72107', 'Zactos']",['CHEMBL1715'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 74 investigational indications. This drug has a black box warning from the FDA.,['Pioglitazone'],['DB01132'],"['EFO_0000756', 'EFO_0004265', 'EFO_0000712', 'EFO_0000400', 'EFO_0000384', 'MONDO_0002108', 'MONDO_0008903', 'HP_0012115', 'HP_0003124', 'EFO_0002546', 'EFO_0000544', 'HP_0002745', 'EFO_0000339', 'MONDO_0005148', 'MONDO_0004975', 'EFO_0003095', 'EFO_0003929', 'EFO_0001421', 'EFO_0000616', 'MONDO_0018305', 'MONDO_0005148', 'MP_0001845', 'EFO_0001361', 'EFO_0001421', 'MONDO_0004976', 'EFO_0003085', 'MONDO_0015339', 'EFO_0000707', 'MONDO_0100339', 'EFO_1001249', 'EFO_0001073', 'EFO_0003884', 'Orphanet_43', 'EFO_0000708', 'HP_0002745', 'EFO_0001645', 'EFO_0003914', 'MONDO_0005301', 'MONDO_0008315', 'EFO_0002618', 'MONDO_0007915', 'EFO_0000613', 'EFO_0000519', 'EFO_0003095', 'EFO_0003047', 'EFO_1000948', 'EFO_0000685', 'EFO_0000537', 'MONDO_0002009', 'EFO_0004272', 'HP_0100543', 'EFO_0002618', 'EFO_0002499', 'EFO_0003756', 'MONDO_0001437', 'EFO_0005611', 'EFO_0002614', 'EFO_0003060', 'MONDO_0007079', 'MONDO_0009061', 'EFO_1001348', 'EFO_0000676', 'EFO_0005669', 'EFO_0000673', 'EFO_0008620', 'EFO_0003060', 'MONDO_0004976', 'MONDO_0004979', 'EFO_0000319', 'EFO_0000660', 'EFO_0000195', 'EFO_0003884', 'HP_0001397', 'MONDO_0005180', 'EFO_0001378', 'MONDO_0016642', 'EFO_0004220', 'MONDO_0005147', 'EFO_0000222', 'MONDO_0001657']",80.0,['ENSG00000132170'],1,1999.0,,,"['137275816', '174007207', '26756476']",['8228'],,,,,
CHEMBL1200323,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl,WQVZLXWQESQGIF-UHFFFAOYSA-N,Small molecule,False,LABETALOL HYDROCHLORIDE,4.0,False,True,"['Labetalol Hydrocloride', 'Labetalol hydrochloride', 'Labetalol hydrochloride in dextrose', 'Labetalol hydrochloride in sodium chloride', 'Labrocol', 'Normodyne', 'Trandate']","['AH 5158A', 'AH-5158A', 'AH-5158A HYDROCHLORIDE', 'Ibidomide hydrochloride', 'Labetalol hcl', 'Labetalol hydrochloride', 'NSC-290312', 'SCH 15719W', 'SCH-15719W', 'SCH-15719W HYDROCHLORIDE']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for hypertension and has 2 investigational indications.,,,"['EFO_0000537', 'EFO_0005669', 'EFO_0000668']",3.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1984.0,CHEMBL429,['labetalol%20hydrochloride'],"['144204174', '144213042', '26747550', '50106500', '56422413', '855542']",,,,,,
CHEMBL1726,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-],VKQFCGNPDRICFG-UHFFFAOYSA-N,Small molecule,False,NISOLDIPINE,4.0,False,True,"['Nisoldipine', 'Sular', 'Syscor mr 10', 'Syscor mr 20', 'Syscor mr 30']","['BAY K 5552', 'BAY-K-5552', 'Baymycard', 'Geomatrix 16e', 'NSC-759106', 'Nisoldipin', 'Nisoldipine', 'Nisoldipine (stn)']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for hypertension and cardiovascular disease.,['Nisoldipine'],['DB00401'],"['EFO_0000537', 'EFO_0000319']",2.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1995.0,,['nisoldipine'],"['144205804', '144212682', '170465320', '26758055']",['76917'],,,,,
CHEMBL2108791,,,Enzyme,False,TENECTEPLASE,4.0,False,True,['Metalyse'],"['Rhtnk-tpa', 'TNK-TPA', 'Tenecteplase']",,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 11 investigational indications.,,,"['EFO_0003827', 'EFO_0009637', 'MONDO_0002679', 'EFO_0000712', 'EFO_0008585', 'EFO_1000637', 'EFO_0008583', 'HP_0002140', 'HP_0004419', 'EFO_0000612', 'EFO_0000618', 'MONDO_0005299', 'MONDO_0000831', 'EFO_0004278', 'EFO_1001154']",15.0,['ENSG00000104368'],1,2000.0,,['tenecteplase'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/metalyse'],,,['5066'],
CHEMBL2109282,,,Antibody drug conjugate,False,RG-7636,1.0,False,False,[],"['DEDN-6526A', 'RG-7636']",,Antibody drug conjugate drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000136160']",16,,,,,,,,,,
CHEMBL354077,Nc1ccncc1N,OYTKINVCDFNREN-UHFFFAOYSA-N,Small molecule,False,AMIFAMPRIDINE,4.0,False,True,['Ruzurgi'],"['3,4-DAP', '3,4-Diammoniopyridinium', '4-DAP', 'Amifampridine', 'DAP', 'Dynamine', 'NSC-521760', 'Pyridine-3,4-Diamine']",['CHEMBL3301611'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for myasthenia gravis and lambert-eaton myasthenic syndrome and has 6 investigational indications.,"['3,4-Diaminopyridine']",['DB11640'],"['EFO_0008525', 'EFO_0004991', 'MONDO_0005301', 'EFO_0005542', 'EFO_0004991', 'MONDO_0015263', 'EFO_0020094', 'EFO_0004991', 'EFO_0004991', 'EFO_0020094', 'EFO_0009851']",11.0,"['ENSG00000053918', 'ENSG00000171385', 'ENSG00000055118', 'ENSG00000177301', 'ENSG00000111262', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000104848', 'ENSG00000185760', 'ENSG00000117013', 'ENSG00000143473', 'ENSG00000182255', 'ENSG00000130037', 'ENSG00000177272', 'ENSG00000151079', 'ENSG00000129159', 'ENSG00000184408', 'ENSG00000182674', 'ENSG00000116396', 'ENSG00000131398', 'ENSG00000158445', 'ENSG00000143105', 'ENSG00000164794', 'ENSG00000140015', 'ENSG00000171126', 'ENSG00000168418', 'ENSG00000168263', 'ENSG00000124134', 'ENSG00000183960', 'ENSG00000166006', 'ENSG00000170745', 'ENSG00000173826', 'ENSG00000162975', 'ENSG00000184611', 'ENSG00000102057', 'ENSG00000026559', 'ENSG00000178342', 'ENSG00000135519', 'ENSG00000156486', 'ENSG00000089558']",40,2009.0,,,"['144206108', '170466846', '50112814', '51088028', '56323425']",,,,,,
CHEMBL3707365,,,Oligosaccharide,False,BEMIPARIN,3.0,False,False,[],['Bemiparin'],,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['EFO_0001422', 'HP_0000083', 'EFO_0000702', 'EFO_1001459', 'MONDO_0100096', 'HP_0004419']",6.0,['ENSG00000126218'],1,,,,,,,,,['4840'],
CHEMBL482968,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,BLQYVHBZHAISJM-CMDGGOBGSA-N,Small molecule,False,ENMD-2076,2.0,False,False,[],"['ENMD-2076', 'Enmd 2076', 'Enmd-2076']",['CHEMBL3237191'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,,"['EFO_0001642', 'MONDO_0004992', 'EFO_0000348', 'EFO_1001968', 'MONDO_0002087', 'EFO_1000251', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0001378', 'EFO_0000182']",10.0,"['ENSG00000128052', 'ENSG00000182578', 'ENSG00000087586', 'ENSG00000178999', 'ENSG00000157404', 'ENSG00000122025', 'ENSG00000068078']",7,,,,,,,,,,
CHEMBL647,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1,IEJXVRYNEISIKR-UHFFFAOYSA-N,Small molecule,False,APRACLONIDINE,4.0,False,True,['Iopidine'],['Apraclonidine'],['CHEMBL1200379'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for glaucoma and has 1 investigational indication.,['Apraclonidine'],['DB00964'],"['MONDO_0005041', 'EFO_0004991']",2.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1987.0,,,"['11110712', '50110931', '90341674']",['2788'],,,,,
CHEMBL1021,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,QEFAQIPZVLVERP-UHFFFAOYSA-N,Small molecule,False,NEPAFENAC,4.0,False,True,"['Ilevro', 'Nepafenac', 'Nevanac']","['AHR-9434', 'AL-6515', 'Nepafenac']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 approved and 2 investigational indications.,['Nepafenac'],['DB06802'],"['HP_0000616', 'MONDO_0005129', 'MONDO_0003005', 'EFO_0005752', 'MP_0001845', 'EFO_0003843']",6.0,"['ENSG00000073756', 'ENSG00000095303']",2,2005.0,,['nepafenac'],"['124896627', '144206538', '170465203']",['75922'],['https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac'],,,,
CHEMBL1200804,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],KXZOIWWTXOCYKR-UHFFFAOYSA-M,Small molecule,True,DICLOFENAC POTASSIUM,4.0,False,True,"['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint pain', 'Voltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapid', 'Zipsor']","['CGP 45840B', 'CGP-45840B', 'Diclofenac potassium', 'Diclofenac potassium salt', 'Potassium diclofenac']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 4 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000685', 'EFO_1001139', 'EFO_0003843', 'HP_0100607', 'EFO_0010072', 'MONDO_0005178', 'EFO_0009454', 'MONDO_0005277']",8.0,"['ENSG00000073756', 'ENSG00000095303']",2,1993.0,CHEMBL139,['diclofenac%20potassium'],,['4508'],,,,,
CHEMBL1201438,,,Protein,True,ALDESLEUKIN,4.0,False,True,['Proleukin'],"['Aldesleukin', 'Human interleukin-2', 'Human interleukin-2 125-serine', 'ILT-101', 'Il2 (2-133) c125s', 'Ilt-101', 'Ilt-101 (low dose il-2)', 'Interleukin 2', 'Interleukin-2', 'Interleukin-2 aldesleukin', 'Interleukin-2(2-133),125-ser', 'Recombinant interleukin-2 human']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 5 approved and 108 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000564', 'EFO_1000954', 'EFO_0000673', 'EFO_0005672', 'EFO_0003780', 'EFO_0000565', 'EFO_0000389', 'EFO_0000616', 'EFO_0009709', 'EFO_0000223', 'EFO_0009708', 'EFO_0004251', 'EFO_0000222', 'EFO_0004599', 'EFO_0001062', 'MONDO_0100096', 'EFO_0000783', 'EFO_0003811', 'EFO_0004719', 'EFO_0000691', 'EFO_0002617', 'EFO_1000251', 'EFO_0003865', 'EFO_0000403', 'MONDO_0020547', 'MONDO_0004975', 'EFO_0000313', 'MONDO_0001187', 'EFO_0000681', 'EFO_0003025', 'EFO_0001378', 'MONDO_0002367', 'EFO_1001375', 'EFO_0000220', 'EFO_0000729', 'EFO_1001051', 'MONDO_0007915', 'EFO_0005531', 'EFO_0008518', 'EFO_0000339', 'EFO_0000588', 'MONDO_0007254', 'MONDO_0002108', 'MONDO_0007576', 'MONDO_0024475', 'EFO_0000574', 'EFO_0000182', 'EFO_0000765', 'MONDO_0019956', 'MONDO_0002087', 'EFO_0000699', 'EFO_1001148', 'EFO_0000180', 'EFO_0001061', 'EFO_1001806', 'EFO_1000984', 'MONDO_0013730', 'EFO_0001075', 'EFO_0000183', 'MONDO_0002158', 'MONDO_0018906', 'MONDO_0008170', 'EFO_1000158', 'EFO_0000398', 'MONDO_0004992', 'EFO_0008528', 'EFO_0004255', 'EFO_0000198', 'EFO_1000131', 'MONDO_0008903', 'MONDO_0020077', 'EFO_0003060', 'EFO_0000095', 'EFO_1001471', 'EFO_0000571', 'MONDO_0008315', 'MONDO_0044881', 'EFO_0003869', 'EFO_0006861', 'EFO_0005846', 'EFO_0000756', 'EFO_0005952', 'EFO_1000785', 'EFO_0003029', 'EFO_0000621', 'EFO_0007141', 'EFO_0000309', 'EFO_0000349', 'EFO_0001668', 'MONDO_0002691', 'MONDO_0004976', 'EFO_0003027', 'EFO_0000764', 'MONDO_0002898', 'HP_0001871', 'EFO_0004192', 'EFO_0000384', 'EFO_0001376', 'EFO_0002428', 'EFO_0000708', 'EFO_0003893', 'EFO_0006859', 'EFO_0000218', 'EFO_0003047', 'EFO_1001951', 'EFO_1001264', 'MONDO_0005147', 'EFO_1001779', 'EFO_0000096', 'MONDO_0010518', 'EFO_1001465', 'EFO_0003802', 'EFO_0000221']",113.0,"['ENSG00000134460', 'ENSG00000147168', 'ENSG00000100385']",3,1992.0,,['aldesleukin'],,,,,,['5011'],
CHEMBL1762,Cc1cccc(C)c1NC(=O)C(C)N,BUJAGSGYPOAWEI-UHFFFAOYSA-N,Small molecule,True,TOCAINIDE,4.0,False,True,[],"['Tocainide', 'W-36095']",['CHEMBL1200773'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for cardiac arrhythmia. This drug has a black box warning from the FDA.,['Tocainide'],['DB01056'],['EFO_0004269'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1984.0,,,['90341559'],['9611'],,,,,
CHEMBL2096631,O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],QCHSEDTUUKDTIG-UHFFFAOYSA-L,Small molecule,True,CLORAZEPATE DIPOTASSIUM,4.0,False,True,"['Clorazepate dipotassium', 'Gen-xene', 'Tranxene', 'Tranxene sd']","['4306 CB', '4306-CB', '4306CB', 'AB 35616', 'ABBOTT-35616', 'CB 4306', 'CM 4306', 'Clorazepate dipotassium', 'Clorazepate dipotassium civ', 'Clorazepic acid dipotassium salt', 'Dipotassium clorazepate', 'Potassium Clorazepate', 'TR 19119']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for seizure and anxiety disorder. This drug has a black box warning from the FDA.,,,"['HP_0001250', 'EFO_0006788']",2.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1972.0,CHEMBL1213252,['clorazepate%20dipotassium'],,['3762'],,,,,
CHEMBL2108986,,,Protein,False,ARGIPRESSIN TANNATE,4.0,False,True,[],"['Argipressin', 'Argipressin tannate', 'CI-107']",,Protein drug with a maximum clinical trial phase of IV.,,,,,"['ENSG00000126895', 'ENSG00000166148', 'ENSG00000198049']",3,,,,,,,,,,
CHEMBL2109434,,,Antibody,False,IMC-GP100,-1.0,False,False,[],['IMC-GP100'],,Antibody drug.,,,,,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000185664']",4,,,,,,,,,,
CHEMBL2109475,,,Antibody,False,PG-102,2.0,False,False,[],"['PG-102', 'Pg-102']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003778'],1.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL2355456,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.O=C(O)/C=C/C(=O)O,PCIOHQNIRPWFMV-WXXKFALUSA-N,Small molecule,True,IBUTILIDE FUMARATE,4.0,False,True,"['Corvert', 'Ibutilide fumarate']","['Ibutilide fumarate', 'U-70226E']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995. This drug has a black box warning from the FDA.,,,,,['ENSG00000055118'],1,1995.0,CHEMBL533,['ibutilide%20fumarate'],['144206557'],,,,,,
CHEMBL3360203,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,QINPEPAQOBZPOF-UHFFFAOYSA-N,Small molecule,False,PILARALISIB,2.0,False,False,[],"['Pilaralisib', 'SAR-245408', 'SAR245408', 'Sar-245408', 'XL-147', 'XL147']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB11772'],"['EFO_0000574', 'EFO_0000519', 'EFO_0004230', 'EFO_0003060', 'MONDO_0011962', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254']",8.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,,,,,,,
CHEMBL3545137,Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1,YFNWWNRZJGMDBR-UHFFFAOYSA-N,Small molecule,False,PF-00477736,1.0,False,False,[],"['PF-00477736', 'PF-477736', 'PF477736', 'Pf 477736', 'Pf-00477736']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000149554'],1,,,,,,,,,,
CHEMBL3545191,,,Antibody,False,EVINACUMAB,4.0,False,True,['Evkeeza'],"['Evinacumab', 'Evinacumab dgnb', 'REGN-1500', 'REGN1500']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 2 investigational indications.,,,"['HP_0003124', 'EFO_0000589', 'EFO_0000319', 'EFO_0004911', 'EFO_0004211', 'MONDO_0018328']",6.0,['ENSG00000132855'],1,2021.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/evkeeza'],,,,
CHEMBL206815,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO,MAVDNGWEBZTACC-HNNXBMFYSA-N,Small molecule,False,APRATASTAT,2.0,False,False,[],"['Apratastat', 'TMI-005', 'TMI-05']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB13020'],['EFO_0000685'],1.0,"['ENSG00000151694', 'ENSG00000137745']",2,,,,,,,,,,
CHEMBL3545059,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)/C=C/C(=O)O,KLRSDBSKUSSCGU-KRQUFFFQSA-N,Small molecule,True,ALISKIREN FUMARATE,4.0,False,True,"['Rasilez', 'Tekturna']","['Aliskiren fumarate', 'Aliskiren hemifumarate', 'NSC-759185', 'SPP-100B', 'SPP100']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hypertension and stroke. This drug has a black box warning from the FDA.,,,"['EFO_0000537', 'EFO_0000712']",2.0,['ENSG00000143839'],1,2007.0,CHEMBL1639,['aliskiren%20hemifumarate'],,['53777'],['https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez'],,,,
CHEMBL4297064,CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl,XNCDYJFPRPDERF-UHFFFAOYSA-N,Small molecule,True,MILNACIPRAN HYDROCHLORIDE,4.0,False,True,"['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']","['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for fibromyalgia and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['HP_0003418', 'EFO_0005687']",2.0,"['ENSG00000103546', 'ENSG00000108576']",2,2009.0,CHEMBL259209,['milnacipran%20hydrochloride'],,,,,,,
CHEMBL492399,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,SNHCRNMVYDHVDT-UHFFFAOYSA-N,Small molecule,False,VERUBULIN,2.0,False,False,['Azixa'],"['MPC-6827', 'MX-128495', 'Verubulin']","['CHEMBL3910844', 'CHEMBL2105697']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB05585'],"['EFO_0000616', 'EFO_0000519', 'EFO_0003833']",3.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL5315087,,,Unknown,False,PROTEIN C CONCENTRATE (HUMAN),4.0,False,True,['Ceprotin'],"['Human protein c', 'Protein c', 'Protein c (coagulation inhibitor)', 'Protein c (homo sapiens)', 'Protein c human', 'Protexel']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved indications.,,,"['EFO_0009316', 'EFO_1001913', 'HP_0004419']",3.0,['ENSG00000115718'],1,2001.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin'],,,,
CHEMBL558752,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,YABJJWZLRMPFSI-UHFFFAOYSA-N,Small molecule,False,RAF-265,2.0,False,False,[],"['CHIR-265', 'NVP-RAF265', 'RAF265', 'Raf 265', 'Raf-265']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB05984'],"['EFO_0002617', 'EFO_0000616']",2.0,"['ENSG00000128052', 'ENSG00000157764']",2,,,,"['137275908', '50100093']",,,,,,
CHEMBL585,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,FNYLWPVRPXGIIP-UHFFFAOYSA-N,Small molecule,True,TRIAMTERENE,4.0,False,True,"['Dyrenium', 'Dytac']","['NSC-639359', 'NSC-77625', 'SK&F 8542', 'SK&F-8542', 'SK-8542', 'Triamterene']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 8 approved and 5 investigational indications. This drug has a black box warning from the FDA.,['Triamterene'],['DB00384'],"['EFO_0000537', 'EFO_0003914', 'EFO_0001422', 'EFO_0004255', 'MONDO_0005148', 'EFO_0009452', 'EFO_0000668', 'EFO_0000373', 'EFO_0004278', 'EFO_0001645', 'EFO_0009373', 'HP_0003124', 'EFO_0000319']",13.0,"['ENSG00000111319', 'ENSG00000168447', 'ENSG00000166828']",3,1964.0,,['triamterene'],"['104171252', '11111878', '11111879', '124881638', '124881640', '144203834', '144209219', '144213150', '170464706', '17389703', '26747035', '26751552', '50100356', '50104154', '50104155', '85231255', '855896', '90341047']",,,,['101'],,
CHEMBL1170,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,PDMMFKSKQVNJMI-BLQWBTBKSA-N,Small molecule,False,TESTOSTERONE PROPIONATE,4.0,False,True,['Testosterone propionate'],"['NRB-03689', 'NSC-9166', 'Orchisterone', 'Testosteron 17-propionate', 'Testosterone 17.beta.-propionate', 'Testosterone Propionate', 'Testosterone propionate', 'Testosterone propionate ciii', 'Testosteroni propionas', 'Virormone']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and has 1 investigational indication.,,['DB01420'],['EFO_1001271'],1.0,['ENSG00000169083'],1,1974.0,,,"['11112138', '144203881', '144212587', '170464835', '56463044']",['9466'],,,,,
CHEMBL1201178,CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,CETWSOHVEGTIBR-FORAGAHYSA-N,Small molecule,True,LISDEXAMFETAMINE DIMESYLATE,4.0,False,True,"['Elvanse', 'Elvanse adult', 'Vyvanse']","['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylate', 'Lisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilate', 'Lisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489', 'Tyvense']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 6 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0001073', 'MONDO_0002009', 'MONDO_0002277', 'MONDO_0005090', 'EFO_0005203', 'EFO_0003890', 'EFO_0005924', 'EFO_0004698', 'EFO_0005204', 'MONDO_0005041', 'EFO_0003888']",11.0,"['ENSG00000165646', 'ENSG00000103546', 'ENSG00000142319']",3,2007.0,CHEMBL1201222,['lisdexamfetamine%20dimesylate'],,,,,,,
CHEMBL2107786,Cc1ccc2c(c1CCC(=O)O)CC[C@@H](NS(=O)(=O)c1ccc(Cl)cc1)C2,HWEOXFSBSQIWSY-MRXNPFEDSA-N,Small molecule,False,TERUTROBAN,3.0,False,False,['Triplion'],"['S18886', 'Terutroban']",,Small molecule drug with a maximum clinical trial phase of III.,,,,,['ENSG00000006638'],1,,,,,,,,,,
CHEMBL2108029,,,Antibody,False,ERTUMAXOMAB,2.0,False,False,['Rexomun'],['Ertumaxomab'],,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0007254', 'EFO_0000616']",2.0,"['ENSG00000141736', 'ENSG00000198851']",2,,,,,,,,,,
CHEMBL2109124,,,Antibody drug conjugate,False,DORLIMOMAB ARITOX,2.0,False,False,[],"['Dorlimomab aritox', 'MDX-RA', 'ST-1 4197X-RA']",,Antibody drug conjugate drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000168028', 'ENSG00000177954', 'ENSG00000137154', 'ENSG00000140988', 'ENSG00000149273', 'ENSG00000145425', 'ENSG00000198034', 'ENSG00000129824', 'ENSG00000083845', 'ENSG00000171863', 'ENSG00000142937', 'ENSG00000170889', 'ENSG00000124614', 'ENSG00000142534', 'ENSG00000112306', 'ENSG00000110700', 'ENSG00000164587', 'ENSG00000115268', 'ENSG00000134419', 'ENSG00000105193', 'ENSG00000182774', 'ENSG00000231500', 'ENSG00000105372', 'ENSG00000008988', 'ENSG00000171858', 'ENSG00000186468', 'ENSG00000138326', 'ENSG00000118181', 'ENSG00000197728', 'ENSG00000143947', 'ENSG00000233927', 'ENSG00000213741', 'ENSG00000149806', 'ENSG00000100316', 'ENSG00000174444', 'ENSG00000122406', 'ENSG00000089009', 'ENSG00000147604', 'ENSG00000148303', 'ENSG00000161016', 'ENSG00000163682', 'ENSG00000147403', 'ENSG00000198755', 'ENSG00000142676', 'ENSG00000197958', 'ENSG00000167526', 'ENSG00000142541', 'ENSG00000188846', 'ENSG00000174748', 'ENSG00000265681', 'ENSG00000063177', 'ENSG00000105640', 'ENSG00000108298', 'ENSG00000122026', 'ENSG00000116251', 'ENSG00000125691', 'ENSG00000198242', 'ENSG00000114391', 'ENSG00000161970', 'ENSG00000131469', 'ENSG00000166441', 'ENSG00000108107', 'ENSG00000162244', 'ENSG00000156482', 'ENSG00000071082', 'ENSG00000144713', 'ENSG00000109475', 'ENSG00000136942', 'ENSG00000182899', 'ENSG00000130255', 'ENSG00000241343', 'ENSG00000145592', 'ENSG00000197756', 'ENSG00000172809', 'ENSG00000198918', 'ENSG00000229117', 'ENSG00000089157', 'ENSG00000137818']",78,,,,,,,,,,
CHEMBL3707277,,,Antibody drug conjugate,False,DEPATUXIZUMAB MAFODOTIN,3.0,False,False,[],"['ABT-414', 'Abt-414', 'Depatuxizumab mafodotin']",,Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0000519', 'EFO_1001465', 'EFO_0000616']",3.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL3786343,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,FDMQDKQUTRLUBU-UHFFFAOYSA-N,Small molecule,False,OLMUTINIB,4.0,False,True,[],"['BI 1482694', 'BI-1482694', 'HM-61713', 'HM61713', 'Hm-61713', 'Olmutinib']",['CHEMBL3989930'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 2 investigational indications.,,['DB13164'],"['EFO_0000616', 'EFO_0003060']",2.0,['ENSG00000146648'],1,2016.0,,,,,,,,,
CHEMBL4297521,COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(C(F)(F)F)nc2s1,DCXFIOLWWRXEQH-SSDOTTSWSA-N,Small molecule,False,PADSEVONIL,3.0,False,False,[],"['Padsevonil', 'UCB-0942', 'UCB-1415943-000', 'UCB0942', 'UCB1415943-000', 'Ucb0942']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB14977'],"['EFO_0001421', 'HP_0001250', 'EFO_0000474', 'EFO_0004263']",4.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000159164', 'ENSG00000185518', 'ENSG00000122012']",19,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PADSEVONIL/relevant/1/'],,,
CHEMBL5314405,COC(=O)/C(=C/c1cc(OC)cc(OC)c1)c1ccc(Oc2ccc(CC3SC(=O)NC3=O)cc2)cc1,IVAQJHSXBVHUQT-ZVHZXABRSA-N,Small molecule,False,CLX-0921,1.0,False,False,[],"['Clx-0921', 'THR-0921']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL1200472,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,IKMPWMZBZSAONZ-UHFFFAOYSA-N,Small molecule,True,QUAZEPAM,4.0,False,True,['Doral'],"['NSC-309702', 'Quazepam', 'Quazepam civ', 'SCH 16134', 'SCH-16134']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for insomnia. This drug has a black box warning from the FDA.,['Quazepam'],['DB01589'],['EFO_0004698'],1.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1985.0,,['quazepam'],,['8694'],,,,,
CHEMBL2105684,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21.O=S(=O)(O)O,GRKFGZYYYYISDX-UHFFFAOYSA-N,Small molecule,False,SELUMETINIB SULFATE,4.0,False,True,['Koselugo'],"['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATE', 'AZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphate', 'Azd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neurofibromatosis and neurofibromatosis type 1 and has 7 investigational indications.,,,"['EFO_0000272', 'EFO_0001075', 'EFO_1001512', 'EFO_1000251', 'EFO_0002617', 'EFO_0008514', 'MONDO_0018975', 'EFO_0002618', 'EFO_0000389']",9.0,"['ENSG00000126934', 'ENSG00000169032']",2,2020.0,CHEMBL1614701,['selumetinib%20sulfate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo'],,,,
CHEMBL2109308,,,Antibody,False,ONCOLYSIN B,2.0,False,False,[],['ONCOLYSIN B'],,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL3581647,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2,GNMUEVRJHCWKTO-FQEVSTJZSA-N,Small molecule,False,BIRABRESIB,2.0,False,False,[],"['Birabresib', 'MK-8628', 'OTX-015', 'OTX-015 ANHYDROUS', 'OTX015', 'OTX015 ANHYDROUS', 'Y-803 anhydrous']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,['DB15189'],"['EFO_0003060', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0000403', 'MONDO_0005184', 'EFO_0000519', 'EFO_0000222']",7.0,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']",4,,,,,,,,,,
CHEMBL3989939,O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1.O=S(=O)(O)O,PXHANKVTFWSDSG-QLOBERJESA-N,Small molecule,False,LAROTRECTINIB SULFATE,4.0,False,True,['Vitrakvi'],"['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications.,,,"['EFO_0009708', 'MONDO_0004992', 'EFO_0000616']",3.0,"['ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']",3,2018.0,CHEMBL3889654,['larotrectinib%20sulfate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi'],,,,
CHEMBL4298129,,,Unknown,False,HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX,4.0,False,True,['Voncento'],"['Human coagulation factor viii/von willebrand factor complex', 'Wilate']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for hemophilia a and von willebrand disease.,,,"['MONDO_0010602', 'Orphanet_903']",2.0,"['ENSG00000110799', 'ENSG00000185010']",2,2013.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/voncento'],,,,
CHEMBL4594567,,,Antibody,False,ROCATINLIMAB,3.0,False,False,[],"['AMG 451', 'AMG-451', 'AMG451', 'KHK-4083', 'KHK4083', 'KLK4083', 'Khk-4083', 'Khk4083', 'Rocatinlimab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000729', 'EFO_0000274']",2.0,['ENSG00000186827'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ROCATINLIMAB/relevant/1/'],,,
CHEMBL5095033,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1,BRKWREZNORONDU-UHFFFAOYSA-N,Small molecule,False,IBCASERTIB,3.0,False,False,[],"['CS-2164', 'CS2164', 'Chiauranib', 'Cs-2164', 'Ibcasertib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,,"['EFO_0005537', 'EFO_0000182', 'EFO_0000616', 'EFO_0000702', 'EFO_0005952', 'EFO_1001968', 'MONDO_0008170']",7.0,"['ENSG00000178999', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",4,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-127']
CHEMBL5314348,,,Protein,False,BIVALIRUDIN,4.0,False,True,"['Angiomax', 'Angiomax rtu', 'Angiox', 'Bivalirudin', 'Bivalirudin in 0.9% sodium chloride']","['BG-8967', 'BG8967', 'Bivalirudin']",['CHEMBL5314353'],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 10 investigational indications.,,,"['HP_0004419', 'HP_0001871', 'EFO_0005672', 'EFO_0008583', 'EFO_0000266', 'HP_0001873', 'EFO_0000713', 'EFO_0001645', 'EFO_0003777', 'MP_0001914', 'EFO_1000985', 'EFO_0003907', 'EFO_0000612', 'EFO_0000319', 'MONDO_0000831']",15.0,['ENSG00000180210'],1,2000.0,,['bivalirudin'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/angiox'],,,,
CHEMBL58323,COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1,VPPJLAIAVCUEMN-GFCCVEGCSA-N,Small molecule,False,LACOSAMIDE,4.0,False,True,"['Lacosamide', 'Vimpat']","['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'ADD243037', 'Erlosamide', 'Lacosamide', 'Lacosamide cv', 'Motpoly', 'SPM 927', 'SPM-927', 'SPM927']",['CHEMBL1213900'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for epilepsy and seizure and has 20 investigational indications.,['Lacosamide'],['DB06218'],"['EFO_0005543', 'EFO_0003833', 'EFO_0000474', 'MONDO_0007571', 'EFO_0005230', 'HP_0001250', 'EFO_0005762', 'MONDO_0002050', 'EFO_0008526', 'EFO_0005687', 'MONDO_0005090', 'MONDO_0004976', 'EFO_0000326', 'MONDO_0005277', 'MONDO_0041052', 'MONDO_0007079', 'MONDO_0005178', 'HP_0000726', 'EFO_0004263', 'EFO_0003086', 'HP_0011868', 'EFO_1000783']",22.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2008.0,,['lacosamide'],['170466190'],,['https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat'],,,,
CHEMBL1200437,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,XHKUDCCTVQUHJQ-LCYSNFERSA-N,Small molecule,True,QUINIDINE GLUCONATE,4.0,False,True,"['Duraquin', 'Quinact', 'Quinaglute', 'Quinalan', 'Quinatime', 'Quinidine gluconate']","['Dura-tab', 'Gluconic acid quinidine salt', 'Gluquinate', 'NSC-757297', 'Quinidine gluconate', 'Quinidine mono-d-gluconate', 'Quinidine monogluconate, d-']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for malaria and ventricular arrhythmia. This drug has a black box warning from the FDA.,,,"['EFO_0001068', 'HP_0004308']",2.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1950.0,CHEMBL1294,['quinidine%20gluconate'],,['27502'],,,,,
CHEMBL1201124,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,BWHLPLXXIDYSNW-UHFFFAOYSA-N,Small molecule,True,KETOROLAC TROMETHAMINE,4.0,False,True,"['Acular', 'Acular ls', 'Acular preservative free', 'Acuvail', 'Ketorolac tromethamine', 'Sprix', 'Toradol']","['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'Lixidol', 'NSC-758637', 'Tarasyn']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003777', 'MONDO_0005129', 'MONDO_0005184', 'EFO_1000859', 'EFO_1001139', 'MONDO_0005277', 'EFO_1001412', 'MP_0001845', 'EFO_0003843', 'EFO_1001178', 'HP_0003418', 'EFO_0005854', 'EFO_0004253', 'MONDO_0003005', 'HP_0200026']",15.0,"['ENSG00000073756', 'ENSG00000095303']",2,1989.0,CHEMBL469,['ketorolac%20tromethamine'],"['124881877', '26747544', '49681816', '50106489', '8139924']",['6130'],,,,,
CHEMBL2068839,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,RECBFDWSXWAXHY-IAGOWNOFSA-N,Small molecule,False,RISLENEMDAZ,2.0,False,False,[],"['CERC-301', 'Cerc-301', 'MK-0657', 'MK-0657, (-)-', 'Rislenemdaz', 'Rislenemdaz, (-)-']",['CHEMBL2036513'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB12063'],"['MONDO_0002050', 'MONDO_0002009']",2.0,"['ENSG00000176884', 'ENSG00000273079']",2,,,,,,,,,,
CHEMBL3545231,c1ccc(-c2nnc(O[C@@H]3C4CC5C[C@H]3CN(C5)C4)s2)cc1,QZDCYUCETTWCMO-CDFKWJNJSA-N,Small molecule,False,ABT-126,2.0,False,False,[],"['ABT-126', 'Abt-126', 'Nelonicline']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0004975', 'MONDO_0005090']",2.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL445813,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,OVPNQJVDAFNBDN-UHFFFAOYSA-N,Small molecule,False,AT-7519,2.0,False,False,[],"['AT 7519', 'AT-7519', 'AT7519', 'At-7519', 'Cdki at7519']",['CHEMBL497478'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB08142'],"['EFO_0000616', 'EFO_0001378', 'EFO_1001469', 'EFO_0000574', 'EFO_0000095']",5.0,"['ENSG00000170312', 'ENSG00000135446', 'ENSG00000123374', 'ENSG00000164885', 'ENSG00000105810', 'ENSG00000134058', 'ENSG00000250506', 'ENSG00000102225', 'ENSG00000117266', 'ENSG00000132964', 'ENSG00000059758', 'ENSG00000248333', 'ENSG00000138395', 'ENSG00000155111', 'ENSG00000058091', 'ENSG00000136807', 'ENSG00000185324', 'ENSG00000065883', 'ENSG00000156345', 'ENSG00000167258']",20,,,,"['137275934', '137275935']",,,,,,
CHEMBL4594275,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1,NLFLXLJXEIUQDL-UHFFFAOYSA-N,Small molecule,False,GUSACITINIB,2.0,False,False,[],"['ASN-002', 'ASN002', 'Asn-002', 'Asn002', 'EN-3351', 'EN3351', 'Gusacitinib']",['CHEMBL4594276'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_0005809', 'EFO_0005809', 'MONDO_0002334', 'MONDO_0002406', 'MONDO_0002334', 'MONDO_0018906', 'EFO_1001469', 'EFO_0000403', 'EFO_0000274']",9.0,"['ENSG00000165025', 'ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",5,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/GUSACITINIB/relevant/1/'],,,
CHEMBL568,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,ADIMAYPTOBDMTL-UHFFFAOYSA-N,Small molecule,True,OXAZEPAM,4.0,False,True,"['Lederpam', 'Oxazepam', 'Serax', 'Serenid fte', 'Zaxopam']","['J3.308A', 'NSC-169448', 'Oxazepam', 'Oxazepam civ', 'Oxozepam', 'Temazepam impurity, oxazepam-', 'WY-3498']",['CHEMBL3251468'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.,['Oxazepam'],['DB00842'],"['HP_0000713', 'EFO_0003768', 'HP_0000726', 'EFO_0006788', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0000764', 'EFO_0005230']",8.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1965.0,,['oxazepam'],"['144205125', '144206372', '144207898', '144213809', '29215230']",['7823'],,,,,
CHEMBL159,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,JXLYSJRDGCGARV-CFWMRBGOSA-N,Small molecule,False,VINBLASTINE,4.0,False,True,[],"['NSC-47842', 'Velban', 'Vinblastine', '[3H]-Vinblastine']",['CHEMBL378544'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 6 approved and 36 investigational indications.,['Vinblastine'],['DB00570'],"['EFO_0000588', 'EFO_0000574', 'EFO_0000574', 'EFO_0000681', 'EFO_0000691', 'MONDO_0008170', 'MONDO_0009348', 'MONDO_0002898', 'MONDO_0018975', 'MONDO_0001187', 'EFO_0000220', 'EFO_0000222', 'MONDO_0004192', 'EFO_0004281', 'MONDO_0004986', 'EFO_0006818', 'MONDO_0003751', 'MONDO_0008315', 'MONDO_0009348', 'EFO_0000183', 'EFO_0000183', 'EFO_1000318', 'EFO_0000565', 'EFO_0002617', 'EFO_0000389', 'EFO_0000616', 'EFO_0003833', 'EFO_0005543', 'EFO_0000389', 'EFO_0000211', 'MONDO_0002041', 'MONDO_0008315', 'MONDO_0008903', 'MONDO_0002367', 'MONDO_0004986', 'EFO_0000756', 'EFO_1000158', 'MONDO_0001187', 'EFO_0000756', 'EFO_0009907', 'MONDO_0008903', 'EFO_0004281', 'EFO_0001642', 'MONDO_0004192', 'EFO_0008528', 'MONDO_0002974', 'EFO_0000403']",47.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1965.0,,,,,,,,,
CHEMBL2165620,O=C(O)c1ccc(NC(=O)[C@H](CC2CCCC2)n2cnc(C(F)(F)F)c2)nc1,GKMLFBRLRVQVJO-ZDUSSCGKSA-N,Small molecule,False,PF-04991532,2.0,False,False,[],['Pf-04991532'],,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB11765'],['MONDO_0005148'],1.0,['ENSG00000106633'],1,,,,,,,,,,
CHEMBL282052,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,JEYCTXHKTXCGPB-UHFFFAOYSA-N,Small molecule,False,METHAQUALONE,4.0,True,True,[],"['CI-705', 'CN 38703', 'CN-38703', 'Methaqualone', 'Methaqualoneinone', 'Metolquizolone', 'NSC-111388', 'NSC-111388-', 'NSC-126877', 'NSC-631628', 'QZ-2', 'R-148', 'TR-495']",['CHEMBL2106829'],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,['Methaqualone'],['DB04833'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,"['144206055', '144206422', '24804237']",['6821'],,,,,
CHEMBL3545371,,,Antibody drug conjugate,False,DENINTUZUMAB MAFODOTIN,2.0,False,False,[],"['Denintuzumab mafodotin', 'SGN-19A', 'SGN-CD19A']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,,"['EFO_1001469', 'EFO_0000220', 'EFO_0000403', 'EFO_0000309', 'MONDO_0018906']",5.0,['ENSG00000177455'],1,,,,,,,,,,
CHEMBL360055,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,OZLPUNFFCJDMJD-UHFFFAOYSA-N,Small molecule,False,GALLAMINE,4.0,False,True,[],['Gallamine'],['CHEMBL1200993'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1982.0,,,"['11111237', '11111238', '124880248', '26756602', '90341095']",,,,,,
CHEMBL5095031,CCCCCCN(CCOc1ccc(CCCCNC(=N)NC(=O)c2nc(Cl)c(N)nc2N)cc1)C[C@H](O)C(O)[C@H](O)[C@H](O)CO,HBZAZSCNDMDWEU-GNZRQIOVSA-N,Small molecule,False,IDREVLORIDE,2.0,False,False,[],"['GS-560876', 'GS-5737', 'Idrevloride', 'P-1037', 'VRT-1499138', 'VX-371']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000684', 'MONDO_0016575', 'MONDO_0009061']",3.0,"['ENSG00000111319', 'ENSG00000168447', 'ENSG00000166828']",3,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/IDREVLORIDE/relevant/1/'],,,
CHEMBL572881,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,RAHBGWKEPAQNFF-UHFFFAOYSA-N,Small molecule,False,MOTESANIB,3.0,False,False,[],"['AMG 706', 'AMG-706', 'Motesanib']",['CHEMBL2107357'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.,,['DB05575'],"['MONDO_0007254', 'MONDO_0021063', 'MONDO_0008903', 'MONDO_0007254', 'EFO_1000657', 'MONDO_0007576', 'EFO_0003060', 'MONDO_0002087', 'MONDO_0008170', 'MONDO_0011719', 'EFO_0002618', 'EFO_0000616', 'EFO_0007331', 'EFO_0003060', 'MONDO_0002158', 'MONDO_0002108', 'EFO_0004243', 'EFO_0000574', 'MONDO_0016537']",19.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000165731', 'ENSG00000113721', 'ENSG00000134853']",7,,,,"['137276049', '50100087']",['51098'],,,,,
CHEMBL250270,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1,ZDXUKAKRHYTAKV-UHFFFAOYSA-N,Small molecule,False,LERCANIDIPINE,4.0,False,True,[],"['Lercanidipine', 'Lercanil']",['CHEMBL2106419'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications.,['Lercanidipine'],['DB00528'],"['EFO_0000537', 'MONDO_0001134', 'EFO_0000319']",3.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,"['50112745', '90340703']",,,,,,
CHEMBL3188267,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,LIOLIMKSCNQPLV-UHFFFAOYSA-N,Small molecule,False,CAPMATINIB,4.0,False,True,[],"['Capmatinib', 'INC-280', 'INC280', 'INCB-28060', 'INCB-28060 FREE BASE', 'Incb-28060', 'NVP-INC280', 'NVP-INC280-NX', 'NYP-INC280-NX']",['CHEMBL3989937'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 10 investigational indications.,,['DB11791'],"['MONDO_0008903', 'MONDO_0007254', 'EFO_0000182', 'MONDO_0002367', 'EFO_0003060', 'EFO_0000389', 'EFO_0000756', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000519', 'EFO_1001968', 'EFO_0001421', 'EFO_0003060']",13.0,['ENSG00000105976'],1,2020.0,,,['174006562'],,,,,,
CHEMBL4094894,CC(C)c1cccc([C@H](C)C2CC2)c1O,BMEARIQHWSVDBS-SNVBAGLBSA-N,Small molecule,False,CIPEPOFOL,3.0,False,False,[],"['Cipepofol', 'Ciprofol', 'HSK-3486', 'HSK-3486, (R)-', 'HSK3486', 'Hsk-3486', 'Hsk3486']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['MONDO_0002050', 'EFO_0003086']",2.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL75880,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,CYXKNKQEMFBLER-UHFFFAOYSA-N,Small molecule,False,PERHEXILINE,4.0,True,True,[],['Perhexiline'],['CHEMBL1334033'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for cardiovascular disease and has 4 investigational indications.,['Perhexiline'],['DB01074'],"['EFO_1000899', 'EFO_0003144', 'EFO_0000538', 'EFO_1001458', 'EFO_0000319']",5.0,"['ENSG00000198793', 'ENSG00000205560', 'ENSG00000157184']",3,1974.0,,,['174006795'],['35553'],,,['45'],,
CHEMBL1200549,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1.[Br-],LVQTUXZKLGXYIU-GWSNJHLMSA-M,Small molecule,False,RAPACURONIUM BROMIDE,4.0,True,True,['Raplon'],"['ORG 9487', 'ORG-9487', 'Rapacuronium bromide']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999. It was withdrawn in at least one region.,,,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1999.0,CHEMBL1201352,,['144206855'],,,,,,
CHEMBL1481,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,WIGIZIANZCJQQY-RUCARUNLSA-N,Small molecule,False,GLIMEPIRIDE,4.0,False,True,"['Amaryl', 'Glimepiride', 'Niddaryl']","['Amaryl', 'Glimepiride', 'HOE 490', 'HOE-490', 'NSC-759809']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 4 investigational indications.,['Glimepiride'],['DB00222'],"['EFO_0003914', 'MONDO_0005148', 'EFO_0000400', 'Orphanet_552', 'EFO_0000537', 'EFO_0001645', 'HP_0003124']",7.0,"['ENSG00000187486', 'ENSG00000006071']",2,1995.0,,['glimepiride'],"['144204264', '170464966', '49648856']",['5383'],,,,,
CHEMBL2087361,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,QQLKULDARVNMAL-UHFFFAOYSA-N,Small molecule,False,ICOTINIB,3.0,False,False,[],"['BPI-2009H', 'Bpi-2009', 'Icotinib']",['CHEMBL4297665'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,['DB11737'],"['EFO_0000708', 'MONDO_0008903', 'EFO_0000616', 'MONDO_0007254', 'EFO_0003060', 'EFO_0004252', 'EFO_0002618', 'EFO_1000849', 'MONDO_0007576', 'EFO_0005922', 'EFO_0000313', 'EFO_0000676', 'EFO_0000571']",13.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL3545146,,,Small molecule,False,SRX251,1.0,False,False,[],['Srx251'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000166148'],1,,,,,,,,,,
CHEMBL5095026,C[C@@H](NCc1nc2ccc(Oc3cc(F)c(F)c(F)c3)nc2n1C1CCC1)C(N)=O,HHXCJIMPEJSJTG-SNVBAGLBSA-N,Small molecule,False,DSP-2230,1.0,False,False,[],['Dsp-2230'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000185313', 'ENSG00000169432']",2,,,,,,,,,,
CHEMBL519504,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,DAYKLWSKQJBGCS-NRFANRHFSA-N,Small molecule,False,ALEGLITAZAR,3.0,False,False,[],"['Aleglitazar', 'R-1439', 'R1439', 'RO-0728804', 'RO0728804', 'Ro-0728804']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,['Aleglitazar'],['DB08915'],['MONDO_0005148'],1.0,"['ENSG00000132170', 'ENSG00000186951']",2,,,,,,,,,,
CHEMBL1198855,CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F,FQJISUPNMFRIFZ-HXUWFJFHSA-N,Small molecule,False,RONACALERET,2.0,False,False,[],"['Ronacaleret', 'Sb-751689']",['CHEMBL1083998'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB05255'],"['EFO_0003931', 'EFO_0003882']",2.0,['ENSG00000036828'],1,,,,,,,,,,
CHEMBL1200,CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N,CMHHMUWAYWTMGS-UHFFFAOYSA-N,Small molecule,False,BENOXINATE,4.0,False,True,[],"['Benoxinate', 'Conjucain', 'Dorsacain', 'Monofree oxybuprocaine', 'Oxybucaine', 'Oxybuprocaine']",['CHEMBL1200654'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for pruritus.,['Oxybuprocaine'],['DB00892'],['HP_0000989'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,,,"['11112575', '56320722']",['309594'],,,,,
CHEMBL1201202,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,KANJSNBRCNMZMV-ABRZTLGGSA-N,Oligosaccharide,True,FONDAPARINUX,4.0,False,True,[],['Fondaparinux'],['CHEMBL1200644'],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 approved and 12 investigational indications. This drug has a black box warning from the FDA.,['Fondaparinux'],['DB00569'],"['HP_0001907', 'HP_0004936', 'EFO_0000275', 'EFO_0000612', 'EFO_0003907', 'EFO_0004286', 'EFO_0007541', 'EFO_0001074', 'EFO_0005672', 'HP_0004419', 'HP_0004936', 'EFO_0004286', 'HP_0001873', 'EFO_0003827', 'MONDO_0100096', 'HP_0000083', 'EFO_1000985', 'EFO_0009686', 'HP_0001907', 'EFO_0001075']",20.0,['ENSG00000117601'],1,2001.0,,,,['61033'],,,,,
CHEMBL1201821,,,Protein,False,PALIFERMIN,4.0,False,True,['Kepivance'],['Palifermin'],,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 25 investigational indications.,['Palifermin'],,"['MONDO_0004979', 'EFO_0000574', 'MONDO_0004992', 'MONDO_0005301', 'EFO_0000707', 'EFO_0000764', 'EFO_0004276', 'MONDO_0015760', 'EFO_0005555', 'EFO_0006475', 'EFO_1001904', 'EFO_0005952', 'EFO_0000198', 'EFO_0009688', 'EFO_0000222', 'EFO_1001898', 'MONDO_0013730', 'MONDO_0044881', 'EFO_0000565', 'EFO_0000183', 'EFO_0004599', 'EFO_1001451', 'EFO_0001378', 'MONDO_0021193', 'EFO_0006859', 'EFO_1000690', 'MONDO_0004907', 'MONDO_0021063']",28.0,['ENSG00000066468'],1,2005.0,,['palifermin'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kepivance'],,,['4804'],
CHEMBL1409,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O,LFMYNZPAVPMEGP-PIDGMYBPSA-N,Small molecule,True,FLUVOXAMINE MALEATE,4.0,False,True,"['Faverin 100', 'Faverin 50', 'Floxyfral', 'Fluvoxamine maleate', 'Luvox', 'Luvox cr']","['DU-23000', 'DU23000', 'Faverin', 'Fevarin', 'Fluvoxamine hydrogenmaleate', 'Fluvoxamine maleate', 'NSC-759602']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for obsessive-compulsive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000694', 'EFO_0004262', 'MONDO_0100096', 'EFO_0004242']",4.0,['ENSG00000108576'],1,1994.0,CHEMBL814,['fluvoxamine%20maleate'],"['50106274', '50106275', '93576625']",,,,,,
CHEMBL3187812,CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C,FXKFFTMLFPWYFH-RDGPPVDQSA-N,Small molecule,False,ILEPATRIL,2.0,False,False,[],"['AVE-7688', 'AVE7688', 'Ave7688', 'Ilepatril']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB06604'],['EFO_0000537'],1.0,"['ENSG00000196549', 'ENSG00000159640']",2,,,,['144210558'],,,,,,
CHEMBL4650476,,,Oligonucleotide,False,COFIRASERSEN,2.0,False,False,[],"['Cofirasersen', 'ION-827359', 'IONIS-ENACRX', 'Ion-827359', 'Ionis-enacrx']",,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0006505', 'MONDO_0009061']",2.0,"['ENSG00000166828', 'ENSG00000111319', 'ENSG00000168447']",3,,,,,,,,,,
CHEMBL5303393,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,TWYFGYXQSYOKLK-UFIFRZAQSA-N,Small molecule,False,VARENICLINE TARTRATE,4.0,False,True,"['Champix', 'Chantix', 'Tyrvaya']","['CP-526,555-18', 'CP-526555-18', 'Tyrvaya', 'Varenicline tartrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 investigational indications.,,,"['EFO_0004319', 'EFO_0003768', 'EFO_1000906', 'MONDO_0007079']",4.0,"['ENSG00000160716', 'ENSG00000101204']",2,2006.0,CHEMBL1076903,['varenicline%20tartrate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/champix'],,,,
CHEMBL778,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CUHVIMMYOGQXCV-NSHDSACASA-N,Small molecule,False,DEXMEDETOMIDINE,4.0,False,True,[],"['Dexmedetomidine', 'MPV-1440', 'Medetomidine, (s)-']",['CHEMBL2106195'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 73 investigational indications.,['Dexmedetomidine'],['DB00633'],"['EFO_0003843', 'EFO_0003918', 'EFO_0002460', 'EFO_1002048', 'MONDO_0007172', 'MONDO_0005129', 'HP_0030834', 'EFO_0006834', 'EFO_0005774', 'EFO_0004698', 'EFO_0003777', 'EFO_0009516', 'EFO_0005279', 'EFO_0001074', 'MONDO_0004976', 'EFO_0005251', 'HP_0000713', 'MP_0001845', 'EFO_0003957', 'EFO_0001645', 'EFO_0000275', 'EFO_0001073', 'EFO_0003843', 'EFO_0004888', 'EFO_1000391', 'MONDO_0007254', 'HP_0012532', 'EFO_0000668', 'MONDO_0005090', 'EFO_0005207', 'MONDO_0001056', 'HP_0012735', 'EFO_0005762', 'HP_0001919', 'EFO_0005323', 'HP_0002093', 'EFO_0003833', 'EFO_0005411', 'EFO_0002950', 'EFO_0000474', 'EFO_0005230', 'EFO_0009267', 'EFO_0000239', 'EFO_0002610', 'MONDO_0002258', 'EFO_0000546', 'MONDO_0005149', 'MONDO_0003544', 'EFO_0004273', 'EFO_1001210', 'HP_0000713', 'HP_0100543', 'MONDO_0004975', 'EFO_0000537', 'EFO_0009267', 'EFO_0000677', 'EFO_0009620', 'EFO_0009686', 'MONDO_0005299', 'MONDO_0043510', 'MONDO_0004992', 'HP_0000175', 'EFO_0005611', 'EFO_0003756', 'EFO_0010282', 'EFO_0003931', 'EFO_0000713', 'MONDO_0043510', 'EFO_1001884', 'EFO_0004264', 'HP_0002315', 'HP_0001337', 'EFO_1001454', 'HP_0000023']",74.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1999.0,,,['11114268'],['4466'],,,,,
CHEMBL1096882,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,GIUYCYHIANZCFB-FJFJXFQQSA-N,Small molecule,True,FLUDARABINE PHOSPHATE,4.0,False,True,"['Fludara', 'Fludarabine phosphate', 'Oforta']","['2-f-ara-amp', '2-f-araa', '2-fluoro ara-a', '2-fluorovidarabine', 'Fludarabine', ""Fludarabine 5'-monophosphate"", 'Fludarabine monophosphate', 'Fludarabine phosphate', 'Fluradosa', 'NSC-118218', 'NSC-118218H', 'NSC-312887', 'NSC-328002']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 138 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000691', 'EFO_0000403', 'EFO_0000221', 'HP_0001871', 'EFO_0009709', 'EFO_0000209', 'EFO_0003027', 'EFO_0004256', 'EFO_0003811', 'EFO_0004599', 'EFO_1000292', 'MONDO_0008170', 'EFO_0009441', 'EFO_0003778', 'MONDO_0021063', 'EFO_0004251', 'EFO_0000309', 'MONDO_0002334', 'MONDO_0015760', 'EFO_0001642', 'EFO_0005952', 'EFO_1000690', 'EFO_0000389', 'EFO_0000220', 'MONDO_0001023', 'EFO_0003802', 'EFO_0000255', 'EFO_0000621', 'EFO_0000196', 'HP_0001915', 'MONDO_0004992', 'Orphanet_848', 'MONDO_0019391', 'EFO_0000339', 'MONDO_0009348', 'MONDO_0021193', 'EFO_0003032', 'HP_0012410', 'EFO_0006927', 'EFO_0005761', 'MONDO_0007576', 'EFO_1001257', 'MONDO_0015277', 'EFO_1000560', 'EFO_0003025', 'MONDO_0002691', 'EFO_0004272', 'EFO_0000222', 'EFO_0000095', 'EFO_1001779', 'EFO_0000349', 'EFO_0000182', 'EFO_0000096', 'MONDO_0018906', 'MONDO_0015253', 'MONDO_0009833', 'MONDO_0019469', 'EFO_0006803', 'EFO_0002617', 'EFO_0001075', 'MONDO_0011382', 'EFO_0000565', 'MONDO_0015974', 'EFO_0000540', 'EFO_0000708', 'EFO_0009708', 'MONDO_0019460', 'MONDO_0002158', 'MONDO_0017198', 'EFO_1001051', 'EFO_0000519', 'EFO_0001378', 'MONDO_0008903', 'EFO_0000384', 'MONDO_0000159', 'EFO_1001465', 'EFO_0003869', 'EFO_1001996', 'EFO_1000131', 'EFO_0000574', 'MONDO_0044881', 'MONDO_0008315', 'EFO_0000223', 'EFO_0000174', 'MONDO_0100244', 'MONDO_0002898', 'EFO_1000309', 'EFO_0004252', 'EFO_0000183', 'EFO_0000685', 'EFO_0000616', 'EFO_0003865', 'MONDO_0000870', 'EFO_0000637', 'EFO_1002048', 'MONDO_0020077', 'EFO_0000211', 'EFO_0006475', 'EFO_0002429', 'EFO_1001469', 'EFO_0006859', 'EFO_0000588', 'EFO_0000094', 'MONDO_0002108', 'EFO_0000218', 'EFO_0000198', 'EFO_0002428', 'MONDO_0002087', 'MONDO_0010518', 'MONDO_0013730', 'MONDO_0018922', 'EFO_0003060', 'EFO_1000956', 'MONDO_0044903', 'EFO_0000717', 'EFO_0001061', 'EFO_0000681', 'EFO_0000756', 'MONDO_0005184', 'EFO_1000318', 'HP_0100727', 'MONDO_0019472', 'MONDO_0018305', 'MONDO_0002367', 'HP_0002721', 'EFO_0002430', 'EFO_1001938', 'EFO_0005803', 'EFO_0000571', 'EFO_0004289', 'MONDO_0005301', 'EFO_0000676', 'EFO_1000785', 'MONDO_0000873', 'MONDO_0019471', 'EFO_1000102', 'MONDO_0007915', 'EFO_0000326', 'EFO_0000191', 'MONDO_0007254', 'MONDO_0001657']",141.0,"['ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848', 'ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229']",14,1991.0,,['fludarabine%20phosphate'],,['63599'],,,,,
CHEMBL1200694,FCOC(C(F)(F)F)C(F)(F)F,DFEYYRMXOJXZRJ-UHFFFAOYSA-N,Small molecule,False,SEVOFLURANE,4.0,False,True,"['Sevoflurane', 'Sevohale (previously known as sevocalm)', 'Sojourn', 'Ultane']","['MR-6S4', 'MR6S4', 'NSC-760367', 'Sevocalm', 'Sevoflo', 'Sevoflurane', 'Sevorane']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 33 investigational indications.,['Sevoflurane'],['DB01236'],"['EFO_0009267', 'EFO_0003870', 'EFO_0000713', 'EFO_0001074', 'MONDO_0021698', 'EFO_0009686', 'EFO_0005207', 'EFO_1001328', 'HP_0011110', 'HP_0003418', 'EFO_0003884', 'EFO_0001073', 'EFO_0003843', 'EFO_0002687', 'MONDO_0007254', 'MONDO_0007576', 'EFO_0003777', 'EFO_0005323', 'HP_0001919', 'MONDO_0100096', 'EFO_0001645', 'EFO_0008583', 'MONDO_0004992', 'EFO_0005611', 'EFO_1002048', 'EFO_0000694', 'MONDO_0043510', 'MP_0001845', 'EFO_0006834', 'EFO_1000637', 'EFO_1001951', 'MONDO_0021117', 'EFO_1001884']",33.0,"['ENSG00000169427', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000186795', 'ENSG00000082482', 'ENSG00000145888', 'ENSG00000109738', 'ENSG00000171303', 'ENSG00000100433']",23,1995.0,,['sevoflurane'],"['144205978', '50112674']",['9130'],['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/sevohale-previously-known-sevocalm'],,,,
CHEMBL1201192,NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,YFGHCGITMMYXAQ-LJQANCHMSA-N,Small molecule,False,ARMODAFINIL,4.0,False,True,"['Armodafinil', 'Nuvigil']","['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-', 'NSC-751850', 'NSC-758711', 'R-(-)-modafinil']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 14 investigational indications.,['Armodafinil'],['DB06413'],"['MONDO_0100342', 'EFO_0003060', 'HP_0012378', 'MONDO_0021107', 'EFO_0003888', 'MONDO_0007576', 'MONDO_0005090', 'EFO_0006859', 'MONDO_0016158', 'EFO_0001073', 'EFO_0008568', 'MONDO_0002050', 'EFO_0004698', 'MONDO_0043510', 'EFO_0003918', 'EFO_0005246', 'EFO_0000712', 'EFO_0000616', 'MONDO_0005301']",19.0,['ENSG00000142319'],1,2007.0,,['armodafinil'],,['77590'],,,,,
CHEMBL1201448,,,Oligosaccharide,False,ARDEPARIN SODIUM,4.0,False,True,['Normiflo'],"['Ardeparin sodium', 'Ardeparin sodium salt', 'RD-11885', 'WY-90493 RD', 'WY-90493-RD']",,Oligosaccharide drug with a maximum clinical trial phase of IV that was first approved in 1997.,['Ardeparin_sodium'],,,,['ENSG00000117601'],1,1997.0,,,,,,,,,
CHEMBL2107863,,,Unknown,False,RINDOPEPIMUT,3.0,False,False,[],"['CDX-110', 'PF-04948568', 'PF-04948568 (FORMERLY CDX-110)', 'Rindopepimut']",,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['MONDO_0100342', 'EFO_1001465', 'MONDO_0001657']",3.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL2108339,,,Protein,False,EGAPTIVON PEGOL,2.0,False,False,[],"['ARC-1779', 'ARC1779', 'Arc1779', 'Egaptivon pegol']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0018896', 'Orphanet_903', 'MONDO_0000831']",3.0,['ENSG00000110799'],1,,,,,,,,,,
CHEMBL2177390,CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1,GRZXWCHAXNAUHY-NSISKUIASA-N,Small molecule,False,IPATASERTIB,3.0,False,False,[],"['GDC-0068', 'Ipatasertib', 'RG-7440', 'RG7440', 'Rg-7440']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications.,,['DB11743'],"['MONDO_0008315', 'MONDO_0007254', 'EFO_0000196', 'EFO_0001075', 'MONDO_0001056', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0003893', 'EFO_0003869', 'MONDO_0011962', 'EFO_0000616', 'EFO_0005537', 'EFO_0000503', 'EFO_1001512', 'EFO_0003060', 'EFO_1000251']",16.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,,,,,,,,,,
CHEMBL4594517,,,Antibody,False,GILORALIMAB,2.0,False,False,[],"['ABBV-927', 'Abbv-927', 'Giloralimab', 'PR-1614645']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['MONDO_0004992', 'EFO_0002618', 'MONDO_0007254', 'EFO_0006859']",4.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL5095024,C=CC(=O)Nc1cc(C#CC(C)(C)N2CCN(C)CC2)cc2ncnc(Nc3ccc(F)c(Cl)c3)c12.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1,BRZCZOWSDKKGGK-UHFFFAOYSA-N,Small molecule,False,MP-412,1.0,False,False,[],"['AV-412', 'Mp 412', 'Mp-412']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['MONDO_0004992', 'EFO_0000616']",2.0,"['ENSG00000141736', 'ENSG00000146648']",2,,CHEMBL5095492,,,,,,,,
CHEMBL1434513,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O,LNBCGLZYLJMGKP-JZGIKJSDSA-N,Small molecule,True,NOREPINEPHRINE BITARTRATE,4.0,False,True,"['Adrenor', 'Aktamin', 'Levarterenol Bitartrate', 'Levophed', 'Noradrenaline', 'Norepinephrine bitartrate', 'Norepinephrine bitartrate in 5% dextrose']","['Aktamin', 'Arterenol, tartrate, monohydrate', 'Binodrenal', 'Levarterenol bitartrate', 'NSC-169106', 'Noradrenaline', 'Noradrenaline (as tartrate)', 'Noradrenaline bitartrate', 'Noradrenaline tartrate', 'Norepinephrine', 'Norepinephrine bitartrate', 'Norepinephrine bitartrate monohydrate', 'Norepinephrine d-bitartrate', 'Norepinephrine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000319', 'MONDO_0001382', 'HP_0100806', 'EFO_0005251', 'EFO_0004610', 'HP_0002140', 'EFO_0007450', 'EFO_0002497', 'MONDO_0008867']",9.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,1950.0,CHEMBL1437,['norepinephrine%20bitartrate'],['56463315'],,,,,,
CHEMBL2108348,,,Protein,False,NONACOG BETA PEGOL,4.0,False,True,['Refixia'],"['Nonacog beta pegol', 'Rebinyn', 'Refixia']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia b.,,,['MONDO_0010604'],1.0,['ENSG00000101981'],1,2017.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/refixia'],,,,
CHEMBL4279047,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,QCZAWDGAVJMPTA-RNFRBKRXSA-N,Small molecule,False,VORASIDENIB,3.0,False,False,[],"['AG-881', 'Ag-881', 'Vorasidenib']",['CHEMBL4594378'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0000616', 'EFO_0000616', 'EFO_0000272', 'EFO_0001421', 'EFO_0000326']",5.0,"['ENSG00000138413', 'ENSG00000182054']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/VORASIDENIB/relevant/1/'],,,
CHEMBL4297770,,,Oligonucleotide,False,INOTERSEN,4.0,False,True,[],"['GSK-2998728', 'ISIS 420915', 'ISIS-420915', 'Inotersen']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,,"['EFO_1001875', 'EFO_0004129']",2.0,['ENSG00000118271'],1,,,,,,,,,,
CHEMBL4298209,,,Antibody drug conjugate,True,BELANTAMAB MAFODOTIN,4.0,False,True,['Blenrep'],"['Belantamab mafodotin', 'Belantamab mafodotin blmf', 'GSK-2857916', 'GSK2857916']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and multiple myeloma and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0019438', 'EFO_0000403', 'EFO_0000616', 'EFO_0001378']",4.0,"['ENSG00000048462', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,2020.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep'],['https://searchusan.ama-assn.org/finder/usan/search/BELANTAMAB%20MAFODOTIN/relevant/1/'],,,
CHEMBL4802129,C[C@@H]1NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2,MKXOUIKTXREBLX-NDKBASPVSA-N,Protein,False,BALIXAFORTIDE,3.0,False,False,[],"['Balixafortide', 'POL-6326', 'POL6326', 'Pol6326']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,,"['EFO_0005809', 'EFO_0000616', 'EFO_0000339', 'EFO_0000612', 'EFO_0000198', 'EFO_0000222', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000095']",9.0,['ENSG00000121966'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/BALIXAFORTIDE/relevant/1/'],,,
CHEMBL1200782,C[C@H](N)Cc1ccccc1.O=C(O)CCCCC(=O)O,OFCJKOOVFDGTLY-QRPNPIFTSA-N,Small molecule,False,DEXTROAMPHETAMINE ADIPATE,4.0,False,True,[],"['D-amphetamine adipate', 'Dextroamphetamine adipate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975.,,,,,"['ENSG00000103546', 'ENSG00000165646', 'ENSG00000142319']",3,1975.0,CHEMBL612,,,,,,,,
CHEMBL2017974,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CWHUFRVAEUJCEF-UHFFFAOYSA-N,Small molecule,False,BUPARLISIB,3.0,False,False,[],"['BKM-120', 'BKM-120NX', 'BKM120-NX', 'Bkm-120', 'Buparlisib', 'NVP-BKM-120', 'NVP-BKM120']",['CHEMBL2364604'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,,['DB11666'],"['EFO_1000581', 'MONDO_0044903', 'EFO_0000519', 'EFO_0000403', 'EFO_0000702', 'EFO_0000565', 'EFO_0003060', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0008903', 'MONDO_0011719', 'MONDO_0007576', 'MONDO_0007254', 'EFO_0006859', 'MONDO_0002108', 'EFO_1001469', 'EFO_0001421', 'EFO_0003086', 'EFO_0000616', 'EFO_0000756', 'EFO_1001951', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0002974', 'EFO_0000181', 'MONDO_0008315']",26.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,['137275918'],['71954'],,,,,
CHEMBL2105741,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1.C[S+](C)[O-],OQUFJVRYDFIQBW-UHFFFAOYSA-N,Small molecule,False,TRAMETINIB DIMETHYL SULFOXIDE,4.0,False,True,['Mekinist'],"['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 3 investigational indications.,,,"['EFO_0002617', 'MONDO_0004992', 'MONDO_0002108', 'EFO_1000926', 'MONDO_0008903', 'EFO_0000389', 'EFO_0001378']",7.0,"['ENSG00000126934', 'ENSG00000169032']",2,2013.0,,['trametinib%20dimethyl%20sulfoxide'],,['75991'],['https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist'],,,,
CHEMBL2108292,,,Protein,False,EPTACOG ALFA PEGOL (ACTIVATED),2.0,False,False,[],"['Activated recombinant human factor vii, long acting', 'Eptacog alfa pegol (activated)']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0010604', 'MONDO_0010602']",2.0,['ENSG00000057593'],1,,,,,,,,,,
CHEMBL4297537,,,Oligonucleotide,True,INOTERSEN SODIUM,4.0,False,True,['Tegsedi'],[],,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications. This drug has a black box warning from the FDA.,,,"['EFO_0004129', 'EFO_1001875', 'EFO_0009562']",3.0,['ENSG00000118271'],1,2018.0,,['inotersen%20sodium'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi'],,,,
CHEMBL4297862,,,Protein,True,BOTULINUM TOXIN TYPE A,4.0,False,True,['Nuceiva'],"['Agn-151607', 'Ant-1401', 'Ant-1403', 'Botulift', 'Botulinum a toxin', 'Botulinum toxin type a', 'Btx-a', 'Cunox', 'Neuronox', 'RTI-150', 'RTI150']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,,"['Orphanet_93955', 'EFO_0009846', 'HP_0000473', 'MONDO_0005277', 'HP_0000975', 'EFO_1000781', 'EFO_0005422', 'EFO_0006865', 'EFO_1000999']",9.0,['ENSG00000132639'],1,2019.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/nuceiva'],,,,
CHEMBL1200329,Cl.Clc1ccc2nsnc2c1NC1=NCCN1,ZWUKMNZJRDGCTQ-UHFFFAOYSA-N,Small molecule,False,TIZANIDINE HYDROCHLORIDE,4.0,False,True,"['Sirdalud', 'Sirdalud mr', 'Tizanidine hydrochloride', 'Zanaflex']","['AN-021', 'AN021', 'DS 103-282', 'DS-103-282', 'Tizanidine (as hydrochloride)', 'Tizanidine hcl', 'Tizanidine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for spasticity and has 4 investigational indications.,,,"['MONDO_0043510', 'MONDO_0100431', 'HP_0001257', 'MONDO_0005475', 'MONDO_0002959']",5.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1996.0,CHEMBL1079,['tizanidine%20hydrochloride'],['56320475'],,,,,,
CHEMBL1201352,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1,HTIKWNNIPGXLGM-YLINKJIISA-N,Small molecule,False,RAPACURONIUM,4.0,True,True,[],"['Rapacuronium', 'Rapacuronium cation', 'Rapacuronium ion']",['CHEMBL1200549'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999.,['Rapacuronium'],['DB04834'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1999.0,,,,,,,,,
CHEMBL1648,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12,HMJIYCCIJYRONP-UHFFFAOYSA-N,Small molecule,False,ISRADIPINE,4.0,False,True,"['Dynacirc', 'Dynacirc cr', 'Isradipine', 'Prescal']","['Isradipine', 'Isrodipine', 'NSC-759892', 'PN 200-110', 'PN-200-110']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for hypertension and cardiovascular disease and has 6 investigational indications.,['Isradipine'],['DB00270'],"['EFO_0003890', 'EFO_0004319', 'EFO_0000537', 'EFO_0005611', 'EFO_0000319', 'EFO_0003768', 'MONDO_0005180', 'MONDO_0004985']",8.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1990.0,,['isradipine'],"['144204241', '170465070']",,,,,,
CHEMBL1743023,,,Antibody,False,FULRANUMAB,3.0,False,False,[],"['AMG 403', 'AMG-403', 'AMG403', 'Fulranumab', 'JNJ 42160443', 'JNJ-42160443']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['EFO_1000783', 'EFO_0003843', 'MONDO_0005178', 'HP_0012532', 'EFO_1000869', 'HP_0003419']",6.0,['ENSG00000134259'],1,,,,,,,,,,
CHEMBL1743051,,,Antibody,False,ONARTUZUMAB,3.0,False,False,[],"['METMA-B', 'Metmab', 'Onartuzumab', 'PRO-143966', 'PRO-143996', 'PRO143966', 'RO-5490258', 'RO5490258']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,,"['EFO_0000182', 'MONDO_0008903', 'MONDO_0004992', 'MONDO_0001056', 'MONDO_0007254', 'EFO_0000519', 'EFO_0003060', 'EFO_0000616', 'EFO_1001951']",9.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL19,CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C,FLOSMHQXBMRNHR-QPJJXVBHSA-N,Small molecule,False,METHAZOLAMIDE,4.0,False,True,"['Methazolamide', 'Neptazane']","['L-584601', 'Methazolamide', 'Methenamide', 'NSC-758426', 'Neptazaneat', 'VVP-808', 'VVP808']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for glaucoma and open-angle glaucoma and has 2 investigational indications.,['Methazolamide'],,"['MONDO_0005041', 'EFO_1000782', 'EFO_0004190', 'MONDO_0002974']",4.0,"['ENSG00000133742', 'ENSG00000104267', 'ENSG00000167434', 'ENSG00000168748']",4,1959.0,,['methazolamide'],"['11112413', '56422398', '855821']",['6822'],,,,,
CHEMBL2105682,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1,ZLFZITWZOYXXAW-QXXZOGQOSA-N,Small molecule,True,EDOXABAN TOSYLATE,4.0,False,True,"['Roteas', 'Savaysa']","['DU-176B', 'Edoxaban tosilate', 'Edoxaban tosylate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0003827', 'EFO_0003907', 'EFO_0000712', 'MONDO_0000831', 'EFO_0004286', 'EFO_0000275']",6.0,['ENSG00000126218'],1,2015.0,CHEMBL1269025,['edoxaban%20tosylate'],,['85975'],['https://www.ema.europa.eu/en/medicines/human/EPAR/roteas'],,,,
CHEMBL2110814,CNCCC(c1cccc(F)c1)c1cccc(F)c1,MUGNLPWYHGOJEG-UHFFFAOYSA-N,Small molecule,False,DELUCEMINE,2.0,False,False,[],['Delucemine'],['CHEMBL2106165'],Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL2111110,C1CCC2(C1)[C@H]1CN(CC3CC3)C[C@@H]2CN(CC2CC2)C1,CTIRHWCPXYGDGF-HDICACEKSA-N,Small molecule,False,TEDISAMIL,3.0,False,False,[],"['KC-8857', 'KC8857', 'Tedisamil']",['CHEMBL2107378'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0003911', 'EFO_0004269', 'EFO_0000275']",3.0,"['ENSG00000053918', 'ENSG00000171385', 'ENSG00000055118', 'ENSG00000177301', 'ENSG00000111262', 'ENSG00000075043', 'ENSG00000184156', 'ENSG00000104848', 'ENSG00000185760', 'ENSG00000117013', 'ENSG00000143473', 'ENSG00000182255', 'ENSG00000130037', 'ENSG00000177272', 'ENSG00000151079', 'ENSG00000129159', 'ENSG00000184408', 'ENSG00000182674', 'ENSG00000116396', 'ENSG00000131398', 'ENSG00000158445', 'ENSG00000143105', 'ENSG00000164794', 'ENSG00000140015', 'ENSG00000171126', 'ENSG00000168418', 'ENSG00000168263', 'ENSG00000124134', 'ENSG00000183960', 'ENSG00000166006', 'ENSG00000170745', 'ENSG00000173826', 'ENSG00000162975', 'ENSG00000184611', 'ENSG00000102057', 'ENSG00000026559', 'ENSG00000178342', 'ENSG00000135519', 'ENSG00000156486', 'ENSG00000089558']",40,,,,,,,,,,
CHEMBL3545299,,,Small molecule,False,BMS-698769,1.0,False,False,[],['Bms-698769'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL509,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,SBDNJUWAMKYJOX-UHFFFAOYSA-N,Small molecule,True,MECLOFENAMIC ACID,4.0,False,True,[],"['CI-583', 'CL-583', 'INF 4668', 'INF-4668', 'Meclodium', 'Meclofenamate', 'Meclofenamic acid', 'Meclomen', 'NSC-95309']","['CHEMBL1562610', 'CHEMBL876']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 8 approved indications. This drug has a black box warning from the FDA.,['Meclofenamic_acid'],['DB00939'],"['HP_0003326', 'MONDO_0005178', 'EFO_0005755', 'HP_0001945', 'EFO_0000685', 'HP_0002829', 'EFO_0002609', 'HP_0100607']",8.0,"['ENSG00000012779', 'ENSG00000073756', 'ENSG00000095303']",3,1980.0,,,"['24424562', '26751537', '90341585']",['6710'],,,,,
CHEMBL518924,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21,WVLHHLRVNDMIAR-IBGZPJMESA-N,Small molecule,False,MAVORIXAFOR,3.0,False,False,[],"['AMD-070', 'AMD-11070', 'AMD070', 'AMD11070', 'Amd 070', 'Cxcr4 inhibitor x4p-001', 'Mavorixafor', 'X 4P-001', 'X4P-001', 'X4p001']",['CHEMBL4203190'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,['DB05501'],"['EFO_0000349', 'EFO_0000756', 'EFO_0000616', 'EFO_0000764', 'MONDO_0007254', 'MONDO_0001475', 'EFO_0009441']",7.0,['ENSG00000121966'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/MAVORIXAFOR/relevant/1/'],,,
CHEMBL931,FC(F)(F)C(Cl)Br,BCQZXOMGPXTTIC-UHFFFAOYSA-N,Small molecule,False,HALOTHANE,4.0,False,True,"['Fluothane', 'Halothane', 'Rhidialothan']","['FREON 123B1', 'Halothane', 'Halothanum', 'NSC-143490']",['CHEMBL3250431'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958.,['Halothane'],['DB01159'],,,"['ENSG00000082482', 'ENSG00000169427', 'ENSG00000100433', 'ENSG00000171303', 'ENSG00000186795', 'ENSG00000145888', 'ENSG00000109738', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",23,1958.0,,,"['144204584', '144208048', '170464645', '17388981']",['5615'],,,,,
CHEMBL1195,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,CAJIGINSTLKQMM-UHFFFAOYSA-N,Small molecule,False,PROPOXYCAINE,4.0,False,True,[],['Propoxycaine'],['CHEMBL1769'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Propoxycaine'],['DB09342'],,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,,,['11112410'],['8496'],,,,,
CHEMBL1637,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,OKKDEIYWILRZIA-OSZBKLCCSA-N,Small molecule,False,GEMCITABINE HYDROCHLORIDE,4.0,False,True,"['Gemcitabine hydrochloride', 'Gemzar', 'Infugem']","['Gemcitabine (as hydrochloride)', 'Gemcitabine hcl', 'Gemcitabine hydrochloride', 'Gemzar', 'LY-188011', 'LY-188011 HYDROCHLORIDE', 'LY188011 HYDROCHLORIDE']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 48 investigational indications.,,,"['MONDO_0008170', 'MONDO_0008627', 'EFO_0006859', 'EFO_0000183', 'EFO_0000574', 'Orphanet_145', 'EFO_0006475', 'EFO_0000681', 'EFO_1000613', 'MONDO_0005184', 'EFO_0008528', 'EFO_0000616', 'EFO_1000359', 'EFO_1000043', 'EFO_0000313', 'EFO_0001075', 'EFO_0000096', 'EFO_0000565', 'MONDO_0011962', 'EFO_0000691', 'MONDO_0002087', 'EFO_1000251', 'EFO_1001961', 'EFO_0007532', 'MONDO_0004192', 'EFO_0006861', 'MONDO_0016537', 'EFO_0006738', 'EFO_0000588', 'MONDO_0002158', 'MONDO_0015760', 'MONDO_0001056', 'EFO_0000305', 'MONDO_0005411', 'EFO_0005537', 'MONDO_0004986', 'EFO_1001951', 'MONDO_0007254', 'MONDO_0002974', 'MONDO_0002367', 'MONDO_0004992', 'EFO_0001416', 'HP_0001907', 'EFO_0000466', 'EFO_0004252', 'EFO_1001469', 'EFO_1001051', 'EFO_1001959', 'MONDO_0008315', 'EFO_0001378', 'MONDO_0001187', 'EFO_0003060', 'MONDO_0008903', 'EFO_0002618', 'MONDO_0002691']",55.0,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229', 'ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848']",14,1996.0,CHEMBL888,['gemcitabine%20hydrochloride'],"['144206197', '170465129']",['31647'],,,,,
CHEMBL2105675,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1,DQJDBUPLRMRBAB-WZTVWXICSA-N,Small molecule,False,TAFAMIDIS MEGLUMINE,4.0,False,True,['Vyndaqel'],"['FX-1006A', 'Tafamidis meglumine']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 2 investigational indications.,,,"['EFO_1001875', 'EFO_0009562', 'EFO_0000318', 'MONDO_0019438', 'EFO_0004129']",5.0,['ENSG00000118271'],1,2011.0,CHEMBL2103837,['tafamidis%20meglumine'],,['79345'],['https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel'],,,,
CHEMBL2346976,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,JMEYDSHPKCSIJC-UHFFFAOYSA-N,Small molecule,False,AZD3514,1.0,False,False,[],"['AZD-3514', 'Azd 3514', 'Azd3514', 'CS-1443']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0008315'],1.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL3545096,COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1.O=C(O)/C=C\C(=O)O,YUXMAKUNSXIEKN-BTJKTKAUSA-N,Small molecule,False,BGT-226,2.0,False,False,[],"['BGT226', 'Bgt-226', 'NVP-BGT-226', 'NVP-BGT226']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0016063', 'MONDO_0007254', 'MONDO_0004992']",3.0,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",9,,CHEMBL3218578,,,['71953'],,,,,
CHEMBL3545145,,,Small molecule,False,WX-554,1.0,False,False,[],['Wx-554'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,,,,,,,
CHEMBL3707249,,,Small molecule,False,ASM-024,2.0,False,False,[],['Asm-024'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0004979', 'EFO_0000341']",2.0,"['ENSG00000175344', 'ENSG00000117971', 'ENSG00000080644', 'ENSG00000181072', 'ENSG00000133019', 'ENSG00000168539']",6,,,,,,,,,,
CHEMBL3910075,COc1ccc(C(=O)c2cn(C(C)C)c3ncnc(N)c23)cc1NC(=O)Nc1ccc(Cl)cc1Cl,VFCRSIORGUNNGT-UHFFFAOYSA-N,Small molecule,False,CE-245677,1.0,False,False,[],"['Ce 245677', 'Ce-245677']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000120156'],1,,,,,,,,,,
CHEMBL471737,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,ACRHBAYQBXXRTO-OAQYLSRUSA-N,Small molecule,False,IVABRADINE,4.0,False,True,"['Corlanor', 'Procoralan']","['Ivabradine', 'S-16257']",['CHEMBL2145077'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 18 investigational indications.,['Ivabradine'],['DB09083'],"['EFO_1001207', 'EFO_0003144', 'EFO_0006834', 'EFO_0007372', 'EFO_1000645', 'EFO_0003144', 'EFO_1000899', 'EFO_1001373', 'EFO_0000574', 'EFO_0003913', 'EFO_0005252', 'HP_0001649', 'EFO_0000401', 'EFO_0008586', 'EFO_0000373', 'EFO_0001645', 'EFO_0000319', 'EFO_0005251', 'EFO_0000275', 'EFO_0000373', 'EFO_0003913', 'MONDO_0004992']",22.0,['ENSG00000138622'],1,2015.0,,['ivabradine'],['50125937'],['85966'],,,,,
CHEMBL521851,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,LHNIIDJUOCFXAP-UHFFFAOYSA-N,Small molecule,False,PICTILISIB,2.0,False,False,[],"['CDC-0941', 'GDC 0941', 'GDC-0941', 'Pictilisib', 'Pictrelisib', 'Rg-7321']","['CHEMBL4097197', 'CHEMBL1922096']",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB11663'],"['MONDO_0007254', 'MONDO_0004992', 'EFO_0005952', 'EFO_0003060', 'EFO_0000616']",5.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']",8,,,,['103905592'],['65326'],,,,,
CHEMBL5314401,Cc1ncccc1C(=O)N1CCN(S(=O)(=O)c2ccc(C(F)(F)F)cc2)C[C@@H]1C,BLFJGFDZMABYMY-ZDUSSCGKSA-N,Small molecule,False,CNV2197944,2.0,False,False,[],"['CNV2197944', 'Cnv-2197944', 'Cnv2197944']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_1000783', 'MONDO_0041052']",2.0,['ENSG00000148408'],1,,,,,,,,,,
CHEMBL1182833,COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2,ILVYCEVXHALBSC-OTBYEXOQSA-N,Small molecule,False,MIVACURIUM,4.0,False,True,[],"['BW B109OU', 'BW-B109OU', 'Mivacurium', 'Mivacurium cation', 'Mivacurium ion']",['CHEMBL984'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and has 1 investigational indication.,,['DB01226'],['HP_0001410'],1.0,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1992.0,,,"['144206462', '50112723']",['6958'],,,,,
CHEMBL2106195,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,VPNGEIHDPSLNMU-MERQFXBCSA-N,Small molecule,False,DEXMEDETOMIDINE HYDROCHLORIDE,4.0,False,True,"['Dexmedetomidine accord', 'Dexmedetomidine hydrochloride', 'Igalmi', 'Precedex']","['Cepedex', 'Dexdomitor', 'Dexdor', 'Dexmedetomidine hcl', 'Dexmedetomidine hydrochloride', 'Igalmi', 'Sedadex', 'Sileo']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 8 investigational indications.,,,"['HP_0000713', 'MONDO_0005090', 'MONDO_0003544', 'EFO_0005411', 'EFO_0003843', 'MONDO_0043510', 'EFO_1001454', 'EFO_0009267']",8.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1999.0,CHEMBL778,['dexmedetomidine%20hydrochloride'],,['31472'],['https://www.ema.europa.eu/en/medicines/human/EPAR/dexmedetomidine-accord'],,,,
CHEMBL3039545,,,Protein,False,LUSPATERCEPT,4.0,False,True,['Reblozyl'],"['ACE-536', 'Luspatercept', 'Luspatercept aamt']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 3 investigational indications.,,,"['EFO_0004272', 'Orphanet_848', 'EFO_1001996', 'EFO_0004251', 'HP_0001915', 'EFO_0000198', 'EFO_1001996', 'MONDO_0002280']",8.0,"['ENSG00000105329', 'ENSG00000092969', 'ENSG00000119699']",3,2019.0,,['luspatercept-aamt'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl'],,,,
CHEMBL328560,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,HMHVCUVYZFYAJI-UHFFFAOYSA-N,Small molecule,False,SULTHIAME,4.0,False,True,['Ospolot'],"['RIKER 594', 'RIKER-594', 'Sulthiame', 'Sultiame']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for epilepsy and has 1 investigational indication.,['Sultiame'],['DB08329'],"['EFO_0003918', 'EFO_0000474']",2.0,"['ENSG00000104267', 'ENSG00000168748', 'ENSG00000133742', 'ENSG00000164879', 'ENSG00000131686', 'ENSG00000074410', 'ENSG00000118298', 'ENSG00000107159', 'ENSG00000167434', 'ENSG00000185015', 'ENSG00000169239', 'ENSG00000174990']",12,,,,['170465788'],['32171'],,,,,
CHEMBL3301585,,,Antibody drug conjugate,False,PINATUZUMAB VEDOTIN,2.0,False,False,[],"['ACD-22-VCMMAE', 'ACD-22VCMMAE', 'ACD22-VCMMAE', 'DCDT-2980S', 'DCDT2980S', 'FCU-2703', 'FCU2703', 'Pinatuzumab vedotin', 'RG-7593', 'RO-5541072-000', 'RO-5541072000', 'RO5541072-000']",,Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['MONDO_0018906', 'EFO_0000095', 'EFO_0000403']",3.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000012124']",16,,,,,,,,,,
CHEMBL3707294,,,Antibody,False,DEPATUXIZUMAB,2.0,False,False,[],"['ABT-806', 'Anti-egfr mab abt-806', 'Anti-egfr moab abt-806', 'Depatuxizumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000616', 'EFO_0000228']",2.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL4594505,,,Antibody,True,TECLISTAMAB,4.0,False,True,['Tecvayli'],"['BCMAxCD3', 'JNJ-64007957', 'Jnj 64007957', 'Teclistamab', 'Teclistamab cqyv']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for multiple myeloma and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0001642', 'MONDO_0004992', 'EFO_0001378']",3.0,"['ENSG00000048462', 'ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286']",4,2022.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli'],['https://searchusan.ama-assn.org/finder/usan/search/TECLISTAMAB/relevant/1/'],,,
CHEMBL538867,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C,HZLFFNCLTRVYJG-WWGOJCOQSA-N,Small molecule,False,PATIDEGIB,3.0,False,False,[],"['FIN-5', 'IP-9', 'IP9 FREE BASE', 'IPI 926', 'IPI-926', 'IPI-926 FREE BASE', 'Ipi-926', 'Patidegib', 'Saridegib']",['CHEMBL2105764'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,['IPI-926'],['DB12655'],"['EFO_0000616', 'EFO_0004193', 'EFO_0000333', 'MONDO_0007187', 'EFO_0002618', 'EFO_0004193']",6.0,['ENSG00000128602'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PATIDEGIB/relevant/1/'],,,
CHEMBL932,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,IZEKFCXSFNUWAM-UHFFFAOYSA-N,Small molecule,False,DIPYRIDAMOLE,4.0,False,True,"['Attia', 'Cerebrovase 100', 'Cerebrovase 25', 'Dipyridamole', 'Iv persantine', 'Modaplate', 'Ofcram pr', 'Persantin', 'Persantin ret', 'Persantine', 'Pyridantin', 'Vasyrol']","['B01AC07', 'Dipyridamole', 'NSC-515776', 'RA-8']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 13 investigational indications.,['Dipyridamole'],['DB00975'],"['EFO_0001645', 'MONDO_0100096', 'EFO_0000685', 'EFO_1002000', 'EFO_1001375', 'MONDO_0008170', 'MONDO_0011382', 'EFO_0000764', 'EFO_0003777', 'EFO_0000712', 'EFO_0003913', 'EFO_0002615', 'EFO_1000965', 'EFO_0000537', 'HP_0004419', 'EFO_0002618']",16.0,"['ENSG00000138735', 'ENSG00000065989', 'ENSG00000172572', 'ENSG00000139053', 'ENSG00000185527', 'ENSG00000186642', 'ENSG00000205268', 'ENSG00000115252', 'ENSG00000160191', 'ENSG00000133256', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000156973', 'ENSG00000132915', 'ENSG00000152270', 'ENSG00000095464', 'ENSG00000113231', 'ENSG00000112541', 'ENSG00000123360', 'ENSG00000105650', 'ENSG00000154678', 'ENSG00000073417', 'ENSG00000171408', 'ENSG00000112759']",24,1961.0,,['dipyridamole'],"['104171148', '11111116', '11111117', '11113358', '124879978', '124879980', '124879984', '144203684', '170464694', '26747068', '26751580', '26751581', '489152', '50104213', '50104215', '56423153', '85231021', '855977', '90340971']",['4653'],,,,,
CHEMBL1200822,CC(=O)O.O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,RKXNZRPQSOPPRN-UHFFFAOYSA-N,Small molecule,True,FLECAINIDE ACETATE,4.0,False,True,"['Flecainide acetate', 'Tambocor']","['Flecainide acetate', 'Flecainide monoacetate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for ventricular arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0004308', 'EFO_0003843', 'EFO_0000275']",3.0,['ENSG00000183873'],1,1985.0,CHEMBL652,['flecainide%20acetate'],"['144207406', '50106340', '56422486', '855927']",['5091'],,,,,
CHEMBL134,Clc1cccc(Cl)c1NC1=NCCN1,GJSURZIOUXUGAL-UHFFFAOYSA-N,Small molecule,True,CLONIDINE,4.0,False,True,"['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'Clonidine', 'Nexiclon xr']","['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended release', 'Clorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']",['CHEMBL1705'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA.,['Clonidine'],['DB00575'],"['EFO_0005762', 'MONDO_0005041', 'EFO_0002950', 'MONDO_0005299', 'MONDO_0002959', 'EFO_0005230', 'MONDO_0005277', 'EFO_0007355', 'EFO_0000274', 'HP_0002307', 'EFO_0002610', 'EFO_0001358', 'EFO_0005252', 'EFO_0003888', 'MONDO_0043510', 'EFO_0003756', 'EFO_0004240', 'EFO_0009676', 'EFO_0005611', 'EFO_0004273', 'MONDO_0004992', 'EFO_0003843', 'MP_0001914', 'EFO_1000783', 'EFO_0007191', 'EFO_0000537', 'EFO_0009267', 'EFO_0000537', 'EFO_0003890', 'EFO_1000971', 'EFO_0003888', 'EFO_0005323', 'EFO_1000645', 'EFO_0005799', 'HP_0003419', 'EFO_0009523', 'MONDO_0007254', 'EFO_0003843', 'EFO_1001904', 'EFO_0000319']",40.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1974.0,,['clonidine'],"['104171138', '11110984', '11110985', '11113648', '144203669', '170464900', '26751841', '90341662']",['3757'],,,,,
CHEMBL2107572,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1.Cl,YJXUXANREVNZLH-PFEQFJNWSA-N,Small molecule,False,TECALCET HYDROCHLORIDE,2.0,False,False,['Norcalin'],"['KRN-568', 'NPS R-568', 'NPS-R-568', 'NPSR-568', 'R-568', 'Tecalcet hcl', 'Tecalcet hydrochloride']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000036828'],1,,CHEMBL292376,,,,,,,,
CHEMBL2107829,Cl.NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1,BPZWRYOUJMDQSY-PKLMIRHRSA-N,Small molecule,False,EMIXUSTAT HYDROCHLORIDE,2.0,False,False,['Acu-4429 hcl'],"['ACU-4429 HCL', 'ACU-4429 HYDROCHLORIDE', 'Emixustat hydrochloride']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000116745'],1,,CHEMBL2107821,,,,,,,,
CHEMBL3544949,CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)C(N)=O,VUYRSKROGTWHDC-HZGLMRDYSA-N,Protein,False,CTCE-9908,2.0,False,False,[],"['CTCE 9908', 'Ctce-9908']",,Protein drug with a maximum clinical trial phase of II.,,,,,['ENSG00000121966'],1,,,,,,,,,,
CHEMBL1421,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Small molecule,False,DASATINIB,4.0,False,True,"['Dasatinib', 'Dasatinib accordpharma', 'Sprycel']","['BMS-354825', 'BMS-354825 HYDRATE', 'BMS-354825-03', 'Dasatinib', 'Dasatinib hydrate', 'Dasatinib monohydrate', 'NSC-759877']",['CHEMBL5314601'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 9 approved and 76 investigational indications.,['Dasatinib'],['DB01254'],"['EFO_0000768', 'EFO_0000616', 'EFO_1000956', 'EFO_0000255', 'EFO_0003884', 'MONDO_0019469', 'MONDO_0011719', 'EFO_0000191', 'EFO_0000588', 'MONDO_0019472', 'EFO_1001469', 'EFO_0002429', 'EFO_1000475', 'MONDO_0004975', 'MONDO_0018906', 'EFO_0000770', 'EFO_1001951', 'MONDO_0000870', 'EFO_0000702', 'EFO_0000095', 'MONDO_0002087', 'EFO_0006859', 'MONDO_0004992', 'EFO_0005774', 'EFO_0000708', 'MONDO_0000873', 'EFO_1000131', 'MONDO_0100096', 'MONDO_0008903', 'EFO_0000309', 'EFO_1001465', 'EFO_0002617', 'MONDO_0016586', 'MONDO_0004643', 'EFO_0000220', 'EFO_0000621', 'EFO_0003869', 'EFO_0000183', 'MONDO_0021063', 'EFO_1000026', 'EFO_0000565', 'EFO_0002618', 'MONDO_0011962', 'EFO_0000764', 'EFO_0000339', 'EFO_0000707', 'EFO_0000181', 'EFO_0001073', 'EFO_0000673', 'EFO_0002918', 'EFO_0000196', 'EFO_0003032', 'EFO_0000180', 'EFO_0001378', 'EFO_0000389', 'EFO_1001993', 'EFO_0000182', 'EFO_0000403', 'EFO_1000158', 'MONDO_0008315', 'EFO_0009441', 'EFO_0000756', 'EFO_0000574', 'EFO_0004289', 'MONDO_0100342', 'EFO_0000211', 'EFO_1001051', 'EFO_0000198', 'EFO_0003833', 'EFO_0005952', 'EFO_1000657', 'EFO_0003060', 'EFO_0000222', 'EFO_1000654', 'EFO_1000785', 'MONDO_0008170', 'EFO_0000305', 'MONDO_0019471', 'EFO_0004289', 'EFO_0000519', 'MONDO_0003175', 'EFO_0005221', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0002158']",85.0,"['ENSG00000113721', 'ENSG00000157404', 'ENSG00000097007', 'ENSG00000186716', 'ENSG00000010810', 'ENSG00000197122', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000136573', 'ENSG00000101336', 'ENSG00000254087', 'ENSG00000111816', 'ENSG00000000938', 'ENSG00000125508', 'ENSG00000142627']",15,2006.0,,['dasatinib'],"['103905543', '124893650', '124893651', '124893652', '144206289', '164339436', '170465390', '50100097', '50125840']",['49375'],['https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma'],,,,
CHEMBL1699,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,LDDHMLJTFXJGPI-UHFFFAOYSA-N,Small molecule,False,MEMANTINE HYDROCHLORIDE,4.0,False,True,"['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochloride', 'Memantine merz', 'Memantine mylan', 'Namenda', 'Namenda xr', 'Nemdatine', 'Valios']","['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hcl', 'Memantine hydrochloride', 'Memantine lek', 'Memantine merz', 'Memantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290', 'SUN-Y7017']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and dementia and has 12 investigational indications.,,,"['EFO_0004699', 'EFO_0000326', 'EFO_1001801', 'MONDO_0004681', 'MONDO_0004975', 'EFO_0003758', 'HP_0000726', 'MONDO_0004976', 'EFO_0007328', 'MONDO_0017276', 'EFO_0003757', 'EFO_1001465', 'EFO_0003833', 'MONDO_0011382']",14.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,2003.0,CHEMBL807,['memantine%20hydrochloride'],"['26747595', '50106707', '50106708', '57260151']",['64323'],"['https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-merz', 'https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-mylan']",,,,
CHEMBL1742992,,,Antibody,True,BLINATUMOMAB,4.0,False,True,['Blincyto'],"['Blinatumomab', 'Blincyto', 'MEDI-538', 'MT-103']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000095', 'EFO_0004289', 'EFO_0000565', 'EFO_0005952', 'EFO_0001642', 'EFO_0000616', 'EFO_0004289', 'EFO_0000403', 'EFO_0000574', 'EFO_0000094', 'MONDO_0000873', 'EFO_0001378', 'EFO_0000220', 'EFO_0000209', 'EFO_0000309']",15.0,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000177455']",4,2014.0,,['blinatumomab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto'],,,['4915'],
CHEMBL2108313,,,Protein,False,CONBERCEPT,3.0,False,False,[],"['Conbercept', 'KH-902']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['EFO_0004683', 'MONDO_0008380', 'EFO_0001365', 'EFO_1001157', 'EFO_1000880', 'EFO_0004207']",6.0,"['ENSG00000173511', 'ENSG00000119630', 'ENSG00000150630', 'ENSG00000112715']",4,,,,,,,,,,
CHEMBL2408045,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,DFJSJLGUIXFDJP-UHFFFAOYSA-N,Small molecule,False,SAPITINIB,2.0,False,False,[],"['AZD-8931', 'AZD8931', 'Azd-8931', 'Sapitinib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,['DB12183'],"['EFO_0003060', 'EFO_0000365', 'MONDO_0007254', 'EFO_0003869', 'MONDO_0004992']",5.0,"['ENSG00000146648', 'ENSG00000065361', 'ENSG00000141736']",3,,,,['174006599'],,,,,,
CHEMBL3545248,,,Small molecule,False,DS-7423,1.0,False,False,[],['Ds-7423'],,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['MONDO_0011962', 'EFO_1001951']",2.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000198793']",9,,,,,,,,,,
CHEMBL4088896,C[C@H](CN1CCOCC1)n1/c(=N\C(N)=O)[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc21,YPCLDHGBEKZGEB-RUDKWAFVSA-N,Small molecule,False,LY2623091,2.0,False,False,[],"['Ly-2623091', 'Ly2623091']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB15367'],"['EFO_0003884', 'MONDO_0001134']",2.0,['ENSG00000151623'],1,,,,,,,,,,
CHEMBL4594456,,,Antibody,False,CADONILIMAB,3.0,False,False,[],"['AK-104', 'AK104', 'Ak-104', 'Ak104', 'Cadonilimab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.,,,"['MONDO_0008170', 'EFO_0000519', 'MONDO_0001056', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0001061', 'EFO_1001968', 'EFO_0004252', 'EFO_0001416', 'EFO_1001951', 'EFO_0002618', 'EFO_0000681', 'EFO_0000349', 'EFO_0000616', 'EFO_0003060', 'EFO_0000211', 'MONDO_0044937', 'MONDO_0003060', 'MONDO_0008903', 'EFO_0005922', 'EFO_0000756', 'EFO_0000182', 'EFO_1001961', 'EFO_1000657']",24.0,"['ENSG00000163599', 'ENSG00000188389']",2,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/CADONILIMAB/relevant/1/'],,,
CHEMBL843,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,SUFUKZSWUHZXAV-BTJKTKAUSA-N,Small molecule,True,ROSIGLITAZONE MALEATE,4.0,True,True,"['Avandia', 'Rosiglitazone maleate']","['Avandia', 'BRL-49653', 'BRL-49653-C', 'BRL-49653C', 'NSC-717764', 'Rosiglitazone maleate', 'Rosiglitzazone maleate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 10 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.,,,"['EFO_0000691', 'HP_0002745', 'EFO_0000400', 'EFO_0003914', 'MONDO_0005148', 'EFO_1000158', 'EFO_0000764', 'EFO_1001110', 'EFO_0006859', 'EFO_0000373', 'EFO_0002614', 'EFO_1001249']",12.0,['ENSG00000132170'],1,1999.0,CHEMBL121,['rosiglitazone%20maleate'],"['144212684', '49681563']",['8892'],['https://www.ema.europa.eu/en/medicines/human/EPAR/avandia'],,,,
CHEMBL1743005,,,Antibody,False,DACETUZUMAB,2.0,False,False,[],"['Dacetuzumab', 'HU-S2C6', 'HUS2C6', 'SGN-40']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000095', 'EFO_0005952', 'EFO_0001378', 'EFO_0000403']",4.0,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL1771,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,GKTWGGQPFAXNFI-HNNXBMFYSA-N,Small molecule,True,CLOPIDOGREL,4.0,False,True,"['Grepid', 'Iscover', 'Plavix']","['Clopidogrel', 'Clopidogrel 1a-pharma', 'Clopidogrel acino', 'Clopidogrel apotex', 'Clopidogrel benzenesulfonate', 'Clopidogrel besilate', 'Clopidogrel besylate', 'Clopidogrel hexal', 'Clopidogrel sandoz', 'Clopidogrel-ratiopharm', 'NSC-758613', 'R 130964', 'R-130964', 'SR 25990', 'SR-25990', 'Zyllt']",['CHEMBL1083385'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 8 approved and 50 investigational indications. This drug has a black box warning from the FDA.,['Clopidogrel'],['DB00758'],"['EFO_0000712', 'MONDO_0000831', 'EFO_0003777', 'EFO_0003764', 'HP_0002140', 'EFO_1000985', 'EFO_0000612', 'EFO_0008583', 'EFO_0000764', 'EFO_0003106', 'EFO_0005672', 'EFO_0003144', 'EFO_1000860', 'EFO_0001645', 'EFO_0007328', 'EFO_0006859', 'EFO_0000275', 'EFO_0002615', 'EFO_0004265', 'EFO_0004264', 'EFO_0002950', 'EFO_0000180', 'EFO_0000717', 'EFO_0000612', 'EFO_0003914', 'EFO_0004277', 'EFO_0003869', 'MONDO_0004979', 'HP_0030680', 'EFO_0009315', 'EFO_0004265', 'MONDO_0002009', 'EFO_0003875', 'EFO_0008585', 'EFO_0001645', 'EFO_0000556', 'EFO_0000712', 'EFO_0003870', 'EFO_0000266', 'EFO_0003913', 'EFO_0002429', 'EFO_0004286', 'EFO_0000319', 'EFO_0009686', 'EFO_0005672', 'MONDO_0007915', 'EFO_0009086', 'MONDO_0100096', 'EFO_1001375', 'MP_0001914', 'EFO_0007541', 'HP_0002239', 'EFO_0003876', 'EFO_0003884', 'EFO_0001361', 'EFO_0000556', 'HP_0002140', 'MONDO_0005148', 'HP_0004419']",59.0,['ENSG00000169313'],1,1997.0,,,"['49666065', '49666423']",['37941'],,,,,
CHEMBL2107885,,,Enzyme,False,RETEPLASE,4.0,False,True,"['Rapilysin', 'Retavase']","['BM 06.022', 'BM-06.022', 'BM-06022', 'Ecokinase', 'Retavase', 'Reteplase', 'Reteplase, recombinant', 'Reteplase,recombinant', 'Retevase']",,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 1 investigational indication.,,,"['EFO_0000712', 'EFO_0008585', 'EFO_0003144', 'EFO_0000612', 'HP_0004419']",5.0,['ENSG00000104368'],1,1996.0,,['reteplase'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/rapilysin'],,,['5044'],
CHEMBL2108594,,,Protein,False,EPTOTERMIN ALFA,4.0,False,True,['Osigraft'],"['Bmp-7', 'Bone morphogenetic protein 7', 'Eptotermin alfa', 'Hbmp7', 'Opgenra', 'Osigraft', 'Osteogenic protein 1', 'Rh-polypeptide-52']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for bone disease and tibia fracture and has 1 investigational indication.,,,"['EFO_0004260', 'EFO_0004616', 'EFO_0003944']",3.0,"['ENSG00000138696', 'ENSG00000115170', 'ENSG00000107779', 'ENSG00000204217']",4,2001.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/osigraft'],,,['5175'],
CHEMBL2325741,NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1,JDUBGYFRJFOXQC-KRWDZBQOSA-N,Small molecule,False,CAPIVASERTIB,4.0,False,True,['Truqap'],"['AZC5363', 'AZD-5363', 'AZD5363', 'Azd 5363', 'Azd-5363', 'Capivasertib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 22 investigational indications.,,['DB12218'],"['MONDO_0011962', 'EFO_0005537', 'EFO_0000096', 'EFO_0000707', 'MONDO_0008170', 'EFO_0003060', 'EFO_0000673', 'MONDO_0008315', 'MONDO_0001056', 'MONDO_0002974', 'MONDO_0007254', 'EFO_0000616', 'EFO_0001378', 'EFO_1000251', 'MONDO_0004992', 'EFO_0000228', 'EFO_0000503', 'EFO_0003869', 'EFO_0001642', 'EFO_0007532', 'MONDO_0016642', 'Orphanet_145']",22.0,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",3,2023.0,,,,,,,,,
CHEMBL361812,O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2,LDXDSHIEDAPSSA-OAHLLOKOSA-N,Small molecule,False,RAMATROBAN,4.0,False,True,[],"['BAY U 3405', 'BAY-U-3405', 'Baynas', 'EN 137774', 'EN-137774', 'Ramatroban']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 2 investigational indications.,['Ramatroban'],['DB13036'],"['MONDO_0004979', 'MONDO_0100096']",2.0,"['ENSG00000183134', 'ENSG00000006638']",2,2000.0,,,"['144206069', '170465980']",,,,,,
CHEMBL3707399,,,Small molecule,False,CX1739,2.0,False,False,[],"['CX-1739', 'Cx1739']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,,,,
CHEMBL704,Nc1ccc(O)c(C(=O)O)c1,KBOPZPXVLCULAV-UHFFFAOYSA-N,Small molecule,False,MESALAMINE,4.0,False,True,"['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'Ipocol', 'Lialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'Pentasa', 'Pentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']","['Benzoic acid, 5-amino-2-hydroxy-', 'Fisalamine', 'Iialda', 'MAX-002', 'Mesalamine', 'Mesalazine', 'Mesalazine ', 'NSC-38877']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for proctitis and ulcerative colitis and has 16 investigational indications.,['Mesalazine'],['DB00244'],"['EFO_0005628', 'EFO_0007168', 'EFO_1001293', 'EFO_0003767', 'MONDO_0005835', 'EFO_0008572', 'EFO_0009959', 'HP_0002253', 'EFO_1001951', 'EFO_0000729', 'EFO_0000555', 'EFO_0004232', 'EFO_0003872', 'EFO_0000384', 'EFO_0005406', 'EFO_0000764', 'EFO_1001294', 'MONDO_0004235']",18.0,"['ENSG00000132170', 'ENSG00000012779', 'ENSG00000073756', 'ENSG00000095303']",4,1987.0,,['mesalamine'],"['104171289', '11112235', '144203935', '144208808', '144213442', '170464840', '17389224', '26752847', '49681712']",['6775'],,,,,
CHEMBL1201556,,,Protein,False,BECAPLERMIN,4.0,False,True,['Regranex'],"['Becaplermin', 'GEM 21S', 'GEM-21S', 'Gemesis', 'Pdgf-2', 'Pdgf-bb', 'Pdgfb', 'Platelet derived growth factor-bb', 'Platelet-derived growth factor becaplermin', 'RWJ 60235', 'RWJ-60235', 'Sh-polypeptide-59']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for wound healing and skin ulcer and has 2 investigational indications.,['Becaplermin'],,"['EFO_1001459', 'GO_0042060', 'MONDO_0043839', 'HP_0200042']",4.0,"['ENSG00000113721', 'ENSG00000134853']",2,1997.0,,['becaplermin'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/regranex'],,,['4925'],
CHEMBL2103829,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1,JIRYWFYYBBRJAN-ZFWWWQNUSA-N,Small molecule,False,FAXELADOL,2.0,False,False,[],"['EM-906', 'EM906', 'Faxeladol', 'GCR-9905', 'GCR9905', 'GRT-TA300', 'GRTA-0009906', 'GRTA-9906', 'GRTA0009906', 'GRTA9906', 'Grt9906']",['CHEMBL3893776'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['HP_0012532', 'EFO_0005762', 'EFO_0005687']",3.0,"['ENSG00000112038', 'ENSG00000103546', 'ENSG00000108576']",3,,,,,,,,,,
CHEMBL2109295,,,Antibody,False,ASCRINVACUMAB,2.0,False,False,[],"['Ascrinvacumab', 'PF-03446962']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0000182', 'EFO_1001951', 'EFO_0000616', 'EFO_0000770']",4.0,['ENSG00000139567'],1,,,,,,,,,,
CHEMBL2109360,,,Antibody,False,AS-1403,1.0,False,False,['Therafab'],['AS-1403'],,Antibody drug with a maximum clinical trial phase of I.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL3264610,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1,ZBRAJOQFSNYJMF-SFHVURJKSA-N,Small molecule,False,SEVITERONEL,2.0,False,False,[],"['Seviteronel', 'Vt-464']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB12275'],"['EFO_0000616', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0008315']",4.0,"['ENSG00000169083', 'ENSG00000148795']",2,,,,,,,,,,
CHEMBL4594444,C[C@H](O)c1nc(Cn2nc(-c3ccc(Cl)cc3)n(C[C@H](O)C(F)(F)F)c2=O)nn1-c1cccc(Cl)c1,AZXOTZCWQDJCLY-SJCJKPOMSA-N,Small molecule,False,PECAVAPTAN,2.0,False,False,[],"['BAY 1753011', 'BAY-1753011', 'Bay 1753011', 'Pecavaptan']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0003144'],1.0,"['ENSG00000126895', 'ENSG00000166148']",2,,,,,,,,,,
CHEMBL536151,O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,CHILCFMQWMQVAL-UHFFFAOYSA-N,Small molecule,False,IMD-0354,1.0,False,False,[],"['IMD-0354', 'Imd-0354', 'TCMDC-125465']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,['ENSG00000104365'],1,,,,"['103904747', '29217569', '50111708']",,,,,,
CHEMBL1360,COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC,YXSLJKQTIDHPOT-UHFFFAOYSA-N,Small molecule,False,ATRACURIUM,4.0,False,True,[],"['Atracurium', 'Atracurium cation', 'Atracurium ion', 'Tracrium']","['CHEMBL4584552', 'CHEMBL1200527']",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983.,['Atracurium_besilate'],,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1983.0,,,,['2914'],,,,,
CHEMBL1614725,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,ZYQXEVJIFYIBHZ-UHFFFAOYSA-N,Small molecule,False,TAK-285,1.0,False,False,[],"['TAK-285', 'Tak 285', 'Tak-285', 'Tak285']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0004992'],1.0,"['ENSG00000141736', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL1754,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,XFDJYSQDBULQSI-UHFFFAOYSA-N,Small molecule,False,DOXAPRAM,4.0,False,True,[],"['Docatone', 'Doxapram']","['CHEMBL1200876', 'CHEMBL3989519']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for respiratory system disease and lung disease and has 1 investigational indication.,['Doxapram'],['DB00561'],"['EFO_0000684', 'EFO_0004262', 'EFO_0003818']",3.0,"['ENSG00000171303', 'ENSG00000169427']",2,1965.0,,,['50112713'],['681848'],,,,,
CHEMBL2135460,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,BENFXAYNYRLAIU-QSVFAHTRSA-N,Protein,True,TERLIPRESSIN,4.0,False,True,"['Terlivaz', 'Variquel']","['Glycylpressin', 'Glypressin', 'Terlipressin', 'Terlipressin acetate']",['CHEMBL4088899'],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,['DB02638'],"['HP_0000083', 'EFO_0001422', 'MONDO_0001382', 'HP_0001399', 'MP_0001914', 'HP_0002105', 'EFO_0006834', 'EFO_1002048']",8.0,"['ENSG00000166148', 'ENSG00000198049', 'ENSG00000126895']",3,2022.0,,,"['124896640', '144206925']",,,,,,
CHEMBL3647420,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,SADXACCFNXBCFY-IYNHSRRRSA-N,Small molecule,False,PYROTINIB,3.0,False,False,[],"['Pyrotinib', 'SHR-1258']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,['DB14993'],"['EFO_0008549', 'MONDO_0001056', 'EFO_0000339', 'EFO_0003060', 'EFO_1001951', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000182', 'EFO_0003869', 'EFO_0005537']",10.0,"['ENSG00000146648', 'ENSG00000141736']",2,,,,,,,,,,
CHEMBL904,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1.Cl,JUMYIBMBTDDLNG-OJERSXHUSA-N,Small molecule,True,DEXMETHYLPHENIDATE HYDROCHLORIDE,4.0,False,True,"['Dexmethylphenidate hydrochloride', 'Focalin', 'Focalin xr']","['Dex-methylphenidate hydrochloride', 'Dexmethylphenidate hcl', 'Dexmethylphenidate hydrochloride', 'Methylphenidate d-threo-form hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA.,,,['EFO_0003888'],1.0,"['ENSG00000103546', 'ENSG00000142319']",2,2001.0,CHEMBL827,['dexmethylphenidate%20hydrochloride'],,,,,,,
CHEMBL2108709,,,Enzyme,False,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,4.0,False,True,"['Santyl', 'Xiaflex', 'Xiapex']","['AA-4500', 'AA4500', 'Clostridial collagenase', 'Clostridium histolyticum enzymes', 'Collagenase', 'Collagenase (clostridium histolyticum)', 'Collagenase clostridium histolyticum', 'Cordase', 'Iruxol', 'MZ-004', 'Plaquase']",,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 7 investigational indications.,,,"['HP_0200042', 'HP_0012227', 'EFO_0004229', 'EFO_1001459', 'EFO_1000941', 'EFO_1000466', 'EFO_0000759', 'EFO_1000438', 'MONDO_0043839', 'EFO_1001434', 'EFO_0007067', 'HP_0003549', 'EFO_0003899']",13.0,"['ENSG00000164692', 'ENSG00000108821', 'ENSG00000139219', 'ENSG00000168542', 'ENSG00000187498', 'ENSG00000130635', 'ENSG00000142156', 'ENSG00000060718', 'ENSG00000204291', 'ENSG00000182871', 'ENSG00000171502', 'ENSG00000196739', 'ENSG00000215018', 'ENSG00000134871', 'ENSG00000204262', 'ENSG00000142173', 'ENSG00000204248', 'ENSG00000169031', 'ENSG00000080573', 'ENSG00000163359', 'ENSG00000081052', 'ENSG00000188153', 'ENSG00000172752', 'ENSG00000197565', 'ENSG00000206384']",25,2010.0,,['collagenase%20clostridium%20histolyticum'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex'],,,['5051'],
CHEMBL3545403,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1,KLRRGBHZCJLIEL-UHFFFAOYSA-N,Small molecule,False,BMS-833923,2.0,False,False,[],"['BMS-833923', 'BMS-833923 DIMESYLATE MONOHYDRATE', 'Bms-833923', 'XL-139', 'XL139']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,,"['EFO_0000702', 'EFO_0002916', 'EFO_0003897', 'EFO_0000565', 'MONDO_0007187', 'EFO_0004193', 'MONDO_0004992']",7.0,['ENSG00000128602'],1,,,,,,,,,,
CHEMBL4298077,,,Antibody,False,PRASINEZUMAB,2.0,False,False,[],"['PRX002', 'Prasinezumab', 'Prx-002', 'Prx002', 'RG-7935', 'RG7935', 'RO-7046015', 'RO7046015', 'Ro7046015']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005180'],1.0,['ENSG00000145335'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PRASINEZUMAB/relevant/1/'],,,
CHEMBL430497,Clc1ccc(OC[C@H]2CCN2)cn1,MKTAGSRKQIGEBH-SSDOTTSWSA-N,Small molecule,False,TEBANICLINE,2.0,False,False,[],['Tebanicline'],"['CHEMBL2104964', 'CHEMBL5303486']",Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL5314384,C#CCOc1ccc(Nc2nc(Nc3ccc(C)c(S(=O)(=O)NC(=O)CC)c3)ncc2F)cc1,IGLNXKVGKIFNBQ-UHFFFAOYSA-N,Small molecule,False,R-348,2.0,False,False,[],['R-348'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['MONDO_0020547', 'EFO_1000906']",2.0,"['ENSG00000165025', 'ENSG00000105639']",2,,,,,,,,,,
CHEMBL621,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,PHLBKPHSAVXXEF-UHFFFAOYSA-N,Small molecule,True,TRAZODONE,4.0,False,True,[],"['Desyrel', 'J10.767K', 'Trazodone', 'Trialodine', 'Trittico']",['CHEMBL1200798'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA.,['Trazodone'],['DB00656'],"['EFO_0007453', 'EFO_0005230', 'MONDO_0002009', 'EFO_0003918', 'MONDO_0005090', 'EFO_1000783', 'EFO_0003761', 'EFO_0008568', 'EFO_0003761', 'MONDO_0004976', 'MONDO_0002050', 'HP_0000726', 'MONDO_0007079', 'MONDO_0002050', 'MONDO_0004975', 'MONDO_0002009', 'EFO_0004698']",17.0,"['ENSG00000102468', 'ENSG00000147246', 'ENSG00000108576']",3,1981.0,,,"['11111900', '11111901', '174007449', '90341328']",['9654'],,,,,
CHEMBL1200862,C[C@](N)(Cc1ccc(O)cc1)C(=O)O,NHTGHBARYWONDQ-JTQLQIEISA-N,Small molecule,False,METYROSINE,4.0,False,True,['Demser'],"['L-588357-0', 'MK-781', 'Metirosine', 'Metyrosine', 'Racemetirosine, (s)-']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for adrenal gland pheochromocytoma and hypertension and has 2 investigational indications.,['Metirosine'],['DB00765'],"['EFO_0000239', 'EFO_0000537', 'EFO_0000174', 'EFO_0005407']",4.0,['ENSG00000180176'],1,1979.0,,['metyrosine'],"['170465112', '29215162', '50106644', '50106645', '50106646', '90341393']",['6912'],,,,,
CHEMBL1739,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3.[I-].[I-],DIGFQJFCDPKEPF-OIUSMDOTSA-L,Small molecule,False,METOCURINE IODIDE,4.0,False,True,['Metubine iodide'],"['Dimethyl tubocurarine iodide', 'Dimethylchondrocurarine iodide', 'Dimethyltubocurarinium iodide', 'Metocurine iodide', 'NSC-36388']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,['DB00416'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1982.0,CHEMBL1259,,"['144206308', '170465111']",,,,,,
CHEMBL19299,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,YMBXTVYHTMGZDW-UHFFFAOYSA-N,Small molecule,False,LOXOPROFEN,4.0,False,True,[],"['Loxoprofen', 'Loxoprofen acid', 'Loxoprofen sodium']",['CHEMBL66552'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 investigational indications.,['Loxoprofen'],['DB09212'],"['HP_0002829', 'HP_0003326', 'EFO_0000685', 'EFO_0002970', 'EFO_0003843', 'HP_0030833', 'HP_0003419']",7.0,"['ENSG00000073756', 'ENSG00000095303']",2,1986.0,,,"['144203729', '170465808', '50106490', '85231106', '90341428']",['76172'],,,,,
CHEMBL3545050,,,Small molecule,False,BMS-817378,1.0,False,False,[],['Bms-817378'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000105976', 'ENSG00000128052']",2,,,,,,,,,,
CHEMBL3545200,,,Small molecule,False,S-222611,1.0,False,False,[],['S-222611'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000146648', 'ENSG00000141736']",2,,,,,,,,,,
CHEMBL3545259,,,Antibody,False,VANUCIZUMAB,2.0,False,False,[],"['C0u97738ae', 'RG-7221', 'RG7221', 'RO-5520985', 'RO5520985', 'Vanucizumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000616', 'EFO_1001951']",2.0,"['ENSG00000112715', 'ENSG00000091879']",2,,,,,,,,,,
CHEMBL3936761,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,RNOAOAWBMHREKO-QFIPXVFZSA-N,Small molecule,False,ZANUBRUTINIB,4.0,False,True,['Brukinsa'],"['BGB-3111', 'Bgb-3111', 'Zanubrutinib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 16 investigational indications.,,['DB15035'],"['EFO_0004256', 'MONDO_0015540', 'EFO_0000096', 'MONDO_0004992', 'EFO_0003086', 'EFO_0005761', 'EFO_1001469', 'EFO_1000630', 'EFO_0009441', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0017287', 'EFO_0000403', 'EFO_1001264', 'EFO_0000616', 'MONDO_0015564', 'EFO_0007160', 'MONDO_0100096', 'EFO_0000574', 'EFO_0000565']",20.0,['ENSG00000010671'],1,2019.0,,['zanubrutinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa'],['https://searchusan.ama-assn.org/finder/usan/search/ZANUBRUTINIB/relevant/1/'],,,
CHEMBL409,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,LKJPYSCBVHEWIU-UHFFFAOYSA-N,Small molecule,False,BICALUTAMIDE,4.0,False,True,"['Bicalutamide', 'Calutide', 'Casodex', 'Cosudex', 'Kalumid']","['Bicalutamide', 'Casodex', 'ICI 176,334', 'ICI-176334', 'ICI176,334-1', 'NSC-759816']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for carcinoma and neoplasm and has 16 investigational indications.,,['DB01128'],"['EFO_0000196', 'MONDO_0002087', 'MONDO_0001187', 'EFO_0000313', 'EFO_0000673', 'EFO_0003869', 'MONDO_0008315', 'MONDO_0000088', 'MONDO_0002158', 'EFO_0000694', 'MONDO_0008170', 'MONDO_0100096', 'EFO_0000305', 'EFO_0001663', 'HP_0000771', 'EFO_0000616', 'MONDO_0004669', 'MONDO_0007254']",18.0,['ENSG00000169083'],1,1995.0,,['bicalutamide'],['26719836'],,,,,,
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],YOEWQQVKRJEPAE-UHFFFAOYSA-L,Small molecule,True,SUCCINYLCHOLINE CHLORIDE,4.0,False,True,"['Anectine', 'Quelicin', 'Quelicin preservative free', 'Scoline', 'Succinylcholine chloride', 'Sucostrin', 'Suxamethonium Chloride']","['Choline chloride succinate (2:1)', 'NSC-49132', 'Succinylcholine chloride', 'Suxamethone', 'Suxamethonii chloridum', 'Suxamethonium chloride', 'Suxamethonium chloride dihydrate', 'Suxamethonium chloride hydrate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1952. This drug has a black box warning from the FDA.,['Suxamethonium_chloride'],,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1952.0,CHEMBL703,['succinylcholine%20chloride'],"['144204820', '170464625', '50106980']",['61219'],,,,,
CHEMBL1197,CC(CNC1CCCCC1)OC(=O)c1ccccc1,DKLKMKYDWHYZTD-UHFFFAOYSA-N,Small molecule,False,HEXYLCAINE,4.0,False,True,[],"['Cyclaine', 'Hexylcaine', 'Osmocaine']",['CHEMBL1200715'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Hexylcaine'],['DB00473'],,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1982.0,,,,['34791'],,,,,
CHEMBL1200641,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1,XXZSQOVSEBAPGS-DONVQRBFSA-L,Small molecule,False,CISATRACURIUM BESYLATE,4.0,False,True,"['Cisatracurium besylate', 'Cisatracurium besylate preservative free', 'Nimbex', 'Nimbex preservative free']","['51 W89', '51-W-89', '51-W89', '51W-89', '51W89', 'Cisatracurium (as besilate)', 'Cisatracurium besilate', 'Cisatracurium besylate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication.,,,['EFO_1000637'],1.0,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1995.0,CHEMBL1201248,['cisatracurium%20besylate'],['11113043'],['3721'],,,,,
CHEMBL1201414,,,Oligosaccharide,True,TINZAPARIN SODIUM,4.0,False,True,"['Innohep', 'Logiparin']","['LNH-1', 'LNH1', 'Tinzaparin', 'Tinzaparin na', 'Tinzaparin sodium', 'Tinzaparin sodium, porcine']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for deep vein thrombosis and recurrent thrombophlebitis and has 9 investigational indications. This drug has a black box warning from the FDA.,['Tinzaparin_sodium'],,"['EFO_0003907', 'EFO_0000365', 'EFO_0003106', 'HP_0002140', 'MONDO_0002367', 'EFO_0001378', 'MONDO_0100096', 'EFO_0003060', 'HP_0001907', 'HP_0004419', 'MONDO_0008170']",11.0,['ENSG00000117601'],1,2000.0,,,,,,,,,
CHEMBL1201606,,,Antibody drug conjugate,False,IBRITUMOMAB TIUXETAN,4.0,False,True,"['Zevalin', 'Zevalin Kit-Indium-111']","['IDEC-129', 'IDEC-IN2B8', 'IDEC-Y2B8', 'IDEC-Y2B8 IDEC-129', 'Ibritumomab tiuxetan']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 16 investigational indications.,['Ibritumomab_tiuxetan'],,"['MONDO_0013730', 'EFO_0000095', 'EFO_0000191', 'EFO_0000183', 'EFO_0009441', 'EFO_0000565', 'EFO_0000096', 'EFO_0001378', 'EFO_0000403', 'MONDO_0018906', 'EFO_0000574', 'EFO_1001365', 'EFO_0000309', 'EFO_0005952', 'EFO_1001469', 'MONDO_0000873']",16.0,['ENSG00000156738'],1,2002.0,,['ibritumomab%20tiuxetan'],,,,,,['4984'],
CHEMBL134713,COc1ccc(/C=C2\CCCN=C2c2cccnc2)c(OC)c1,RPYWXZCFYPVCNQ-RVDMUPIBSA-N,Small molecule,False,GTS-21,2.0,False,False,[],"['3-(2,4-Dimethoxybenzylidene)Anabaseine', 'Dimethoxybenzylidene anabaseine', 'Dmxb-a', 'Gts-21']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,['DB05708'],"['EFO_0003768', 'EFO_0001073', 'MONDO_0004975', 'EFO_0005411', 'EFO_0003758', 'MONDO_0005090']",6.0,['ENSG00000175344'],1,,,,,,,,,,
CHEMBL1388,Oc1ccc(OCc2ccccc2)cc1,VYQNWZOUAUKGHI-UHFFFAOYSA-N,Small molecule,False,MONOBENZONE,4.0,False,True,['Benoquin'],"['Monobenzone', 'Monobenzyl ether of hydroquinone', 'NSC-2132', 'P-(benzyloxy)phenol', 'P-benzyloxyphenol']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1952.,['Monobenzone'],['DB00600'],,,['ENSG00000077498'],1,1952.0,,,"['11112252', '144203947', '144208345', '170464724', '174006811']",['34380'],,,,,
CHEMBL2108286,,,Protein,False,TUROCTOCOG ALFA,4.0,False,True,['Novoeight'],"['NN-7008', 'NN7008', 'Novoeight', 'Turoctocog alfa']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for hemophilia a.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,2013.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/novoeight'],,,['5019'],
CHEMBL2141712,COc1ccc(COc2cc3oc(=O)c4cc(C(C)O)ccc4c3cc2OC)cc1,YEAHTLOYHVWAKW-UHFFFAOYSA-N,Small molecule,False,PALOMID-529,1.0,False,False,[],"['P-529', 'P529', 'PALOMID-529', 'Palomid 529', 'Palomid-529', 'SG 00529', 'SG-00529']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,['DB12812'],['EFO_0001365'],1.0,['ENSG00000198793'],1,,,,['137275969'],,,,,,
CHEMBL3545027,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1,MMNNTJYFHUDSKL-UHFFFAOYSA-N,Small molecule,False,XL-281,2.0,False,False,[],"['BMS-908662', 'Bms-908662 free base', 'EXEL-2819', 'Xl 281', 'Xl-281']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB12854'],"['EFO_0000756', 'EFO_0000641', 'EFO_1001951', 'EFO_0003060']",4.0,"['ENSG00000132155', 'ENSG00000157764']",2,,,,,,,,,,
CHEMBL3545360,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1,MGGBYMDAPCCKCT-UHFFFAOYSA-N,Small molecule,False,ASP-3026,1.0,False,False,[],"['ASP3026', 'Asp 3026', 'Asp-3026']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,['DB12729'],"['MONDO_0004992', 'EFO_0000096', 'EFO_0000616']",3.0,['ENSG00000171094'],1,,,,,,,,,,
CHEMBL3989843,N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1,IGLYMJRIWWIQQE-QUOODJBBSA-N,Small molecule,True,TRANYLCYPROMINE,4.0,False,True,[],"['NSC-80664', 'Tranylcypromine']",['CHEMBL3989698'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0002009', 'EFO_0005230', 'HP_0000726', 'EFO_0000198', 'MONDO_0002009', 'EFO_1002014', 'EFO_0000222', 'MONDO_0005090', 'EFO_0003761', 'MONDO_0002050', 'EFO_0005252']",11.0,"['ENSG00000189221', 'ENSG00000069535']",2,1961.0,,,,,,,,,
CHEMBL4297315,N=C(N)c1ccc2nc(-c3cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc(-c4cc(S(N)(=O)=O)ccc4O)c3O)[nH]c2c1,WDJHHCAKBRKCLW-IBGZPJMESA-N,Small molecule,False,PCI-27483,2.0,False,False,[],"['Cra-027483', 'Pci-27483']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB13000'],['EFO_0002618'],1.0,['ENSG00000057593'],1,,,,,,,,,,
CHEMBL4297522,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,HCDMJFOHIXMBOV-UHFFFAOYSA-N,Small molecule,False,PEMIGATINIB,4.0,False,True,['Pemazyre'],"['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828', 'Pemigatinib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 11 investigational indications.,,['DB15102'],"['EFO_0003863', 'EFO_0003060', 'EFO_1001961', 'EFO_0008528', 'EFO_0000616', 'EFO_0000519', 'EFO_0004251', 'MONDO_0004992', 'MONDO_0007254', 'EFO_1001951', 'MONDO_0011962', 'EFO_0000222', 'MONDO_0001187', 'EFO_0002618', 'EFO_0005221']",15.0,"['ENSG00000077782', 'ENSG00000068078', 'ENSG00000066468']",3,2020.0,,['pemigatinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre'],['https://searchusan.ama-assn.org/finder/usan/search/PEMIGATINIB/relevant/1/'],,,
CHEMBL4298167,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O,BFENHEAPFWQJFL-BTJKTKAUSA-N,Small molecule,False,FILGOTINIB MALEATE,4.0,False,True,['Jyseleca'],"['Filgotinib maleate', 'GS-6034']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for rheumatoid arthritis.,,,['EFO_0000685'],1.0,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']",4,2020.0,CHEMBL3301607,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca'],,,,
CHEMBL502097,COCCO[C@@H]1[C@H](SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cnc4c(N)ncnc43)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2O)[C@@H](COP(=O)([O-])S[C@H]2[C@@H](OCCOC)[C@H](n3cc(C)c(N)nc3=O)O[C@@H]2COP(=O)([O-])S[C@H]2[C@@H](OCCOC)[C@H](n3cnc4c(=O)[nH]c(N)nc43)O[C@@H]2CO)O[C@H]1n1cc(C)c(N)nc1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],OSGPYAHSKOGBFY-KMHHXCEHSA-A,Oligonucleotide,True,MIPOMERSEN SODIUM,4.0,False,True,['Kynamro'],"['ISIS 301012', 'ISIS-301012', 'Mipomersen sodium', 'Mipomersen sodium salt']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for familial hypercholesterolemia and has 1 investigational indication. This drug has a black box warning from the FDA.,['Mipomersen'],,"['EFO_0004911', 'HP_0003124']",2.0,['ENSG00000084674'],1,2013.0,CHEMBL2219536,['mipomersen%20sodium'],,,,,,,
CHEMBL1134,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C.[Br-].[Br-],HLXQFVXURMXRPU-UHFFFAOYSA-L,Small molecule,False,DECAMETHONIUM BROMIDE,4.0,False,True,['Syncurine'],"['Decamethonium Bromide', 'Decamethonium bromide', 'Decamethonium diiodide', 'Decamethonium iodide', 'NSC-23004']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Decamethonium'],,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1982.0,CHEMBL1190,,"['144205588', '170465349', '50106154', '855712']",,,,,,
CHEMBL1200722,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1.[Br-].[Br-],TXWBOBJCRVVBJF-YTGGZNJNSA-L,Small molecule,False,PIPECURONIUM BROMIDE,4.0,False,True,['Arduan'],"['Pipecurium bromide', 'Pipecuronium bromide', 'Pipecuronium bromide anhydrous', 'Pipecuronium bromide dihydrate', 'Pipecuronium bromide hydrate', 'RGH 1106', 'RGH-1106']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990.,['Pipecuronium_bromide'],,,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1990.0,CHEMBL1201206,,,,,,,,
CHEMBL2109204,,,Oligosaccharide,False,NADROPARIN CALCIUM,3.0,False,False,[],"['CY 216', 'CY-216', 'Fraxiparin', 'Fraxiparina', 'Fraxiparine', 'Nadroparin', 'Nadroparin calcium', 'Seleparina', 'Ultraparina']",,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['EFO_0004286', 'EFO_0009315', 'HP_0004936', 'HP_0004419', 'EFO_0003907', 'MONDO_0008903']",6.0,['ENSG00000117601'],1,,,,,,,,,['5162'],
CHEMBL2109531,,,Antibody,False,MEDI-6469,2.0,False,False,[],"['9b12, a murine igg1 antibody', 'MEDI-6469', 'MEDI6469', 'Medi 6469', 'Medi-6469']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0002617', 'EFO_0006859', 'EFO_0004142', 'EFO_0000574', 'EFO_0000196', 'MONDO_0007254']",6.0,['ENSG00000186827'],1,,,,,,,,,,
CHEMBL284483,OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O,YOOVTUPUBVHMPG-LODYRLCVSA-N,Small molecule,False,COFORMYCIN,2.0,False,False,[],"['Coformycin', 'NSC-277817']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000565'],1.0,['ENSG00000196839'],1,,,,,['16213'],,,,,
CHEMBL325424,Cc1cccc(-c2ccc3c(c2)c(C(=O)C(=O)O)cn3Cc2ccc(C(C)(C)C)cc2)c1,HSXLMAFNWCSZGP-UHFFFAOYSA-N,Small molecule,False,ALEPLASININ,2.0,False,False,[],"['Aleplasinin', 'PAZ-417']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12635'],['MONDO_0004975'],1.0,['ENSG00000106366'],1,,,,,,,,,,
CHEMBL3408248,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,LMJFJIDLEAWOQJ-CQSZACIVSA-N,Small molecule,False,AZD-8186,1.0,False,False,[],"['AZD8186', 'Azd 8186', 'Azd-8186']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications.,,['DB15029'],"['EFO_0000196', 'EFO_0005537', 'MONDO_0008315', 'MONDO_0007254', 'MONDO_0001056', 'EFO_0003060']",6.0,"['ENSG00000051382', 'ENSG00000171608']",2,,,,,,,,,,
CHEMBL3707311,CCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@@]21C,AJAMXPWEAPICIM-XCAPYKEYSA-N,Small molecule,False,VAMOROLONE,4.0,False,True,['Agamree'],"['9,11-dehydro dexamethasone', '9,11-dehydrodexamethasone acetate', 'VBP-15', 'Vamorolone', 'Vamorolone acetate', 'Vbp-15 free alcohol']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for duchenne muscular dystrophy and becker muscular dystrophy and has 1 investigational indication.,,,"['EFO_0000729', 'MONDO_0010679', 'MONDO_0010311']",3.0,"['ENSG00000113580', 'ENSG00000151623']",2,2023.0,,,,,,,,,
CHEMBL4297621,C[C@@H](N[C@H]1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12,RZNUIYPHQFXBAN-XLIONFOSSA-N,Small molecule,False,EVOCALCET,3.0,False,False,[],"['Evocalcet', 'KHK-7580', 'KHK7580', 'Khk7580', 'MT-4580']",['CHEMBL4128835'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB12388'],"['EFO_1001173', 'EFO_0008506']",2.0,['ENSG00000036828'],1,,,,,,,,,,
CHEMBL439849,N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,SGEGOXDYSFKCPT-UHFFFAOYSA-N,Small molecule,True,VILAZODONE,4.0,False,True,[],"['EMD 515259', 'EMD-515259', 'EMD-68-843', 'Vilazodone']",['CHEMBL1615374'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for unipolar depression and has 5 investigational indications. This drug has a black box warning from the FDA.,['Vilazodone'],['DB06684'],"['EFO_1001892', 'EFO_0001358', 'EFO_0007191', 'EFO_0001072', 'MONDO_0002009', 'EFO_0003761', 'EFO_0003761']",7.0,"['ENSG00000178394', 'ENSG00000108576']",2,2011.0,,,,['70707'],,,,,
CHEMBL4650289,,,Unknown,False,KBP5209,1.0,False,False,[],"['KBP5209', 'Kbp5209']",,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568', 'ENSG00000065361']",4,,,,,,,,,,
CHEMBL490,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,AHOUBRCZNHFOSL-YOEHRIQHSA-N,Small molecule,True,PAROXETINE,4.0,False,True,[],"['(-)3s,4r-paroxetine', 'Arketis', 'Arotin', 'BRL 29060', 'BRL-29060', 'Besitram', 'Casbol', 'Daparox', 'Fg-7051', 'Frosinor', 'Motivan', 'Parogen', 'Paroxetine', 'Paxil', 'Paxpar', 'Pexeva', 'Xetanor']","['CHEMBL1449490', 'CHEMBL1200609', 'CHEMBL1708', 'CHEMBL1256912', 'CHEMBL3133300', 'CHEMBL1628650']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 9 approved and 25 investigational indications. This drug has a black box warning from the FDA.,['Paroxetine'],['DB00715'],"['MONDO_0005180', 'EFO_0006788', 'EFO_0000612', 'EFO_1001917', 'EFO_0004242', 'EFO_1001892', 'EFO_1001917', 'GO_0042697', 'MONDO_0002050', 'EFO_0005762', 'HP_0000726', 'EFO_0005230', 'HP_0031217', 'EFO_0004262', 'EFO_0005687', 'EFO_0001358', 'EFO_0004242', 'MONDO_0002009', 'EFO_0803321', 'EFO_0001358', 'EFO_0005230', 'MONDO_0002009', 'EFO_0803321', 'MONDO_0004985', 'HP_0000360', 'MONDO_0005090', 'EFO_0004220', 'MONDO_0002050', 'MONDO_0007079', 'EFO_1001917', 'EFO_0003761', 'EFO_0006788', 'EFO_0004262', 'EFO_0004262', 'EFO_0003761', 'EFO_0004242', 'EFO_1001872', 'MONDO_0002775', 'EFO_0001358', 'EFO_0000685', 'EFO_0000768', 'MONDO_0002009']",42.0,['ENSG00000108576'],1,1992.0,,,"['144206674', '170465075', '26752262', '29215051', '50104978', '50104979', '50104980', '50104981', '90341371']",['7936'],,,,,
CHEMBL1201219,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,BGSZAXLLHYERSY-XQIGCQGXSA-N,Small molecule,True,VECURONIUM,4.0,False,True,[],"['Vecuronium', 'Vecuronium cation', 'Vecuronium ion']",['CHEMBL1200629'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA.,['Vecuronium_bromide'],['DB01339'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1984.0,,,['50112721'],['9939'],,,,,
CHEMBL1491,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,HTIQEAQVCYTUBX-UHFFFAOYSA-N,Small molecule,True,AMLODIPINE,4.0,False,True,"['Astudal 5', 'Istin', 'Norvas', 'Norvasc']","['Amlodipine', 'CKD-330 COMPONENT AMLODIPINE', 'HGP-0904', 'HGP0904']","['CHEMBL1200402', 'CHEMBL4594262', 'CHEMBL1200984']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 14 approved and 30 investigational indications. This drug has a black box warning from the FDA.,['Amlodipine'],['DB00381'],"['EFO_0000319', 'EFO_0000612', 'MONDO_0016486', 'HP_0000093', 'MONDO_0000477', 'HP_0003124', 'EFO_1001145', 'EFO_0001421', 'EFO_0003144', 'EFO_0004911', 'EFO_0000537', 'EFO_0000278', 'MONDO_0021187', 'HP_0003124', 'Orphanet_79292', 'EFO_0000373', 'EFO_0007148', 'EFO_0000612', 'EFO_0003086', 'MONDO_0001422', 'MONDO_0002050', 'EFO_0000764', 'EFO_0003913', 'EFO_0000400', 'EFO_0000537', 'EFO_0003144', 'EFO_1000013', 'EFO_0000537', 'MONDO_0021187', 'EFO_0000400', 'EFO_0000373', 'MONDO_0005178', 'MONDO_0005148', 'EFO_0004234', 'EFO_0000712', 'MONDO_0001134', 'EFO_0001645', 'EFO_0003914', 'MONDO_0007254', 'EFO_1001996', 'EFO_1001375', 'MONDO_0001134', 'EFO_0003777', 'EFO_0000538', 'EFO_0001645', 'EFO_0004214']",46.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1992.0,,,"['124893198', '225144262', '29217715', '50111725']",['2668'],,,,,
CHEMBL1743062,,,Antibody,False,RAMUCIRUMAB,4.0,False,True,['Cyramza'],"['1121B', 'IMC-1121B', 'LY3009806', 'Ramucirumab']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 7 approved and 30 investigational indications.,,,"['EFO_0000616', 'EFO_0000588', 'EFO_0000756', 'MONDO_0004992', 'EFO_0000519', 'EFO_0004243', 'EFO_0000681', 'EFO_0008528', 'EFO_0000708', 'EFO_1000895', 'EFO_0000228', 'MONDO_0003060', 'EFO_0001376', 'EFO_1000657', 'EFO_0002916', 'EFO_0000503', 'EFO_0003060', 'EFO_1001951', 'EFO_1001961', 'MONDO_0007254', 'EFO_0000181', 'MONDO_0007576', 'MONDO_0021063', 'EFO_0000182', 'MONDO_0008315', 'EFO_0000389', 'EFO_0000326', 'EFO_0003897', 'EFO_1000576', 'MONDO_0005411', 'EFO_0005922', 'EFO_1001469', 'MONDO_0001056', 'EFO_1000581', 'EFO_0005952', 'EFO_0000178', 'EFO_0002618']",37.0,['ENSG00000128052'],1,2014.0,,['ramucirumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza'],,,['4917'],
CHEMBL181,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1,GDLBFKVLRPITMI-UHFFFAOYSA-N,Small molecule,False,DIAZOXIDE,4.0,False,True,"['Diazoxide', 'Eudemine', 'Eudimine', 'Hyperstat', 'Mutabase', 'Proglycem']","['Diazoxide', 'Diazoxidum', 'Eudemine injection', 'Hypertonalum', 'NSC-64198', 'NSC-76130', 'SCH 6783', 'SCH-6783', 'SRG 95213', 'SRG-95213']",['CHEMBL4297276'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved and 6 investigational indications.,['Diazoxide'],['DB01119'],"['MONDO_0002177', 'EFO_0001073', 'MONDO_0002050', 'EFO_0004211', 'HP_0001943', 'MONDO_0008300', 'EFO_0000537', 'MONDO_0005148', 'MONDO_0024677', 'EFO_0001073']",10.0,"['ENSG00000187486', 'ENSG00000121361']",2,1973.0,,['diazoxide'],"['11111111', '11113823', '124879964', '144203683', '170465328', '26747146', '26751995', '50104671', '56422090', '855807']",['4495'],,,,,
CHEMBL1980297,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,WPHKIQPVPYJNAX-UHFFFAOYSA-N,Small molecule,False,ILORASERTIB,2.0,False,False,"['Abt-348, a-968660']","['A-968660', 'A-968660.0', 'ABBOTT-968660', 'ABT-348', 'Abt-348', 'Ilorasertib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB11694'],"['MONDO_0004992', 'EFO_0000616']",2.0,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000178999', 'ENSG00000105146', 'ENSG00000087586', 'ENSG00000010810', 'ENSG00000197122', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000136573', 'ENSG00000101336', 'ENSG00000254087', 'ENSG00000111816', 'ENSG00000000938', 'ENSG00000125508', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",18,,,,['103904272'],,,,,,
CHEMBL2145077,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2.Cl,HLUKNZUABFFNQS-ZMBIFBSDSA-N,Small molecule,False,IVABRADINE HYDROCHLORIDE,4.0,False,True,"['Corlanor', 'Ivabradine zentiva', 'Procoralan']","['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine hcl', 'Ivabradine hydrochloride', 'S 16257', 'S-16257-2']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved indications.,,,"['EFO_0003144', 'EFO_0000373', 'EFO_0003913']",3.0,['ENSG00000138622'],1,2015.0,CHEMBL471737,['ivabradine%20hydrochloride'],['144206355'],['85969'],['https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-zentiva'],,,,
CHEMBL3181947,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+],PPOSVVJOVKVBPW-UHFFFAOYSA-L,Small molecule,False,BROMFENAC SODIUM,4.0,True,True,"['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom', 'Yellox']","['AHR-10282B', 'Bromfenac monosodium salt', 'Bromfenac monosodium salt sesquihydrate', 'Bromfenac sodium', 'Bromfenac sodium hydrate', 'Bromfenac sodium sesquihydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved indications. It was withdrawn in at least one region.,,,"['HP_0200026', 'MONDO_0005129', 'EFO_0003843', 'MP_0001845']",4.0,"['ENSG00000073756', 'ENSG00000095303']",2,1997.0,CHEMBL1077,['bromfenac%20sodium'],"['144205734', '170465189']",['59176'],['https://www.ema.europa.eu/en/medicines/human/EPAR/yellox'],,,,
CHEMBL408,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,GXPHKUHSUJUWKP-UHFFFAOYSA-N,Small molecule,False,TROGLITAZONE,4.0,True,True,"['Prelay', 'Rezulin', 'Romozin']","['CI-991', 'CS-045', 'GR-92132X', 'GR92132X', 'Rezulin', 'Troglitazone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for diabetes mellitus and has 1 investigational indication. It was withdrawn in at least one region.,['Troglitazone'],['DB00197'],"['EFO_0000400', 'EFO_0000691']",2.0,['ENSG00000132170'],1,1997.0,,,"['137275811', '144205672', '144210788', '170465091', '174007238', '26755242', '26755243', '26757864', '29216382']",['9753'],,,,,
CHEMBL5316170,CO[C@]1(COC(=O)CCNC(=O)C(N)CCCCN)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,GFNQJZFJGAULCC-BWENMZSBSA-N,Small molecule,False,CEP-2563,1.0,False,False,[],[],['CHEMBL5314390'],Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538', 'ENSG00000115825', 'ENSG00000163558', 'ENSG00000154229', 'ENSG00000126583', 'ENSG00000163932', 'ENSG00000166501', 'ENSG00000067606', 'ENSG00000171132', 'ENSG00000027075', 'ENSG00000184304', 'ENSG00000065675', 'ENSG00000165731', 'ENSG00000122025', 'ENSG00000113721']",17,,,,,,,,,,
CHEMBL1200955,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2.Cl,OWLCGJBUTJXNOF-HDNKIUSMSA-N,Small molecule,True,MYCOPHENOLATE MOFETIL HYDROCHLORIDE,4.0,False,True,"['Cellcept', 'Mycophenolate mofetil hydrochloride']","['Mycophenolate mofetil hcl', 'Mycophenolate mofetil hydrochloride', 'RS-61443-190']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998. This drug has a black box warning from the FDA.,,,,,"['ENSG00000106348', 'ENSG00000178035']",2,1998.0,CHEMBL1456,['mycophenolate%20mofetil%20hydrochloride'],,,,,,,
CHEMBL312448,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,HUCJFAOMUPXHDK-UHFFFAOYSA-N,Small molecule,False,XYLOMETAZOLINE,4.0,False,True,[],"['Balminil', 'Xylometazoline']",['CHEMBL1256400'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for nasal congestion and eye allergy and has 1 investigational indication.,['Xylometazoline'],['DB06694'],"['HP_0001742', 'EFO_0005751', 'EFO_0007214']",3.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,,,,"['11111974', '11111975', '174007471', '50100368', '50104259', '90340774']",['10082'],,,,,
CHEMBL398435,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,OEKWJQXRCDYSHL-FNOIDJSQSA-N,Small molecule,True,TICAGRELOR,4.0,False,True,"['Brilinta', 'Brilique']","['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 9 approved and 19 investigational indications. This drug has a black box warning from the FDA.,['Ticagrelor'],['DB08816'],"['EFO_0008585', 'EFO_0003884', 'EFO_0003870', 'EFO_0002615', 'EFO_0008586', 'EFO_0000341', 'EFO_0000266', 'EFO_0000612', 'EFO_0008583', 'EFO_0007328', 'EFO_0003086', 'EFO_0005672', 'MONDO_0011382', 'MONDO_0000831', 'EFO_0003106', 'EFO_0004214', 'EFO_0000556', 'EFO_0003875', 'MONDO_0005148', 'EFO_0003913', 'EFO_0000275', 'EFO_0004265', 'EFO_0000319', 'EFO_0000712', 'HP_0004419', 'MONDO_0100096', 'HP_0002140', 'EFO_0001645']",28.0,['ENSG00000169313'],1,2010.0,,['ticagrelor'],,['68558'],['https://www.ema.europa.eu/en/medicines/human/EPAR/brilique'],,,,
CHEMBL4209157,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1,NGFFVZQXSRKHBM-FKBYEOEOSA-N,Small molecule,False,LIFIRAFENIB,2.0,False,False,[],"['BGB-283', 'Beigene-283', 'Bgb 283', 'Bgb-283', 'Lifirafenib']",['CHEMBL4298146'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication.,,['DB14773'],"['EFO_0000616', 'EFO_0000616']",2.0,['ENSG00000157764'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/LIFIRAFENIB/relevant/1/'],,,
CHEMBL4297566,,,Oligonucleotide,False,CASIMERSEN,4.0,False,True,['Amondys 45'],"['Casimersen', 'EXON-45: NG-12-0064', 'SRP-4045']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for duchenne muscular dystrophy and muscular dystrophy.,,,"['MONDO_0010679', 'MONDO_0020121']",2.0,['ENSG00000198947'],1,2021.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/CASIMERSEN/relevant/1/'],,,
CHEMBL4297694,,,Protein,False,ANFIBATIDE,2.0,False,False,[],"['Agkisacucetin', 'Anfibatide']",,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000612', 'MONDO_0019740']",2.0,['ENSG00000185245'],1,,,,,,,,,,
CHEMBL911,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,ZAFYATHCZYHLPB-UHFFFAOYSA-N,Small molecule,True,ZOLPIDEM,4.0,False,True,[],"['Ambien', 'Sanval', 'Zolpidem', 'Zolpidem civ']","['CHEMBL3989820', 'CHEMBL1723343']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for insomnia and has 16 investigational indications. This drug has a black box warning from the FDA.,['Zolpidem'],['DB00425'],"['EFO_0004698', 'MONDO_0005180', 'EFO_0003888', 'MONDO_0000477', 'MONDO_0005090', 'EFO_0007191', 'EFO_0003758', 'EFO_0000673', 'EFO_0001073', 'EFO_0003890', 'EFO_0008568', 'EFO_0005230', 'HP_0000726', 'EFO_0008568', 'EFO_0004698', 'HP_0003419', 'MONDO_0002050']",17.0,"['ENSG00000022355', 'ENSG00000113327', 'ENSG00000163288']",3,1992.0,,,"['144205024', '170465242', '26749064']",['10125'],,,,,
CHEMBL928,O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)[N-]1.[Na+],KSRLIXGNPXAZHD-HAZZGOGXSA-M,Small molecule,True,DANTROLENE SODIUM,4.0,False,True,"['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']","['Dantamacrin', 'Dantrolen', 'Dantrolene sodium', 'Dantrolene sodium heptahydrate', 'Dantrolene sodium hydrate', 'Dantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000712', 'EFO_1001919', 'EFO_0020003', 'EFO_1000632', 'HP_0001257', 'EFO_1001340', 'MONDO_0018105', 'MONDO_0005301', 'HP_0001945']",9.0,"['ENSG00000198838', 'ENSG00000196218']",2,1974.0,CHEMBL1201288,['dantrolene%20sodium'],['50106202'],,,,,,
CHEMBL1175,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,ZEUITGRIYCTCEM-KRWDZBQOSA-N,Small molecule,True,DULOXETINE,4.0,False,True,[],"['Cymbalta', 'Duloxetine', 'LY-248686', 'LY248686']",['CHEMBL1200328'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 39 investigational indications. This drug has a black box warning from the FDA.,['Duloxetine'],['DB00476'],"['MONDO_0005301', 'HP_0012532', 'HP_0000020', 'EFO_0000401', 'EFO_0001358', 'EFO_0005762', 'EFO_0005687', 'MONDO_0002009', 'EFO_0000400', 'EFO_0005762', 'MONDO_0005180', 'MONDO_0005178', 'EFO_0003888', 'HP_0010992', 'HP_0000726', 'MONDO_0002009', 'MONDO_0002050', 'HP_0003418', 'EFO_0006788', 'EFO_0003761', 'EFO_1000783', 'EFO_0004701', 'EFO_0005687', 'EFO_0005230', 'EFO_0000712', 'EFO_0007169', 'HP_0030834', 'EFO_0005230', 'EFO_1001951', 'MONDO_0001583', 'EFO_0004244', 'MONDO_0005090', 'EFO_0004540', 'HP_0000020', 'HP_0003326', 'EFO_1001951', 'HP_0003419', 'HP_0100543', 'MONDO_0005301', 'EFO_0003761', 'EFO_0003843', 'EFO_0003843', 'EFO_0003100', 'EFO_0004616', 'MONDO_0007079', 'MONDO_0002050', 'MONDO_0005178', 'EFO_1001892', 'EFO_0001358', 'EFO_0002970', 'EFO_1000783']",51.0,"['ENSG00000103546', 'ENSG00000108576']",2,2004.0,,,"['124893161', '26719725', '26757978', '49681583']",['36795'],,,,,
CHEMBL1200819,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC.Cl,GDWDBGSWGNEMGJ-UHFFFAOYSA-N,Small molecule,False,ARTICAINE HYDROCHLORIDE,4.0,False,True,[],"['40 045', 'Articaine hcl', 'Articaine hydrochloride', 'Carticaine hydrochloride', 'HOE 045', 'HOE-045', 'HOE-40045', 'Ubistesine', 'Ultracain']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2000.0,CHEMBL1093,['articaine%20hydrochloride'],"['144204160', '170464825', '56463593']",,,,,,
CHEMBL1437,NC[C@H](O)c1ccc(O)c(O)c1,SFLSHLFXELFNJZ-QMMMGPOBSA-N,Small molecule,False,NOREPINEPHRINE,4.0,False,True,[],"['(-)-noradrenaline', 'Levarterenol', 'Levophed', 'NSC-757246', 'Nor adrenalin', 'Norepinephrine', 'R-norepinephrine']","['CHEMBL1356607', 'CHEMBL5087452', 'CHEMBL3273169', 'CHEMBL2311152', 'CHEMBL3248963', 'CHEMBL2130595', 'CHEMBL1434513']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 approved and 19 investigational indications.,['Norepinephrine'],['DB00368'],"['EFO_0005207', 'EFO_0000319', 'MONDO_0043771', 'HP_0031273', 'HP_0002140', 'EFO_0005251', 'EFO_0005252', 'EFO_0004610', 'MONDO_0002050', 'HP_0002140', 'EFO_0002497', 'EFO_0001073', 'MONDO_0008867', 'EFO_0003777', 'HP_0100806', 'MONDO_0001382', 'HP_0100806', 'MONDO_0043510', 'EFO_0005251', 'MP_0001845', 'EFO_0000319', 'EFO_0007450', 'HP_0100543', 'EFO_0006834']",24.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,,,,"['144212261', '26754493', '26754494', '29215339', '50109852', '50109853', '57288371', '90341660']",['18357'],,,,,
CHEMBL180022,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,JWNPDZNEKVCWMY-VQHVLOKHSA-N,Small molecule,False,NERATINIB,4.0,False,True,[],"['CDP-820', 'HKI-272', 'Neratinib', 'WAY-179272']",['CHEMBL3989921'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for breast cancer and breast carcinoma and has 19 investigational indications.,['Neratinib'],['DB11828'],"['EFO_0000339', 'MONDO_0007254', 'EFO_0000313', 'EFO_0003869', 'EFO_1001951', 'EFO_0000305', 'EFO_0000673', 'EFO_0003060', 'EFO_1000294', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0007254', 'EFO_0000182', 'EFO_0000519', 'EFO_0003891', 'EFO_0003968', 'EFO_0000616', 'MONDO_0008170', 'EFO_0000553', 'EFO_0005537', 'EFO_0000305']",21.0,"['ENSG00000141736', 'ENSG00000178568', 'ENSG00000146648']",3,2017.0,,,['124950160'],,,,,,
CHEMBL2108081,,,Protein,False,TRAFERMIN,3.0,False,False,[],"['CAB-2001', 'Trafermin']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['EFO_0000649', 'EFO_0009472', 'EFO_1001459', 'HP_0200042']",4.0,['ENSG00000066468'],1,,,,,,,,,,
CHEMBL2325014,Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,ZYSCOUXLBXGGIM-UHFFFAOYSA-N,Small molecule,False,PF-05089771,2.0,False,False,[],['Pf-05089771'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB14856'],"['EFO_0003843', 'EFO_0010072', 'EFO_1000783', 'MONDO_0016028']",4.0,['ENSG00000169432'],1,,,,,,,,,,
CHEMBL3545396,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,CSGQVNMSRKWUSH-IAGOWNOFSA-N,Small molecule,False,BMS-690514,2.0,False,False,[],"['Bms 6690514', 'Bms 690514', 'Bms-690514']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB11665'],"['MONDO_0004992', 'EFO_0003060', 'MONDO_0007254']",3.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000146648', 'ENSG00000141736', 'ENSG00000178568']",6,,,,,,,,,,
CHEMBL3707383,,,Oligonucleotide,False,MONGERSEN SODIUM,3.0,False,False,[],"['GED-0301', 'GED-0301 SODIUM', 'Mongersen sodium']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0000729', 'EFO_0000384']",2.0,['ENSG00000101665'],1,,,,,,,,,,
CHEMBL428647,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,RCINICONZNJXQF-MZXODVADSA-N,Small molecule,True,PACLITAXEL,4.0,False,True,"['Abraxane', 'Apealea', 'Pacitaxel', 'Paclitaxel', 'Paxene', 'Taxol', 'Taxol 100']","['(-)-paclitaxel', 'ABI-007', 'ABI-007 COMPONENT PACLITAXEL', 'BMS 181339-01', 'BMS-181339-01', 'Capxol', 'Cyclopax', 'DHP 107', 'DHP-107', 'Ebetaxel', 'Empac', 'Endotag 1', 'Genaxol', 'Genetaxyl', 'Genexol', 'Genexol-pm', 'Intaxel', 'Lep-etu', 'MBT 0206', 'MBT-0206', 'Mitotax', 'NK 105', 'NK-105', 'NSC-125973', 'Oncogel', 'Onxal', 'Onxol', 'Pacliex', 'Paclitaxel', 'Paclitaxel (taxus canadensis)', 'Paclitaxol', 'Plaxicel', 'QW-8184', 'Taxalbin', 'Taxol', 'Taxol a', 'Taxus', 'Taxus liberte', 'Taxus stent', 'Tocosol paclitaxel', 'Yewtaxan']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 12 approved and 146 investigational indications. This drug has a black box warning from the FDA.,,['DB01229'],"['EFO_0003869', 'EFO_1000984', 'EFO_0000616', 'EFO_1000350', 'MONDO_0021043', 'EFO_1000043', 'MONDO_0008315', 'EFO_0002938', 'EFO_0004243', 'EFO_1001931', 'MONDO_0002158', 'MONDO_0003060', 'EFO_0006818', 'EFO_0002892', 'MONDO_0001187', 'EFO_0006352', 'EFO_0007535', 'EFO_0000685', 'EFO_0003860', 'EFO_0006859', 'MONDO_0018364', 'EFO_0003893', 'MONDO_0004658', 'EFO_0001061', 'EFO_0002916', 'EFO_0000308', 'EFO_0000305', 'EFO_0005952', 'EFO_0000702', 'EFO_0009708', 'MONDO_0004669', 'MONDO_0021657', 'EFO_0003859', 'MONDO_0021148', 'MONDO_0044704', 'EFO_0000514', 'EFO_0000519', 'MONDO_0005184', 'EFO_0000180', 'EFO_0000294', 'EFO_0004272', 'EFO_1000796', 'EFO_0000466', 'MONDO_0005271', 'MONDO_0003751', 'EFO_1000576', 'MONDO_0021251', 'EFO_1001100', 'EFO_1000158', 'EFO_1000294', 'EFO_0000503', 'MONDO_0004192', 'MONDO_0011719', 'EFO_0000558', 'EFO_0003868', 'EFO_0005567', 'EFO_1001951', 'EFO_0006772', 'EFO_0004224', 'EFO_1000251', 'EFO_1000613', 'EFO_0003826', 'EFO_0000182', 'EFO_0000588', 'MONDO_0001879', 'EFO_0004149', 'MONDO_0007576', 'EFO_1001968', 'MONDO_0004992', 'MONDO_0002108', 'EFO_0000707', 'EFO_0000691', 'EFO_0005537', 'EFO_0003863', 'EFO_0000556', 'EFO_1001961', 'EFO_0001075', 'MONDO_0001402', 'MONDO_0008170', 'MONDO_0002367', 'EFO_0000574', 'MONDO_0002715', 'MONDO_0002120', 'EFO_1001512', 'EFO_0000183', 'EFO_1001331', 'EFO_0001378', 'EFO_0005088', 'EFO_0003060', 'MONDO_0022394', 'EFO_0001642', 'MONDO_0021355', 'MONDO_0002691', 'EFO_0003050', 'EFO_0006861', 'EFO_0003875', 'EFO_1001471', 'EFO_0000199', 'EFO_0004265', 'MONDO_0005411', 'EFO_0000181', 'MONDO_0002974', 'EFO_0003968', 'EFO_0004284', 'EFO_0001416', 'EFO_0002617', 'MONDO_0001528', 'EFO_0005221', 'EFO_0000565', 'EFO_0010282', 'EFO_0004281', 'MONDO_0008903', 'EFO_0004142', 'EFO_0000389', 'EFO_0008524', 'EFO_1000052', 'EFO_0000228', 'EFO_0003833', 'EFO_1000657', 'EFO_0000764', 'MONDO_0002601', 'EFO_0000681', 'MONDO_0004986', 'MONDO_0001056', 'EFO_0000178', 'EFO_0007532', 'MONDO_0044926', 'MONDO_0011962', 'EFO_0000313', 'Orphanet_145', 'EFO_0000432', 'MONDO_0018944', 'EFO_0000284', 'EFO_1001465', 'MONDO_0001325', 'EFO_0000676', 'EFO_0002496', 'EFO_0000708', 'EFO_0005922', 'EFO_0008528', 'EFO_0004230', 'MONDO_0021117', 'EFO_1000359', 'EFO_0000673', 'EFO_0003843', 'EFO_0000095', 'MONDO_0007254', 'MONDO_0002087', 'EFO_0002618', 'EFO_0006318', 'EFO_0000756', 'EFO_0004252', 'EFO_1000581', 'MONDO_0100342', 'EFO_0003100', 'EFO_0003897', 'EFO_0000571', 'EFO_0000365']",158.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1992.0,,['paclitaxel'],"['124893045', '144205660', '418145', '56463361']",['45863'],['https://www.ema.europa.eu/en/medicines/human/EPAR/apealea'],,,,
CHEMBL4298062,,,Oligonucleotide,False,VILTOLARSEN,4.0,False,True,['Viltepso'],"['NCNP-01', 'NS-065', 'NS-065/NCNP-01', 'Ns-065/ncnp-01', 'Viltolarsen']",,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for muscular dystrophy and duchenne muscular dystrophy.,,,"['MONDO_0020121', 'MONDO_0010679']",2.0,['ENSG00000198947'],1,2020.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/VILTOLARSEN/relevant/1/'],,,
CHEMBL4298179,,,Oligonucleotide,False,TEPRASIRAN SODIUM,1.0,False,False,[],['Teprasiran sodium'],,Oligonucleotide drug with a maximum clinical trial phase of I.,,,,,['ENSG00000141510'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TEPRASIRAN%20SODIUM/relevant/1/'],,,
CHEMBL1200993,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC.[I-].[I-].[I-],REEUVFCVXKWOFE-UHFFFAOYSA-K,Small molecule,False,GALLAMINE TRIETHIODIDE,4.0,False,True,"['Benzcurine Iodide', 'Flaxedil', 'Gallomone Triethiodide', 'Relaxan']","['Benzcurine iodide', 'Gallamine triethiodide', 'Gallamini triethiodidum', 'Gallamone triethiodide', 'NSC-102690', 'Remyolan', 'Syncurarine']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Gallamine_triethiodide'],['DB00483'],,,"['ENSG00000138435', 'ENSG00000196811', 'ENSG00000170175', 'ENSG00000135902', 'ENSG00000108556']",5,1982.0,CHEMBL360055,,"['144205593', '170465398', '50106346', '57264265']",,,,,,
CHEMBL1201023,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl,UQZKYYIKWZOKKD-UHFFFAOYSA-N,Small molecule,False,ORPHENADRINE HYDROCHLORIDE,4.0,False,True,"['Biorphen', 'Disipal']","['Mephenamin', 'NSC-82357', 'Orphenadrine (chloride)', 'Orphenadrine Chloride', 'Orphenadrine hcl', 'Orphenadrine hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for parkinson disease.,,,['MONDO_0005180'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785', 'ENSG00000103546', 'ENSG00000196639']",19,1957.0,CHEMBL900,,"['144212244', '26752324', '50106731', '56422385', '855661']",['60902'],,,,,
CHEMBL1645462,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,LUJZZYWHBDHDQX-QFIPXVFZSA-N,Small molecule,False,AC-480,1.0,False,False,[],"['AC-480', 'AC480', 'Ac-480', 'BMS-599626', 'Bms 599626']",['CHEMBL5307497'],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,['DB12318'],"['EFO_0000616', 'MONDO_0004992', 'EFO_0005543']",3.0,"['ENSG00000178568', 'ENSG00000146648', 'ENSG00000141736']",3,,,,,,,,,,
CHEMBL2103827,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,QXWYKJLNLSIPIN-JGVFFNPUSA-N,Small molecule,True,DROXIDOPA,4.0,False,True,['Northera'],"['DOPS', 'Droxidopa', 'L-DOPS', 'L-threo-dops']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,['DB06262'],"['EFO_0005687', 'MONDO_0005180', 'EFO_1000645', 'EFO_1001050', 'EFO_0005251', 'EFO_0005252', 'EFO_0003888', 'EFO_0000319']",8.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,2014.0,,['droxidopa'],,['31524'],,,,,
CHEMBL2109665,,,Antibody,False,OCARATUZUMAB,2.0,False,False,[],"['AME-133v', 'LY2469298', 'Ocaratuzumab']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0005952', 'MONDO_0004992']",2.0,['ENSG00000156738'],1,,,,,,,,,,
CHEMBL2151439,O=C(N[C@@H]1CN2CCC1CC2)c1n[nH]c2ccccc12,TXCYUSKWBHUVEP-CYBMUJFWSA-N,Small molecule,False,FACINICLINE,2.0,False,False,[],"['MEM 3454 FREE BASE', 'MEM-3454 FREE BASE', 'MEM3454 FREE BASE', 'RG-3487 FREE BASE', 'RG3487 FREE BASE', 'RO-5313534 FREE BASE']",['CHEMBL5095032'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB05586'],"['MONDO_0005090', 'MONDO_0004975']",2.0,"['ENSG00000166736', 'ENSG00000186038', 'ENSG00000149305', 'ENSG00000186090', 'ENSG00000178084', 'ENSG00000175344']",6,,,,,,,,,,
CHEMBL231779,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,QNZCBYKSOIHPEH-UHFFFAOYSA-N,Small molecule,True,APIXABAN,4.0,False,True,['Eliquis'],"['Apixaban', 'BMS-562247', 'BMS-562247-01']",['CHEMBL3526474'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 8 approved and 20 investigational indications. This drug has a black box warning from the FDA.,['Apixaban'],['DB06605'],"['EFO_0003884', 'EFO_0003144', 'EFO_0009314', 'EFO_0000266', 'MONDO_0000831', 'EFO_1002000', 'MONDO_0004992', 'HP_0002140', 'EFO_0000275', 'EFO_0004286', 'EFO_0003907', 'MP_0001914', 'HP_0000083', 'EFO_0000556', 'EFO_0004255', 'EFO_0003827', 'EFO_0001422', 'EFO_0003911', 'MONDO_0011382', 'EFO_0005672', 'HP_0001907', 'EFO_0000220', 'EFO_0010680', 'HP_0004419', 'HP_0004936', 'HP_0001655', 'EFO_0000712', 'MONDO_0100096']",28.0,['ENSG00000126218'],1,2011.0,,['apixaban'],['174006823'],['72296'],['https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis'],,,,
CHEMBL273575,CN1Cc2c(N)cccc2C(c2ccccc2)C1,XXPANQJNYNUNES-UHFFFAOYSA-N,Small molecule,False,NOMIFENSINE,4.0,True,True,[],"['Linamiphen', 'Nomifensin', 'Nomifensine']",['CHEMBL1256842'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for unipolar depression.,['Nomifensine'],['DB04821'],['EFO_0003761'],1.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,1984.0,,,"['144212072', '50105261', '90340560']",['116225'],,,,,
CHEMBL3348923,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,VWMJHAFYPMOMGF-ZCFIWIBFSA-N,Small molecule,False,TOVORAFENIB,3.0,False,False,[],"['BIIB-024', 'BIIB024', 'Biib-024', 'DAY-101', 'DAY101', 'MLN-2480', 'Mln-2480', 'TAK-580', 'Tak 580', 'Tak-580', 'Tovorafenib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,['DB15266'],"['MONDO_0004992', 'EFO_0000756', 'EFO_0000616', 'EFO_0002617', 'EFO_1001951', 'EFO_1000209', 'MONDO_0016691', 'EFO_1000318', 'EFO_0000641', 'EFO_0002618', 'EFO_0003060']",11.0,"['ENSG00000132155', 'ENSG00000157764', 'ENSG00000078061']",3,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TOVORAFENIB/relevant/1/'],,,
CHEMBL3545193,,,Small molecule,False,MSC-2364447,1.0,False,False,[],['Msc-2364447'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0007915'],1.0,['ENSG00000010671'],1,,,,,,,,,,
CHEMBL3989803,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+],UNZIDPIPYUMVPA-UHFFFAOYSA-M,Small molecule,False,DIPYRONE,4.0,True,True,[],"['Analgin', 'Dipyrone', 'Dipyrone anhydrous', 'Metamizol', 'Metamizol monohydrate', 'Metamizole sodium', 'Metamizole sodium (anhydrous)', 'Metamizole sodium hydrate', 'Metamizole sodium monohydrate', 'Metamizolum natricum anhydricum', 'Methampyrone', 'NSC-73205', 'NSC-758445', 'Noramidopyrine methanesulfonate sodium', 'Novalgin', 'Sulpyrine', 'Sulpyrine hydrate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 4 investigational indications. It was withdrawn in at least one region.,,,"['HP_0100806', 'MONDO_0005277', 'EFO_0003843', 'HP_0001945', 'EFO_1001463', 'HP_0012532']",6.0,"['ENSG00000073756', 'ENSG00000095303']",2,,CHEMBL461522,,,,,,,,
CHEMBL4558324,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,RRMJMHOQSALEJJ-UHFFFAOYSA-N,Small molecule,False,LAZERTINIB,3.0,False,False,[],"['C-18112003-G', 'GNS-1480', 'GNS1480', 'JNJ-73841937-AAA', 'Lazertinib', 'YH-25448', 'YH25448', 'Yh25448']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,,"['MONDO_0021117', 'EFO_0003060', 'EFO_0001421', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0008903']",6.0,['ENSG00000146648'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/LAZERTINIB/relevant/1/'],,,
CHEMBL4650297,,,Unknown,False,HMPL-453,2.0,False,False,[],"['HMPL-453', 'Hmpl-453']",,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000616', 'EFO_0000588', 'MONDO_0003059']",3.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000066468']",3,,,,,,,,,,
CHEMBL4650313,Cc1cc(S(=O)(=O)Nc2cscn2)c(F)cc1N(C)[C@H]1CCN(Cc2ccccc2)C1,UCSHINHOAVARGQ-SFHVURJKSA-N,Small molecule,False,ZANDATRIGINE,2.0,False,False,[],"['NBI-921352', 'Nbi-921352', 'XEN-901', 'XEN901', 'Xen901', 'Zandatrigine']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000196876'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-127']
CHEMBL5314649,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1,YOZLVAFWYLSRRN-VZXYPILPSA-N,Small molecule,True,RITLECITINIB TOSYLATE,4.0,False,True,['Litfulo'],"['Pf-06651600 tosylate', 'Ritlecitinib tosilate', 'Ritlecitinib toslate']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for alopecia areata. This drug has a black box warning from the FDA.,,,['EFO_0004192'],1.0,"['ENSG00000113263', 'ENSG00000102010', 'ENSG00000135605', 'ENSG00000074966', 'ENSG00000010671', 'ENSG00000105639']",6,2023.0,CHEMBL4085457,,,,,,,,
CHEMBL574738,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,ODPGGGTTYSGTGO-UHFFFAOYSA-N,Small molecule,False,AST-487,1.0,False,False,[],"['AST-487', 'Ast-487', 'NVP-AST-487', 'NVP-AST487']",,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000122025', 'ENSG00000165731']",2,,,,"['103905682', '50100088']",,,,,,
CHEMBL803,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,Small molecule,True,CYTARABINE,4.0,False,True,"['Alexan', 'Alexan 100', 'Cytarabine', 'Cytosar', 'Cytosar-u', 'Depocyt', 'Depocyte', 'Tarabine Pfs']","['Ara-c', 'Ara-cytidine', 'Arabinocytosine', 'Arabinosyl cytosine', 'Aracytidine', 'Aracytin', 'Aracytine', 'Cytarabine', 'Cytarabine liposome', 'Cytarabinoside', 'Cytarabinum', 'NSC-287459', 'Spongocytidine', 'U 19920a', 'U-19,920', 'U-19920']",['CHEMBL1256472'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 11 approved and 70 investigational indications. This drug has a black box warning from the FDA.,['Cytarabine'],['DB00987'],"['MONDO_0044881', 'MONDO_0044917', 'EFO_0000339', 'EFO_1001779', 'EFO_0000220', 'EFO_0000309', 'MONDO_0019460', 'EFO_0003811', 'EFO_1000781', 'MONDO_0001475', 'MONDO_0000831', 'EFO_0003028', 'EFO_0000096', 'MONDO_0007915', 'EFO_0003025', 'EFO_0000095', 'EFO_0000519', 'EFO_0007498', 'EFO_1001257', 'MONDO_0008315', 'EFO_0003851', 'EFO_0000691', 'EFO_0000094', 'EFO_0000211', 'MONDO_0044903', 'MONDO_0018906', 'EFO_0000223', 'EFO_0003802', 'EFO_0002939', 'MONDO_0000870', 'EFO_0000574', 'EFO_0003086', 'EFO_0004991', 'EFO_0006475', 'MONDO_0004992', 'EFO_0003833', 'EFO_0009538', 'EFO_0003029', 'EFO_0001378', 'EFO_0002429', 'EFO_0004191', 'EFO_1001052', 'MONDO_0013730', 'EFO_1001365', 'EFO_0002428', 'EFO_1000131', 'EFO_1001012', 'EFO_0000183', 'EFO_1000823', 'MONDO_0009348', 'MONDO_0000873', 'EFO_0004256', 'EFO_0000616', 'EFO_0003929', 'EFO_0000198', 'EFO_1000318', 'EFO_0000209', 'EFO_0000218', 'EFO_0000756', 'EFO_0000403', 'EFO_0000221', 'EFO_1000158', 'EFO_0000222', 'EFO_1000309', 'MONDO_0019471', 'EFO_0003884', 'EFO_0004289', 'EFO_0003027', 'EFO_0000222', 'EFO_0001068', 'MONDO_0007254', 'EFO_0000224', 'EFO_1001469', 'EFO_1000286', 'EFO_0003032', 'EFO_0000479', 'EFO_0004251', 'EFO_0000565', 'EFO_0005952', 'EFO_1001383', 'MONDO_0008170']",81.0,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229']",11,1969.0,,['cytarabine'],"['131404637', '144204754', '144212288', '26719755', '29215144', '47193873', '90341066']",['28680'],['https://www.ema.europa.eu/en/medicines/human/EPAR/depocyte'],,,,
CHEMBL3544963,,,Small molecule,False,DS-3078A,1.0,False,False,[],['Ds-3078a'],,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000574'],1.0,['ENSG00000198793'],1,,,,,,,,,,
CHEMBL451887,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,BLMPQMFVWMYDKT-NZTKNTHTSA-N,Protein,False,CARFILZOMIB,4.0,False,True,['Kyprolis'],"['Carfilzomib', 'NSC-758252', 'PR-171']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 25 investigational indications.,,['DB08889'],"['EFO_0009441', 'MONDO_0004992', 'MONDO_0002120', 'EFO_1000785', 'MONDO_0018906', 'EFO_0001378', 'MONDO_0008315', 'EFO_0000574', 'EFO_0000616', 'EFO_0000095', 'MONDO_0002367', 'EFO_0000220', 'EFO_0000702', 'EFO_0000096', 'EFO_0005952', 'EFO_1001469', 'EFO_0000183', 'EFO_0000222', 'EFO_0006475', 'EFO_0006738', 'EFO_0000211', 'MONDO_0001023', 'MONDO_0017816', 'EFO_0000565', 'MONDO_0020547', 'EFO_0000403', 'EFO_1001875', 'EFO_1001051']",28.0,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']",38,2009.0,,['carfilzomib'],"['124955654', '144206630', '170466878']",['65347'],['https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis'],,,,
CHEMBL4594603,,,Unknown,False,LONOCTOCOG ALFA,4.0,False,True,['Afstyla'],"['Afstyla', 'CSL-627', 'CSL627', 'Lonoctocog alfa', 'Rviii-singlechain']",,Unknown drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia a.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,2017.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/afstyla'],,,,
CHEMBL5095025,Cn1/c(=N\C#N)n(-c2ccc(C(C)(C)C#N)nc2)c2c3cc(-c4cnc(N)c(C(F)(F)F)c4)ccc3ncc21,VJLRLTSXTLICIR-AUGOTPMTSA-N,Small molecule,False,PANULISIB,2.0,False,False,[],"['P-7170', 'P7170', 'Panulisib']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000198793', 'ENSG00000139567']",10,,,,,,,,,,
CHEMBL1201729,CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1.Cl,DWKVCQXJYURSIQ-UHFFFAOYSA-N,Small molecule,True,DRONEDARONE HYDROCHLORIDE,4.0,False,True,['Multaq'],"['Dronedarone hcl', 'Dronedarone hydrochloride', 'SR-33598B', 'SR33598B']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for atrial fibrillation. This drug has a black box warning from the FDA.,,,['EFO_0000275'],1.0,"['ENSG00000138622', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000123700', 'ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",16,2009.0,CHEMBL184412,['dronedarone%20hydrochloride'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0'],,,,
CHEMBL2062163,C[C@H]1[C@H](c2ccccc2)OCCN1C.O=C(O)C(O)C(O)C(=O)O,VEPOHXYIFQMVHW-XOZOLZJESA-N,Small molecule,False,PHENDIMETRAZINE TARTRATE,4.0,False,True,"['Adphen', 'Alphazine', 'Bontril', 'Bontril pdm', 'Cam-metrazine', 'Di-metrex', 'Melfiat', 'Melfiat-105', 'Metra', 'Phenazine', 'Phenazine-35', 'Phendimetrazine tartrate', 'Plegine', 'Sprx-105', 'Sprx-3', 'Statobex', 'Statobex-g', 'X-trozine', 'X-trozine l.a.']","['Adipost', 'Appecon', 'Azophenylene', 'NSC-13157', 'Phendimetrazine bitartrate', 'Phendimetrazine hydrogen tartrate', 'Phendimetrazine tartrate', 'Phendimetrazine tartrate ciii']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for obesity.,,,['EFO_0001073'],1.0,"['ENSG00000142319', 'ENSG00000103546']",2,1976.0,CHEMBL1615439,['phendimetrazine%20tartrate'],,,,,,,
CHEMBL2104969,O=C(O)c1ccc(CCCc2c(CCNS(=O)(=O)Cc3ccccc3C(F)(F)F)n(C(c3ccccc3)c3ccccc3)c3ccc(Cl)cc23)cc1,NHHBNHIPCSPSHQ-UHFFFAOYSA-N,Small molecule,False,GIRIPLADIB,2.0,False,False,[],"['Giripladib', 'PLA-695']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB15426'],"['EFO_0000685', 'MONDO_0005178']",2.0,['ENSG00000116711'],1,,,,,,,,,,
CHEMBL2109411,,,Antibody,False,RG-7444,1.0,False,False,[],['RG-7444'],,Antibody drug with a maximum clinical trial phase of I.,,,,,['ENSG00000068078'],1,,,,,,,,,,
CHEMBL211456,CN[C@@H](C)[C@H](O)c1ccccc1,KWGRBVOPPLSCSI-WPRPVWTQSA-N,Small molecule,False,EPHEDRINE,4.0,True,True,[],"['(-)-ephedrine', 'Ephedrine', 'Ephedrine, anhydrous', 'Ephedrinum, anhydrous', 'L-ephedrine', 'NSC-170951', 'NSC-8971', 'Xenadrine']","['CHEMBL2146102', 'CHEMBL1523964', 'CHEMBL526872']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 7 approved and 6 investigational indications. It was withdrawn in at least one region.,['Ephedrine'],['DB01364'],"['EFO_0001073', 'HP_0001742', 'EFO_0007214', 'EFO_0003956', 'EFO_0005251', 'EFO_0003843', 'MP_0001914', 'HP_0001742', 'EFO_0005251', 'MONDO_0004979', 'EFO_0000319', 'EFO_0000668', 'MONDO_0004979', 'EFO_0005251', 'EFO_0009314', 'HP_0100543']",16.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']",9,2016.0,,,['124892369'],['15407'],,,,,
CHEMBL228814,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,QJZRFPJCWMNVAV-HHHXNRCGSA-N,Small molecule,False,ISPINESIB,2.0,False,False,[],['Ispinesib'],['CHEMBL2347651'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,['DB06188'],"['MONDO_0004992', 'EFO_0003869', 'EFO_0000681', 'EFO_1000657', 'MONDO_0008170', 'MONDO_0002691', 'EFO_0000673', 'EFO_0003060', 'EFO_0000389', 'MONDO_0021063']",10.0,['ENSG00000138160'],1,,,,,,,,,,
CHEMBL3545196,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1.Cl.Cl,NADLBPWBFGTESN-UHFFFAOYSA-N,Small molecule,False,PD-0166285,1.0,False,False,[],['Pd-0166285'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000077782', 'ENSG00000197122', 'ENSG00000146648', 'ENSG00000113721']",4,,CHEMBL49120,,,,,,,,
CHEMBL3969876,COCCCCn1c(C(=O)N(CC(C)C)[C@@H]2CNC[C@H](C(=O)N3CCOCC3)C2)nc2ccccc21.Cl,PUXOYQIZZIWCHH-NSLUPJTDSA-N,Small molecule,False,IMARIKIREN HYDROCHLORIDE,2.0,False,False,[],"['Imarikiren hydrochloride', 'TAK-272', 'Tak-272']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000143839'],1,,CHEMBL3990145,,,,,,,,
CHEMBL4297969,,,Antibody,False,FELADILIMAB,3.0,False,False,[],"['3359609', 'Feladilimab', 'GSK-3359609', 'GSK-609', 'GSK3359609', 'Gsk 3359609', 'Gsk3359609']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0001378', 'EFO_0005950', 'EFO_0000616']",3.0,['ENSG00000163600'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/FELADILIMAB/relevant/1/'],,,
CHEMBL1200952,CN[C@@H](C)Cc1ccccc1.Cl,TWXDDNPPQUTEOV-FVGYRXGTSA-N,Small molecule,True,METHAMPHETAMINE HYDROCHLORIDE,4.0,False,True,"['Desoxyn', 'Methampex', 'Methamphetamine hydrochloride']","['Desoxyephedrine hydrochloride', 'Metamfetamine hydrochloride', 'Methamphetamine hcl', 'Methamphetamine hydrochloride', 'Methamphetamine hydrochloride cii', 'Methylamfetamine hydrochloride', 'NSC-169505']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1943 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA.,,,['EFO_0003888'],1.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,1943.0,CHEMBL1201201,['methamphetamine%20hydrochloride'],['144206409'],['35340'],,,,,
CHEMBL1770916,CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,VFCRKLWBYMDAED-REWPJTCUSA-N,Small molecule,False,NIROGACESTAT,3.0,False,False,[],"['Nirogacestat', 'PF 03084014', 'PF 3084014', 'PF-03084014', 'PF-3084014']",['CHEMBL4298153'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,['DB12005'],"['EFO_0001378', 'EFO_0003869', 'EFO_0000616', 'EFO_0002618', 'EFO_0009907', 'EFO_0000616', 'MONDO_0007254']",7.0,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']",6,,,,,,,,,,
CHEMBL1879463,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,Small molecule,False,DACTOLISIB,3.0,False,False,[],"['BEZ-235', 'BEZ235', 'Bez-235', 'Dactolisib', 'NSC-751249', 'NVP-BEZ235', 'NVP-BEZ235-NX', 'Nvp-bez-235', 'RTB-101', 'RTB101', 'Rtb101']","['CHEMBL3039506', 'CHEMBL1911126']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,['DB11651'],"['MONDO_0007254', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0100096', 'MONDO_0008315', 'EFO_1000045', 'EFO_0000544', 'MONDO_0002367', 'MONDO_0011962', 'EFO_1000601']",10.0,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000198793']",9,,,,"['103905146', '124898663', '124898665', '99460876']",['71952'],,,,,
CHEMBL2105732,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN.Cl,XNCDYJFPRPDERF-NQQJLSKUSA-N,Small molecule,True,LEVOMILNACIPRAN HYDROCHLORIDE,4.0,False,True,['Fetzima'],"['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDE', 'F-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDE', 'Levomilnacipran hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['MONDO_0002009', 'EFO_0005687', 'EFO_0003761', 'HP_0002140']",4.0,"['ENSG00000108576', 'ENSG00000103546']",2,2013.0,CHEMBL99946,['levomilnacipran%20hydrochloride'],,,,,,,
CHEMBL2108144,,,Antibody,False,TENELIXIMAB,2.0,False,False,[],"['BMS-224819', 'Teneliximab']",,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000101017'],1,,,,,,,,,,
CHEMBL238465,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl,MBQYQLWSBRANKQ-IMTBSYHQSA-N,Small molecule,False,SOFINICLINE,2.0,False,False,[],"['A-422894.0', 'ABT-894', 'Sofinicline']",['CHEMBL2105654'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,['DB12527'],"['EFO_0003888', 'EFO_0005762', 'EFO_0000401', 'MONDO_0001583']",4.0,"['ENSG00000160716', 'ENSG00000101204']",2,,,,,,,,,,
CHEMBL245019,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O,HZQDCMWJEBCWBR-UUOKFMHZSA-N,Small molecule,False,MIZORIBINE,3.0,False,False,[],"['Bredinin', 'Mizoribine', 'NSC-289637']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB12617'],"['EFO_0000685', 'EFO_0005761', 'EFO_0004255']",3.0,"['ENSG00000106348', 'ENSG00000178035', 'ENSG00000163655']",3,,,,"['11532986', '170466027', '50106568', '50106569', '90340602']",,,,,,
CHEMBL3301621,c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1,HKHCSWPSUSWGLI-CABCVRRESA-N,Small molecule,False,CENTANAFADINE,3.0,False,False,[],"['Centanafadine', 'DOV 216,419', 'DOV 216,419 free base', 'DOV-216419', 'EB-1020', 'EB-1020 free base']",['CHEMBL3301615'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB14841'],"['EFO_0004319', 'MONDO_0002009', 'EFO_0003888', 'EFO_0003888', 'EFO_0005203']",5.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,,,,,,,,,,
CHEMBL3647536,CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21,PTTQXDBPTFOCMT-UHFFFAOYSA-N,Small molecule,False,DARIGABAT,2.0,False,False,[],"['CVL-865', 'Cvl-865', 'Darigabat', 'PF-06372865', 'Pf-06372865']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,,"['EFO_0004262', 'HP_0001250', 'HP_0001250', 'HP_0003419', 'EFO_1001892', 'EFO_1001146']",6.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/DARIGABAT/relevant/1/'],,,
CHEMBL429876,CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C,AMLYAMJWYAIXIA-VWNVYAMZSA-N,Protein,False,CILENGITIDE,3.0,False,False,[],"['Cilengitide', 'EMD 121974', 'EMD-12192', 'EMD-121974']",,Protein drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.,['Cilengitide'],['DB11890'],"['EFO_0006861', 'EFO_0000198', 'MONDO_0008315', 'EFO_0000756', 'EFO_1000026', 'MONDO_0021633', 'EFO_0000519', 'EFO_0002428', 'EFO_1001465', 'EFO_0003086', 'EFO_0003060', 'EFO_0001378', 'EFO_0000326', 'EFO_0002499', 'EFO_0000707', 'EFO_0002501', 'EFO_0000565', 'EFO_1000158', 'EFO_0000691', 'EFO_0000616']",20.0,"['ENSG00000138448', 'ENSG00000082781', 'ENSG00000259207']",3,,,,,,,,,,
CHEMBL781,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,Small molecule,False,MAZINDOL,4.0,False,True,"['Mazanor', 'Sanorex', 'Teronac']","['42-548', 'AN-448', 'Magrilon', 'Mazildene', 'Mazindol', 'Mazindol civ', 'SAH-42548', 'Terenac']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for obesity and has 3 investigational indications.,['Mazindol'],['DB00579'],"['EFO_0002610', 'MONDO_0016158', 'EFO_0003888', 'EFO_0001073']",4.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,1973.0,,,,,,,,,
CHEMBL1098,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,LEBVLXFERQHONN-UHFFFAOYSA-N,Small molecule,True,BUPIVACAINE,4.0,False,True,"['Anekain', 'Exparel', 'Exparel liposomal', 'Marcaine', 'Posimir', 'Sensorcaine']","['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865', 'Liposomal bupivacaine', 'Marcaine', 'Ropivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402', 'Sensorcaine']",['CHEMBL1200396'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for pain and hernia and has 76 investigational indications. This drug has a black box warning from the FDA.,['Bupivacaine'],['DB00297'],"['EFO_0003833', 'HP_0002315', 'HP_0001623', 'EFO_0000546', 'EFO_1001866', 'EFO_0005251', 'MONDO_0000728', 'HP_0000175', 'EFO_0007490', 'MONDO_0005277', 'EFO_0003060', 'MONDO_0007254', 'EFO_0002950', 'HP_0000023', 'MONDO_0005178', 'EFO_1001792', 'EFO_1000994', 'EFO_0004229', 'EFO_0009615', 'EFO_1000786', 'EFO_1001250', 'EFO_0000342', 'EFO_1001267', 'HP_0001537', 'EFO_1001909', 'EFO_0003869', 'EFO_0009676', 'EFO_0003964', 'MONDO_0002087', 'EFO_0003931', 'HP_0012227', 'EFO_0010072', 'EFO_0005762', 'MONDO_0041052', 'HP_0012532', 'HP_0000023', 'EFO_0004888', 'EFO_1001331', 'MONDO_0005277', 'HP_0009926', 'EFO_0004209', 'EFO_0002618', 'EFO_0003818', 'MONDO_0004992', 'HP_0030834', 'EFO_0001358', 'MONDO_0021117', 'EFO_0000691', 'EFO_1001139', 'MONDO_0008315', 'HP_0001822', 'HP_0002027', 'EFO_0004616', 'EFO_0009620', 'EFO_0003843', 'MONDO_0004567', 'EFO_0000764', 'HP_0000175', 'EFO_1001087', 'HP_0100790', 'HP_0012735', 'EFO_0003843', 'EFO_0000275', 'HP_0012532', 'MONDO_0007254', 'MONDO_0002959', 'EFO_0004616', 'EFO_0009314', 'HP_0001822', 'HP_0031217', 'EFO_0001074', 'EFO_0001421', 'MONDO_0004992', 'EFO_0007149', 'MP_0001914', 'EFO_0000616', 'EFO_0009552', 'EFO_1001968', 'EFO_0009552', 'EFO_0000546', 'EFO_0007486', 'HP_0003419', 'EFO_0000764', 'EFO_1001898']",84.0,['ENSG00000007314'],1,1972.0,,['bupivacaine'],['160644527'],['77431'],['https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal'],,,,
CHEMBL1569487,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,WLHQHAUOOXYABV-UHFFFAOYSA-N,Small molecule,False,LORNOXICAM,4.0,False,True,['Xefo'],"['CTX', 'Lorcam', 'Lornoxicam', 'NSC-759620', 'RO 13-9297', 'RO-13-9297', 'RO-139297']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 3 investigational indications.,,['DB06725'],"['EFO_0005755', 'MONDO_0005277', 'EFO_0003843', 'MONDO_0004975']",4.0,"['ENSG00000073756', 'ENSG00000095303']",2,,,,['49666507'],['31783'],,,,,
CHEMBL1743082,,,Antibody drug conjugate,True,TRASTUZUMAB EMTANSINE,4.0,False,True,['Kadcyla'],"['PRO-132365', 'RG-3502', 'TRASTUZUMAB-MCC-DM1 T-DM1', 'Trastuzumab emtansine']",,Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 9 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_1000294', 'EFO_1000984', 'MONDO_0000521', 'EFO_0001378', 'EFO_0003869', 'EFO_0000305', 'MONDO_0008170', 'EFO_0009708', 'EFO_0003060', 'MONDO_0004992', 'MONDO_0004669', 'MONDO_0001056', 'MONDO_0011962', 'MONDO_0007254', 'EFO_0000616']",15.0,"['ENSG00000141736', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,2013.0,,['ado-trastuzumab%20emtansine'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla'],,,['4990'],
CHEMBL2108359,,,Antibody,False,NIMOTUZUMAB,3.0,False,False,['Theraloc theracim'],"['HR3', 'Nimotuzumab', 'OSAG 101', 'THERACIM-HR3', 'THERALOC']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications.,,,"['EFO_0007331', 'EFO_0003060', 'MONDO_0002974', 'EFO_0002916', 'MONDO_0001325', 'EFO_0000181', 'EFO_0000326', 'EFO_1001931', 'MONDO_0005575', 'EFO_0003897', 'EFO_0000228', 'EFO_1000657', 'MONDO_0007254', 'EFO_0000199', 'EFO_0000313', 'EFO_0006859', 'EFO_0000616', 'EFO_1000026', 'EFO_0000707', 'EFO_0005922', 'MONDO_0007576', 'EFO_0002618', 'MONDO_0001056', 'EFO_0002938', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0002914', 'EFO_0000519', 'MONDO_0008903', 'EFO_0004252']",30.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL2109072,,,Unknown,False,"FIBRINOGEN, HUMAN",3.0,False,False,[],"['Evarrest', 'Factor i (fibrinogen)', 'Factor i human', 'Fibrinogen', 'Fibrinogen (human)', 'Fibrinogen concentrate (human)', 'Fibrinogen concentrate human', 'Fibrinogen human', 'Fibrinogen human plasma-derived', 'Fibrinogen, human', 'Haemocomplettan p', 'Human fibrinogen', 'Parenogen', 'Raplixa']",,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,,"['HP_0002647', 'EFO_0005207', 'EFO_0009579', 'EFO_0010282', 'MONDO_0008737', 'EFO_0003777', 'HP_0001871', 'HP_0031273', 'EFO_0000546', 'MP_0001914', 'EFO_0001421']",11.0,"['ENSG00000171560', 'ENSG00000171564', 'ENSG00000171557']",3,,,,,,,,,,
CHEMBL3545376,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,OLAHOMJCDNXHFI-UHFFFAOYSA-N,Small molecule,False,ERDAFITINIB,4.0,False,True,['Balversa'],"['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']","['CHEMBL3918638', 'CHEMBL3919709', 'CHEMBL3975791', 'CHEMBL3948043']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 11 investigational indications.,,['DB12147'],"['EFO_0000519', 'EFO_0003863', 'MONDO_0004992', 'EFO_0008528', 'EFO_0003060', 'EFO_0000574', 'MONDO_0007254', 'EFO_0001421', 'EFO_0001378', 'EFO_0000196', 'MONDO_0001187', 'EFO_0000294', 'EFO_0000616', 'EFO_0000708', 'EFO_0000182', 'EFO_0000673']",16.0,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']",4,2019.0,,['erdafitinib'],,,,,,,
CHEMBL359164,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,RXRGZNYSEHTMHC-BQBZGAKWSA-N,Small molecule,False,TROXACITABINE,2.0,False,False,[],"['(-)-ODDC', 'BCH-4556', 'Lamivudine impurity i', 'Lamivudine impurity i rs', 'Troxacitabine', 'Troxatyl']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,['Troxacitabine'],['DB04961'],['EFO_0000565'],1.0,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229']",11,,,,,,,,,,
CHEMBL3707317,,,Small molecule,False,LOREDIPLON,2.0,False,False,[],"['Gf-015535-00', 'Lorediplon']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL4297842,,,Antibody,False,TOMUZOTUXIMAB,2.0,False,False,[],['Tomuzotuximab'],,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL5314407,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+],HXINDCTZKGGRDE-JPKZNVRTSA-L,Small molecule,False,ARQ-736,1.0,False,False,[],"['ARQ-736', 'Arq 736', 'Arq-736']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000157764', 'ENSG00000132155']",2,,CHEMBL5316167,,,,,,,,
CHEMBL563,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,SYTBZMRGLBWNTM-UHFFFAOYSA-N,Small molecule,True,FLURBIPROFEN,4.0,False,True,"['Ansaid', 'Cebutid', 'Flurbiprofen', 'Froben', 'Froben sr', 'Strefen', 'Transact']","['BTS 18,322', 'BTS-18322', 'Flubiprofen', 'Flurbiprofen', 'NSC-757037', 'Ocufen', 'U-27,182', 'U-27182']","['CHEMBL3989754', 'CHEMBL1200990']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA.,['Flurbiprofen'],['DB00712'],"['HP_0003419', 'MONDO_0044970', 'EFO_0005752', 'EFO_0000649', 'EFO_0000685', 'HP_0000616', 'EFO_0000764', 'MONDO_0002258', 'EFO_0003843', 'HP_0003326', 'MONDO_0005148', 'HP_0002829', 'EFO_0003931', 'EFO_0005755', 'EFO_0004272']",15.0,"['ENSG00000073756', 'ENSG00000095303']",2,1986.0,,['flurbiprofen'],"['144204098', '144212670', '174007327', '26747178', '49732000', '520771', '855731', '860839']",['5130'],,,,,
CHEMBL827,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,DUGOZIWVEXMGBE-CHWSQXEVSA-N,Small molecule,False,DEXMETHYLPHENIDATE,4.0,False,True,[],"['Dexmethylphenidate', 'Methylphenidate d-threo-form']",['CHEMBL904'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for attention deficit hyperactivity disorder.,['Dexmethylphenidate'],['DB06701'],"['EFO_0003888', 'EFO_0003888']",2.0,"['ENSG00000142319', 'ENSG00000103546']",2,,,,,['51860'],,,,,
CHEMBL877,NC[C@H]1CC[C@H](C(=O)O)CC1,GYDJEQRTZSCIOI-LJGSYFOKSA-N,Small molecule,False,TRANEXAMIC ACID,4.0,False,True,"['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'Lysteda', 'Menstralite', 'Tranexamic acid']","['Amcha', 'CL 65336', 'CL-65336', 'CL65336', 'Cyclo-f', 'Cyclocapron', 'Cyclokapron', 'Espercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305', 'RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acid', 'Trans AMCHA', 'Transamin']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 58 investigational indications.,['Tranexamic_acid'],['DB00302'],"['HP_0003418', 'EFO_0009579', 'EFO_0004273', 'EFO_1000391', 'EFO_0009516', 'MONDO_0007254', 'EFO_0006834', 'MONDO_0004992', 'EFO_0005669', 'EFO_0000731', 'EFO_0000546', 'EFO_0004272', 'HP_0100806', 'MONDO_0005178', 'EFO_0001645', 'EFO_0007440', 'EFO_1000999', 'EFO_0004214', 'MONDO_0010602', 'MP_0001914', 'MONDO_0021148', 'EFO_0001642', 'EFO_0003843', 'MONDO_0044881', 'EFO_0000756', 'MONDO_0043510', 'MONDO_0008315', 'EFO_0003895', 'EFO_0004710', 'EFO_1001792', 'EFO_1000350', 'HP_0002239', 'EFO_0003833', 'MP_0001845', 'MONDO_0016642', 'EFO_0003931', 'EFO_0003963', 'EFO_0004198', 'HP_0000132', 'EFO_0007442', 'HP_0031273', 'EFO_0009314', 'MONDO_0004567', 'EFO_0004616', 'EFO_0004284', 'EFO_0010680', 'EFO_0000713', 'EFO_0000326', 'MONDO_0019623', 'MONDO_0001187', 'HP_0003040', 'EFO_0000272', 'EFO_1001178', 'HP_0008419', 'HP_0002105', 'EFO_0005251', 'EFO_0003964', 'MONDO_0019180', 'MONDO_0100096', 'EFO_1001801', 'HP_0001873']",61.0,['ENSG00000122194'],1,1986.0,,['tranexamic%20acid'],,['48669'],,,,,
CHEMBL1201728,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O=C(O)CCC(=O)O,ORUUBRMVQCKYHB-UHFFFAOYSA-N,Small molecule,True,DESVENLAFAXINE SUCCINATE,4.0,False,True,"['Desvenlafaxine succinate', 'Pristiq']","['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrous', 'Desvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrate', 'Dvs anhydrous', 'O-desmethyl venlafaxine succinate', 'O-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for major depressive disorder and unipolar depression and has 5 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0005687', 'HP_0031217', 'MONDO_0002009', 'GO_0042697', 'EFO_1000783', 'EFO_0003761', 'MONDO_0002050']",7.0,"['ENSG00000103546', 'ENSG00000108576']",2,2008.0,CHEMBL1118,['desvenlafaxine%20succinate'],,,,,,,
CHEMBL15770,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1,MLKXDPUZXIRXEP-MFOYZWKCSA-N,Small molecule,True,SULINDAC,4.0,False,True,"['Clinoril', 'Sulindac']","['Arthrocine', 'Artribid', 'MK-231', 'NSC-757344', 'Sulindac']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA.,['Sulindac'],['DB00605'],"['EFO_0000389', 'MONDO_0021074', 'EFO_0004142', 'EFO_1001951', 'MONDO_0007254', 'Orphanet_733', 'EFO_0000222', 'EFO_0009907', 'EFO_0000181', 'MONDO_0005178', 'EFO_0005755', 'EFO_0000685', 'MONDO_0010383', 'MONDO_0003937']",14.0,"['ENSG00000073756', 'ENSG00000095303']",2,1978.0,,['sulindac'],"['11111823', '11111824', '11114189', '124881496', '144203821', '144211735', '170464648', '26732639', '50106970', '85231236', '90341400']",['9352'],,,['100'],,
CHEMBL1743016,,,Antibody,False,FARLETUZUMAB,3.0,False,False,[],"['Farletuzumab', 'M3', 'MORAb-003']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0002158', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000571', 'EFO_1001100']",5.0,['ENSG00000110195'],1,,,,,,,,,,
CHEMBL1817709,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O,JCVQBJTWWDYUFQ-MRUTUVJXSA-N,Protein,False,SELEPRESSIN,2.0,False,False,[],"['FE 202158', 'FE-202158', 'FE202158', 'Fe-202158', 'Selepressin']",,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12495'],['EFO_0006834'],1.0,['ENSG00000166148'],1,,,,,,,,,,
CHEMBL2107771,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,BHJIBOFHEFDSAU-LBPRGKRZSA-N,Small molecule,False,RALFINAMIDE,3.0,False,False,[],"['FCE-26742A', 'NW1029', 'Nw-1029', 'PNU-0154339E', 'Priralfinamide', 'Ralfinamide']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB06649'],"['EFO_0005762', 'EFO_0003843']",2.0,"['ENSG00000148408', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313', 'ENSG00000069535', 'ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",19,,,,,,,,,,
CHEMBL2393130,COc1cc(OC)c2c(=O)[nH]c(-c3cc(C)c(OCCO)c(C)c3)nc2c1,NETXMUIMUZJUTB-UHFFFAOYSA-N,Small molecule,False,APABETALONE,3.0,False,False,[],"['Apabetalone', 'RVX-000222', 'RVX-208', 'RVX000222']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB12000'],"['EFO_0003884', 'MONDO_0010526', 'MONDO_0100096', 'EFO_0001361', 'EFO_0000400', 'EFO_0001645']",6.0,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']",4,,,,,,,,,,
CHEMBL3301600,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1,ABSXPNGWJFAPRT-UHFFFAOYSA-N,Small molecule,False,SPEBRUTINIB BESYLATE,2.0,False,False,[],"['AVL-292', 'AVL-292 BESYLATE', 'CC-292', 'CC-292 BESYLATE', 'Spebrutinib', 'Spebrutinib besilate', 'Spebrutinib besylate']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000403', 'EFO_0000685', 'EFO_0000565']",3.0,['ENSG00000010671'],1,,CHEMBL3301625,,,,,,,,
CHEMBL3639788,O=C(Cc1cccc(OC(F)(F)F)c1)Nc1ccc(CCCCc2nnc(NC(=O)Cc3ccccn3)s2)nn1,PRAAPINBUWJLGA-UHFFFAOYSA-N,Small molecule,False,TELAGLENASTAT,2.0,False,False,[],"['CB-839', 'Telaglenastat']",['CHEMBL4594286'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 14 investigational indications.,,['DB15232'],"['EFO_0001061', 'EFO_0000349', 'EFO_0003060', 'EFO_0000681', 'EFO_0000222', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000220', 'EFO_0000272', 'EFO_0000198', 'EFO_0005537', 'EFO_0000616', 'EFO_1001779', 'EFO_0001378', 'EFO_0000760']",15.0,['ENSG00000115419'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TELAGLENASTAT/relevant/1/'],,,
CHEMBL3833306,,,Antibody drug conjugate,False,VANDORTUZUMAB VEDOTIN,2.0,False,False,[],"['DSTP3086S', 'MSTP2109A', 'RG-7450', 'RG7450', 'Vandortuzumab vedotin']",,Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0008315'],1.0,"['ENSG00000164647', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",16,,,,,,,,,,
CHEMBL971,CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+],QGMRQYFBGABWDR-UHFFFAOYSA-M,Small molecule,False,PENTOBARBITAL SODIUM,4.0,True,True,"['Beuthanasia', 'Euthanase', 'Euthatal', 'Nembutal', 'Nembutal sodium', 'Pentobarbital sodium', 'Pentobarbitone Sodium', 'Sagatal', 'Sodium pentobarbital']","['Auropan', 'Barpental', 'Biosedan', 'Diabutal', 'Embutal', 'Entobar', 'Etaminal sodium', 'Ethaminal sodium', 'Euthanyl', 'Euthatal', 'Isobarb', 'Mebubarbital sodium', 'Mebumal sodium', 'NSC-10816', 'Napental', 'Narcoren', 'Pacifan', 'Pental', 'Pentobarbital sodium', 'Pentobarbital sodium salt', 'Pentobarbitone sodium', 'Pentonal', 'Pentone', 'Praecicalm', 'Rs-pentobarbital sodium', 'Sagatal', 'Sodium ethaminal', 'Sodium nembutal', 'Sodium pental', 'Sodium pentobarbitone', 'Sodium pentobarbiturate', 'Sodium-pent', 'Soluble pentobarbital', 'Somnopentyl', 'Somnotol', 'Sopental', 'Sotyl', 'V-pento', 'Vetbutal']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973. It was withdrawn in at least one region.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1973.0,CHEMBL448,['pentobarbital%20sodium'],,['7984'],,,,,
CHEMBL1200805,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.O=C(O)CC(O)C(=O)O,IUSFTUWHKCSCDY-BHDTVMLSSA-N,Small molecule,False,DILTIAZEM MALATE,4.0,False,True,['Tiamate'],"['Diltiazem malate', 'MK-793']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996.,,,,,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1996.0,CHEMBL23,,,,,,,,
CHEMBL1201193,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,LEBVLXFERQHONN-INIZCTEOSA-N,Small molecule,False,LEVOBUPIVACAINE,4.0,False,True,[],"['(-)-bupivacaine', '(s)-bupivacaine', 'Bupivacaine (-)-form', 'Bupivacaine, (-)-', 'Bupivacaine, (s)-', 'L-bupivacaine', 'Levobupivacaine', 'Novabupi']",['CHEMBL1200749'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 7 investigational indications.,['Levobupivacaine'],['DB01002'],"['HP_0002027', 'EFO_0005323', 'EFO_0002950', 'EFO_0000616', 'EFO_0003843', 'EFO_0003843', 'HP_0000175', 'HP_0003418', 'EFO_0002950']",9.0,['ENSG00000007314'],1,1999.0,,,"['11112642', '29215441']",['6149'],,,,,
CHEMBL2108811,,,Antibody,False,VISILIZUMAB,3.0,False,False,['Nuvion'],"['HUM-291', 'Visilizumab', 'huM291']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0013730', 'EFO_0000384', 'EFO_0000729', 'EFO_0000222', 'EFO_0000574']",5.0,['ENSG00000198851'],1,,,,,,,,,,
CHEMBL2141296,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,MXAYKZJJDUDWDS-LBPRGKRZSA-N,Small molecule,False,IXAZOMIB,4.0,False,True,['Ninlaro'],"['Ixazomib', 'MLN-2238', 'MLN-9708 FREE BASE', 'MLN2238']",['CHEMBL5171825'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 19 investigational indications.,,['DB09570'],"['EFO_1001264', 'EFO_0000565', 'EFO_0000220', 'EFO_0009441', 'MONDO_0019438', 'MONDO_0044881', 'EFO_0001378', 'EFO_0005537', 'EFO_0005761', 'EFO_0000681', 'EFO_0006738', 'MONDO_0004992', 'EFO_0000764', 'EFO_0000574', 'EFO_0000616', 'EFO_0007160', 'EFO_0000222', 'EFO_1001469', 'MONDO_0000873', 'EFO_0003884', 'MONDO_0018906']",21.0,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']",38,,,,['124955652'],,,,,,
CHEMBL3187723,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,ACWZRVQXLIRSDF-UHFFFAOYSA-N,Small molecule,False,BINIMETINIB,4.0,False,True,['Mektovi'],"['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162', 'Mek-162', 'NVP-MEK162']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 29 investigational indications.,,['DB11967'],"['EFO_0001421', 'EFO_0003060', 'EFO_0000389', 'EFO_0002617', 'EFO_1000251', 'EFO_1001959', 'MONDO_0004992', 'MONDO_0007254', 'MONDO_0021063', 'EFO_1000956', 'MONDO_0011719', 'MONDO_0008170', 'EFO_0002503', 'EFO_0003833', 'EFO_0005537', 'EFO_0002892', 'EFO_0002618', 'EFO_0000565', 'EFO_1000657', 'EFO_0000305', 'EFO_0009259', 'EFO_0000685', 'EFO_0001075', 'EFO_1001951', 'MONDO_0002158', 'MONDO_0003060', 'EFO_1001512', 'EFO_0000616', 'EFO_0003891', 'EFO_0000756', 'EFO_0004606', 'EFO_0001378', 'MONDO_0008903', 'MONDO_0002087']",34.0,"['ENSG00000169032', 'ENSG00000126934']",2,2018.0,,['binimetinib'],['174006430'],,['https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi'],,,,
CHEMBL3545283,CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO,QLUYMIVVAYRECT-UHFFFAOYSA-N,Small molecule,False,RIVICICLIB,2.0,False,False,[],"['P 276-00 free base', 'P-276-00 free base', 'P276-00', 'Riviciclib']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000170312', 'ENSG00000135446', 'ENSG00000136807']",3,,,,,,,,,,
CHEMBL3545349,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1.Cl.Cl,OJBLXSPBJMGZDN-UHFFFAOYSA-N,Small molecule,False,EVT-101,2.0,False,False,[],"['Evt-101', 'Evt101']",,Small molecule drug with a maximum clinical trial phase of II.,,['DB05956'],,,"['ENSG00000176884', 'ENSG00000273079']",2,,CHEMBL3545350,,,,,,,,
CHEMBL3577124,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1,HHCBMISMPSAZBF-UHFFFAOYSA-N,Small molecule,False,LY-3009120,1.0,False,False,[],"['DP-4978', 'LY3009120', 'Ly-3009120', 'Pan-raf inhibitor ly3009120']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,,"['EFO_0004142', 'EFO_0009708', 'EFO_0003060', 'EFO_0000756']",4.0,"['ENSG00000132155', 'ENSG00000157764', 'ENSG00000078061']",3,,,,,,,,,,
CHEMBL4650277,CC(C)(C)NCCNc1ccc(C2=NN=C(C(F)(F)F)C2)nc1C1CCN(c2ncnc3c2C(C)(C)C(=O)N3)CC1,UVKWCPOZHXNKAZ-UHFFFAOYSA-N,Small molecule,False,TAS0612,1.0,False,False,[],"['TAS0612', 'Tas0612']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000616'],1.0,"['ENSG00000177189', 'ENSG00000071242', 'ENSG00000072133', 'ENSG00000117676', 'ENSG00000175634', 'ENSG00000108443', 'ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']",9,,,,,,,,,,
CHEMBL501867,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,AQTQHPDCURKLKT-JKDPCDLQSA-N,Small molecule,True,VINCRISTINE SULFATE,4.0,False,True,"['Kyocristine', 'Leurocristine Sulfate', 'Marqibo kit', 'Oncovin', 'Vincasar', 'Vincasar pfs', 'Vincrex', 'Vincristine sulfate', 'Vincristine sulfate pfs']","['37231', 'Kyocristine', 'LILLY-37231', 'Marqibo', 'NSC-67574', 'Novopharm', 'Vincristine sulfate', 'Vincristine sulfate liposome', 'Vincristine sulphate', 'Vincristini sulfas', 'Vincrisul']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 58 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000174', 'EFO_0000272', 'EFO_0000094', 'MONDO_0009348', 'EFO_0000248', 'EFO_0000220', 'MONDO_0008380', 'MONDO_0018975', 'EFO_0006859', 'EFO_1001469', 'EFO_0000558', 'EFO_0000183', 'EFO_0002939', 'EFO_0004289', 'EFO_0003032', 'EFO_0000502', 'EFO_0000756', 'EFO_0000211', 'EFO_0000565', 'EFO_1001042', 'EFO_0000096', 'MONDO_0008903', 'MONDO_0002367', 'EFO_1000131', 'EFO_0000616', 'EFO_0001378', 'EFO_0005235', 'EFO_1000292', 'EFO_0000621', 'MONDO_0000430', 'EFO_1001951', 'EFO_0000095', 'MONDO_0000870', 'EFO_0000209', 'MONDO_0018906', 'MONDO_0015540', 'EFO_0005952', 'EFO_0000313', 'MONDO_0002974', 'EFO_0000691', 'EFO_1000158', 'HP_0001871', 'EFO_0000588', 'EFO_0000403', 'MONDO_0000873', 'EFO_0000222', 'EFO_1001365', 'EFO_0000574', 'MONDO_0018271', 'EFO_0009441', 'MONDO_0019004', 'EFO_0003833', 'EFO_0000309', 'MONDO_0019471', 'EFO_0000765', 'EFO_0002918', 'MONDO_0044917', 'EFO_0000437']",58.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1963.0,CHEMBL90555,,['112141'],['79401'],,,,,
CHEMBL1102,CCC1(c2ccccc2)CCC(=O)NC1=O,JMBQKKAJIKAWKF-UHFFFAOYSA-N,Small molecule,False,GLUTETHIMIDE,4.0,False,True,"['Doriden', 'Glutethimide']","['Elrodorm', 'Glutethimide', 'NSC-95239', 'Noxyron', 'Rigenox', 'Sarodormin']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976.,['Glutethimide'],['DB01437'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1976.0,,,"['144205194', '170465223', '29215340']",['5439'],,,,,
CHEMBL1201317,O=P(O)(O)OCC(Cl)(Cl)Cl,YYQRGCZGSFRBAM-UHFFFAOYSA-N,Small molecule,False,TRICLOFOS,4.0,False,True,[],"['Neguvon', 'Tri-beta-chloroethylphosphate', 'Triclofos']",['CHEMBL1200789'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Triclofos'],['DB06753'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,,,['9695'],,,,,
CHEMBL1615025,Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21,RCLQNICOARASSR-SECBINFHSA-N,Small molecule,False,TAK-733,1.0,False,False,[],"['Mek inhibitor tak-733', 'TAK-733', 'TAK733', 'Tak 733', 'Tak-733']",,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,['DB12241'],"['EFO_0002617', 'MONDO_0004992']",2.0,"['ENSG00000169032', 'ENSG00000126934']",2,,,,,,,,,,
CHEMBL2105704,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O,HWLFIUUAYLEFCT-UHFFFAOYSA-N,Small molecule,False,LENVATINIB MESYLATE,4.0,False,True,"['Kisplyx', 'Lenvima']","['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilate', 'Lenvatinib mesylate', 'Lenvatinib methanesulfonate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 7 investigational indications.,,,"['MONDO_0003060', 'EFO_1001961', 'MONDO_0004992', 'EFO_0000681', 'EFO_0003060', 'EFO_0002892', 'MONDO_0005184', 'MONDO_0002108', 'EFO_0002617', 'EFO_0000616']",10.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']",3,2015.0,CHEMBL1289601,['lenvatinib%20mesylate'],,['85995'],['https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx'],,,,
CHEMBL2109529,,,Antibody,False,MU-BC-1,1.0,False,False,['Angiomab'],['MU-BC-1'],,Antibody drug with a maximum clinical trial phase of I.,,,,,['ENSG00000115414'],1,,,,,,,,,,
CHEMBL3899477,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2,NPJCURIANJMFEO-UHFFFAOYSA-N,Small molecule,False,CONTELTINIB ,1.0,False,False,[],['Conteltinib '],,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,,"['EFO_1000359', 'EFO_0003060']",2.0,"['ENSG00000169398', 'ENSG00000140443', 'ENSG00000171094', 'ENSG00000120899']",4,,,,,,,,,,
CHEMBL3977543,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12,KVCQTKNUUQOELD-UHFFFAOYSA-N,Small molecule,False,BELVARAFENIB,2.0,False,False,[],['Belvarafenib'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,,"['EFO_0000756', 'MONDO_0004992', 'EFO_0000616']",3.0,"['ENSG00000132155', 'ENSG00000157764', 'ENSG00000078061']",3,,,,,,,,,,
CHEMBL4216467,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,CEFJVGZHQAGLHS-UHFFFAOYSA-N,Small molecule,False,RIPRETINIB,4.0,False,True,['Qinlock'],"['DCC-2618', 'Dcc-2618', 'Ripretinib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and gastrointestinal stromal tumor.,,['DB14840'],"['EFO_0000616', 'MONDO_0011719']",2.0,"['ENSG00000157404', 'ENSG00000134853']",2,2020.0,,['ripretinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock'],,,,
CHEMBL1179047,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,VDANGULDQQJODZ-UHFFFAOYSA-N,Small molecule,False,CHLOROPROCAINE,4.0,False,True,[],"['2-chloroprocaine', 'Chloroprocaine']",['CHEMBL944'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 4 investigational indications.,['Chloroprocaine'],['DB01161'],"['EFO_0003843', 'EFO_0003843', 'EFO_0002950', 'MONDO_0005129']",4.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1955.0,,,,['3636'],,,,,
CHEMBL1738889,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,JNGVJMBLXIUVRD-SFHVURJKSA-N,Small molecule,False,ENOBOSARM,3.0,False,False,['Ostarine'],"['Enobosarm', 'GTX-024', 'Gtx-024', 'MK-2866']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,['DB12078'],"['EFO_0009851', 'HP_0004326', 'HP_0010992', 'MONDO_0007254', 'EFO_0003060', 'EFO_0005537']",6.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL3707253,,,Antibody,False,BEVACIZUMAB 111IN,-1.0,False,False,[],"['Bevacizumab 111in', 'Bevacizumab in111']",,Antibody drug.,,,,,['ENSG00000112715'],1,,,,,,,,,,
CHEMBL4594554,,,Antibody,False,TAFOLECIMAB,3.0,False,False,[],"['IBI-306', 'IBI306', 'Ibi306', 'Tafolecimab']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['EFO_0004911', 'MONDO_0018328', 'HP_0003124']",3.0,['ENSG00000169174'],1,,,,,,,,,,
CHEMBL5315125,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1.O,FQLHRUBTGKTKPZ-ZOWNYOTGSA-N,Small molecule,True,DUVELISIB MONOHYDRATE,4.0,False,True,['Copiktra'],['Duvelisib hydrate'],,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved indications. This drug has a black box warning from the FDA.,,,"['MONDO_0018906', 'EFO_0000095', 'EFO_0000574', 'EFO_0000096']",4.0,"['ENSG00000171608', 'ENSG00000105851']",2,2018.0,CHEMBL3039502,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra'],,,,
CHEMBL629,CN(C)CCC=C1c2ccccc2CCc2ccccc21,KRMDCWKBEZIMAB-UHFFFAOYSA-N,Small molecule,True,AMITRIPTYLINE,4.0,False,True,[],"['Amitid', 'Amitril', 'Amitriptyline', 'Damitriptyline', 'Elavil', 'Endep', 'Etrafon-A', 'Etrafon-Forte', 'Flavyl', 'Laroxyl', 'Limbitrol', 'Proheptadiene', 'Seroten', 'Triptanol']",['CHEMBL1200964'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for unipolar depression and depressive disorder and has 22 investigational indications. This drug has a black box warning from the FDA.,['Amitriptyline'],['DB00321'],"['EFO_0007169', 'EFO_1000941', 'EFO_0003843', 'EFO_0005230', 'EFO_1001800', 'EFO_0004698', 'EFO_0003761', 'EFO_0000400', 'EFO_0004244', 'MONDO_0005090', 'EFO_0003761', 'MONDO_0005277', 'HP_0002315', 'EFO_0000512', 'EFO_0004149', 'EFO_0009387', 'MONDO_0002050', 'EFO_0005762', 'EFO_0005687', 'EFO_0010282', 'HP_0000989', 'EFO_0008507', 'HP_0000726', 'MONDO_0016028', 'MONDO_0002009']",25.0,"['ENSG00000103546', 'ENSG00000108576']",2,1961.0,,,"['11110782', '11110783', '124879280', '90340850']",['2666'],,,['70'],,
CHEMBL894,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,SNPPWIUOZRMYNY-UHFFFAOYSA-N,Small molecule,True,BUPROPION,4.0,False,True,[],"['Amfebutamone', 'Bupropion', 'Bupropion extended release', 'Bupropion slow release', 'NSC-758686']","['CHEMBL1698', 'CHEMBL1201735']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 38 investigational indications. This drug has a black box warning from the FDA.,['Bupropion'],['DB01156'],"['EFO_0005203', 'MONDO_0002009', 'EFO_0003768', 'EFO_0004714', 'EFO_0003761', 'EFO_0006859', 'EFO_0001073', 'MONDO_0004975', 'MONDO_0002491', 'MONDO_0008315', 'EFO_0009963', 'EFO_0000616', 'EFO_0001073', 'MONDO_0002009', 'HP_0000726', 'MONDO_0004985', 'EFO_0003761', 'MONDO_0007254', 'EFO_0009854', 'MONDO_0004985', 'EFO_0002610', 'MONDO_0007739', 'MONDO_0005148', 'EFO_0003890', 'EFO_0000384', 'EFO_0007191', 'EFO_0002617', 'EFO_0003060', 'EFO_0004319', 'MONDO_0008903', 'EFO_0004701', 'EFO_0005230', 'MONDO_0044970', 'EFO_0003888', 'MONDO_0002050', 'EFO_0004319', 'MONDO_0005090', 'MONDO_0002046', 'MONDO_0007079', 'EFO_0004318', 'EFO_0000095', 'MONDO_0010200', 'MONDO_0002050', 'EFO_0003761', 'EFO_0003768', 'EFO_0004247', 'EFO_0004270']",47.0,"['ENSG00000103546', 'ENSG00000142319']",2,1985.0,,,"['174006913', '90340803']",['3219'],,,,,
CHEMBL109,CCCC(CCC)C(=O)O,NIJJYAXOARWZEE-UHFFFAOYSA-N,Small molecule,True,VALPROIC ACID,4.0,False,True,"['Convulex', 'Depakene', 'Depakote', 'Stavzor', 'Valproic acid']","['44089', 'NSC-93819', 'Pentanoic acid, 2-propyl', 'Valproate', 'Valproic acid', 'Valproic acid extended release']","['CHEMBL2315212', 'CHEMBL2105613', 'CHEMBL433']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 13 approved and 84 investigational indications. This drug has a black box warning from the FDA.,['Valproic_acid'],['DB00313'],"['HP_0000713', 'EFO_0002939', 'HP_0001250', 'MONDO_0019200', 'EFO_0004247', 'EFO_1000158', 'MONDO_0001187', 'MONDO_0019188', 'MONDO_0007254', 'HP_0001250', 'EFO_0005762', 'MONDO_0004985', 'EFO_0004252', 'EFO_0005762', 'EFO_0000095', 'EFO_0000181', 'MONDO_0019037', 'EFO_0005230', 'MONDO_0100342', 'MONDO_0044970', 'EFO_0000717', 'EFO_0000616', 'EFO_0009430', 'EFO_0000519', 'MONDO_0002050', 'EFO_0008526', 'EFO_0003833', 'EFO_0004263', 'MONDO_0004975', 'EFO_0000095', 'EFO_0000691', 'MONDO_0010604', 'EFO_0008525', 'MONDO_0004976', 'EFO_0006859', 'EFO_0009267', 'MONDO_0010826', 'HP_0000713', 'EFO_1001951', 'MONDO_0005277', 'HP_0002121', 'HP_0007359', 'MONDO_0005277', 'HP_0001250', 'EFO_0000180', 'EFO_0000546', 'MONDO_0007079', 'MONDO_0004975', 'EFO_0004191', 'EFO_1000877', 'EFO_0001358', 'Orphanet_83419', 'EFO_0002618', 'EFO_0003758', 'EFO_0000198', 'EFO_0002499', 'EFO_1000877', 'MONDO_0008170', 'MONDO_0005277', 'EFO_1001968', 'EFO_0003761', 'EFO_0000616', 'EFO_0008526', 'MONDO_0043510', 'EFO_0000519', 'MONDO_0008903', 'MONDO_0004992', 'EFO_0003758', 'EFO_0008525', 'HP_0000726', 'EFO_0000574', 'MONDO_0002974', 'EFO_0000403', 'MONDO_0018105', 'EFO_0000616', 'EFO_0000474', 'MONDO_0007254', 'MONDO_0004975', 'HP_0002121', 'MONDO_0007739', 'EFO_0000565', 'MONDO_0004985', 'EFO_0007527', 'MONDO_0007079', 'EFO_0000474', 'EFO_0000474', 'EFO_0000198', 'EFO_0000756', 'EFO_0009963', 'EFO_0000702', 'EFO_0000764', 'MONDO_0005090', 'HP_0010865', 'EFO_0003841', 'EFO_0003060', 'MONDO_0003478', 'HP_0002013', 'MONDO_0008315', 'EFO_0004192', 'MONDO_0009293', 'MONDO_0005090', 'EFO_0009963', 'HP_0031273', 'EFO_0001075', 'EFO_0000222', 'MONDO_0004985', 'EFO_0000339', 'HP_0000726', 'EFO_0000309', 'EFO_0000403', 'EFO_1001469', 'HP_0002039']",112.0,['ENSG00000112294'],1,1978.0,,['valproic%20acid'],"['144204642', '144209161', '144210920', '170465446', '17389523', '26752921', '399407', '90341449']",['39867'],,,['5'],,
CHEMBL1232461,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21,AAAQFGUYHFJNHI-SFHVURJKSA-N,Small molecule,False,MOLIBRESIB,2.0,False,False,[],"['Bet inhibitor gsk525762', 'GSK-525762', 'GSK-525762A', 'GSK525762', 'GSK525762A', 'I-BET 762', 'Molibresib']",['CHEMBL4297217'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0000616', 'EFO_0000313']",2.0,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']",4,,,,,,,,,,
CHEMBL2107870,,,Oligonucleotide,False,PEGNIVACOGIN,3.0,False,False,[],"['Pegnivacogin', 'RB-006', 'RB006', 'REG-1', 'REG1']",,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0005672', 'EFO_0001645']",2.0,['ENSG00000101981'],1,,,,,,,,,,
CHEMBL2108474,,,Antibody,False,MASLIMOMAB,2.0,False,False,[],['Maslimomab'],,Antibody drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000211810', 'ENSG00000277734', 'ENSG00000278030', 'ENSG00000211699']",4,,,,,,,,,,
CHEMBL2109351,,,Antibody,False,FBT-A05,1.0,False,False,[],['FBT-A05'],,Antibody drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000156738']",4,,,,,,,,,,
CHEMBL2109372,,,Antibody,False,MEDI-565,1.0,False,False,[],"['MEDI-565', 'Medi-565']",,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['EFO_0000228'],1.0,"['ENSG00000105388', 'ENSG00000198851']",2,,,,,,,,,,
CHEMBL3545173,,,Small molecule,False,IRX4310,1.0,False,False,[],['Irx4310'],,Small molecule drug with a maximum clinical trial phase of I.,,,,,"['ENSG00000172819', 'ENSG00000077092', 'ENSG00000131759']",3,,,,,,,,,,
CHEMBL378544,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,KDQAABAKXDWYSZ-PNYVAJAMSA-N,Small molecule,False,VINBLASTINE SULFATE,4.0,False,True,"['Velban', 'Velbe', 'Vinblast,lederle', 'Vinblastine sulfate']","['29060-LE', '29060LE', 'Alkaban-aq', 'NSC-49842', 'Vinblastine sulfate', 'Vinblastine sulphate', 'Vinblastini sulfas', 'Vincaleukoblastine sulfate', 'Vlb monosulfate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 5 approved and 15 investigational indications.,,,"['EFO_0000588', 'MONDO_0002041', 'MONDO_0008170', 'EFO_0000691', 'MONDO_0008903', 'EFO_0000574', 'MONDO_0002367', 'MONDO_0004986', 'EFO_0000756', 'EFO_0004281', 'MONDO_0001187', 'MONDO_0003751', 'EFO_0009907', 'MONDO_0008315', 'EFO_0001642', 'MONDO_0009348', 'EFO_0000183', 'MONDO_0002974', 'MONDO_0004192', 'EFO_0000389']",20.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1965.0,CHEMBL159,['vinblastine%20sulfate'],"['144205051', '144206288', '170464976', '170464977', '26663016', '56462989', '855758']",,,,,,
CHEMBL4461070,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5ccc(F)cc5)nn34)cc2s1,ODIUNTQOXRXOIV-UHFFFAOYSA-N,Small molecule,False,SAR-125844,2.0,False,False,[],"['SAR 125844', 'SAR-125844', 'SAR125844', 'Sar-125844']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000105976'],1,,,,,,,,,,
CHEMBL463981,O=S(=O)(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)c1ccc(Cl)s1,PSXOKXJMVRSARX-SCSAIBSYSA-N,Small molecule,False,BEGACESTAT,2.0,False,False,[],"['Begacestat', 'GSI-953']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB12263'],['MONDO_0004975'],1.0,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']",6,,,,,,,,,,
CHEMBL918,NC(=O)NC(=O)Cc1ccccc1,XPFRXWCVYUEORT-UHFFFAOYSA-N,Small molecule,False,PHENACEMIDE,4.0,False,True,['Phenurone'],"['NSC-39458', 'Phenacemide']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for epilepsy.,['Phenacemide'],['DB01121'],['EFO_0000474'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1951.0,,,"['144204878', '170465322', '26748194']",['8049'],,,,,
CHEMBL1200542,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,VPGRYOFKCNULNK-ACXQXYJUSA-N,Small molecule,False,DESOXYCORTICOSTERONE ACETATE,4.0,False,True,"['Doca', 'Percorten']","['11-deoxycorticosterone', '11-deoxycorticosterone acetate', '21-hydroxyprogesterone', 'Deoxycorticosterone', 'Deoxycorticosterone acetate', 'Deoxycortone', 'Desoxycorticosterone', 'Desoxycorticosterone acetate', 'Desoxycortone', 'Desoxycortone acetate', 'NSC-11319', 'NSC-9567']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939.,,['DB06780'],,,['ENSG00000151623'],1,1939.0,,,"['144204427', '170465334', '29215003', '56422097', '855662']",['34671'],,,,,
CHEMBL1742997,,,Antibody drug conjugate,False,CANTUZUMAB MERTANSINE,2.0,False,False,[],"['Cantuzumab mertansine', 'HUC-242-DM1', 'HUC242-DM1', 'SB-408075']",,Antibody drug conjugate drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000185499']",16,,,,,,,,,,
CHEMBL2109137,,,Protein,False,MOROCTOCOG ALFA,4.0,False,True,['Refacto af'],"['Moroctocog alfa', 'Refacto', 'Refacto-af', 'Xyntha']",,Protein drug with a maximum clinical trial phase of IV that was first approved in 1999 and is indicated for hemophilia a.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,1999.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/refacto-af'],,,['5166'],
CHEMBL3989909,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1.O=P(O)(O)O,XXEDEGOAYSGNPS-ZOWNYOTGSA-N,Small molecule,False,LENIOLISIB PHOSPHATE,4.0,False,True,['Joenja'],"['CDZ-173', 'CDZ-173-AZ', 'CDZ173', 'CDZ173-AZ', 'Cdz173', 'Joenja', 'Leniolisib monophosphate', 'Leniolisib phosphate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for inborn error of immunity and has 2 investigational indications.,,,"['MONDO_0015517', 'EFO_0000699', 'MONDO_0003778']",3.0,['ENSG00000171608'],1,2023.0,CHEMBL3643413,,,,,,,,
CHEMBL4297244,,,Oligonucleotide,False,DANVATIRSEN SODIUM,-1.0,False,False,[],"['AZD9150 sodium', 'Danvatirsen pentadecasodium', 'Danvatirsen sodium']",,Oligonucleotide drug.,,,,,['ENSG00000168610'],1,,,,,,,,,,
CHEMBL4650485,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1,FWZAWAUZXYCBKZ-NSHDSACASA-N,Small molecule,False,PIRTOBRUTINIB,4.0,False,True,['Jaypirca'],"['Jaypirca', 'LOXO-305', 'LY-3527727', 'LY3527727', 'Loxo-305', 'Pirtobrutinib', 'RXC-005']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for mantle cell lymphoma and has 4 investigational indications.,,,"['EFO_0000616', 'EFO_1001469', 'EFO_0000095', 'EFO_0000565', 'EFO_0009441']",5.0,['ENSG00000010671'],1,2023.0,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PIRTOBRUTINIB/relevant/1/'],,,
CHEMBL1200341,CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21.Cl,NXNSCUZKMVYAJQ-UHFFFAOYSA-N,Small molecule,False,INDECAINIDE HYDROCHLORIDE,4.0,False,True,['Decabid'],"['Indecainide hcl', 'Indecainide hydrochloride', 'LY 135837', 'LY-135837', 'LY-135857', 'Ricainide']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1989.0,CHEMBL1201242,,,,,,,,
CHEMBL1404,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,XKLMZUWKNUAPSZ-UHFFFAOYSA-N,Small molecule,False,RANOLAZINE,4.0,False,True,"['Aspruzyo sprinkle', 'Ranexa', 'Ranexa (previously latixa)', 'Ranolazine']","['Aspruzyo', 'CVT-303', 'NSC-759100', 'RS-43285-003', 'Ran d', 'Ranolazine']","['CHEMBL1526084', 'CHEMBL537649']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for cardiovascular disease and angina pectoris and has 15 investigational indications.,['Ranolazine'],['DB00243'],"['EFO_0000319', 'MONDO_0004976', 'EFO_1001375', 'EFO_0000384', 'MONDO_0005148', 'EFO_1000899', 'EFO_0001361', 'EFO_0003913', 'EFO_0004264', 'EFO_0000275', 'EFO_0005672', 'MONDO_0008195', 'EFO_0000407', 'EFO_0001645', 'EFO_0000555', 'EFO_0003086', 'HP_0001657']",17.0,"['ENSG00000007314', 'ENSG00000183873']",2,2006.0,,['ranolazine'],"['104171232', '170465435', '174006299', '26749060', '26749061', '50107515', '56463697', '90340842']",['87690'],['https://www.ema.europa.eu/en/medicines/human/EPAR/ranexa-previously-latixa'],,,,
CHEMBL186179,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,IRLWJILLXJGJTD-UHFFFAOYSA-N,Small molecule,False,MURAGLITAZAR,3.0,False,False,[],"['BMS-298585', 'BMS-298585-01', 'MK-0478', 'MK0478', 'Muraglitazar']","['CHEMBL3527055', 'CHEMBL557580']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,['DB06510'],"['Orphanet_309005', 'EFO_0000400', 'MONDO_0005148']",3.0,"['ENSG00000186951', 'ENSG00000132170']",2,,,,['170466259'],,,,,,
CHEMBL2103991,Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O,IETKPTYAGKZLKY-UHFFFAOYSA-N,Small molecule,False,BALAGLITAZONE,3.0,False,False,[],"['Balaglitazone', 'DRF-2593', 'Drf-2593', 'NN-2344']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB12781'],['MONDO_0005148'],1.0,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL2364614,CN1Cc2cc(-c3ccc(N)nn3)ccc2[C@H](c2ccc3ccccc3c2)C1,VCIBGDSRPUOBOG-QFIPXVFZSA-N,Small molecule,False,LIAFENSINE,2.0,False,False,[],"['BMS-820836', 'Liafensine']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB14878'],"['EFO_0009854', 'MONDO_0002050']",2.0,"['ENSG00000108576', 'ENSG00000142319', 'ENSG00000103546']",3,,,,,,,,,,
CHEMBL3545308,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,HUFOZJXAKZVRNJ-UHFFFAOYSA-N,Small molecule,False,ROCILETINIB,3.0,False,False,[],"['AVL-301', 'CNX-419', 'CO-1686', 'CS-1631', 'Rociletinib']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB11907'],"['EFO_0003060', 'EFO_0000616']",2.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL4650521,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N,UCJZOKGUEJUNIO-IINYFYTJSA-N,Small molecule,False,BATOPROTAFIB,2.0,False,False,[],"['Batoprotafib', 'Ptpn11 inhibitor tno155', 'Shp2 inhibitor tno155', 'TNO-155', 'TNO155', 'Tno 155', 'Tno-155', 'Tno155']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0000616'],1.0,['ENSG00000179295'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-127']
CHEMBL538943,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,CILBMBUYJCWATM-UDRBCWGGSA-N,Small molecule,True,VINORELBINE TARTRATE,4.0,False,True,"['Navelbine', 'Vinorelbine tartrate']","['Liposomal vinorelbine tartrate', 'TLC-178', 'TLC178', 'Vinorelbine (as tartrate)', 'Vinorelbine Ditartarate', 'Vinorelbine ditartrate', 'Vinorelbine liposomal', 'Vinorelbine tartrate', 'Vinorelbine tartrate (1:2)']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 28 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000571', 'EFO_0003060', 'EFO_0000211', 'EFO_0000691', 'EFO_0006861', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0000588', 'EFO_0000183', 'MONDO_0021063', 'EFO_0000313', 'MONDO_0008315', 'EFO_0000437', 'MONDO_0007254', 'MONDO_0002367', 'EFO_0000616', 'EFO_0000621', 'EFO_0000248', 'EFO_1000158', 'MONDO_0001187', 'EFO_0003869', 'EFO_0000565', 'MONDO_0008903', 'EFO_0001416', 'MONDO_0001402', 'MONDO_0011962', 'EFO_0005952', 'EFO_0000574']",28.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,1994.0,CHEMBL553025,,"['144205824', '170465330']",,,,,,
CHEMBL668,CNCCCC1c2ccccc2C=Cc2ccccc21,BWPIARFWQZKAIA-UHFFFAOYSA-N,Small molecule,True,PROTRIPTYLINE,4.0,False,True,[],['Protriptyline'],['CHEMBL1200332'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for unipolar depression and depressive disorder. This drug has a black box warning from the FDA.,['Protriptyline'],['DB00344'],"['EFO_0003761', 'MONDO_0002050']",2.0,"['ENSG00000103546', 'ENSG00000108576']",2,1967.0,,,"['11111679', '11111680', '50100330', '50104299', '90341254']",['8597'],,,,,
CHEMBL86304,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,YHXISWVBGDMDLQ-UHFFFAOYSA-N,Small molecule,False,MOCLOBEMIDE,4.0,False,True,['Manerix'],"['Aurorix', 'GNF-PF-695', 'Moclobemide', 'RO 11-1163/000', 'RO-111163000']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for depressive disorder and unipolar depression and has 5 investigational indications.,['Moclobemide'],['DB01171'],"['EFO_0003768', 'EFO_0005230', 'HP_0000726', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0003761', 'EFO_0003890']",7.0,['ENSG00000189221'],1,1990.0,,,"['104171398', '144204522', '144207163', '170465663', '50086440', '50105006', '50105007', '846440', '90340853']",['83531'],,,,,
CHEMBL1008,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,UIEATEWHFDRYRU-UHFFFAOYSA-N,Small molecule,False,BEPRIDIL,4.0,False,True,[],"['Bepadin', 'Bepridil', 'Vascor']","['CHEMBL1257078', 'CHEMBL1200382']",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for cardiovascular disease.,['Bepridil'],['DB01244'],['EFO_0000319'],1.0,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",26,1990.0,,,"['104171114', '124879417', '124879419', '144203640', '170465240', '26755663', '26755664', '50110980', '90341574']",['3061'],,,,,
CHEMBL119625,O=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21,SPXYHZRWPRQLNS-UHFFFAOYSA-N,Small molecule,False,ZONAMPANEL,2.0,False,False,[],"['YM 872 ANHYDROUS', 'YM-872', 'YM-872 ANHYDROUS', 'YM872', 'YM872 ANHYDROUS', 'Ym 872', 'Zonampanel', 'Zonampanel anhydrous', 'Zonampanel monohydrate']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['HP_0002140', 'EFO_0000712']",2.0,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,,,,
CHEMBL1200494,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,DGFYECXYGUIODH-UHFFFAOYSA-N,Small molecule,False,GUANFACINE HYDROCHLORIDE,4.0,False,True,"['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']","['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hcl', 'Guanfacine hydrochloride', 'SPD503']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for hypertension and attention deficit hyperactivity disorder.,,,"['EFO_0000537', 'EFO_0003888']",2.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1986.0,CHEMBL862,['guanfacine%20hydrochloride'],"['11532959', '144203710', '170465381', '50106306', '56422899']",,['https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv'],,,,
CHEMBL1479,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,POZRVZJJTULAOH-LHZXLZLDSA-N,Small molecule,True,DANAZOL,4.0,False,True,"['Danazol', 'Danocrine']","['Danazol', 'NSC-270916', 'WIN 17,757', 'WIN-17757']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for endometriosis and breast fibrocystic disease and has 10 investigational indications. This drug has a black box warning from the FDA.,['Danazol'],['DB01406'],"['EFO_1001366', 'EFO_0007160', 'MONDO_0018896', 'MONDO_0015780', 'EFO_0001065', 'EFO_0000198', 'MONDO_0011962', 'EFO_0000545', 'MONDO_0019098', 'HP_0001915', 'EFO_0003014', 'MONDO_0019391']",12.0,"['ENSG00000082175', 'ENSG00000169083']",2,1976.0,,['danazol'],"['144205667', '144212257', '170464884', '26757819', '49648394']",['4315'],,,['127'],,
CHEMBL1762621,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,WPTTVJLTNAWYAO-KPOXMGGZSA-N,Small molecule,False,BARDOXOLONE METHYL,3.0,False,False,[],"['Bardoxolone methyl', 'Bardoxolone methyl ester', 'CDDO-METHYL ESTER', 'CDDO-Me', 'NSC 713200', 'NSC-713200', 'RTA 402', 'RTA-402', 'RTA402', 'Rta-402']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,['DB05983'],"['EFO_1001496', 'EFO_0000756', 'MONDO_0100096', 'EFO_0000401', 'EFO_0003884', 'EFO_0002618', 'MONDO_0018965', 'EFO_0001642', 'EFO_0001421', 'EFO_0001361', 'MONDO_0005149']",11.0,"['ENSG00000132170', 'ENSG00000116044', 'ENSG00000079999', 'ENSG00000104365']",4,,,,"['144206780', '532003']",,,,,,
CHEMBL2062257,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,QZHBYNSSDLTCRG-UHFFFAOYSA-N,Small molecule,False,BRIMONIDINE TARTRATE,4.0,False,True,"['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'Lumify', 'Mirvaso', 'Qoliana']","['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrate', 'Brimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300', 'OCU300', 'UK-14304-18', 'UK-1430418']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 8 investigational indications.,,,"['MONDO_0021698', 'EFO_0004190', 'EFO_1000906', 'EFO_0000537', 'EFO_1001893', 'MONDO_0001330', 'MONDO_0005041', 'HP_0000951', 'EFO_0003822', 'EFO_1000879', 'HP_0010783', 'EFO_1000760', 'HP_0031284', 'EFO_1001069', 'EFO_0007141']",15.0,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']",3,1996.0,CHEMBL844,['brimonidine%20tartrate'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso'],,,,
CHEMBL3109738,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3,JXDYOSVKVSQGJM-UHFFFAOYSA-N,Small molecule,False,JNJ-26483327,1.0,False,False,[],"['JNJ 26483327', 'JNJ-26483327', 'Jnj-26483327']",,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,,['MONDO_0004992'],1.0,"['ENSG00000178568', 'ENSG00000010810', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000141736', 'ENSG00000197122', 'ENSG00000146648', 'ENSG00000254087', 'ENSG00000037280']",9,,,,,,,,,,
CHEMBL3673452,COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)cnc43)cc2OC)cc1,HVRWZFQFSQUILC-UHFFFAOYSA-N,Small molecule,False,GZ-389988,2.0,False,False,[],"['GZ-389988', 'GZ389988', 'Gz-389988', 'Gz389988']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['MONDO_0005178'],1.0,['ENSG00000198400'],1,,,,,,,,,,
CHEMBL4298126,,,Unknown,False,VON WILLEBRAND FACTOR HUMAN,4.0,False,True,[],"['Human von willebrand factor', 'Von willebrand factor', 'Von willebrand factor (human)', 'Von willebrand factor human', 'Von willebrand factor, human', ""Von willebrand's factor""]",,Unknown drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 3 investigational indications.,,,"['MONDO_0024574', 'Orphanet_903', 'MP_0001914', 'EFO_0009579']",4.0,['ENSG00000110799'],1,,,,,,,,,,
CHEMBL4298211,,,Protein,True,PEGCETACOPLAN,4.0,False,True,"['Aspaveli', 'Empaveli']","['APL-2', 'Pegcetacoplan', 'Syfovre']",,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for paroxysmal nocturnal hemoglobinuria and immune system disease and has 7 investigational indications. This drug has a black box warning from the FDA.,,,"['MONDO_0019737', 'MONDO_0100244', 'MONDO_0004976', 'EFO_0000540', 'EFO_1001492', 'MONDO_0018922', 'MONDO_0019736', 'MONDO_0100244', 'EFO_0001365']",9.0,['ENSG00000125730'],1,2021.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli'],['https://searchusan.ama-assn.org/finder/usan/search/PEGCETACOPLAN/relevant/1/'],,,
CHEMBL4299940,O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1,XAYGBKHKBBXDAK-UHFFFAOYSA-N,Small molecule,False,MITAPIVAT,4.0,False,True,[],"['AG-348', 'Ag-348', 'Mitapivat', 'Pkr-in-1']",['CHEMBL4297223'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 6 investigational indications.,,,"['MONDO_0003689', 'MONDO_0002280', 'Orphanet_846', 'EFO_0000508', 'EFO_0004272', 'MONDO_0011382', 'EFO_1001996', 'Orphanet_848', 'EFO_0001421']",9.0,['ENSG00000143627'],1,2022.0,,,,,,,,,
CHEMBL4650276,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1,KRBMOYIWQCZVHA-INIZCTEOSA-N,Small molecule,False,SHR3680,3.0,False,False,[],"['Rezvilutamide', 'SHR3680', 'Shr3680']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,,"['MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0001421', 'EFO_0005537']",5.0,['ENSG00000169083'],1,,,,,,,,,,
CHEMBL4650989,C[C@@H](N)COc1ccc(-c2cnc3ccc(N[C@H](C)c4cccc(F)c4)nn23)cc1,HEVHTYMYEMEBPX-HZPDHXFCSA-N,Small molecule,False,TALETRECTINIB,2.0,False,False,[],"['AB-106', 'Ab-106', 'DS-6051', 'DS-6051a', 'Taletrectinib']",['CHEMBL4650361'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_0003060', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000616']",4.0,"['ENSG00000047936', 'ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TALETRECTINIB/relevant/1/'],,,
CHEMBL1200586,CCCNC(C)C(=O)Nc1ccccc1C.Cl,BJPJNTKRKALCPP-UHFFFAOYSA-N,Small molecule,False,PRILOCAINE HYDROCHLORIDE,4.0,False,True,"['Citanest', 'Citanest plain', 'Citanest plain dental', 'Prilocaine hydrochloride']","['ASTRA 1512', 'Citanest hydrochloride', 'L-67', 'NSC-758432', 'Prilocaine hcl', 'Prilocaine hydrochloride', 'Propitocaine hydrochloride', 'Xylonest']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965.,,,,,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1965.0,CHEMBL1194,['prilocaine%20hydrochloride'],"['11532855', '144204064', '170464697', '50106902']",['32053'],,,,,
CHEMBL1201476,,,Oligosaccharide,True,ENOXAPARIN SODIUM,4.0,False,True,"['Clexane', 'Enoxaparin sodium', 'Enoxaparin sodium (preservative free)', 'Inhixa', 'Lovenox', 'Lovenox (preservative free)']","['Enoxaparin', 'Enoxaparin sodium', 'Enoxaparin sodium salt', 'Klexane', 'PK 10169', 'PK-10169', 'RP 54563', 'RP-54563']",,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 28 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000275', 'EFO_0000616', 'EFO_0003964', 'MONDO_0008170', 'EFO_0000495', 'EFO_0005681', 'EFO_0005672', 'EFO_0000702', 'HP_0004936', 'MP_0001914', 'HP_0004419', 'EFO_0009314', 'EFO_1001375', 'EFO_0004255', 'MONDO_0000831', 'EFO_0003827', 'EFO_0000712', 'EFO_0000612', 'MONDO_0100096', 'EFO_1000954', 'HP_0001907', 'MONDO_0021148', 'EFO_0003086', 'EFO_0003907', 'EFO_0003060', 'EFO_0002916', 'EFO_0001422', 'EFO_0002618', 'EFO_0001073', 'EFO_0008583', 'MONDO_0004992', 'EFO_0004286', 'EFO_1000985', 'EFO_0008585', 'EFO_0000574', 'EFO_0000544']",36.0,['ENSG00000117601'],1,1993.0,,['enoxaparin%20sodium'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa'],,,['4879'],
CHEMBL1286,CC[C@@H](C(N)=O)N1CCCC1=O,HPHUVLMMVZITSG-LURJTMIESA-N,Small molecule,False,LEVETIRACETAM,4.0,False,True,"['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'Levetiracetam', 'Levetiracetam in sodium chloride', 'Levetiracetam teva', 'Matever', 'Spritam']","['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accord', 'Levetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sun', 'Levetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059', 'UCB L059', 'UCB-22059', 'UCB-L059']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 39 investigational indications.,['Levetiracetam'],['DB01202'],"['HP_0000473', 'EFO_0004270', 'EFO_0003833', 'MONDO_0005180', 'MONDO_0007079', 'MONDO_0002046', 'EFO_0004777', 'MONDO_0010079', 'EFO_0003108', 'EFO_0009562', 'MONDO_0005090', 'EFO_0000621', 'EFO_1000904', 'EFO_0000712', 'HP_0001250', 'EFO_0002610', 'EFO_0005543', 'HP_0002069', 'HP_0000726', 'EFO_0001358', 'EFO_0004263', 'MONDO_0002050', 'MONDO_0015643', 'EFO_0005407', 'EFO_0005230', 'EFO_0000326', 'EFO_0004280', 'EFO_0004262', 'EFO_0004242', 'HP_0100543', 'MONDO_0004975', 'HP_0002121', 'MONDO_0041052', 'HP_0007359', 'EFO_0007262', 'MONDO_0011382', 'EFO_0005611', 'EFO_0008526', 'HP_0002381', 'EFO_0000713', 'EFO_0000222', 'EFO_0000474', 'EFO_0000519', 'MONDO_0004985']",44.0,"['ENSG00000148408', 'ENSG00000159164']",2,1999.0,,['levetiracetam'],"['26719810', '90341134']",['6437'],['https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-teva'],,,,
CHEMBL1456,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,RTGDFNSFWBGLEC-SYZQJQIISA-N,Small molecule,True,MYCOPHENOLATE MOFETIL,4.0,False,True,"['Arzip', 'Cellcept', 'Myclausen', 'Mycophenolate mofetil', 'Myfenax']","['Myclausen', 'Mycophenolate mofetil', 'Mycophenolic acid 2-(4-morpholinyl)ethyl ester', 'Mycophenylate mofetil', 'NSC-724229', 'NSC-758905', 'RS-61443']",['CHEMBL1200955'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 126 investigational indications. This drug has a black box warning from the FDA.,['Mycophenolate_mofetil'],['DB00688'],"['EFO_0000404', 'EFO_0000519', 'EFO_1000784', 'EFO_0004719', 'EFO_1000309', 'EFO_0000220', 'MONDO_0019469', 'EFO_1000965', 'EFO_0004826', 'MONDO_0002334', 'EFO_0000681', 'EFO_0000616', 'EFO_0002618', 'EFO_0003777', 'MONDO_0002367', 'EFO_0000565', 'MONDO_0044881', 'EFO_1001779', 'EFO_0000255', 'EFO_0000211', 'MONDO_0021193', 'EFO_0003032', 'EFO_0004228', 'EFO_0004236', 'EFO_1000560', 'MONDO_0000870', 'MONDO_0010518', 'Orphanet_79292', 'EFO_0000676', 'EFO_0006803', 'EFO_0000319', 'EFO_0000389', 'MONDO_0015253', 'EFO_1002048', 'EFO_0000339', 'EFO_1001857', 'EFO_0006927', 'EFO_0004251', 'MONDO_0007915', 'MONDO_0001705', 'EFO_0004256', 'MONDO_0018906', 'HP_0001915', 'MONDO_0019391', 'EFO_0000574', 'HP_0001871', 'EFO_0004991', 'EFO_0000699', 'EFO_0007196', 'EFO_0000764', 'EFO_0002428', 'EFO_0000318', 'EFO_1001469', 'EFO_1001051', 'MONDO_0004976', 'DOID_13406', 'Orphanet_848', 'EFO_0000621', 'MONDO_0019471', 'EFO_0003047', 'MONDO_0013730', 'EFO_0000191', 'EFO_0004244', 'EFO_0005952', 'EFO_0001365', 'HP_0002721', 'EFO_0000401', 'EFO_0003086', 'EFO_1000785', 'MONDO_0005147', 'EFO_0004274', 'EFO_0000685', 'MONDO_0044903', 'EFO_1001231', 'EFO_1001017', 'EFO_0000096', 'EFO_1000680', 'MONDO_0015760', 'EFO_0000309', 'EFO_0000384', 'EFO_0000198', 'EFO_0000537', 'EFO_0000182', 'EFO_0004255', 'MONDO_0005301', 'EFO_0005297', 'EFO_0002430', 'EFO_0001062', 'MONDO_0009387', 'EFO_0000095', 'EFO_0002429', 'MONDO_0000873', 'EFO_0004194', 'EFO_0001378', 'MONDO_0015974', 'EFO_1000956', 'MONDO_0009833', 'EFO_0003884', 'EFO_1000690', 'EFO_0001642', 'EFO_1000318', 'MONDO_0100244', 'MONDO_0011382', 'EFO_0000222', 'MONDO_0019472', 'EFO_0005140', 'EFO_0000717', 'EFO_1001345', 'MONDO_0018923', 'EFO_0000702', 'EFO_0000403', 'EFO_0004599', 'MONDO_0020547', 'EFO_0009441', 'EFO_0004254', 'EFO_0007187', 'EFO_0007160', 'EFO_0000183', 'EFO_0007359', 'EFO_0005761', 'EFO_0001421', 'EFO_1000102', 'EFO_0008507', 'MONDO_0019262', 'EFO_1001465', 'MONDO_0004992']",126.0,"['ENSG00000106348', 'ENSG00000178035']",2,1995.0,,['mycophenolate%20mofetil'],"['144205239', '170464859', '29215409']",['8764'],['https://www.ema.europa.eu/en/medicines/human/EPAR/myclausen'],,,,
CHEMBL1615439,C[C@H]1[C@H](c2ccccc2)OCCN1C,MFOCDFTXLCYLKU-CMPLNLGQSA-N,Small molecule,False,PHENDIMETRAZINE,4.0,False,True,[],"['NSC-169187', 'Phendimetrazine']",['CHEMBL2062163'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for obesity.,,['DB01579'],['EFO_0001073'],1.0,"['ENSG00000142319', 'ENSG00000103546']",2,1976.0,,,,['8059'],,,,,
CHEMBL2103863,CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12,MAUCONCHVWBMHK-UHFFFAOYSA-N,Small molecule,False,ABEXINOSTAT,3.0,False,False,[],"['Abexinostat', 'CRA 024781', 'CRA 24781', 'CRA-024781', 'PCI 24781', 'PCI-24781', 'PZP-115891', 'PZP115891', 'S-78454', 'S78454']",['CHEMBL2105727'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,['DB12565'],"['MONDO_0018906', 'EFO_0005952', 'EFO_0000616', 'EFO_0000691', 'EFO_0000681', 'EFO_0000183', 'EFO_0000403']",7.0,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']",11,,,,,,,,,,
CHEMBL3545235,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(CC2)C2(C1)OCCO2,OXWUWXCJDBRCCG-UHFFFAOYSA-N,Small molecule,False,SIMOTINIB,3.0,False,False,[],"['Sim-6802', 'Simotinib']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['EFO_0003060'],1.0,['ENSG00000146648'],1,,,,,,,,,,
CHEMBL4650326,C(=C/c1cccs1)\c1cc[nH]n1,FOHWAQGURRYJFK-ONEGZZNKSA-N,Small molecule,False,TEREVALEFIM,3.0,False,False,[],"['ANG-3777', 'Ang-3777', 'BB3', 'Refanalin', 'SNV-003', 'Terevalefim']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['HP_0001919', 'MONDO_0002492']",2.0,['ENSG00000105976'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/TEREVALEFIM/relevant/1/'],,,
CHEMBL539770,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl,RNGHAJVBYQPLAZ-UHFFFAOYSA-N,Small molecule,False,TERODILINE HYDROCHLORIDE,4.0,True,True,"['Micturin 12.5', 'Micturin 25']",['Terodiline hydrochloride'],,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. It was withdrawn in at least one region.,,,,,"['ENSG00000133019', 'ENSG00000180720', 'ENSG00000168539', 'ENSG00000181072', 'ENSG00000184984', 'ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']",31,1986.0,CHEMBL363295,,['144206962'],,,,,,
CHEMBL7413,C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O,NZXKDOXHBHYTKP-UHFFFAOYSA-N,Small molecule,True,METHOHEXITAL,4.0,False,True,[],"['Methohexital', 'Methohexital civ', 'Methohexitone']",['CHEMBL30219'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA.,['Methohexital'],['DB00474'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1960.0,,,,['102216'],,,,,
CHEMBL750,NS(=O)(=O)Cc1noc2ccccc12,UBQNRHZMVUUOMG-UHFFFAOYSA-N,Small molecule,False,ZONISAMIDE,4.0,False,True,"['Zonegran', 'Zonisade', 'Zonisamide']","['AD-810', 'CI-912', 'Excegran', 'N03AX15', 'PD-110843', 'Zonisade', 'Zonisamide']","['CHEMBL1514931', 'CHEMBL1596271']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 16 investigational indications.,['Zonisamide'],['DB00909'],"['EFO_0004238', 'EFO_0003768', 'HP_0001250', 'EFO_0004319', 'MONDO_0002046', 'EFO_0001073', 'MONDO_0005090', 'EFO_0003108', 'EFO_0000474', 'EFO_0004566', 'HP_0007359', 'MONDO_0005180', 'MONDO_0007079', 'EFO_0005203', 'EFO_0004263', 'EFO_1001254', 'MONDO_0005277', 'EFO_0005411', 'EFO_0002610', 'EFO_1000877']",20.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,2000.0,,['zonisamide'],"['144205122', '49666067', '90341782']",['10127'],['https://www.ema.europa.eu/en/medicines/human/EPAR/zonegran'],,,,
CHEMBL1090771,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(-c2ncon2)cc1F)S(=O)(=O)c1ccc(Cl)cc1,XEAOPVUAMONVLA-QGZVFWFLSA-N,Small molecule,False,AVAGACESTAT,2.0,False,False,[],"['Avagacestat', 'BMS 708163', 'BMS-708163', 'BMS-708163-01', 'BMS-70816301', 'BMS708163']",,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,['DB11893'],['MONDO_0004975'],1.0,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']",6,,,,,,,,,,
CHEMBL119549,O=C(Nc1ccc(-c2nnn[nH]2)cc1)c1ccc(-c2nnn[nH]2)cc1,VXEBMQZDPONDFB-UHFFFAOYSA-N,Small molecule,False,ANDOLAST,2.0,False,False,[],"['Andolast', 'Cr2039']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000156113'],1,,,,,,,,,,
CHEMBL1201528,,,Protein,False,VASOPRESSIN TANNATE,4.0,False,True,['Pitressin tannate'],['Vasopressin tannate'],,Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000166148', 'ENSG00000126895', 'ENSG00000198049']",3,1982.0,,,,,,,,,
CHEMBL2079587,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,Small molecule,False,STANOZOLOL,4.0,False,True,"['Stromba', 'Tevabolin', 'Winstrol']","['Androstanazol', 'Androstanazole', 'NSC-233046', 'NSC-43193', 'Stanozolol', 'Stanozolol ciii', 'WIN 14833', 'WIN-14833', 'Winstrol', 'Winstrol Depot']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962 and has 1 investigational indication.,,['DB06718'],['EFO_0000198'],1.0,['ENSG00000169083'],1,1962.0,,,['170465251'],['9249'],,,,,
CHEMBL2104745,CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1,HIUPRQPBWVEQJJ-UHFFFAOYSA-N,Small molecule,False,PAGOCLONE,2.0,False,False,[],"['CI-1043', 'IP 456', 'IP-456', 'Pagoclone', 'RP 62955', 'RP-62955']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB04903'],"['EFO_0803321', 'HP_0025268']",2.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,,,,,,,,,,
CHEMBL2106798,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,CLUKHUGGXSIGRX-UHFFFAOYSA-N,Small molecule,False,NERAMEXANE MESYLATE,3.0,False,False,[],"['Neramexane mesilate', 'Neramexane mesylate']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['HP_0000360'],1.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785', 'ENSG00000174343', 'ENSG00000129749']",9,,CHEMBL2110954,,,,,,,,
CHEMBL2108035,,,Unknown,True,INCOBOTULINUMTOXINA,4.0,False,True,[],"['Incobotulinumtoxina', 'RTI-150', 'RTI150']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 18 investigational indications. This drug has a black box warning from the FDA.,,,"['HP_0025267', 'EFO_0003108', 'HP_0012076', 'EFO_0003843', 'MONDO_0005180', 'EFO_0004191', 'HP_0000473', 'EFO_0003877', 'MONDO_0000396', 'MONDO_0003441', 'EFO_1001219', 'EFO_0000712', 'MONDO_0011728', 'Orphanet_93955', 'HP_0001257', 'HP_0001337', 'EFO_1000783', 'EFO_1000781', 'EFO_1000760']",19.0,['ENSG00000132639'],1,2010.0,,,,,,,,,
CHEMBL3989682,CN(CP(=O)(O)O)c1cc([N+](=O)[O-])cc2[nH]c(=O)c(=O)[nH]c12,DDOAQMGXVXFNSH-UHFFFAOYSA-N,Small molecule,False,BECAMPANEL,2.0,False,False,[],"['AMP-397', 'AMP397', 'Becampanel']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,,,,
CHEMBL4297951,,,Unknown,False,COAGULATION FACTOR X HUMAN,4.0,False,True,['Coagadex'],"['Coagulation factor x', 'Coagulation factor x human', 'Coagulation factor x, human', 'Factor x', 'Human coagulation factor x', 'Human factor x']",,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for hemorrhage and factor x deficiency.,,,"['MP_0001914', 'MONDO_0002247']",2.0,['ENSG00000126218'],1,2016.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/coagadex'],,,,
CHEMBL4297987,,,Antibody drug conjugate,False,ENAPOTAMAB VEDOTIN,2.0,False,False,[],"['Axl-107-mmae', 'Enapotamab vedotin', 'Humax axl adc', 'Humax-axl-adc']",,Antibody drug conjugate drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000167601']",16,,,,,,,,,,
CHEMBL571546,O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,HUNGUWOZPQBXGX-UHFFFAOYSA-N,Small molecule,False,TIRBANIBULIN,4.0,False,True,['Klisyri'],"['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']",['CHEMBL4594279'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for actinic keratosis and has 5 investigational indications.,,['DB06137'],"['EFO_0000574', 'EFO_0000222', 'EFO_0000616', 'EFO_0004193', 'EFO_0002496', 'EFO_0000616', 'MONDO_0008315']",7.0,['ENSG00000197122'],1,2020.0,,,['164339429'],,['https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri'],['https://searchusan.ama-assn.org/finder/usan/search/TIRBANIBULIN/relevant/1/'],,,
CHEMBL576982,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,CVWXJKQAOSCOAB-UHFFFAOYSA-N,Small molecule,True,QUIZARTINIB,4.0,False,True,[],"['AC-010220', 'AC-220', 'AC010220', 'AC220', 'ASP-2689', 'Ac-220', 'Quizartinib']",['CHEMBL2105709'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for acute myeloid leukemia and has 5 investigational indications. This drug has a black box warning from the FDA.,,['DB12874'],"['EFO_0001421', 'EFO_0000220', 'EFO_0000198', 'EFO_0000222', 'EFO_0000616', 'EFO_0000222']",6.0,"['ENSG00000182578', 'ENSG00000165731', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000122025', 'ENSG00000157404']",6,2023.0,,,['137275856'],['90217'],,,,,
CHEMBL783,CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,OELFLUMRDSZNSF-BRWVUGGUSA-N,Small molecule,False,NATEGLINIDE,4.0,False,True,"['Nateglinide', 'Starlix', 'Starsis']","['A-4166', 'AY-4166', 'AY4166', 'D-nateglinide', 'DJN 608', 'DJN-608', 'NSC-758695', 'Nateglinide', 'SDZ DJN 608', 'SDZ-DJN-608', 'Senaglinide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for type 2 diabetes mellitus and diabetes mellitus.,,['DB00731'],"['MONDO_0005148', 'EFO_0000400']",2.0,"['ENSG00000187486', 'ENSG00000006071']",2,2000.0,,['nateglinide'],"['144204985', '170464822', '26719880']",['31897'],['https://www.ema.europa.eu/en/medicines/human/EPAR/starlix'],,,,
CHEMBL1200895,NNCCc1ccccc1.O=S(=O)(O)O,RXBKMJIPNDOHFR-UHFFFAOYSA-N,Small molecule,True,PHENELZINE SULFATE,4.0,False,True,"['Nardil', 'Phenelzine sulfate']","['NSC-170957', 'Phenelzine acid sulfate', 'Phenelzine sulfate', 'Phenelzine sulphate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000673', 'MONDO_0007254']",2.0,"['ENSG00000189221', 'ENSG00000069535']",2,1961.0,CHEMBL1089,['phenelzine%20sulfate'],"['11533068', '144203787', '144207332', '170465229', '26747636', '26747637', '49681616', '50106853']",['8061'],,,,,
CHEMBL1200984,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=C(O)/C=C\C(=O)O,TZNOWAJJWCGILX-BTJKTKAUSA-N,Small molecule,False,AMLODIPINE MALEATE,4.0,False,True,['Amvaz'],"['Amlodipine maleate', 'UK-48,340-11', 'UK-48340-11']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003.,,,,,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,2003.0,CHEMBL1491,,,,,,,,
CHEMBL2104964,Cc1ccc(S(=O)(=O)O)cc1.Clc1ccc(OC[C@H]2CCN2)cn1,JCPWIGCGJUGLJQ-OGFXRTJISA-N,Small molecule,False,TEBANICLINE TOSYLATE,2.0,False,False,[],"['A-165594', 'A-166594.47', 'A-16659447', 'ABT-165594', 'ABT-594', 'Ebanicline tosylate', 'Tebanicline tosilate', 'Tebanicline tosylate']",,Small molecule drug with a maximum clinical trial phase of II.,,,,,"['ENSG00000160716', 'ENSG00000101204']",2,,CHEMBL430497,,,,,,,,
CHEMBL2107831,CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC,NOZIJMHMKORZBA-KJCUYJGMSA-N,Small molecule,False,LUSUTROMBOPAG,4.0,False,True,"['Mulpleo (previously lusutrombopag shionogi)', 'Mulpleta', 'S-888711']","['Lusutrombopag', 'RSC888711', 'S-888711']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for thrombocytopenia and hemorrhage and has 1 investigational indication.,,['DB13125'],"['HP_0001873', 'EFO_0007160', 'MP_0001914']",3.0,['ENSG00000117400'],1,2018.0,,['lusutrombopag'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo'],,,,
CHEMBL2109410,,,Antibody,False,TB-402,2.0,False,False,[],"['TB-402', 'Tb-402']",,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,,['EFO_0004286'],1.0,['ENSG00000185010'],1,,,,,,,,,,
CHEMBL2181927,CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2,BTBHLEZXCOBLCY-QGZVFWFLSA-N,Small molecule,False,FINERENONE,4.0,False,True,['Kerendia'],"['BAY 94-8862', 'BAY-94-8862', 'Bay94-8862', 'Finerenone']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications.,,,"['EFO_0003884', 'EFO_0000401', 'MONDO_0005148', 'EFO_0000319', 'EFO_0003144']",5.0,['ENSG00000151623'],1,2021.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia'],,,,
CHEMBL3545414,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,FYJROXRIVQPKRY-UHFFFAOYSA-N,Small molecule,False,RIVOCERANIB MESYLATE,3.0,False,False,['Aitan'],"['Apatinib (registered name in China)', 'Apatinib mesylate', 'Rivoceranib mesylate', 'YN-968D1', 'Yn-968d1']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 62 investigational indications.,,,"['EFO_1000359', 'EFO_0004252', 'EFO_0000231', 'MONDO_0007254', 'EFO_0001061', 'EFO_0000756', 'EFO_0000702', 'MONDO_0008170', 'EFO_0000178', 'EFO_0006859', 'EFO_1001968', 'EFO_0005221', 'MONDO_0003060', 'MONDO_0002120', 'EFO_0004142', 'MONDO_0001056', 'EFO_0003868', 'EFO_1001951', 'MONDO_0004992', 'EFO_0000182', 'EFO_0000313', 'EFO_0000571', 'MONDO_0008903', 'EFO_1001961', 'MONDO_0021063', 'EFO_1001956', 'EFO_0002939', 'EFO_0001071', 'EFO_0005537', 'MONDO_0100342', 'EFO_0000199', 'MONDO_0002108', 'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869', 'HP_0001541', 'MONDO_0002974', 'EFO_0003891', 'EFO_0000637', 'EFO_0002916', 'EFO_0005543', 'EFO_0003897', 'EFO_0000181', 'EFO_0000616', 'EFO_0005922', 'EFO_0000691', 'EFO_0000621', 'EFO_0003893', 'MONDO_0018944', 'EFO_0000707', 'EFO_0000211', 'MONDO_0007576', 'EFO_0002618', 'EFO_1002017', 'EFO_0009708', 'EFO_0000365', 'EFO_0000574', 'EFO_0000503', 'EFO_0003860', 'EFO_0000681', 'MONDO_0008315']",62.0,['ENSG00000128052'],1,,CHEMBL3186534,,,,,,,,
CHEMBL3900554,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,ZRYMMWAJAFUANM-INIZCTEOSA-N,Small molecule,False,BMS-986142,2.0,False,False,[],['Bms-986142'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,['DB15291'],"['EFO_0000685', 'MONDO_0005178']",2.0,['ENSG00000010671'],1,,,,,,,,,,
CHEMBL5095022,CC(C)S(=O)(=O)N[C@H]1COC[C@H]1Oc1ccc(-c2ccc(C#N)s2)cc1,TTYKUKSFWHEBLI-DLBZAZTESA-N,Small molecule,False,PESAMPATOR,2.0,False,False,[],"['BIIB-104', 'BIIB104', 'PF-04958242', 'PF-4958242', 'Pesampator', 'Pf-04958242']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,,"['EFO_1001176', 'EFO_0000677', 'HP_0001268', 'MONDO_0005090']",4.0,"['ENSG00000152578', 'ENSG00000125675', 'ENSG00000120251', 'ENSG00000155511']",4,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/PESAMPATOR/relevant/1/'],,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL957,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,GJPICJJJRGTNOD-UHFFFAOYSA-N,Small molecule,True,BOSENTAN,4.0,False,True,"['Stayveer', 'Tracleer']","['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrate', 'Bosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']",['CHEMBL175616'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA.,['Bosentan'],['DB00559'],"['EFO_1001103', 'EFO_0000537', 'EFO_0000768', 'EFO_0000373', 'EFO_0003877', 'HP_0001945', 'EFO_0000616', 'EFO_1000809', 'EFO_1001346', 'EFO_0009200', 'EFO_0001361', 'EFO_0001422', 'EFO_0000717', 'MONDO_0004979', 'EFO_0002618', 'MONDO_0004933', 'MONDO_0005148', 'MONDO_0007172', 'EFO_0000400', 'MONDO_0005149', 'EFO_0005207', 'EFO_0005207', 'MONDO_0043839', 'EFO_0000341', 'EFO_0000756', 'MONDO_0005041', 'EFO_0007372']",27.0,"['ENSG00000136160', 'ENSG00000151617']",2,2001.0,,['bosentan'],"['144205997', '170465245']",['51450'],"['https://www.ema.europa.eu/en/medicines/human/EPAR/stayveer', 'https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer']",,,,
CHEMBL1201082,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl,GIYXAJPCNFJEHY-UHFFFAOYSA-N,Small molecule,True,FLUOXETINE HYDROCHLORIDE,4.0,False,True,"['Felicium', 'Fluoxetine', 'Fluoxetine hydrochloride', 'Olena', 'Oxactin', 'Prozac', 'Prozac 60', 'Prozac weekly', 'Prozep', 'Prozit', 'Ranflutin', 'Reconcile', 'Sarafem', 'Selfemra']","['Adofen', 'Fluctin', 'Fluneurin', 'Fluox-puren', 'Fluoxeren', 'Fluoxetine (as hydrochloride)', 'Fluoxetine hydrochloride', 'Flusol', 'Fluxet', 'Fontex', 'Foxetin', 'LY-110140', 'LY110140', 'Lovan', 'Reconcile']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0004242', 'EFO_0004262', 'EFO_0009963', 'MONDO_0004985', 'EFO_0003761', 'MONDO_0002009', 'MONDO_0002050']",7.0,['ENSG00000108576'],1,1987.0,CHEMBL41,['fluoxetine%20hydrochloride'],"['144207380', '26747522', '26747523', '50106352', '50106353', '50106354', '56422172', '855820']",,['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/reconcile'],,,,
CHEMBL1337,O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-],OUBCNLGXQFSTLU-UHFFFAOYSA-N,Small molecule,False,NITISINONE,4.0,False,True,"['Nityr', 'Orfadin']","['Nitisinone', 'SC-0735']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for tyrosinemia and has 2 investigational indications.,['Nitisinone'],['DB00348'],"['MONDO_0004741', 'MONDO_0008753', 'MONDO_0043209']",3.0,['ENSG00000158104'],1,2002.0,,['nitisinone'],['174007248'],['50378'],['https://www.ema.europa.eu/en/medicines/human/EPAR/nityr'],,,,
CHEMBL1418176,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,XWALNWXLMVGSFR-HLXURNFRSA-N,Small molecule,False,METHANDROSTENOLONE,4.0,True,True,['Dianabol'],"['Metandienone', 'Methandienone', 'Methandrostenolone', 'NSC-42722', 'Nerobol', 'Perbolin']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,['Methandrostenolone'],['DB13586'],,,['ENSG00000169083'],1,,,,"['144205200', '170466069', '29215353']",,,,,,
CHEMBL1708,Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,GELRVIPPMNMYGS-RVXRQPKJSA-N,Small molecule,True,PAROXETINE HYDROCHLORIDE,4.0,False,True,"['Paroxetine hydrochloride', 'Paxil', 'Paxil cr', 'Seroxat']","['NSC-758654', 'Paroxetine HCl', 'Paroxetine hydrochloride', 'Paroxetine hydrochloride anhydrous']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 7 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0003761', 'MONDO_0002009', 'EFO_0006788', 'EFO_0001358', 'EFO_0004262', 'EFO_0803321', 'EFO_0005230', 'MONDO_0002050', 'EFO_1001917', 'EFO_0004242']",10.0,['ENSG00000108576'],1,1992.0,CHEMBL490,['paroxetine%20hydrochloride'],"['26753519', '85273719']",,,,,,
CHEMBL2110581,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O,PRYZSLKPMFOUNL-MHIBGBBJSA-N,Oligonucleotide,False,BEVASIRANIB,3.0,False,False,[],['Bevasiranib'],['CHEMBL2103797'],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,,"['EFO_0001365', 'EFO_0009606']",2.0,"['ENSG00000112715', 'ENSG00000164342']",2,,,,,,,,,,
CHEMBL315838,COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1,PJWPNDMDCLXCOM-UHFFFAOYSA-N,Small molecule,False,ENCAINIDE,4.0,True,True,[],['Encainide'],['CHEMBL2106155'],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for cardiac arrhythmia.,,['DB01228'],['EFO_0004269'],1.0,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",10,1986.0,,,,['4788'],,,,,
CHEMBL3545351,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O,HQLHZNDJQSRKDT-UHFFFAOYSA-N,Small molecule,False,AV-101,3.0,False,False,[],"['4-chlorokynurenine', '4-cl-kyn', 'Av-101', 'J578.071C', 'L-4-chlorokynurenine', 'L-4-cl-kyn']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,,"['MONDO_0002050', 'MONDO_0002009', 'EFO_0001361', 'EFO_0005762']",4.0,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']",7,,,,,,,,,,
CHEMBL4298194,,,Gene,False,GIROCTOCOGENE FITELPARVOVEC,3.0,False,False,[],"['Giroctocogene fitelparvovec', 'PF-07055480', 'SB-525']",,Gene drug with a maximum clinical trial phase of III and has 1 investigational indication.,,,['MONDO_0010602'],1.0,['ENSG00000185010'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/GIROCTOCOGENE%20FITELPARVOVEC/relevant/1/'],,,
CHEMBL4761468,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,DOEOECWDNSEFDN-UHFFFAOYSA-N,Small molecule,False,AUMOLERTINIB,3.0,False,False,"['Ameile', 'Amerol']","['Almonertinib', 'Ameile', 'Amerol', 'Aumolertinib', 'EQ-143', 'EQ143', 'Egfr t790m inhibitor hs-10296', 'HS-10206', 'HS-10296', 'Hs 10296', 'Hs-10296']",['CHEMBL5095491'],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,,"['EFO_0001421', 'EFO_0000707', 'MONDO_0008903', 'EFO_0000571', 'EFO_0000313', 'EFO_0000616', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000616']",9.0,['ENSG00000146648'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/AUMOLERTINIB/relevant/1/'],,,
CHEMBL5095052,,,Oligonucleotide,False,INCLISIRAN SODIUM,4.0,False,True,['Leqvio'],['Leqvio sodium'],,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for atherosclerosis and familial hypercholesterolemia.,,,"['EFO_0003914', 'EFO_0004911']",2.0,['ENSG00000169174'],1,2020.0,,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio'],,,,
CHEMBL552212,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1,MTJHLONVHHPNSI-IBGZPJMESA-N,Small molecule,False,LEXIBULIN,2.0,False,False,[],"['CYT 997', 'CYT-997', 'CYT997', 'Lexibulin']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0001378', 'EFO_0000519']",2.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL65375,Cl.N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,KGHYQYACJRXCAT-UHFFFAOYSA-N,Small molecule,False,TIPIRACIL HYDROCHLORIDE,4.0,False,True,[],"['TAS-1-462', 'TPI', 'Tipiracil hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 2 investigational indications.,,,"['MONDO_0044937', 'EFO_1000657', 'EFO_0000365']",3.0,['ENSG00000025708'],1,2015.0,CHEMBL235668,['tipiracil%20hydrochloride'],,,,,,,
CHEMBL1200623,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,AOXRBFRFYPMWLR-XGXHKTLJSA-N,Small molecule,False,ETHYLESTRENOL,4.0,False,True,['Maxibolin'],"['Durabolin-o', 'Duraboral', 'Ethylestrenol', 'Ethylnandrol', 'Ethyloestrenol', 'NSC-37726', 'Orabolin']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1964.,['Ethylestrenol'],['DB01493'],,,['ENSG00000169083'],1,1964.0,,,"['144206065', '170465211', '50112767']",['31578'],,,,,
CHEMBL1200873,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,OGIYDFVHFQEFKQ-UHFFFAOYSA-N,Small molecule,False,PHENTOLAMINE MESYLATE,4.0,False,True,"['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']","['Mesylate phentolamine', 'NV-101', 'Phentolamine mesilate', 'Phentolamine mesylate', 'Phentolamine methanesulfonate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and is indicated for adrenal gland pheochromocytoma and has 3 investigational indications.,,,"['MONDO_0008315', 'EFO_0000239', 'EFO_0000319', 'EFO_0001073']",4.0,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']",6,1952.0,CHEMBL597,['phentolamine%20mesylate'],"['11112076', '50106870', '56423107', '85231326', '855630']",,,,,,
CHEMBL1200874,CCCCNC(=O)[N-]S(=O)(=O)c1ccc(C)cc1.[Na+],QKHDBRQBSNZFAK-UHFFFAOYSA-M,Small molecule,False,"TOLBUTAMIDE SODIUM, STERILE",4.0,False,True,['Orinase diagnostic'],"['Sodium tolbutamide', 'Tolbutamide sodium', 'Tolbutamide sodium salt', 'Tolbutamide sodium, sterile']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.,,,,,"['ENSG00000187486', 'ENSG00000006071']",2,1961.0,CHEMBL782,,,,,,,,
CHEMBL1445,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,YLRFCQOZQXIBAB-RBZZARIASA-N,Small molecule,False,FLUOXYMESTERONE,4.0,False,True,"['Android-f', 'Androxy', 'Fluoxymesterone', 'Halotestin', 'Ora-testryl']","['Fluoximesterone', 'Fluoxymesterone', 'Fluoxymesterone ciii', 'NSC-10704', 'NSC-12165']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 3 approved and 1 investigational indication.,['Fluoxymesterone'],['DB01185'],"['EFO_1001078', 'MONDO_0007254', 'MONDO_0002146', 'EFO_0000616']",4.0,['ENSG00000169083'],1,1956.0,,,"['144206709', '144208052', '17388998', '56422069']",['5120'],,,,,
CHEMBL1528134,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,HNNIWKQLJSNAEQ-UHFFFAOYSA-N,Small molecule,False,BENZYDAMINE HYDROCHLORIDE,4.0,False,True,"['Difflam', 'Difflam-p', 'Lozamine']","['AF-864', 'Benzidamine hydrochloride', 'Benzydamine hcl', 'Benzydamine hydrochloride', 'NSC-759276']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,,"['EFO_1001904', 'EFO_0009688']",2.0,"['ENSG00000073756', 'ENSG00000095303']",2,,CHEMBL12610,,"['144203971', '170465576', '49665028']",,,,,,
CHEMBL2103868,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O,HFCFMRYTXDINDK-WNQIDUERSA-N,Small molecule,True,CABOZANTINIB S-MALATE,4.0,False,True,"['Cabometyx', 'Cometriq']","['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184', 'XL184']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 7 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000681', 'EFO_0000519', 'EFO_0001075', 'MONDO_0004992', 'EFO_0000326', 'EFO_0000272', 'EFO_0000501', 'EFO_0000637', 'EFO_0000673', 'EFO_1001465', 'EFO_0000641', 'EFO_0003968', 'EFO_0000239', 'EFO_0002892', 'EFO_0000640', 'EFO_0000182', 'MONDO_0002108', 'EFO_1000251', 'EFO_0000616', 'EFO_1001512', 'EFO_0007532', 'EFO_0000305', 'EFO_0008524', 'EFO_0004252', 'EFO_0000349', 'EFO_0003060']",26.0,"['ENSG00000128052', 'ENSG00000105976']",2,2012.0,CHEMBL2105717,['cabozantinib%20s-malate'],,['72319'],['https://www.ema.europa.eu/en/medicines/human/EPAR/cabometyx'],,,,
CHEMBL2108893,,,Enzyme,False,ALFIMEPRASE,3.0,False,False,[],['Alfimeprase'],,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['HP_0002140', 'HP_0004936', 'MONDO_0000831']",3.0,"['ENSG00000171560', 'ENSG00000171564', 'ENSG00000171557']",3,,,,,,,,,,
CHEMBL341812,CC(C)Cc1ccc(CC(=O)O)cc1,CYWFCPPBTWOZSF-UHFFFAOYSA-N,Small molecule,False,IBUFENAC,4.0,True,True,[],"['(p-isobutylphenyl)acetic acid', 'Ibufenac', 'NSC-99976', 'RD 11654', 'RD-11654']",,Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.,,,,,"['ENSG00000073756', 'ENSG00000095303']",2,,,,"['170465922', '29216132']",['76158'],,,,,
CHEMBL5095027,CCP(=S)(Oc1ccc([N+](=O)[O-])cc1Cl)OC(C)C,QINWTFKFPMRNJP-UHFFFAOYSA-N,Small molecule,False,OMS405,2.0,False,False,[],['Oms405'],,Small molecule drug with a maximum clinical trial phase of II.,,,,,['ENSG00000132170'],1,,,,,,,,,,
CHEMBL1200485,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,IVDHYUQIDRJSTI-UHFFFAOYSA-N,Small molecule,False,SORAFENIB TOSYLATE,4.0,False,True,['Nexavar'],"['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 7 approved and 54 investigational indications.,,,"['MONDO_0004192', 'MONDO_0011719', 'EFO_0000691', 'EFO_0000349', 'EFO_0006352', 'EFO_1001968', 'EFO_0006861', 'EFO_0000756', 'EFO_0002501', 'EFO_0000389', 'EFO_0000641', 'MONDO_0002367', 'MONDO_0004992', 'EFO_0000365', 'MONDO_0008903', 'MONDO_0008170', 'EFO_0007535', 'EFO_0000220', 'EFO_0002618', 'EFO_0000616', 'EFO_1000613', 'EFO_1001465', 'EFO_1000657', 'MONDO_0021063', 'EFO_0002938', 'MONDO_0044926', 'EFO_0002499', 'EFO_0000588', 'EFO_1001469', 'EFO_0000501', 'EFO_0000673', 'MONDO_0002691', 'EFO_1001052', 'MONDO_0044937', 'MONDO_0004986', 'EFO_0003060', 'EFO_0001378', 'EFO_0000224', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0002108', 'EFO_0003833', 'EFO_1001951', 'EFO_0000640', 'EFO_0000182', 'EFO_0000519', 'EFO_0009907', 'EFO_0000702', 'EFO_1000158', 'EFO_0000095', 'MONDO_0002087', 'EFO_0000681', 'EFO_0000222', 'MONDO_0001187', 'EFO_0000403', 'EFO_0000637', 'EFO_0000335', 'EFO_0003871', 'EFO_0002892', 'EFO_0003032', 'MONDO_0002158']",61.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157764', 'ENSG00000122025', 'ENSG00000132155', 'ENSG00000113721', 'ENSG00000165731', 'ENSG00000157404']",9,2005.0,CHEMBL1336,['sorafenib%20tosylate'],"['144206042', '170465175', '85147444']",['50928'],['https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar'],,,,
CHEMBL1509,C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12,METQSPRSQINEEU-HXCATZOESA-N,Small molecule,False,DROSPIRENONE,4.0,False,True,"['Angeliq', 'Slynd']","['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for acne and has 7 investigational indications.,['Drospirenone'],['DB01395'],"['EFO_1000710', 'EFO_0000660', 'EFO_0003894', 'EFO_0005204', 'MONDO_0004169', 'EFO_0005924', 'HP_0100607', 'MONDO_0002050']",8.0,"['ENSG00000082175', 'ENSG00000151623']",2,2001.0,,['drospirenone'],"['144205769', '170464870']",['50838'],,,,,
CHEMBL2109364,,,Antibody,False,AR-20.5,2.0,False,False,[],['AR-20.5'],,Antibody drug with a maximum clinical trial phase of II.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL2109598,,,Antibody,False,BIIB-023,2.0,False,False,[],"['BIIB-023', 'Biib-023']",,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_0005761', 'EFO_0000685']",2.0,['ENSG00000239697'],1,,,,,,,,,,
CHEMBL25,CC(=O)Oc1ccccc1C(=O)O,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,Small molecule,False,ASPIRIN,4.0,False,True,"['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acid', 'Acetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75', 'Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine pain', 'Danamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'Enprin', 'Equi-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'Measurin', 'Micropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75', 'Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300', 'Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']","['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidum', 'Acidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'Aspirin', 'BAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']","['CHEMBL1697753', 'CHEMBL2296002']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 19 approved and 143 investigational indications.,['Aspirin'],['DB00945'],"['EFO_0000495', 'MONDO_0007576', 'EFO_0000180', 'EFO_0001645', 'Orphanet_733', 'EFO_0002615', 'EFO_0008586', 'EFO_0004607', 'HP_0012042', 'EFO_0007328', 'MONDO_0002009', 'EFO_0003843', 'MONDO_0004247', 'EFO_0000266', 'EFO_0003144', 'EFO_0000275', 'EFO_0009364', 'HP_0012378', 'EFO_0003770', 'EFO_0000519', 'MONDO_0005277', 'EFO_0003868', 'EFO_0000339', 'MONDO_0011962', 'EFO_0004698', 'EFO_1001157', 'EFO_0003106', 'EFO_0005411', 'EFO_1001161', 'MP_0001845', 'EFO_0003914', 'EFO_0000571', 'MONDO_0005178', 'EFO_0003060', 'EFO_0004277', 'MONDO_0008170', 'EFO_0009315', 'EFO_0008573', 'EFO_0000389', 'MONDO_0005090', 'EFO_0010282', 'EFO_0000764', 'EFO_0003964', 'EFO_1000637', 'EFO_1001951', 'HP_0002140', 'MONDO_0043839', 'MONDO_0005835', 'EFO_0003870', 'MONDO_0010888', 'EFO_0005406', 'MONDO_0004979', 'HP_0005521', 'EFO_0000319', 'EFO_0000195', 'MONDO_0007254', 'MONDO_0021108', 'MONDO_0005129', 'MP_0001914', 'EFO_0000673', 'EFO_0000712', 'EFO_0001378', 'EFO_0007443', 'EFO_0000266', 'EFO_0003931', 'EFO_0009606', 'EFO_0001361', 'EFO_0000545', 'HP_0100806', 'MONDO_0041052', 'EFO_0000668', 'EFO_0005856', 'EFO_0007541', 'HP_0002239', 'MONDO_0100096', 'MONDO_0018896', 'MONDO_0018076', 'EFO_0004610', 'MONDO_0001056', 'EFO_0004286', 'HP_0002315', 'EFO_1000860', 'EFO_0000182', 'HP_0004398', 'EFO_0000537', 'MONDO_0004985', 'EFO_0003893', 'EFO_0008585', 'EFO_0004259', 'EFO_0003913', 'HP_0003326', 'EFO_0003764', 'EFO_0000280', 'EFO_0009454', 'EFO_0007129', 'EFO_1001375', 'HP_0003394', 'EFO_0000341', 'EFO_0000616', 'EFO_0000707', 'EFO_0003763', 'EFO_0001663', 'EFO_0003875', 'EFO_0006859', 'EFO_0003869', 'EFO_0002429', 'EFO_0003884', 'EFO_0004264', 'EFO_1001154', 'EFO_0003777', 'EFO_0000400', 'EFO_0002950', 'EFO_0000649', 'EFO_1000954', 'HP_0100607', 'EFO_0009854', 'EFO_0000479', 'EFO_0000729', 'EFO_0009314', 'Orphanet_309005', 'MONDO_0005301', 'EFO_0000556', 'EFO_0000684', 'EFO_1000657', 'MONDO_0011382', 'EFO_1002022', 'EFO_0000538', 'EFO_0002618', 'HP_0002745', 'EFO_0003762', 'EFO_0005407', 'EFO_0003768', 'EFO_0000694', 'HP_0003418', 'EFO_0004252', 'EFO_0009846', 'EFO_0008583', 'EFO_0000546', 'MONDO_0002679', 'HP_0000618', 'EFO_0009686', 'HP_0004936', 'MONDO_0021063', 'MONDO_0002974', 'MONDO_0007915', 'MONDO_0004992', 'HP_0001945', 'MONDO_0002258', 'HP_0004419', 'EFO_0004265', 'MONDO_0008315', 'EFO_0010072', 'EFO_0005672', 'HP_0003419', 'HP_0012228', 'EFO_0000612', 'EFO_1001923', 'HP_0003124', 'MONDO_0005148', 'MONDO_0000831', 'EFO_0004246', 'EFO_0007214', 'EFO_0004211']",163.0,"['ENSG00000073756', 'ENSG00000095303']",2,1950.0,,['aspirin'],"['144203627', '144209315', '144210466', '170465039', '17389202', '17390036', '174007205', '26747283', '26752858', '47193676', '50105490', '85230910', '87798', '90340586']",['15365'],,,['14'],,
CHEMBL264374,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,IIBYAHWJQTYFKB-UHFFFAOYSA-N,Small molecule,False,BEZAFIBRATE,4.0,False,True,"['Bezagen xl', 'Bezalip', 'Bezalip-mono', 'Fibrazate xl', 'Liparol xl', 'Zimbacol xl']","['BM 15.075', 'BM-15.075', 'BM-15075', 'Bezafibrate', 'Bezatol sr', 'NSC-758174']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 7 investigational indications.,['Bezafibrate'],['DB01393'],"['MONDO_0005148', 'MONDO_0004985', 'EFO_0004268', 'EFO_0000198', 'Orphanet_79211', 'MONDO_0044970', 'EFO_1001486', 'EFO_0000319']",8.0,"['ENSG00000132170', 'ENSG00000186951', 'ENSG00000112033']",3,,,,"['11112764', '144204196', '144212162', '170465743', '26751546', '26751547', '56422496', '855877', '90341401']",['47612'],,,,,
CHEMBL3545311,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,AILRADAXUVEEIR-UHFFFAOYSA-N,Small molecule,False,BRIGATINIB,4.0,False,True,['Alunbrig'],"['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for neoplasm and non-small cell lung carcinoma and has 1 investigational indication.,,['DB12267'],"['EFO_0000616', 'EFO_0003060', 'EFO_0003032']",3.0,"['ENSG00000171094', 'ENSG00000146648']",2,2017.0,,['brigatinib'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig'],,,,
CHEMBL3786673,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)c1ccccc1O,JQLBBYLGWHUHRW-KUBAVDMBSA-N,Small molecule,False,EDASALONEXENT,3.0,False,False,[],"['CAT 1004', 'CAT-1004', 'CAT1004', 'Cat 1004', 'Cat-1004', 'Edasalonexent']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,['DB15010'],"['MONDO_0010679', 'MONDO_0005148']",2.0,"['ENSG00000077150', 'ENSG00000109320', 'ENSG00000173039']",3,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/EDASALONEXENT/relevant/1/'],,,
CHEMBL405,CC(N)Cc1ccccc1,KWTSXDURSIMDCE-UHFFFAOYSA-N,Small molecule,True,AMPHETAMINE,4.0,False,True,"['Adzenys er', 'Adzenys xr-odt', 'Dyanavel xr']","['Amfetamin', 'Amfetamine', 'Amphetamine', 'Amphetamine, dl-', 'Dyanavel', 'NSC-27159', 'Norephedrane']","['CHEMBL3250774', 'CHEMBL1200377', 'CHEMBL3250773', 'CHEMBL3250775', 'CHEMBL554211', 'CHEMBL1200387', 'CHEMBL3250772', 'CHEMBL3250770', 'CHEMBL3250771', 'CHEMBL501']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.,"['Adderall', 'Amphetamine']",['DB00182'],"['EFO_0003888', 'EFO_0001073', 'MONDO_0016158', 'EFO_0003925', 'EFO_0003888', 'EFO_0003888', 'EFO_0002610', 'EFO_0002610']",8.0,"['ENSG00000103546', 'ENSG00000142319']",2,1955.0,,['amphetamine'],,['2679'],,,,,
CHEMBL475534,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1,PVHUJELLJLJGLN-UHFFFAOYSA-N,Small molecule,False,NITRENDIPINE,4.0,False,True,['Baypress'],"['BAY E 5009', 'BAY-E-5009', 'Bayotensin', 'Deiten', 'NSC-758466', 'Nidrel', 'Nitrendipine', 'Nitrepin']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.,['Nitrendipine'],['DB01054'],"['EFO_0000319', 'EFO_0000537']",2.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,,,,"['104171193', '124880808', '144203752', '170465897', '26751794', '26751795', '50104488', '85231144', '90341570']",['7582'],,,,,
CHEMBL1200402,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=S(=O)(O)c1ccccc1,ZPBWCRDSRKPIDG-UHFFFAOYSA-N,Small molecule,True,AMLODIPINE BESYLATE,4.0,False,True,"['Amlodipine besylate', 'Norliqva', 'Norvasc']","['Amlodipine (as besilate)', 'Amlodipine benzenesulfonate', 'Amlodipine besilate', 'Amlodipine besylate', 'Amlor', 'Antacal', 'Lodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26', 'UK-48340-26']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 13 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,,"['EFO_0000400', 'EFO_0003144', 'EFO_0000612', 'HP_0000093', 'EFO_0004911', 'EFO_1000013', 'MONDO_0005178', 'MONDO_0021187', 'EFO_0000373', 'EFO_0000537', 'EFO_0000712', 'MONDO_0001134', 'HP_0003124', 'Orphanet_79292', 'EFO_0003913', 'EFO_0001645']",16.0,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']",4,1992.0,CHEMBL1491,['amlodipine%20besylate'],"['144205078', '144207025', '26749852']",['2669'],,,,,
CHEMBL1200789,O=P([O-])(O)OCC(Cl)(Cl)Cl.[Na+],WFKJEZKHPGDCRK-UHFFFAOYSA-M,Small molecule,False,TRICLOFOS SODIUM,4.0,False,True,['Triclos'],"['SCH 10159', 'SCH-10159', 'Trichloroethyl phosphate sodium', 'Triclofos monosodium salt', 'Triclofos sodium', 'Tricloryl']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,,,,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,CHEMBL1201317,,,,,,,,
CHEMBL1201063,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1.Cl,XWIHRGFIPXWGEF-UHFFFAOYSA-N,Small molecule,True,PROPAFENONE HYDROCHLORIDE,4.0,False,True,"['Arythmol', 'Propafenone hydrochloride', 'Rythmol', 'Rythmol sr', 'Rytmonorm']","['NSC-758640', 'Propafenone hcl', 'Propafenone hydrochloride']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for ventricular arrhythmia and atrial fibrillation and has 1 investigational indication. This drug has a black box warning from the FDA.,,,"['HP_0004308', 'EFO_0000275', 'EFO_0003144']",3.0,"['ENSG00000043591', 'ENSG00000169252', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']",12,1989.0,CHEMBL631,['propafenone%20hydrochloride'],"['26747617', '26747618', '50106779', '50106780', '50106781', '56422489', '855997']",['8466'],,,,,
CHEMBL1398126,Cl.N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.O.O,LTKVFMLMEYCWMK-UHFFFAOYSA-N,Small molecule,True,AMILORIDE HYDROCHLORIDE,4.0,False,True,"['Amilamont', 'Amiloride hydrochloride', 'Amilospare 5', 'Amoride', 'Berkamil', 'Midamor']","['Amiloride hcl', 'Amiloride hydrochloride', 'Amiloride hydrochloride anhydrous', 'Amiloride hydrochloride dehydrate', 'Amiloride hydrochloride dihydrate', 'Amiloridi hydrochloridum', 'Amipramidine', 'Anhydrous amiloride hydrochloride', 'NSC-755847']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,,"['EFO_0004269', 'MONDO_0009061', 'EFO_0000537', 'EFO_0000373']",4.0,"['ENSG00000111319', 'ENSG00000168447', 'ENSG00000166828']",3,1981.0,CHEMBL945,['amiloride%20hydrochloride'],['11113002'],['2640'],,,,,
CHEMBL1755,Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2,IKENVDNFQMCRTR-UHFFFAOYSA-N,Small molecule,False,CONIVAPTAN,4.0,False,True,[],['Conivaptan'],['CHEMBL1201108'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for heart failure and cardiovascular disease and has 5 investigational indications.,['Conivaptan'],['DB00872'],"['HP_0002902', 'MONDO_0043510', 'HP_0002902', 'EFO_0001422', 'EFO_0003144', 'EFO_0001421', 'EFO_0003144', 'EFO_0000319']",8.0,"['ENSG00000126895', 'ENSG00000166148']",2,2005.0,,,,['681850'],,,,,
CHEMBL2108628,,,Small molecule,False,PACLITAXEL POLIGLUMEX,3.0,False,False,[],"['CT-2103', 'L-polyglutamic paclitaxel', 'Opaxio', 'PG-TXL', 'Paclitaxel conjugate with poly-l-glutamic acid', 'Paclitaxel poliglumex']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,,"['EFO_0006772', 'MONDO_0008170', 'MONDO_0002158', 'MONDO_0008315', 'EFO_0000466', 'MONDO_0005575', 'EFO_0000616', 'MONDO_0007254', 'EFO_0003060', 'MONDO_0002087', 'EFO_0000673', 'EFO_0003833', 'MONDO_0008903', 'EFO_0000707']",14.0,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",15,,,,,,,,,,
CHEMBL34124,COc1ccc2c(c1OCc1ccccc1)C[C@@H](C(=O)O)N(C(=O)C(c1ccccc1)c1ccccc1)C2,GHBCIXGRCZIPNQ-MHZLTWQESA-N,Small molecule,False,OLODANRIGAN,2.0,False,False,[],"['EMA-401', 'EMA401', 'Ema401', 'Olodanrigan', 'PD-126055']",['CHEMBL157510'],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,,"['EFO_1000783', 'MONDO_0041052']",2.0,['ENSG00000180772'],1,,,,,,,,,,
CHEMBL3586404,CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1,UFKLYTOEMRFKAD-SHTZXODSSA-N,Small molecule,False,ONATASERTIB,2.0,False,False,[],"['ATG-008', 'ATG008', 'CC-223', 'CC223', 'Cc-223', 'Onatasertib']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,['DB12570'],"['EFO_1001901', 'EFO_0001378', 'EFO_0003060', 'EFO_0000519', 'EFO_0000182', 'EFO_0000616', 'EFO_0000403', 'MONDO_0007254']",8.0,['ENSG00000198793'],1,,,,,,,['https://searchusan.ama-assn.org/finder/usan/search/ONATASERTIB/relevant/1/'],,,
CHEMBL3916929,CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2,MBKYLPOPYYLTNW-ZDUSSCGKSA-N,Small molecule,False,BALCINRENONE,2.0,False,False,[],"['AZD-9977', 'AZD9977', 'Azd 9977', 'Azd-9977', 'Azd9977', 'Balcinrenone']",,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,['DB15418'],"['EFO_0000319', 'EFO_0003086', 'EFO_0003144']",3.0,['ENSG00000151623'],1,,,,,,,,,,['https://www.who.int/publications/m/item/inn-pl-126']
CHEMBL4297865,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,UOFYSRZSLXWIQB-UHFFFAOYSA-N,Small molecule,False,ABIVERTINIB,3.0,False,False,[],"['A610', 'AC-0010', 'AC0010', 'ACEA100610', 'Abivertinib', 'Ac0010', 'Avitinib', 'EX-ACEA0010']","['CHEMBL4297866', 'CHEMBL5307684']",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,['DB15327'],"['EFO_0000096', 'MONDO_0100096', 'EFO_0003060', 'EFO_0003060', 'MONDO_0100096', 'MONDO_0008315']",6.0,"['ENSG00000010671', 'ENSG00000146648']",2,,,,,,,,,,
CHEMBL4298134,,,Antibody,False,OBEXELIMAB,3.0,False,False,[],"['Obexelimab', 'XMAB-5871', 'XMAB5871', 'Xmab5871']",,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,,"['MONDO_0007915', 'EFO_1001264', 'MONDO_0017287']",3.0,"['ENSG00000072694', 'ENSG00000177455']",2,,,,,,,,,,
CHEMBL452231,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,NRUKOCRGYNPUPR-QBPJDGROSA-N,Small molecule,True,TENIPOSIDE,4.0,False,True,['Vumon'],"['NSC-122819', 'Teniposide', 'VM-26', 'VM26']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for neoplasm and has 3 investigational indications. This drug has a black box warning from the FDA.,,['DB00444'],"['EFO_0000616', 'EFO_0000220', 'EFO_0000574', 'EFO_0000565']",4.0,"['ENSG00000131747', 'ENSG00000077097']",2,1992.0,,,,,,,,,
CHEMBL1118,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,KYYIDSXMWOZKMP-UHFFFAOYSA-N,Small molecule,True,DESVENLAFAXINE,4.0,False,True,"['Desvenlafaxine', 'Khedezla', 'Pristiq']","['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxine', 'ODV']","['CHEMBL3989861', 'CHEMBL1201728']",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.,['Desvenlafaxine'],['DB06700'],"['EFO_0005687', 'EFO_0003761', 'HP_0031217', 'EFO_0004220', 'MONDO_0002009', 'GO_0042697', 'MONDO_0002050', 'EFO_1000783', 'EFO_0005687', 'EFO_0003761', 'MONDO_0002050', 'EFO_0003761', 'MONDO_0002009']",13.0,"['ENSG00000103546', 'ENSG00000108576']",2,2008.0,,['desvenlafaxine'],,['83527'],,,,,
CHEMBL12,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,AAOVKJBEBIDNHE-UHFFFAOYSA-N,Small molecule,True,DIAZEPAM,4.0,False,True,"['Alupram 10', 'Alupram 2', 'Alupram 5', 'Apozepam', 'Atensine', 'Dialar', 'Dialar fte', 'Diastat', 'Diastat acudial', 'Diazepam', 'Diazepam intensol', 'Dizac', 'E-Pam', 'Paxel', 'Q-pam', 'Relanium', 'Scriptopam', 'Serenack', 'Solis', 'Stesolid', 'Tensium', 'Tranimul', 'Valclair', 'Valium', 'Valrelease', 'Valtoco', 'Vivol']","['Ansiolisina', 'Centrazepam', 'Diacepin', 'Diazepam', 'Diazepam civ', 'LA III', 'LA-III', 'NRL-1', 'NSC-169897', 'NSC-77518', 'Nrl-1', 'RO 5-2807', 'RO-5-2807', 'RO-52807', 'Servizepam', 'Tranquase', 'WY-3467']",['CHEMBL543191'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA.,['Diazepam'],['DB00829'],"['HP_0001250', 'HP_0003419', 'EFO_0005230', 'EFO_0000474', 'EFO_0008526', 'MONDO_0002050', 'EFO_0003843', 'MONDO_0005090', 'EFO_0006788', 'EFO_0000546', 'HP_0000713', 'EFO_1001250', 'HP_0000726', 'EFO_0007498', 'EFO_1001010', 'EFO_1000877', 'EFO_1000632']",17.0,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1963.0,,['diazepam'],"['124893574', '144206622', '144209656', '170464626']",['49575'],,,['23'],,
CHEMBL1200790,CCC1(CC)C(=O)NCC(C)C1=O,SIDLZWOQUZRBRU-UHFFFAOYSA-N,Small molecule,False,METHYPRYLON,4.0,False,True,['Noludar'],"['Methyprylon', 'NSC-30442']",,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.,['Methyprylon'],['DB01107'],,,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']",16,1982.0,,,,,,,,,
CHEMBL175,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,HEFNNWSXXWATRW-JTQLQIEISA-N,Small molecule,False,DEXIBUPROFEN,4.0,False,True,['Seractil'],"['(s)-ibuprofen', 'Dexibuprofen', 'IBU-TAB', 'NSC-759814', 'Neoprofen', 'Rufen', 'S-ibuprofen']",['CHEMBL1778537'],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for rheumatic disease and has 2 investigational indications.,['Dexibuprofen'],['DB09213'],"['EFO_0005755', 'HP_0001945', 'EFO_0003843']",3.0,"['ENSG00000073756', 'ENSG00000095303']",2,1994.0,,,"['11111293', '11111294', '11112775', '144206692', '47193724', '50100253', '50106464', '85231335', '90340840']",['43415'],,,,,
CHEMBL1800955,COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,RFUBTTPMWSKEIW-UHFFFAOYSA-N,Small molecule,False,OMECAMTIV MECARBIL,3.0,False,False,[],"['CK-1827452', 'Omecamtiv mecarbil']",,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,['DB11816'],['EFO_0003144'],1.0,"['ENSG00000092054', 'ENSG00000197616', 'ENSG00000078814', 'ENSG00000160808', 'ENSG00000111245', 'ENSG00000106631', 'ENSG00000198336']",7,,,,['174007336'],,,,,,
CHEMBL2107354,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],SARBMGXGWXCXFW-GJHVZSAVSA-M,Small molecule,False,MIFAMURTIDE,4.0,False,True,['Mepact'],"['L-MTP-PE', 'Mifamurtide', 'Mifamurtide sodium hydrate', 'Mifamurtide sodium salt monohydrate', 'Sodium mifamurtide']",,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications.,,,"['MONDO_0002629', 'EFO_0000637', 'EFO_0000616']",3.0,['ENSG00000167207'],1,2009.0,CHEMBL2111100,,,,['https://www.ema.europa.eu/en/medicines/human/EPAR/mepact'],,,,
CHEMBL2109365,,,Antibody,False,HUPAM4,1.0,False,False,[],['HUPAM4'],,Antibody drug with a maximum clinical trial phase of I.,,,,,['ENSG00000185499'],1,,,,,,,,,,
CHEMBL276711,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,WUWDLXZGHZSWQZ-WQLSENKSSA-N,Small molecule,False,SEMAXANIB,3.0,False,False,[],"['NSC-696819', 'SU-5416', 'SU005416', 'SU5416', 'Semaxanib', 'Semaxinib', 'Su-5416']",,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,['Semaxanib'],['DB06436'],"['EFO_1000158', 'EFO_1000657', 'EFO_1001951', 'MONDO_0002974', 'EFO_0001378', 'EFO_0000588', 'EFO_0000616', 'EFO_0006859', 'MONDO_0007254', 'MONDO_0021063', 'EFO_0000389', 'EFO_0000681', 'MONDO_0002367', 'EFO_0000756', 'MONDO_0008315', 'EFO_0000365', 'EFO_0000691']",17.0,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404']",4,,,,"['124891688', '49674962', '50107014', '50107016', '525180', '56322916', '90341564']",,,,,,
CHEMBL3833393,,,Antibody,True,EMICIZUMAB,4.0,False,True,['Hemlibra'],"['ACE-910', 'ACE910', 'Emicizumab', 'Emicizumab kxwh', 'Emicizumab-kxwh']",,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for hemorrhage and hemophilia a. This drug has a black box warning from the FDA.,,,"['MP_0001914', 'MONDO_0010602']",2.0,"['ENSG00000101981', 'ENSG00000126218']",2,2017.0,,['emicizumab'],,,['https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra'],,,,
CHEMBL4091801,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2,YJCZPJQGFSSFOL-MNZPCBJKSA-N,Small molecule,False,APG115,2.0,False,False,[],['Apg115'],,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,,"['EFO_0000569', 'EFO_1001779', 'EFO_0000574', 'MONDO_0004669', 'EFO_0004289', 'EFO_0000621', 'EFO_0000222', 'EFO_0000198']",8.0,"['ENSG00000141510', 'ENSG00000135679']",2,,,,,,,,,,
